PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Cordes, MHJ; Walsh, NP; McKnight, CJ; Sauer, RT				Cordes, MHJ; Walsh, NP; McKnight, CJ; Sauer, RT			Evolution of a protein fold in vitro	SCIENCE			English	Article							ARC REPRESSOR; STAPHYLOCOCCAL NUCLEASE; T4 LYSOZYME; CRYSTAL-STRUCTURE; HYDROPHOBIC CORE; SIDE-CHAIN; INSERTION; MUTANT; ACCOMMODATION; CONSEQUENCES	A "switch" mutant of the Arc repressor homodimer was constructed by interchanging the sequence positions of a hydrophobic core residue, Leucine 12, and an adjacent surface polar residue, asparagine 11, in each strand of an intersubunit beta sheet. The mutant protein adopts a fold in which each beta strand is replaced by a right-handed helix and side chains in this region undergo significant repacking, The observed structural changes allow the protein to maintain solvent exposure of polar side chains and optimal burial of hydrophobic side chains. These results suggest that new protein folds can evolve from existing folds without drastic or large-scale mutagenesis.	MIT, Dept Biol, Cambridge, MA 02139 USA; Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA	Massachusetts Institute of Technology (MIT); Boston University	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sauer, Robert/0000-0002-1719-5399; McKnight, Christopher/0000-0002-3237-0896	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015706, R37AI015706] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-15706] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BONVIN AMJJ, 1994, J MOL BIOL, V236, P328, DOI 10.1006/jmbi.1994.1138; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BREG JN, 1989, BIOCHEMISTRY-US, V28, P9826, DOI 10.1021/bi00451a042; BRUNGER AT, 1987, X PLOR V3 1 MANUAL; BURGERING MJM, 1995, BIOPOLYMERS, V35, P217, DOI 10.1002/bip.360350210; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; HEINZ DW, 1994, J MOL BIOL, V236, P869, DOI 10.1006/jmbi.1994.1195; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; KEEFE LJ, 1994, PROTEIN SCI, V3, P391; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; MILLA ME, 1994, NAT STRUCT BIOL, V1, P518, DOI 10.1038/nsb0894-518; MILLA ME, 1995, BIOCHEMISTRY-US, V34, P3344, DOI 10.1021/bi00010a025; Murzin AG, 1998, CURR OPIN STRUC BIOL, V8, P380, DOI 10.1016/S0959-440X(98)80073-0; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; OHLENDORF DH, 1983, J MOL BIOL, V169, P757, DOI 10.1016/S0022-2836(83)80169-7; PERUTZ MF, 1965, J MOL BIOL, V13, P669, DOI 10.1016/S0022-2836(65)80134-6; PRUSINER SB, 1994, PHILOS T ROY SOC B, V343, P447, DOI 10.1098/rstb.1994.0043; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; SCHILDBACH JF, 1995, BIOCHEMISTRY-US, V34, P1405, DOI 10.1021/bi00004a035; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)80195-Z; Vetter IR, 1996, PROTEIN SCI, V5, P2399, DOI 10.1002/pro.5560051203; WEST MW, 1995, PROTEIN SCI, V4, P2032, DOI 10.1002/pro.5560041008	26	95	95	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					325	327		10.1126/science.284.5412.325	http://dx.doi.org/10.1126/science.284.5412.325			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195898				2022-12-01	WOS:000079636400044
J	Skjaerven, R; Wilcox, AJ; Lie, RT				Skjaerven, R; Wilcox, AJ; Lie, RT			A population-based study of survival and childbearing among female subjects with birth defects and the risk of recurrence in their children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGENITAL-MALFORMATIONS; MATERNAL AGE; CLEFT-LIP	Background and Methods Persons with birth defects are at high risk for death during the perinatal period and infancy. Less is known about the rater survival or reproduction of such persons. We studied a cohort that comprised 8192 women and adolescent girls with registered birth defects and 451,241 women and adolescent girls with no birth defects, all of whom were born in Norway from 1967 through 1982. The rate of survival was determined through 1992, and the rate of childbearing was determined through October 1997. We also estimated the risk of birth defects in the children of these subjects. Results Among the subjects with birth defects, 80 percent survived to 15 years of age, as compared with 98 percent of those with no birth defects. Among the surviving subjects, 53 percent of those with birth defects gave birth to at least one infant by the age of 30 years, as compared with 67 percent of those with no birth defects. The subjects with birth defects were one third less likely to give birth by the age of 30 than those with no birth defects. The children of the subjects with birth defects had a significantly higher risk of birth defects than the children of those with no birth defects (relative risk, 1.6; 95 percent confidence interval, 1.3 to 2.1). This increased risk was confined entirely to the specific defect carried by the mother, with the relative risk of recurrence varying from 5.5 to 82 according to the defect. In contrast, there was no increase in the risk of having an infant with a different type of defect. Conclusions Women and girls with birth defects have decreased survival as compared with those with no birth defects, especially in the first years of life, and are less likely to have children. in addition, they have an increased risk of having children with the same defect. (N Engl J Med 1999;340:1057-62.) (C) 1999, Massachusetts Medical Society.	Univ Bergen, Sect Med Stat, N-5021 Bergen, Norway; Univ Bergen, Med Birth Registry Norway, Bergen, Norway; NIEHS, Res Triangle Pk, NC 27709 USA	University of Bergen; University of Bergen; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Skjaerven, R (corresponding author), Univ Bergen, Sect Med Stat, Armauer Hansens Bldg, N-5021 Bergen, Norway.		Wilcox, Allen J/C-7723-2019	Wilcox, Allen J/0000-0002-3376-1311	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES049027, ZIAES049027] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS MM, 1985, AM J DIS CHILD, V139, P518, DOI 10.1001/archpedi.1985.02140070092045; BAIRD PA, 1991, LANCET, V337, P527, DOI 10.1016/0140-6736(91)91306-F; Burn J, 1998, LANCET, V351, P311, DOI 10.1016/S0140-6736(97)06486-6; CARTER CO, 1982, J MED GENET, V19, P246, DOI 10.1136/jmg.19.4.246; CROEN LA, 1995, AM J PUBLIC HEALTH, V85, P710, DOI 10.2105/AJPH.85.5.710; CZEIZEL A, 1984, MUTAT RES, V128, P73, DOI 10.1016/0027-5107(84)90049-6; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; LIE RT, 1994, BIOMETRICS, V50, P433, DOI 10.2307/2533386; MASTROIACOVO P, 1992, AM J MED GENET, V42, P208, DOI 10.1002/ajmg.1320420214; MEHTA C, 1999, STATXACT WINDOWS; Mitchell LE, 1997, EPIDEMIOL REV, V19, P61, DOI 10.1093/oxfordjournals.epirev.a017947; Norusis M J, 1993, SPSS WINDOWS ADV STA; Rothman KJ, 1986, MODERN EPIDEMIOLOGY	13	47	48	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	1999	340	14					1057	1062		10.1056/NEJM199904083401401	http://dx.doi.org/10.1056/NEJM199904083401401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184AK	10194234				2022-12-01	WOS:000079587000001
J	Tookey, PA; Peckham, CS				Tookey, PA; Peckham, CS			Surveillance of congenital rubella in Great Britain, 1971-96	BRITISH MEDICAL JOURNAL			English	Article									Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London	Tookey, PA (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.		peckham, catherine s/I-6300-2013; Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387				Hall SM, 1998, CHILD CARE HLTH DEV, V24, P129; HMSO, 1996, IMM INF DIS; THOMAS HIJ, 1995, PHLS MICROBIOLOGY DI, V12, P97; 1998, COMMUN DIS REP CDR W, V8, P320; 1998, COMMUN DIS REP CDR W, V8, P317	5	47	47	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1999	318	7186					769	770		10.1136/bmj.318.7186.769	http://dx.doi.org/10.1136/bmj.318.7186.769			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BX	10082699	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000079421700024
J	Jackson, GS; Hosszu, LLP; Power, A; Hill, AF; Kenney, J; Saibil, H; Craven, CJ; Waltho, JP; Clarke, AR; Collinge, J				Jackson, GS; Hosszu, LLP; Power, A; Hill, AF; Kenney, J; Saibil, H; Craven, CJ; Waltho, JP; Clarke, AR; Collinge, J			Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations	SCIENCE			English	Article							CREUTZFELDT-JAKOB DISEASE; MOLTEN GLOBULE STATE; ALPHA-LACTALBUMIN; SCRAPIE; ORGANELLES; STABILITY; LYSOSOMES; ISOFORM; DOMAIN; CELLS	Prion propagation involves the conversion of cellular prion protein (PrPc) into a disease-specific isomer, PrPSc, shifting from a predominantly alpha-helical to beta-sheet structure. Here, conditions were established in which recombinant human PrP could switch between the native a conformation, characteristic of PrPc, and a compact, highly soluble, monomeric form rich in beta structure. The soluble beta form (beta-PrP) exhibited partial resistance to proteinase kappa digestion, characteristic of PrPSc, and was a direct precursor of fibrillar structures closely similar to those isolated from diseased brains. The conversion of PrPc to beta-PrP in suitable cellular compartments, and its subsequent stabilization by intermolecular association, provide a molecular mechanism for prion propagation.	Univ London Imperial Coll Sci Technol & Med, St Marys, Sch Med, Dept Neurogenet,Prion Dis Grp, London W2 1NY, England; Univ Sheffield, Krebs Inst Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Imperial College London; University of Sheffield; University of London; Birkbeck University London; University of Bristol	Collinge, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, St Marys, Sch Med, Dept Neurogenet,Prion Dis Grp, London W2 1NY, England.		Hill, Andrew F/B-4527-2009; Hill, Andrew/GZL-4124-2022; Hill, Andrew F./AAH-2854-2020	Hill, Andrew F/0000-0001-5581-2354; Hill, Andrew/0000-0001-5581-2354; Hill, Andrew F./0000-0001-5581-2354; Jackson, Graham/0000-0002-3125-2011	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; ARNOLD JE, 1995, J PATHOL, V176, P403, DOI 10.1002/path.1711760412; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Collinge J, 1997, HUM MOL GENET, V6, P1699, DOI 10.1093/hmg/6.10.1699; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; JACKSON GL, UNPUB; JACKSON GS, IN PRESS BIOCH BIOPH; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; LASZLO L, 1992, J PATHOL, V166, P333, DOI 10.1002/path.1711660404; LIBERSKI PP, 1991, J COMP PATHOL, V105, P377, DOI 10.1016/S0021-9975(08)80107-7; MAYER RJ, 1992, LANCET, V340, P156, DOI 10.1016/0140-6736(92)93224-B; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	23	345	356	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1935	1937		10.1126/science.283.5409.1935	http://dx.doi.org/10.1126/science.283.5409.1935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10082469				2022-12-01	WOS:000079228600053
J	Li, SJ; Hochstrasser, M				Li, SJ; Hochstrasser, M			A new protease required for cell-cycle progression in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; UBIQUITIN; GENE; DEGRADATION; PROTEINS; ENCODES; SUMO-1; ENZYME	In eukaryotes, protein function can be modulated by ligation to ubiquitin or to ubiquitin-like proteins (Ub1 proteins)(1-3). The vertebrate Ub1 protein SUMO-1 is only 18% identical to ubiquitin but is 48% identical to the yeast protein Smt3. Both SUMO-1 and Smt3 are ligated to cellular proteins, and protein conjugation to SUMO-1/Smt3 is involved in many physiological processes(3-10). It remained unknown, however, whether deconjugation of SUMO1/Smt3 from proteins is also essential. Here we describe a yeast Ub1-specific protease, Ulp1,which cleaves proteins from Smt3 and SUMO-1 but not from ubiquitin. Ulp1 is unrelated to any known deubiquitinating enzyme but shows distant similarity to certain viral proteases, indicating the existence of a widely conserved protease fold. Proteins related to Ulp1 are present in many organisms, including several human pathogens, The pattern of Smt3-coupled proteins in yeast changes markedly throughout the cell cycle, and specific conjugates accumulate in ulp1 mutants. Ulp1 has several functions, including an essential role in the G2/M phase of the fell cycle.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Hochstrasser, M (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.	hoc1@midway.uchicago.edu		Hochstrasser, Mark/0000-0002-1131-5484				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; LEE PY, 1994, J BIOL CHEM, V269, P8616; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99	26	590	620	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	1999	398	6724					246	251		10.1038/18457	http://dx.doi.org/10.1038/18457			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UA	10094048				2022-12-01	WOS:000079228400055
J	Zhu, JY; McKeon, F				Zhu, JY; McKeon, F			NF-AT activation requires suppression of Crm1-dependent export by calcineurin	NATURE			English	Article							NUCLEAR EXPORT; FUNCTIONAL-CHARACTERIZATION; LEPTOMYCIN-B; CRM1; PROTEIN; SIGNAL; TRANSLOCATION; LOCALIZATION; MUTAGENESIS; DOMAIN	Nuclear import of the NF-AT transcription factors during T-cell activation requires the calcium-activated phosphatase calcineurin, which unmasks nuclear-location signals on NF-AT (refs 1-5), We show here that the nuclear import of NF-ATs is not sufficient to activate NF-AT target genes, as NF-ATs are subject to a futile cycling across the nuclear em elope owing to engagement with the exportin protein Crm1 (refs 6-8), Calcineurin suppresses this futile cycling by a non-catalytic mechanism involving the masking of nuclear export signals on NF-AT targeted by Crm1, This clustering of binding sites for calcineurin and Crm1 on NF-AT establishes an inherent competition between these molecules that imparts exquisite calcium sensitivity to the shuttling dynamics of the NF-AT transcription factors. Such a balance between nuclear import and export may regulate the action of other transcription factors.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	McKeon, F (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	frank_mckeon@hms.harvard.edu						Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Costa G L, 1996, Methods Mol Biol, V57, P239; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Liu J, 1997, MOL BIOL CELL, V8, P157, DOI 10.1091/mbc.8.1.157; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Tessier D C, 1996, Methods Mol Biol, V57, P229; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	23	159	167	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	1999	398	6724					256	260		10.1038/18473	http://dx.doi.org/10.1038/18473			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UA	10094050				2022-12-01	WOS:000079228400057
J	Merrill, C; Bayraktaroglu, L; Kusano, A; Ganetzky, B				Merrill, C; Bayraktaroglu, L; Kusano, A; Ganetzky, B			Truncated RanGAP encoded by the Segregation Distorter locus of Drosophila	SCIENCE			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; SD LOCUS; MELANOGASTER; COMPONENTS; RESPONDER	Segregation Distorter (SD) in Drosophila melanogaster is a naturally occurring meiotic drive system in which the SD chromosome is transmitted from SD/SD+ males in vast: excess over its homolog owing to the induced dysfunction of SD+-bearing spermatids. The Sd Locus is the key distorting gene responsible for this phenotype. A genomic fragment from the Sd region conferred full distorting activity when introduced into the appropriate genetic background by germline transformation. The only functional product encoded by this fragment is a truncated version of the RanGAP nuclear transport protein. These results demonstrate that this mutant RanGAP is the functional Sd product.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bayraktaroglu, L (corresponding author), Univ Wisconsin, Genet Lab, 445 Henry Mall, Madison, WI 53706 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRITTNACHER JG, 1983, GENETICS, V103, P659; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Dasso M, 1998, AM J HUM GENET, V63, P311, DOI 10.1086/301990; GANETZKY B, 1977, GENETICS, V86, P321; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HARTL DL, 1974, GENETICS, V76, P477; HIRAIZUMI Y, 1980, GENETICS, V95, P693; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; LYTTLE TW, 1993, TRENDS GENET, V9, P205, DOI 10.1016/0168-9525(93)90120-7; LYTTLE TW, 1991, ANNU REV GENET, V25, P511, DOI 10.1146/annurev.ge.25.120191.002455; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; MCLEAN JR, 1994, GENETICS, V137, P201; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PIMPINELLI S, 1989, GENETICS, V121, P765; POWERS PA, 1991, GENETICS, V129, P133; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; SANDLER L, 1960, GENETICS, V45, P1269; TEMIN RG, 1991, AM NAT, V137, P287, DOI 10.1086/285164; TOKUYASU KT, 1977, J ULTRA MOL STRUCT R, V58, P96, DOI 10.1016/S0022-5320(77)80011-7; WU CI, 1988, CELL, V54, P179, DOI 10.1016/0092-8674(88)90550-8	23	110	113	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	1999	283	5408					1742	1745		10.1126/science.283.5408.1742	http://dx.doi.org/10.1126/science.283.5408.1742			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175PF	10073941				2022-12-01	WOS:000079102800054
J	Hingorani, M; Wong, T; Vafidis, G				Hingorani, M; Wong, T; Vafidis, G			Patients' and doctors' attitudes to amount of information given after unintended injury during treatment: cross sectional questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Cent Middlesex Hosp, Cent Eye Unit, London NW10 7NS, England	Imperial College London	Hingorani, M (corresponding author), Cent Middlesex Hosp, Cent Eye Unit, London NW10 7NS, England.							BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; *GEN MED COUNC, 1998, GOOD MED PRACT; LAURANCE J, 1998, INDEPENDENT     0520, P5; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; VINCENT C, 1994, LANCET, V343, P1609, DOI 10.1016/S0140-6736(94)93062-7	5	78	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					640	641		10.1136/bmj.318.7184.640	http://dx.doi.org/10.1136/bmj.318.7184.640			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066205	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000079089200028
J	Cash, J; Boyd, K				Cash, J; Boyd, K			Blood transfusion: Bayer's initiative	LANCET			English	Editorial Material									Univ Edinburgh, Royal Infirm, Dept Med, Edinburgh EH3 9YW, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh	Cash, J (corresponding author), Otterburn Pk, Edinburgh EH14 1JX, Midlothian, Scotland.							AACH RD, 1980, ANN INTERN MED, V92, P539, DOI 10.7326/0003-4819-92-4-539; ALTER HJ, 1988, VIRAL HEPATITIS LIVE, P537; Busch M P, 1994, Curr Opin Hematol, V1, P438; *DAN COUNC ETH, 1998, 1977 ANN REP; *NUFF COUNC BIOETH, 1998, MENT DIS ETH ETH CON	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 27	1999	353	9154					691	692		10.1016/S0140-6736(98)90048-4	http://dx.doi.org/10.1016/S0140-6736(98)90048-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DR	10073509				2022-12-01	WOS:000078966400007
J	Foote, M; Hunter, JP; Janis, CM; Sepkoski, JJ				Foote, M; Hunter, JP; Janis, CM; Sepkoski, JJ			Evolutionary and preservational constraints on origins of biologic groups: Divergence times of eutherian mammals	SCIENCE			English	Article							STRATIGRAPHIC RANGES; MOLECULAR-CLOCK; FOSSIL PRESERVATION; ANGIOSPERM ORIGINS; ANIMAL PHYLA; PHYLOGENY; MONTANA; RECORD; RATES; DNA	Some molecular clack estimates of divergence times of taxonomic groups undergoing evolutionary radiation are much older than the groups' first observed fossil record. Mathematical models of branching evolution are used to estimate the maximal rate of fossil preservation consistent with a postulated missing history, given the sum of species durations implied by early origins under a range of species origination and extinction rates. The plausibility of postulated divergence times depends on origination, extinction, and preservation Fates estimated from the fossil record. For eutherian mammals, this approach suggests that it is unlikely that many modern orders arose much earlier than their oldest fossil records.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; New York Inst Technol, New York Coll Osteopath Med, Old Westbury, NY 11568 USA; Brown Univ, Dept Ecol & Evolut Biol, Providence, RI 02912 USA	University of Chicago; New York Institute Technology; Brown University	Foote, M (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	mfoote@midway.uchicago.edu	Hunter, John/A-2573-2013; Janis, Christine/GPT-3398-2022					Alroy J, 1998, SCIENCE, V280, P731, DOI 10.1126/science.280.5364.731; Archibald JD, 1996, SCIENCE, V272, P1150, DOI 10.1126/science.272.5265.1150; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; Bleiweiss R, 1998, GEOLOGY, V26, P323, DOI 10.1130/0091-7613(1998)026<0323:FGASET>2.3.CO;2; BRITTEN RJ, 1986, SCIENCE, V231, P1393, DOI 10.1126/science.3082006; BUTLER PM, 1990, BIOL REV, V65, P529, DOI 10.1111/j.1469-185X.1990.tb01237.x; BUTLER PM, 1988, PHYLOGENY CLASSIFICA, V2, P117; Carroll RL., 1988, VERTEBRATE PALEONTOL; Cooper A, 1998, TRENDS ECOL EVOL, V13, P151, DOI 10.1016/S0169-5347(97)01277-9; CRANE PR, 1989, NATURE, V342, P131, DOI 10.1038/342131b0; de Jong WW, 1998, TRENDS ECOL EVOL, V13, P270, DOI 10.1016/S0169-5347(98)01335-4; Doyle James A., 1997, American Journal of Botany, V84, P132; Fitch W., 1976, MOL EVOLUTION, P160; Foote M, 1996, PALEOBIOLOGY, V22, P121, DOI 10.1017/S0094837300016134; Foote M, 1996, PALEOBIOLOGY, V22, P141, DOI 10.1017/S0094837300016146; Foote M, 1997, PALEOBIOLOGY, V23, P278, DOI 10.1017/S0094837300019692; FOX RC, 1994, J VERTEBR PALEONTOL, V14, P382, DOI 10.1080/02724634.1994.10011566; FOX RC, 1984, CARNEGIE MUS NAT HIS, V9, P9; Gheerbrant E, 1996, NATURE, V383, P68, DOI 10.1038/383068a0; GILLESPIE JH, 1984, P NATL ACAD SCI-BIOL, V81, P8009, DOI 10.1073/pnas.81.24.8009; GILLESPIE JH, 1986, MOL BIOL EVOL, V3, P138; GILLESPIE JH, 1986, GENETICS, V113, P1077; GINGERICH PD, 1986, MOL BIOL EVOL, V3, P205; GOODWIN MB, 1989, CAN J EARTH SCI, V26, P1384, DOI 10.1139/e89-118; GRADSTEIN FM, GEOCHRONOLOGY TIME S, P95; Harland W.B., 1990, GEOLOGIC TIME SCALE; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Hitchin R, 1997, PALEOBIOLOGY, V23, P20, DOI 10.1017/S0094837300016626; HUELSENBECK JP, 1994, PALEOBIOLOGY, V20, P470, DOI 10.1017/S009483730001294X; Jacobs L.L., 1998, EVOLUTION TERTIARY M; KENDALL DG, 1948, ANN MATH STAT, V19, P1, DOI 10.1214/aoms/1177730285; KIMURA M, 1987, J MOL EVOL, V26, P24, DOI 10.1007/BF02111279; KRISHTALKA L, 1979, MILWAUKEE PUBL MUS C, V27, P1; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lillegraven J.A., 1972, Contributions Sci, VNo. 232, P1; Lillegraven J. A., 1990, GEOLOGICAL SOC AM SP, P1, DOI DOI 10.1130/SPE243-P1; MARSHALL CR, 1990, PALEOBIOLOGY, V16, P1, DOI 10.1017/S0094837300009672; Marshall CR, 1999, GEOLOGY, V27, P95, DOI 10.1130/0091-7613(1999)027<0095:FGASET>2.3.CO;2; MARTIN W, 1989, NATURE, V339, P46, DOI 10.1038/339046a0; MARTIN W, 1993, MOL BIOL EVOL, V10, P140; McKenna MC, 1997, CLASSIFICATION MAMMA; Messer Michael, 1998, Journal of Mammalian Evolution, V5, P95, DOI 10.1023/A:1020523120739; MIYAMOTO MM, 1995, MOL BIOL EVOL, V12, P503; Nessov Lev A., 1998, Bulletin of Carnegie Museum of Natural History, V34, P40; NORELL MA, 1992, SCIENCE, V255, P1690, DOI 10.1126/science.255.5052.1690; Normile D, 1998, SCIENCE, V281, P774, DOI 10.1126/science.281.5378.774; Novacek M.J., 1976, Contributions Sci Los Angeles, VNo. 283, P1; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Patzkowsky ME, 1995, PALEOBIOLOGY, V21, P440, DOI 10.1017/S0094837300013476; RAUP DM, 1985, PALEOBIOLOGY, V11, P42, DOI 10.1017/S0094837300011386; RAUP DM, 1978, PALEOBIOLOGY, V4, P1; RAUP DM, 1983, P NATL ACAD SCI-BIOL, V80, P2981, DOI 10.1073/pnas.80.10.2981; RAUP DM, 1991, PALEOBIOLOGY, V17, P37, DOI 10.1017/S0094837300010332; RAUP DM, 1983, PALEOBIOLOGY, V9, P107, DOI 10.1017/S0094837300007491; RAUP DM, 1986, RATES EVOLUTION, P1; ROGERS RR, 1993, CAN J EARTH SCI, V30, P1066, DOI 10.1139/e93-090; RUNNEGAR B, 1982, LETHAIA, V15, P199, DOI 10.1111/j.1502-3931.1982.tb00645.x; Sanderson MJ, 1997, MOL BIOL EVOL, V14, P1218, DOI 10.1093/oxfordjournals.molbev.a025731; Seilacher A, 1998, SCIENCE, V282, P80, DOI 10.1126/science.282.5386.80; Shoshani J, 1998, MOL PHYLOGENET EVOL, V9, P572, DOI 10.1006/mpev.1998.0520; Solow AR, 1997, PALEOBIOLOGY, V23, P271, DOI 10.1017/S0094837300019680; Springer Mark S., 1997, Journal of Mammalian Evolution, V4, P285, DOI 10.1023/A:1027378615412; Springer MS, 1997, NATURE, V388, P61, DOI 10.1038/40386; Stanhope MJ, 1998, P NATL ACAD SCI USA, V95, P9967, DOI 10.1073/pnas.95.17.9967; Stanhope MJ, 1998, MOL PHYLOGENET EVOL, V9, P501, DOI 10.1006/mpev.1998.0517; Stanley S.M., 1990, P103; Stanley S. M., 1979, MACROEVOLUTION; STANLEY SM, 1985, PALEOBIOLOGY, V11, P13, DOI 10.1017/S0094837300011362; STRATHMANN RR, 1983, PALEOBIOLOGY, V9, P97, DOI 10.1017/S009483730000748X; STUCKY RK, 1993, FOSS REC, V2, P739; SWISHER CC, 1993, CAN J EARTH SCI, V30, P1981, DOI 10.1139/e93-174; SYSTMA KJ, 1996, FLOWERING PLANT ORIG, P314; Van Valen L., 1973, EVOL THEORY, V1, P1, DOI DOI 10.1038/344864A0; VANVALEN LM, 1985, EVOL THEOR, V7, P127; WAGNER PJ, 1995, PALEOBIOLOGY, V21, P153, DOI 10.1017/S009483730001318X; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; Yule G. V., 1924, Philosophical Transactions of the Royal Society London B, V213, P21; ZUCKERKANDL EMILE, 1965, P97; [No title captured]	81	202	208	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1310	1314		10.1126/science.283.5406.1310	http://dx.doi.org/10.1126/science.283.5406.1310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037598				2022-12-01	WOS:000078839900037
J	Scholich, K; Mullenix, JB; Wittpoth, C; Poppleton, HM; Pierre, SC; Lindorfer, MA; Garrison, JC; Patel, TB				Scholich, K; Mullenix, JB; Wittpoth, C; Poppleton, HM; Pierre, SC; Lindorfer, MA; Garrison, JC; Patel, TB			Facilitation of signal onset and termination by adenylyl cyclase	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEINS; ALPHA-SUBUNITS; PURIFICATION; DOMAINS; ENZYME; FAMILY; SYSTEM; GAIP; RGS4; BETA	The alpha subunit (G(5 alpha)) of the stimulatory heterotrimeric guanosine triphosphate binding protein (G protein) G(s) activates all isoforms of mammalian adenylyl cyclase. Adenylyl cyclase (Type V) and its subdomains, which interact with G(5 alpha), promoted inactivation of the G protein by increasing its guanosine triphosphatase (GTPase) activity. Adenylyl cyclase and its subdomains also augmented the receptor-mediated activation of heterotrimeric G, and thereby facilitated the rapid onset of signaling. These findings demonstrate that adenylyl cyclase functions as a GTPase activating protein (GAP) for the monomeric G(5 alpha) and enhances the GTP/GDP exchange factor (EF) activity of receptors.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Virginia	Patel, TB (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	tpatel@physio1.utmem.edu			NHLBI NIH HHS [HL48308, HL59679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679, R01HL048308] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERNSTEIN G, 1992, CELL, V70, P411; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; SCHOLICH K, UNPUB; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621	26	58	59	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1999	283	5406					1328	1331		10.1126/science.283.5406.1328	http://dx.doi.org/10.1126/science.283.5406.1328			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037603				2022-12-01	WOS:000078839900042
J	Yanagisawa, J; Yanagi, Y; Masuhiro, Y; Suzawa, M; Watanabe, M; Kashiwagi, K; Toriyabe, T; Kawabata, M; Miyazono, K; Kato, S				Yanagisawa, J; Yanagi, Y; Masuhiro, Y; Suzawa, M; Watanabe, M; Kashiwagi, K; Toriyabe, T; Kawabata, M; Miyazono, K; Kato, S			Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators	SCIENCE			English	Article							D ENDOCRINE SYSTEM; NUCLEAR-RECEPTOR; MAD PROTEINS; HISTONE ACETYLTRANSFERASE; SUPERFAMILY; ACTIVATION; BINDING; PHOSPHORYLATION; METABOLISM; CBP/P300	Cell proliferation and differentiation are regulated by growth regulatory factors such as transforming growth factor-beta (TGF-beta) and the liphophilic hormone vitamin D. TGF-beta causes activation of SMAD proteins acting as coactivators or transcription factors in the nucleus. Vitamin D controls transcription of target genes through the vitamin D receptor (VDR). Smad3, one of the SMAD proteins downstream in the TGF-beta signaling pathway, was found in mammalian cells to act as a coactivator specific for Ligand-induced transactivation of VDR by forming a complex with a member of the steroid receptor coactivator-l protein family in the nucleus. Thus, Smad3 may mediate cross-talk between vitamin D and TGF-beta signaling pathways.	Japan Sci & Technol, CREST, Kawaguchi, Saitama 332, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japan Soc Promot Sci, Res Future Program, Toshima Ku, Tokyo 1708455, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science	Kato, S (corresponding author), Japan Sci & Technol, CREST, 4-1-8 Honcho, Kawaguchi, Saitama 332, Japan.	uskato@hongo.ecc.u-tokyo.ac.jp	Yanagi, Yasuo/AAF-2670-2020					Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; DeLuca H F, 1986, Adv Exp Med Biol, V196, P361; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; KAMEL Y, 1997, CELL, V85, P403; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATO S, 1995, MOL CELL BIOL, V15, P5858; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; ONATE SA, 1995, SCIENCE, V270, P1354; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STERN PH, 1997, VITAMIN D, P343; SUZUKI A, 1997, DEV BIOL, V184, P207; Takeshita A, 1998, J BIOL CHEM, V273, P14738, DOI 10.1074/jbc.273.24.14738; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YANAGISAWA J, UNPUB; YAO T, 1997, P NATL ACAD SCI USA, V93, P10626; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	44	390	409	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1317	1321		10.1126/science.283.5406.1317	http://dx.doi.org/10.1126/science.283.5406.1317			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037600				2022-12-01	WOS:000078839900039
J	Zhu, BP; Rolfs, RT; Nangle, BE; Horan, JM				Zhu, BP; Rolfs, RT; Nangle, BE; Horan, JM			Effect of the interval between pregnancies on perinatal outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	31st Annual Meeting of the Society-for-Epidemiological-Research	JUN 24-26, 1998	CHICAGO, IL	Soc Epidemiol Res			BIRTH-WEIGHT; INTERPREGNANCY INTERVAL; GESTATIONAL-AGE; MORTALITY; RISK	Background A short interval between pregnancies has been associated with adverse perinatal outcomes. Whether that association is due to confounding by other risk factors, such as maternal age, socioeconomic status, and reproductive history, is unknown. Methods We evaluated the interpregnancy interval in relation to low birth weight, preterm birth, and small size for gestational age by analyzing data from the birth certificates of 173,205 singleton infants born alive to multiparous mothers in Utah from 1989 to 1996. Results Infants conceived 18 to 23 months after a previous live birth had the lowest risks of adverse perinatal outcomes; shorter and longer interpregnancy intervals were associated with higher risks. These associations persisted when the data were stratified according to and controlled for 16 biologic, sociodemographic, and behavioral risk factors. As compared with infants conceived 18 to 23 months after a live birth, infants conceived less than 6 months after a live birth had odds ratios of 1.4 (95 percent confidence interval, 1.3 to 1.6) for low birth weight, 1.4 (95 percent confidence interval, 1.3 to 1.5) for preterm birth, and 1.3 (95 percent confidence interval, 1.2 to 1.4) for small size for gestational age; infants conceived 120 months or more after a live birth had odds ratios of 2.0 (95 percent confidence interval, 1.7 to 2.4), 1.5 (95 percent confidence interval, 1.3 to 1.7), and 1.8 (95 percent confidence interval, 1.6 to 2.0) for these three adverse outcomes, respectively, when we controlled for all 16 risk factors with logistic regression. Conclusions The optimal interpregnancy interval for preventing adverse perinatal outcomes is 18 to 23 months. (N Engl J Med 1999;340:589-94.) (C)1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA USA; Utah Dept Hlth, Off Publ Hlth Data, Salt Lake City, UT 84116 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Zhu, BP (corresponding author), Michigan Dept Community Hlth, Div Epidemiol Serv, 3423 Martin Luther King Jr Blvd, Lansing, MI 48909 USA.	zhub@state.mi.us		Zhu, Baoping/0000-0003-0065-0153				Adams MM, 1997, PAEDIATR PERINAT EP, V11, P48, DOI 10.1046/j.1365-3016.11.s1.8.x; ALEXANDER GR, 1995, PUBLIC HEALTH REP, V110, P395; [Anonymous], 1985, PREV LOW BIRTHW; Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; *BUR SURV AN, 1998, OV 1996 HLTH STAT SU, P64; COPPER RL, 1993, AM J OBSTET GYNECOL, V168, P78, DOI 10.1016/S0002-9378(12)90889-3; DOUGLAS JWB, 1950, J OBSTET GYN BRIT EM, V57, P143; Eastman NJ, 1944, AM J OBSTET GYNECOL, V47, P445, DOI 10.1016/S0002-9378(15)32197-9; ERICKSON JD, 1978, J EPIDEMIOL COMMUN H, V32, P124, DOI 10.1136/jech.32.2.124; FEDRICK J, 1973, BMJ-BRIT MED J, V4, P753, DOI 10.1136/bmj.4.5895.753; Fleiss J.L., 1981, STAT METHODS RATES P; FREEMAN JM, 1985, NIH PUBLICATION; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; Illsley R, 1984, LOW BIRTH WEIGHT MED; Klerman LV, 1998, AM J PUBLIC HEALTH, V88, P1182, DOI 10.2105/AJPH.88.8.1182; LANG JM, 1990, AM J EPIDEMIOL, V132, P304, DOI 10.1093/oxfordjournals.aje.a115659; MACDORMAN MF, 1998, MON VITAL STAT REP S, V46; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MILLER JE, 1991, FAM PLANN PERSPECT, V23, P62, DOI 10.2307/2135451; NELSON WE, 1996, NELSON TXB PEDIAT, P454; Resnik R., 1984, MATERNAL FETAL MED P, P141; VENTURA SJ, 1997, MON VITAL STAT REP S, V45; WINKVIST A, 1992, AM J PUBLIC HEALTH, V82, P691, DOI 10.2105/AJPH.82.5.691; WOODBURY RM, 1925, CHILDRENS BUREAU PUB, V142; Yerushalmy J., 1945, HUMAN BIOL, V17, P65	26	338	348	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					589	594		10.1056/NEJM199902253400801	http://dx.doi.org/10.1056/NEJM199902253400801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	169NP	10029642				2022-12-01	WOS:000078755700001
J	Lupoli, G; Vitale, G; Caraglia, M; Fittipaldi, MR; Abbruzzese, A; Tagliaferri, P; Bianco, AR				Lupoli, G; Vitale, G; Caraglia, M; Fittipaldi, MR; Abbruzzese, A; Tagliaferri, P; Bianco, AR			Familial papillary thyroid microcarcinoma: a new clinical entity	LANCET			English	Article							WARRANTS AGGRESSIVE TREATMENT; EMERGING ENTITY; FOLLOW-UP; CARCINOMA; CANCER	Background Familial, non-medullary thyroid carcinoma is clinically more aggressive than the sporadic form. Mle wanted to find out whether papillary thyroid microcarcinoma also occurs in a familiar pattern, and, if so, to identify specific clinical and prognostic features. Methods We reviewed the clinical records of 119 patients with papillary thyroid microcarcinoma. Familial occurrence, together with clinical presentation, surgical treatment, pathological characteristics, and follow-up were recorded. Findings We identified a family history of thyroid carcinoma in seven patients. The tumour was multifocal in five patients, bilateral in three, and vascular invasion occurred in three of the seven patients. Lymph-node metastases were found in four patients. Three patients had a recurrence and one patient with pulmonary metastases died within 11 months. Interpretation We identified familial occurrence in 5.9% of cases of papillary thyroid microcarcinoma. The unfavourable behaviour in the familal form of papillary thyroid microcarcinoma suggests that radical treatment and careful follow-up are warranted.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Endocrinol & Oncol Mol & Clin, Naples, Italy; Univ Naples 2, Dipartimento Biochim & Biofis, Naples, Italy	University of Naples Federico II; Universita della Campania Vanvitelli	Lupoli, G (corresponding author), Via E Nicolardi 145,Pco Arcadia 8, I-80131 Naples, Italy.		Vitale, Giovanni/B-6548-2008; Caraglia, Michele/AAK-4569-2020; Caraglia, Michele/AFY-9729-2022; Caraglia, Michele/N-5670-2015; Tagliaferri, Pierosandro/K-9546-2016	Vitale, Giovanni/0000-0003-2478-683X; Caraglia, Michele/0000-0003-2408-6091; Caraglia, Michele/0000-0003-2408-6091; Caraglia, Michele/0000-0003-2408-6091; Lupoli, Giovanni/0000-0001-5278-380X				ALM T, 1973, CLIN GASTROENTEROL, V2, P577; Fagin JA, 1997, J CLIN ENDOCR METAB, V82, P342, DOI 10.1210/jc.82.2.342; FISHER DK, 1989, CANC INVEST, V7, P323; GROSSMAN RF, 1995, ARCH SURG-CHICAGO, V130, P892; HAY ID, 1992, SURGERY, V112, P1139; Hedinger C, 1988, INT HISTOLOGICAL CLA, P9; HRAFNKELSSON J, 1989, ACTA ONCOL, V28, P785, DOI 10.3109/02841868909092308; KOBAYASHI K, 1995, J SURG ONCOL, V58, P274, DOI 10.1002/jso.2930580415; Kupelian PA, 1997, J CLIN ONCOL, V15, P1478, DOI 10.1200/JCO.1997.15.4.1478; KWOK CG, 1995, THYROID, V5, P395, DOI 10.1089/thy.1995.5.395; Loh KC, 1997, THYROID, V7, P107, DOI 10.1089/thy.1997.7.107; LOTE K, 1980, CANCER, V46, P1291, DOI 10.1002/1097-0142(19800901)46:5<1291::AID-CNCR2820460534>3.0.CO;2-Q; MAZZAFERRI EL, 1981, AM J MED, V70, P511, DOI 10.1016/0002-9343(81)90573-8; Noguchi S, 1996, ARCH SURG-CHICAGO, V131, P187; OZAKI O, 1988, WORLD J SURG, V12, P565, DOI 10.1007/BF01655453; PLAIL RO, 1987, BRIT J SURG, V74, P377, DOI 10.1002/bjs.1800740517; RON E, 1991, ONCOLOGY, V48, P309; SCHNEIDER AB, 1996, THYROID, P902; STOFFER SS, 1986, AM J MED GENET, V25, P775, DOI 10.1002/ajmg.1320250415; Takami H, 1996, ARCH SURG-CHICAGO, V131, P676	20	140	145	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					637	639		10.1016/S0140-6736(98)08004-0	http://dx.doi.org/10.1016/S0140-6736(98)08004-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030330				2022-12-01	WOS:000078818200014
J	Bao, ZZ; Bruneau, BG; Seidman, JG; Seidman, CE; Cepko, CL				Bao, ZZ; Bruneau, BG; Seidman, JG; Seidman, CE; Cepko, CL			Regulation of chamber-specific gene expression in the developing heart by Irx4	SCIENCE			English	Article							MYOSIN HEAVY-CHAIN; CAUPOLICAN; LINEAGES; ARAUCAN; EYE	The vertebrate heart consists of two types of chambers, the atria and the ventricles, which differ in their contractile and electrophysiological properties. Little is known of the molecular mechanisms by which these chambers are specified during embryogenesis. Here a chicken iroquois-related homeobox gene, lrx4, was identified that has a ventricle-restricted expression pattern at all stages of heart development. lrx4 protein was shown to regulate the chamber-specific expression of myosin isoforms by activating the expression of the ventricle myosin heavy chain-1 (VMHC1) and suppressing the expression of the atrial myosin heavy chain-1 (AMHC1) in the ventricles. Thus, lrx4 may play a critical role in establishing chamber-specific gene expression in the developing heart.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital	Cepko, CL (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 200 Longwood Ave, Boston, MA 02115 USA.			Bruneau, Benoit/0000-0002-0804-7597				BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BAO Z, UNPUB; Bao ZZ, 1997, J NEUROSCI, V17, P1425; Bellefroid EJ, 1998, EMBO J, V17, P191, DOI 10.1093/emboj/17.1.191; BELLEFROID EJ, 1998, EMBO J, P181; BISAHA JG, 1991, DEV BIOL, V148, P355, DOI 10.1016/0012-1606(91)90343-2; BRUNEAU BG, UNPUB; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Conlon FL, 1996, DEVELOPMENT, V122, P2427; DEHAAN RL, 1965, ORGANOGENESIS, P377; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; GomezSkarmeta JL, 1996, GENE DEV, V10, P2935, DOI 10.1101/gad.10.22.2935; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; Gruber PJ, 1998, DEVELOPMENT, V125, P4427; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; LYONS GE, 1994, TRENDS CARDIOVAS MED, V3, P184; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; Mikawa T, 1996, ANNU REV PHYSIOL, V58, P509, DOI 10.1146/annurev.ph.58.030196.002453; Pawloski-Dahm CM, 1998, CIRCULATION, V97, P1508; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SATIN J, 1988, DEV BIOL, V129, P103, DOI 10.1016/0012-1606(88)90165-0; STAINIER DYR, 1993, DEVELOPMENT, V119, P31; Wang GF, 1998, MOL CELL BIOL, V18, P6023, DOI 10.1128/MCB.18.10.6023; Wang GF, 1996, J BIOL CHEM, V271, P19836, DOI 10.1074/jbc.271.33.19836; YELON D, UNPUB; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; YUTZEY KE, 1995, DEV BIOL, V170, P531, DOI 10.1006/dbio.1995.1234; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	31	183	205	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1161	1164		10.1126/science.283.5405.1161	http://dx.doi.org/10.1126/science.283.5405.1161			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024241				2022-12-01	WOS:000078738400050
J	Piper, DE; Batchelor, AH; Chang, CP; Cleary, ML; Wolberger, C				Piper, DE; Batchelor, AH; Chang, CP; Cleary, ML; Wolberger, C			Structure of a HoxB1-Pbx1 heterodimer bound to DNA: Role of the hexapeptide and a fourth homeodomain helix in complex formation	CELL			English	Article							CRYSTAL-STRUCTURE; BINDING SPECIFICITY; HOX PROTEINS; TRANSCRIPTIONAL ACTIVATOR; ENGRAILED HOMEODOMAIN; SECONDARY STRUCTURE; HOMEOBOX GENES; PBX PROTEINS; PRE-B; EXTRADENTICLE	Hox homeodomain proteins are developmental regulators that determine body plan in a variety of organisms. A majority of the vertebrate Hox proteins bind DNA as heterodimers with the Pbx1 homeodomain protein. We report here the 2.35 Angstrom structure of a ternary complex containing a human HoxB1-Pbx1 heterodimer bound to DNA. Heterodimer contacts are mediated by the hexapeptide of HoxB1, which binds in a pocket in the Pbx1 protein formed in part by a three-amino acid insertion in the Pbx1 homeodomain. The Pbx1 DNA-binding domain is larger than the canonical homeodomain, containing an additional alpha helix that appears to contribute to binding of the HoxB1 hexapeptide and to stable binding of Pbx1 to DNA. The structure suggests a model for modulation of Hox DNA binding activity by Pbx1 and related proteins.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Stanford University	Wolberger, C (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.	cwolberg@jhmi.edu		Wolberger, Cynthia/0000-0001-8578-2969	NATIONAL CANCER INSTITUTE [R37CA042971, R01CA042971] Funding Source: NIH RePORTER; NCI NIH HHS [CA42971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CLARKE ND, 1994, PROTEIN SCI, V3, P1779, DOI 10.1002/pro.5560031018; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; COX M, 1995, J BIOMOL NMR, V6, P23, DOI 10.1007/BF00417488; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fraenkel E, 1998, J MOL BIOL, V284, P351, DOI 10.1006/jmbi.1998.2147; Fraenkel E, 1998, NAT STRUCT BIOL, V5, P692, DOI 10.1038/1382; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; Green NC, 1998, J BIOL CHEM, V273, P13273, DOI 10.1074/jbc.273.21.13273; Grieder NC, 1997, EMBO J, V16, P7402, DOI 10.1093/emboj/16.24.7402; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; MACONOCHIE MK, 1997, GENE DEV, V11, P1883; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OTINOWSKI Z, 1996, METHOD ENZYMOL, V276, P307; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QIAN YQ, 1993, J MOL BIOL, V234, P1070, DOI 10.1006/jmbi.1993.1660; QIAN YQ, 1992, P NATL ACAD SCI USA, V89, P10738, DOI 10.1073/pnas.89.22.10738; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; TuckerKellogg L, 1997, STRUCTURE, V5, P1047, DOI 10.1016/S0969-2126(97)00256-6; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	62	269	276	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					587	597		10.1016/S0092-8674(00)80662-5	http://dx.doi.org/10.1016/S0092-8674(00)80662-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052460	Bronze			2022-12-01	WOS:000078718600009
J	O'Connor, S; Deeks, O; Hawton, K; Simkin, S; Keen, A; Altman, DG; Philo, G; Bulstrode, C				O'Connor, S; Deeks, O; Hawton, K; Simkin, S; Keen, A; Altman, DG; Philo, G; Bulstrode, C			Effects of a drug overdose in a television drama on knowledge of specific dangers of self poisoning: population based surveys	BRITISH MEDICAL JOURNAL			English	Article									Barrow Hosp, Directorate Mental Hlth, United Bristol Healthcare Trust, Bristol BS19 3SG, Avon, England; Imperial Canc Res Fund, NHS Ctr Stat Med, Inst Hlth Sci, Oxford OX3 7LF, England; Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Orthopaed Surg, Oxford OX3 9DU, England; Univ Glasgow, Media Unit, Glasgow G12 8LF, Lanark, Scotland	University of Oxford; University of Oxford; University of Oxford; University of Glasgow	O'Connor, S (corresponding author), Barrow Hosp, Directorate Mental Hlth, United Bristol Healthcare Trust, Bristol BS19 3SG, Avon, England.		Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971				BRAY GP, 1993, BRIT MED J, V306, P157, DOI 10.1136/bmj.306.6871.157; Gunnell D., 1994, BMJ-BRIT MED J, V308, P1446, DOI DOI 10.1136/BMJ.308.6941.1446; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Hawton K, 1999, BRIT MED J, V318, P972, DOI 10.1136/bmj.318.7189.972	4	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					978	979		10.1136/bmj.318.7189.978	http://dx.doi.org/10.1136/bmj.318.7189.978			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195968	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000079751500020
J	Keating, NL; Cleary, PD; Rossi, AS; Zaslavsky, AM; Ayanian, JZ				Keating, NL; Cleary, PD; Rossi, AS; Zaslavsky, AM; Ayanian, JZ			Use of hormone replacement therapy by postmenopausal women in the United States	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	20th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med		estrogen replacement therapy; demography; socioeconomic factors; educational status; hysterectomy	NUTRITION EXAMINATION SURVEY; CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; CARDIOVASCULAR-DISEASE; RANCHO-BERNARDO; NATIONAL-HEALTH; RISK; OSTEOPOROSIS; PROGESTIN; DETERMINANTS	Background: The benefits and risks of hormone replacement therapy (HRT) in postmenopausal women are not fully defined, and individual characteristics and preferences may influence decisions to use this therapy. Previous studies of postmenopausal women who use HRT have been conducted in local or highly selected cohorts or have not focused on current use. Objective: To examine sociodemographic, clinical, and psychological factors associated with current use of HRT in a national population-based cohort. Design: Random-digit telephone survey. Setting: Probability sample of U.S. households with a telephone. Participants: 495 postmenopausal women 50 to 74 years of age in 1995. Measurements: Current use of HRT. Results: Current use of HRT was reported by 37.6% of women (58.7% of those who underwent hysterectomy and 19.6% of those who did not undergo hysterectomy; P = 0.001). In multivariable analyses, use of HRT was more common among women in the South (adjusted odds ratio, 2.67 [95% CI, 1.08 to 6.59]) and West (odds ratio, 2.76 [CI, 1.01 to 7.53]) than the Northeast. Use was more common among college graduates (odds ratio, 3.72 [CI, 1.29 to 10.71]) and less common among women with diabetes mellitus (odds ratio, 0.17 [CI, 0.05 to 0.51]). Other cardiac risk factors and most psychological characteristics were not associated with HRT use. Conclusions: Sociodemographic factors, such as region and education, may be more strongly associated with use of HRT than clinical factors, such as risk for cardiovascular disease. Future efforts should focus on understanding sociodemographic variations, defining which women are most likely to benefit, and targeting therapy to them.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Massachusetts, Amherst, MA 01003 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Massachusetts System; University of Massachusetts Amherst	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.		Cleary, Paul/AAF-7048-2019; Keating, Nancy L/I-9968-2019	Keating, Nancy L/0000-0002-8274-4681				[Anonymous], 1987, BRIT MED J, V295, P914; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BARSKY AJ, 1988, PSYCHOSOM MED, V50, P510, DOI 10.1097/00006842-198809000-00007; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; Bem S.L., 1981, MENTAL MEASUREMENTS; Brett KM, 1997, AM J EPIDEMIOL, V145, P536; Brinton LA, 1997, NEW ENGL J MED, V336, P1821, DOI 10.1056/NEJM199706193362509; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; Col N. F., 1997, JGIM, V12, P60; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Connelly M. T., 1997, JGIM, V12, P126; DERBY CA, 1993, AM J EPIDEMIOL, V137, P1125, DOI 10.1093/oxfordjournals.aje.a116616; Dunn LB, 1997, ARCH DERMATOL, V133, P339, DOI 10.1001/archderm.133.3.339; EGELAND GM, 1991, PREV MED, V20, P343, DOI 10.1016/0091-7435(91)90033-Z; EGELAND GM, 1988, PREV MED, V17, P403, DOI 10.1016/0091-7435(88)90039-4; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; Ford ES, 1998, J CLIN EPIDEMIOL, V51, P55, DOI 10.1016/S0895-4356(97)00225-4; FOWLER FJ, 1993, SURVEY RES METHODS, P40; FRANE J, 1989, SUDAAN PROFESSIONAL; Goldberg L.R., 1992, PSYCHOL ASSESSMENT, V4, P26, DOI [10.1037/1040-3590.4.1.26, DOI 10.1037/1040-3590.4.1.26]; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; GREENDALE GA, 1990, J GEN INTERN MED, V5, P464, DOI 10.1007/BF02600870; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Handa VL, 1996, J AM GERIATR SOC, V44, P1; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; Heitjan DF, 1997, AM J PUBLIC HEALTH, V87, P548, DOI 10.2105/AJPH.87.4.548; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; John O. P., 1990, HDB PERSONALITY THEO; KJERULFF K, 1993, AM J PUBLIC HEALTH, V83, P106, DOI 10.2105/AJPH.83.1.106; LEAPE LL, 1992, ANNU REV PUBL HEALTH, V13, P363, DOI 10.1146/annurev.publhealth.13.1.363; Levy P., 1991, SAMPLING POPULATIONS; MANTEL N, 1959, J NATL CANCER I, V22, P719; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; Matthews KA, 1996, AM J EPIDEMIOL, V143, P983; McNagny SE, 1997, ANN INTERN MED, V127, P1093, DOI 10.7326/0003-4819-127-12-199712150-00007; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; Newton KM, 1997, J WOMENS HEALTH, V6, P459, DOI 10.1089/jwh.1997.6.459; Persson I, 1997, J CLIN EPIDEMIOL, V50, P611, DOI 10.1016/S0895-4356(97)00004-8; POKRAS R, 1988, AM J PUBLIC HEALTH, V78, P852, DOI 10.2105/AJPH.78.7.852; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Rose G.A., 1982, CARDIOVASCULAR SURVE; Rossouw J E, 1995, J Am Med Womens Assoc (1972), V50, P50; Rubin D., 1978, P SURVEY RES METHODS, V1, P20, DOI DOI 10.1631/JZUS.C10B0359; Rubin D.B., 1987, MULTIPLE IMPUTATION, P1; SCALLEY EK, 1993, J WOMENS HEALTH, V2, P289; Schafer J. L., 1997, ANAL INCOMPLETE MULT, DOI [10.1201/9781439821862, DOI 10.1201/]; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; SCHWARTZ M, 1985, CLIN ORTHOP RELAT R, P180; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; SOLOMON CG, 1996, CIRCULATION S1, V94, P339; Stafford RS, 1997, AM J OBSTET GYNECOL, V177, P381, DOI 10.1016/S0002-9378(97)70202-3; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STANDEVEN M, 1986, AM J EPIDEMIOL, V124, P268, DOI 10.1093/oxfordjournals.aje.a114385; THORNBERRY TO, 1988, TELEPHONE SURVEY MET, P25; TRAPNELL PD, 1990, J PERS SOC PSYCHOL, V59, P781, DOI 10.1037/0022-3514.59.4.781; Wennberg J E, 1984, Health Aff (Millwood), V3, P6, DOI 10.1377/hlthaff.3.2.6; *WHO, 1996, COMP INT DIAGN INT 2; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	69	266	277	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	1999	130	7					545	553		10.7326/0003-4819-130-7-199904060-00002	http://dx.doi.org/10.7326/0003-4819-130-7-199904060-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	183BG	10189323				2022-12-01	WOS:000079533300001
J	Raitakari, OT; Adams, MR; McCredie, RJ; Griffiths, KA; Celermajer, DS				Raitakari, OT; Adams, MR; McCredie, RJ; Griffiths, KA; Celermajer, DS			Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults	ANNALS OF INTERNAL MEDICINE			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; CARDIOVASCULAR-DISEASE; HEART-DISEASE; RISK; ATHEROSCLEROSIS; CHOLESTEROL; DILATATION; MEN	Background: Passive smoking is associated with early arterial damage, but the potential for reversibility of this damage is unknown. objective: To assess the reversibility of arterial endothelial dysfunction, a key marker of early atherosclerosis. Design: Cross-sectional study. Setting: Academic medical center. Participants: 60 healthy persons 15 to 39 years of age: 20 with no exposure to active or passive smoking, 20 nonsmoking passive smokers (exposure to environmental tobacco smoke for greater than or equal to 1 hour per day for greater than or equal to 2 years), and 20 former passive smokers. Measurements: Arterial endothelial function measured by noninvasive ultrasonography. Results: Endothelium-dependent dilatation was significantly better in former passive smokers (5.1% +/- 4.1% [range, -1.2% to 15.6%]) than in current passive smokers (2.3% +/- 2.1% [range, -0.2% to 6.7%]) (P = 0.01), although both groups were significantly impaired compared with nonsmoking controls (8.9% +/- 3.2% [range, 2.1% to 16.7%]) (P less than or equal to 0.01 for both comparisons). Conclusions: In healthy young adults, arterial endothelial dysfunction related to passive smoking seems to be partially reversible.	Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW 2050, Australia; Heart Res Inst, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Univ Turku, Turku, Finland	University of Sydney; University of Sydney; Heart Research Institute; University of Sydney; University of Turku	Celermajer, DS (corresponding author), Royal Prince Alfred Hosp, Dept Cardiol, Missenden Rd, Sydney, NSW 2050, Australia.		Raitakari, Olli/AAQ-7389-2021					Brownson RC, 1997, ANNU REV PUBL HEALTH, V18, P163, DOI 10.1146/annurev.publhealth.18.1.163; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Celermajer DS, 1997, J AM COLL CARDIOL, V30, P325, DOI 10.1016/S0735-1097(97)00189-7; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; DWYER EM, 1989, NEW ENGL J MED, V321, P1474, DOI 10.1056/NEJM198911233212110; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; PENN A, 1993, CIRCULATION, V88, P1820, DOI 10.1161/01.CIR.88.4.1820; PIERCE JP, 1987, J CHRON DIS, V40, P689, DOI 10.1016/0021-9681(87)90105-6; ROSENBERG L, 1985, NEW ENGL J MED, V313, P1511, DOI 10.1056/NEJM198512123132404; SORENSEN KE, 1995, BRIT HEART J, V74, P247; Stefanadis C, 1998, ANN INTERN MED, V128, P426, DOI 10.7326/0003-4819-128-6-199803150-00002; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAYLOR AE, 1992, CIRCULATION, V86, P699, DOI 10.1161/01.CIR.86.2.699; ZHU BQ, 1993, J AM COLL CARDIOL, V21, P225, DOI 10.1016/0735-1097(93)90741-I	19	101	104	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	1999	130	7					578	581		10.7326/0003-4819-130-7-199904060-00017	http://dx.doi.org/10.7326/0003-4819-130-7-199904060-00017			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183BG	10189327				2022-12-01	WOS:000079533300005
J	Wotton, D; Lo, RS; Lee, S; Massague, J				Wotton, D; Lo, RS; Lee, S; Massague, J			A Smad transcriptional corepressor	CELL			English	Article							MAD-RELATED PROTEIN; TGF-BETA RECEPTOR; TUMOR-SUPPRESSOR GENE; FAMILY MEDIATOR SMAD1; TATA-BINDING PROTEIN; GROWTH-FACTOR-BETA; HISTONE DEACETYLASE; SIGNALING PATHWAYS; NUCLEOSOMAL DNA; MOUSE EMBRYO	Following TGF beta receptor-mediated phosphorylation and association with Smad4, Smad2 moves into the nucleus, binds to target promoters in association with DNA-binding cofactors, and recruits coactivators such as p300/CBP to activate transcription. We identified the homeodomain protein TGIF as a Smad2-binding protein and a repressor of transcription. A TGF beta-activated Smad complex can recruit TGIF and histone deacetylases (HDACs) to a Smad target promoter, repressing transcription. Thus, upon entering the nucleus, a Smad2-Smad4 complex may interact with coactivators, forming a transcriptional activation complex, or with TGIF and HDACs, forming a transcriptional repressor complex. Formation of one of these two mutually exclusive complexes is determined by the relative levels of Smad corepressors and coactivators within the cell.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA.	j-massague@ski.mskcc.org		Wotton, David/0000-0002-4652-5350; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA34610] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Whitman M, 1997, NATURE, V389, P549, DOI 10.1038/39202; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang BG, 1997, DYN CONTIN DISCRET I, V3, P89; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	73	466	487	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					29	39		10.1016/S0092-8674(00)80712-6	http://dx.doi.org/10.1016/S0092-8674(00)80712-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199400	Bronze			2022-12-01	WOS:000079843900006
J	Perez, F; Diamantopoulos, GS; Stalder, R; Kreis, TE				Perez, F; Diamantopoulos, GS; Stalder, R; Kreis, TE			CLIP-170 highlights growing microtubule ends in vivo	CELL			English	Article							DYNAMIC INSTABILITY; GOLGI-APPARATUS; MITOTIC SPINDLE; LIVING CELLS; IN-VIVO; STABILIZE MICROTUBULES; BINDING PROTEIN; XENOPUS EGGS; HELA-CELLS; PLUS-END	A chimera with the green fluorescent protein (GFP) has been constructed to visualize the dynamic properties of the endosome-microtubule linker protein CLIP170 (GFP-CLIP170). GFP-CLIP170 binds in stretches along a subset of microtubule ends. These fluorescent stretches appear to move with the growing tips of microtubules at 0.15-0.4 mu m/s, comparable to microtubule elongation in vivo. Analysis of speckles along dynamic GFP-CLIP170 stretches suggests that CLIP170 treadmills on growing microtubule ends, rather than being continuously transported toward these ends. Drugs affecting microtubule dynamics rapidly inhibit movement of GFP-CLIP170 dashes. We propose that GFP-CLIP170 highlights growing microtubule ends by specifically recognizing the structure of a segment of newly polymerized tubulin.	Univ Geneva, Dept Cell Biol Sci 3, CH-1204 Geneva, Switzerland	University of Geneva	Perez, F (corresponding author), Univ Geneva, Dept Cell Biol Sci 3, CH-1204 Geneva, Switzerland.	franck.perez@cellbio.unige.ch	Perez, Franck/A-1558-2014	Perez, Franck/0000-0002-9129-9401				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Andersen SSL, 1997, J CELL BIOL, V139, P975, DOI 10.1083/jcb.139.4.975; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bloom GS, 1998, J CELL BIOL, V140, P1277, DOI 10.1083/jcb.140.6.1277; CAPLOW M, 1992, Current Opinion in Cell Biology, V4, P58, DOI 10.1016/0955-0674(92)90059-L; Caplow M, 1996, MOL BIOL CELL, V7, P663, DOI 10.1091/mbc.7.4.663; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CHAPIN SJ, 1995, BIOCHEMISTRY-US, V34, P2289, DOI 10.1021/bi00007a025; Charrasse S, 1998, J CELL SCI, V111, P1371; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DHAMODHARAN R, 1995, J CELL SCI, V108, P1679; Diamantopoulos GS, 1999, J CELL BIOL, V144, P99, DOI 10.1083/jcb.144.1.99; DRECHSEL DN, 1994, CURR BIOL, V4, P1053, DOI 10.1016/S0960-9822(00)00243-8; Dujardin D, 1998, J CELL BIOL, V141, P849, DOI 10.1083/jcb.141.4.849; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GEIGER B, 1982, J CELL BIOL, V95, P137, DOI 10.1083/jcb.95.1.137; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; Lewis SA, 1997, TRENDS CELL BIOL, V7, P479, DOI 10.1016/S0962-8924(97)01168-9; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; MIMIN AA, 1997, J CELL SCI, V110, P2495; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PIERRE P, 1994, J CELL SCI, V107, P1909; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; Severin FF, 1997, NATURE, V388, P888, DOI 10.1038/42270; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; SIMON JR, 1990, J CELL SCI, V96, P571; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; VALE RD, 1999, IN PRESS GUIDEBOOK C; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Waterman-Storer CM, 1998, BIOPHYS J, V75, P2059, DOI 10.1016/S0006-3495(98)77648-9; Waterman-Storer CM, 1998, CURR BIOL, V8, P798, DOI 10.1016/S0960-9822(98)70321-5; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wilson Leslie, 1994, V13, P59	60	310	315	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 19	1999	96	4					517	527		10.1016/S0092-8674(00)80656-X	http://dx.doi.org/10.1016/S0092-8674(00)80656-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052454	Bronze			2022-12-01	WOS:000078718600003
J	Christoforidis, S; McBride, HM; Burgoyne, RD; Zerial, M				Christoforidis, S; McBride, HM; Burgoyne, RD; Zerial, M			The Rab5 effector EEA1 is a core component of endosome docking	NATURE			English	Article							VESICLE TRANSPORT; SNARE ACTIVATION; YEAST VACUOLES; ALPHA-SNAP; PROTEIN; FUSION; NSF; ER	Intracellular membrane docking and fusion requires the interplay between soluble factors and SNAREs. The SNARE hypothesis' postulates that pairing between a vesicular v-SNARE and a target membrane z-SNARE is the primary molecular interaction underlying the specificity of vesicle targeting as well as lipid bilayer fusion. This proposal is supported by recent studies using a minimal artificial system(2). However, several observations demonstrate that SNAREs function at multiple transport steps and can pair promiscuously, questioning the role of SNAREs in conveying vesicle targeting(3-6). Moreover, other proteins have been shown to be important in membrane docking or tethering(7-9). Therefore, if the minimal machinery is defined as the set of proteins sufficient to reproduce in vitro the fidelity of vesicle targeting, docking and fusion as in vivo, then SNAREs are not sufficient to specify vesicle targeting. Endosome fusion also requires cytosolic factors and is regulated by the small GTPase Rab5 (refs 10-20). Here we show that Rab5-interacting soluble proteins can completely substitute for cytosol in an in vivo endosome-fusion assay, and that the Rab5 effector EEA1 is the only factor necessary to confer minimal fusion activity. Rab5 and other associated proteins seem to act upstream of EEA1, implying that Ra65 effecters comprise both regulatory molecules and mechanical components of the membrane transport machinery. We further show that EEA1 mediates endosome docking and, together with SNAREs, leads to membrane fusion.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	European Molecular Biology Laboratory (EMBL); Max Planck Society; University of Liverpool	Zerial, M (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Burgoyne, Robert D/P-6641-2019; McBride, Heidi M./ABD-5774-2021; Burgoyne, Robert/C-6706-2008; McBride, Heidi M/C-1162-2008	Burgoyne, Robert D/0000-0002-9219-0387; McBride, Heidi M./0000-0003-4666-2280; Burgoyne, Robert/0000-0002-9219-0387; McBride, Heidi M/0000-0003-4666-2280; Christoforidis, Savvas/0000-0002-0210-0713				Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Robinson LJ, 1998, CURR OPIN CELL BIOL, V10, P483, DOI 10.1016/S0955-0674(98)80063-X; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752	30	629	639	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 18	1999	397	6720					621	625		10.1038/17618	http://dx.doi.org/10.1038/17618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050856				2022-12-01	WOS:000078738500051
J	Moss-Morris, R; Petrie, KJ				Moss-Morris, R; Petrie, KJ			Link between psychiatric dysfunction and dizziness	LANCET			English	Editorial Material							CHRONIC FATIGUE SYNDROME; BACK-PAIN; DISTRESS		Univ Auckland, Fac Med & Hlth Sci, Dept Psychiat & Behav Sci, Auckland, New Zealand	University of Auckland	Moss-Morris, R (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Psychiat & Behav Sci, Private Bag 92 019, Auckland, New Zealand.			Moss-Morris, Rona/0000-0002-2927-3446				Brandt TH, 1998, J NEUROL NEUROSUR PS, V65, P619, DOI 10.1136/jnnp.65.5.619; Croft PR, 1995, SPINE, V20, P2731, DOI 10.1097/00007632-199512150-00015; Fry AM, 1996, J PSYCHOSOM RES, V41, P415, DOI 10.1016/S0022-3999(96)00190-0; HUDSON JI, 1994, BAILLIERE CLIN RHEUM, V8, P839, DOI 10.1016/S0950-3579(05)80051-2; INGRAM RE, 1990, PSYCHOL BULL, V107, P156, DOI 10.1037/0033-2909.107.2.156; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; MossMorris R, 1996, J NEUROL NEUROSUR PS, V60, P474, DOI 10.1136/jnnp.60.5.474; PENNEBAKER JW, 1982, PSYCHOL PHYSICAL SYM; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234; WEINMAN J, 1997, J PSYCHOSOM RES, V42, P116; WESSELY S, 1995, LANCET, V345, P1333, DOI 10.1016/S0140-6736(95)92537-6; Yardley L, 1998, J NEUROL NEUROSUR PS, V65, P679, DOI 10.1136/jnnp.65.5.679	12	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					515	516		10.1016/S0140-6736(98)00348-1	http://dx.doi.org/10.1016/S0140-6736(98)00348-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028975				2022-12-01	WOS:000078670200004
J	Cooper, MTD; Bray, SJ				Cooper, MTD; Bray, SJ			Frizzled regulation of Notch signalling polarizes cell fate in the Drosophila eye	NATURE			English	Article							SIGNALING PATHWAY; DELTA-EXPRESSION; ENHANCER; COMPLEX; GENE; WINGLESS; SUBSET	The Drosophila eye, a paradigm for epithelial organization, is highly polarized with mirror-image symmetry about the equator. The R3 and R4 photoreceptors in each ommatidium are vital in this polarity; they adopt asymmetrical positions in adult ommatidia and are the site of action for several essential genes(1-5). Two such genes are frizzled (fz) and dishevelled (dsh), the products of which are components of a signalling pathway required in R3, and which are thought to be activated by a diffusible signal(3,6-10). Here we show that the transmembrane receptor Notch is required downstream of dsh in R3/R4 for them to adopt distinct fates, By using an enhancer for the Notch target gene Enhancer of split m delta, we show that Notch becomes activated specifically in R4, We propose that Fz/Dsh promotes activity of the Notch ligand Delta and inhibits Notch receptor activity in R3, creating a difference in Notch signalling capacity between R3 and R4. Subsequent feedback in the Notch pathway ensures that this difference becomes amplified. This interplay between Fz/Dsh and Notch indicates that polarity is established through local comparisons between two cells and explains how a signal from one position (for example, the equator in the eye) could be interpreted by all ommatidia in the field.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	University of Cambridge	Bray, SJ (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.			Bray, Sarah/0000-0002-1642-599X				Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Baker NE, 1996, CURR BIOL, V6, P1290, DOI 10.1016/S0960-9822(02)70715-X; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; Chen CWJ, 1997, DEV BIOL, V188, P181, DOI 10.1006/dbio.1997.8643; Choi KW, 1996, P NATL ACAD SCI USA, V93, P5737, DOI 10.1073/pnas.93.12.5737; deCelis JF, 1996, DEVELOPMENT, V122, P2719; Eastman DS, 1997, MOL CELL BIOL, V17, P5620, DOI 10.1128/MCB.17.9.5620; Fanto M, 1998, MECH DEVELOP, V74, P51, DOI 10.1016/S0925-4773(98)00063-X; FEHON RG, 1994, DEVELOPMENT, V120, P545; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Gubb D, 1998, INT J DEV BIOL, V42, P369; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Klein T, 1997, DEV BIOL, V189, P123, DOI 10.1006/dbio.1997.8564; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; PARKS AL, 1995, MECH DEVELOP, V50, P201, DOI 10.1016/0925-4773(94)00336-L; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; Wehrli M, 1998, DEVELOPMENT, V125, P1421; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wolff Tanya, 1993, P1277; ZHENG L, 1995, DEVELOPMENT, V121, P3045	30	194	196	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					526	530		10.1038/17395	http://dx.doi.org/10.1038/17395			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028969				2022-12-01	WOS:000078574900051
J	Schneider, EL				Schneider, EL			Demographics - Aging in the third millennium	SCIENCE			English	Editorial Material									Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Leonard Davis Sch Gerontol, Los Angeles, CA 90089 USA	University of Southern California	Schneider, EL (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Leonard Davis Sch Gerontol, Los Angeles, CA 90089 USA.	eschneid@usc.edu						*AARP, 1997, PROF OLD AM; Crimmins EM, 1997, J GERONTOL B-PSYCHOL, V52, pS59, DOI 10.1093/geronb/52B.2.S59; *HCFA, 1998, HIGHL NAT HLTH EXP P; HOLMES OW, 1891, DEACONS MASTERPIECE; Lee R, 1997, DEMOGRAPHY, V34, P67, DOI 10.2307/2061660; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; *NAT CTR HLTH STAT, 1998, 1995 VIT STAT US A, V2, P14; NELSON TM, 1993, INT J AGING HUM DEV, V36, P239, DOI 10.2190/TAG8-9WA4-YX0M-9T17; OUSLANDER JG, 1997, MED CARE NURSING HOM; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; REGNIER V, 1996, CRITICAL ISSUES ASSI; Singer BH, 1998, P NATL ACAD SCI USA, V95, P15618, DOI 10.1073/pnas.95.26.15618; Smith S, 1998, HEALTH AFFAIR, V17, P128, DOI 10.1377/hlthaff.17.5.128; U.S. Census Bureau, 1967, TABLE 4 YEARS SCH CO; Wachter KW, 1997, PHILOS T R SOC B, V352, P1811, DOI 10.1098/rstb.1997.0166	15	69	70	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					796	797		10.1126/science.283.5403.796	http://dx.doi.org/10.1126/science.283.5403.796			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	165AT	10049123				2022-12-01	WOS:000078496800025
J	Jiang, YP; Woronicz, JD; Liu, W; Goeddel, DV				Jiang, YP; Woronicz, JD; Liu, W; Goeddel, DV			Prevention of constitutive TNF receptor 1 signaling by silencer of death domains	SCIENCE			English	Article							NF-KAPPA-B; CELL-DEATH; ACTIVATION; COMPLEX; APOPTOSIS; BETA	Tumor necrosis factor receptor type 1 (TNF-R1) contains a cytoplasmic death domain that is required for the signaling of TNF activities such as apoptosis and nuclear factor kappa B (NF-kappa B) activation. Normally, these signals are generated only after TNF-induced receptor aggregation. However, TNF-R1 self-associates and signals independently of Ligand when overexpressed. This apparent paradox may be explained by silencer of death domains (SODD), widely expressed similar to 60-kilodalton protein that was found to be associated with the death domain of TNF-R1. TNF treatment released SODD from TNF-R1, permitting the recruitment of proteins such as TRADD and TRAF2 to the active TNF-R1 signaling complex. SODD also interacted with death receptor-3 (DR3), another member of the TNF receptor superfamily. Thus, SODD association may be representative of a general mechanism for preventing spontaneous signaling by death domain-containing receptors.	Tularik, S San Francisco, CA 94080 USA		Goeddel, DV (corresponding author), Tularik, 2 Corp Dr, S San Francisco, CA 94080 USA.							Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; *GENB, H10621 GENB; *GENB, T33545 GENB; *GENB, AA319013 GENB; *GENB, AA362082 GENB; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JIANG YH, UNPUB, P12720; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SONG HY, 1994, J BIOL CHEM, V269, P22492; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	22	323	348	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					543	546		10.1126/science.283.5401.543	http://dx.doi.org/10.1126/science.283.5401.543			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915703				2022-12-01	WOS:000078203300039
J	Scott, DL; Gishen, P				Scott, DL; Gishen, P			Radiological assessment of hip osteoarthritis	LANCET			English	Editorial Material							ARTHROPLASTY; PROGRESSION		Kings Coll Hosp London, Dept Rheumatol, London SE22 8PT, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Scott, DL (corresponding author), Kings Coll Hosp London, Dept Rheumatol, London SE22 8PT, England.							Auleley GR, 1998, ANN RHEUM DIS, V57, P519, DOI 10.1136/ard.57.9.519; Chang RW, 1996, JAMA-J AM MED ASSOC, V275, P858, DOI 10.1001/jama.275.11.858; CONROZIER T, 1995, OSTEOARTHR CARTILAGE, V3, P81; Cooper C, 1998, AM J EPIDEMIOL, V147, P516; DANIELSSON L, 1997, CLIN ORTHOP RELAT R, V20, P107; Dougados M, 1996, ANN RHEUM DIS, V55, P356, DOI 10.1136/ard.55.6.356; Fox KM, 1996, J RHEUMATOL, V23, P693; HANSSON G, 1993, ACTA RADIOL, V34, P117; Hirsch R, 1998, ARTHRITIS RHEUM, V41, P361, DOI 10.1002/1529-0131(199802)41:2<361::AID-ART21>3.0.CO;2-2; HUSKISSON EC, 1995, J RHEUMATOL, V22, P1941; LEDINGHAM J, 1993, ANN RHEUM DIS, V52, P263, DOI 10.1136/ard.52.4.263; Odding E, 1998, ANN RHEUM DIS, V57, P203, DOI 10.1136/ard.57.4.203; Petersson IF, 1996, ANN RHEUM DIS, V55, P659, DOI 10.1136/ard.55.9.659; RAVAUD P, HIP RADIOGRAPHY; Theiler R, 1996, OSTEOARTHR CARTILAGE, V4, P35, DOI 10.1016/S1063-4584(96)80005-7	15	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					87	88		10.1016/S0140-6736(05)76152-3	http://dx.doi.org/10.1016/S0140-6736(05)76152-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023891				2022-12-01	WOS:000078087200007
J	Cornu, C; Cano, A; Pornel, B; Melis, GB; Boissel, JP				Cornu, C; Cano, A; Pornel, B; Melis, GB; Boissel, JP		EUTERP Pilot Study Grp	Could institutional clinical trials exist in Europe?	LANCET			English	Editorial Material									Univ Valencia, Dept Pediat, Valencia, Spain; Univ Lyon 1, Serv Pharmacol EA643, F-69365 Lyon, France; Brussels Menopause Ctr, Brussels, Belgium; Univ Cagliari, Ist Ginecol Ostetricia & Fisiopatol Reprod Umana, Cagliari, Italy	University of Valencia; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Cagliari	Cornu, C (corresponding author), 162 Ave Lacassagne,BP3041, F-69394 Lyon 03, France.								0	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					63	64		10.1016/S0140-6736(98)07611-9	http://dx.doi.org/10.1016/S0140-6736(98)07611-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023967				2022-12-01	WOS:000077934800046
J	Cousens, SN; Linsell, L; Smith, PG; Chandrakumar, M; Wilesmith, JW; Knight, RSG; Zeidler, M; Stewart, G; Will, RG				Cousens, SN; Linsell, L; Smith, PG; Chandrakumar, M; Wilesmith, JW; Knight, RSG; Zeidler, M; Stewart, G; Will, RG			Geographical distribution of variant CJD in the UK (excluding Northern Ireland)	LANCET			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; DISEASE; BSE	Background The agent that causes variant Creutzfeldt-Jakob disease (variant CJD) is indistinguishable from the causative agent of bovine spongiform encephalopathy (BSE). The transmission route by which human beings are infected has not been established. One hypothesis is that cases of variant CJD have resulted from exposure to the BSE agent via rendering plants involved in the production of meat and bone meal, the main vehicle of the BSE epidemic. Methods We identified cases of variant CJD through the National CJD Surveillance Unit, and obtained lifetime residential histories of cases by interviewing a relative. The addresses of all rendering plants in the UK (excluding Northern Ireland) in production in 1988 were available from a survey done in that year. We calculated the distance between each case's place of residence on Jan 1, 1988, and the nearest rendering plant from postcode data, and used data from the 1991 UK census to estimate the population living within various distances of rendering plants. We compared the observed number of cases of variant CJD within a particular distance of a rendering plant with the number expected if there is no association between residential proximity to a rendering plant and the risk of developing variant CJD. Findings Up to Aug 31, 1998, 26 cases of variant CJD with onset in the UK (Northern ireland not included) had been identified. The observed and expected numbers of variant CJD cases living within a specified distance of any rendering plant up to 50 km were almost the same. Two plants in the county of Kent each had four cases within 50 km in 1988, significantly more cases than expected (plant A, 1.04 expected; plant B, 0.74 expected). Multiple significance tests were done, so some tests would be expected to appear significant by chance alone. Computer simulations suggested that the observation of four cases of variant CJD living in an area with a population of 1.5 million (the size of Kent) is not unexpected. Interpretation There is no evidence that people with variant CJD tended to live closer than the population as a whole to rendering plants in the 1980s. The reported cluster of variant CJD cases in Kent is most probably a chance finding.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; E Kent Hlth Author, Dover, Kent, England; Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of London; London School of Hygiene & Tropical Medicine; University of Edinburgh	Cousens, SN (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560				Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; *DNV TECHN, 1997, RISKS DISP BSE INF C; *DNV TECHN, 1997, RISKS BURN REND PROD; *DNV TECHN, 1997, THRUXT MILL REND PLA; GAGE P, 1998, J APPL MICROBIOL, V84, P467; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HILLS M, 1989, J ROY STAT SOC A STA, V152, P353, DOI 10.2307/2983132; *NAT CJD SURV UN L, 1997, CREUTZF JAK DIS SURV; WATKINS A, 1996, GUARDIAN        0611; WILESMITH JW, 1992, VET REC, V130, P90, DOI 10.1136/vr.130.5.90; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; YOUNG R, 1997, TIMES           0826	13	31	31	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 2	1999	353	9146					18	21		10.1016/S0140-6736(98)08062-3	http://dx.doi.org/10.1016/S0140-6736(98)08062-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023945				2022-12-01	WOS:000077934800011
J	Kachalova, GS; Popov, AN; Bartunik, HD				Kachalova, GS; Popov, AN; Bartunik, HD			A steric mechanism for inhibition of CO binding to heme proteins	SCIENCE			English	Article							X-RAY STRUCTURE; CARBONMONOXY-MYOGLOBIN; INFRARED CRYSTALLOGRAPHY; MOLECULAR-DYNAMICS; ACTIVE-SITE; MODELS; STEREOCHEMISTRY; HEMOGLOBIN; REFINEMENT; RESOLUTION	The crystal structures of myoglobin in the deoxy- and carbon monoxide-ligated states at a resolution of 1.15 angstroms show that carbon monoxide binding at ambient temperatures requires concerted motions of the heme, the iron, and helices E and F for relief of steric inhibition. These steps constitute the main mechanism by which heme proteins lower the affinity of the heme group for the toxic ligand carbon monoxide.	Max Planck Arbeitsgrp Strukturelle Mol Biol, Arbeitsgrp Prot Dynam, D-22603 Hamburg, Germany	Max Planck Society	Bartunik, HD (corresponding author), Max Planck Arbeitsgrp Strukturelle Mol Biol, Arbeitsgrp Prot Dynam, Notkestr 85, D-22603 Hamburg, Germany.		Popov, Alexander/A-8827-2008; Kachalova, Galina S/J-9437-2015	Kachalova, Galina S/0000-0002-8240-6287; Popov, Alexander/0000-0002-3058-8912				CASE DA, 1978, J MOL BIOL, V123, P697, DOI 10.1016/0022-2836(78)90214-0; Collman JP, 1997, J AM CHEM SOC, V119, P3481, DOI 10.1021/ja963945i; COLLMAN JP, 1976, P NATL ACAD SCI USA, V73, P3333, DOI 10.1073/pnas.73.10.3333; COTTON FA, 1965, INORG CHEM, V4, P314, DOI 10.1021/ic50025a012; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Hartmann H, 1996, P NATL ACAD SCI USA, V93, P7013, DOI 10.1073/pnas.93.14.7013; HU SZ, 1994, J AM CHEM SOC, V116, P11187, DOI 10.1021/ja00103a056; IVANOV D, 1994, J AM CHEM SOC, V116, P4139, DOI 10.1021/ja00088a084; JAMESON GB, 1980, J AM CHEM SOC, V102, P3224, DOI 10.1021/ja00529a055; JEWSBURY P, 1994, BIOPHYS J, V67, P2236, DOI 10.1016/S0006-3495(94)80708-8; JEWSBURY P, 1994, J AM CHEM SOC, V116, P11586, DOI 10.1021/ja00104a056; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; McMahon MT, 1998, J AM CHEM SOC, V120, P4784, DOI 10.1021/ja973272j; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENG SM, 1976, J AM CHEM SOC, V98, P8032, DOI 10.1021/ja00441a025; QUILLIN M L, 1992, Biophysical Journal, V61, pA466; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; ROUSSEL A, 1992, BURBO FRODO BIOGRAPH; Sage JT, 1997, J MOL BIOL, V274, P21, DOI 10.1006/jmbi.1997.1367; Sage JT, 1997, APPL SPECTROSC, V51, P568, DOI 10.1366/0003702971940611; SCHEIDT WR, 1981, BIOCHEMISTRY-US, V20, P3653, DOI 10.1021/bi00515a054; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Sheldrick G.M., 2018, SHELX 20183 PROGRAM; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; TAKANO T, 1977, J MOL BIOL, V110, P569, DOI 10.1016/S0022-2836(77)80112-5; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; Vitkup D, 1997, NAT STRUCT BIOL, V4, P202, DOI 10.1038/nsb0397-202; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123	35	304	305	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					473	476		10.1126/science.284.5413.473	http://dx.doi.org/10.1126/science.284.5413.473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205052				2022-12-01	WOS:000079792200043
J	Timmermans, MCP; Hudson, A; Becraft, PW; Nelson, T				Timmermans, MCP; Hudson, A; Becraft, PW; Nelson, T			ROUGH SHEATH2: A Myb protein that represses knox homeobox genes in maize lateral organ primordia	SCIENCE			English	Article							ECTOPIC EXPRESSION; CELL FATES; BOX GENE; LEAF; KNOTTED-1; MUTATION; IDENTITY; LEAVES; BARLEY; MUTANT	The regulation of members of the knotted1-like homeobox (knox) gene family is required for the normal initiation and development of lateral organs. The maize rough sheath2 (rs2) gene, which encodes a Myb-domain protein, is expressed in Lateral organ primordia and their initials. Mutations in the rs2 gene permit ectopic expression of knox genes in leaf and floral primordia, causing a variety of developmental defects. Ectopic KNOX protein accumulation in rs2 mutants occurs in a subset of the normal rs2-expressing cells. This variegated accumulation of KNOX proteins in rs2 mutants suggests that rs2 represses knox expression through epigenetic means.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland; Iowa State Univ, Dept Zool & Genet, Ames, IA 50011 USA	Yale University; Cold Spring Harbor Laboratory; University of Edinburgh; Iowa State University	Nelson, T (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA.	timothy.nelson@yale.edu		Becraft, Philip/0000-0002-3299-2126				Brun C, 1997, TRENDS CELL BIOL, V7, P317, DOI 10.1016/S0962-8924(97)01092-1; BURR B, 1988, GENETICS, V118, P519; Chuck G, 1996, PLANT CELL, V8, P1277, DOI 10.1105/tpc.8.8.1277; Fowler JE, 1996, DEV GENET, V18, P198, DOI 10.1002/(SICI)1520-6408(1996)18:3&lt;198::AID-DVG2&gt;3.0.CO;2-4; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Hareven D, 1996, CELL, V84, P735, DOI 10.1016/S0092-8674(00)81051-X; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jackson D., 1991, MOL PLANT PATHOLOGY, P163; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; Martin C, 1997, TRENDS GENET, V13, P67, DOI 10.1016/S0168-9525(96)10049-4; Muehlbauer GJ, 1997, DEVELOPMENT, V124, P5097; MULLER KJ, 1995, NATURE, V374, P727, DOI 10.1038/374727a0; Poethig RS., 1984, CONT PROBLEMS PLANT, P235; Scanlon MJ, 1996, DEVELOPMENT, V122, P1683; Schneeberger R, 1998, DEVELOPMENT, V125, P2857; SCHNEEBERGER RG, 1995, GENE DEV, V9, P2292, DOI 10.1101/gad.9.18.2292; Sharman BC, 1942, ANN BOT-LONDON, V6, P245, DOI 10.1093/oxfordjournals.aob.a088407; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1992, DEVELOPMENT, V116, P21; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sylvester AW, 1996, ANNU REV CELL DEV BI, V12, P257, DOI 10.1146/annurev.cellbio.12.1.257; Timmermans MCP, 1998, DEVELOPMENT, V125, P2813; WAITES R, 1995, DEVELOPMENT, V121, P2143; Waites R, 1998, CELL, V93, P779, DOI 10.1016/S0092-8674(00)81439-7; WilliamsCarrier RE, 1997, DEVELOPMENT, V124, P3737	27	256	285	3	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1999	284	5411					151	153		10.1126/science.284.5411.151	http://dx.doi.org/10.1126/science.284.5411.151			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102816				2022-12-01	WOS:000079509000055
J	Lagergren, J; Bergstrom, R; Lindgren, A; Nyren, O				Lagergren, J; Bergstrom, R; Lindgren, A; Nyren, O			Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLUMNAR-LINED ESOPHAGUS; BARRETTS-ESOPHAGUS; GASTRIC CARDIA; INCREASING INCIDENCE; OVERRATED RISK; DISEASE; METAPLASIA; CARCINOMAS; TOBACCO; ALCOHOL	Background The causes of adenocarcinomas of the esophagus and gastric cardia are poorly understood. We conducted an epidemiologic investigation of the possible association between gastroesophageal reflux and these tumors. Methods We performed a nationwide, population-based, case-control study in Sweden. Case ascertainment was rapid, and all cases were classified uniformly. information on the subjects' history of gastroesophageal reflux was collected in personal interviews. The odds ratios were calculated by logistic regression, with multivariate adjustment for potentially confounding variables. Results Of the patients interviewed, the 189 with esophageal adenocarcinoma and the 262 with adenocarcinoma of the cardia constituted 85 percent of the 529 patients in Sweden who were eligible for the study during the period from 1995 through 1997. For comparison, we interviewed 820 control subjects from the general population and 167 patients with esophageal squamous-cell carcinoma. Among persons with recurrent symptoms of reflux, as compared with persons without such symptoms, the odds ratios were 7.7 (95 percent confidence interval, 5.3 to 11.4) for esophageal adenocarcinoma and 2.0 (95 percent confidence interval, 1.4 to 2.9) for adenocarcinoma of the cardia. The more frequent, more severe, and longer-lasting the symptoms of reflux, the greater the risk. Among persons with long-standing and severe symptoms of reflux, the odds ratios were 43.5 (95 percent confidence interval, 18.3 to 103.5) for esophageal adenocarcinoma and 4.4 (95 percent confidence interval, 1.7 to 11.0) for adenocarcinoma of the cardia. The risk of esophageal squamous-cell carcinoma was not associated with reflux (odds ratio, 1.1; 95 percent confidence interval, 0.7 to 1.9). Conclusions There is a strong and probably causal relation between gastroesophageal reflux and esophageal adenocarcinoma. The relation between reflux and adenocarcinoma of the gastric cardia is relatively weak. (N Engl J Med 1999; 340:825-31.) (C) 1999, Massachusetts Medical Society.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Surg, Stockholm, Sweden; Danderyd Hosp, Stockholm, Sweden; Uppsala Univ, Dept Stat, Uppsala, Sweden; Falun Cent Hosp, Dept Pathol, Falun, Sweden	Karolinska Institutet; Karolinska Institutet; Danderyds Hospital; Uppsala University; Falun Hospital	Lagergren, J (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, S-17177 Stockholm, Sweden.	jesper.lagergren@mep.ki.se		Lagergren, Jesper/0000-0002-5143-5448	NATIONAL CANCER INSTITUTE [R01CA057947] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57947-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTORKI NK, 1990, SEMIN SURG ONCOL, V6, P274, DOI 10.1002/ssu.2980060509; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Breslow NE, 1980, IARC SCI PUBL, VI; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; Cameron AJ, 1997, GASTROENTEROL CLIN N, V26, P487, DOI 10.1016/S0889-8553(05)70308-3; CHOW WH, 1995, JAMA-J AM MED ASSOC, V274, P474, DOI 10.1001/jama.274.6.474; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; CLARK GWB, 1994, ARCH SURG-CHICAGO, V129, P609; Correa P, 1998, BRIT MED BULL, V54, P151; Drewitz DJ, 1997, AM J GASTROENTEROL, V92, P212; Gammon MD, 1997, J NATL CANCER I, V89, P1277, DOI 10.1093/jnci/89.17.1277; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HANSSON LE, 1993, BRIT J SURG, V80, P374, DOI 10.1002/bjs.1800800338; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; Kim R, 1997, CANCER EPIDEM BIOMAR, V6, P369; KLAUSER AG, 1990, LANCET, V335, P205, DOI 10.1016/0140-6736(90)90287-F; LOCKE GR, 1994, MAYO CLIN PROC, V69, P539, DOI 10.1016/S0025-6196(12)62245-9; Marshall REK, 1997, BRIT J SURG, V84, P21; MIWA K, 1994, BRIT J CANCER, V70, P185, DOI 10.1038/bjc.1994.277; Morales TG, 1997, DIGEST DIS, V15, P346, DOI 10.1159/000171610; OVASKA J, 1989, DIGEST DIS SCI, V34, P1336, DOI 10.1007/BF01538065; PERA M, 1993, GASTROENTEROLOGY, V104, P510, DOI 10.1016/0016-5085(93)90420-H; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; Revicki DA, 1998, QUAL LIFE RES, V7, P75; ROBERTSON CS, 1988, BRIT J SURG, V75, P760, DOI 10.1002/bjs.1800750813; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P53; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P43; SPECHLER SJ, 1984, GASTROENTEROLOGY, V87, P927; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; Streitz JM, 1998, AM J GASTROENTEROL, V93, P911; Ter RB, 1997, GASTROENTEROL CLIN N, V26, P549, DOI 10.1016/S0889-8553(05)70313-7; VANDERVEEN AH, 1989, GUT, V30, P14, DOI 10.1136/gut.30.1.14; WILLIFORD WO, 1994, CONTROL CLIN TRIALS, V15, P335, DOI 10.1016/0197-2456(94)90031-0; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Winters C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X; Wright TA, 1996, GUT, V39, P574, DOI 10.1136/gut.39.4.574; Zhang ZF, 1996, CANCER EPIDEM BIOMAR, V5, P761	37	2188	2238	1	65	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1999	340	11					825	831		10.1056/NEJM199903183401101	http://dx.doi.org/10.1056/NEJM199903183401101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	176ZW	10080844				2022-12-01	WOS:000079183200001
J	Rudolph, KL; Chang, S; Lee, HW; Blasco, M; Gottlieb, GJ; Greider, C; DePinho, RA				Rudolph, KL; Chang, S; Lee, HW; Blasco, M; Gottlieb, GJ; Greider, C; DePinho, RA			Longevity, stress response, and cancer in aging telomerase-deficient mice	CELL			English	Article							LIFE-SPAN; CELLULAR SENESCENCE; SACCHAROMYCES-CEREVISIAE; REPLICATIVE SENESCENCE; HUMAN FIBROBLASTS; HUMAN-LYMPHOCYTES; MOUSE CELLS; LENGTH; AGE; MORPHOLOGY	Telomere maintenance is thought to play a role in signaling cellular senescence; however, a link with organismal aging processes has not been established. The telomerase null mouse provides an opportunity to understand the effects associated with critical telomere shortening at the organismal level. We studied a variety of physiological processes in an aging cohort of mTR(-/-) mice. Loss of telomere function did not elicit a full spectrum of classical pathophysiological symptoms of aging. However, age-dependent telomere shortening and accompanying genetic instability were associated with shortened life span as well as a reduced capacity to respond to stresses such as wound healing and hematopoietic ablation. In addition, we found an increased incidence of spontaneous malignancies. These findings demonstrate a critical role for telomere length in the overall fitness, reserve, and well being of the aging organism.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02110 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02110 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02110 USA; Quest diagnost Inc, Anat Pathol, Teterboro, NJ 07608 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Sungkyunkwan Univ, Sch Med, Ctr Mol Med, Samsung Biomed Res Inst, Seoul 135230, South Korea; Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Johns Hopkins University; Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St,M413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu	Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X; Rudolph, Karl Lenhard/0000-0002-4839-2862; Greider, Carol/0000-0002-5494-8126; DePinho, Ronald/0000-0002-5625-577X	NATIONAL INSTITUTE ON AGING [K08AG001019] Funding Source: NIH RePORTER; NIA NIH HHS [K08 AG001019] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Ashcroft GS, 1997, J ANAT, V190, P351, DOI 10.1046/j.1469-7580.1997.19030351.x; Ashcroft GS, 1997, J INVEST DERMATOL, V108, P430, DOI 10.1111/1523-1747.ep12289705; Austriaco NR, 1997, P NATL ACAD SCI USA, V94, P9768, DOI 10.1073/pnas.94.18.9768; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 1998, J Investig Dermatol Symp Proc, V3, P1; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; CHEN TS, 1990, J GERONTOL, V45, pB129, DOI 10.1093/geronj/45.4.B129; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; Counter CM, 1996, MUTAT RES-REV GENET, V366, P45, DOI 10.1016/S0165-1110(96)90006-8; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COURTOIS M, 1994, SKIN PHARMACOL, V7, P84; COURTOIS M, 1995, BRIT J DERMATOL, V132, P86, DOI 10.1111/j.1365-2133.1995.tb08630.x; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DELANGE T, 1995, TELOMERES, P265; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; DORMAN JB, 1995, GENETICS, V141, P1399; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; ELANGE T, 1998, SCIENCE, V27, P334; Frenck RW, 1998, P NATL ACAD SCI USA, V95, P5607, DOI 10.1073/pnas.95.10.5607; GOODRICK CL, 1977, GERONTOLOGY, V23, P405, DOI 10.1159/000212216; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; GREIDER CW, 1996, NAN REV BIOCH, V65, P337; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; HAENEY M, 1994, J ANTIMICROB CHEMOTH, V34, P1; HANDE P, 1999, IN PRESS J CELL BIOL; Harley CB, 1997, CANCER SURV, V29, P263; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harley CB, 1997, CIBA F SYMP, V211, P139; Harley CB, 1997, CIBA F SYMP, V211, P129; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HERRERA E, 1999, IN PRESS EMBO J; HOLT DR, 1992, SURGERY, V112, P293; Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651; Ingram D K, 1987, Basic Life Sci, V42, P247; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Johnson FB, 1998, CURR OPIN CELL BIOL, V10, P332, DOI 10.1016/S0955-0674(98)80008-2; Jurivich DA, 1997, MECH AGEING DEV, V94, P233, DOI 10.1016/S0047-6374(96)01856-8; KEELAN M, 1985, MECH AGEING DEV, V31, P49, DOI 10.1016/0047-6374(85)90026-0; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KITADA T, 1995, BIOCHEM BIOPH RES CO, V211, P33, DOI 10.1006/bbrc.1995.1774; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Pathak S., 1994, In Vivo (Attiki), V8, P843; PRETLOW TP, 1991, CANCER RES, V51, P1564; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; SALK D, 1982, J AM GERIATR SOC, V30, P334, DOI 10.1111/j.1532-5415.1982.tb05624.x; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Smeal T, 1997, CURR OPIN GENET DEV, V7, P281, DOI 10.1016/S0959-437X(97)80139-6; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinberg RA, 1998, NATURE, V396, P23, DOI 10.1038/23825; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wright WE, 1996, DEV GENET, V18, P173; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423; Zivicnjak M, 1997, COLLEGIUM ANTROPOL, V21, P117	65	1048	1098	8	109	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	1999	96	5					701	712		10.1016/S0092-8674(00)80580-2	http://dx.doi.org/10.1016/S0092-8674(00)80580-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	174TB	10089885	Green Published, Bronze			2022-12-01	WOS:000079050100013
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Difference mapping Cryo-EM	SCIENCE			English	Article																		Conway JF, 1998, P NATL ACAD SCI USA, V95, P14622, DOI 10.1073/pnas.95.25.14622	1	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1133	1133						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10075576				2022-12-01	WOS:000078738400040
J	Unger, VM; Kumar, NM; Gilula, NB; Yeager, M				Unger, VM; Kumar, NM; Gilula, NB; Yeager, M			Three-dimensional structure of a recombinant gap junction membrane channel	SCIENCE			English	Article							MARIE-TOOTH-DISEASE; ELECTRON CRYOMICROSCOPY; 3-DIMENSIONAL STRUCTURE; WATER CHANNEL; RESOLUTION; CONNEXIN43; MUTATIONS; PROTEIN; HEART; COMMUNICATION	Gap junction membrane channels mediate electrical and metabolic coupling between adjacent cells. The structure of a recombinant cardiac gap junction channel was determined by electron crystallography at resolutions of 7.5 angstroms in the membrane plane and 21 angstroms in the vertical direction. The dodecameric channel was formed by the end-to-end docking of two hexamers, each of which displayed 24 rods of density in the membrane interior, which is consistent with an alpha-helical conformation for the four transmembrane domains of each connexin subunit. The transmembrane alpha-helical rods contrasted with the double-layered appearance of the extracellular domains. Although not indicative for a particular type of secondary structure, the protein density that formed the extracellular vestibule provided a tight seal to exclude the exchange of substances with the extracellular milieu.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Clin & Res Fdn, Div Cardiovasc Dis, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Yeager, M (corresponding author), Max Planck Inst Biophys, Abt Strukturbiol, Heinrich Hoffman Str 7, D-60528 Frankfurt, Germany.							AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEYER EC, 1994, HDB MEMBRANE CHANNEL, P379; Bone LJ, 1997, NEUROBIOL DIS, V4, P221, DOI 10.1006/nbdi.1997.0152; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Ewart JL, 1997, DEVELOPMENT, V124, P1281; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; Guerrero PA, 1997, J CLIN INVEST, V99, P1991, DOI 10.1172/JCI119367; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; Perkins G, 1997, BIOPHYS J, V72, P533, DOI 10.1016/S0006-3495(97)78693-4; Perkins GA, 1998, J MOL BIOL, V277, P171, DOI 10.1006/jmbi.1997.1580; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; Unger VM, 1997, NAT STRUCT BIOL, V4, P39, DOI 10.1038/nsb0197-39; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; White TW, 1998, NATURE, V394, P630, DOI 10.1038/29202; WHITE TW, 1995, MOL BIOL CELL, V6, P459, DOI 10.1091/mbc.6.4.459; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G; Yeager M, 1999, Methods Enzymol, V294, P135; Yeager M, 1998, J STRUCT BIOL, V121, P231, DOI 10.1006/jsbi.1998.3972; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	41	411	421	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1176	1180		10.1126/science.283.5405.1176	http://dx.doi.org/10.1126/science.283.5405.1176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024245				2022-12-01	WOS:000078738400054
J	Rantanen, T; Guralnik, JM; Foley, D; Masaki, K; Leveille, S; Curb, JD; White, L				Rantanen, T; Guralnik, JM; Foley, D; Masaki, K; Leveille, S; Curb, JD; White, L			Midlife hand grip strength as a predictor of old age disability	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; LATE-LIFE; WOMEN; MEN; PEOPLE; HEALTH	Context Poor muscle strength, functional limitations, and disability often coexist, but whether muscle strength during midlife predicts old age functional ability is not known. Objective To determine whether hand grip strength measured during midlife predicts old age functional limitations and disability in initially healthy men, Design and Setting A 25-year prospective cohort study, the Honolulu Heart Program, which began in 1965 among Japanese-American men living on Oahu, Hawaii. Participants A total of 6089 45- to 68-year-old men who were healthy at baseline and whose maximal hand grip strength was measured from 1965 through 1970, Altogether, 2259 men died over the follow-up period and 3218 survivors participated in the disability assessment in 1991 through 1993, Main Outcome Measures Functional limitations including slow customary walking speed (less than or equal to 0.4 m/s) and inability to rise from a seated position without using the arms, and multiple self-reported upper extremity, mobility, and self-care disability outcomes, Results After adjustment for multiple potential confounders, risk of functional limitations and disability 25 years later increased as baseline hand grip strength. divided into tertiles, declined. The odds ratio (OR) of walking speed of 0.4 m/s or slower was 2.87 (95% confidence interval [CI], 1.76-4.67) in those in the lowest third and 1.79 (95% CI, 1.14-2.81) in the middle third of grip strength vs those in the highest third, The risk of self-care disability was more than 2 times greater in the lowest vs the highest grip strength tertile. Adding chronic conditions identified at follow-up to the models predicting disability reduced the ORs related to grip strength only minimally, Conclusions Among healthy 45- to 68-year-old men, hand grip strength was highly predictive of functional limitations and disability 25 years later. Good muscle strength in midlife may protect people from old age disability by providing a greater safety margin above the threshold of disability.	NIA, Epidemiol Demog Biometry Program, NIH, Bethesda, MD 20892 USA; Kuakini Med Ctr, Asia Aging Study, Honolulu, HI USA; Honolulu Heart Program, Honolulu, HI USA; Univ Hawaii, Sch Med, Honolulu, HI 96822 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Hawaii System	Rantanen, T (corresponding author), Univ Jyvaskyla, Dept Hlth Sci, POB 35, SF-40351 Jyvaskyla, Finland.	Taina@maila.jyu.fi	Rantanen, Taina/O-6579-2016	Rantanen, Taina/0000-0002-1604-1945				Buchner DM, 1996, AGE AGEING, V25, P386, DOI 10.1093/ageing/25.5.386; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; Ferrucci L, 1997, J GERONTOL A-BIOL, V52, pM275, DOI 10.1093/gerona/52A.5.M275; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LaPlante MP, 1992, 7 US DEP ED NAT I DI; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; Pinsky JL, 1987, J CHRONIC DIS S1, V40, p181S; Rantanen T, 1996, SCAND J REHABIL MED, V28, P89; Rantanen T, 1998, J APPL PHYSIOL, V85, P2047, DOI 10.1152/jappl.1998.85.6.2047; Rantanen T, 1998, AM J PHYS MED REHAB, V77, P299, DOI 10.1097/00002060-199807000-00008; Rantanen T., 2016, J AGING PHYS ACTIV, V2, P206, DOI 10.1123/japa.2.3.206; Rodriguez BL, 1996, DIABETES CARE, V19, P587, DOI 10.2337/diacare.19.6.587; Sakari-Rantala R, 1998, SCAND J REHABIL MED, V30, P121; Sipila S, 1996, ACTA PHYSIOL SCAND, V156, P457, DOI 10.1046/j.1365-201X.1996.461177000.x; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; White L, 1996, JAMA-J AM MED ASSOC, V276, P955, DOI 10.1001/jama.276.12.955	23	971	988	0	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					558	560		10.1001/jama.281.6.558	http://dx.doi.org/10.1001/jama.281.6.558			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	164FQ	10022113	Bronze			2022-12-01	WOS:000078452900035
J	Ostrom, E; Burger, J; Field, CB; Norgaard, RB; Policansky, D				Ostrom, E; Burger, J; Field, CB; Norgaard, RB; Policansky, D			Sustainability - Revisiting the commons: Local lessons, global challenges	SCIENCE			English	Review							TRAGEDY; INSTITUTIONS; PERFORMANCE; GOVERNANCE; BEHAVIOR	In a seminal paper, Garrett Hardin argued in 1968 that users of a commons are caught in an inevitable process that leads to the destruction of the resources on which they depend. This article discusses new insights about such problems and the conditions most likely to favor sustainable uses of common-pool resources. Some of the most difficult challenges concern the management of large-scale resources that depend on international cooperation, such as fresh water in international basins or large marine ecosystems. Institutional diversity may be as important as biological diversity for our long-term survival.	Indiana Univ, Ctr Study Inst Populat & Environm Change, Bloomington, IN 47408 USA; Indiana Univ, Workshop Polit Theory & Policy Anal, Bloomington, IN 47408 USA; Rutgers State Univ, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Carnegie Inst Washington, Stanford, CA 94305 USA; Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA; Natl Res Council, Washington, DC 20418 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Rutgers State University New Brunswick; Carnegie Institution for Science; University of California System; University of California Berkeley; National Academies of Sciences, Engineering & Medicine	Ostrom, E (corresponding author), Indiana Univ, Ctr Study Inst Populat & Environm Change, Bloomington, IN 47408 USA.	ostrom@indiana.edu			NIEHS NIH HHS [ESO 5022] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agrawal Arun, 1999, GREENER PASTURES POL; [Anonymous], 1996, HALTING DEGRADATION; [Anonymous], 1999, POLITICIANS POACHERS; AXELROD R, 1986, AM POLIT SCI REV, V80, P1095, DOI 10.2307/1960858; Berkes F., 1989, COMMON PROPERTY RESO; Blomquist W., 1992, DIVIDING WATERS GOVE; Bowles Samuel, 1997, HOMO RECIPROCANS RES; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582; Bromley D. W., 1992, MAKING COMMONS WORK; Buchanan J.M., 1962, CALCULUS CONSENT; Buck Susan J, 1998, GLOBAL COMMONS INTRO; Burger J, 1998, CONDOR, V100, P528, DOI 10.2307/1369719; CLARK CW, 1994, INVESTING IN NATURAL CAPITAL, P343; COSMIDES L, 1994, AM ECON REV, V84, P327; Cosmides L., 1992, ADAPTED MIND EVOLUTI, P163, DOI DOI 10.1098/RSTB.2006.1991; Costanza R, 1998, SCIENCE, V281, P198, DOI 10.1126/science.281.5374.198; Demsetz H, 1967, AM ECON REV, V57, P347; Feeny D, 1996, LAND ECON, V72, P187, DOI 10.2307/3146965; FEENY D, 1990, HUM ECOL, V18, P1, DOI 10.1007/BF00889070; FINLAYSON AC, 1998, LINKING SOCIAL ECOLO, P331; Folke C., 1998, LINKING SOCIAL ECOLO; Gordon HS, 1954, J POLIT ECON, V62, P124, DOI 10.1086/257497; Haas, 1993, I EARTH SOURCES EFFE; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hardin G, 1998, SCIENCE, V280, P682, DOI 10.1126/science.280.5364.682; HESS C, 1996, COMMON POOL RESOURCE, V3; Hilton R. M., 1992, Journal of Theoretical Politics, V4, P283, DOI 10.1177/0951692892004003003; Hoffman E, 1996, AM ECON REV, V86, P653; Humphrey Caroline, 1996, CULTURE ENV INNER AS, V1; Kagel JH, 1995, HDB EXPT EC; Keohane R. O., 1995, LOCAL COMMONS GLOBAL; KRIER JE, 1992, HARVARD J LAW PUBL P, V15, P325; Lam W. F., 1998, GOVERNING IRRIGATION; Lam WF, 1996, WORLD DEV, V24, P1301, DOI 10.1016/0305-750X(96)00043-5; LIBECAP GD, 1989, J INST THEOR ECON, V145, P6; LUDWIG D, 1993, SCIENCE, V260, P17, DOI 10.1126/science.260.5104.17; McGinnis M., 1996, INT POLITICAL EC INT, V2, P465; McKean M. A., 1992, J THEORETICAL POLITI, V4, P247, DOI DOI 10.1177/0951692892004003002; MICHELMAN F, 1990, LIBERTY PROPERTY FUT; National Research Council, 1999, SUST MAR FISH; NORGAARD RB, 1995, ADV HUMAN ECOLOGY, V4, P141; NORTH DC, 1994, AM ECON REV, V84, P359; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; ORBELL JM, 1988, J PERS SOC PSYCHOL, V54, P811, DOI 10.1037/0022-3514.54.5.811; *ORG EC COOP DEV, 1997, SUST FISH EC ASP MAN; Ostrom E, 1998, AM POLIT SCI REV, V92, P1, DOI 10.2307/2585925; OSTROM E, IN PRESS COMMONS REV; Ostrom E., 1997, PERSPECTIVES PUBLIC, P35; Ostrom E., 1992, CRAFTING I SELF GOVE; Ostrom E., 1994, RULES GAMES COMMON P; OSTROM V, 1990, B YOUNG U LAW REV, V3, P857; PINKERTON E, 1989, COOPERATIVE MANAGEME; PLOTT CR, 1986, SCIENCE, V232, P732, DOI 10.1126/science.232.4751.732; REPETTO R, 1985, 4 WORLD RES I; Rose C, 1994, PROPERTY PERSUASION; SAFINA C, 1994, ISSUES SCI TECHNOL, V10, P37; SCHLAGER E, 1994, LAND ECON, V70, P294, DOI 10.2307/3146531; Sneath D, 1998, SCIENCE, V281, P1147, DOI 10.1126/science.281.5380.1147; Speck Frank G., 1946, AM ANTHROPOL, V48, P355; Tang Shui Yan, 1992, I COLLECTIVE ACTION; Wade R., 1994, VILLAGE REPUBLICS EC; WHITEMAN L, 1997, NATL PARKS, V71, P22; Wiener JB, 1999, YALE LAW J, V108, P677, DOI 10.2307/797394; WIERNER JB, IN PRESS GEORGETOWN; Young O., 1999, SCI PLAN I DIMENSION; YOUNG OR, 1997, GLOBAL GOVERNANCE DR; [No title captured]; [No title captured]	68	1449	1482	19	616	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					278	282		10.1126/science.284.5412.278	http://dx.doi.org/10.1126/science.284.5412.278			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	184WH	10195886				2022-12-01	WOS:000079636400032
J	Jacobs, C; Domian, IJ; Maddock, JR; Shapiro, L				Jacobs, C; Domian, IJ; Maddock, JR; Shapiro, L			Cell cycle-dependent polar localization of an essential bacterial histidine kinase that controls DNA replication and cell division	CELL			English	Article							SIGNAL-TRANSDUCTION; CAULOBACTER-CRESCENTUS; 2-COMPONENT REGULATORS; ESCHERICHIA-COLI; PROTEIN-KINASES; IDENTIFICATION; TRANSLOCATION; CHEMOTAXIS; CHROMOSOME; ORIGIN	The master CtrA response regulator functions in Caulobacter to repress replication initiation in different phases of the cell cycle. Here, we identify an essential histidine kinase, CckA, that is responsible for CtrA activation by phosphorylation. Although CckA is present throughout the cell cycle, it moves to a cell pole in S phase, and upon cell division it disperses. Removal of the membrane-spanning region of CckA results in loss of polar localization and cell death. We propose that polar CckA functions to activate CtrA just after the initiation of DNA replication, thereby preventing premature reinitiations of chromosome replication. Thus, dynamic changes in cellular location of critical signal proteins provide a novel mechanism for the control of the prokaryote cell cycle.	Stanford Univ, Dept Dev Biol, Sch Med, Stanford, CA 94305 USA; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	Stanford University; University of Michigan System; University of Michigan	Shapiro, L (corresponding author), Stanford Univ, Dept Dev Biol, Sch Med, Stanford, CA 94305 USA.	shapiro@cmgm.stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, R01GM032506] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51426, GM3250615120MZ] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALLEY MRK, 1991, GENETICS, V129, P333; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Domian IJ, 1997, CELL, V90, P415, DOI 10.1016/S0092-8674(00)80502-4; DOMIAN IJ, 1998, THESIS STANFORD U SC; ELY B, 1991, METHOD ENZYMOL, V204, P372; Hofmann K., 1993, BIOL CHEM, V374, P166; Jenal U, 1998, EMBO J, V17, P5658, DOI 10.1093/emboj/17.19.5658; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Loomis WF, 1998, CURR OPIN MICROBIOL, V1, P643, DOI 10.1016/S1369-5274(98)80109-4; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PAZOUR GJ, 1991, P NATL ACAD SCI USA, V88, P6941, DOI 10.1073/pnas.88.16.6941; Quon KC, 1998, P NATL ACAD SCI USA, V95, P120, DOI 10.1073/pnas.95.1.120; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; Roberts RC, 1996, J BACTERIOL, V178, P1829, DOI 10.1128/jb.178.7.1829-1841.1996; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; Stephens C, 1997, J BACTERIOL, V179, P5355, DOI 10.1128/jb.179.17.5355-5365.1997; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Webb CD, 1998, MOL MICROBIOL, V28, P883, DOI 10.1046/j.1365-2958.1998.00808.x; WINZELER E, 1995, J MOL BIOL, V251, P346, DOI 10.1006/jmbi.1995.0439	28	204	206	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					111	120		10.1016/S0092-8674(00)80719-9	http://dx.doi.org/10.1016/S0092-8674(00)80719-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199407	Bronze			2022-12-01	WOS:000079843900013
J	Lanz, RB; McKenna, NJ; Onate, SA; Albrecht, U; Wong, JM; Tsai, SY; Tsai, MJ; O'Malley, BW				Lanz, RB; McKenna, NJ; Onate, SA; Albrecht, U; Wong, JM; Tsai, SY; Tsai, MJ; O'Malley, BW			A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex	CELL			English	Article							TRANSCRIPTION FACTOR COUP; THYROID-HORMONE RECEPTOR; PROGESTERONE-RECEPTOR; RESPONSE ELEMENTS; ANDROGEN RECEPTOR; NUCLEAR RECEPTORS; ACTIVATION; GENE; PROTEIN; TRANSACTIVATION	Nuclear receptors play critical roles in the regulation of eukaryotic gene expression. We report the isolation and functional characterization of a novel transcriptional coactivator, termed steroid receptor RNA activator (SRA). SRA is selective for steroid hormone receptors and mediates transactivation via their aminoterminal activation function. We provide functional and mechanistic evidence that SRA acts as an RNA transcript; transfected SRA, unlike other steroid receptor coregulators, functions in the presence of cycloheximide, and SRA mutants containing multiple translational stop signals retain their ability to activate steroid receptor-dependent gene expression. Biochemical fractionation shows that SRA exists in distinct ribonucleoprotein complexes, one of which contains the nuclear receptor coactivator steroid receptor coactivator 1. We suggest that SRA may act to confer functional specificity upon multiprotein complexes recruited by liganded receptors during transcriptional activation.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Albrecht, Urs/A-9831-2011	Albrecht, Urs/0000-0002-0663-8676; McKenna, Neil/0000-0001-6689-0104; Wong, Jiemin/0000-0002-5311-842X				Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CRESPI MD, 1994, EMBO J, V13, P5099, DOI 10.1002/j.1460-2075.1994.tb06839.x; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELASHRYSTOWERS D, 1988, CANCER RES, V48, P6462; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jaeger L, 1997, CURR OPIN STRUC BIOL, V7, P324, DOI 10.1016/S0959-440X(97)80047-4; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUIPER GGJM, 1993, BIOCHEM J, V296, P161, DOI 10.1042/bj2960161; LANZ RB, 1995, NUCLEIC ACIDS RES, V23, P138, DOI 10.1093/nar/23.1.138; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LENG XH, 1994, J BIOL CHEM, V269, P31436; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; MCKENNA NJ, 1999, IN PRESS ENDOCRINE R; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; Sit TL, 1998, SCIENCE, V281, P829, DOI 10.1126/science.281.5378.829; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Zhang BL, 1997, NATURE, V390, P96, DOI 10.1038/36375	41	628	666	1	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					17	27		10.1016/S0092-8674(00)80711-4	http://dx.doi.org/10.1016/S0092-8674(00)80711-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199399	Bronze			2022-12-01	WOS:000079843900005
J	Chiu, DT; Wilson, CF; Ryttsen, F; Stromberg, A; Farre, C; Karlsson, A; Nordholm, S; Gaggar, A; Modi, BP; Moscho, A; Garza-Lopez, RA; Orwar, O; Zare, RN				Chiu, DT; Wilson, CF; Ryttsen, F; Stromberg, A; Farre, C; Karlsson, A; Nordholm, S; Gaggar, A; Modi, BP; Moscho, A; Garza-Lopez, RA; Orwar, O; Zare, RN			Chemical transformations in individual ultrasmall biomimetic containers	SCIENCE			English	Article							ELECTRICAL BREAKDOWN; SINGLE MOLECULES; AQUEOUS CONTENTS; MEMBRANES; KINETICS; FUSION; CELL	Individual phospholipid vesicles, 1 to 5 micrometers in diameter, containing a single reagent or a complete reaction system, were immobilized with an infrared laser optical trap or by adhesion to modified borosilicate glass surfaces. Chemical transformations were initiated either by electroporation or by electrofusion, in each case through application of a short (10-microsecond), intense (20 to 50 kilovolts per centimeter) electric pulse delivered across ultramicroelectrodes. Product formation was monitored by far-field laser fluorescence microscopy. The ultrasmall characteristic of this reaction volume led to rapid diffusional mixing that permits the study of fast chemical kinetics. This technique is also well suited for the study of reaction dynamics of biological molecules within lipid-enclosed nanoenvironments that mimic cell membranes.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Univ Gothenburg, Dept Chem, S-41296 Gothenburg, Sweden; Pomona Coll, Dept Chem, Claremont, CA 91711 USA	Stanford University; University of Gothenburg; Claremont Colleges; Pomona College	Zare, RN (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		Zare, Richard N./A-8410-2009; Nordholm, Sture/A-8506-2010	Zare, Richard/0000-0001-5266-4253	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009873] Funding Source: NIH RePORTER; NIDA NIH HHS [DA09873] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CHANG DC, 1990, BIOPHYS J, V58, P1, DOI 10.1016/S0006-3495(90)82348-1; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V902, P360, DOI 10.1016/0005-2736(87)90204-5; Chiu DT, 1997, ANAL CHEM, V69, P1801, DOI 10.1021/ac961226g; Clark RA, 1997, ANAL CHEM, V69, P259, DOI 10.1021/ac960559a; Drott J, 1998, THIN SOLID FILMS, V330, P161, DOI 10.1016/S0040-6090(98)00543-4; DUZGUNES N, 1993, METHOD ENZYMOL, V220, P3, DOI 10.1016/0076-6879(93)20069-F; ERMAK DL, 1975, J CHEM PHYS, V62, P4189, DOI 10.1063/1.430300; FUNAKURA S, 1994, J PHYS CHEM-US, V98, P3073, DOI 10.1021/j100063a003; Jensen K, 1998, NATURE, V393, P735, DOI 10.1038/31590; Knight JB, 1998, PHYS REV LETT, V80, P3863, DOI 10.1103/PhysRevLett.80.3863; Kovacs GTA, 1996, ANAL CHEM, V68, pA407, DOI 10.1021/ac961977i; Kung CY, 1998, ANAL CHEM, V70, P658, DOI 10.1021/ac971107g; Masuhara H., 1994, MICROCHEMISTRY SPECT; Moscho A, 1996, P NATL ACAD SCI USA, V93, P11443, DOI 10.1073/pnas.93.21.11443; NEEDHAM D, 1993, METHOD ENZYMOL, V220, P111, DOI 10.1016/0076-6879(93)20078-H; Nie SM, 1997, ANNU REV BIOPH BIOM, V26, P567, DOI 10.1146/annurev.biophys.26.1.567; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; STENGER DA, 1988, BIOPHYS J, V53, P833, DOI 10.1016/S0006-3495(88)83162-X; Tan WH, 1997, ANAL CHEM, V69, P4242, DOI 10.1021/ac970631k; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; TURQ P, 1977, J CHEM PHYS, V66, P3039, DOI 10.1063/1.434317; WILHELM C, 1993, BIOPHYS J, V64, P121, DOI 10.1016/S0006-3495(93)81346-8; You AJ, 1997, CHEM BIOL, V4, P969, DOI 10.1016/S1074-5521(97)90305-7; ZIMMERMANN U, 1982, BIOCHIM BIOPHYS ACTA, V694, P227, DOI 10.1016/0304-4157(82)90007-7	24	223	257	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1892	1895		10.1126/science.283.5409.1892	http://dx.doi.org/10.1126/science.283.5409.1892			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10082457				2022-12-01	WOS:000079228600040
J	Ledergerber, B; Egger, M; Opravil, M; Telenti, A; Hirschel, B; Battegay, M; Vernazza, P; Sudre, P; Flepp, M; Furrer, H; Francioli, P; Weber, R				Ledergerber, B; Egger, M; Opravil, M; Telenti, A; Hirschel, B; Battegay, M; Vernazza, P; Sudre, P; Flepp, M; Furrer, H; Francioli, P; Weber, R		Swiss HIV Cohort Study	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; INDINAVIR; COUNTS	Background The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in routine practice. Methods We analysed prospective data from the Swiss HIV Cohort Study on suppression of viral load and progression to AIDS or death in 2674 outpatients (median age 36 years, 27.3% women) who started HAART in 1995-98. Viral rebound was defined as two consecutive HIV-1-RNA measurements of more than 400 copies/mL. We analysed separately outcomes in patients with a history of antiretroviral treatment and in treatment-naive patients. Findings An estimated 90.7% of treatment-naive patients reached undetectable viral load (<400 copies/mL) by 12 months. Among pretreated patients, estimates ranged from 70.3% treated with one new drug to 78.7% on three new drugs. 2 years after reaching undetectable concentrations, an estimated 20.1% of treatment-naive patients and 35.7-40.1% of pretreated patients had viral rebound. At 30 months, an estimated 6.6% (95% CI 4.6-8.6) of patients who had maintained undetectable concentrations, 9.0% (5.5-12.5) who had viral rebound, and 20.1% (15.3-24.9) who had never reached undetectable concentrations developed AIDS or died. Compared with patients who maintained undetectable viral load, the adjusted relative hazard of AIDS or death was 1.00 (0.66-1.55) for patients with viral rebound, and 2.40 (1.72-3.33) for patients who failed to reach undetectable concentrations. Interpretation The rate of virological failure of HAART was high among these patients, but the probability of clinical progression was low even in patients with viral rebound.	Univ Zurich, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England; Univ Lausanne, Div Infect Dis, Lausanne, Switzerland; Univ Lausanne, Div Hosp Prevent Med, Lausanne, Switzerland; Univ Geneva, Div Infect Dis, Geneva, Switzerland; Univ Basel, Outpatient Dept Internal Med, Basel, Switzerland; Cantonal Hosp St Gall, Div Internal Med, St Gallen, Switzerland; Univ Bern, Outpatient Dept Internal Med, Bern, Switzerland	University of Zurich; University of Bristol; University of Lausanne; University of Lausanne; University of Geneva; University of Basel; Kantonsspital St. Gallen; University of Bern	Ledergerber, B (corresponding author), Univ Zurich Hosp, Div Infect Dis, U RAE 33, CH-8091 Zurich, Switzerland.	infled@usz.unizh.ch	Weber, Rainer/D-5175-2012; Furrer, Hansjakob/G-6768-2013; Ledergerber, Bruno/B-5656-2009; Telenti, Amalio/AAY-1674-2021	Furrer, Hansjakob/0000-0002-1375-3146; Ledergerber, Bruno/0000-0002-6881-4401; Egger, Matthias/0000-0001-7462-5132				BABIKER A, 1997, 6 EUR C CLIN ASP TRE, P207; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Casado JL, 1998, AIDS, V12, pF131, DOI 10.1097/00002030-199811000-00005; *CDCP, 1992, MMWR-MORBID MORTAL W, V41; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; FEINSTEIN A, 1984, STAT MED, V3, P341, DOI 10.1002/sim.4780030409; FLEMING TR, 1994, STAT MED, V13, P955, DOI 10.1002/sim.4780130906; Gazzard B, 1998, LANCET, V352, P314, DOI 10.1016/S0140-6736(98)04084-7; GREEN SB, 1984, STAT MED, V3, P361, DOI 10.1002/sim.4780030413; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; Levy JA, 1998, LANCET, V352, P982, DOI 10.1016/S0140-6736(98)05391-4; Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Monforte AD, 1998, AIDS, V12, P1631, DOI 10.1097/00002030-199813000-00010; MONTANE RJSG, 1998, JAMA-J AM MED ASSOC, V279, P930; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perry CM, 1998, DRUGS, V55, P461, DOI 10.2165/00003495-199855030-00014	28	790	803	0	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1999	353	9156					863	868		10.1016/S0140-6736(99)01122-8	http://dx.doi.org/10.1016/S0140-6736(99)01122-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BU	10093977				2022-12-01	WOS:000079421400007
J	Cocks, TM; Fong, B; Chow, JM; Anderson, GP; Frauman, AG; Goldie, RG; Henry, PJ; Carr, MJ; Hamilton, JR; Moffatt, JD				Cocks, TM; Fong, B; Chow, JM; Anderson, GP; Frauman, AG; Goldie, RG; Henry, PJ; Carr, MJ; Hamilton, JR; Moffatt, JD			A protective role for protease-activated receptors in the airways	NATURE			English	Article							THROMBIN RECEPTOR; MOLECULAR-CLONING; NITRIC-OXIDE; EXPRESSION; MECHANISMS; BRADYKININ	The protection of cells in the upper intestine against digestion by pancreatic trypsin depends on the prostanoid prostaglandin E-2 (PGE(2)) and is mediated by protease-activated receptors in the epithelium(1,2). As the airway epithelium is morphologically similar and also expresses one of these receptors, PAR2 (ref. 3), and is a major source of PGE2 (ref. 4), we reasoned that bronchial epithelial PAR2 might also participate in prostanoid-dependent cytoprotection in the airways, Here we show that activation of PAR2, which co-localizes immunohistochemically with trypsin(ogen) in airway epithelium, causes the relaxation of airway preparations from mouse, rat, guinea-pig and humans by the release of a cyclooxygenase product from the epithelium.This physiological protective response in isolated airways also occurred in anaesthetized rats, where activation of PAR2 caused a marked and prolonged inhibition of bronchoconstriction. After desensitization of PAR2, the response to trypsin recovered rapidly by mechanisms dependent on de novo synthesis and trafficking of proteins. Our results indicate that trypsin released from the epithelium can initiate powerful bronchoprotection in the airways by activation of epithelial PAR2.	Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia; Univ Western Australia, Dept Pharmacol, Perth, WA 6907, Australia	University of Melbourne; University of Melbourne; University of Western Australia	Cocks, TM (corresponding author), Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia.	t.cocks@pharmacology.unimelb.edu.au		Anderson, Gary/0000-0001-6580-3398; Henry, Peter/0000-0002-8213-0508				Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; CHOUDRY NB, 1989, AM REV RESPIR DIS, V140, P137, DOI 10.1164/ajrccm/140.1.137; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kawano N, 1997, HUM PATHOL, V28, P613, DOI 10.1016/S0046-8177(97)90085-X; Kemp BK, 1997, BRIT J PHARMACOL, V120, P757, DOI 10.1038/sj.bjp.0700928; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; MANNING PJ, 1987, J APPL PHYSIOL, V63, P1572, DOI 10.1152/jappl.1987.63.4.1572; Molino M, 1997, J BIOL CHEM, V272, P11133; MONCADA S, 1991, PHARMACOL REV, V43, P109; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P8208; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; PAVORD ID, 1994, LANCET, V344, P436; Szarek JL, 1998, AM J PHYSIOL-LUNG C, V275, pL1006, DOI 10.1152/ajplung.1998.275.5.L1006; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEIDEMANN HP, 1996, CURR OPIN PULM MED, V2, P155; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	22	309	318	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	1999	398	6723					156	160		10.1038/18223	http://dx.doi.org/10.1038/18223			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176DG	10086357				2022-12-01	WOS:000079135200046
J	Logan, DT; Andersson, J; Sjoberg, BM; Nordlund, P				Logan, DT; Andersson, J; Sjoberg, BM; Nordlund, P			A glycyl radical site in the crystal structure of a class III ribonucleotide reductase	SCIENCE			English	Article							PYRUVATE FORMATE-LYASE; IRON-SULFUR CENTER; ESCHERICHIA-COLI; CYSTEINE RESIDUES; ACTIVATING ENZYME; PROTEIN R1; MECHANISM; GLYCINE-734; REFINEMENT; MOLSCRIPT	Ribonucleotide reductases catalyze the reduction of ribonucleotides to deoxyribonucleotides. Three classes have been identified, all using free-radical chemistry but based on different cofactors. Classes I and II have been shown to be evolutionarily related, whereas the origin of anaerobic class III has remained elusive. The structure of a class III enzyme suggests a common origin,for the three classes but shows differences in the active site that can be understood on the basis of the radical-initiation system and source of reductive electrons, as well as a unique protein glycyl radical site. A possible evolutionary relationship between early deoxyribonucleotide metabolism and primary anaerobic metabolism is suggested.	Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden; Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden	Stockholm University; Stockholm University	Nordlund, P (corresponding author), Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden.	derek@biokemi.su.se; par@milvus.biokemi.su.se	Logan, Derek T/A-1114-2011; Logan, Derek/O-2497-2019	Logan, Derek T/0000-0002-0098-8560; Logan, Derek/0000-0002-0098-8560; Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ANDERSSON J, UNPUB; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; ELIASSON R, 1995, BIOCHEM BIOPH RES CO, V214, P28, DOI 10.1006/bbrc.1995.2252; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FREY M, 1994, J BIOL CHEM, V269, P12432; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; KNAPPE J, 1995, METHOD ENZYMOL, V258, P343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Lenz R, 1997, J AM CHEM SOC, V119, P2784, DOI 10.1021/ja962974q; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Olcott MC, 1998, J BIOL CHEM, V273, P24853, DOI 10.1074/jbc.273.38.24853; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P2393, DOI 10.1021/bi00008a001; Persson AL, 1998, J BIOL CHEM, V273, P31016, DOI 10.1074/jbc.273.47.31016; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Riera J, 1997, P NATL ACAD SCI USA, V94, P475, DOI 10.1073/pnas.94.2.475; Sawers G, 1998, MOL MICROBIOL, V29, P945, DOI 10.1046/j.1365-2958.1998.00941.x; Siegbahn PEM, 1998, J AM CHEM SOC, V120, P8417, DOI 10.1021/ja9736065; Sjoberg BM, 1997, STRUCT BOND, V88, P139; STUART DI, UNPUB; STUBBE J, 1983, J BIOL CHEM, V258, P1625; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; TRONRUD DE, 1987, ACTA CRYSTALLOGR D, V53, P240; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Young P, 1996, J BIOL CHEM, V271, P20770, DOI 10.1074/jbc.271.34.20770	49	159	166	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1499	1504		10.1126/science.283.5407.1499	http://dx.doi.org/10.1126/science.283.5407.1499			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066165				2022-12-01	WOS:000078959200037
J	Guse, AH; da Silva, CP; Berg, I; Skapenko, AL; Weber, K; Heyer, P; Hohenegger, M; Ashamu, GA; Schulze-Koops, H; Potter, BVL; Mayr, GW				Guse, AH; da Silva, CP; Berg, I; Skapenko, AL; Weber, K; Heyer, P; Hohenegger, M; Ashamu, GA; Schulze-Koops, H; Potter, BVL; Mayr, GW			Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CA2+-INDUCED CA2+ RELEASE; RYANODINE RECEPTOR; CELL RECEPTOR; ENTRY; CHANNELS; MEMBRANE; MODULATION; HYDROLYSIS; DEPLETION	Cyclic ADP-ribose (cADPR) is a natural compound that mobilizes calcium ions in several eukaryotic cells(1-3). Although it can lead to the release of calcium ions in T lymphocytes(4-7), it has not been firmly established as a second messenger in these cells. Here, using high-performance liquid chromatography analysis(8), we show that stimulation of the T-cell receptor/CD3 (TCR/CD3) complex results in activation of a soluble ADP-ribosyl cyclase and a sustained increase in intracellular levels of cADPR. There is a causal relation between increased cADPR concentrations, sustained calcium signalling and activation of T cells, as shown by inhibition of TCR/CD3-stimulated calcium sig-nailing, cell proliferation and expression of the early- and late-activation markers I CD25 and HLA-DR by using cADPR antagonists(9). The molecular target for cADPR, the type-3 ryanodine receptor/calcium channel, is expressed in T cells. Increased cADPR significantly and specifically stimulates the apparent association of [H-3]ryanodine with the type-3 ryanodine receptor, indicating a direct modulatory effect of cADPR on channel opening. Thus we show the presence, causal relation and biological significance of the major constituents of the cADPR/calcium-signalling pathway in human T cells.	Univ Hamburg, Inst Physiol Chem, Dept Enzyme Chem, D-20146 Hamburg, Germany; Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany; Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England	University of Hamburg; University of Erlangen Nuremberg; University of Vienna; University of Bath	Guse, AH (corresponding author), Univ Hamburg, Inst Physiol Chem, Dept Enzyme Chem, Grindelallee 117, D-20146 Hamburg, Germany.	guse@uke.uni-hamburg.de	Potter, Barry VL/A-1845-2012; Potter, Barry/AAX-4781-2020; Hohenegger, Martin/AAF-6479-2020	Hohenegger, Martin/0000-0001-6537-9574	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; Cancela JM, 1998, CURR BIOL, V8, P865, DOI 10.1016/S0960-9822(07)00347-8; da Silva CP, 1998, J CHROMATOGR B, V707, P43, DOI 10.1016/S0378-4347(97)00622-1; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Guse AH, 1998, CRIT REV IMMUNOL, V18, P419, DOI 10.1615/CritRevImmunol.v18.i5.20; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; GUSE AH, 1995, J IMMUNOL, V155, P3353; Guse AH, 1996, J BIOL CHEM, V271, P23946, DOI 10.1074/jbc.271.39.23946; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; IMOTO M, 1993, J ANTIBIOT, V46, P1342, DOI 10.7164/antibiotics.46.1342; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Ricard I, 1997, CELL SIGNAL, V9, P197, DOI 10.1016/S0898-6568(96)00141-6; Schulze-Koops H, 1998, EUR J IMMUNOL, V28, P2517, DOI 10.1002/(SICI)1521-4141(199808)28:08<2517::AID-IMMU2517>3.0.CO;2-5; SCHULZEKOOPS H, 1995, J IMMUNOL, V155, P5029; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Takemura H, 1996, BIOCHEM J, V319, P393, DOI 10.1042/bj3190393; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	30	257	283	2	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 4	1999	398	6722					70	73		10.1038/18024	http://dx.doi.org/10.1038/18024			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174KG	10078531				2022-12-01	WOS:000079033900053
J	Yokota, Y; Mansouri, A; Mori, S; Sugawara, S; Adachi, S; Nishikawa, S; Gruss, P				Yokota, Y; Mansouri, A; Mori, S; Sugawara, S; Adachi, S; Nishikawa, S; Gruss, P			Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2	NATURE			English	Article							GERMINAL-CENTERS; MONOCLONAL-ANTIBODY; DNA-BINDING; T-CELL; B-CELL; MICE; LYMPHOTOXIN; RECEPTOR; SPLEEN; LYMPHOCYTES	Transcription factors with a basic helix-loop-helix (HLH) moth have been shown to be crucial for various cell differentiation processes during development of multicellular organisms(1), Id proteins inhibit the functions of these transcription factors in a dominant-negative manner by suppressing their heterodimerization partners through the HLH domains(2-4). Members of the Id family also promote cell proliferation(4,5), implying a role in the control of cell differentiation. Here we show that Id2 is indispensable for normal development of mice, Id2(-/-) mice lack lymph nodes and Peyer's patches. However, their splenic architecture is normal, exhibiting T-cell and B-cell compartments and distinct germinal centres, The cell population that produces lymphotoxins, essential factors for the development of secondary lymphoid organs(6-11), is barely detectable in the Id2(-/-) intestine, Furthermore, the null mutants show a greatly reduced population of natural killer (NK) cells, which is due to an intrinsic defect in NK-cell precursors, Our results indicate that Id2 has an essential role in the generation of peripheral lymphoid organs and NK cells.	Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; Kyoto Univ, Grad Sch Med, Dept Mol Genet, Sakyo Ku, Kyoto 6068507, Japan	Max Planck Society; Kyoto University	Yokota, Y (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Cell Biol, Am Fassberg, D-37077 Gottingen, Germany.							Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Fu YX, 1997, P NATL ACAD SCI USA, V94, P5739, DOI 10.1073/pnas.94.11.5739; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KRAAL G, 1986, IMMUNOLOGY, V58, P665; KRAAL G, 1995, AM J PATHOL, V147, P763; Liu YJ, 1996, INT REV CYTOL, V166, P139, DOI 10.1016/S0074-7696(08)62508-5; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; PICARELLA DE, 1993, J IMMUNOL, V150, P4136; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074-7613(00)80589-0; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANAKA T, 1993, J EXP MED, V178, P1103, DOI 10.1084/jem.178.3.1103; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YOSHIDA H, IN PRESS INT IMMUNOL	30	706	723	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 25	1999	397	6721					702	706		10.1038/17812	http://dx.doi.org/10.1038/17812			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067894				2022-12-01	WOS:000078840100052
J	Cody, SH; Glynn, MK; Farrar, JA; Cairns, KL; Griffin, PM; Kobayashi, J; Fyfe, M; Hoffman, R; King, AS; Lewis, JH; Swaminathan, B; Bryant, RG; Vugia, DJ				Cody, SH; Glynn, MK; Farrar, JA; Cairns, KL; Griffin, PM; Kobayashi, J; Fyfe, M; Hoffman, R; King, AS; Lewis, JH; Swaminathan, B; Bryant, RG; Vugia, DJ			An outbreak of Escherichia coli O157 : H7 infection from unpasteurized commercial apple juice	ANNALS OF INTERNAL MEDICINE			English	Article							HEMOLYTIC-UREMIC-SYNDROME; MULTISTATE OUTBREAK; CIDER; CYCLOSPORIASIS; RASPBERRIES; DIARRHEA; SURVIVAL; MODEL; SHEEP; FATE	Background: Escherichia coli O157:H7 infections have traditionally been associated with animal products, but outbreaks associated with produce have been reported with increasing frequency. In fall 1996, a small cluster of E. coli O157:H7 infections was epidemiologically linked to a particular brand (brand A) of unpasteurized apple juice. Objective: To define the extent of the outbreak, confirm the source, and determine how the apple juice became contaminated. Design: Descriptive epidemiologic study and traceback investigation. Setting: Western United States and British Columbia, Canada. Patients: Patients with E. coli O157:H7 infection who were exposed to brand A apple juice. Measurements: Clinical outcome and juice exposure histories of case-patients, pulsed-field gel electrophoresis of case and juice isolates, and juice production practices. Results: Seventy persons with E. coli O157:H7 infection and exposure to brand A unpasteurized apple juice were identified. Of these persons, 25 (36%) were hospitalized, 14 (20%) developed the hemolytic uremic syndrome, and 1 (1%) died. Recalled apple juice that was produced on 7 October 1996 grew E, coli O157:H7 with a pulsed-field gel electrophoresis pattern indistinguishable from that of case isolates. Apple juice produced on 7 October 1996 accounted for almost all of the cases, and the source of contamination was suspected to be incoming apples. Three lots of apples could explain contamination of the juice: Two lots originated from an orchard frequented by deer that were subsequently shown to carry E. coli O157:H7, and one lot contained decayed apples that had been waxed. Conclusions: Standard procedures at a state-of-the-art plant that produced unpasteurized juices were inadequate to eliminate contamination with E. coli O157:H7. This outbreak demonstrated that unpasteurized juices must be considered a potentially hazardous food and led to widespread changes in the fresh juice industry.	Calif Dept Hlth Serv, Food & Drug Branch, Sacramento, CA 94234 USA; Ctr Dis Control & Prevent, Div Publ Hlth Surveillance & Informat, Epidemiol Program Off, Atlanta, GA 30333 USA; Washington State Dept Hlth, Shoreline, WA 98155 USA; British Columbia Ctr Dis Control, Vancouver, BC V52Z 4R4, Canada; Hlth Canada, Lab Ctr Dis Control, Ottawa, ON, Canada; Colorado Dept Publ Hlth & Environm, Denver, CO 80246 USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA; Calif Dept Hlth Serv, Microbial Dis Lab, Berkeley, CA 94704 USA; Calif Dept Hlth Serv, Div Communicable Dis Control, Berkeley, CA 94704 USA	California Department of Health Care Services; Centers for Disease Control & Prevention - USA; Health Canada; Colorado Department of Public Health & Environment; Centers for Disease Control & Prevention - USA; California Department of Health Care Services; California Department of Health Care Services	Cody, SH (corresponding author), Santa Clara Cty Dept Publ Hlth, 2220 Moorpark Ave 115, San Jose, CA 95128 USA.							Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; BARRETT TJ, 1991, CURR MICROBIOL, V23, P189, DOI 10.1007/BF02092278; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; BELL BP, 1994, JAMA-J AM MED ASSOC, V272, P1349, DOI 10.1001/jama.272.17.1349; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; Besser TE, 1997, J INFECT DIS, V175, P726, DOI 10.1093/infdis/175.3.726; BOYCE TG, 1995, NEW ENGL J MED, V333, P364, DOI 10.1056/NEJM199508103330608; CEBULA TA, 1995, J CLIN MICROBIOL, V33, P248, DOI 10.1128/JCM.33.1.248-250.1995; CONNER DE, 1995, APPL ENVIRON MICROB, V61, P382, DOI 10.1128/AEM.61.1.382-385.1995; Cook KA, 1998, JAMA-J AM MED ASSOC, V280, P1504, DOI 10.1001/jama.280.17.1504; DEAN A, 1995, EPI INFO VERSION 6 W; DOYLE MP, 1987, APPL ENVIRON MICROB, V53, P2394, DOI 10.1128/AEM.53.10.2394-2396.1987; *FDA, 1998, FED REGISTER, V63, P20486; *FDA, 1998, FED REGISTER, V63, P20449; GLASS KA, 1992, APPL ENVIRON MICROB, V58, P2513, DOI 10.1128/AEM.58.8.2513-2516.1992; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3203, DOI 10.1001/jama.268.22.3203; Herwaldt BL, 1997, NEW ENGL J MED, V336, P1548, DOI 10.1056/NEJM199705293362202; Keene WE, 1997, JAMA-J AM MED ASSOC, V277, P1229, DOI 10.1001/jama.277.15.1229; Kudva IT, 1996, J CLIN MICROBIOL, V34, P431, DOI 10.1128/JCM.34.2.431-433.1996; KUDVA IT, 1995, APPL ENVIRON MICROB, V61, P1363, DOI 10.1128/AEM.61.4.1363-1370.1995; MILLARD PS, 1994, JAMA-J AM MED ASSOC, V272, P1592, DOI 10.1001/jama.272.20.1592; MILLER LG, 1994, J FOOD PROTECT, V57, P460, DOI 10.4315/0362-028X-57.6.460; Olsvik Orjan, 1993, P271; Osterholm MT, 1997, NEW ENGL J MED, V336, P1597, DOI 10.1056/NEJM199705293362210; Shukla R, 1995, Commun Dis Rep CDR Rev, V5, pR86; STEELE BT, 1982, J PEDIATR-US, V101, P963, DOI 10.1016/S0022-3476(82)80021-8; TABERSHAW IR, 1967, ARCH ENVIRON HEALTH, V15, P72, DOI 10.1080/00039896.1967.10664878; ZADIK PM, 1993, J MED MICROBIOL, V39, P155, DOI 10.1099/00222615-39-2-155; ZHAO T, 1993, APPL ENVIRON MICROB, V59, P2526, DOI 10.1128/AEM.59.8.2526-2530.1993; 1975, MMWR MORB MORTAL WKL, V24, P87; 1996, MMWR MORB MORTAL WKL, V45, P975; 1997, MMWR MORB MORTAL WKL, V46, P4; 1997, MMWR MORB MORTAL WKL, V46, P288; 1997, MMWR MORB MORTAL WKL, V46, P295	34	296	305	1	38	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					202	+		10.7326/0003-4819-130-3-199902020-00005	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049198				2022-12-01	WOS:000078355000004
J	Kool, JL; Carpenter, JC; Fields, BS				Kool, JL; Carpenter, JC; Fields, BS			Effect of monochloramine disinfection of municipal drinking water on risk of nosocomial Legionnaires' disease	LANCET			English	Article							LEGIONELLA-PNEUMOPHILA; POTABLE WATER; TAP WATER; HOT WATER; PNEUMONIA; OUTBREAK; BIOFILM; CONTAMINATION; TRANSMISSION; SURVEILLANCE	Background Many Legionella infections are acquired through inhalation or aspiration of drinking water. Although about 25% of municipalities in the USA use monochloramine for disinfection of drinking water. the effect of monochloramine on the occurrence of Legionnaires' disease has never been studied. Methods We used a case-control study to compare disinfection methods for drinking water supplied to 32 hospitals that had had outbreaks of Legionnaires' disease with the disinfection method for water supplied to 48 control-hospitals, with central for selected hospital characteristics and water treatment factors. Findings Hospitals supplied with drinking water containing free chlorine as a residual disinfectant were more likely to have a reported outbreak of Legionnaires' disease than those that used water with monochloramine as a residual disinfectant (odds ratio 10.2 [95% CI 1.4-460]), This result suggests that 90% of outbreaks associated with drinking water might not have occurred if monochloramine had been used Instead of free chlorine for residual disinfection (attributable proportion 0.90 [029-1.00]). Interpretation The protective effect of monochloramine against legionella should be confirmed by other studies. Chloramination of drinking water may be a cost-effective method for control of Legionnaires' disease at the municipal level or in individual hospitals, and widespread implementation could prevent thousands of cases.	Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Resp Dis Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Kool, JL (corresponding author), Univ So Calif, 313 N Figueroa St,Room 212, Los Angeles, CA 90012 USA.	jkool@ibm.net		Kool, Jacob/0000-0002-9605-2918				ALARY M, 1992, J INFECT DIS, V165, P565, DOI 10.1093/infdis/165.3.565; *AM HOSP ASS, 1993, AHA GUID HLTH CAR FI; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; ARNOW PM, 1982, J INFECT DIS, V146, P460, DOI 10.1093/infdis/146.4.460; BEST M, 1983, LANCET, V2, P307; BHOPAL RS, 1991, BRIT MED J, V302, P378, DOI 10.1136/bmj.302.6773.378; BLATT SP, 1993, AM J MED, V95, P16, DOI 10.1016/0002-9343(93)90227-G; BRADY MT, 1989, J PEDIATR-US, V115, P46, DOI 10.1016/S0022-3476(89)80327-0; BREIMAN RF, 1990, JAMA-J AM MED ASSOC, V263, P2924, DOI 10.1001/jama.263.21.2924; BROWN A, 1985, INFECTION, V13, P163, DOI 10.1007/BF01642803; BUCHHOLZ U, 1998, 38 INT C ANT AG CHEM, P583; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P416; Chen X, 1996, ENVIRON SCI TECHNOL, V30, P2078, DOI 10.1021/es9509184; CIESIELSKI CA, 1984, APPL ENVIRON MICROB, V48, P984, DOI 10.1128/AEM.48.5.984-987.1984; CORDES LG, 1981, ANN INTERN MED, V94, P195, DOI 10.7326/0003-4819-94-2-195; CUNLIFFE DA, 1990, J APPL BACTERIOL, V68, P453, DOI 10.1111/j.1365-2672.1990.tb02896.x; DICE JC, 1985, J AM WATER WORKS ASS, V77, P34; DOEBBELING BN, 1989, J HOSP INFECT, V13, P289, DOI 10.1016/0195-6701(89)90010-8; Graman PS, 1997, INFECT CONT HOSP EP, V18, P637, DOI 10.2307/30141491; Green M, 1996, J CLIN MICROBIOL, V34, P175, DOI 10.1128/JCM.34.1.175-176.1996; HANRAHAN JP, 1987, AM J EPIDEMIOL, V125, P639, DOI 10.1093/oxfordjournals.aje.a114577; HANRAHAN JP, 1984, LEGIONELLA, P224; HEIMBERGER T, 1991, J INFECT DIS, V163, P413, DOI 10.1093/infdis/163.2.413; HELMS CM, 1988, JAMA-J AM MED ASSOC, V259, P2423, DOI 10.1001/jama.259.16.2423; JOHNSON JT, 1985, LANCET, V2, P298; JOHNSTON JM, 1987, INFECT CONT HOSP EP, V8, P53, DOI 10.1017/S0195941700067072; KIRMEYER GJ, 1993, OPTIMIZING CHLORAMIN; Kool JL, 1998, INFECT CONT HOSP EP, V19, P898; Kool JL, 1998, LANCET, V351, P1030, DOI 10.1016/S0140-6736(05)78996-0; KOOL JL, 1998, 8 ANN M SOC HEALTHC, P39; LECHEVALLIER MW, 1988, APPL ENVIRON MICROB, V54, P2492, DOI 10.1128/AEM.54.10.2492-2499.1988; LEPINE L, 1995, 35 INT C ANT AG CHEM, P267; LOWRY PW, 1991, NEW ENGL J MED, V324, P109, DOI 10.1056/NEJM199101103240207; MARSTON BJ, 1994, ARCH INTERN MED, V154, P2417, DOI 10.1001/archinte.154.21.2417; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MASTRO TD, 1991, J INFECT DIS, V163, P667, DOI 10.1093/infdis/163.3.667; MATULONIS U, 1993, INFECT CONT HOSP EP, V14, P571, DOI 10.1086/646639; MERMEL LA, 1995, INFECT CONT HOSP EP, V16, P76, DOI 10.1086/647060; Nafziger DA, 1998, INFECT DIS CLIN PRAC, V7, P118; NOLTE FS, 1984, J INFECT DIS, V149, P251, DOI 10.1093/infdis/149.2.251; PARRY MF, 1985, ANN INTERN MED, V103, P205, DOI 10.7326/0003-4819-103-2-205; PLOUFFE JF, 1983, APPL ENVIRON MICROB, V46, P769, DOI 10.1128/AEM.46.3.769-770.1983; PLOUFFE JF, 1983, LANCET, V2, P649; Samrakandi MM, 1997, CAN J MICROBIOL, V43, P751, DOI 10.1139/m97-108; SCHOONMAKER D, 1992, J CLIN MICROBIOL, V30, P1491, DOI 10.1128/JCM.30.6.1491-1498.1992; SELLICK JA, 1993, LEGIONELLA, P43; SHANDS KN, 1985, JAMA-J AM MED ASSOC, V253, P1412, DOI 10.1001/jama.253.10.1412; STOUT JE, 1992, NEW ENGL J MED, V326, P151, DOI 10.1056/NEJM199201163260302; Straus WL, 1996, ARCH INTERN MED, V156, P1685, DOI 10.1001/archinte.156.15.1685; SYNDER MB, 1990, J INFECT DIS, V162, P127, DOI 10.1093/infdis/162.1.127; VENEZIA RA, 1994, INFECT CONT HOSP EP, V15, P529	51	97	102	2	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1999	353	9149					272	277		10.1016/S0140-6736(98)06394-6	http://dx.doi.org/10.1016/S0140-6736(98)06394-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929019				2022-12-01	WOS:000078292200009
J	McKenzie, D; Nimmo, F				McKenzie, D; Nimmo, F			The generation of Martian floods by the melting of ground ice above dykes	NATURE			English	Article							MARS; HISTORY; VALLES; EARTH; VENUS	The surface of Mars is cut by long linear faults with displacements of metres to kilometres, most of which are thought to have been formed by extension(1). The surface has also been modified by enormous floods, probably of water, which often flowed out of valleys formed by the largest of these faults(2). By analogy with structures on Earth(3,4), we propose here that the faults are in fact the surface expression of dykes(5), and not of large-scale tectonic movements. We use a numerical model to show that the intrusion of large dykes can generate structures like Valles Marineris. Such dykes can provide a heat source to melt ground ice, and so provide a source of water for the floods that have been inferred to originate in some of the large valleys(2).	Univ Cambridge, Inst Theoret Geophys, Bullard Labs, Dept Earth Sci, Cambridge CB3 0EZ, England	University of Cambridge	Nimmo, F (corresponding author), Univ Cambridge, Inst Theoret Geophys, Bullard Labs, Dept Earth Sci, Madingley Rd, Cambridge CB3 0EZ, England.							Baker V.R., 1982, THE CHANNELS OF MARS, DOI [10.1029/EO063i045p00862, DOI 10.1029/EO063I045P00862]; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; *BASAL VOLC STUD P, 1983, BAS VOLC TERR PLAN; BLICHERTTOFT J, 1998, MINERAL MAG A, V62, P168; Borg LE, 1997, GEOCHIM COSMOCHIM AC, V61, P4915, DOI 10.1016/S0016-7037(97)00276-7; Carr M. H., 1977, Journal of Geophysical Research, V82, P4055, DOI 10.1029/JS082i028p04055; ERNST RE, 1995, EARTH-SCI REV, V39, P1, DOI 10.1016/0012-8252(95)00017-5; Fahrig W. F., 1987, MAFIC DYKE SWARMS, V34, P331; FAHRIG WF, 1986, DIABASE DYKE SWARMS; Lucchitta B.K., 1992, CANYON SYSTEM MARS, P453; Masursky H., 1977, Journal of Geophysical Research, V82, P4016, DOI 10.1029/JS082i028p04016; MCKENZIE D, 1992, J GEOPHYS RES-PLANET, V97, P15977, DOI 10.1029/92JE01559; Mege D, 1996, PLANET SPACE SCI, V44, P1499, DOI 10.1016/S0032-0633(96)00113-4; PLESCIA JB, 1982, J GEOPHYS RES, V87, P9775, DOI 10.1029/JB087iB12p09775; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; Schultz RA, 1997, J GEOPHYS RES-SOL EA, V102, P12009, DOI 10.1029/97JB00751; SIGURDSSON O, 1980, J GEOPHYS-Z GEOPHYS, V47, P154; SOLOMON SC, 1990, J GEOPHYS RES-SOLID, V95, P11073, DOI 10.1029/JB095iB07p11073; SQUYRES SW, 1987, ICARUS, V70, P385, DOI 10.1016/0019-1035(87)90085-6; SQUYRES SW, 1992, MARS, P526; WHITE RS, 1995, J GEOPHYS RES-SOL EA, V100, P17543, DOI 10.1029/95JB01585; ZIMBELMAN JR, 1992, J GEOPHYS RES-PLANET, V97, P18309, DOI 10.1029/92JE02054; [No title captured]	23	102	102	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					231	233		10.1038/16649	http://dx.doi.org/10.1038/16649			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930697				2022-12-01	WOS:000078184800044
J	Liu, L; Li, PS; Asher, SA				Liu, L; Li, PS; Asher, SA			Entropic trapping of macromolecules by mesoscopic periodic voids in a polymer hydrogel	NATURE			English	Article							CRYSTALLINE COLLOIDAL ARRAYS; GEL-ELECTROPHORESIS; TRACER DIFFUSION; DNA; DIFFRACTION; POLYSTYRENE	The separation of macromolecules such as polymers and DNA by means of electrophoresis, gel permeation chromatography or filtration exploits size-dependent differences in the time it takes for the molecules to migrate through a random porous network. Transport through the gel matrices, which usually consist of full swollen crosslinked polymers(1-11), depends on the relative size of the macromolecule compared with the pore radius. Sufficiently small molecules are thought to adopt an approximately spherical conformation when diffusing through the gel matrix(1), whereas larger ones are forced to migrate in a snake-like fashion(3-5). Molecules of intermediate size, however, can get temporarily trapped in the largest pores of the matrix, where the molecule can extend and thus maximize its conformational entropy, This 'entropic trapping' is thought to increase the dependence of diffusion rate an molecular size(6-16). Here we report the direct experimental verification of this phenomenon. Bragg diffraction from a hydrogel containing a periodic array of monodisperse water voids confirms that polymers of different weights partition between the hydrogel matrix and the water voids according to the predictions of the entropic trapping theory. Our approach might also lead to the design of improved separation media based on entropic trapping.	Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Asher, SA (corresponding author), Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.	asher+@pitt.edu						Asher S.A., 1986, Patent No. [US4632517A, 4632517]; ASHER SA, 1986, Patent No. 4627689; BAUMGARTNER A, 1987, J CHEM PHYS, V87, P3082, DOI 10.1063/1.453045; CASASSA EF, 1967, J POLYM SCI POL LETT, V5, P773, DOI 10.1002/pol.1967.110050907; CLARK NA, 1979, NATURE, V281, P57, DOI 10.1038/281057a0; De Gennes P-G., 1979, SCALING CONCEPTS POL; Flory PJ., 1953, PRINCIPLES POLYM CHE; GUILLOT G, 1985, MACROMOLECULES, V18, P2531, DOI 10.1021/ma00154a030; HILTNER PA, 1969, J PHYS CHEM-US, V73, P2386, DOI 10.1021/j100727a049; HOAGLAND DA, 1992, MACROMOLECULES, V25, P6696, DOI 10.1021/ma00050a046; Holtz JH, 1997, NATURE, V389, P829, DOI 10.1038/39834; KESAVAMOORTHY R, 1992, J COLLOID INTERF SCI, V153, P188, DOI 10.1016/0021-9797(92)90310-I; KIM HD, 1986, MACROMOLECULES, V19, P2737, DOI 10.1021/ma00165a013; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; Liu L, 1997, J AM CHEM SOC, V119, P2729, DOI 10.1021/ja963885g; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MUTHUKUMAR M, 1989, MACROMOLECULES, V22, P1937, DOI 10.1021/ma00194a070; NEMOTO N, 1990, MACROMOLECULES, V23, P659, DOI 10.1021/ma00204a045; NOOLANDI J, 1987, PHYS REV LETT, V58, P2428, DOI 10.1103/PhysRevLett.58.2428; RIGHETTI PG, 1995, J CHROMATOGR A, V698, P3, DOI 10.1016/0021-9673(94)00068-K; RODBARD D, 1970, P NATL ACAD SCI USA, V65, P970, DOI 10.1073/pnas.65.4.970; ROTSTEIN NA, 1992, MACROMOLECULES, V25, P1316, DOI 10.1021/ma00030a018; Rousseau J, 1997, PHYS REV LETT, V79, P1945, DOI 10.1103/PhysRevLett.79.1945; RUNDQUIST PA, 1989, J CHEM PHYS, V91, P4932, DOI 10.1063/1.456734; SLATER GW, 1995, PHYS REV LETT, V75, P164, DOI 10.1103/PhysRevLett.75.164; SLATER GW, 1986, BIOPOLYMERS, V25, P431, DOI 10.1002/bip.360250305; SMISEK DL, 1990, SCIENCE, V248, P1221, DOI 10.1126/science.2349481; Teraoka I, 1996, MACROMOLECULES, V29, P2430, DOI 10.1021/ma951146z; Weissman JM, 1996, SCIENCE, V274, P959, DOI 10.1126/science.274.5289.959	29	183	186	4	118	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					141	144		10.1038/16426	http://dx.doi.org/10.1038/16426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923674				2022-12-01	WOS:000078085000039
J	Nightingale, SL				Nightingale, SL			New easy-to-understand labels for OTC drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1164	1164		10.1001/jama.281.13.1164	http://dx.doi.org/10.1001/jama.281.13.1164			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199413				2022-12-01	WOS:000079464400010
J	Turner, PE; Chao, L				Turner, PE; Chao, L			Prisoner's dilemma in an RNA virus	NATURE			English	Article							PARASITE VIRULENCE; EVOLUTION; PSEUDOMONAS; SELECTION; MUTANTS; MODEL; HOST	The evolution of competitive interactions among viruses(1) was studied in the RNA phage phi 6 at high and low multiplicities of infection (that is, at high and low ratios of infecting phage to host cells). At high multiplicities, many phage infect and reproduce in the same host cell, whereas at low multiplicities the viruses reproduce mainly as clones. An unexpected result of this study(1) was that phage grown at high rates of co-infection increased in fitness initially, but then evolved lowered fitness. Here we show that the fitness of the high-multiplicity phage relative to their ancestors generates a pay-off matrix conforming to the prisoner's dilemma strategy of game theory(2,3). In this strategy, defection (selfishness) evolves, despite the greater fitness pay-off that would result if all players were to cooperate. Viral cooperation and defection can be defined as, respectively, the manufacturing and sequestering of diffusible (shared) intracellular products. Because the low-multiplicity phage did not evolve lowered fitness, we attribute the evolution of selfishness to the lack of clonal structure and the mixing of unrelated genotypes at high multiplicity(4-6).	Univ Maryland, Dept Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Turner, PE (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.	paul.e.turner@uv.es						AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; BONHOEFFER S, 1994, P NATL ACAD SCI USA, V91, P8062, DOI 10.1073/pnas.91.17.8062; BREMERMANN HJ, 1983, J THEOR BIOL, V100, P411, DOI 10.1016/0022-5193(83)90438-1; Chao L, 1997, BEHAV ECOL, V8, P668, DOI 10.1093/beheco/8.6.668; Chao Lin, 1994, P233; CRAIG JL, 1984, BEHAV ECOL SOCIOBIOL, V14, P147, DOI 10.1007/BF00291905; DUGATKIN LA, 1997, ANIMALS EVOLUTIONARY; FISCHER EA, 1988, ETHOL SOCIOBIOL, V9, P119, DOI 10.1016/0162-3095(88)90017-9; Fisher R.A., 1930, GENETICAL THEORY NAT; Frank SA, 1996, Q REV BIOL, V71, P37, DOI 10.1086/419267; FRANK SA, 1992, P ROY SOC B-BIOL SCI, V250, P195, DOI 10.1098/rspb.1992.0149; Hamilton W.D., 1972, Annual Rev Ecol Syst, V3, P193, DOI 10.1146/annurev.es.03.110172.001205; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HERRE EA, 1993, SCIENCE, V259, P1442, DOI 10.1126/science.259.5100.1442; HOLLAND J J, 1991, P151; HUANG AS, 1970, NATURE, V226, P325, DOI 10.1038/226325a0; KNOLLE H, 1989, J THEOR BIOL, V136, P199, DOI 10.1016/S0022-5193(89)80226-7; Lewontin R.C., 1970, ANNU REV ECOL SYST, V1, P1, DOI [DOI 10.1146/ANNUREV.ES.01.110170.000245, 10.1146/annurev.es.01.110170.000245]; Maynard Smith J., 1982, pi; MINDICH L, 1976, J BACTERIOL, V126, P177, DOI 10.1128/JB.126.1.177-182.1976; NOWAK MA, 1994, P ROY SOC B-BIOL SCI, V255, P81, DOI 10.1098/rspb.1994.0012; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; SINCLAIR JF, 1976, VIROLOGY, V75, P198, DOI 10.1016/0042-6822(76)90018-0; Stent G., 1963, MOL BIOL BACTERIAL V; Turner PE, 1998, GENETICS, V150, P523; VIDAVER AK, 1973, J VIROL, V11, P799, DOI 10.1128/JVI.11.5.799-805.1973; VONMAGNUS P, 1954, ADV VIRUS RES, V2, P59, DOI 10.1016/S0065-3527(08)60529-1	27	430	433	1	60	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 1	1999	398	6726					441	443		10.1038/18913	http://dx.doi.org/10.1038/18913			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201376				2022-12-01	WOS:000079508200056
J	Leonhard, K; Stiegler, A; Neupert, W; Langer, T				Leonhard, K; Stiegler, A; Neupert, W; Langer, T			Chaperone-like activity of the AAA domain of the yeast Yme1 AAA protease	NATURE			English	Article							ATP-DEPENDENT DEGRADATION; PRECURSOR PROTEIN; MEMBRANE-FUSION; INNER MEMBRANE; MITOCHONDRIA; BIOGENESIS; FAMILY; IMPORT	The AAA domain, a conserved Walker-type ATPase module, is a feature of members of the AAA family of proteins(1,2), which are involved in many cellular processes, including vesicular transport(3-7), organelle biogenesis(8), microtubule rearrangement(9) and protein degradation(10-12), The function of the AAA domain, however, has not been explained. Membrane-anchored AAA proteases of prokaryotic and eukaryotic cells comprise a subfamily of AAA proteins(13-15) that have metal-dependent peptidase activity and mediate the degradation of non-assembled membrane proteins. Inactivation of an orthologue of this protease family in humans causes neurodegeneration in hereditary spastic paraplegia(16). Here we investigate the AAA domain of the yeast protein Yme1, a subunit of the i-AAA protease located in the inner membrane of mitochondria(17,18). We show that Yme1 senses the folding state of solvent-exposed domains and specifically degrades unfolded membrane proteins. Substrate recognition and binding are mediated by the amino-terminal region of the AAA domain. The purified AAA. domain of Yme1 binds unfolded polypeptides and suppresses their aggregation. Our results indicate that the AAA domain of Yme1 has a chaperone-like activity and suggest that the AAA domains of other AAA proteins may have a similar function.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	University of Munich	Langer, T (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.	langer@bio-med.uni-muenchen.de		Langer, Thomas/0000-0003-1250-1462				Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Beyer A, 1997, PROTEIN SCI, V6, P2043; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; HUANG SM, 1989, BIOCHEMISTRY-US, V28, P471, DOI 10.1021/bi00428a010; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PEARCE DA, 1995, J BIOL CHEM, V270, P1; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schumann W, 1999, FEMS MICROBIOL REV, V23, P1; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; TANDON S, 1989, J BIOL CHEM, V264, P9859; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945	29	172	175	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 25	1999	398	6725					348	351		10.1038/18704	http://dx.doi.org/10.1038/18704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DF	10192337				2022-12-01	WOS:000079369600055
J	Valeur-Jensen, AK; Pedersen, CB; Westergaard, T; Jensen, IP; Lebech, M; Andersen, PK; Aaby, P; Pedersen, BN; Melbye, M				Valeur-Jensen, AK; Pedersen, CB; Westergaard, T; Jensen, IP; Lebech, M; Andersen, PK; Aaby, P; Pedersen, BN; Melbye, M			Risk factors for parvovirus B19 infection in pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ERYTHEMA-INFECTIOSUM; OCCUPATIONAL RISK; HUMAN-DISEASE; 5TH DISEASE; OUTBREAK; WOMEN; ANTIBODIES; SCHOOL; CARE	Context Parvovirus B19 infection during pregnancy has been associated with fetal death. However, the incidence of and risk factors for infection in pregnant women have not been well studied. Objectives To estimate a pregnant woman's risk of infection with parvovirus B19 in epidemic and endemic situations and to study risk factors for infection. Design Population-based cohort study conducted between November 1992 and June 1994. Setting Three regions in Denmark. Participants A total of 30 946 pregnant women from a consecutive and population-based screening. Main Outcome Measures Specific IgG antibodies in serum samples obtained in the first trimester of pregnancy and from the newborn infant to assess past infection and seroconversion. Information on family structure, educational background, socioeconomic status, and pregnancy outcome was obtained from national registers. Results Based on 30 946 serum samples, 65.0% of pregnant women had evidence of past infection. Annual seroconversion rates among susceptible women during endemic and epidemic periods were 1.5% (95% confidence interval [CI], 0.2%-1.9%) and 13.0% (95% CI, 8.7%-23.1%), respectively. Baseline seropositivity was significantly correlated with increasing number of siblings, having a sibling of the same age, number of own children, and occupational exposure to children. Risk of acute infection increased with the number of children in the household as follows: 0 children odds ratio (OR), 1 (reference); 1 child OR, 3.17 (95% CI, 2.24-4.49); 2 children OR, 5.47 (95% CI, 3.55-8.45); 3 or more children OR, 7.54 (95% CI, 3.80-14.94). Having children aged 6 to 7 years resulted in the highest rate of seroconversion among mothers (6.8%; OR, 4.07; 95% CI, 1.89-8.73). Compared with other pregnant women, nursery school teachers had a 3-fold increased risk of acute infection (OR, 3.09; 95% CI, 1.62-5.89). Population-attributable risk of seroconversion was 55.4% for number of own children and 6.0% for occupational exposure. Conclusions The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children. Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Copenhagen, Denmark; State Serum Inst, Dept Virol, Copenhagen, Denmark; State Serum Inst, Dept Clin Biochem, Copenhagen, Denmark	Aarhus University; Statens Serum Institut; Statens Serum Institut	Melbye, M (corresponding author), State Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark.	mme@ssi.dk	Pedersen, Carsten Bøcker/B-8441-2013	Pedersen, Carsten Bøcker/0000-0003-2077-8533; melbye, mads/0000-0001-8264-6785; Aaby, Peter/0000-0001-8331-1389				ANDERSON LJ, 1986, J CLIN MICROBIOL, V24, P522, DOI 10.1128/JCM.24.4.522-526.1986; ANDERSON MJ, 1983, LANCET, V1, P1378; Azzi A, 1996, EPIDEMIOL INFECT, V117, P401, DOI 10.1017/S095026880000159X; BELL LM, 1989, NEW ENGL J MED, V321, P485, DOI 10.1056/NEJM198908243210801; Brown KE, 1997, ANNU REV MED, V48, P59; BROWN T, 1984, LANCET, V2, P1033; Carstensen B, 1996, STAT MED, V15, P2177, DOI 10.1002/(SICI)1097-0258(19961030)15:20&lt;2177::AID-SIM345&gt;3.0.CO;2-7; CARTTER ML, 1991, J INFECT DIS, V163, P282, DOI 10.1093/infdis/163.2.282; CHORBA T, 1986, J INFECT DIS, V154, P383, DOI 10.1093/infdis/154.3.383; COHEN B, 1995, BMJ-BRIT MED J, V311, P1549, DOI 10.1136/bmj.311.7019.1549; COHEN BJ, 1988, J MED MICROBIOL, V25, P151, DOI 10.1099/00222615-25-2-151; COHEN BJ, 1993, J PUBLIC HEALTH MED, V15, P281; ELSHUBINGER AM, 1996, ZENTRALBL BAKTERIOL, V284, P232; GILLESPIE SM, 1990, JAMA-J AM MED ASSOC, V263, P2061, DOI 10.1001/jama.263.15.2061; GRATACOS E, 1995, J INFECT DIS, V171, P1360, DOI 10.1093/infdis/171.5.1360; HALL SM, 1990, BMJ-BRIT MED J, V300, P1166; Harger JH, 1998, OBSTET GYNECOL, V91, P413, DOI 10.1016/S0029-7844(97)00701-1; KNUDSEN LB, 1986, COMMUNITY MED, V8, P29; KOCH WC, 1989, PEDIATR INFECT DIS J, V8, P83; Melbye M, 1997, NEW ENGL J MED, V336, P81, DOI 10.1056/NEJM199701093360201; PILLAY D, 1992, LANCET, V339, P107, DOI 10.1016/0140-6736(92)91009-W; Rice PS, 1996, EPIDEMIOL INFECT, V116, P331, DOI 10.1017/S0950268800052651; RODIS JF, 1990, AM J OBSTET GYNECOL, V163, P1168, DOI 10.1016/0002-9378(90)90681-V; SkjoldebrandSparre L, 1996, ACTA OBSTET GYN SCAN, V75, P336, DOI 10.3109/00016349609033326; TOROK TJ, 1992, ADV INTERNAL MED, V37, P431; Westergaard T, 1997, J NATL CANCER I, V89, P939, DOI 10.1093/jnci/89.13.939; WOOLF AD, 1989, ARCH INTERN MED, V149, P1153, DOI 10.1001/archinte.149.5.1153	27	118	127	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1999	281	12					1099	1105		10.1001/jama.281.12.1099	http://dx.doi.org/10.1001/jama.281.12.1099			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	177EP	10188660	Bronze			2022-12-01	WOS:000079197100031
J	Nolan, CM; Goldberg, SV; Buskin, SE				Nolan, CM; Goldberg, SV; Buskin, SE			Hepatotoxicity associated with isoniazid preventive therapy - A 7-year survey from a public health tuberculosis clinic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; DECISION-ANALYSIS; HEPATITIS; RISK; CHEMOPROPHYLAXIS; LIVER; REACTORS; DEATHS; ADULTS; AGE	Context Isoniazid preventive therapy for latent tuberculosis (TB) infection has been debated because of the risk of hepatotoxicity. The frequency of hepatotoxicity was 0.5% to 2.0% in early studies but may have changed with new criteria for diagnosis and patient selection. Objective To determine the rate of isoniazid hepatotoxicity in patients managed according to current guidelines and practice standards. Design Prospective cohort study. Setting A public health clinic operated by the TB control program of a city-county public health agency. Patients A total of 11 141 consecutive patients who started a regimen of isoniazid preventive therapy for latent TB infection from January 1989 through December 1995, Main Outcome Measures The rate of developing symptoms and signs of hepatotoxicity among all persons starting isoniazid preventive therapy, among all those completing therapy, and by age, sex, and race. Results Eleven patients (0.10% of those starting, and 0.15% of those completing treatment) had hepatotoxic reactions to isoniazid during preventive treatment. The rate of hepatotoxicity in persons receiving preventive therapy increased with increasing age (chi(2) for linear trend = 5.22, P = .02) and there were trends toward increased rates in women (odds ratio [OR], 3.30; 95% confidence interval [CI], 0.87-12.45; chi(2) = 3.28; P = .07) and in whites (OR, 2.60; 95% CI, 0.75-8.95; chi(2) = 3.08; P = .08). Conclusions The rate of isoniazid hepatotoxicity during clinically monitored preventive therapy was lower than has been reported previously. Clinicians should have greater confidence in the safety of isoniazid preventive therapy.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Nolan, CM (corresponding author), Harborview Med Ctr, Seattle King Cty Dept Publ Hlth, TB Control Program, 325 9th Ave, Seattle, WA 98104 USA.	charles.nolan@metrokc.gov						American Thoracic Society, 1965, AM REV RESPIR DIS, V96, P558; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BLACK M, 1975, GASTROENTEROLOGY, V69, P289; *CDC, 1989, MMWR-MORBID M      S, V3, P1; COLICE GL, 1990, ARCH INTERN MED, V150, P2517, DOI 10.1001/archinte.150.12.2517; COMSTOCK GW, 1981, ANN INTERN MED, V94, P817, DOI 10.7326/0003-4819-94-6-817; DICKINSON DS, 1981, J CLIN GASTROENTEROL, V3, P271, DOI 10.1097/00004836-198109000-00012; FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151; GARABALDI RA, 1972, AM REV RESPIR DIS, V106, P357; GORDIN F, 1998, 5 C RETR OPP INF FEB; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; ISEMAN MD, 1989, AM REV RESPIR DIS, V140, P575, DOI 10.1164/ajrccm/140.3.575; ISRAEL HL, 1992, CHEST, V101, P1298, DOI 10.1378/chest.101.5.1298; JORDAN TJ, 1991, AM REV RESPIR DIS, V144, P1357, DOI 10.1164/ajrccm/144.6.1357; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706; Leff DR, 1997, AM J RESP CRIT CARE, V156, P1487, DOI 10.1164/ajrccm.156.5.9704105; McCray E, 1997, CLIN CHEST MED, V18, P99, DOI 10.1016/S0272-5231(05)70359-2; Millard PS, 1996, WESTERN J MED, V164, P486; Miller B, 1996, JAMA-J AM MED ASSOC, V276, P1916; MITCHELL JR, 1976, ANN INTERN MED, V84, P181, DOI 10.7326/0003-4819-84-2-181; MOULDING TS, 1989, AM REV RESPIR DIS, V140, P700, DOI 10.1164/ajrccm/140.3.700; MWINGA AG, 1997, INT J TUBERC LUNG S1, V1, pS164; RISKA N, 1976, Bulletin of the International Union Against Tuberculosis, V51, P203; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; SALPETER SR, 1993, WESTERN J MED, V159, P560; Salpeter SR, 1997, ANN INTERN MED, V127, P1051, DOI 10.7326/0003-4819-127-12-199712150-00001; SARASIN FP, 1995, TUBERCLE LUNG DIS, V76, P394, DOI 10.1016/0962-8479(95)90004-7; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; STEELE MA, 1991, CHEST, V99, P465, DOI 10.1378/chest.99.2.465; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; Zuber PLF, 1997, JAMA-J AM MED ASSOC, V278, P304, DOI 10.1001/jama.278.4.304	34	345	355	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1999	281	11					1014	1018		10.1001/jama.281.11.1014	http://dx.doi.org/10.1001/jama.281.11.1014			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175EE	10086436	Bronze			2022-12-01	WOS:000079079400028
J	Nagle, DL; McGrail, SH; Vitale, J; Woolf', EA; Dussault, BJ; DiRocco, L; Holmgren, L; Montagno, J; Bork, P; Huszar, D; Fairchild-Huntress, V; Ge, P; Keilty, J; Ebeling, C; Baldini, L; Gilchrist, J; Burn, P; Carlson, GA; Moore, KJ				Nagle, DL; McGrail, SH; Vitale, J; Woolf', EA; Dussault, BJ; DiRocco, L; Holmgren, L; Montagno, J; Bork, P; Huszar, D; Fairchild-Huntress, V; Ge, P; Keilty, J; Ebeling, C; Baldini, L; Gilchrist, J; Burn, P; Carlson, GA; Moore, KJ			The mahogany protein is a receptor involved in suppression of obesity	NATURE			English	Article							AGOUTI; TOOL; GENE; IDENTIFICATION; ALIGNMENT; MUTATIONS; FAMILY; MOTIF; MICE; MAP	Genetic studies have shown that mutations within the mahogany locus(1) suppress the pleiotropic phenotypes, including obesity, of the agouti-lethal-yellow mutant(2,3). Here we identify the mahogany gene and its product; this study, to our knowledge, represents the first positional cloning of a suppressor gene in the mouse. Expression of the mahogany gene is broad; however, in situ hybridization analysis emphasizes the importance of its expression in the ventromedial hypothalamic nucleus, a region that is intimately involved in the regulation of body weight and feeding. We present new genetic studies that indicate that the mahogany locus does not suppress the obese phenotype of the melanocortin-4-receptor null allele(4) or those of the monogenic obese models (Lep(db), tub and Cpe(fat)). However, mahogany can suppress diet-induced obesity, the mechanism of which is likely to have implications for therapeutic intervention in common human obesity. The amino-acid sequence of the mahogany protein suggests that it is a large, single-transmembrane-domain receptor-like molecule, with a short cytoplasmic tail containing a site that is conserved between Caenorhabditis elegans and mammals. We propose two potential, alternative modes of action for mahogany: one draws parallels with the mechanism of action of low-affinity proteoglycan receptors such as fibroblast growth factor and transforming growth factor-beta, and the other suggests that mahogany itself is a signalling receptor.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; European Mol Biol Lab, D-69012 Heidelberg, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; McLaughlin Res Inst Biomed Sci, Great Falls, MT 59405 USA; Hoffmann La Roche Inc, Dept Metab Dis, Nutley, NJ 07110 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; McLaughlin Research Institute for Biomedical Sciences, Inc.; Roche Holding	Moore, KJ (corresponding author), Millennium Pharmaceut Inc, 640 Mem Dr, Cambridge, MA 02139 USA.	moore@mpi.com	Bork, Peer/F-1813-2013	Bork, Peer/0000-0002-2627-833X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; DEITRICH WF, 1996, NATURE, V380, P149; Dinulescu DM, 1998, P NATL ACAD SCI USA, V95, P12707, DOI 10.1073/pnas.95.21.12707; DRICKAMER K, 1995, NAT STRUCT BIOL, V2, P437, DOI 10.1038/nsb0695-437; Duke-Cohan JS, 1998, P NATL ACAD SCI USA, V95, P11336, DOI 10.1073/pnas.95.19.11336; Duncan LM, 1998, CANCER RES, V58, P1515; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; LANE PRISCILLA W., 1960, JOUR HEREDITY, V51, P228; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Miller KA, 1997, GENETICS, V146, P1407; Misumi DJ, 1997, GENOMICS, V40, P147, DOI 10.1006/geno.1996.4549; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SCLESSINGER J, 1995, CELL, V88, P357; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; SING CF, 1998, GENOME RES, V8, P175; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274	30	140	153	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	1999	398	6723					148	152		10.1038/18210	http://dx.doi.org/10.1038/18210			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176DG	10086355				2022-12-01	WOS:000079135200044
J	Brewer, TF				Brewer, TF			Preventive therapy for tuberculosis in HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH-RISK; ANERGY		Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Brewer, TF (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	timothy.brewer@channing.harvard.edu						*CDCP, 1990, MMWR-MORBID MORTAL W, V39, P9; Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505; *INT UN TUB LUNG D, 1994, TUBERCLE LUNG DIS, V75, P96; Msamanga GI, 1997, NEW ENGL J MED, V337, P849, DOI 10.1056/NEJM199709183371210; NUNN PP, 1994, THORAX, V49, P511, DOI 10.1136/thx.49.5.511; PANICH V, 1994, 10 WORLD AIDS C AUG; SACKS H, 1998, 12 WORLD AIDS C JUN; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625; Yanai H, 1996, AIDS, V10, P527, DOI 10.1097/00002030-199605000-00012	10	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1999	281	10					881	882		10.1001/jama.281.10.881	http://dx.doi.org/10.1001/jama.281.10.881			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172XH	10078465				2022-12-01	WOS:000078950600003
J	Skelton, JR; Hobbs, FDR				Skelton, JR; Hobbs, FDR			Descriptive study of cooperative language in primary care consultations by male and female doctors	BRITISH MEDICAL JOURNAL			English	Article							PATIENT	Objective To compare the use of some of the characteristics of male and female language by male and female primary care practitioners during consultations. Design Doctors' use of the language of dominance and support was explored by using concordancing software. Three areas were examined: mean number of words per consultation; relative frequency of question tags; and use of migrated directives The analysis of language associated with cooperative talk examines relevant words or phrases and their immediate context Subjects 26 male and 14 female doctors in general practice, in a total of 373 consecutive consultations. Setting West Midlands. Results Doctors spoke significantly more words than patients, but the number of words spoken by male and female doctors did not differ significantly. Question tags were used far more frequently by doctors (P<0.001) than by patients or companions. Frequency of use was similar in male and female doctors, and the speech styles in consultation were similar. Conclusions These data show that male and female doctors use a speech style which is not gender specific, contrary to findings elsewhere; doctors consulted in an overtly non-directive, negotiated style, which is realised through suggestions and affective comments. This mode of communication is the core teaching of communication skills courses. These results suggest that men have more to learn to achieve competence as professional communicators.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Skelton, JR (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.			hobbs, richard/0000-0001-7976-7172				ATKINSON JM, 1984, STRUCTURES SOCIAL A; CALDASCOULTHARD CR, 1996, TEXTS PRACTICE READI; Cameron D., 1992, FEMINISM LINGUISTIC; Cameron Deborah, 1989, WOMEN THEIR SPEECH C, P74; Candlin C., 1976, P 4 INT C APPL LING, P297; Coates J., 1993, WOMEN MEN LANGUAGE; COULTHARD M, 1975, J COMMUN, V25, P140, DOI 10.1111/j.1460-2466.1975.tb00616.x; COULTHARD M, 1993, DATA DESCRIPTION DIS, P86; Elyan O, 1978, SOCIOLINGUISTIC PATT, P122; FISHER S, 1983, SOCIAL ORG DOCTOR PA; Glaser BG, 1968, DISCOVERY GROUNDED T; GODWIN MJ, 1980, WOMEN LANGUAGE LIT S, P153; Hoey Michael., 1991, PATTERNS LEXIS TEXT; Holmes Janet, 1984, TE REO, V27, P47; Mishler E, 1984, DISCOURSE MED DIALEC; Roter DL, 1989, COMMUNICATING MED PA; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; SINCLAIR J, 1989, LOOKING ACCOUNT COBU; Sinclair J., 1975, ANAL DISCOURSE ENGLI; Sinclair John, 1987, COBUILD ENGLISH LANG; Stewart MA, 1995, CAN MED ASS, V152, P423; WEST C, 1984, SYMB INTERACT, V7, P87, DOI 10.1525/si.1984.7.1.87; West C., 1990, DISCOURSE SOC, V1, P85, DOI 10.1177/0957926590001001005; WEST C, 1983, ROUTINE COMPLICATION; WOODS N, 1989, WOMEN THEIR SPEECH C	25	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					576	579		10.1136/bmj.318.7183.576	http://dx.doi.org/10.1136/bmj.318.7183.576			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037635	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000078966300030
J	Gupta, K; Scholes, U; Stamm, WE				Gupta, K; Scholes, U; Stamm, WE			Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	38th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 24-28, 1998	SAN DIEGO, CALIFORNIA				URINARY-TRACT INFECTIONS	Context Guidelines for the management of acute uncomplicated cystitis in women that recommend empirical therapy in properly selected patients rely on the predictability of the agents causing cystitis and knowledge of their antimicrobial susceptibility patterns. Objective To assess the prevalence of and trends in antimicrobial resistance among uropathogens causing well-defined episodes of acute uncomplicated cystitis in a large population of women. Design Cross-sectional survey of antimicrobial susceptibilities of urine isolates collected during a 5-year period (January, May, and September 1992-1996). Setting Health maintenance organization. Patients Women aged 18 to 50 years with an outpatient diagnosis of acute cystitis. Main Outcome Measures Proportion of uropathogens demonstrating in vitro resistance to selected antimicrobials; trends in resistance over the 5-year study period. Results Escherichia coli and Staphylococcus saprophyticus were the most common uropathogens, accounting for 90% of the 4342 urine isolates studied. The prevalence of resistance among E coli and all isolates combined was more than 20% for ampicillin, cephalothin, and sulfamethoxazole in each year studied. The prevalence of resistance to trimethoprim and trimethoprim-sulfamethoxazole rose from more than 9% in 1992 to more than 18% in 1996 among E coli, and from 8% to 16% among all isolates combined. There was a statistically significant increasing linear trend in the prevalence of resistance from 1992 to 1996 among E coli and all isolates combined to ampicillin (P<.002), and to cephalothin, trimethoprim, and trimethoprim-sulfamethoxazole (P<.001). in contrast, the prevalence of resistance to nitrofurantoin, gentamicin, and ciprofloxacin hydrochloride was 0% to 2% among E coli and less than 10% among all isolates combined, and did not change significantly during the 5-year period. Conclusions While the prevalence of resistance to trimethoprim-sulfamethoxazole, ampicillin, and cephalothin increased significantly among uropathogens causing acute cystitis, resistance to nitrofurantoin and ciprofloxacin remained infrequent. These in vitro susceptibility patterns should be considered along with other factors, such as efficacy, cost, and cost-effectiveness in selecting empirical therapy for acute uncomplicated cystitis in women.	Univ Washington, Sch Med, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; Group Health Cooperative	Stamm, WE (corresponding author), Univ Washington, Sch Med, Dept Med, Div Allergy & Infect Dis, 1959 NE Pacific St,BB1225,Box 356523, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053369] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53369] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bacheller CD, 1997, MED CLIN N AM, V81, P719, DOI 10.1016/S0025-7125(05)70542-3; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; GRUNEBERG RN, 1994, J ANTIMICROB CHEMO S, V33, pS1; HOOTON TM, 1995, JAMA-J AM MED ASSOC, V273, P41; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Jinnah F, 1996, J INT MED RES, V24, P296, DOI 10.1177/030006059602400310; KONEMAN EW, 1992, COLOR ATLAS TXB DIAG, P77; KUNIN CM, 1994, CLIN INFECT DIS, V18, P1, DOI 10.1093/clinids/18.1.1; MAARTENS G, 1994, S AFR MED J, V84, P600; PATTON JP, 1991, MED CLIN N AM, V75, P495, DOI 10.1016/S0025-7125(16)30466-7; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P397; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; THOMSON KS, 1994, J ANTIMICROB CHEMOTH, V33, P9, DOI 10.1093/jac/33.suppl_A.9; Weber G, 1997, EUR J CLIN MICROBIOL, V16, P834, DOI 10.1007/BF01700414; Winstanley TG, 1997, J ANTIMICROB CHEMOTH, V40, P591, DOI 10.1093/jac/40.4.591	15	376	396	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					736	738		10.1001/jama.281.8.736	http://dx.doi.org/10.1001/jama.281.8.736			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BD	10052444				2022-12-01	WOS:000078669900033
J	Imai, E; Honda, H; Hatori, K; Brack, A; Matsuno, K				Imai, E; Honda, H; Hatori, K; Brack, A; Matsuno, K			Elongation of oligopeptides in a simulated submarine hydrothermal system	SCIENCE			English	Article							PREBIOTIC SYNTHESIS; PEPTIDE FORMATION; EMERGENCE; CHEMISTRY; SPRINGS; WATER; LIFE	Oligomerization of a peptide was attempted in a flow reactor that simulated a submarine hydrothermal system. When fluid containing glycine repeatedly circulated through the hot and cold regions in the reactor, oligopeptides were made from glycine. When divalent ions (such as copper ions) were added under acidic conditions, oligoglycine was elongated up to hexaglycine, This observation suggests that prebiotic monomers could have oligomerized in the vicinity of submarine hydrothermal vents on primitive Earth.	Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 9402188, Japan; CNRS, Ctr Biophys Mol, F-45071 Orleans, France	Nagaoka University of Technology; Centre National de la Recherche Scientifique (CNRS)	Matsuno, K (corresponding author), Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 9402188, Japan.	kmatsuno@vos.nagaokaut.ac.jp		Hatori, Kuniyuki/0000-0003-4042-1259				BADA JL, 1995, ORIGINS LIFE EVOL B, V25, P111, DOI 10.1007/BF01581577; BRACK A, 1987, ORIGINS LIFE EVOL B, V17, P367, DOI 10.1007/BF02386475; Brinton KLF, 1998, ORIGINS LIFE EVOL B, V28, P413, DOI 10.1023/A:1006548905523; BUJDAK J, 1995, ORIGINS LIFE EVOL B, V25, P431, DOI 10.1007/BF01581994; CORLISS JB, 1979, SCIENCE, V203, P1073, DOI 10.1126/science.203.4385.1073; EDMOND JM, 1982, NATURE, V297, P187, DOI 10.1038/297187a0; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; FERRIS JP, 1992, ORIGINS LIFE EVOL B, V22, P109, DOI 10.1007/BF01808020; Huber C, 1998, SCIENCE, V281, P670, DOI 10.1126/science.281.5377.670; KAUFFMAN SA, 1986, J THEOR BIOL, V119, P1, DOI 10.1016/S0022-5193(86)80047-9; KEEFE AD, 1995, NATURE, V373, P683, DOI 10.1038/373683a0; KELLER M, 1994, NATURE, V368, P836, DOI 10.1038/368836a0; MATSUNO K, 1982, BIOSYSTEMS, V15, P1, DOI 10.1016/0303-2647(82)90012-0; MATSUNO K, 1997, VIVA ORIGINO, V25, P191; MATSUNO K, 1989, PROTOBIOLOGY PHYSICA; NAGAYAMA M, 1990, ORIGINS LIFE EVOL B, V20, P249, DOI 10.1007/BF01808107; NAKASHIMA T, 1977, INT J QUANTUM CHEM, P65; Orgel LE, 1998, ORIGINS LIFE EVOL B, V28, P227, DOI 10.1023/A:1006595411403; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; ROBERTSON MP, 1995, NATURE, V375, P772, DOI 10.1038/375772a0; RODE BM, 1990, ORIGINS LIFE EVOL B, V20, P401, DOI 10.1007/BF01808134; RUSSELL MJ, 1988, NATURE, V336, P117, DOI 10.1038/336117a0; Shock EL, 1996, CIBA F SYMP, V202, P40; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; YANAGAWA H, 1985, J BIOCHEM-TOKYO, V97, P1521, DOI 10.1093/oxfordjournals.jbchem.a135208	26	243	250	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					831	833		10.1126/science.283.5403.831	http://dx.doi.org/10.1126/science.283.5403.831			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933163				2022-12-01	WOS:000078496800040
J	Li, LS; Yee, C; Beavo, JA				Li, LS; Yee, C; Beavo, JA			CD3- and CD28-dependent induction of PDE7 required for T cell activation	SCIENCE			English	Article							N-TERMINAL KINASE; PROTEIN-KINASE; CYCLIC-AMP; MAP KINASE; CAMP; IDENTIFICATION; LYMPHOCYTES; INHIBITION; PHOSPHODIESTERASES; INTERLEUKIN-2	Costimulation of both the CD3 and CD28 receptors is essential for T cell activation. Induction of adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase-7 (PDE7) was found to be a consequence of such costimulation. Increased PDE7 in T cells correlated with decreased cAMP, increased interleukin-2 expression, and increased proliferation. Selectively reducing PDE7 expression with a PDE7 antisense oligonucleotide inhibited T cell proliferation; inhibition was reversed by blocking the cAMP signaling pathways that operate through cAMP-dependent protein kinase (PKA). Thus, PDE7 induction and consequent suppression of PKA activity is required for T cell activation, and inhibition of PDE7 could be an approach to treating T cell-dependent disorders.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Beavo, JA (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.			li, ling song/0000-0003-4824-3389	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21723] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bloom TJ, 1996, P NATL ACAD SCI USA, V93, P14188, DOI 10.1073/pnas.93.24.14188; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; Li Lin, UNPUB; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; Mischak H, 1996, MOL CELL BIOL, V16, P5409; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROBICSEK SA, 1991, BIOCHEM PHARMACOL, V42, P869, DOI 10.1016/0006-2952(91)90047-9; Seybold J, 1998, J BIOL CHEM, V273, P20575, DOI 10.1074/jbc.273.32.20575; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHERIDAN CM, 1998, GORD RES C KIMB UN N; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; Tamir A, 1996, J IMMUNOL, V157, P1514; TSURUTA L, 1995, J IMMUNOL, V154, P5255; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	24	205	227	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					848	851		10.1126/science.283.5403.848	http://dx.doi.org/10.1126/science.283.5403.848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933169				2022-12-01	WOS:000078496800046
J	Munger, JS; Huang, XZ; Kawakatsu, H; Griffiths, MJD; Dalton, SL; Wu, JF; Pittet, JF; Kaminski, N; Garat, C; Matthay, MA; Rifkin, DB; Sheppard, D				Munger, JS; Huang, XZ; Kawakatsu, H; Griffiths, MJD; Dalton, SL; Wu, JF; Pittet, JF; Kaminski, N; Garat, C; Matthay, MA; Rifkin, DB; Sheppard, D			The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis	CELL			English	Article							GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; TGF-BETA; EPITHELIAL INTEGRINS; FIBRONECTIN RECEPTOR; GENE-EXPRESSION; FACTOR-BETA-1; MICE	Transforming growth factor beta (TGF beta) family members are secreted in inactive complexes with a latency-associated peptide (LAP), a protein derived from the N-terminal region of the TGF beta gene product. Extracellular activation of these complexes is a critical but incompletely understood step in regulation of TGF beta function in vivo. We show that TGF beta 1 LAP is a ligand for the integrin alpha v beta 6 and that alpha v beta 6-expressing cells induce spatially restricted activation of TGF beta 1, This finding explains why mice lacking this integrin develop exaggerated inflammation and, as we show, are protected from pulmonary fibrosis. These data identify a novel mechanism for locally regulating TGF beta 1 function in vivo by regulating expression of the alpha v beta 6 integrin.	Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; New York University; New York University	Sheppard, D (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA.			Kaminski, Naftali/0000-0001-5917-4601; Munger, John/0000-0002-9679-2983	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056385, R01HL047412, P01HL056385, R01HL053949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56385, HL53949, HL47412] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; BARCELLOSHOFF MH, 1995, AM J PATHOL, V147, P1228; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BREUSS JM, 1995, J CELL SCI, V108, P2241; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; BUSK M, 1992, J BIOL CHEM, V267, P5790; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; GRAINGER DJ, 1995, NAT MED, V1, P932, DOI 10.1038/nm0995-932; Huang XZ, 1998, J CELL SCI, V111, P2189; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Huang XZ, 1998, AM J RESP CELL MOL, V19, P636, DOI 10.1165/ajrcmb.19.4.3293; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SCHULZ E, 1994, ACROS CHIMICA ACTA, V1, P1; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	40	1526	1608	0	107	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					319	328		10.1016/S0092-8674(00)80545-0	http://dx.doi.org/10.1016/S0092-8674(00)80545-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025398	Bronze			2022-12-01	WOS:000078514600005
J	Nguyen, MH; Kauffman, CA; Goodman, RP; Squier, C; Arbeit, RD; Singh, N; Wagener, MM; Yu, VL				Nguyen, MH; Kauffman, CA; Goodman, RP; Squier, C; Arbeit, RD; Singh, N; Wagener, MM; Yu, VL			Nasal carriage of and infection with Staphylococcus aureus in HIV-infected patients	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS-RELATED COMPLEX; BACTEREMIA; VIRUS; HEMODIALYSIS; COLONIZATION	Background: Staphylococcus aureus is a common cause of serious infection in patients infected with HIV. Objectives: To evaluate risk factors for and quantitative effect of S. aureus infection in HIV-infected patients, with special attention to nasal carriage. Design: Prospective, multihospital cohort study. Setting: Three tertiary care Veterans Affairs Medical Centers. Participants: 231 ambulatory HIV-infected patients. Results: Thirty-four percent of patients were nasal carriers of S. aureus. Of these patients, 38% were persistent carriers and 62% were intermittent carriers. Twenty-one episodes of infection occurred in 13 patients: Ten were bacteremias (including 2 cases of endocarditis), 1 was pneumonia, and 10 were cutaneous or subcutaneous infections. Seventeen (85%) of these episodes occurred in patients with CD4 counts less than 100 cells/mm(3). Recurrent infections occurred in 3 of 7 patients who survived an initial S. aureus infection. The mortality rate was higher among patients with S. aureus infection than among those without infection (P = 0.03). Factors significantly associated with S. aureus infection were nasal carriage, presence of a vascular catheter, low CD4 count, and neutropenia. Molecular strain typing indicated that for 6 of 7 infected patients, the strain of S. aureus isolated from the infected sites was the same as that previously cultured from the nares. Conclusion: Nasal carriage is an important risk factor for S. aureus infection in HIV-infected patients. Controlled studies are indicated to determine whether eradication of nasal carriage in a selected subset of patients (for example, those with a low CD4 cell count) might prevent invasive S. aureus infection in patients with HIV infection.	Vet Affairs Med Ctr, Infect Dis Sect 111, Pittsburgh, PA 15240 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Vet Affairs Med Ctr, Div Infect Dis, Ann Arbor, MI 48105 USA; Boston Univ, Med Ctr, Boston, MA USA; Vet Affairs Med Ctr, Boston, MA 02130 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Yu, VL (corresponding author), Vet Affairs Med Ctr, Infect Dis Sect 111, Univ Dr C, Pittsburgh, PA 15240 USA.	vly+@pitt.edu						BOELAERT JR, 1993, NEPHROL DIAL TRANSPL, V8, P235; ELLIS M, 1988, J INFECT DIS, V158, P1268, DOI 10.1093/infdis/158.6.1268; FICHTENBAUM CJ, 1995, J ACQ IMMUN DEF SYND, V8, P51; Fleiss JL, 1981, STATISTICAL METHODS, P75; GANESH R, 1989, LANCET, V2, P558; GOETZ AM, 1994, AM J INFECT CONTROL, V22, P334, DOI 10.1016/0196-6553(94)90031-0; JACOBSON MA, 1988, AM J MED, V85, P172, DOI 10.1016/S0002-9343(88)80337-1; Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P780; LUZAR MA, 1990, NEW ENGL J MED, V322, P505, DOI 10.1056/NEJM199002223220804; MASLOW JN, 1995, EUR J CLIN MICROBIOL, V14, P282, DOI 10.1007/BF02116520; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MURPHY PM, 1988, J INFECT DIS, V158, P627, DOI 10.1093/infdis/158.3.627; POS O, 1992, CLIN EXP IMMUNOL, V88, P23; RAVIGLIONE MC, 1990, AM J INFECT CONTROL, V18, P64, DOI 10.1016/0196-6553(90)90083-5; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; TUMBARELLO M, 1995, J INFECTION, V31, P123, DOI 10.1016/S0163-4453(95)92110-9; WEINKE T, 1992, EUR J CLIN MICROBIOL, V11, P985, DOI 10.1007/BF01967787; WHIMBEY E, 1986, ANN INTERN MED, V104, P511, DOI 10.7326/0003-4819-104-4-511; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	19	99	103	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					221	225		10.7326/0003-4819-130-3-199902020-00026	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00026			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049200				2022-12-01	WOS:000078355000006
J	Vitek, CR; Brennan, MB; Gotway, CA; Bragina, VY; Govorukina, NV; Kravtsova, ON; Rhodes, PH; Bisgard, KM; Strebel, PM				Vitek, CR; Brennan, MB; Gotway, CA; Bragina, VY; Govorukina, NV; Kravtsova, ON; Rhodes, PH; Bisgard, KM; Strebel, PM			Risk of diphtheria among schoolchildren in the Russian Federation in relation to time since last vaccination	LANCET			English	Article								Background Between 1990 and 1996, more than 110000 cases and 2900 deaths from diphtheria were reported in the Russian Federation. in 1994, because disease rates were high among children aged 7-10 years, the age of administration of the second booster dose of diphtheria vaccine was lowered from 9 years to 6 years, the age of school entry. To assess the impact of this policy change, we did a matched case-control study in three Russian cities. Methods Children aged 6-8 years who had diphtheria between September, 1994, and December, 1996, were each matched with five to seven children acting as controls who were within 3 months of age of the case and were from the same class at school. We did a matched analysis using conditional logistic regression. Findings We analysed the immunisation records of 58 cases and 306 controls. All but one case and all controls had received at least three doses of diphtheria-toxoid vaccine. 19 (33%) cases and 144 (47%) controls had received a booster dose of diphtheria toroid within the previous 2 years. Cases were more likely than were controls to have received only four doses rather than five (odds ratio 2.8 [95% CI 1.2-6.5]) and to have a time since the last dose of diphtheria toroid of 3-4 years (3.1 [1.1-9.1]) or 5-7 years (15.0 [2.5-89.0]), compared with children for whom it was 2 years or less. On multivariate analysis only a time since the last dose of 5-7 years remained significantly associated with disease (matched odds ratio adjusted for total number of doses 10.9 [1.6-75.1]). Conclusion A booster dose of diphtheria-toxoid Vaccine given to children in the Russian Federation at 6-8 years of age reduced the interval since the last dose of diphtheria toroid and improved protection against diphtheria.	Ctr Dis Control & Prevent, Child Vaccine Preventable Dis Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Stat Anal Branch, Data Management Div, Natl Immunizat Program, Atlanta, GA 30333 USA; Minist Hlth, Sanitary Epidemiol Surveillance Div, Vladimir, Russia; Minist Hlth, Sanitary Epidemiol Surveillance Div, Nizhnii Novgorod, Russia; Minist Hlth, Sanitary Epidemiol Surveillance Div, Voronezh, Russia	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Ministry of Health of the Russian Federation; Ministry of Health of the Russian Federation; Ministry of Health of the Russian Federation	Vitek, CR (corresponding author), Ctr Dis Control, Natl Immunizat Program, Mailstop E-61, Atlanta, GA 30333 USA.							BISGARD KM, IN PRESS J INFECT DI; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P693; *CDC, 1995, MMWR-MORBID MORTAL W, V44, P177; DALMOTOV VV, 1986, ZH MIKROBIOL EPIDEMI, V63, P43; DITTMANN S, 1997, CMDS0701037 WHO; Doull JA, 1925, AM J HYG, V5, P508, DOI 10.1093/oxfordjournals.aje.a119677; Galazka AM, 1996, VACCINE, V14, P845, DOI 10.1016/0264-410X(96)00021-7; GALAZKA AM, 1993, WHOEPIGEN9312; HARDY I, 1993, P M DIPHTH EUR JUL 5, P118; Hardy IRB, 1996, LANCET, V347, P1739, DOI 10.1016/S0140-6736(96)90811-9; IPSEN J, 1946, J IMMUNOL, V54, P325; MAKSIMOVA NM, 1991, THESIS MOSCOW USSR; MAKSIMOVA NM, 1987, ZH MIKROBIOL EPIDEMI, V64, P50; MAKSIMOVA NM, 1990, ZH MIKROBIOL EPIDEMI, V67, P56; MARKINA SS, 1994, HLTH POPULATION ENV, P10; *MIN HLTH, 1987, INSTR IMPR IMM POL P; *MIN HLTH, 1986, ED 450 MEAS PREV DIP; *MIN HLTH RUSS FED, 1995, DIPHTH AD CLIN CHAR; NARKEVICH MI, 1990, ZH MIKROBIOL EPIDEMI, V67, P44; *WHO, 1995, WHOEURICPCMDS02	20	25	25	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					355	358		10.1016/S0140-6736(98)03488-6	http://dx.doi.org/10.1016/S0140-6736(98)03488-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950440				2022-12-01	WOS:000078437000010
J	Hawkey, CJ				Hawkey, CJ			COX-2 inhibitors	LANCET			English	Article							MELOXICAM 7.5 MG; PIROXICAM 20 MG; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; SYNTHASE CYCLOOXYGENASE; 15 MG; EFFICACY; COMPARE; SAFETY; OSTEOARTHRITIS	In the past 100 years aspirin has demonstrated its value as an analgesic, anti-inflammatory, and antithrombotic agent. However, by 1938, it was clear that aspirin was gastrotoxic. Non-steroidal anti-inflammatory drugs (NSAIDs), developed since the 1960s, failed to achieve the goal of "a safer aspirin". The demonstration that inhibition of prostaglandin synthesis via a cyclo-oxygenase (COX) enzyme was central to both the therapeutic and toxic effects of aspirin and non-aspirin NSAIDs appeared to establish the principle of no gain without pain. This link may have been broken by drugs that selectively inhibit the inducible COX-2 enzyme. The COX enzyme is now a target of drug interventions against the inflammatory process. Might the "safe aspirin" be here at last?	Univ Nottingham, Queens Med Ctr, Nottingham NG7 2UH, England	University of Nottingham	Hawkey, CJ (corresponding author), Univ Nottingham, Queens Med Ctr, Nottingham NG7 2UH, England.							BJARNASON I, 1998, AM J GASTROENTEROL, V93, pA246; BROOKS P, IN PRESS BR J RHEUMA; CHAN CC, 1997, INFLAMM RES, V46, pS242; CIPOLLONE F, 1995, CLIN PHARMACOL THER, V58, P335, DOI 10.1016/0009-9236(95)90251-1; CRANKSHAW DJ, 1994, CAN J PHYSIOL PHARM, V72, P870, DOI 10.1139/y94-123; CRYER B, 1998, AM J GASTROENTEROL, V93, pA104; DAVIS R, 1994, DRUGS, V48, P431, DOI 10.2165/00003495-199448030-00008; DEPRE M, 1998, RHEUMATOL EUR S1, V27; Dequeker J, 1998, BRIT J RHEUMATOL, V37, P946; Distel M, 1996, BRIT J RHEUMATOL, V35, P68; Donnelly MT, 1998, GASTROENTEROLOGY, V114, pA107; Donnelly MT, 1997, ALIMENT PHARM THER, V11, P227, DOI 10.1046/j.1365-2036.1997.154330000.x; EHRICH E, EFFECT MK 0966 VIOXX; Ehrich Elliot, 1996, Arthritis and Rheumatism, V39, pS81; Ehrich Elliot, 1997, Arthritis and Rheumatism, V40, pS85; EHRICH EW, IN PRESS CLIN PHARM; ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0; Ernkey R, 1998, ARTHRITIS RHEUM, V41, pS44; FORDHUTCHINSON AW, 1997, SELECTIVE COX 2 INHI, P117; FU JY, 1990, J BIOL CHEM, V265, P16737; GANS KR, 1990, J PHARMACOL EXP THER, V254, P180; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GLASER K, 1995, EUR J PHARMACOL, V281, P107, DOI 10.1016/0014-2999(95)00302-2; GOEITHE HS, 1997, OSTEOARTHR CARTILAGE, V15, P283; Griffiths MM, 1998, ARTHRITIS RHEUM, V41, pS99; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Hawkey C, 1998, BRIT J RHEUMATOL, V37, P937; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; HAWKEY CJ, 1995, GASTROENTEROLOGY, V109, P614, DOI 10.1016/0016-5085(95)90353-4; HAYLLAR J, 1995, LANCET, V346, P521, DOI 10.1016/S0140-6736(95)91378-5; Hosie J, 1997, CLIN DRUG INVEST, V13, P175, DOI 10.2165/00044011-199713040-00001; Hosie J, 1996, BRIT J RHEUMATOL, V35, P39; Hubbard RC, 1996, J INVEST MED, V44, pA293; HUBBARD RC, 1998, RHEUMATOL EUR, V27, P118; HUNT R, 1998, AM J GASTROENTEROL, V93, pA247; ISAKSON P, 1997, SELECTIVE COX 2 INHI, P127; Jackson LM, 1998, GASTROENTEROLOGY, V114, pA160, DOI 10.1016/S0016-5085(98)80647-1; Jasper RD, 1997, CLIN PHARMACOL THER, V61, pPII19; Kawamori T, 1998, CANCER RES, V58, P409; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Lanza FL, 1997, GASTROENTEROLOGY, V112, pA194; Lanzo CA, 1998, BIOCHEMISTRY-US, V37, P217, DOI 10.1021/bi971691n; Linden B, 1996, BRIT J RHEUMATOL, V35, P35; Lipsky PE, 1997, J RHEUMATOL, V24, P9; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Mahler JF, 1996, TOXICOL PATHOL, V24, P717, DOI 10.1177/019262339602400607; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McLaughlan J, 1996, GASTROENTEROLOGY, V110, pA964; Mehlisch DR, 1998, CLIN PHARMACOL THER, V63, P139; Mengle-Gaw Laurel, 1997, Arthritis and Rheumatism, V40, pS93; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Noble S, 1996, DRUGS, V51, P424, DOI 10.2165/00003495-199651030-00007; PAIRET M, 1997, SELECTIVE COX 2 INHI, V3, P27; PASINETTE GM, IN PRESS NEUROSCIENC; Patoia L, 1996, BRIT J RHEUMATOL, V35, P61; Patrignani P, 1997, J PHYSIOL PHARMACOL, V48, P623; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rodriguez LAG, 1998, ARCH INTERN MED, V158, P33, DOI 10.1001/archinte.158.1.33; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Schwartz J, 1998, CLIN PHARMACOL THER, V63, P167; *SEARL, 1999, CEL DAT SHEET; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; SMOLEN J, 1998, PROMISE SPECIFIC COX, P21; Stack WA, 1998, GASTROENTEROLOGY, V114, pA294, DOI 10.1016/S0016-5085(98)81196-7; TAVARES IA, 1995, ARZNEIMITTEL-FORSCH, V45-2, P1093; Wallace JL, 1998, GASTROENTEROLOGY, V115, P101, DOI 10.1016/S0016-5085(98)70370-1; Wojtulewski JA, 1996, BRIT J RHEUMATOL, V35, P22; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104; Zhao Sean Z., 1997, Arthritis and Rheumatism, V40, pS88; [No title captured]	73	848	880	3	77	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1999	353	9149					307	314		10.1016/S0140-6736(98)12154-2	http://dx.doi.org/10.1016/S0140-6736(98)12154-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929039				2022-12-01	WOS:000078292200040
J	Stankovic, T; Weber, P; Stewart, G; Bedenham, T; Murray, J; Byrd, PJ; Moss, PAH; Taylor, AMR				Stankovic, T; Weber, P; Stewart, G; Bedenham, T; Murray, J; Byrd, PJ; Moss, PAH; Taylor, AMR			Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia	LANCET			English	Article							T-PROLYMPHOCYTIC LEUKEMIA; ATM GENE; MUTATIONS; DIFFERENTIATION; EXPRESSION; DELETIONS; DISEASE; REGION; BCL-2; CLL	Background Patients with the inherited disorder ataxia telangiectasia (A-T) have an increased susceptibility to lymphoid malignancies. in these patients mutations affect both alleles of the A-T gene (ATM). We have looked for mutations in the ATM gene in sporadic cases of B-cell chronic lymphocytic leukaemia (B-CLL). Methods 32 cases of B-CLL were analysed by restriction endonuclease fingerprinting to detect mutations within ATM. In six of the cases in which mutations were detected in tumour samples, germline DNA was screened to assess ATM carrier status. The samples in 20 cases were also studied by western blot for abnormal expression of ATM protein. Findings Expression of the ATM protein was impaired in eight (40%) of the 20 tumours analysed, being absent in three and decreased in five. Mutations within ATM were detected in six (18%) of the 32 patients. These point mutations, deletions, and one insertion were distributed across the coding sequence of ATM, Germline mutations, which indicate ATM carrier status, were found in two of these six patients compared with a frequency within the general population of below 1 in 200. Interpretation Abnormal expression of ATM protein is a frequent finding in B-CLL, Although the precise function of this protein is unknown, it is thought to have a role in programmed cell death, a deficiency of which would fit with the characteristic phenotype of prolonged cell survival seen in B-CLL tumour cells. Our results also suggest that carriers of ATM mutations may be at a particular risk for the development of B-CLL and this may partly explain the known genetic susceptibility to this disease.	Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Edgbaston B15 2TA, England; Univ Birmingham, Sch Med, Dept Haematol, Edgbaston B15 2TA, England	University of Birmingham; University of Birmingham	Taylor, AMR (corresponding author), Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Edgbaston B15 2TA, England.	a.m.r.taylor@bham.ac.uk	Moss, Paul/D-1728-2009	Moss, Paul/0000-0002-6895-1967; Stankovic, Tatjana/0000-0002-3780-274X; Stewart, Grant/0000-0002-0960-3241	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; Cordone I, 1998, BLOOD, V91, P4342, DOI 10.1182/blood.V91.11.4342.411k39_4342_4349; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Fegan C, 1995, LEUKEMIA, V9, P2003; FRAUMENI JF, 1969, ANN INTERN MED, V71, P279, DOI 10.7326/0003-4819-71-2-279; Lens D, 1997, BRIT J HAEMATOL, V99, P848, DOI 10.1046/j.1365-2141.1997.4723278.x; LIU Q, 1995, BIOTECHNIQUES, V18, P470; Luo LP, 1998, CANCER RES, V58, P2293; LUO LP, 1998, CANCER RES, V58, P4552; MARIANO MT, 1992, BLOOD, V80, P768; Neilson JR, 1997, LEUKEMIA, V11, P1929, DOI 10.1038/sj.leu.2400819; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHENA M, 1992, BLOOD, V79, P2981; Spector BD, 1982, ATAXIA TELANGIECTASI, P103; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; STAROSTIK P, 1991, BLOOD, V78, P3269; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Stoppa-Lyonnet D, 1998, BLOOD, V91, P3920, DOI 10.1182/blood.V91.10.3920.3920_3920_3926; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Vorechovsky I, 1996, CANCER RES, V56, P2726; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397	26	266	276	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1999	353	9146					26	29		10.1016/S0140-6736(98)10117-4	http://dx.doi.org/10.1016/S0140-6736(98)10117-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023947				2022-12-01	WOS:000077934800013
J	Wolfe, MS; Xia, WM; Ostaszewski, BL; Diehl, TS; Kimberly, WT; Selkoe, DJ				Wolfe, MS; Xia, WM; Ostaszewski, BL; Diehl, TS; Kimberly, WT; Selkoe, DJ			Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; C-TERMINAL FRAGMENTS; CAENORHABDITIS-ELEGANS; SEL-12 PRESENILIN; BETA-PROTEIN; CLEAVAGE; CELLS; LOCALIZATION; EXPRESSION; MUTATION	Accumulation of the amyloid-beta protein (A beta) in the cerebral cortex is an early and invariant event in the pathogenesis of Alzheimer's disease. The final step in the generation of A beta from the beta-amyloid precursor protein is an apparently intramembranous proteolysis by the elusive gamma-secretase(s)(1). The most common cause of familial Alzheimer's disease is mutation of the genes encoding presenilins 1 and 2, which alters gamma-secretase activity to increase the production of the highly amyloidogenic A beta, isoform(2). Moreover, deletion of presenilin-2 in mice greatly reduces gamma-secretase activity(3), indicating that presenilin-1 mediates most of this proteolytic event. Here we report that mutation of either of two conserved transmembrane (TM) aspartate residues in presenilin-1, Asp 257 (in TM6) and Asp 385 (in TM7), substantially reduces A beta production and increases the amounts of the carboxy-terminal fragments of beta-amyloid precursor protein that are the substrates of gamma-secretase. We observed these effects in three different cell lines as well as in cell-free microsomes. Either of the Asp-->Ala mutations also prevented the normal endoproteolysis of preseniIin-1 in the TM6 -->TM7 cytoplasmic loop. In a functional presenilin-1 variant (carrying a deletion in exon 9) that is associated with familial Alzheimer's disease and which does not require this cleavage(4), the Asp385-->Ala mutation still inhibited gamma-secretase activity. Our results indicate that the two transmembrane aspartate residues are critical for both presenilin-1 endoproteolysis and gamma-secretase activity, and suggest that presenilin-1 is either a unique diaspartyl cofactor for gamma-secretase or is itself gamma-secretase, an autoactivated intramembranous aspartyl protease.	Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Tennessee, Dept Pharmaceut Sci, Memphis, TN 38163 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Tennessee System; University of Tennessee Health Science Center	Wolfe, MS (corresponding author), Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.	mwolfe@utmem.edu; selkoe@cnd.bwh.harvard.edu	xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295				Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Johnson D, 1997, EDN, V42, P94; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Levitan D, 1998, DEVELOPMENT, V125, P3599; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VENTER JC, 1989, BIOCHEM PHARMACOL, V38, P1197, DOI 10.1016/0006-2952(89)90325-0; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; WOLFE MS, IN PRESS BIOCHEMISTR; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	30	1642	1698	2	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	1999	398	6727					513	517		10.1038/19077	http://dx.doi.org/10.1038/19077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206644				2022-12-01	WOS:000079662800048
J	Zhang, HS; Postigo, AA; Dean, DC				Zhang, HS; Postigo, AA; Dean, DC			Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16(INK4a), TGF beta, and contact inhibition	CELL			English	Article							CELL-CYCLE ARREST; S-PHASE ENTRY; RETINOBLASTOMA GENE-PRODUCT; E2F FAMILY MEMBERS; HISTONE DEACETYLASE; GROWTH SUPPRESSION; DEPENDENT KINASE; DEREGULATED EXPRESSION; CDK INHIBITOR; DNA-BINDING	Rb inhibits progression from G1 to S phase of the cell cycle. It associates with a number of cellular proteins; however, the nature of these interactions and their relative significance in cell cycle regulation are still unclear. We present evidence that Rb must normally interact with the E2F family of transcription factors to arrest cells in G1, and that this arrest results from active transcriptional repression by the Rb-E2F complex, not from inactivation of E2F. Thus, a major role of E2F in cell cycle regulation is assembly of this repressor complex. We demonstrate that active repression by Rb-E2F mediates the G1 arrest triggered by TGF beta, p16(INK4a), and contact inhibition.	Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dean, DC (corresponding author), Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.			Postigo, Antonio/0000-0003-4605-2634				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Fan JG, 1997, ONCOGENE, V14, P1191, DOI 10.1038/sj.onc.1200940; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Iavarone A, 1997, NATURE, V387, P417; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1992, SCIENCE, V258, P424; Palmero I, 1996, CANCER SURV, V27, P351; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	65	269	277	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					53	61		10.1016/S0092-8674(00)80714-X	http://dx.doi.org/10.1016/S0092-8674(00)80714-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199402	Bronze			2022-12-01	WOS:000079843900008
J	Zhou, D; Mooseker, MS; Galan, JE				Zhou, D; Mooseker, MS; Galan, JE			Role of the S-typhimurium actin-binding protein SipA in bacterial internalization	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; HOST-CELLS; ENTRY; HOMOLOGY; SYSTEM	Entry of the bacterium Salmonella typhimurium into host cells, requires membrane ruffling and rearrangement of the actin cytoskeleton. Here, it is shown that the bacterial protein SipA plays a critical role in this process. SipA binds directly to actin, decreases its critical concentration, and inhibits depolymerization of actin filaments, These activities result in the spatial localization and more pronounced outward extension of the Salmonella-induced membrane ruffles, thereby facilitating bacterial uptake.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA	Yale University; Yale University	Galan, JE (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030492, R01AI030492, R37AI030492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025387, R37DK025387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052543] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30492] Funding Source: Medline; NIDDK NIH HHS [DK25387] Funding Source: Medline; NIGMS NIH HHS [GM52543] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; Galyov E. E., 1997, MOL MICROBIOL, V25, P1903; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; KANIGA K, 1995, J BACTERIOL, V177, P7078, DOI 10.1128/jb.177.24.7078-7085.1995; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; NAMBA Y, 1992, J BIOCHEM-TOKYO, V112, P503, DOI 10.1093/oxfordjournals.jbchem.a123929; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Van Nhieu GT, 1999, CURR OPIN MICROBIOL, V2, P51; VanNhieu GT, 1997, EMBO J, V16, P2717, DOI 10.1093/emboj/16.10.2717; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; Zhou D., UNPUB	18	312	326	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2092	2095		10.1126/science.283.5410.2092	http://dx.doi.org/10.1126/science.283.5410.2092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10092234				2022-12-01	WOS:000079369800049
J	Honkinen, O; Lehtonen, OP; Ruuskanen, O; Huovinen, P; Mertsola, J				Honkinen, O; Lehtonen, OP; Ruuskanen, O; Huovinen, P; Mertsola, J			Cohort study of bacterial species causing urinary tract infection and urinary tract abnormalities in children	BRITISH MEDICAL JOURNAL			English	Article									Turku Univ Hosp, Dept Paediat, FIN-20520 Turku, Finland; Turku Univ Hosp, Lab Clin Microbiol, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, Turku Dept, Turku, Finland	University of Turku; University of Turku; Finland National Institute for Health & Welfare	Mertsola, J (corresponding author), Turku Univ Hosp, Dept Paediat, FIN-20520 Turku, Finland.		Huovinen, Pentti/C-1917-2009; Mertsola, Jussi/AAE-3460-2021					DEMAN P, 1989, J PEDIATR-US, V115, P915, DOI 10.1016/S0022-3476(89)80742-5; Dick PT, 1996, J PEDIATR-US, V128, P15, DOI 10.1016/S0022-3476(96)70422-5; Rushton HG, 1997, PEDIATR CLIN N AM, V44, P1133, DOI 10.1016/S0031-3955(05)70551-4; SMELLIE JM, 1995, ARCH DIS CHILD, V72, P247, DOI 10.1136/adc.72.3.247; 1991, J R COLL PHYSICIANS, V25, P36	5	35	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1999	318	7186					770	+		10.1136/bmj.318.7186.770	http://dx.doi.org/10.1136/bmj.318.7186.770			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BX	10082700	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000079421700025
J	Thrift, AG; McNeil, JJ; Forbes, A; Donnan, GA				Thrift, AG; McNeil, JJ; Forbes, A; Donnan, GA			Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL-ISCHEMIA; CONTROLLED TRIAL; COMMUNITY STROKE; HEMORRHAGE; PREVENTION; INFARCTION; DISEASE; PERTH; WOMEN	Objective To examine the association between use of aspirin or other non-steroidal anti-inflammatory drugs and intracerebral haemorrhage. Design Case-control study. Setting 13 major city hospitals in the Melbourne and metropolitan area. Subjects 331 consecutive cases of stroke verified by computed tomography or postmortem examination, and 331 age (+/- 5 years) and sex matched controls who were community based neighbours. Interventions (Questionnaire administered to all subjects either directly or by proxy with the next of kin. Drug use was validated by reviewing prescribing records held by the participants' doctors. Main outcome measures Previous use of aspirin or other non-steroidal anti-inflammatory drugs. Results Univariate analysis showed no increased risk of intracerebral haemorrhage with low dose aspirin use in the preceding 2 weeks. Using multiple logistic regression to control for possible confounding factors, the odds ratio associated with die use of aspirin was 1.00 (95% confidence interval 0.60 to 1.66, P = 0.998) and the odds ratio associated with the use of other non-steroidal anti-inflammatory drugs was 0.85 (0.45 to 1.61, P = 0.611) compared with respective non-users in the preceding fortnight. Moderate to high doses of aspirin (> 1225 mg/week spread over at least three doses) yielded an odds ratio of 3.05 (1.02 to 9.14, P= 0.047). There was no evidence of an increased risk among subgroups defined by age, sex, Mood pressure status, alcohol intake, smoking, and the presence or absence of previous cardiovascular disease. Conclusions No increase in risk of intracerebral haemorrhage was found among aspirin users overall or among those who took low doses of the drug or other non-steroidal anti-inflammatory drugs. These data provide evidence that doses of aspirin usually used for prophylaxis against vascular disease produce no substantial increase in risk of intracerebral haemorrhage.	Alfred Hosp, Monash Med Sch, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia; Austin Hosp, Dept Neurol, Heidelberg, Vic 3084, Australia; Repatriat Gen Hosp, Dept Neurol, Heidelberg, Vic 3084, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health	Thrift, AG (corresponding author), Austin & Repatriat Med Ctr, Natl Stroke Res Inst, Heidelberg West, Vic 3081, Australia.	thrift@austin.unimelb.edu.au	DONNAN, GEOFFREY A/A-9947-2008; McNeil, John/L-6440-2019; Thrift, Amanda/I-6251-2012	McNeil, John/0000-0002-1049-5129; Thrift, Amanda/0000-0001-8533-4170; Forbes, Andrew/0000-0003-4269-914X; Donnan, Geoffrey/0000-0001-6324-3403				ABUZEID HAH, 1977, STROKE, V8, P106, DOI 10.1161/01.STR.8.1.106; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON CS, 1993, MED J AUSTRALIA, V158, P85, DOI 10.5694/j.1326-5377.1993.tb137529.x; [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BOUSSER MG, 1983, PRESSE MED, V12, P3049; BRESLOW NE, 1980, STAT METHODS CANC RE, P247; CALANDRE L, 1986, STROKE, V17, P1126, DOI 10.1161/01.STR.17.6.1126; *CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FIELDS WS, 1978, STROKE, V9, P309, DOI 10.1161/01.STR.9.4.309; Goldstein LB, 1996, STROKE, V27, P32; HARKER LA, 1986, J AM COLL CARDIOL, V8, pB21, DOI 10.1016/S0735-1097(86)80004-3; HELMERS C, 1987, STROKE, V18, P325; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; JAMROZIK K, 1994, STROKE, V25, P51, DOI 10.1161/01.STR.25.1.51; LEMAK NA, 1986, NEUROLOGY, V36, P705; LOWENTHAL A, 1990, STROKE, V21, P1122; Magaziner J, 1996, AM J EPIDEMIOL, V143, P283; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; NORRVING B, 1991, LANCET, V338, P1345; PATRONO C, 1980, THROMB RES, V17, P317, DOI 10.1016/0049-3848(80)90066-3; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; RICCI S, 1991, J NEUROL NEUROSUR PS, V54, P695, DOI 10.1136/jnnp.54.8.695; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; *STAT EP RES CORP, 1991, EP GRAPH EST TEST PA; Thrift AG, 1996, STROKE, V27, P2020, DOI 10.1161/01.STR.27.11.2020; VANE J, 1987, DRUGS, V33, P18, DOI 10.2165/00003495-198700331-00005; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801	31	65	67	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	1999	318	7186					759	764		10.1136/bmj.318.7186.759	http://dx.doi.org/10.1136/bmj.318.7186.759			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BX	10082697	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000079421700020
J	Wang, RL; Stec, A; Hey, J; Lukens, L; Doebley, J				Wang, RL; Stec, A; Hey, J; Lukens, L; Doebley, J			The limits of selection during maize domestication	NATURE			English	Article							EVOLUTION; RECOMBINATION; GENE; TEOSINTE; DOMINANCE; SEQUENCE; ORIGIN	The domestication of all major crop plants occurred during a brief period in human history about 10,000 years ago(1). During this time, ancient agriculturalists selected seed of preferred forms and culled out seed of undesirable types to produce each subsequent generation. Consequently favoured alleles at genes controlling traits of interest increased in frequency, ultimately reaching fixation. When selection is strong, domestication has the potential to drastically reduce genetic diversity in a crop. To understand the impact of selection during maize domestication, we examined nucleotide polymorphism in teosinte branched1, a gene involved in maize evolution(2). Here we show that the effects of selection were limited to the gene's regulatory region and cannot be detected in the protein-coding region. Although selection was apparently strong, high rates of recombination and a prolonged domestication period probably limited its effects. Our results help to explain why maize is such a variable crop. They also suggest that maize domestication required hundreds of years, and confirm precious evidence that maize was domesticated from Balsas teosinte of southwestern Mexico.	Univ Minnesota, Dept Plant Biol, St Paul, MN 55108 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	University of Minnesota System; University of Minnesota Twin Cities; Rutgers State University New Brunswick	Doebley, J (corresponding author), Univ Minnesota, Dept Plant Biol, St Paul, MN 55108 USA.		Hey, Jody/D-1257-2009	Hey, Jody/0000-0001-5358-6488; Lukens, Lewis/0000-0003-3963-2008				Beadle GW, 1939, J HERED, V30, P245, DOI 10.1093/oxfordjournals.jhered.a104728; BEAN M, 1998, NATURE, V391, P485; Buckler ES, 1996, MOL BIOL EVOL, V13, P612, DOI 10.1093/oxfordjournals.molbev.a025621; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; DOEBLEY J, 1995, GENETICS, V141, P333; DOEBLEY J, 1998, MAIZE GENET COOP NEW, V73; DOEBLEY JF, 1984, SYST BOT, V9, P203, DOI 10.2307/2418824; Dooner HK, 1997, PLANT CELL, V9, P1633, DOI 10.1105/tpc.9.9.1633; Eyre-Walker A, 1998, P NATL ACAD SCI USA, V95, P4441, DOI 10.1073/pnas.95.8.4441; GALINAT WC, 1983, MAYDICA, V28, P121; GOLOUBINOFF P, 1993, P NATL ACAD SCI USA, V90, P1997, DOI 10.1073/pnas.90.5.1997; Hanson MA, 1996, GENETICS, V143, P1395; Harlan JR., 1992, CROPS MAN; Hilton H, 1998, GENETICS, V150, P863; HUDSON RR, 1987, GENETICS, V116, P153; HUDSON RR, 1983, THEOR POPUL BIOL, V23, P183, DOI 10.1016/0040-5809(83)90013-8; ILTIS HH, 1983, SCIENCE, V222, P886, DOI 10.1126/science.222.4626.886; KAPLAN NL, 1989, GENETICS, V123, P887; KIMURA M, 1969, GENETICS, V61, P763; Okagaki RJ, 1997, GENETICS, V147, P815; PATTERSON GI, 1995, GENETICS, V140, P1389; Smith BD, 1995, EMERGENCE AGR; Stam LF, 1996, GENETICS, V144, P1559; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P188; Xu XJ, 1995, PLANT CELL, V7, P2151, DOI 10.1105/tpc.7.12.2151	25	545	613	3	124	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	1999	398	6724					236	239		10.1038/18435	http://dx.doi.org/10.1038/18435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UA	10094045				2022-12-01	WOS:000079228400052
J	Hofmann, RM; Pickart, CM				Hofmann, RM; Pickart, CM			Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MULTIUBIQUITIN CHAINS; PROTEASOME PATHWAY; PROTEIN LIGASE; GENE-PRODUCT; KAPPA-B; YEAST; ENCODES; RAD6; EXPRESSION	Ubiquitin-conjugating enzyme variant (UEV) proteins resemble ubiquitin-conjugating enzymes (E2s) but lack the defining E2 active-site residue. The MMS2-encoded UEV protein has been genetically implicated in error-free postreplicative DNA repair in Saccharomyces cerevisiae. We show that Mms2p forms a specific heteromeric complex with the UBC13-encoded E2 and is required for the Ubc13p-dependent assembly of polyubiquitin chains linked through lysine 63. A ubc13 yeast strain is UV sensitive, and single, double, and triple mutants of the UBC13, MMS2, and ubiquitin (ubiK63R) genes display a comparable phenotype. These findings support a model in which an Mms2p/Ubc13p complex assembles novel polyubiquitin chains for signaling in DNA repair, and they suggest that UEV proteins may act to increase diversity and selectivity in ubiquitin conjugation.	Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University	Pickart, CM (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA.	cpickart@welchlink.welch.jhu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007141] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46984] Funding Source: Medline; NIEHS NIH HHS [T32 ES07141] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Ausubel FM, 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Haas AL, 1997, FASEB J, V11, P1257; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; LIU HP, 1992, GENETICS, V132, P665; Ma L, 1998, ONCOGENE, V17, P1321, DOI 10.1038/sj.onc.1202058; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; OH CE, 1994, J NEUROSCI, V14, P3166; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; PETERS JM, 1998, UBIQUITIN BIOL CELL, P345; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; PICKART CM, 1988, J BIOL CHEM, V263, P12028; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Ponting CP, 1997, J MOL MED-JMM, V75, P467; PRAKASH L, 1977, GENETICS, V86, P33; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SAXENA P, 1992, J BACTERIOL, V174, P1956, DOI 10.1128/jb.174.6.1956-1964.1992; Siede W, 1998, CONT CANC RES, P307; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Thomson TM, 1998, FEBS LETT, V423, P49, DOI 10.1016/S0014-5793(98)00060-X; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; Xiao W, 1998, NUCLEIC ACIDS RES, V26, P3908, DOI 10.1093/nar/26.17.3908; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yamaguchi T, 1996, J BIOCHEM-TOKYO, V120, P494	54	646	679	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	1999	96	5					645	653		10.1016/S0092-8674(00)80575-9	http://dx.doi.org/10.1016/S0092-8674(00)80575-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	174TB	10089880	Bronze			2022-12-01	WOS:000079050100008
J	Grimbacher, B; Holland, SM; Gallin, JI; Greenberg, F; Hill, SC; Malech, HL; Miller, JA; O'Connell, AC; Puck, JM				Grimbacher, B; Holland, SM; Gallin, JI; Greenberg, F; Hill, SC; Malech, HL; Miller, JA; O'Connell, AC; Puck, JM			Hyper-IgE syndrome with recurrent infections - An autosomal dominant multisystem disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERIMMUNOGLOBULINEMIA-E SYNDROME; INTERFERON-GAMMA PRODUCTION; JOBS SYNDROME; CLEIDOCRANIAL DYSPLASIA; T-CELLS; INTERLEUKIN-4; ASSOCIATION; DEFICIENCY; LYMPHOMA; OSTEOPOROSIS	Background The hyper-IgE syndrome with recurrent infections is a rare immunodeficiency characterized by recurrent skin and pulmonary abscesses and extremely elevated levels of IgE in serum. Associated facial and skeletal features have been recognized, but their frequency is unknown, and the genetic basis of the hyper-IgE syndrome is poorly understood. Methods We studied 30 patients with the hyper-IgE syndrome and 70 of their relatives. We took histories, reviewed records, performed physical and dental examinations, took anthropometric measurements, and conducted laboratory studies. Results Nonimmunologic features of the hyper-IgE syndrome were present in all patients older than eight years. Seventy-two percent had the previously unrecognized feature of failure or delay of shedding of the primary teeth owing to lack of root resorption. Common findings among patients were recurrent fractures (in 57 percent of patients), hyperextensible joints (in 68 percent), and scoliosis tin 76 percent of patients 16 years of age or older). The classic triad of abscesses, pneumonia, and an elevated IgE level was identified in 77 percent of all patients and in 85 percent of those older than eight. In 6 of 23 adults (26 percent), IgE levels declined over time and came closer to or fell within the normal range. Autosomal dominant transmission of the hyper-IgE syndrome was found, but with variable expressivity. Of the 27 relatives at risk for inheriting the hyper-IgE syndrome, 10 were fully affected, 11 were unaffected, and 6 had combinations of mild immunologic, dental, and skeletal features of the hyper-IgE syndrome. Conclusions The hyper-IgE syndrome is a multisystem disorder that affects the dentition, the skeleton, connective tissue, and the immune system. It is inherited as a single-locus autosomal dominant trait with variable expressivity. (N Engl J Med 1999;340:692-702.) (C) 1999, Massachusetts Medical Society.	NIH, Natl Human Genome Res Inst, Genet & Mol Biol Branch, Immunol Genet Sect, Bethesda, MD 20892 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NIH, Warren Grant Magnuson Clin Ctr, Dept Radiol, Bethesda, MD 20892 USA; NIDCR, NIH, Bethesda, MD 20892 USA; NIH, Natl Human Genome Res Inst, Genet Dis Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Puck, JM (corresponding author), NIH, Natl Human Genome Res Inst, Genet & Mol Biol Branch, Immunol Genet Sect, Bldg 49,Rm 3A14,40 Convent Dr, Bethesda, MD 20892 USA.	jpuck@nhgri.nih.gov		Malech, Harry/0000-0001-5874-5775; O'Connell, Anne C/0000-0002-1495-3983	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000646, Z01AI000644, ZIAAI000646, ZIAAI000644] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRICH MP, 1993, CLIN NUCL MED, V18, P153, DOI 10.1097/00003072-199302000-00017; BALE JF, 1977, CANCER, V39, P2386, DOI 10.1002/1097-0142(197706)39:6<2386::AID-CNCR2820390612>3.0.CO;2-X; BANNATYNE RM, 1969, J PEDIATR-US, V75, P236, DOI 10.1016/S0022-3476(69)80394-X; Belohradsky B H, 1987, Ergeb Inn Med Kinderheilkd, V55, P1; BLUM R, 1977, J PEDIATR-US, V90, P607, DOI 10.1016/S0022-3476(77)80380-6; Borges WG, 1998, J PEDIATR-US, V133, P303, DOI 10.1016/S0022-3476(98)70243-4; BRESTEL EP, 1982, AM J DIS CHILD, V136, P774, DOI 10.1001/archpedi.1982.03970450016003; BUCKLEY R H, 1991, Journal of Allergy and Clinical Immunology, V87, P313, DOI 10.1016/0091-6749(91)91978-3; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; BUCKLEY RH, 1981, CLIN IMMUNOLOGY UPDA, P147; BUNCH WH, 1989, SCOLIOSIS MAKING CLI, P44; CLAASSEN JJ, 1991, J ALLERGY CLIN IMMUN, V88, P713, DOI 10.1016/0091-6749(91)90177-P; Cohen M M Jr, 1988, Am J Med Genet Suppl, V4, P99; DAUMLING S, 1980, INFECTION, V8, P248; DAVIS SD, 1966, LANCET, V1, P1013; DEMIRJIAN A, 1973, HUM BIOL, V45, P211; DONABEDIAN H, 1983, MEDICINE, V62, P195, DOI 10.1097/00005792-198307000-00001; DRESKIN SC, 1987, J CLIN INVEST, V79, P1764, DOI 10.1172/JCI113017; DRESKIN SC, 1985, J CLIN INVEST, V75, P26, DOI 10.1172/JCI111683; DRESKIN SC, 1987, J ALLERGY CLIN IMMUN, V80, P746, DOI 10.1016/0091-6749(87)90297-1; DRESKIN SC, 1987, J ALLERGY CLIN IMMUN, V79, P515, DOI 10.1016/0091-6749(87)90370-8; Driscoll DA, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P198; EINSELE H, 1990, DEUT MED WOCHENSCHR, V115, P1141, DOI 10.1055/s-2008-1065133; FARKAS LG, 1994, ANTHROPOMETRY HEAD F, P242; GAHR M, 1987, MONATSSCHR KINDERH, V135, P329; GAHR M, 1987, HELV PAEDIATR ACTA, V42, P185; Geha R S, 1989, Immunodefic Rev, V1, P155; GEHA RS, 1981, J CLIN INVEST, V68, P783, DOI 10.1172/JCI110315; GORIN LJ, 1989, J ALLERGY CLIN IMMUN, V83, P5, DOI 10.1016/0091-6749(89)90471-5; Gottlieb S, 1997, AM J HUM GENET, V60, P1194; Grimbacher B, 1998, NEW ENGL J MED, V338, P1073; HALL RA, 1995, ANN THORAC SURG, V59, P759, DOI 10.1016/0003-4975(94)00730-6; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HILL HR, 1974, LANCET, V2, P617; HILL HR, 1974, LANCET, V1, P183; HOCHREUTENER H, 1991, DERMATOLOGICA, V182, P7, DOI 10.1159/000247728; HOGER PH, 1985, EUR J PEDIATR, V144, P414, DOI 10.1007/BF00441793; HOLLAND SM, 1998, HARRISONS PRINCIPLES, V1, P351; HURME V O, 1949, J Dent Child, V16, P11; JACOBS DH, 1984, GASTROENTEROLOGY, V87, P201; JENSEN BL, 1990, J ORAL PATHOL MED, V19, P89, DOI 10.1111/j.1600-0714.1990.tb00803.x; KIMATA H, 1995, J ALLERGY CLIN IMMUN, V95, P771, DOI 10.1016/S0091-6749(95)70185-0; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KIRCHNER SG, 1985, RADIOLOGY, V156, P362, DOI 10.1148/radiology.156.2.4011897; LALLEMAND D, 1979, ANN RADIOL, V22, P108; LEUNG DYM, 1988, J IMMUNOL, V140, P84; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; McKusick V.A., 1998, MENDELIAN INHERITANC; MERTEN DF, 1979, RADIOLOGY, V132, P71, DOI 10.1148/132.1.71; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OHTSUKA Y, 1988, SPINE, V13, P1251, DOI 10.1097/00007632-198811000-00008; PAGANELLI R, 1991, CLIN EXP IMMUNOL, V84, P28; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SCHOPFER K, 1983, BRIT MED J, V287, P524, DOI 10.1136/bmj.287.6391.524; SMITHWICK EM, 1978, LANCET, V1, P826; Soucacos PN, 1997, J BONE JOINT SURG AM, V79A, P1498, DOI 10.2106/00004623-199710000-00006; STIEHM ER, 1996, IMMUNOLOGIC DISORDER, P413; VANEPPS DE, 1983, CLIN EXP IMMUNOL, V53, P678; VANSCOY RE, 1975, ANN INTERN MED, V82, P766, DOI 10.7326/0003-4819-82-6-766; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; WRIGHT BA, 1978, ORAL SURG ORAL MED O, V46, P806, DOI 10.1016/0030-4220(78)90312-2	62	510	536	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					692	702		10.1056/NEJM199903043400904	http://dx.doi.org/10.1056/NEJM199903043400904			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172ZB	10053178	Bronze			2022-12-01	WOS:000078955200004
J	Yuan, LL; Ganetzky, B				Yuan, LL; Ganetzky, B			A glial-neuronal signaling pathway revealed by mutations in a neurexin-related protein	SCIENCE			English	Article							DROSOPHILA; CELLS; CHANNELS; LOCUS; INHIBITOR; PEPTIDE; SWITCH; GENES	In the nervous system, glial cells greatly outnumber neurons but the full extent of their role in determining neural activity remains unknown. Here the axotactin (axo) gene of Drosophila was shown to encode a member of the neurexin protein superfamily secreted by glia and subsequently localized to axonal tracts, Null mutations of axo caused temperature-sensitive paralysis and a corresponding blockade of axonal conduction. Thus, the AXO protein appears to be a component of a glial-neuronal signaling mechanism that helps to determine the membrane electrical properties of target axons.	Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ganetzky, B (corresponding author), Univ Wisconsin, Neurosci Training Program, 445 Henry Mall, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015390] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43100] Funding Source: Medline; NINDS NIH HHS [NS15390] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHBURNER M, 1989, DROSOPHILA LAB HDB, P207; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BARRES BA, 1991, J NEUROSCI, V11, P3685; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bellen HJ, 1998, TRENDS NEUROSCI, V21, P444, DOI 10.1016/S0166-2236(98)01267-3; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; Goodman Corey S., 1993, P1131; HONG CS, 1994, J NEUROSCI, V14, P5160; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; ITO K, 1995, ROUX ARCH DEV BIOL, V204, P284, DOI 10.1007/BF02179499; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; KERNAN MJ, 1991, CELL, V66, P949, DOI 10.1016/0092-8674(91)90440-A; Kunitz M, 1936, J GEN PHYSIOL, V19, P991, DOI 10.1085/jgp.19.6.991; LITTLETON JT, 1997, J CELL BIOL, V137; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; LUCCHESI KJ, 1991, J GEN PHYSIOL, V97, P1295, DOI 10.1085/jgp.97.6.1295; Menegoz M, 1997, NEURON, V19, P319, DOI 10.1016/S0896-6273(00)80942-3; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; ORDWAY RW, 1994, P NATL ACAD SCI USA, V91, P5715, DOI 10.1073/pnas.91.12.5715; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; SCHWEITZ H, 1994, P NATL ACAD SCI USA, V91, P878, DOI 10.1073/pnas.91.3.878; Titus SA, 1997, J NEUROSCI, V17, P875; Wang XJ, 1997, J NEUROSCI, V17, P882; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; WU RL, 1994, J NEUROSCI, V14, P1677, DOI 10.1523/JNEUROSCI.14-03-01677.1994	30	53	54	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1343	1345		10.1126/science.283.5406.1343	http://dx.doi.org/10.1126/science.283.5406.1343			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037607				2022-12-01	WOS:000078839900046
J	Pal, B				Pal, B			Questionnaire survey of advice given to patients with fractures	BRITISH MEDICAL JOURNAL			English	Article									Withington Hosp, Univ S Manchester Hosp NHS Trust, Manchester M20 2LR, Lancs, England		Pal, B (corresponding author), Withington Hosp, Univ S Manchester Hosp NHS Trust, Manchester M20 2LR, Lancs, England.							BARLOW DM, 1994, ADVISORY GROUP OSTEO; Ekman A, 1997, LANCET, V350, P563, DOI 10.1016/S0140-6736(05)63140-6; *ROYAL COLL PHYS, 1995, J R COLL PHYS LOND, V23, P8; Scheiber LB, 1998, SEMIN ARTHRITIS RHEU, V27, P245, DOI 10.1016/S0049-0172(98)80004-8; Van Staa TP, 1998, BRIT J RHEUMATOL, V37, P87	5	63	63	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					500	501		10.1136/bmj.318.7182.500	http://dx.doi.org/10.1136/bmj.318.7182.500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024257	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000078818100026
J	Benbadis, SR; Mascha, E; Perry, MC; Wolgamuth, BR; Smolley, LA; Dinner, DS				Benbadis, SR; Mascha, E; Perry, MC; Wolgamuth, BR; Smolley, LA; Dinner, DS			Association between the Epworth Sleepiness Scale and the multiple sleep latency test in a clinical population	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Associated-Professional-Sleep-Societies 11th Annual Meeting	JUN 03, 1997	SAN FRANCISCO, CA	Assoc Profess Sleep Soc			DAYTIME SLEEPINESS	Background: Excessive daytime sleepiness can be evaluated with both subjective and objective tests. Objective: To examine the association between Epworth Sleepiness Scale scores and sleep latency on the multiple sleep latency test. Design: Case series. Setting: Referral sleep disorders center. Patients: 102 consecutive patients evaluated for excessive daytime sleepiness. Measurements: Epworth Sleepiness Scale scores and mean sleep latency on the multiple sleep latency test. Results: No significant association was seen between Epworth scores and mean sleep latency (Pearson correlation, -0.17 [95% CI, -0.35 to 0.03]; P = 0.09) (analysis of variance, P = 0.13). The mean Epworth score did not differ in three groups of patients who were defined by mean sleep latency as having normal sleep latency (>10 minutes), moderate sleep latency (5 to 10 minutes), or severe sleep latency (<5 minutes) (analysis of variance, P = 0.13). Conclusions: No statistically or clinically significant association was seen between Epworth scores and mean sleep latency. The subjective Epworth Sleepiness Scale and the objective multiple sleep latency test may evaluate different, complementary aspects of sleepiness.	Cleveland Clin, Dept Pulm Med, Ft Lauderdale, FL 33309 USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Benbadis, SR (corresponding author), Univ S Florida, Coll Med, Dept Neurol, Harbourside Med Tower,4 Columbia Dr,Suite 730, Tampa, FL 33606 USA.	sbenbadi@com1.med.usf.edu						*AM EL SOC, 1994, J CLIN NEUROPHYSIOL, V11, P116; Benbadis SR, 1996, SLEEP, V19, P632; Briones B, 1996, SLEEP, V19, P583, DOI 10.1093/sleep/19.7.583; Broughton RJ, 1997, NEUROLOGY, V49, P444, DOI 10.1212/WNL.49.2.444; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Chervin RD, 1997, J PSYCHOSOM RES, V42, P145, DOI 10.1016/S0022-3999(96)00239-5; GREENLAND S, 1986, AM J EPIDEMIOL, V123, P203, DOI 10.1093/oxfordjournals.aje.a114229; HARNISH MJ, 1996, SLEEP RES, V25, P492; HOCH CC, 1992, NEUROBIOL AGING, V13, P353, DOI 10.1016/0197-4580(92)90049-4; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Mitler MM, 1998, ANN NEUROL, V43, P88; PRESSMAN MR, 1989, SLEEP, V12, P239, DOI 10.1093/sleep/12.3.239; Rechtschaffen A, 1968, BRAIN INF SERV; SANDER AM, 1996, SLEEP RES, V25, P355; Sangal R, 1997, SLEEP RES, V26, P492; SANGAL RB, 1997, SLEEP RES, V26, P493; SEIDEL WF, 1984, SLEEP, V7, P230, DOI 10.1093/sleep/7.3.230; Smolley LA, 1993, SLEEP RES, V22, P389; THORPY MJ, 1992, SLEEP, V15, P268	20	132	138	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				289	292		10.7326/0003-4819-130-4-199902160-00014	http://dx.doi.org/10.7326/0003-4819-130-4-199902160-00014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	166PY	10068387				2022-12-01	WOS:000078587200006
J	Bronkhorst, AW; Houtgast, T				Bronkhorst, AW; Houtgast, T			Auditory distance perception in rooms	NATURE			English	Article							REVERBERATION	The perceived distance of a sound source in a room has been shown to depend on the ratio of the energies of direct and reflected sound(1). Although this relationship was verified in later studies(2-4), the research has never led to a quantitative model. The advent of techniques for the generation of virtual sound sources(5,6) has made it possible to study distance perception using controlled, deterministic stimuli. Here we present two experiments that make use of such stimuli and we show that a simple model, based on a modified direct-to-reverberant energy ratio, can accurately predict the results and also provide an explanation for the 'auditory horizon' in distance perception. The modification of the ratio consists of the use of an integration time of 6 milliseconds in the calculation of the energy of the direct sound. This time constant seems to be important in spatial hearing-the precedence effect is also based on a similar integration window(7).	TNO, Human Factors Res Inst, NL-3769 ZG Soesterberg, Netherlands	Netherlands Organization Applied Science Research	Bronkhorst, AW (corresponding author), TNO, Human Factors Res Inst, POB 23, NL-3769 ZG Soesterberg, Netherlands.							BEGAULT DR, 1992, J AUDIO ENG SOC, V40, P895; Blauert J., 1997, SPATIAL HEARING PSYC, DOI [10.7551/mitpress/6391.001.0001, DOI 10.7551/MITPRESS/6391.001.0001]; BRONKHORST AW, 1995, J ACOUST SOC AM, V98, P2542, DOI 10.1121/1.413219; COLEMAN PD, 1963, PSYCHOL BULL, V60, P302, DOI 10.1037/h0045716; COLEMAN PD, 1962, J ACOUST SOC AM, V34, P345, DOI 10.1121/1.1928121; HOUTGAST T, 1994, HEARING RES, V72, P29, DOI 10.1016/0378-5955(94)90202-X; Kuttruff H., 1973, ROOM ACOUSTICS, V4th; MERSHON DH, 1979, PERCEPTION, V8, P311, DOI 10.1068/p080311; MERSHON DH, 1975, PERCEPT PSYCHOPHYS, V18, P409, DOI 10.3758/BF03204113; MOLLER H, 1995, J AUDIO ENG SOC, V43, P300; MOORE BCJ, 1988, J ACOUST SOC AM, V83, P1102, DOI 10.1121/1.396055; NIELSEN SH, 1993, J AUDIO ENG SOC, V41, P755; von Bekesy G., 1938, AKUST Z, V3, P21; WETTSCHURECK R, 1973, ACUSTICA, V29, P260; WIGHTMAN FL, 1989, J ACOUST SOC AM, V85, P868, DOI 10.1121/1.397558	15	168	170	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					517	520		10.1038/17374	http://dx.doi.org/10.1038/17374			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028966				2022-12-01	WOS:000078574900048
J	Dvorak, AM				Dvorak, AM			An apoptotic eosinophil	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Dvorak, AM (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.								0	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					437	437		10.1056/NEJM199902113400605	http://dx.doi.org/10.1056/NEJM199902113400605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971868				2022-12-01	WOS:000078571000005
J	Roorda, A; Williams, DR				Roorda, A; Williams, DR			The arrangement of the three cone classes in the living human eye	NATURE			English	Article							COLOR-VISION; BLUE; SENSITIVITY; PIGMENTS	Human colour vision depends on three classes of receptor, the short- (S), medium- (M), and long- (L) wavelength-sensitive cones. These cone classes are interleaved in a single mosaic so that, at each point in the retina, only a single class of cone samples the retinal image. As a consequence, observers with normal trichromatic colour vision are necessarily colour blind on a local spatial scale(1). The limits this places on vision depend on the relative numbers and arrangement of cones. Although the topography of human S cones is known(2,3), the human L- and M-cone submosaics have resisted analysis. Adaptive optics, a technique used to overcome blur in ground-based telescopes(4), can also overcome blur in the eye, allowing the sharpest images ever taken of the living retina(5). Were we combine adaptive optics and retinal densitometry(6) to obtain what are, to our knowledge, the first. images of the arrangement of S, M and L cones in the living human eye. The proportion of L to M cones is strikingly different in two male subjects, each of whom has normal colour vision. The mosaics of both subjects have large patches in which either M or L cones are missing. This arrangement reduces the eye's ability to recover colour variations of high spatial frequency in the environment but may improve the recovery of luminance variations of high spatial frequency.	Univ Rochester, Ctr Visual Sci, Rochester, NY 14627 USA	University of Rochester	Roorda, A (corresponding author), Univ Houston, Coll Optometry, Houston, TX 77204 USA.	aroorda@popmail.opt.uh.edu		Williams, David R/0000-0003-3227-8333				Babcock HW, 1953, PUBL ASTRON SOC PAC, V65, P229, DOI DOI 10.1086/126606; BOWMER TN, 1980, MAKROMOL CHEM-RAPID, V1, P1; BREWSTER D, 1832, LONDON EDINBURGH PHI, V1, P169; CAMPBELL FW, 1955, J PHYSIOL-LONDON, V130, P131, DOI 10.1113/jphysiol.1955.sp005399; CICERONE CM, 1989, VISION RES, V29, P115, DOI 10.1016/0042-6989(89)90178-8; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; Diggle PJ, 1983, STAT ANAL SPATIAL PO; Hagstrom SA, 1998, NEUROREPORT, V9, P1963, DOI 10.1097/00001756-199806220-00009; Holmgren F., 1884, COMP REND C PERIOD I, V1, P80; Jacobs GH, 1997, VISUAL NEUROSCI, V14, P921, DOI 10.1017/S0952523800011639; Jacobs GH, 1993, COLOUR VISION DEFICI, VXI, P107; KRAUSKOPF J, 1964, J OPT SOC AM, V54, P1171, DOI 10.1364/JOSA.54.001171; Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884; Miyahara E, 1998, VISION RES, V38, P601, DOI 10.1016/S0042-6989(97)88334-4; MOLLON JD, 1989, J EXP BIOL, V146, P21; MOLLON JD, 1992, NATURE, V360, P677, DOI 10.1038/360677a0; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Packer OS, 1996, J NEUROSCI, V16, P2251; POKORNY J, 1991, NATO ADV SCI I A-LIF, V203, P23; RUSHTON WAH, 1964, VISION RES, V4, P75, DOI 10.1016/0042-6989(64)90034-3; SEKIGUCHI N, 1993, J OPT SOC AM A, V10, P2118, DOI 10.1364/JOSAA.10.002118; VIMAL RLP, 1989, VISION RES, V29, P61, DOI 10.1016/0042-6989(89)90174-0; WILLIAMS DR, 1981, VISION RES, V21, P1357, DOI 10.1016/0042-6989(81)90242-X; WILLIAMS DR, 1991, NATO ADV SCI I A-LIF, V203, P11; WILLIAMS DR, 1990, ADVANCES IN PHOTORECEPTION, P135; Yamaguchi T, 1997, HUM MOL GENET, V6, P981, DOI 10.1093/hmg/6.7.981	27	640	659	1	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					520	522		10.1038/17383	http://dx.doi.org/10.1038/17383			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028967				2022-12-01	WOS:000078574900049
J	Hiyagon, H; Hashimoto, A				Hiyagon, H; Hashimoto, A			O-16 excesses in Olivine inclusions in Yamato-86009 and Murchison chondrites and their relation to CAIs	SCIENCE			English	Article							CARBONACEOUS CHONDRITES; ALLENDE METEORITE; ISOTOPE; OXYGEN; CONSEQUENCES; COMPONENT	In situ ion microprobe analyses of oxygen isotopes in Yamato-86009 and Murchison chondrites show that they contain abundant olivine-rich inclusions that have large oxygen-16 (O-16) excesses, similar to those in spinel grains in calcium-aluminium-rich inclusions in Allende and other carbonaceous chondrites. The existence of O-16-enriched olivine-rich inclusions suggests that oxygen isotopic anomalies were more extensive in the early solar system than was previously thought a nd that their origin may be attributed to a nebular chemical process rather than to an unidentified O-16-rich carrier of presolar origin.	Univ Tokyo, Dept Earth & Planetary Sci, Bunkyo Ku, Tokyo 1130033, Japan; Hokkaido Univ, Dept Earth & Planetary Sci, Sapporo, Hokkaido 0600810, Japan	University of Tokyo; Hokkaido University	Hiyagon, H (corresponding author), Univ Tokyo, Dept Earth & Planetary Sci, Bunkyo Ku, Tokyo 1130033, Japan.	hiyagon@geoph.s.u-tokyo.ac.jp		Hashimoto, Akihiko/0000-0002-2914-2809				CLAYTON DD, 1989, ASTROPHYS J, V346, P531, DOI 10.1086/168035; CLAYTON DD, 1988, ASTROPHYS J, V334, P191, DOI 10.1086/166829; CLAYTON RN, 1977, EARTH PLANET SC LETT, V34, P209, DOI 10.1016/0012-821X(77)90005-X; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; CLAYTON RN, 1976, EARTH PLANET SC LETT, V30, P10, DOI 10.1016/0012-821X(76)90003-0; CLAYTON RN, 1984, EARTH PLANET SC LETT, V67, P151, DOI 10.1016/0012-821X(84)90110-9; CRAIG H, 1961, SCIENCE, V133, P1833, DOI 10.1126/science.133.3467.1833; GREENWOOD RC, 1994, GEOCHIM COSMOCHIM AC, V58, P1913, DOI 10.1016/0016-7037(94)90424-3; GROSSMAN L, 1976, GEOCHIM COSMOCHIM AC, V40, P149, DOI 10.1016/0016-7037(76)90172-1; HASHIMOTO A, 1987, GEOCHIM COSMOCHIM AC, V51, P1685, DOI 10.1016/0016-7037(87)90348-6; HASHIMOTO A, 1997, ANTARCTIC METEORITES, V22, P49; HASHIMOTO A, 1997, 22 S ANT MET NAT I P; HIYAGON H, 1998, LUNAR PLANET SCI, V29; HIYAGON H, 1997, ANTARCT METEORITE RE, V10, P249; JABEEN I, 1998, ANTARCT METEORITE RE, V11, P122; KIMURA M, 1993, GEOCHIM COSMOCHIM AC, V57, P2329, DOI 10.1016/0016-7037(93)90573-F; LATTIMER JM, 1978, ASTROPHYS J, V219, P230, DOI 10.1086/155771; LIFFMAN K, 1988, P LUN PLAN SCI C, V18, P657; MacPherson G. J., 1981, P LUNAR PLANET SCI, V12B, P1079; MACPHERSON GJ, 1984, J GEOPHYS RES, V89, pC299, DOI 10.1029/JB089iS01p0C299; MACPHERSON GJ, 1985, GEOCHIM COSMOCHIM AC, V49, P2267, DOI 10.1016/0016-7037(85)90227-3; MCKEEGAN KD, 1998, METEORIT PLANET SC S, V32; Nittler LR, 1998, NATURE, V393, P222, DOI 10.1038/30377; Nittler LR, 1997, AIP CONF PROC, P59, DOI 10.1063/1.51767; Prinn R.G.P., 1989, ORIGIN EVOLUTION PLA, P78; Thiemen M.H, 1996, CHONDRULES PROTOPLAN, P107; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; Wark D. A., 1977, LUNAR PLANETARY SCI, P95; WEN J, 1993, J GEOPHYS RES-ATMOS, V98, P12801, DOI 10.1029/93JD00565; WOOD JA, 1993, GEOCHIM COSMOCHIM AC, V57, P2377, DOI 10.1016/0016-7037(93)90575-H	30	67	67	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					828	831		10.1126/science.283.5403.828	http://dx.doi.org/10.1126/science.283.5403.828			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933162				2022-12-01	WOS:000078496800039
J	Herwaldt, BL; Beach, MJ				Herwaldt, BL; Beach, MJ		Cyclospora Working Grp	The return of Cyclospora in 1997: Another outbreak of cyclosporiasis in North America associated with imported raspberries	ANNALS OF INTERNAL MEDICINE			English	Article							FOREIGN RESIDENTS; EPIDEMIOLOGY; FOOD; INFECTIONS; TRAVELERS; DIARRHEA; PATHOGEN; LESSONS; DISEASE; NEPAL	Background: In the spring of 1996, an outbreak of cyclosporiasis associated with fresh Guatemalan raspberries occurred in the United States and Canada. Another multistate outbreak of cyclosporiasis occurred in North America in the spring of 1997. Objective: To identify the vehicle of the outbreak that occurred in the spring of 1997. Design: Retrospective cohort studies of clusters of cases associated with events (such as banquets) and traceback investigations of sources of implicated produce. Setting: United States and Canada. Patients: Persons who attended events associated with clusters of cases of cyclosporiasis. Measurements: identification of clinically defined or laboratory-confirmed cases of cyclosporiasis and risk factors for infection. Results: 41 clusters of cases were reported in association with events held from 1 April through 26 May in 13 U.S. states, the District of Columbia, and 1 Canadian province. The clusters comprised 762 cases of cyclosporiasis, 192 (25.2%) of which were laboratory confirmed. In addition, 250 laboratory-confirmed sporadic cases were reported in persons who developed gastrointestinal symptoms from April through 15 June, for a total of 1012 cases. Fresh raspberries were the only food common to all 41 events and were the only type of berry served at 9 events (22.0%). Statistically significant associations between consumption of raspberry-containing items and cyclosporiasis were documented for 15 events (40.5% of 37), For 31 of the 33 events with well-documented traceback data, the raspberries either definitely came from Guatemala (8 events) or could have come from Guatemala (23 events). The mode of contamination of the raspberries remains unknown. The outbreak ended shortly after the exportation of fresh raspberries from Guatemala was voluntarily suspended at the end of May 1997. Conclusions: Similar multistate, multicluster outbreaks of cyclosporiasis associated with consumption of Guatemalan raspberries have occurred in consecutive years. These outbreaks highlight the need for better understanding of the biology and epidemiology of Cyclospora cayetanensis and for stronger prevention and control measures to ensure the safety of produce eaten raw.	Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Herwaldt, BL (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, 4770 Buford Highway NE,Mailstop F22, Atlanta, GA 30341 USA.							Barriga O. O., 1997, Parasitologia al Dia, V21, P122; Blaser MJ, 1996, NEW ENGL J MED, V334, P1324, DOI 10.1056/NEJM199605163342009; CONNOR BA, 1993, ANN INTERN MED, V119, P377, DOI 10.7326/0003-4819-119-5-199309010-00005; DeGraw E., 1997, Morbidity and Mortality Weekly Report, V46, P521; Dubey JP, 1998, INT J PARASITOL, V28, P369, DOI 10.1016/S0020-7519(97)83432-7; Eberhard ML, 1997, ARCH PATHOL LAB MED, V121, P792; FITZGERALD PR, 1968, J PARASITOL, V54, P233, DOI 10.2307/3276927; GARCIA LS, 1997, DIAGNOSTIC MED PARAS, P66; GarciaLopez HL, 1996, EMERG INFECT DIS, V2, P356, DOI 10.3201/eid0204.960414; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; Herwaldt BL, 1997, NEW ENGL J MED, V336, P1548, DOI 10.1056/NEJM199705293362202; Herwaldt BL, 1997, NEW ENGL J MED, V337, P1171; HOGE CW, 1995, LANCET, V345, P691, DOI 10.1016/S0140-6736(95)90868-4; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; HUANG P, 1995, ANN INTERN MED, V123, P409, DOI 10.7326/0003-4819-123-6-199509150-00002; Koumans EHA, 1998, AM J TROP MED HYG, V59, P235, DOI 10.4269/ajtmh.1998.59.235; Madico G, 1997, CLIN INFECT DIS, V24, P977, DOI 10.1093/clinids/24.5.977; Ortega YR, 1997, AM J TROP MED HYG, V57, P683, DOI 10.4269/ajtmh.1997.57.683; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; Osterholm MT, 1997, NEW ENGL J MED, V336, P1597, DOI 10.1056/NEJM199705293362210; Pieniazek NJ, 1997, EMERG INFECT DIS, V3, P381, DOI 10.3201/eid0303.970319; Relman DA, 1996, J INFECT DIS, V173, P440, DOI 10.1093/infdis/173.2.440; Smith HV, 1996, VET REC, V138, P528; Soave R, 1998, INFECT DIS CLIN N AM, V12, P1, DOI 10.1016/S0891-5520(05)70404-9; Soave R, 1996, CLIN INFECT DIS, V23, P429, DOI 10.1093/clinids/23.3.429; Tauxe R, 1997, J FOOD PROTECT, V60, P1400, DOI 10.4315/0362-028X-60.11.1400; Tauxe RV, 1996, BMJ-BRIT MED J, V313, P1093, DOI 10.1136/bmj.313.7065.1093; U. S. Environmental Protection Agency (USEPA) U. S. Department of Agriculture Department of Health and Human Services, 1997, FOOD SAF FARM TABL N; Visvesvara GS, 1997, J CLIN MICROBIOL, V35, P730, DOI 10.1128/JCM.35.3.730-733.1997; ZERPA R, 1995, J TROP MED HYG, V98, P325; 1997, MMWR MORB MORTAL WKL, V46, P689; 1997, MMWR MORB MORTAL WKL, V46, P461; 1997, MMWR MORB MORTAL WKL, V46, P451; 1998, MMWR MORB MORTAL WKL, V47, P782; 1998, MMWR MORB MORTAL WKL, V47, P806	35	97	103	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					210	+		10.7326/0003-4819-130-3-199902020-00006	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049199				2022-12-01	WOS:000078355000005
J	Davies, PA; Pistis, M; Hanna, MC; Peters, JA; Lambert, JJ; Hales, TG; Kirkness, EF				Davies, PA; Pistis, M; Hanna, MC; Peters, JA; Lambert, JJ; Hales, TG; Kirkness, EF			The 5-HT3B subunit is a major determinant of serotonin-receptor function	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; AMINO-ACIDS; 5-HYDROXYTRYPTAMINE; CHANNEL; EXPRESSION; NEURONS; CLONING; GENE	The neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) mediates rapid excitatory responses through ligand-gated channels (5-HT3 receptors). Recombinant expression of the only identified receptor subunit (5-HT3A) yields functional 5-HT3 receptors(1). However, the conductance of these homomeric receptors (sub-picosiemens) is too small to be resolved directly, and contrasts with a robust channel conductance displayed by neuronal 5-HT3 receptors (9-17pS)(2-7). Neuronal 5-HT3 receptors also display a permeability to calcium ions and a current-voltage relationship that differ from those of homomeric receptors(3-5,8) Here we describe a new class of 5-HT3-receptor subunit (5-HT3B). Transcripts of this subunit are co-expressed with the 5-HT3A subunit in the amygdala, caudate and hippocampus. Heteromeric assemblies of 5-HT3A and 5-HT3B subunits display a large single-channel conductance (16 pS), low permeability to calcium ions, and a current-voltage relationship which resembles that of characterized neuronal 5-HT3 channels. The heteromeric receptors also display distinctive pharmacological properties. Surprisingly, the M2 region of the 5-HT3B subunit lacks any of the structural features that are known to promote the conductance of related receptors. In addition to providing a new target for therapeutic agents, the 5-HT3B subunit will be a valuable resource for defining the molecular mechanisms of ion-channel function.	Inst Genom Res, Rockville, MD 20850 USA; Univ Dundee, Ninewells Hosp & Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA	J. Craig Venter Institute; University of Dundee; George Washington University	Kirkness, EF (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.		Davies, Paul A/P-4595-2017; Pistis, Marco/A-3773-2013	Davies, Paul A/0000-0002-3973-3143; Pistis, Marco/0000-0002-4622-3205	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER; NIDA NIH HHS [P50 DA005010] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Wellcome Trust(Wellcome TrustEuropean Commission)		ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; Belelli D, 1995, MOL PHARMACOL, V48, P1054; BERTRAND D, 1952, P NATL ACAD SCI USA, V6971, P93; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; BUFTON KE, 1993, NEUROPHARMACOLOGY, V32, P1325, DOI 10.1016/0028-3908(93)90027-Z; DERKACH V, 1989, NATURE, V339, P706, DOI 10.1038/339706a0; Fletcher S, 1998, TRENDS PHARMACOL SCI, V19, P212, DOI 10.1016/S0165-6147(98)01210-3; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; HUSSY N, 1994, J PHYSIOL-LONDON, V481, P311, DOI 10.1113/jphysiol.1994.sp020441; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JONES KA, 1994, NEUROSCI LETT, V174, P133, DOI 10.1016/0304-3940(94)90004-3; KING FD, 1994, 5 HYDROXYTRYPTAMINE3; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MIYAKE A, 1995, MOL PHARMACOL, V48, P407; PETERS JA, 1997, RECOMBINANT CELL SUR, P119; Ronde P, 1998, J NEUROCHEM, V70, P1094; SUGITA S, 1992, NEURON, V8, P199, DOI 10.1016/0896-6273(92)90121-S; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VILLARROEL A, 1992, P ROY SOC B-BIOL SCI, V249, P317, DOI 10.1098/rspb.1992.0121; WEISS B, 1995, GENOMICS, V29, P304, DOI 10.1006/geno.1995.1254; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; YANG J, 1992, J PHYSIOL-LONDON, V448, P237, DOI 10.1113/jphysiol.1992.sp019039	23	441	453	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					359	363		10.1038/16941	http://dx.doi.org/10.1038/16941			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950429				2022-12-01	WOS:000078324600052
J	Heikkinen, T; Thint, M; Chonmaitree, T				Heikkinen, T; Thint, M; Chonmaitree, T			Prevalence of various respiratory viruses in the middle ear during acute otitis media	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNCYTIAL VIRUS; CHILDREN; FLUIDS; INFECTIONS; EFFUSION; PREVENTION; BACTERIA; VACCINES; ETIOLOGY; ANTIGENS	Background Vaccines against respiratory viruses may be able to reduce the frequency of acute otitis media. Although the role of respiratory viruses in the pathogenesis of acute otitis media is well established, the relative importance of various Viruses is unknown. Methods We determined the prevalence of various respiratory viruses in the middle-ear fluid in 456 children (age, two months to seven years) with acute otitis media. At enrollment and after two to five days of antibiotic therapy, specimens of middle-ear fluid and nasal-wash specimens were obtained for viral and bacterial cultures and the detection of viral antigens. The viral cause of the infections was also assessed by serologic studies of serum samples obtained during the acute illness and convalescence. Results A specific viral cause of the respiratory tract infections was identified in 186 of the 456 children (41 percent). Respiratory syncytial virus was the most common virus identified in middle-ear fluid: it was detected in the middle-ear fluid of 48 of the 65 children (74 percent) infected by this virus (P less than or equal to 0.04 for the comparison with any other virus). Parainfluenza viruses (15 of 29 children [52 percent]) and influenzaviruses (10 of 24 children [42 percent]) were detected in the middle-ear fluid significantly more often than enteroviruses (3 of 27 children [11 percent]) or adenoviruses (1 of 23 children [4 percent]) (P less than or equal to 0.01 for all comparisons). Conclusions Respiratory syncytial virus is the principal virus invading the middle ear during acute otitis media. An effective vaccine against upper respiratory tract infections caused by respiratory syncytial virus may reduce the incidence of acute otitis media in children, (N Engl J Med 1999;340:260-4.) (C) 1999, Massachusetts Medical Society.	Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Chonmaitree, T (corresponding author), Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA.	tchonmai@utmb.edu		Heikkinen, Terho/0000-0001-6504-0116	NIDCD NIH HHS [R01 DC02620] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002620] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AROLA M, 1988, J PEDIATR-US, V113, P693, DOI 10.1016/S0022-3476(88)80380-9; AROLA M, 1990, J PEDIATR-US, V116, P697, DOI 10.1016/S0022-3476(05)82650-2; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307; CHONMAITREE T, 1994, J INFECT DIS, V169, P1265, DOI 10.1093/infdis/169.6.1265; CHONMAITREE T, 1990, J INFECT DIS, V162, P546, DOI 10.1093/infdis/162.2.546; CHONMAITREE T, 1992, J PEDIATR-US, V120, P856, DOI 10.1016/S0022-3476(05)81950-X; CHONMAITREE T, 1986, PEDIATRICS, V77, P698; CHONMAITREE T, 1992, CLIN INFECT DIS, V15, P650, DOI 10.1093/clind/15.4.650; Chonmaitree T, 1996, ANN OTO RHINOL LARYN, V105, P968; Chonmaitree T, 1997, ANN NY ACAD SCI, V830, P143, DOI 10.1111/j.1749-6632.1997.tb51886.x; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; CONE RW, 1993, CLIN INFECT DIS, V17, P558; CROWE JE, 1995, VACCINE, V13, P415, DOI 10.1016/0264-410X(95)98266-D; GIEBINK GS, 1994, ANN OTO RHINOL LARYN, V103, P20, DOI 10.1177/00034894941030S506; Groothuis JR, 1998, J INFECT DIS, V177, P467, DOI 10.1086/517377; GWALTNEY JM, 1995, MANDELL DOUGLAS BENN, P561; HALL CB, 1975, J INFECT DIS, V131, P1, DOI 10.1093/infdis/131.1.1; HALL CB, 1995, MANDELL DOUGLAS BENN, P1501; HEIKKINEN T, 1995, ACTA PAEDIATR, V84, P419, DOI 10.1111/j.1651-2227.1995.tb13663.x; Heikkinen T, 1996, ANN MED, V28, P23, DOI 10.3109/07853899608999070; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; HENDERSON FW, 1982, NEW ENGL J MED, V306, P1377, DOI 10.1056/NEJM198206103062301; Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138; KLEIN BS, 1982, J PEDIATR-US, V101, P16, DOI 10.1016/S0022-3476(82)80172-8; MANDEL EM, 1982, PEDIATR INFECT DIS J, V1, P310, DOI 10.1097/00006454-198209000-00006; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCCAIG LF, 1998, JAMA-J AM MED ASSOC, V279, P434; Patel JA, 1996, RECENT ADVANCES IN OTITIS MEDIA, P178; Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291; RUUSKANEN O, 1991, PEDIATR INFECT DIS J, V10, P425, DOI 10.1097/00006454-199106000-00001; RUUSKANEN O, 1989, PEDIATR INFECT DIS J, V8, P94; SARKKINEN H, 1985, J INFECT DIS, V151, P444, DOI 10.1093/infdis/151.3.444; SARKKINEN HK, 1983, ACTA PAEDIATR SCAND, V72, P137, DOI 10.1111/j.1651-2227.1983.tb09681.x; SHURIN PA, 1979, NEW ENGL J MED, V300, P1121, DOI 10.1056/NEJM197905173002001; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; UHARI M, 1995, CLIN INFECT DIS, V20, P521, DOI 10.1093/clinids/20.3.521; Wright Peter F., 1998, Pediatric Research, V43, p161A	38	345	362	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					260	264		10.1056/NEJM199901283400402	http://dx.doi.org/10.1056/NEJM199901283400402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9920949				2022-12-01	WOS:000078318700002
J	Spencer, JM				Spencer, JM			Nail-apparatus melanoma	LANCET			English	Editorial Material							SUBUNGUAL MALIGNANT-MELANOMA		CUNY, Mt Sinai Med Ctr, Div Dermatol Surg, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Spencer, JM (corresponding author), CUNY, Mt Sinai Med Ctr, Div Dermatol Surg, New York, NY 10029 USA.							Banfield CC, 1998, BRIT J DERMATOL, V139, P276; DAWBER RPR, 1991, SEMIN DERMATOL, V10, P82; FINLEY RK, 1994, SURGERY, V116, P96; HEATON KM, 1994, ANN SURG, V219, P197, DOI 10.1097/00000658-199402000-00012; KOPF AW, 1977, J DERMATOL SURG ONC, V3, P49; PACK GT, 1967, SURG GYNECOL OBSTETR, V124, P571; PATTERSON RH, 1980, CANCER-AM CANCER SOC, V46, P2074, DOI 10.1002/1097-0142(19801101)46:9<2074::AID-CNCR2820460928>3.0.CO;2-K; SAIDA T, 1989, CANCER, V63, P556, DOI 10.1002/1097-0142(19890201)63:3<556::AID-CNCR2820630326>3.0.CO;2-Q; SAIDA T, 1992, BRIT J DERMATOL, V126, P529, DOI 10.1111/j.1365-2133.1992.tb11836.x	9	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					84	85		10.1016/S0140-6736(05)76149-3	http://dx.doi.org/10.1016/S0140-6736(05)76149-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023888				2022-12-01	WOS:000078087200004
J	Osganian, SK; Stampfer, MJ; Spiegelman, D; Rimm, E; Cutler, JA; Feldman, HA; Montgomery, DH; Webber, LS; Lytle, LA; Bausserman, L; Nader, PR				Osganian, SK; Stampfer, MJ; Spiegelman, D; Rimm, E; Cutler, JA; Feldman, HA; Montgomery, DH; Webber, LS; Lytle, LA; Bausserman, L; Nader, PR			Distribution of and factors associated with serum homocysteine levels in children - Child and Adolescent Trial for Cardiovascular Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; PLASMA HOMOCYST(E)INE; RISK FACTOR; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; DIETARY PATTERNS; BLOOD-PRESSURE; UNITED-STATES; FOLIC-ACID; FOLATE	Context Although evidence suggests that homocysteine is a risk factor for cardiovascular disease in adults, little information exists on homocysteine levels in children. Objectives To describe the distribution of serum homocysteine concentrations among children and to examine the association between homocysteine levels and several characteristics, including serum levels of folic acid and vitamins B-12 and B-6. Design Cross-sectional analysis. Setting School-based cohort from California, Louisiana, Minnesota, and Texas. Participants A total of 3524 US schoolchildren, aged 13 and 14 years, from the Child and Adolescent Trial for Cardiovascular Health (completed in 1994). Measurement conducted in 1997. Main Outcome Measure Nonfasting serum total homocysteine concentration. Results The distribution of homocysteine values ranged from 0.1 to 25.7 mu mol/L (median, 4.9 mu mol/L). Geometric mean homocysteine concentration was significantly higher in boys (5.22 mu mol/L) than girls (4.84 mu mol/L); blacks (5.51 mu mol/L) than whites (4.96 mu mol/L) or Hispanics (4.93 mu mol/L); nonusers of multivitamins (5.09 mu mol/L) than users (4.82 mu mol/L); and smokers (5.19 mu mol/L) than nonsmokers (5.00 mu mol/ L). Serum homocysteine was significantly inversely correlated with serum levels of folic acid (r = -0.36; P = .001), vitamin B-12 (r = -0.21; P = .001), and vitamin B, (r = -0.18; P = .001). Serum homocysteine was not significantly associated with serum lipid levels or family history of cardiovascular disease and was only weakly related to body mass index and systolic blood pressure. After multivariate adjustment, homocysteine remained independently associated with sex, race, serum folic acid and vitamin B-12 levels, and systolic blood pressure. Conclusions The distribution of homocysteine levels in children is substantially lower than that observed for adults; however, a small percentage of children are still potentially at elevated risk for future cardiovascular disease. Serum folic acid may be an important determinant of homocysteine levels in children.	New England Res Inst, Watertown, MA 02472 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA; Univ Texas, Hlth Sci Ctr, Ctr Hlth Promot Res & Dev, Houston, TX USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN USA; Univ Calif San Diego, Div Community Pediat, San Diego, CA USA; Miriam Hosp, Lipoprot Anal Lab, Providence, RI USA; Brown Univ, Sch Med, Providence, RI 02912 USA	HealthCore, Inc; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Tulane University; Tulane University; University of Texas System; University of Texas Health Science Center Houston; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Diego; Lifespan Health Rhode Island; Miriam Hospital; Brown University	Osganian, SK (corresponding author), New England Res Inst, 9 Galen St, Watertown, MA 02472 USA.	voulao@neri.org	Lytle, Leslie/AAA-8226-2020; Feldman, Henry/M-2302-2013	Hoelscher, Deanna/0000-0002-0910-5031	NHLBI NIH HHS [U01-HL-39880, U01-HL-39906, U01-HL-39852] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL039906, U01HL039880, U01HL039852] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfthan G, 1997, LANCET, V349, P397, DOI 10.1016/S0140-6736(97)80014-1; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ALLAIN CC, 1974, CLIN CHEM, V20, P470; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; ARMITAGE P, 1971, STATISTICAL METHODS, P271; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BERG K, 1992, CLIN GENET, V41, P315; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1996, J NUTR, V126, pS1276, DOI 10.1093/jn/126.suppl_4.1276S; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; COOPER BA, 1984, CLIN BIOCHEM, V17, P95, DOI 10.1016/S0009-9120(84)90266-2; CRANE NT, 1995, AM J PUBLIC HEALTH, V85, P660, DOI 10.2105/AJPH.85.5.660; ELSHAMI AS, 1983, CLIN CHEM, V29, P2115; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; KANNEL WB, 1972, J PEDIATR-US, V80, P544, DOI 10.1016/S0022-3476(72)80049-0; LAUER RM, 1988, PEDIATRICS, V82, P309; LINDENBAUM J, 1983, BLOOD, V61, P624; Littel RC, 1996, SAS SYSTEM MIXED MOD; Luepker RV, 1996, JAMA-J AM MED ASSOC, V275, P768, DOI 10.1001/jama.275.10.768; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; MCGILL HC, 1980, CHILDHOOD PREVENTION, P41; McNeely MDD, 1984, CLIN CHEM, P1402; MORRISON JA, 1981, CARDIOVASC REV REP, V2, P1269; Nygard O, 1998, AM J CLIN NUTR, V67, P263, DOI 10.1093/ajcn/67.2.263; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; REED T, 1991, CLIN GENET, V39, P425; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; Shimakawa T, 1997, ANN EPIDEMIOL, V7, P285, DOI 10.1016/S1047-2797(97)00004-5; SHIN YS, 1983, CLIN CHIM ACTA, V127, P77, DOI 10.1016/0009-8981(83)90077-3; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Stone EJ, 1996, PREV MED, V25, P384, DOI 10.1006/pmed.1996.0071; SUBAR AF, 1990, AM J PUBLIC HEALTH, V80, P1323, DOI 10.2105/AJPH.80.11.1323; Tamura T, 1997, AM J CLIN NUTR, V66, P1299, DOI 10.1093/ajcn/66.6.1299; Tonstad S, 1996, PEDIATR RES, V40, P47, DOI 10.1203/00006450-199607000-00009; Tucker KL, 1996, J NUTR, V126, P3025, DOI 10.1093/jn/126.12.3025; Ubbink JB, 1996, J NUTR, V126, pS1254, DOI 10.1093/jn/126.suppl_4.1254S; UBBINK JB, 1994, NUTR REV, V52, P383, DOI 10.1111/j.1753-4887.1994.tb01369.x; UELAND PM, 1989, J LAB CLIN MED, V114, P473; *US DEP HHS, 1996, NATL CTR HLTH STAT 3; *US FDA, 1996, FED REGISTER, V61, P8781; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549; Vilaseca MA, 1997, CLIN CHEM, V43, P690; VONECKARDSTEIN A, 1994, ARTERIOSCLER THROMB, V14, P460, DOI 10.1161/01.ATV.14.3.460; VOORS AW, 1979, AM J EPIDEMIOL, V109, P320, DOI 10.1093/oxfordjournals.aje.a112685; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; WEBBER LS, 1995, AM J EPIDEMIOL, V141, P428, DOI 10.1093/oxfordjournals.aje.a117445; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; WILLIAMS RR, 1990, CORONARY ARTERY DIS, V1, P681, DOI 10.1097/00019501-199011000-00008; Zondervan KT, 1996, INT J EPIDEMIOL, V25, P70, DOI 10.1093/ije/25.1.70	58	117	123	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1189	1196		10.1001/jama.281.13.1189	http://dx.doi.org/10.1001/jama.281.13.1189			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199428	Bronze			2022-12-01	WOS:000079464400033
J	Dusheiko, G				Dusheiko, G			A pill a day, or two, for hepatitis B?	LANCET			English	Editorial Material							LIVER-TRANSPLANTATION; LAMIVUDINE; VIRUS; PROPHYLAXIS; REPLICATION; RECIPIENTS; RECURRENCE; SELECTION; TRIAL		UCL Royal Free & Univ Coll Sch Med, Dept Med, London NW3 2QG, England	University of London; University College London	Dusheiko, G (corresponding author), UCL Royal Free & Univ Coll Sch Med, Dept Med, London NW3 2QG, England.		Dusheiko, Geoffrey M/C-7677-2010					Boni C, 1998, J CLIN INVEST, V102, P968, DOI 10.1172/JCI3731; Chan TM, 1998, GASTROENTEROLOGY, V115, P177, DOI 10.1016/S0016-5085(98)70380-4; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; Foli A, 1996, ANTIVIR RES, V32, P91, DOI 10.1016/0166-3542(95)00985-X; Gilson R. J. C., 1996, Hepatology, V24, p281A; Grellier L, 1996, LANCET, V348, P1212, DOI 10.1016/S0140-6736(96)04444-3; Heald AE, 1996, ANTIMICROB AGENTS CH, V40, P1514, DOI 10.1128/AAC.40.6.1514; Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444, DOI 10.1128/AAC.41.7.1444; Jung YO, 1998, TRANSPLANTATION, V66, P733, DOI 10.1097/00007890-199809270-00007; Korba BE, 1996, ANTIVIR RES, V29, P49, DOI 10.1016/0166-3542(95)00915-9; Kruger M, 1996, Liver Transpl Surg, V2, P253, DOI 10.1002/lt.500020402; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; Markowitz JS, 1998, HEPATOLOGY, V28, P585, DOI 10.1002/hep.510280241; Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243; Nery JR, 1998, TRANSPLANTATION, V65, P1615, DOI 10.1097/00007890-199806270-00013; Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321	17	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1032	1033		10.1016/S0140-6736(98)00294-3	http://dx.doi.org/10.1016/S0140-6736(98)00294-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199347				2022-12-01	WOS:000079614000006
J	Hibberd, ML; Sumiya, M; Summerfield, JA; Booy, R; Levin, M				Hibberd, ML; Sumiya, M; Summerfield, JA; Booy, R; Levin, M		Meningococcal Res Grp	Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease	LANCET			English	Article							NEISSERIA-MENINGITIDIS; PROTEIN GENE; COMPLEMENT DEFICIENCIES; INNATE IMMUNITY; SERINE-PROTEASE; MUTATIONS; DEFECT; POLYMORPHISM; POPULATION; ACTIVATION	Background The reasons why meningococcal disease develops in only a small proportion of individuals carrying the causative bacteria are unknown. Differences in host responses to bacterial colonisation are thought to be involved, since people with deficiencies in the terminal components of the complement pathway, or of properdin, are susceptible to meningococcal disease. We postulate that genetic variants of mannose-binding lectin (MBL), a plasma opsonin that initiates another pathway of complement activation, might similarly cause susceptibility to meningococcal disease. Methods The frequency of variants of the MBL gene was ascertained in children with meningococcal disease and controls from two independent studies; one hospital-based (194 patients and 272 controls [patients with noninfectious disorders]), and one community-based (72 patients and 110 controls [healthy individuals]), by means of PCR and restriction-enzyme digestion, with confirmation by DNA sequencing. Findings The proportion of people homozygous for MBL-variant alleles was higher in patients with meningococcal disease than in controls in the hospital study (15 [7.7%] vs four [1.5%]; odds ratio 6.5 [95% CI 2.0-27.2]) and in the community study (six [8.3%] vs three [2.7%]; 4.5 [0.9-29.1]). The population attributable fraction of cases attributable to MBL variants (homozygous and heterozygous) was 32%, Interpretation The MBL pathway is a critical determinant of meningococcal-disease susceptibility, and genetic variants of MBL might account for a third of all disease cases.	St Marys, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Paediat, London W2 1PG, England; St Marys, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med, London W2 1PG, England; Inst Child Hlth, London, England	Imperial College London; Imperial College London; University of London; University College London	Levin, M (corresponding author), St Marys, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Paediat, London W2 1PG, England.	m.levin@ic.ac.uk	Hibberd, Martin L/D-5050-2009	Hibberd, Martin/0000-0001-8587-1849; Levin, Michael/0000-0003-2767-6919				CARTWRIGHT K, 1995, MENINGOCOCCAL DIS, P159; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; DENSEN P, 1987, NEW ENGL J MED, V316, P922, DOI 10.1056/NEJM198704093161506; deVries FP, 1996, INFECT IMMUN, V64, P2998, DOI 10.1128/IAI.64.8.2998-3006.1996; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fearon DT, 1977, NATURE, V388, P323, DOI DOI 10.1038/40967; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; FIJEN CAP, 1989, LANCET, V2, P585; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GARRED P, 1992, EUR J IMMUNOGENET, V19, P403, DOI 10.1111/j.1744-313X.1992.tb00083.x; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; GOTSCHLICH EC, 1969, J EXP MED, V129, P1385, DOI 10.1084/jem.129.6.1385; Hammerschmidt S, 1996, EMBO J, V15, P192, DOI 10.1002/j.1460-2075.1996.tb00347.x; Jack DL, 1998, J IMMUNOL, V160, P1346; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MARSDEN HO, 1995, J IMMUNOL, V155, P3013; Mead R, 1997, LANCET, V349, P1669, DOI 10.1016/S0140-6736(05)62635-9; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; NADEL S, 1995, MENINGOCOCCAL DIS, P207; OHTA M, 1990, J BIOL CHEM, V265, P1980; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; Summerfield JA, 1997, BRIT MED J, V314, P1229, DOI 10.1136/bmj.314.7089.1229; SUPER M, 1989, LANCET, V2, P1236; TABONA P, 1995, IMMUNOLOGY, V85, P153; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1	33	289	295	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1049	1053		10.1016/S0140-6736(98)08350-0	http://dx.doi.org/10.1016/S0140-6736(98)08350-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199352				2022-12-01	WOS:000079614000011
J	Center, JR; Nguyen, TV; Schneider, D; Sambrook, PN; Eisman, JA				Center, JR; Nguyen, TV; Schneider, D; Sambrook, PN; Eisman, JA			Mortality after all major types of osteoporotic fracture in men and women: an observational study	LANCET			English	Article							HIP FRACTURE; SURVIVAL; MORBIDITY; HEALTH; COHORT; SEX; AGE	Background Mortality increases after hip fractures in women and more so in men. Little is known, however, about mortality after other fractures. We investigated the mortality associated with all fracture types in elderly women and men. Methods We did a 5-year prospective cohort study in the semi-urban city of Dubbo, Australia, of all residents aged 60 years and older (2413 women and 1898 men). Low-trauma osteoporotic fractures that occurred between 1989 and 1994, confirmed by radiography and personal interview, were classified as proximal femur, vertebral, and groupings of other major and minor fractures. We calculated standardised mortality rates from death certificates for people with fractures compared with the Dubbo population. Findings 356 women and 137 men had low-trauma fractures. In women and men, mortality was increased in the first year after all major fractures. In women, age-standardised mortality ratios were 2.18(95% CI 2.03-2.32) for proximal femur, 1.66 (1.51-1.80) for vertebral, 1.92 (1.70-2.14) for other major, and 0.75 (0.66-0.84) for minor fractures. In men, these ratios were 3.17 (2.90-3.44) for proximal femur, 2.38 (2.17-2.59) for vertebral, 2.22 (1.91-2.52) for other major, and 1.45 (1.25-1.65) for minor fractures. There were excess deaths (excluding minor fractures in women) in all age-groups. Interpretation All major fractures were associated with increased mortality, especially in men. The loss of potential years of life in the younger age-group shows that preventative strategies for fracture should not focus on older patients at the expense of younger women and of men.	St Vincents Hosp, Garvan Inst Med Res, Bone & Mineral Res Div, Sydney, NSW 2010, Australia; Univ Sydney, Royal N Shore Hosp, Sydney, NSW, Australia; Univ Calif San Diego, La Jolla, CA 92093 USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Royal North Shore Hospital; University of Sydney; University of California System; University of California San Diego	Center, JR (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Bone & Mineral Res Div, Sydney, NSW 2010, Australia.	j.center@garvan.unsw.edu.au	Eisman, John A/C-2886-2014; Nguyen, Tuan V./AAD-9503-2020; Center, Jacqueline/AAY-8712-2021; Nguyen, Tuan V/B-6147-2008	Nguyen, Tuan V./0000-0002-3246-6281; Center, Jacqueline/0000-0002-5278-4527; Nguyen, Tuan V/0000-0002-3246-6281				AITKEN JM, 1987, INT S OST DENM OST, P45; *AUSTR BUR STAT, 1994, 33020 AUSTR BUR STAT; BOEREBOOM FTJ, 1992, NETH J MED, V41, P4; Breslow NE, 1980, ANAL CASE CONTROL ST; Browner WS, 1996, ARCH INTERN MED, V156, P1521, DOI 10.1001/archinte.156.14.1521; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; COLLETT D, 1995, TESTS STAT SCI, P40; COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756; DAHL E, 1980, ACTA ORTHOP SCAND, V51, P163, DOI 10.3109/17453678008990781; Fisher E S, 1991, Epidemiology, V2, P116, DOI 10.1097/00001648-199103000-00005; Hennekens CH., 1987, EPIDEMIOLOGY MED, P87; HOLMBERG S, 1986, ACTA ORTHOP SCAND, V57, P8, DOI 10.3109/17453678608993205; JACOBSEN SJ, 1992, AM J PUBLIC HEALTH, V82, P1147, DOI 10.2105/AJPH.82.8.1147; JALOVAARA P, 1991, ACTA ORTHOP SCAND, V62, P208, DOI 10.3109/17453679108993594; Katelaris AG, 1996, AM J PUBLIC HEALTH, V86, P557, DOI 10.2105/AJPH.86.4.557; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477, DOI 10.1093/oxfordjournals.aje.a116314; KENZORA JE, 1984, CLIN ORTHOP RELAT R, P45; LUYAO GL, 1994, AM J PUBLIC HEALTH, V84, P1287, DOI 10.2105/AJPH.84.8.1287; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; MAROTTOLI RA, 1994, AM J PUBLIC HEALTH, V84, P1807, DOI 10.2105/AJPH.84.11.1807; MULLEN JO, 1992, CLIN ORTHOP RELAT R, V20, P214; OLSSON H, 1992, AM J EPIDEMIOL, V136, P422, DOI 10.1093/oxfordjournals.aje.a116515; PARKER MJ, 1991, PUBLIC HEALTH, V105, P443, DOI 10.1016/S0033-3506(05)80614-6; PETITTI DB, 1989, CLIN ORTHOP RELAT R, P150; Poor G, 1995, OSTEOPOROSIS INT, V5, P419, DOI 10.1007/BF01626602; POOR G, 1995, CLIN ORTHOP RELAT R, P260; SCHRODER HM, 1993, J ORTHOP TRAUMA, V7, P525, DOI 10.1097/00005131-199312000-00007; SIMONS LA, 1990, AUST NZ J MED, V20, P783, DOI 10.1111/j.1445-5994.1990.tb00423.x; WEISS NS, 1983, J CHRON DIS, V36, P879, DOI 10.1016/0021-9681(83)90009-7; WHITE BL, 1987, J BONE JOINT SURG AM, V69A, P1335	31	1365	1415	3	52	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1999	353	9156					878	882		10.1016/S0140-6736(98)09075-8	http://dx.doi.org/10.1016/S0140-6736(98)09075-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	181BU	10093980				2022-12-01	WOS:000079421400010
J	Sutcliffe, AG; Taylor, B; Li, J; Thornton, S; Grudzinskas, JG; Lieberman, BA				Sutcliffe, AG; Taylor, B; Li, J; Thornton, S; Grudzinskas, JG; Lieberman, BA			Children born after intracytoplasmic sperm injection: population control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UCL Royal Free & Univ Coll Med Sch, Dept Child Hlth, London NW3 2PF, England; Pk Hosp, Ctr Assisted Reprod CARE, Nottingham NG5 8RX, England; Royal London Hosp, St Bartholomews & Royal London Sch Med & Dent, Dept Obstet & Gynaecol, London E1 1BB, England; St Marys Hosp, Dept Reprod Med, Manchester M13 0JH, Lancs, England	University of London; University College London; UCL Medical School; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; University of Manchester	Sutcliffe, AG (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Child Hlth, Royal Free Campus, London NW3 2PF, England.	icsi@rthsm.ac.uk		Sutcliffe, Alastair/0000-0001-8542-6155				Bonduelle M, 1998, LANCET, V351, P1553, DOI 10.1016/S0140-6736(98)24021-9; BOTTING B, 1997, HLTH OUR CHILDREN, P148; Bowen JR, 1998, LANCET, V351, P1529, DOI 10.1016/S0140-6736(98)10168-X; DEMOUZON J, 1997, J ASSIST REPROD GE S, V14, P251; Griffiths R., 1996, GRIFFITHS MENTAL DEV	5	65	67	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	1999	318	7185					704	705						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182JK	10074014				2022-12-01	WOS:000079495700024
J	Koegl, M; Hoppe, T; Schlenker, S; Ulrich, HD; Mayer, TU; Jentsch, S				Koegl, M; Hoppe, T; Schlenker, S; Ulrich, HD; Mayer, TU; Jentsch, S			A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; ENZYME; PROTEOLYSIS; PROTEASOME; ENCODES; PATHWAY; SIGNAL; SHOWS; RAD23	Proteins modified by multiubiquitin chains are the preferred substrates of the proteasome. Ubiquitination involves a ubiquitin-activating enzyme, E1, a ubiquitin-conjugating enzyme, E2, and often a substrate-specific ubiquitin-protein ligase, E3. Here we show that efficient multiubiquitination needed for proteasomal targeting of a model substrate requires an additional conjugation factor, named E4. This protein, previously known as UFD2 in yeast, binds to the ubiquitin moieties of preformed conjugates and catalyzes ubiquitin chain assembly in conjunction with E1, E2, and E3. Intriguingly, E4 defines a novel protein family that includes two human members and the regulatory protein NOSA from Dictyostelium required for fruiting body development. In yeast, E4 activity is linked to cell survival under stress conditions, indicating that eukaryotes utilize E4-dependent proteolysis pathways for multiple cellular functions.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Jentsch, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Am Klopferspitz 18A, D-82152 Martinsried, Germany.	jentsch@biochem.mpg.de	Hoppe, Thorsten/AAC-7880-2020	Mayer, Thomas/0000-0001-6954-2287; Hoppe, Thorsten/0000-0002-4734-9352; Ulrich, Helle D./0000-0003-0431-2223				Ausubel F. M., 1994, CURRENT PROTOCOLS MO; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MORTZ E, 1994, BIOL MASS SPECTROM, V23, P249, DOI 10.1002/bms.1200230503; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pukatzki S, 1998, J BIOL CHEM, V273, P24131, DOI 10.1074/jbc.273.37.24131; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	27	794	830	2	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 5	1999	96	5					635	644		10.1016/S0092-8674(00)80574-7	http://dx.doi.org/10.1016/S0092-8674(00)80574-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	174TB	10089879	Green Submitted, hybrid			2022-12-01	WOS:000079050100007
J	Morrison, SJ; White, PM; Zock, C; Anderson, DJ				Morrison, SJ; White, PM; Zock, C; Anderson, DJ			Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GLIAL GROWTH-FACTOR; HEMATOPOIETIC STEM; CLONAL ANALYSIS; DEVELOPMENTAL SWITCH; EMBRYONIC NERVES; CEREBRAL-CORTEX; SCHWANN-CELLS; QUAIL EMBRYO; DORSAL-ROOT	Multipotent and self-renewing neural stem cells have been isolated in culture, but equivalent cells have not yet been prospectively identified in neural tissue. Using cell surface markers and flow cytometry, we have isolated neural crest stem cells (NCSCs) from mammalian fetal peripheral nerve. These cells are phenotypically and functionally indistinguishable from NCSCs previously isolated by culturing embryonic neural tube explants. Moreover, in vivo BrdU labeling indicates that these stem cells self-renew in vivo. NCSCs freshly isolated from nerve tissue can be directly transplanted in vivo, where they generate both neurons and glia. These data indicate that neural stem cells persist in peripheral nerve into late gestation by undergoing self-renewal. Such persistence may explain the origins of some PNS tumors in humans.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Anderson, DJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.		Morrison, Sean/ABD-5326-2021	Morrison, Sean/0000-0003-1587-8329				Anderson D J, 1993, Curr Opin Neurobiol, V3, P8, DOI 10.1016/0959-4388(93)90028-W; BARAKATWALTER I, 1994, DEV BIOL, V161, P263; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1980, DEV BIOL, V77, P130, DOI 10.1016/0012-1606(80)90461-3; Cai L, 1997, J NEUROSCI, V17, P2079; Cameron HA, 1998, CURR OPIN NEUROBIOL, V8, P677, DOI 10.1016/S0959-4388(98)80099-8; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; Darzynkiewicz Z., 1997, CURRENT PROTOCOLS CY; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DEVILLE FSSC, 1992, DEV BRAIN RES, V66, P1, DOI 10.1016/0165-3806(92)90134-I; DEVILLE FSSC, 1994, DEV BIOL, V163, P141, DOI 10.1006/dbio.1994.1130; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; DUFF RS, 1991, DEV BIOL, V147, P451, DOI 10.1016/0012-1606(91)90303-K; FRANK E, 1991, DEVELOPMENT, V111, P895; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; Gritti A, 1996, J NEUROSCI, V16, P1091; HAIMOTO H, 1987, LAB INVEST, V57, P489; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Jessen K R, 1992, Curr Opin Neurobiol, V2, P575, DOI 10.1016/0959-4388(92)90021-C; JESSEN KR, 1994, NEURON, V12, P509, DOI 10.1016/0896-6273(94)90209-7; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kalyani A, 1997, DEV BIOL, V186, P202, DOI 10.1006/dbio.1997.8592; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; Le Douarin N.M., 1982, NEURAL CREST; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEDOUARIN NM, 1980, NATURE, V286, P663, DOI 10.1038/286663a0; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; Lee MJ, 1997, MOL CELL NEUROSCI, V8, P336, DOI 10.1006/mcne.1996.0589; LEMKE GE, 1984, J NEUROSCI, V4, P75; Lo LC, 1997, CURR BIOL, V7, P440, DOI 10.1016/S0960-9822(06)00191-6; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cellbio.11.1.35; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Morshead CM, 1998, DEVELOPMENT, V125, P2251; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; PARYSEK LM, 1988, J NEUROSCI, V8, P555; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; REID CB, 1995, NEURON, V15, P299, DOI 10.1016/0896-6273(95)90035-7; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RICHARDSON MK, 1993, DEV BIOL, V157, P348, DOI 10.1006/dbio.1993.1140; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; SAPPINO AP, 1990, LAB INVEST, V63, P144; Shah NM, 1997, P NATL ACAD SCI USA, V94, P11369, DOI 10.1073/pnas.94.21.11369; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Takahashi T, 1996, J NEUROSCI, V16, P6183; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; THIELE CJ, 1991, CANCER METAST REV, V10, P311, DOI 10.1007/BF00554793; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; Zinyk DL, 1998, CURR BIOL, V8, P665, DOI 10.1016/S0960-9822(98)70255-6	69	579	642	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 5	1999	96	5					737	749		10.1016/S0092-8674(00)80583-8	http://dx.doi.org/10.1016/S0092-8674(00)80583-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	174TB	10089888	Bronze			2022-12-01	WOS:000079050100016
J	Shlipak, MG; Lyons, WL; Go, AS; Chou, TM; Evans, GT; Browner, WS				Shlipak, MG; Lyons, WL; Go, AS; Chou, TM; Evans, GT; Browner, WS			Should the electrocardiogram be used to guide therapy for patients with left bundle-branch block and suspected myocardial infarction?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONVALVULAR ATRIAL-FIBRILLATION; CARDIAC TROPONIN-T; THROMBOLYTIC THERAPY; COST-EFFECTIVENESS; DECISION-ANALYSIS; ELDERLY PATIENTS; Q-WAVE; DIAGNOSIS; ISOENZYME; ASSAY	Context Recently, an algorithm based on the electrocardiogram (ECG) was reported to predict myocardial infarction (MI) in patients with left bundle-branch block (LBBB), but the clinical impact of this testing strategy is unknown. Objective To determine the diagnostic test characteristics and clinical utility of this ECC algorithm for patients with suspected MI. Design Retrospective cohort study to which an algorithm was applied, followed by decision analysis regarding thrombolysis made with or without the algorithm. Setting University emergency department, 1994 through 1997. Patients Eighty-three patients with LBBB who presented 103 times with symptoms suggestive of MI. Main Outcome Measures Myocardial infarction determined by serial cardiac enzyme analyses and stroke-free survival. Results Of 9 ECG findings assessed, none effectively distinguished the 30% of patients with MI from those with other diagnoses. The ECG algorithm indicated positive findings in only 3% of presentations and had a sensitivity of 10% (95% confidence interval, 2%-26%). The decision analysis showed that among 1000 patients with LBBB and chest pain, 929 would survive without major stroke if all received thrombolysis compared with 918 if the ECC algorithm was used as a screening test. Conclusions The ECG is a poor predictor of MI in a community-based cohort of patients with LBBB and acute cardiopulmonary symptoms. Acute thrombolytic therapy should be considered for all patients with LBBB who have symptoms consistent with MI.	Univ Calif San Francisco, Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA; Kaiser Permanente Med Care Program No Calif, Div Res, Oakland, CA USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	Shlipak, MG (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.		Go, Alan S./AAE-7745-2019					ADAMS JE, 1994, CLIN CHEM, V40, P1291; ALEXANDER RW, 1998, HURSTS HEART; ANTMAN EM, 1995, JAMA-J AM MED ASSOC, V273, P1279, DOI 10.1001/jama.273.16.1279; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Braunwald E., 1997, HEART DIS TXB CARDIO, V5th; BYRNE J, 1996, NEW ENGL J MED, V334, P528; CABRERA E, 1953, Arch Inst Cardiol Mex, V23, P441; Cannon CP, 1997, J AM COLL CARDIOL, V30, P133, DOI 10.1016/S0735-1097(97)00160-5; CHAPMAN MG, 1957, CIRCULATION, V16, P558, DOI 10.1161/01.CIR.16.4.558; CHOU TC, 1991, ELECTROCARDIOGRAPHY; CLYNE CA, 1989, AM HEART J, V118, P901, DOI 10.1016/0002-8703(89)90221-4; DOUCET P, 1966, AM J CARDIOL, V17, P171, DOI 10.1016/0002-9149(66)90349-3; DRESSLER W, 1950, AM HEART J, V39, P217, DOI 10.1016/0002-8703(50)90218-3; EHSANI A, 1976, AM J CARDIOL, V37, P12, DOI 10.1016/0002-9149(76)90492-6; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; FENDRICK AM, 1994, ARCH INTERN MED, V154, P1605, DOI 10.1001/archinte.154.14.1605; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GLASZIOU PP, 1994, MED J AUSTRALIA, V161, P532, DOI 10.5694/j.1326-5377.1994.tb127596.x; HAMBY RI, 1983, AM HEART J, V106, P471, DOI 10.1016/0002-8703(83)90688-9; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; HANDS ME, 1988, AM HEART J, V116, P23, DOI 10.1016/0002-8703(88)90245-1; HELLER GV, 1983, AM J CARDIOL, V51, P24, DOI 10.1016/S0002-9149(83)80006-X; HINDMAN MC, 1978, CIRCULATION, V58, P679, DOI 10.1161/01.CIR.58.4.679; HORAN LG, 1971, CIRCULATION, V43, P428, DOI 10.1161/01.CIR.43.3.428; KALISH SC, 1995, J GEN INTERN MED, V10, P321, DOI 10.1007/BF02599951; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LAJI K, 1995, AM HEART J, V130, P705, DOI 10.1016/0002-8703(95)90067-5; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; LEVENSON J, 1996, NEW ENGL J MED, V334, P528; LUY G, 1973, AM HEART J, V85, P332, DOI 10.1016/0002-8703(73)90367-0; MACLURE M, 1987, AM J EPIDEMIOL, V126, P161, DOI 10.1093/aje/126.2.161; MATCHAR DB, 1987, JAMA-J AM MED ASSOC, V258, P793, DOI 10.1001/jama.258.6.793; Mendelson T., 1998, EVIDENCE BASED MED F; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; Newby KH, 1996, CIRCULATION, V94, P2424, DOI 10.1161/01.CIR.94.10.2424; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; Sgarbossa EB, 1996, NEW ENGL J MED, V334, P481, DOI 10.1056/NEJM199602223340801; Sgarbossa EB, 1998, J AM COLL CARDIOL, V31, P105, DOI 10.1016/S0735-1097(97)00446-4; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Sodeman WA, 1944, AM HEART J, V28, P271, DOI 10.1016/S0002-8703(44)90087-6; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; *STAT CORP, 1997, STAT COMP PROGR VERS; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; Tiefenbrunn AJ, 1998, J AM COLL CARDIOL, V31, P1240, DOI 10.1016/S0735-1097(98)00094-1; *TREEAG SOFTW INC, 1997, DATA DEC AN TREEA CO; TURI ZG, 1985, AM J CARDIOL, V55, P1463, DOI 10.1016/0002-9149(85)90954-3; Wackers F J, 1987, Cardiol Clin, V5, P393; WACKERS FJ, 1983, INT J CARDIOL, V2, P521, DOI 10.1016/0167-5273(83)90157-2; Wellens HJJ, 1996, NEW ENGL J MED, V334, P528, DOI 10.1056/NEJM199602223340809; Wilson F. N., 1945, ARCH INST CARDIOL [MEXICO], V14, P201; YUSUF S, 1987, AM J CARDIOL, V59, P245, DOI 10.1016/0002-9149(87)90793-4	55	70	71	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1999	281	8					714	719		10.1001/jama.281.8.714	http://dx.doi.org/10.1001/jama.281.8.714			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BD	10052441	Bronze			2022-12-01	WOS:000078669900030
J	Cauley, JA; Lucas, FL; Kuller, LH; Stone, K; Browner, W; Cummings, SR				Cauley, JA; Lucas, FL; Kuller, LH; Stone, K; Browner, W; Cummings, SR		Study of Osteoporotic Fractures Res Grp	Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article						breast neoplasms; estradiol; testosterone; estrogen antagonists; risk factors	SEX-HORMONE LEVELS; POSTMENOPAUSAL WOMEN; ALCOHOL-CONSUMPTION; AROMATASE-ACTIVITY; STEROID-HORMONES; ADIPOSE-TISSUE; ESTROGEN; FAT; PREMENOPAUSAL; EPIDEMIOLOGY	Background: The relation between endogenous steroid hormones and risk for breast cancer is uncertain. Measurement of sex hormone levels may identify women at high risk for breast cancer who should consider preventive therapies. Objective: To test the hypothesis that serum concentrations of estradiol and testosterone predict risk for breast cancer. Design: Prospective case-cohort study. Setting: Four clinical centers in the United States. Participants: 97 women with confirmed incident breast cancer and 244 randomly selected controls; all women were white, 65 years of age or older, and were not receiving estrogen. Measurements: Sex-steroid hormone concentrations were assayed by using serum that was collected at baseline and stored at -190 degrees C. Risk factors for breast cancer were ascertained by questionnaire. Incident cases of breast cancer were confirmed by review of medical records during an average period of 3.2 years. Results: The relative risk for breast cancer in women with the highest concentration of bioavailable estradiol (greater than or equal to 6.83 pmol/L or 1.9 pg/mL) was 3.6 (95% CI, 1.3 to 10.0) compared with women with the lowest concentration. The risk for breast cancer in women with the highest concentration of free testosterone compared with those with the lowest concentration was 3.3 (CI, 1.1 to 10.3). The estimated incidence of breast cancer per 1000 person-years was 0.4 (CI, 0.0 to 1.3) in women with the lowest levels of bioavailable estradiol and free testosterone compared with 6.5 (CI 2.7 to 10.3) in women with the highest concentrations of these hormones. Traditional risk factors for breast cancer were similar in case-patients and controls. Adjustments for these risk factors had little effect on the results. Conclusions: Estradiol and testosterone levels may play important roles in the development of breast cancer in older women. A single measurement of bioavailable estradiol and free testosterone may be used to estimate a woman's risk for breast cancer. Women identified as being at high risk for breast cancer as determined by these hormone levels may benefit from antiestrogen treatment for primary prevention.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA; Maine Med Ctr, Portland, ME 04102 USA; Univ Calif San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94105 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Maine Medical Center; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Cauley, JA (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, 130 DeSoto St,Crabtree Hall A524, Pittsburgh, PA 15261 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408	NIADDK NIH HHS [AM35584] Funding Source: Medline; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05407] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; ARMSTRONG BK, 1981, J NATL CANCER I, V67, P761; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; BLANKENSTEIN MA, 1992, J STEROID BIOCHEM, V41, P891, DOI 10.1016/0960-0760(92)90443-M; BULBROOK RD, 1986, ANN NY ACAD SCI, V464, P378, DOI 10.1111/j.1749-6632.1986.tb16017.x; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1998, P AM SOC CLIN ONC PR; DEWAARD F, 1982, MATURITAS, V4, P155, DOI 10.1016/0378-5122(82)90042-1; Dorgan JF, 1997, CANCER EPIDEM BIOMAR, V6, P177; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; Dorgan JF, 1996, AM J CLIN NUTR, V64, P25, DOI 10.1093/ajcn/64.1.25; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GARLAND CF, 1992, AM J EPIDEMIOL, V135, P1220, DOI 10.1093/oxfordjournals.aje.a116228; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; HANKINSON SE, 1995, CANCER EPIDEM BIOMAR, V4, P649; HELZLSOUER KJ, 1994, CANCER DETECT PREV, V18, P79; JAFFE RB, 1986, REPRODUCTIVE ENDOCRI, P406; Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.pu.17.050196.000403; KILLINGER D W, 1987, Steroids, V50, P523, DOI 10.1016/0039-128X(87)90036-5; KULLER LH, 1990, ARTERIOSCLEROSIS, V10, P1058, DOI 10.1161/01.ATV.10.6.1058; MACINDOE JH, 1981, J CLIN ENDOCR METAB, V53, P836, DOI 10.1210/jcem-53-4-836; Mannisto S, 1996, INT J CANCER, V68, P8, DOI 10.1002/(SICI)1097-0215(19960927)68:1<8::AID-IJC2>3.0.CO;2-V; MEEMA S, 1966, CANCER, V19, P433, DOI 10.1002/1097-0142(196603)19:3<433::AID-CNCR2820190318>3.0.CO;2-I; MILLER BA, 1994, SIGNIFICANCE RISING, P193; MOORE JW, 1986, INT J CANCER, V38, P625, DOI 10.1002/ijc.2910380502; Muti P, 1996, CANCER EPIDEM BIOMAR, V5, P917; ONEILL JS, 1987, BRIT J CANCER, V56, P601, DOI 10.1038/bjc.1987.248; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEREL E, 1980, J STEROID BIOCHEM, V13, P89, DOI 10.1016/0022-4731(80)90117-X; PRENTICE R, 1990, J NATL CANCER I, V82, P129, DOI 10.1093/jnci/82.2.129; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; Rink JD, 1996, J CLIN ENDOCR METAB, V81, P2443, DOI 10.1210/jc.81.7.2443; Rockhill B, 1998, AM J EPIDEMIOL, V147, P826, DOI 10.1093/oxfordjournals.aje.a009535; ROSE DP, 1993, BREAST CANCER RES TR, V27, P253, DOI 10.1007/BF00665695; SANTEN RJ, 1986, ANN NY ACAD SCI, V464, P126, DOI 10.1111/j.1749-6632.1986.tb16000.x; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SELLERS TA, 1993, AM J EPIDEMIOL, V138, P799, DOI 10.1093/oxfordjournals.aje.a116783; Spratt JS, 1996, J SURG ONCOL, V61, P68, DOI 10.1002/1096-9098(199601)61:1<68::AID-JSO2930610102>3.0.CO;2-E; THIJSSEN JHH, 1991, J STEROID BIOCHEM, V39, P799, DOI 10.1016/0960-0760(91)90028-4; Thomas HV, 1997, CANCER CAUSE CONTROL, V8, P922, DOI 10.1023/A:1018476631561; Thomas HV, 1997, BRIT J CANCER, V76, P401, DOI 10.1038/bjc.1997.398; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; *US DEP HHS, 1993, NIH PUBL; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WYSOWSKI DK, 1987, AM J EPIDEMIOL, V125, P791, DOI 10.1093/oxfordjournals.aje.a114596; ZeleniuchJacquotte A, 1997, AM J EPIDEMIOL, V145, P1030, DOI 10.1093/oxfordjournals.aje.a009059; Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903; 1998, EVISTA PACKAGE INSER	51	328	333	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				270	+		10.7326/0003-4819-130-4_Part_1-199902160-00004	http://dx.doi.org/10.7326/0003-4819-130-4_Part_1-199902160-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166PY	10068384				2022-12-01	WOS:000078587200003
J	Lauer, MS; Francis, GS; Okin, PM; Pashkow, FJ; Snader, CE; Marwick, TH				Lauer, MS; Francis, GS; Okin, PM; Pashkow, FJ; Snader, CE; Marwick, TH			Impaired chronotropic response to exercise stress testing as a predictor of mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; CONGESTIVE HEART-FAILURE; ST-SEGMENT DEPRESSION; PROGNOSTIC IMPLICATIONS; RATE-VARIABILITY; INCOMPETENCE; PERFORMANCE; ADJUSTMENT; EXTENT	Context Chronotropic incompetence, an attenuated heart rate response to exercise, is a predictor of all-cause mortality in healthy populations. This association may be independent of exercise-induced myocardial perfusion defects, Objective To examine the prognostic significance of chronotropic incompetence in a low-risk cohort of patients referred for treadmill stress testing with thallium imaging. Design Prospective cohort study conducted between September 1990 and December 1993, Setting Tertiary care academic medical center, Patients Consecutive patients (1877 men and 1076 women; mean age, 58 years) who were not taking beta-blockers and who were referred for symptom-limited treadmill thallium testing. Main Outcome Measures Association of chronotropic incompetence, defined as either failure to achieve 85% of the age-predicted maximum heart rate or a low chronotropic index, a heart rate response measure that accounts for effects of age, resting heart rate, and physical fitness, with all-cause mortality during 2 years of follow-up. Results Three hundred sixteen patients (11%) failed to reach 85% of the age-adjusted maximum heart rate, 762 (26%) had a low chronotropic index, and 672 (21%) had thallium perfusion defects. Ninety-one patients died during the follow-up period, After adjustment for age, sex, thallium perfusion defects, and other confounders, failure to reach 85% of the age-predicted maximum heart rate was associated with increased risk of death (adjusted relative risk [RR], 1.84; 95% confidence interval [CI], 1.13-3.00; P=.01), as was a low chronotropic index (adjusted RR, 2.19; 95% CI, 1.43-3.44; P<.001). Conclusion Among patients with known or suspected coronary disease, chronotropic incompetence is independently predictive of all-cause mortality, even after considering thallium perfusion defects, Incorporation of chronotropic response into the routine interpretation of stress thallium studies may improve the prognostic power of this test.	Cleveland Clin Fdn, Dept Cardiol, Ctr Heart Failure, Cleveland, OH 44195 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Cardiol, New York, NY 10021 USA	Cleveland Clinic Foundation; Cornell University; NewYork-Presbyterian Hospital	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Ctr Heart Failure, Desk F-25,9500 Euclid Ave, Cleveland, OH 44195 USA.	lauerm@cesmtp.ccf.org	Lauer, Michael S/L-9656-2013; Marwick, Thomas H/C-7261-2013	Lauer, Michael S/0000-0002-9217-8177; Marwick, Thomas H/0000-0001-9065-0899				Barron HV, 1996, J AM COLL CARDIOL, V27, P1053, DOI 10.1016/0735-1097(95)00615-X; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; COLUCCI WS, 1989, CIRCULATION, V80, P314, DOI 10.1161/01.CIR.80.2.314; COX DR, 1972, J R STAT SOC B, V34, P187; Ellestad MH, 1996, CIRCULATION, V93, P1485, DOI 10.1161/01.CIR.93.8.1485; Fauchier L, 1997, J AM COLL CARDIOL, V30, P1009, DOI 10.1016/S0735-1097(97)00265-9; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; FRANCIS GS, 1985, J AM COLL CARDIOL, V5, P832, DOI 10.1016/S0735-1097(85)80420-4; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GO RT, 1990, J NUCL MED, V31, P1899; HELLER GV, 1992, AM HEART J, V123, P909, DOI 10.1016/0002-8703(92)90695-R; Huang Por-Jau, 1992, Journal of the Formosan Medical Association, V91, P1096; LADENHEIM ML, 1986, J AM COLL CARDIOL, V7, P464, DOI 10.1016/S0735-1097(86)80454-5; Lauer MS, 1996, CIRCULATION, V93, P1520, DOI 10.1161/01.CIR.93.8.1520; LAUER MS, 1995, J AM COLL CARDIOL, V26, P1630, DOI 10.1016/0735-1097(95)00388-6; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; Marwick TH, 1997, J AM COLL CARDIOL, V30, P83, DOI 10.1016/S0735-1097(97)00148-4; MYERS J, 1991, J AM COLL CARDIOL, V17, P1334, DOI 10.1016/S0735-1097(10)80144-5; Okin PM, 1996, CIRCULATION, V94, P3226, DOI 10.1161/01.CIR.94.12.3226; OKIN PM, 1995, J AM COLL CARDIOL, V25, P1726, DOI 10.1016/0735-1097(95)00085-I; Perkiomaki JS, 1997, J AM COLL CARDIOL, V30, P1331, DOI 10.1016/S0735-1097(97)00301-X; SCHWARTZ PJ, 1992, CIRCULATION S1, V85, P177; Snader CE, 1997, J AM COLL CARDIOL, V30, P641, DOI 10.1016/S0735-1097(97)00217-9; Wilkoff Bruce L., 1992, Cardiology Clinics, V10, P705	24	406	432	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					524	529		10.1001/jama.281.6.524	http://dx.doi.org/10.1001/jama.281.6.524			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022108				2022-12-01	WOS:000078452900030
J	Wiener, J; Quinn, JP; Bradford, PA; Goering, RV; Nathan, C; Bush, K; Weinstein, RA				Wiener, J; Quinn, JP; Bradford, PA; Goering, RV; Nathan, C; Bush, K; Weinstein, RA			Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECTRUM BETA-LACTAMASES; MOLECULAR EPIDEMIOLOGY; 3RD-GENERATION CEPHALOSPORINS; TRANSFERABLE RESISTANCE; CEFTAZIDIME RESISTANCE; NOSOCOMIAL OUTBREAK; MEDICAL-CENTER; PLASMID DNA; PNEUMONIAE; ENTEROBACTERIACEAE	Context infections caused by ceftazidime sodium-resistant gram-negative bacteria that harbor extended-spectrum beta-lactamases (ESBLs) are increasing in frequency in hospitals in the United States. Objectives To report a citywide nursing home-centered outbreak of infections caused by ESBL-producing gram-negative bacilli and to describe the clinical and molecular epidemiology of the outbreak. Design Hospital-based case-control study and a nursing home point-prevalence survey. Molecular epidemiological techniques were applied to resistant strains. Settings A 400-bed tertiary care hospital and a community nursing home. Patients Patients who were infected and/or colonized with ceftazidime-resistant Escherichia coli, Klebsiella pneumoniae, or both and controls who were admitted from nursing homes between November 1990 and July 1992, Main Outcome Measures Clinical and epidemiological factors associated with colonization or infection by ceftazidime-resistant E coli or K pneumoniae; molecular genetic characteristics of plasmid-mediated ceftazidime resistance. Results Between November 1990 and October 1992, 55 hospital patients infected or colonized with ceftazidime-resistant E coli, K pneumoniae, or both were identified. Of the 35 admitted from 8 nursing homes, 31 harbored the resistant strain on admission. All strains were resistant to ceftazidime, gentamicin, and tobramycin; 96% were resistant to trimethoprim-sulfamethoxazole and 41% to ciprofloxacin hydrochloride, In a case-control study, 24 nursing home patients colonized with resistant strains on hospital admission were compared with 16 nursing home patients who were not colonized on hospital admission; independent risk factors for colonization included poor functional level, presence of a gastrostomy tube or decubitus ulcers, and prior receipt of ciprofloxacin and/or trimethoprim-sulfamethoxazole. In a nursing home point-prevalence survey, 18 of 39 patients were colonized with ceftazidime-resistant E coli; prior receipt of ciprofloxacin or trimethoprim-sulfamethoxazole and presence of a gastrostomy tube were independent predictors of resistance. Plasmid studies on isolates from 20 hospital and nursing home patients revealed that 17 had a common 54-kilobase plasmid, which conferred ceftazidime resistance via the ESBL TEM-10, and mediated resistance to trimethoprim-sulfamethoxazole, gentamicin, and tobramycin; all 20 isolates harbored this ESBL. Molecular fingerprinting showed 7 different strain types of resistant K pneumoniae and E coli distributed among the nursing homes. Conclusions Nursing home patients may be an important reservoir of ESBL-containing multiple antibiotic-resistant E coli and K pneumoniae. Widespread dissemination of a predominant antibiotic resistance plasmid has occurred. Use of broad-spectrum oral antibiotics and probably poor infection control practices may facilitate spread of this plasmid-mediated resistance. Nursing homes should monitor and control antibiotic use and regularly survey antibiotic resistance patterns among pathogens.	Michael Reese Hosp & Med Ctr, Chicago, IL 60616 USA; Wyeth Ayerst Res, Pearl River, NY USA; Creighton Univ, Omaha, NE 68178 USA; RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA	Michael Reese Hospital & Medical Center; Pfizer; Creighton University; Johnson & Johnson; Johnson & Johnson USA	Weinstein, RA (corresponding author), Cook Cty Hosp, Div Infect Dis, 1835 W Harrison St, Chicago, IL 60612 USA.	rweinste@rush.edu	Bush, Karen/O-2820-2017	Bradford, Patricia/0000-0002-1285-2978; Goering, Richard/0000-0001-7502-7185				ARLET G, 1994, J CLIN MICROBIOL, V32, P2553, DOI 10.1128/JCM.32.10.2553-2558.1994; BINGEN EH, 1993, J CLIN MICROBIOL, V31, P179, DOI 10.1128/JCM.31.2.179-184.1993; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD PA, 1994, ANTIMICROB AGENTS CH, V38, P760; BRUNBUISSON C, 1987, LANCET, V2, P302; Coudron PE, 1997, J CLIN MICROBIOL, V35, P2593, DOI 10.1128/JCM.35.10.2593-2597.1997; Denman S., 1993, Morbidity and Mortality Weekly Report, V42, P672; DiMartino P, 1997, J CLIN MICROBIOL, V35, P1499, DOI 10.1128/JCM.35.6.1499-1503.1997; ELSOLH N, 1986, ANTIMICROB AGENTS CH, V30, P161, DOI 10.1128/AAC.30.1.161; Emery CL, 1997, J CLIN MICROBIOL, V35, P2061, DOI 10.1128/JCM.35.8.2061-2067.1997; GOERING RV, 1995, EUR J CLIN MICROBIOL, V14, pS3; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; GOUBY A, 1994, J CLIN MICROBIOL, V32, P301, DOI 10.1128/JCM.32.2.301-305.1994; JARLIER V, 1988, REV INFECT DIS, V10, P867; JETT BD, 1995, ANTIMICROB AGENTS CH, V39, P1187, DOI 10.1128/AAC.39.5.1187; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; KITZIS MD, 1988, ANTIMICROB AGENTS CH, V32, P9, DOI 10.1128/AAC.32.1.9; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; LEVY SB, 1982, ANTIBIOTIC PARADOX; M'Zali FH, 1997, J ANTIMICROB CHEMOTH, V40, P823, DOI 10.1093/jac/40.6.823; Martinez-Martinez L, 1998, LANCET, V351, P797, DOI 10.1016/S0140-6736(97)07322-4; Medeiros AA, 1997, CLIN INFECT DIS, V24, pS19, DOI 10.1093/clinids/24.Supplement_1.S19; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; National Committee for Clinical Laboratory Standards, 1998, M100S8 NAT COMM CLIN; NAUMOVSKI L, 1992, ANTIMICROB AGENTS CH, V36, P1991, DOI 10.1128/AAC.36.9.1991; PAPANICOLAOU GA, 1990, ANTIMICROB AGENTS CH, V34, P2200, DOI 10.1128/AAC.34.11.2200; PETIT A, 1990, ANTIMICROB AGENTS CH, V34, P219, DOI 10.1128/AAC.34.2.219; Prodinger WM, 1996, J CLIN MICROBIOL, V34, P564, DOI 10.1128/JCM.34.3.564-568.1996; QUINN JP, 1989, ANTIMICROB AGENTS CH, V33, P1451, DOI 10.1128/AAC.33.9.1451; QUINN JP, 1996, 34 ANN INFECT DIS SO; RASMUSSEN BA, 1993, ANTIMICROB AGENTS CH, V37, P1989, DOI 10.1128/AAC.37.9.1989; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; Sambrook J, 1989, MOL CLONING LAB MANU, V1; SCHABERG DR, 1977, ANTIMICROB AGENTS CH, V11, P449, DOI 10.1128/AAC.11.3.449; Schiappa DA, 1996, J INFECT DIS, V174, P529, DOI 10.1093/infdis/174.3.529; SIROT J, 1988, REV INFECT DIS, V10, P850; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; URBAN C, 1994, ANTIMICROB AGENTS CH, V38, P392, DOI 10.1128/AAC.38.2.392; WEINSTEIN RA, 1981, AM J MED, V70, P449; White AC, 1997, CLIN INFECT DIS, V25, P230	42	355	374	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					517	523		10.1001/jama.281.6.517	http://dx.doi.org/10.1001/jama.281.6.517			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022107				2022-12-01	WOS:000078452900029
J	Kong, YY; Yoshida, H; Sarosi, I; Tan, HL; Timms, E; Capparelli, C; Morony, S; Oliveira-dos-Santos, AJ; Van, G; Itie, A; Khoo, W; Wakeham, A; Dunstan, CR; Lacey, DL; Mak, TW; Boyle, WJ; Penninger, JM				Kong, YY; Yoshida, H; Sarosi, I; Tan, HL; Timms, E; Capparelli, C; Morony, S; Oliveira-dos-Santos, AJ; Van, G; Itie, A; Khoo, W; Wakeham, A; Dunstan, CR; Lacey, DL; Mak, TW; Boyle, WJ; Penninger, JM			OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis	NATURE			English	Article							COLONY-STIMULATING FACTOR; T-CELL-RECEPTOR; BETA-DEFICIENT MICE; DENDRITIC CELLS; ABNORMAL-DEVELOPMENT; GERMINAL-CENTERS; MARROW CULTURES; TNF RECEPTOR; BONE-MARROW; OP/OP MICE	The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and Cop) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and Is an essential osteoclast differentiation factor in vivo	Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Amgen; Amgen	Penninger, JM (corresponding author), Ontario Canc Inst, Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.	jpenning@amgen.com	Penninger, Josef M/I-6860-2013; Dunstan, Colin/G-6214-2013	Penninger, Josef M/0000-0002-8194-3777; Dunstan, Colin/0000-0001-7586-4071				Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029; Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; BAILEY RP, 1975, AM J ANAT, V142, P15, DOI 10.1002/aja.1001420103; BEGG SK, 1993, J EXP MED, V177, P237, DOI 10.1084/jem.177.1.237; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DeBenedette MA, 1997, J IMMUNOL, V158, P551; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Irving BA, 1998, SCIENCE, V280, P905, DOI 10.1126/science.280.5365.905; KANIS JA, 1995, BONE, V17, pS101, DOI 10.1016/8756-3282(95)00194-I; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; KURIHARA N, 1989, BLOOD, V74, P1295; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Popoff SN, 1996, MOL MED TODAY, V2, P349, DOI 10.1016/1357-4310(96)81801-6; Reddi AH, 1997, CELL, V89, P159, DOI 10.1016/S0092-8674(00)80193-2; Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074-7613(00)80589-0; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Rosen CJ, 1997, ENDOCRIN METAB CLIN, V26, P295, DOI 10.1016/S0889-8529(05)70248-6; Saoulli K, 1998, J EXP MED, V187, P1849, DOI 10.1084/jem.187.11.1849; SEITZ M, 1985, ANN RHEUM DIS, V44, P438, DOI 10.1136/ard.44.7.438; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEINMAN RM, 1979, J EXP MED, V149, P1, DOI 10.1084/jem.149.1.1; TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo-128-4-1792; Teitelbaum SL, 1996, MT SINAI J MED, V63, P399; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	50	2646	2820	2	132	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 28	1999	397	6717					315	323		10.1038/16852	http://dx.doi.org/10.1038/16852			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950424				2022-12-01	WOS:000078324600040
J	Goldie, SJ; Weinstein, MC; Kuntz, KM; Freedberg, KA				Goldie, SJ; Weinstein, MC; Kuntz, KM; Freedberg, KA			The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	20th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med		cost-benefit analysis; cervix neoplasms; human immunodeficiency virus infections; vaginal smears; colposcopy	HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS INFECTION; LOOP ELECTROSURGICAL EXCISION; TERM FOLLOW-UP; SEROPOSITIVE WOMEN; PAPANICOLAOU SMEARS; POSITIVE WOMEN; RISK-FACTORS; NEOPLASIA	Background: Women with HIV infection have a higher risk for cervical squamous intraepithelial lesions than do women without HIV infection, and the optimal regimen for cervical cancer screening in these women is uncertain. Objective: To assess the net health consequences, costs, and cost-effectiveness of Various screening strategies for cervical neoplasia and cancer in HIV-infected women. Design: A cost-effectiveness analysis from a societal perspective done by using a state-transition Markov model. Values for incidence, progression, and regression of cervical neoplasia; efficacy of screening and treatment; progression of HIV disease; mortality from HIV infection and cancer; quality of life; and costs were obtained from the literature. Setting: Simulated clinical practice in the United States. Patients: HIV-infected women representative of the U.S. population. Intervention: Six main screening strategies-no screening, annual Papanicolaou smears, annual Papanicolaou smears after two negative smears obtained 6 months apart (recommended by the Centers for Disease Control and Prevention), semiannual Papanicolaou smears, annual colposcopy, and semiannual colposcopy-were considered. Measurements: Quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness. Results: Annual Papanicolaou smear screening resulted in a 2.1-month gain in quality-adjusted life expectancy for an incremental cost of $12 800 per QALY saved. Annual Papanicolaou smear screening after two negative smears obtained 6 months apart provided an additional 0.04 QALYs at a cost of $14 800 per QALY saved. Semiannual Papanicolaou smear screening provided a further 0.17 QALYs at a cost of $27 600 per QALY saved. Annual colposcopy cost more but provided no additional benefit compared with that given by semiannual Papanicolaou smear screening, and semiannual colposcopy exceeded $375 000 per QALY saved. Results were most sensitive to the rate of progression of neoplasia to invasive cancer. Conclusions: in HIV-infected women, cervical cancer screening with annual Papanicolaou smears after two negative smears obtained 6 months apart offers quality-adjusted life expectancy benefits at a cost comparable to that of other clinical preventive interventions.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Dept Hlth Policy & Management, Boston, MA 02115 USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; Boston Med Ctr, Evans Med Fdn, Boston, MA 02118 USA	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston Medical Center	Goldie, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Dept Hlth Policy & Management, 718 Huntington Ave,2nd Floor, Boston, MA 02115 USA.	sgoldie@hsph.harvard.edu			AHRQ HHS [R01-HS07317-01A1] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADACHI A, 1993, OBSTET GYNECOL, V81, P372; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BARRON BA, 1978, GYNECOL ONCOL, V6, P196, DOI 10.1016/0090-8258(78)90022-7; BARRON BA, 1970, J NATL CANCER I, V45, P1025; Belafsky P, 1996, J ACQ IMMUN DEF SYND, V11, P511, DOI 10.1097/00042560-199604150-00013; BELAFSKY P, 1996, GYNECOL ONCOL, V60, P118; BERK ML, 1993, AHCPR PUBLICATION; BIBBO M, 1971, J REPROD MED, V6, P184; BIGGERS SD, 1996, 11 INT C AIDS 7 12 J; BOARDMAN LA, 1994, OBSTET GYNECOL, V84, P1016; Bongain A, 1996, EUR J OBSTET GYN R B, V65, P195, DOI 10.1016/0301-2115(95)02357-7; Branca M., 1995, European Journal of Gynaecological Oncology, V16, P410; BROSGART C, 1995, 2 NAT C HUM RETR REL, P90; CAMPION MJ, 1986, LANCET, V2, P237; CAMPION MJ, 1990, OBSTET GYN CLIN N AM, V17, P695; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; *CDCP, 1996, HIV AIDS SURV REP AT; *CDCP, 1997, HIV AIDS SURV REP, P5; CELENTANO D P, 1989, Public Health Reviews, V17, P173; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; Chertow GM, 1996, ARCH INTERN MED, V156, P1345, DOI 10.1001/archinte.156.12.1345; Chiasson MA, 1997, OBSTET GYNECOL, V89, P690, DOI 10.1016/S0029-7844(97)00069-0; CLARK RA, 1993, CLIN INFECT DIS, V17, P165, DOI 10.1093/clinids/17.2.165; Condra JH, 1998, ANN INTERN MED, V128, P951, DOI 10.7326/0003-4819-128-11-199806010-00017; CONTI M, 1993, GYNECOL ONCOL, V49, P344, DOI 10.1006/gyno.1993.1137; CONTI M, 1992, 7 INT C AIDS 3 STD W, V8, pB95; COPPLESON LW, 1974, AM J OBSTET GYNECOL, V119, P953, DOI 10.1016/0002-9378(74)90013-1; Cornelius L, 1991, AHCPR PUBLICATION; DELMAS MC, 1998, 12 WORLD AIDS C 28 J; DelPriore G, 1996, J REPROD MED, V41, P653; DELPRIORE G, 1995, GYNECOL ONCOL, V56, P395, DOI 10.1006/gyno.1995.1069; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EHMANN WC, 1994, J ACQ IMMUN DEF SYND, V7, P1095; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; FAHS MC, 1992, ANN INTERN MED, V117, P520, DOI 10.7326/0003-4819-117-6-520; FINK MJ, 1994, GYNECOL ONCOL, V55, P133, DOI 10.1006/gyno.1994.1262; FLANIGAN TP, 1992, J WOMENS HEALTH, V1, P231, DOI DOI 10.1089/JWH.1992.1.231; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; FRUCHTER RG, 1994, AM J OBSTET GYNECOL, V171, P531, DOI 10.1016/0002-9378(94)90294-1; Fruchter RG, 1996, OBSTET GYNECOL, V87, P338, DOI 10.1016/0029-7844(95)00408-4; FRUCHTER RG, 1997, 1 NAT MAL AIDS C 28; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; Gold MR., 1996, COST EFFECTIVENESS H; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HANKINS CA, 1994, CAN MED ASSOC J, V150, P681; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; Heard I, 1997, INT J STD AIDS, V8, P388, DOI 10.1258/0956462971920316; HEARD I, 1995, OBSTET GYNECOL, V86, P749, DOI 10.1016/0029-7844(95)00282-V; HEARD I, 1998, 12 WORLD AIDS C 28 J, P325; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; Hillemanns P, 1996, AIDS, V10, P1641, DOI 10.1097/00002030-199612000-00008; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hockstad R L, 1992, Fam Pract Res J, V12, P53; HOCUTT JE, 1992, J FAM PRACTICE, V34, P38; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; HSIAO WC, 1988, JAMA-J AM MED ASSOC, V260, P2347, DOI 10.1001/jama.260.16.2347; JONES MH, 1992, LANCET, V339, P1440, DOI 10.1016/0140-6736(92)92031-A; KASHGARI.M, 1970, AM J EPIDEMIOL, V92, P211, DOI 10.1093/oxfordjournals.aje.a121201; KLEIN RS, 1994, J INFECT DIS, V170, P1404, DOI 10.1093/infdis/170.6.1404; KLEIN RS, 1997, 4 C RETR OPP INF 22, V126, P339; KORN AP, 1994, OBSTET GYNECOL, V83, P401; KORN AP, 1995, J ACQ IMMUN DEF SYND, V9, P361; LONGINI IM, 1991, J ACQ IMMUN DEF SYND, V4, P1141; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; MAIMAN M, 1991, OBSTET GYNECOL, V78, P84; MAIMAN M, 1993, OBSTET GYNECOL, V82, P170; Mandelblatt JS, 1997, J GEN INTERN MED, V12, P551, DOI 10.1046/j.1525-1497.1997.07107.x; MANDELBLATT JS, 1992, AIDS, V6, P173, DOI 10.1097/00002030-199202000-00005; *MED EC, 1996, DRUG TOP RED BOOK; MULLER C, 1990, COSTS EFFECTIVENESS; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; *NAT TECHN INF SER, 1994, AIDS COST SERV UT SU; *NAT TECHN INF SER, 1995, MULT AIDS COH STUD M; NIGHTINGALE SD, 1993, ARCH INTERN MED, V153, P1313, DOI 10.1001/archinte.153.11.1313; Northfelt D W, 1994, Oncology (Williston Park), V8, P33; Olaitan A, 1997, OBSTET GYNECOL, V89, P71, DOI 10.1016/S0029-7844(96)00377-8; PALEFSKY J, 1997, 1 NAT MAL AIDS C 28; Palefsky Joel, 1995, Current Opinion in Oncology, V7, P437, DOI 10.1097/00001622-199509000-00009; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PETRY KU, 1994, INT J CANCER, V57, P836, DOI 10.1002/ijc.2910570612; Petry KU, 1996, GYNECOL ONCOL, V60, P30, DOI 10.1006/gyno.1996.0007; Phillips P, 1997, JAMA-J AM MED ASSOC, V277, P1747, DOI 10.1001/jama.277.22.1747; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; RYLANDER E, 1977, ACTA OBSTET GYN SCAN, V56, P115, DOI 10.3109/00016347709158352; Schechter CB, 1996, ACTA CYTOL, V40, P1272; SEDLIS A, 1997, 1 NAT MAL AIDS C 28, P131; SEGAL MJ, 1997, MEDICARE RBRVS PHYSI; SHA BE, 1995, J ACQ IMMUN DEF SYND, V8, P486, DOI 10.1097/00042560-199504120-00009; Six C, 1998, AIDS, V12, P1047, DOI 10.1097/00002030-199809000-00012; STERN E, 1964, CANCER, V17, P508, DOI 10.1002/1097-0142(196404)17:4<508::AID-CNCR2820170412>3.0.CO;2-S; Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903; SUN XW, 1995, OBSTET GYNECOL, V85, P680, DOI 10.1016/0029-7844(95)00025-M; U. S. Bureau of the Census, 1996, STAT ABSTR US; *US BUR LAB STAT, 1996, 98186 USDL US BUR LA; *US DEP HHS PHS NI, 1997, SURV EP END RES SEER; VERMUND SH, 1997, MED MANAGEMENT AIDS, P125; Vermund Sten H., 1995, P189; WATTS DH, 1996, 11 INT C AIDS 7 12 J; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911; WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591; Wright TC, 1996, OBSTET GYN CLIN N AM, V23, P861, DOI 10.1016/S0889-8545(05)70280-1; Wright TC, 1996, OBSTET GYNECOL, V87, P515, DOI 10.1016/0029-7844(95)00472-6; WRIGHT TC, 1994, GYNECOL ONCOL, V55, P253, DOI 10.1006/gyno.1994.1286; WRIGHT TC, 1995, 2 NAT C HUM RETR REL	110	87	90	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					97	+		10.7326/0003-4819-130-2-199901190-00003	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00003			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	158KG	10068381				2022-12-01	WOS:000078114200002
J	Willis, TG; Jadayel, DM; Du, MQ; Peng, HZ; Perry, AR; Abdul-Rauf, M; Price, H; Karran, L; Majekodunmi, O; Wlodarska, I; Pan, LX; Crook, T; Hamoudi, R; Isaacson, PG; Dyer, MJS				Willis, TG; Jadayel, DM; Du, MQ; Peng, HZ; Perry, AR; Abdul-Rauf, M; Price, H; Karran, L; Majekodunmi, O; Wlodarska, I; Pan, LX; Crook, T; Hamoudi, R; Isaacson, PG; Dyer, MJS			Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types	CELL			English	Article							POLYMERASE CHAIN-REACTION; FOLLICULAR LYMPHOMA; TISSUE; GENE; TRANSFORMATION; P53; VISUALIZATION; ABNORMALITIES; ACTIVATION; APOPTOSIS	MALT B cell lymphomas with t(1;14)(p22;q32) showed a recurrent breakpoint upstream of the promoter of a novel gene, Bcl10. Bcl10 is a cellular homolog of the equine herpesvirus-2 E10 gene: both contain an amino-terminal caspase recruitment domain (CARD) homologous to that found in several apoptotic molecules. Bcl10 and E10 activated NF-KB but caused apoptosis of 293 cells. Bcl10 expressed in a MALT lymphoma exhibited a frameshift mutation resulting in truncation distal to the CARD. Truncated Bcl10 activated NF-KB but did not induce apoptosis. Wild-type Bcl10 suppressed transformation, whereas mutant forms had lost this activity and displayed gain-of-function transforming activity. Similar mutations were detected in other tumor types, indicating that Bcl10 may be commonly involved in the pathogenesis of human malignancy.	Inst Canc Res, Acad Dept Haematol & Cytogenet, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Canc Gene Cloning Ctr, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, Sutton SM2 5NG, Surrey, England; UCL, Sch Med, Dept Histopathol, London WC1E 6JJ, England; Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; Katholieke Univ Leuven VIB, Louvain, Belgium	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; University College London; UCL Medical School; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Dyer, MJS (corresponding author), Inst Canc Res, Acad Dept Haematol & Cytogenet, Sutton SM2 5NG, Surrey, England.	mdyer@icr.ac.uk	; Dyer, Martin/F-2691-2014	Hamoudi, Rifat/0000-0002-1402-0868; Price, Helen/0000-0003-1537-4390; Du, Ming-Qing/0000-0002-1017-5045; Dyer, Martin/0000-0002-5033-2236				ALBERT T, 1994, ONCOGENE, V9, P759; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Gutierrez MI, 1998, BLOOD, V92, P600, DOI 10.1182/blood.V92.2.600.414k33_600_606; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HUSSELL T, 1993, J PATHOL, V169, P221, DOI 10.1002/path.1711690208; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; ISAACSON PG, 1995, J CLIN PATHOL, V48, P395, DOI 10.1136/jcp.48.5.395; JAIN VK, 1993, J IMMUNOL, V150, P5418; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Lee WC, 1996, CANCER RES, V56, P4297; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MATHEW S, 1994, CANCER RES, V54, P6265; Matolcsy A, 1996, BLOOD, V88, P3937, DOI 10.1182/blood.V88.10.3937.bloodjournal88103937; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mertens F, 1997, CANCER RES, V57, P2765; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Pan LX, 1997, AM J PATHOL, V150, P1245; Park D, 1996, J FOOD LIPIDS, V3, P1, DOI 10.1111/j.1745-4522.1996.tb00050.x; Peng H, 1997, HISTOPATHOLOGY, V30, P425, DOI 10.1046/j.1365-2559.1997.5450786.x; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Thangavelu M, 1997, BLOOD, V89, P3371, DOI 10.1182/blood.V89.9.3371; THORNE M, 1998, CURR BIOL, V8, P885; TILLY H, 1994, BLOOD, V84, P1043; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Willis TG, 1997, BLOOD, V90, P2456; Willis TG, 1998, BLOOD, V91, P1873, DOI 10.1182/blood.V91.6.1873.1873_1873_1881; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1992, CANCER GENET CYTOGEN, V58, P35, DOI 10.1016/0165-4608(92)90130-Z; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; ZUTTER M, 1991, BLOOD, V78, P1062	46	518	567	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					35	45		10.1016/S0092-8674(00)80957-5	http://dx.doi.org/10.1016/S0092-8674(00)80957-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989495	Bronze			2022-12-01	WOS:000078023200006
J	Strachan, DP; Carrington, D; Mendall, MA; Ballam, L; Morris, J; Butland, BK; Sweetnam, PM; Elwood, PC				Strachan, DP; Carrington, D; Mendall, MA; Ballam, L; Morris, J; Butland, BK; Sweetnam, PM; Elwood, PC			Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over years in the Caerphilly prospective heart disease study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY DISEASE; CARDIOVASCULAR RISK-FACTORS; HELICOBACTER-PYLORI; MYOCARDIAL-INFARCTION; ASSOCIATION; INFECTION; ATHEROSCLEROSIS; ANTIBODIES; MEN; SEROPOSITIVITY	Objectives To investigate the effect of Chlamydia pneumoniae infection on future development of ischaemic heart disease and mortality Design Prospective longitudinal study. Setting Caerphilly South Wales. Subjects Plasma specimens were collected during 1979-83 from 1773 men aged 45-59 years. These were tested for IgG and IgA antibodies to C pneumoniae (TW183) by microimmunonfluorescence. Outcome measures 13 year mortality and incident ischaemic heart disease events were ascertained from death certificates, hospital records, and electrocardiographic changes at follow up every 4 to 5 years. Results 642 men (36.2%) had Ige antibodies at a titre of greater than or equal to 1 in 16, of whom 362 (20.4% of all men) also had detectable IgA antibodies. The prevalence of ischaemic heart disease (a history of past or current disease) at entry was similar at all IgG antibody titres but was positively related to IgA antibody titre. IgA antibody titre was positively correlated with plasma viscosity but not with other cardiovascular risk factors. Incidence of ischaemic heart disease was not associated with either IgG antibody titre or IgA antibody titre, but there were stronger and significant relations of IgA antibodies with all cause mortality and fatal ischaemic heart disease, which persisted after adjustment for conventional cardiovascular risk factors. The odds ratios associated with detectable IgA antibodies were 1.07 (95% confidence interval 0.75 to 1.53) for all incident ischaemic heart disease, 1.83 (1.17 to 2.85) for fatal ischaemic heart disease, and 1.50 (1.10 to 2.04) for all cause mortality Conclusion This is the first prospective demonstration of an association between IgA antibodies to C pneumoniae, a putative marker of chronic infection, and subsequent risk of death from ischaemic heart disease. In contrast to earlier case-control studies, Ige antibodies were not associated with either prevalent or incident ischaemic heart disease.	St Georges Hosp Med Sch, Dept Publ Hlth Sci, London SW17 0RE, England; St Georges Hosp Med Sch, Dept Med Microbiol, London SW17 0RE, England; St Georges Hosp Med Sch, Div Gastroenterol Endocrinol & Metab, London SW17 0RE, England; Llandough Hosp, Epidemiol Unit S Wales, MRC, Penarth CF64 2XW, S Glam, Wales	St Georges University London; St Georges University London; St Georges University London	Strachan, DP (corresponding author), St Georges Hosp Med Sch, Dept Publ Hlth Sci, London SW17 0RE, England.	d.strachan@sghms.ac.uk		Butland, Barbara/0000-0001-9952-3108				BAINTON D, 1992, BRIT HEART J, V68, P60; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Davidson M, 1998, CIRCULATION, V98, P628, DOI 10.1161/01.CIR.98.7.628; ELWOOD PC, 1984, J EPIDEMIOL COMMUN H, V38, P259, DOI 10.1136/jech.38.3.259; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; HAHN DL, 1992, ARTERIOSCLER THROMB, V12, P945, DOI 10.1161/01.ATV.12.8.945; Jackson LA, 1997, AM J PATHOL, V150, P1785; KARVONEN M, 1994, INT J EPIDEMIOL, V23, P1315, DOI 10.1093/ije/23.6.1315; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; Laurila A, 1997, BRIT MED J, V314, P1456, DOI 10.1136/bmj.314.7092.1456; Maass M, 1998, J AM COLL CARDIOL, V31, P827, DOI 10.1016/S0735-1097(98)00016-3; Mendall MA, 1996, BRIT MED J, V312, P1061; MENDALL MA, 1995, J INFECTION, V30, P121, DOI 10.1016/S0163-4453(95)80006-9; Miettinen H, 1996, EUR HEART J, V17, P682; MORRISON RP, 1989, J EXP MED, V170, P1271, DOI 10.1084/jem.170.4.1271; Office of Population Censuses and Surveys, 1980, CLASS OCC; Ossewaarde JM, 1998, EPIDEMIOL INFECT, V120, P93, DOI 10.1017/S0950268897008303; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Ramirez JA, 1996, ANN INTERN MED, V125, P979, DOI 10.7326/0003-4819-125-12-199612150-00008; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Saikku P, 1997, SCAND J INFECT DIS, P53; *STAT CORP, 1999, STAT REF MAN REL 3 1, V81, P248; Strachan DP, 1998, CIRCULATION, V98, P1286, DOI 10.1161/01.CIR.98.13.1286; Strachan DP, 1999, HEART, V81, P248, DOI 10.1136/hrt.81.3.248; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; WAGELS G, 1994, J CLIN MICROBIOL, V32, P2820, DOI 10.1128/JCM.32.11.2820-2823.1994; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	30	104	108	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1999	318	7190					1035	1039		10.1136/bmj.318.7190.1035	http://dx.doi.org/10.1136/bmj.318.7190.1035			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205100	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000080140000022
J	Quintner, JL; Cohen, ML				Quintner, JL; Cohen, ML			Fibromyalgia falls foul of a fallacy	LANCET			English	Editorial Material							PAIN; DISABILITY; FIBROSITIS; DISORDER		Wyllie Arthrit Ctr, Shenton Pk, WA 6008, Australia; St Vincent Med Ctr, Darlinghurst Arthrit Ctr, Darlinghurst, NSW, Australia; St Vincent Med Ctr, Pain Res Clin, Darlinghurst, NSW, Australia		Quintner, JL (corresponding author), Wyllie Arthrit Ctr, 17 Lemnos St, Shenton Pk, WA 6008, Australia.							ARMSTRONG J, 1825, LANCET, V7, P65; Beard George, 1869, BOSTON MED SURG J, V3, P217, DOI [10.1056/nejm186904290801301, DOI 10.1056/NEJM186904290801301]; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Cohen M. L., 1996, RAIN REV, V3, P181; COHEN ML, 1993, LANCET, V342, P906, DOI 10.1016/0140-6736(93)91950-Q; Cohen ML, 1998, MED J AUSTRALIA, V168, P402, DOI 10.5694/j.1326-5377.1998.tb138995.x; COHEN ML, 1995, J MUSCULOSKELET PAIN, V3, P49; CROFT P, 1994, BRIT MED J, V309, P696, DOI 10.1136/bmj.309.6956.696; GOLDENBERG DL, 1995, ANN RHEUM DIS, V54, P3, DOI 10.1136/ard.54.1.3; Gowers W R, 1904, Br Med J, V1, P117; Habershon S O, 1868, Br Med J, V1, P603; Hadler NM, 1997, POSTGRAD MED, V102, P161, DOI 10.3810/pgm.1997.08.284; Head H, 1922, Br Med J, V1, P1; HORMELL RS, 1940, JAMA-J AM MED ASSOC, V223, P754; International Association for the Study of Pain, 1986, PAIN, V3, pS216; Kosek E, 1995, PAIN, V63, P335, DOI 10.1016/0304-3959(95)00061-5; LAUTENBACHER S, 1994, PAIN, V59, P45, DOI 10.1016/0304-3959(94)90046-9; Lewis T, 1944, LANCET, V1, P619; Littlejohn GO, 1998, MED J AUSTRALIA, V168, P398; McDermid AJ, 1996, PAIN, V66, P133, DOI 10.1016/0304-3959(96)03059-X; MOLDOFSKY H, 1976, PSYCHOSOM MED, V38, P35, DOI 10.1097/00006842-197601000-00006; Rockwell A. D., 1971, PRACTICAL TREATISE N; Scadding JG, 1996, LANCET, V348, P594, DOI 10.1016/S0140-6736(96)02049-1; SMYTHE H A, 1977, Bulletin on the Rheumatic Diseases, V28, P928; SMYTHE HA, 1979, CLIN RHEUM DIS, V5, P823; Wolfe F, 1996, J RHEUMATOL, V23, P534; Wolfe F, 1997, J RHEUMATOL, V24, P1247; Wolfe F, 1997, ANN RHEUM DIS, V56, P268, DOI 10.1136/ard.56.4.268; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2	30	40	40	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1092	1094		10.1016/S0140-6736(98)06468-X	http://dx.doi.org/10.1016/S0140-6736(98)06468-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199368				2022-12-01	WOS:000079614000044
J	Ayanian, JZ; Cleary, PD				Ayanian, JZ; Cleary, PD			Perceived risks of heart disease and cancer among cigarette smokers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; SMOKING RISK; HEALTH; PERCEPTIONS; BELIEFS	Context Cigarette smoking causes more preventable deaths from cardiovascular disease and cancer than any other modifiable risk factor, but smokers may discount the increased personal risk they face from continued smoking. Objective To assess smokers' perceptions of their risks of heart disease and cancer. Design and Setting Telephone and self-administered survey in 1995 of a probability sample of US households with telephones. Participants A total of 3031 adults aged 25 to 74 years, including 737 current smokers (24.3%). Main Outcome Measures Respondents with no history of myocardial infarction (MI) (96.2%) or cancer (92.9%) assessed their risk of these conditions relative to other people of the same age and sex. Among current smokers, perceived risks were analyzed by demographic and clinical factors using logistic regression. Results Only 29% and 40% of current smokers believed they have a higher-than-average risk of MI or cancer, respectively, and only 39% and 49% of heavy smokers (greater than or equal to 40 cigarettes per day) acknowledged these risks. Even among smokers with hypertension, angina, or a family history of MI, 48%, 49%, and 39%, respectively, perceived their risk of MI as higher than average. In multivariate analyses, older (greater than or equal to 65 years), less educated (< high school graduate), and light smokers (1-19 cigarettes per day) were less likely than younger, more educated, and heavy smokers to perceive an increased personal risk of MI or cancer. Conclusions Most smokers do not view themselves at increased risk of heart disease or cancer. As part of multifaceted approaches to smoking cessation, physicians and public health professionals should identify and educate smokers who are not aware of smoking-related health risks.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	ayanian@hcp.med.harvard.edu	Cleary, Paul/AAF-7048-2019					AVIS NE, 1989, AM J PUBLIC HEALTH, V79, P1608, DOI 10.2105/AJPH.79.12.1608; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P99, DOI 10.2105/AJPH.82.1.99; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P645; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P854; Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P588; Cromwell J, 1997, JAMA-J AM MED ASSOC, V278, P1759, DOI 10.1001/jama.278.21.1759; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; Gibbons FX, 1997, J PERS SOC PSYCHOL, V72, P184, DOI 10.1037//0022-3514.72.1.184; GLYNN TJ, 1997, NIH PUBL; LEVENTHAL H, 1980, PSYCHOL BULL, V88, P370, DOI 10.1037/0033-2909.88.2.370; LEVENTHAL H, 1987, JAMA-J AM MED ASSOC, V257, P3373, DOI 10.1001/jama.257.24.3373; Levy P., 1991, SAMPLING POPULATIONS; Marmot MG, 1998, MILBANK Q, V76, P403, DOI 10.1111/1468-0009.00097; MCCOY SB, 1992, J BEHAV MED, V15, P469, DOI 10.1007/BF00844942; National Cancer Institute, 1997, NIH PUBL; Schoenbaum M, 1997, AM J PUBLIC HEALTH, V87, P755, DOI 10.2105/AJPH.87.5.755; STRECHER VJ, 1995, J BEHAV MED, V18, P45, DOI 10.1007/BF01857704; Thorndike AN, 1998, JAMA-J AM MED ASSOC, V279, P604, DOI 10.1001/jama.279.8.604; *US DEP HHS, 1990, HLTH BEN SMOK CESS; *US DEP HHS, 1989, DHHS PUBL CDC; VISCUSI WK, 1992, SMOKING MAKING RISKY; Weinstein ND, 1998, ANN BEHAV MED, V20, P135, DOI 10.1007/BF02884459; WEINSTEIN ND, 1987, J BEHAV MED, V10, P481, DOI 10.1007/BF00846146; WEINSTEIN ND, 1988, HEALTH PSYCHOL, V7, P355, DOI 10.1037/0278-6133.7.4.355	25	176	180	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1999	281	11					1019	1021		10.1001/jama.281.11.1019	http://dx.doi.org/10.1001/jama.281.11.1019			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	175EE	10086437	Bronze			2022-12-01	WOS:000079079400029
J	Syngal, S; Coakley, EH; Willett, WC; Byers, T; Williamson, DF; Colditz, GA				Syngal, S; Coakley, EH; Willett, WC; Byers, T; Williamson, DF; Colditz, GA			Long-term weight patterns and risk for cholecystectomy in women	ANNALS OF INTERNAL MEDICINE			English	Article						cholelithiasis; weight loss; weight gain; cholecystectomy	GASTRIC BYPASS-SURGERY; GALLSTONE DISEASE; GALLBLADDER-DISEASE; SYMPTOMATIC GALLSTONES; MORBID-OBESITY; URSODEOXYCHOLIC ACID; PHYSICAL-ACTIVITY; RELATIVE WEIGHT; UNITED-STATES; GALL-STONES	Background: Obesity and rapid weight loss in obese persons are known risk factors for gallstones. However, the effect of intentional, long-term, moderate weight changes on the risk for gallstones is unclear. Objective: To study long-term weight patterns in a cohort of women and to examine the relation between weight pattern and risk for cholecystectomy. Design: Prospective cohort study. Setting: 11 U.S. states. Participants: 47 153 female registered nurses who did not undergo cholecystectomy before 1988. Measurements: Cholecystectomy between 1988 and 1994 (ascertained by patient self-report). Results: During the exposure period (1972 to 1988), there was evidence of substantial Variation in weight due to intentional weight loss during adulthood. Among cohort patients, 54.9% reported weight cycling with at least one episode of intentional weight loss associated with regain. Of the total cohort, 20.1% were light cyclers (5 to 9 Ib of weight loss and gain), 18.8% were moderate cyclers(10 to 19 lb of weight loss and gain), and 16.0% were severe cyclers (greater than or equal to 20 lb of weight loss and gain). Net weight gain without cycling occurred in 29.3% of women; net weight loss without cycling was the least common pattern (4.6%). Only 11.1% of the cohort maintained weight within 5 lb over the 16-year period. In the study, 1751 women had undergone cholecystectomy between 1988 and 1994. Compared with weight maintainers, the relative risk for cholecystectomy (adjusted for body mass index, age, alcohol intake, fat intake, and smoking) was 1.20 (95% CI, 0.96 to 1.50) among light cyclers, 1.31 among moderate cyclers (CI, 1.05 to 1.64), and 1.68 among severe cyclers (CI, 1.34 to 2.10). Conclusion: Weight cycling was highly prevalent in this large cohort of middle-aged women. The risk for cholecystectomy associated with weight cycling was substantial, independent of attained relative body weight.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dana Farber Canc Inst, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Ctr Dis Control & Prevent, Div Diabet Translat K10, Atlanta, GA 30341 USA; Univ Colorado, Sch Med, Dept Prevent Med & Biometr, Denver, CO 80262 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Colditz, GA (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356, 5R25CA57711] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356, R25CA057711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARAL JF, 1985, AM J SURG, V149, P551, DOI 10.1016/S0002-9610(85)80055-6; ANGELICO M, 1988, HEPATOLOGY, V8, P907; ATKINSON RL, 1994, JAMA-J AM MED ASSOC, V272, P1196, DOI 10.1001/jama.272.15.1196; BARBARA L, 1987, HEPATOLOGY, V7, P913, DOI 10.1002/hep.1840070520; BENNION LJ, 1978, NEW ENGL J MED, V299, P1221, DOI 10.1056/NEJM197811302992205; BLACKBURN GL, 1989, AM J CLIN NUTR, V49, P1105, DOI 10.1093/ajcn/49.5.1105; BRAY GA, 1976, ANN INTERN MED, V85, P97, DOI 10.7326/0003-4819-85-1-97; BRAY GA, 1985, ANN INTERN MED, V103, P1052, DOI 10.7326/0003-4819-103-6-1052; BROOMFIELD PH, 1988, NEW ENGL J MED, V319, P1567, DOI 10.1056/NEJM198812153192403; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DEITEL M, 1987, SURG GYNECOL OBSTET, V164, P549; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; FRENCH SA, 1995, INT J OBESITY, V19, P22; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; Jeffery RW, 1996, AM J CLIN NUTR, V63, P452; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; KAMRATH RO, 1992, AM J CLIN NUTR, V56, P255; KATO I, 1992, DIGEST DIS SCI, V37, P784, DOI 10.1007/BF01296440; KNECHT BH, 1978, AM SURGEON, V44, P496; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAYDE PM, 1982, J EPIDEMIOL COMMUN H, V36, P274, DOI 10.1136/jech.36.4.274; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MARKS JW, 1992, GASTROENTEROLOGY, V103, P566, DOI 10.1016/0016-5085(92)90848-S; MARZIO L, 1988, DIGEST DIS SCI, V33, P4, DOI 10.1007/BF01536623; MAURER KR, 1990, AM J EPIDEMIOL, V131, P836, DOI 10.1093/oxfordjournals.aje.a115574; RODIN J, 1993, ANN INTERN MED, V119, P643, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00003; SCHLESINGER MH, 1989, GASTROINTESTINAL DIS; SCRAGG RKR, 1984, BRIT MED J, V288, P1113, DOI 10.1136/bmj.288.6424.1113; SHIFFMAN ML, 1991, AM J GASTROENTEROL, V86, P1000; SHIFFMAN ML, 1995, ANN INTERN MED, V122, P899, DOI 10.7326/0003-4819-122-12-199506150-00002; SICHIERI R, 1991, AM J PUBLIC HEALTH, V81, P880, DOI 10.2105/AJPH.81.7.880; SICHIERI R, 1990, AM J EPIDEMIOL, V131, P826, DOI 10.1093/oxfordjournals.aje.a115573; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; SUGERMAN HJ, 1989, AM J SURG, V157, P93, DOI 10.1016/0002-9610(89)90427-3; THIJS C, 1992, AM J EPIDEMIOL, V135, P274, DOI 10.1093/oxfordjournals.aje.a116281; *US DEPT HHS, 1987, VIT HLTH STAT, V11; WATTCHOW DA, 1983, BRIT MED J, V286, P763, DOI 10.1136/bmj.286.6367.763; WHO, 1995, PHYS STAT US INT ANT; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YANG HY, 1992, DIGEST DIS SCI, V37, P912, DOI 10.1007/BF01300390	44	69	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	1999	130	6					471	+		10.7326/0003-4819-130-6-199903160-00003	http://dx.doi.org/10.7326/0003-4819-130-6-199903160-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	176RL	10075614				2022-12-01	WOS:000079165500002
J	Beringer, J				Beringer, J			Keeping watch over genetically modified crops and foods	LANCET			English	Editorial Material									Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England	University of Bristol	Beringer, J (corresponding author), Univ Bristol, Sch Biol Sci, Woodland Rd, Bristol BS8 1UG, Avon, England.							DURANT J, 1998, BIOTECHNOLOGY PUBLIC; GILLARD M, 1999, GUARDIAN        0212; HORNSBY M, 1999, TIMES           0211; *HOUS LORDS SEL CO, 1992, REG UK BIOT IND GLOB; Nielsen KM, 1998, FEMS MICROBIOL REV, V22, P79, DOI 10.1016/S0168-6445(98)00009-6; *PARL OFF SCI TECH, 1998, GEN MOD FOODS BEN RI; *SEL COMM EUR COMM, 1998, EC REG GEN MOD AGR	7	4	5	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					605	606		10.1016/S0140-6736(99)00041-0	http://dx.doi.org/10.1016/S0140-6736(99)00041-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QU	10030321				2022-12-01	WOS:000078818200003
J	Rissoan, MC; Soumelis, V; Kadowaki, N; Grouard, G; Briere, F; Malefyt, RD; Liu, YJ				Rissoan, MC; Soumelis, V; Kadowaki, N; Grouard, G; Briere, F; Malefyt, RD; Liu, YJ			Reciprocal control of T helper cell and dendritic cell differentiation	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; PRECURSOR POPULATION; HUMAN BLOOD; IN-VIVO; RESPONSES; PHENOTYPE; ANTIGEN; SUBSETS; LINEAGE; CD40	It is not known whether subsets of dendritic cells provide different cytokine microenvironments that determine the differentiation of either type-1 T helper (T(H)1) or T(H)2 cells. Human monocyte (pDC1)-derived dendritic cells (DC1) were found to induce T(H)1 differentiation, whereas dendritic cells (DC2) derived from CD4(+)CD3(-)CD11c(-) plasmacytoid cells (pDC2) induced T(H)2 differentiation by use of a mechanism unaffected by interleukin-4 (IL-4) or IL-12. The T(H)2 cytokine IL-4 enhanced DC1 maturation and killed pDC2, an effect potentiated by IL-10 but blocked by CD40 Ligand and interferon-gamma, Thus, a negative feedback Loop from the mature T helper cells may selectively inhibit prolonged T(H)1 or T(H)2 responses by regulating survival of the appropriate dendritic cell subset.	Schering Plough Corp, Lab Immunol Res, F-69571 Dardilly, France; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Liu, YJ (corresponding author), Schering Plough Corp, Lab Immunol Res, 27 Chemin Peupliers,Boite Postale 11, F-69571 Dardilly, France.	yliu@dnax.org		de Waal Malefyt, Rene/0000-0002-2663-383X				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bruno L, 1997, J EXP MED, V185, P875, DOI 10.1084/jem.185.5.875; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Inaba K, 1997, J EXP MED, V186, P665, DOI 10.1084/jem.186.5.665; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Pulendran B, 1997, J IMMUNOL, V159, P2222; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Saunders D, 1996, J EXP MED, V184, P2185, DOI 10.1084/jem.184.6.2185; Seder RA, 1998, J IMMUNOL, V160, P5719; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; Wu L, 1996, J EXP MED, V184, P903, DOI 10.1084/jem.184.3.903	29	1558	1663	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	1999	283	5405					1183	1186		10.1126/science.283.5405.1183	http://dx.doi.org/10.1126/science.283.5405.1183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024247				2022-12-01	WOS:000078738400056
J	Ryu, SJ; Zhou, S; Ladurner, AG; Tjian, R				Ryu, SJ; Zhou, S; Ladurner, AG; Tjian, R			The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1	NATURE			English	Article							RNA-POLYMERASE-II; GENE-TRANSCRIPTION; HORMONE RECEPTOR; ACTIVATION; COACTIVATORS; CLONING; PURIFICATION; COMPONENTS; MEDIATOR; DOMAIN	Activation of gene transcription in metazoans is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA, These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus(1), One class of co-activator, the TAF(II) subunits of transcription factor TFIID, can serve as targets of activators and as proteins that recognize core promoter sequences necessary for transcription initiation(2-5). Transcriptional activation by enhancer-binding factors such as Sp1 (ref, 6) requires TFIID, but the identity of other necessary cofactors has remained unknown. Here we describe a new human factor, CRSP, that is required together with the TAF(II)s for transcriptional activation by Sp1. Purification of CRSP identifies a complex of approximate relative molecular mass 700,000 (M(r)similar to 700K) that contains nine subunits with M-r values ranging from 33K to 200K. Cloning of genes encoding CRSP subunits reveals that CRSP33 is a homologue of the yeast mediator subunit Med7 (ref. 7), whereas CRSP150 contains a domain conserved in yeast mediator subunit Rgr1 (ref. 8), CRSP p200 is identical to the nuclear hormone-receptor co-activator subunit TRIP2/PBP9,10. CRSPs 34, 77 and 130 are new proteins, but the amino terminus of CRSP70 is homologous to elongation factor TFIIS11. Immunodepletion studies confirm that these subunits have an essential cofactor function. The presence of common subunits in distinct cofactor complexes suggests a combinatorial mechanism of co-activator assembly during transcriptional activation.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Tjian, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, 401 Barker Hall, Berkeley, CA 94720 USA.		Ryu, Soojin/GWV-4004-2022	Ryu, Soojin/0000-0002-7059-0160; Ladurner, Andreas/0000-0003-3835-232X				Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/0968-0004(96)10043-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LeRoy G, 1998, J BIOL CHEM, V273, P7134, DOI 10.1074/jbc.273.12.7134; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; ONATE SA, 1995, SCIENCE, V270, P1354; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Yoshikawa H, 1998, GENOMICS, V49, P237, DOI 10.1006/geno.1998.5246; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	30	294	312	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 4	1999	397	6718					446	450		10.1038/17141	http://dx.doi.org/10.1038/17141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989412	Green Published			2022-12-01	WOS:000078461700051
J	Meier, CR; Derby, LE; Jick, SS; Vasilakis, C; Jick, H				Meier, CR; Derby, LE; Jick, SS; Vasilakis, C; Jick, H			Antibiotics and risk of subsequent first-time acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CHLAMYDIA-PNEUMONIAE; ASSOCIATION; INFECTIONS; TWAR; AZITHROMYCIN; HYPERTENSION; DATABASE	Context Increasing evidence supports the hypothesis of a causal association between certain bacterial infections and increased risk of developing acute myocardial infarction. If such a causal association exists, subjects who used antibiotics active against the bacteria, regardless of indication, might be at lower risk of developing acute myocardial infarction than nonusers. Objective To determine whether previous use of antibiotics decreases the risk of developing a first-time acute myocardial infarction, Design Population-based case-control analysis. Setting The United Kingdom-based General Practice Research Database comprising 350 general practices. Patients A total of 3315 case patients aged 75 years or younger with a diagnosis of first-time acute myocardial infarction between 1992 and 1997 and 13139 controls without myocardial infarction matched to cases for age, sex, general practice attended, and calendar time. Main Outcome Measures Use of antibiotics among those who did or did not have a first-time acute myocardial infarction. Results Cases were significantly less likely to have used tetracycline antibiotics (adjusted odds ratio [OR], 0.70; 95% confidence interval [CI], 0.55-0.90) or quinolones (adjusted OR, 0.45; 95% CI, 0.21-0.95). No effect was found for previous use of macrolides (primarily erythromycin), sulfonamides, penicillins, or cephalosporins. Conclusions The findings from this large case-control analysis provide further, albeit indirect, evidence for an association between bacterial infections with organisms susceptible to tetracycline or quinolone antibiotics and the risk of acute myocardial infarction. These results of preliminary nature should stimulate more research to further explore the role of infections in the etiology of acute myocardial infarction.	Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA	Boston University	Meier, CR (corresponding author), Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02421 USA.			Jick, Susan/0000-0002-2215-1067; Jick, Hershel/0000-0003-4270-5992				Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; FALCK G, 1994, SCAND J INFECT DIS, V26, P179, DOI 10.3109/00365549409011782; GRAYSTON JT, 1993, CIRCULATION, V87, P1408, DOI 10.1161/01.CIR.87.4.1408; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; Gupta S, 1997, BRIT MED J, V314, P1778, DOI 10.1136/bmj.314.7097.1778; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; HAMMERSCHLAG MR, 1992, ANTIMICROB AGENTS CH, V36, P1573, DOI 10.1128/AAC.36.7.1573; HAMMERSCHLAG MR, 1994, ANTIMICROB AGENTS CH, V38, P1873, DOI 10.1128/AAC.38.9.1873; Jick H, 1997, LANCET, V350, P1045, DOI 10.1016/S0140-6736(05)70451-7; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1996, PHARMACOTHERAPY, V16, P321; Jick H, 1997, EPIDEMIOLOGY, V8, P446, DOI 10.1097/00001648-199707000-00017; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Kauppinen M, 1995, CLIN INFECT DIS, V21, pS244, DOI 10.1093/clind/21.Supplement_3.S244; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; Meier CR, 1998, LANCET, V351, P1467, DOI 10.1016/S0140-6736(97)11084-4; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Wimmer MLJ, 1996, STROKE, V27, P2207, DOI 10.1161/01.STR.27.12.2207	22	142	145	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					427	431		10.1001/jama.281.5.427	http://dx.doi.org/10.1001/jama.281.5.427			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952202	Bronze			2022-12-01	WOS:000078318500030
J	Leadbetter, JR; Schmidt, TM; Graber, JR; Breznak, JA				Leadbetter, JR; Schmidt, TM; Graber, JR; Breznak, JA			Acetogenesis from H-2 plus CO2 by spirochetes from termite guts	SCIENCE			English	Article							SP-NOV; MASTOTERMES DARWINIENSIS; RETICULITERMES FLAVIPES; PHYLOGENETIC ANALYSIS; HINDGUT; ACETATE; METHANOGENS; BACTERIUM; SEQUENCE; SPERATUS	Pure cultures of termite gut spirochetes were obtained and were shown to catalyze the synthesis of acetate from H-2 plus CO2. The 16S ribosomal DNA sequences of two strains were 98 percent similar and were affiliated with those of the genus Treponema. However, neither was closely related to any known treponeme. These findings imply an important role for spirochetes in termite nutrition, help to reconcile the dominance of acetogenesis over methanogenesis as an H-2 sink in termite hindguts, suggest that the motility of termite gut protozoa by means of attached spirochetes may be based on interspecies H-2 transfer, and underscore the importance of termites as a rich reservoir of novel microbial diversity.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Breznak, JA (corresponding author), Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA.			Schmidt, Thomas/0000-0002-8209-6055; Leadbetter, Jared/0000-0002-7033-0844				Berchtold M, 1996, SYST APPL MICROBIOL, V19, P66, DOI 10.1016/S0723-2020(96)80011-7; BERCHTOLD M, 1994, FEMS MICROBIOL LETT, V123, P269, DOI 10.1111/j.1574-6968.1994.tb07235.x; BRAUMAN A, 1992, SCIENCE, V257, P1384, DOI 10.1126/science.257.5075.1384; Breznak, 1973, CRIT REV MICROBIOL, V2, P457; Breznak J.A., 1984, BERGEYS MANUAL SYSTE, V1, P67; Breznak J.A., 1994, ACETOGENESIS, P303; BREZNAK JA, 1986, APPL ENVIRON MICROB, V52, P623, DOI 10.1128/AEM.52.4.623-630.1986; BREZNAK JA, 1988, ARCH MICROBIOL, V150, P282, DOI 10.1007/BF00407793; Breznak John A., 1994, P137; CANALEPAROLA E, 1992, PROKARYOTES HDB BIOL, V4, P3524; CLARK JE, 1982, J BACTERIOL, V151, P507, DOI 10.1128/JB.151.1.507-509.1982; CLEVELAND LR, 1964, PROC R SOC SER B-BIO, V159, P668, DOI 10.1098/rspb.1964.0025; Daniels Lacy, 1994, P512; Drake H. L., 1994, ACETOGENESIS, P3, DOI DOI 10.1007/978-1-4615-1777-1_1; Ebert A, 1997, APPL ENVIRON MICROB, V63, P4039, DOI 10.1128/AEM.63.10.4039-4046.1997; EUTICK ML, 1978, J INSECT PHYSIOL, V24, P363, DOI 10.1016/0022-1910(78)90076-8; KANE MD, 1991, ARCH MICROBIOL, V156, P91, DOI 10.1007/BF00290979; KANE MD, 1991, ARCH MICROBIOL, V156, P99, DOI 10.1007/BF00290980; Kim KS, 1998, APPL ENVIRON MICROB, V64, P1919; Leadbetter JR, 1996, APPL ENVIRON MICROB, V62, P3620, DOI 10.1128/AEM.62.10.3620-3631.1996; LEIDY J, 1874, J ACAD NAT SCI-PHILA, V8, P425; LILBURN TG, UNPUB; MARGULIS L, 1992, HDB BIOL BACTERIA EC, V4, P3965; Mikx FHM, 1997, ORAL MICROBIOL IMMUN, V12, P249, DOI 10.1111/j.1399-302X.1997.tb00387.x; Ochiai S, 1997, MICROBIOL IMMUNOL, V41, P445, DOI 10.1111/j.1348-0421.1997.tb01877.x; OCHIAI S, 1998, INT J SYST BACTERIOL, V48, P327; OHKUMA M, 1995, FEMS MICROBIOL LETT, V134, P45, DOI 10.1111/j.1574-6968.1995.tb07912.x; Ohkuma M, 1998, FEMS MICROBIOL LETT, V164, P389, DOI 10.1111/j.1574-6968.1998.tb13114.x; Ohkuma M, 1996, APPL ENVIRON MICROB, V62, P461, DOI 10.1128/AEM.62.2.461-468.1996; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; Omerland, 1988, BIOL ANAEROBIC MICRO, P641; PASTER BJ, 1991, J BACTERIOL, V173, P6101, DOI 10.1128/JB.173.19.6101-6109.1991; Paster BJ, 1996, APPL ENVIRON MICROB, V62, P347, DOI 10.1128/AEM.62.2.347-352.1996; STACKEBRANDT E, 1994, INT J SYST BACTERIOL, V44, P846, DOI 10.1099/00207713-44-4-846; STRUNK O, 1997, ARB SOFTWARE PHYLOGE; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; WINTER JU, 1980, ARCH MICROBIOL, V124, P73, DOI 10.1007/BF00407031; Wyss C, 1996, INT J SYST BACTERIOL, V46, P745, DOI 10.1099/00207713-46-3-745	38	221	230	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					686	689		10.1126/science.283.5402.686	http://dx.doi.org/10.1126/science.283.5402.686			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924028				2022-12-01	WOS:000078324400042
J	Miller, V; Mocroft, A; Reiss, P; Katlama, C; Papadopoulos, AI; Katzenstein, T; van Lunzen, J; Antunes, F; Phillips, AN; Lundgren, JD				Miller, V; Mocroft, A; Reiss, P; Katlama, C; Papadopoulos, AI; Katzenstein, T; van Lunzen, J; Antunes, F; Phillips, AN; Lundgren, JD		EuroSIDA Study Grp	Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency; virus infections; disease progression; CD4 lymphocyte count; anti-HIV agents; acquired immunodeficiency syndrome	IMMUNODEFICIENCY-VIRUS INFECTION; CUBIC MILLIMETER; RITONAVIR; INHIBITOR; INDINAVIR; MORTALITY; PROTEASE; MARKERS; ADULTS; EUROPE	Background: The effect of previous CD4 cell count nadir on clinical progression in patients with increases in CD4 cell counts has not been investigated. Objective: To assess risk for progression of HIV disease in patients with CD4 counts of at least 200 cells/mm(3) (stratified by the lowest previous CD4 count) and compare the rate of progression in patients with CD4 counts less than 50 cells/ mm(3) with that in patients whose CD4 counts rebounded from less than 50 cells/mm(3) to at least 200 cells/mm(3) Design: Prospective, observational multicenter study, Setting: 52 HIV outpatient clinics in Europe. Patients: Two groups were identified: those with CD4 counts of at least 200 cells/mm(3) (group A) and those with CD4 counts less than 50 cells/mm(3) (group B). Group A was stratified according to the lowest previous CD4 count: at least 150 cells/mm(3) (stratum 1), 100 to 149 cells/mm(3) (stratum 2), 50 to 99 cells/mm(3) (stratum 3), and 1 to 50 cells/ mm(3) (stratum 4). Measurements: Patients were followed until a progression event occurred (first AIDS-defining event, new AIDS-defining event, or death) or until the CD4 count decreased to less than 200 cells/mm(3) (group A) or increased to more than 50 cells/mm(3) (group B). Incidence rates were based on a patient-years analysis and reported as events per 100 patient-years of follow-up; the relative hazards for progression were based on Cox proportional hazards models. Results: The overall rate of disease progression in group A was 3.9 per 100 patient-years (95% CI, 3.5 to 4.3 per 100 patient-years), whereas in group B it was much higher (72.9 per 100 patient-years [CI, 69.0 to 76.8 per 100 patient-years]). in group A, the rate increased in patients with previous low CD4 cell count nadirs, resulting in a significant increase in the relative hazard for progression. The relative hazards for strata 2, 3, and 4 were 2.29 (CI, 1.30 to 4.03), 3.65 (CI, 1.94 to 6.85), and 2.94 (CI, 1.44 to 6.00), respectively. Conclusions: Increases in CD4 counts from very low levels to at least 200 cells/mm(3) are associated with a much reduced rate of disease progression. However, a previously low CD4 cell count nadir remains associated with a moderately higher risk for disease progression among patients with CD4 counts of at least 200 cells/mm(3).	Goethe Univ Frankfurt, Zentrum Inneren Med, Infekt Ambulanz Haus 68, D-60590 Frankfurt, Germany; Univ Hamburg, Hosp Eppendorf, Zentrum Inneren Med, Infekt Ambulanz, D-20246 Hamburg, Germany; UCL Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, London NW3 2PF, England; Univ Amsterdam, Acad Med Ctr, NATEC, NL-1105 AZ Amsterdam, Netherlands; Hop La Pitie Salpetriere, Dept Trop Med, F-75013 Paris, France; 1st IKA Hosp Penteli, Athens 15127, Greece; 7721 Rigshosp, Dept Infect Dis, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark; Hosp Santa Maria, Dept Infect Dis, P-1600 Lisbon, Portugal	Goethe University Frankfurt; University of Hamburg; University of London; University College London; UCL Medical School; University of Amsterdam; Academic Medical Center Amsterdam; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Copenhagen; Universidade de Lisboa; Hospital Santa Maria	Miller, V (corresponding author), Univ Frankfurt Klinikum, Zentrum Inneren Med, Infekt Ambulanz Haus 68, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	miller@em.uni-frankfurt.de	PAPADOPOULOS, ANTONIOS/AAD-7808-2019; Mocroft, Amanda/C-1527-2008; Phillips, Andrew N/B-4427-2008; Mocroft, Amanda/G-8748-2011; Lundgren, Jens/AAE-6876-2019	Phillips, Andrew N/0000-0003-2384-4807; Mocroft, Amanda/0000-0001-8316-1122; Antunes, Francisco/0000-0001-7932-1154; Katzenstein, Terese L/0000-0002-2233-500X; Lundgren, Jens/0000-0001-8901-7850; Johnson, Anne/0000-0003-1330-7100				*1997 USPHS IDSA, 1997, ANN INTERN MED, V127, P922; Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Sepkowitz KA, 1998, LANCET, V351, P228, DOI 10.1016/S0140-6736(05)78279-9	16	123	127	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	1999	130	7					570	577		10.7326/0003-4819-130-7-199904060-00005	http://dx.doi.org/10.7326/0003-4819-130-7-199904060-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183BG	10189326				2022-12-01	WOS:000079533300004
J	Soengas, MS; Alarcon, RM; Yoshida, H; Giaccia, AJ; Hakem, R; Mak, TW; Lowe, SW				Soengas, MS; Alarcon, RM; Yoshida, H; Giaccia, AJ; Hakem, R; Mak, TW; Lowe, SW			Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition	SCIENCE			English	Article							MYC-INDUCED APOPTOSIS; SUPPRESSOR GENES; P53; PROTEIN	The ability of p53 to promote apoptosis in response to mitogenic oncogenes appears to be critical for its tumor suppressor function, Caspase-9 and its cofactor Apaf-1 were found to be essential downstream components of p53 in Myc-induced apoptosis. Like p53 null cells, mouse embryo fibroblast cells deficient in Apaf-1 and caspase-9, and expressing c-Myc, were resistant to apoptotic stimuli that mimic conditions in developing tumors. Inactivation of Apaf-1 or caspase-9 substituted for p53 Loss in promoting the oncogenic transformation of Myc-expressing cells. These results imply a role for Apaf-1 and caspase-9 in controlling tumor development.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Stanford Univ, Med Ctr, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; Univ Toronto, Ontario Canc Inst, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada	Cold Spring Harbor Laboratory; Stanford University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Lowe, SW (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Hakem, Razqallah/0000-0001-5948-7931	NCI NIH HHS [CA64489, CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106, R01CA064489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHENG NC, 1995, ONCOGENE, V10, P291; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOMURO H, 1993, CANCER RES, V53, P5284; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALMERO I, 1998, NATURE, V92, P713; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG X, 1998, GENE DEV, V12, P1764; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN J, UNPUB; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	48	566	587	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	1999	284	5411					156	159		10.1126/science.284.5411.156	http://dx.doi.org/10.1126/science.284.5411.156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102818				2022-12-01	WOS:000079509000057
J	Sanders, LC; Matsumura, F; Bokoch, GM; de Lanerolle, P				Sanders, LC; Matsumura, F; Bokoch, GM; de Lanerolle, P			Inhibition of myosin light chain kinase by p21-activated kinase	SCIENCE			English	Article							SMOOTH-MUSCLE; CELL MOTILITY; FOCAL ADHESIONS; PROTEIN-KINASE; STRESS FIBERS; PHOSPHORYLATION; ACTIN; CONTRACTILITY; INCREASE; RHO	p21-activated kinases (PAKs) are implicated in the cytoskeletal changes induced by the Rho family of guanosine triphosphatases. Cytoskeletal dynamics are primarily modulated by interactions of actin and myosin II that are regulated by myosin light chain kinase (MLCK)-mediated phosphorylation of the regulatory myosin Light chain (MLC). p21-activated kinase 1 (PAK1) phosphorylates MLCK, resulting in decreased MLCK activity. MLCK activity and MLC phosphorylation were decreased, and cell spreading was inhibited in baby hamster kidney-21 and HeLa cells expressing constitutively active PAK1. These data indicate that MLCK is a target for PAKs and that PAKs may regulate cytoskeletal dynamics by decreasing MLCK activity and MLC phosphorylation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA	Scripps Research Institute; Scripps Research Institute; Rutgers State University New Brunswick; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.			Matsumura, Fumio/0000-0002-8204-153X				AMANO M, 1996, J BIOL CHEM, V271, P29246; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; DEBIASIO RL, 1988, J CELL BIOL, V107, P2631, DOI 10.1083/jcb.107.6.2631; DELANEROLLE P, 1984, SCIENCE, V223, P1415, DOI 10.1126/science.6322302; DELANEROLLE P, 1991, CIRC RES, V68, P457, DOI 10.1161/01.RES.68.2.457; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; DELANEROLLE P, UNPUB; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LUNDSTROM K, 1994, EUR J BIOCHEM, V224, P917, DOI 10.1111/j.1432-1033.1994.00917.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MATSUMURA F, UNPUB; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; SAITOH M, 1997, J BIOL CHEM, V262, P7801; SANDERS LM, UNPUB; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; WILSON AK, 1992, CANCER METAST REV, V11, P79, DOI 10.1007/BF00047605; WILSON AK, 1991, J CELL BIOL, V114, P277, DOI 10.1083/jcb.114.2.277; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129	31	490	497	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2083	2085		10.1126/science.283.5410.2083	http://dx.doi.org/10.1126/science.283.5410.2083			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10092231				2022-12-01	WOS:000079369800046
J	Kurts, C; Carbone, FR; Krummel, MF; Koch, KM; Miller, JFAP; Heath, WR				Kurts, C; Carbone, FR; Krummel, MF; Koch, KM; Miller, JFAP; Heath, WR			Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells	NATURE			English	Article							HODGKINS-DISEASE; ANTIGENS; SELECTION; INDUCTION; DELETION; DEATH; MICE	Autoantigens found on pancreatic islets can move to draining lymph nodes, where they are able to cause the activation and consequent deletion of autoreactive T cells by a mechanism termed cross-tolerance(1,2), This deletion depends on signalling through CD95 (also known as Fas), a member of the superfamily of tumour-necrosis-factor receptors(3). Here we describe a new mechanism that protects against autoimmunity: this mechanism involves another member of this superfamily, CD30, whose function was largely unknown. CD30-deficient islet-specific CD8-positive T cells are roughly 6,000-fold more autoaggressive than wild-type cells, with the transfer of as few as 160 CD30-deficient T cells leading to the complete destruction of pancreatic islets and the rapid onset of diabetes. We show that, in the absence of CD30 signalling, cells activated but not yet deleted by the CD95-dependent cross-tolerance mechanism gain the ability to proliferate extensively upon secondary encounter with antigen on parenchymal tissues, such as the pancreatic islets. Thus, CD30 signalling limits the proliferative potential of autoreactive CD8 effector T cells and protects the body against autoimmunity.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Parkville, Vic 3050, Australia; Monash Med Sch, Dept Pathol & Immunol, Prahran, Vic 3181, Australia; Med Hsch Hannover, Dept Nephrol, D-30625 Hannover, Germany	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Monash University; Hannover Medical School	Heath, WR (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Parkville, Vic 3050, Australia.	carbone@cobra.path.monash.edu.au; Heath@wehi.edu.au	Carbone, Francis/ABF-2141-2020	Heath, William/0000-0001-9670-259X				Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; BERTOLINO P, 1995, EUR J IMMUNOL, V25, P1932, DOI 10.1002/eji.1830250721; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BOWEN MA, 1993, J IMMUNOL, V151, P5896; Bowen MA, 1996, J IMMUNOL, V156, P442; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Gilfillan MC, 1998, J IMMUNOL, V160, P2180; Hamann D, 1996, J IMMUNOL, V156, P1387; Heath WR, 1998, J EXP MED, V187, P1549, DOI 10.1084/jem.187.10.1549; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Kurts C, 1998, J EXP MED, V188, P415, DOI 10.1084/jem.188.2.415; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; NIKOLICZUGIC J, 1990, EUR J IMMUNOL, V20, P2431, DOI 10.1002/eji.1830201111; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; Telford WG, 1997, CELL IMMUNOL, V182, P125, DOI 10.1006/cimm.1997.1228; VELLA AT, 1995, IMMUNITY, V2, P261, DOI 10.1016/1074-7613(95)90050-0	23	103	104	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	1999	398	6725					341	344		10.1038/18692	http://dx.doi.org/10.1038/18692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DF	10192335				2022-12-01	WOS:000079369600053
J	Kolmos, HJ				Kolmos, HJ			Should general practitioners perform diagnostic tests on patients before prescribing antibiotics? For	BRITISH MEDICAL JOURNAL			English	Article									Univ Copenhagen, Hvidovre Hosp, Dept Clin Microbiol, DK-2650 Hvidovre, Denmark	University of Copenhagen	Kolmos, HJ (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Clin Microbiol, DK-2650 Hvidovre, Denmark.			Little, Paul/0000-0003-3664-1873				Andersen J S, 1994, Ugeskr Laeger, V156, P6869; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; Kolmos H J, 1992, Ugeskr Laeger, V154, P2810; Munck A P, 1995, Ugeskr Laeger, V157, P2851; NOE-NYGAARD E, 1987, Ugeskrift for Laeger, V149, P2325; Wise R, 1998, BMJ-BRIT MED J, V317, P609, DOI 10.1136/bmj.317.7159.609	6	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1999	318	7186					799	800		10.1136/bmj.318.7186.799	http://dx.doi.org/10.1136/bmj.318.7186.799			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BX	10082712	Green Published			2022-12-01	WOS:000079421700037
J	Fimia, GM; De Cesare, D; Sassone-Corsi, P				Fimia, GM; De Cesare, D; Sassone-Corsi, P			CBP-independent activation of CREM and CREB by the LIM-only protein ACT	NATURE			English	Article							TRANSCRIPTION FACTOR CREB; CYCLIC-AMP; CAMP; GENE; SPERMATOGENESIS; PHOSPHORYLATION; ASSOCIATION; EXPRESSION; MULTIPLE; PROMOTER	Transcriptional activation by CREB and CREM requires phosphorylation of a serine residue within the activation domain (Ser 133 in CREB; Ser 117 in CREM) which as a result interacts with the coactivator CBP1,2. The activator CREM is highly expressed in male germ cells and is required for post-meiotic gene expression(2-4). Using a two-hybrid screen, we have isolated a testis-derived complementary DNA encoding a protein that we term ACT (for activator of CREM in testis), a LIM-only protein which specifically associates with CREM, ACT is expressed coordinately with CREM in a tissue- and developmentally regulated manner. It strongly stimulates CREM transcriptional activity in yeast and mammalian cells and contains an intrinsic activation function. As ACT bypasses the classical requirements for activation, namely phosphorylation of Ser 117 and interaction with CBP, it represents a new route for transcriptional activation by CREM and CREB. ACT may define a previously undiscovered class of tissue-specific coactivators whose function could be specific for distinct cellular differentiation programmes.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Sassone-Corsi, P (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Strasbourg, France.	paolosc@igbmc.u-strasbg.fr	Sassone-Corsi, Paolo/H-6182-2011; Fimia, Gian Maria/K-3232-2016	Fimia, Gian Maria/0000-0003-4438-3325				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Curtiss J, 1998, BIOESSAYS, V20, P58, DOI 10.1002/(SICI)1521-1878(199801)20:1&lt;58::AID-BIES9&gt;3.0.CO;2-O; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SassoneCorsi P, 1997, CELL, V88, P163, DOI 10.1016/S0092-8674(00)81834-6; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	29	191	204	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	1999	398	6723					165	169		10.1038/18237	http://dx.doi.org/10.1038/18237			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176DG	10086359				2022-12-01	WOS:000079135200048
J	Amaya-Farfan, J				Amaya-Farfan, J			Aflatoxin B-1-induced hepatic steatosis: role of carbonyl compounds and active diols on steatogenesis	LANCET			English	Article							SERUM-ALBUMIN ADDUCT; RATS; LIPOPROTEINS; BINDING; PLASMA; INVIVO	Aflatoxin B1 (AFB1) exerts a chronic carcinogenic and an acute toxic effect on animals. Whereas the mechanism for carcinogenicity is known, no mechanism has been proposed for the toxic action. Among the most prominent signs of aflatoxicosis in several species, including birds and mammals, are hypolipidaemia, hypocholesterolaemia, and hypocarotenaemia, associated with severe hepatic steatosis and weight loss. We suggest that these signs of acute imbalance of lipid metabolism can be the result of the chemical modification (blocking) of key lysyl residues on the LDL protein B-100 by the activated AFB1 molecule. Modified LDLs are not recognised by their specific receptors and thus are rejected by peripheral cells. Upon return to the liver, the modified particles bind to the sinusoidal lining cells. Lipid starvation of peripheral tissues takes place while fat accumulates in the liver. This abnormal state is maintained and reinforced by further modification of nascent apoproteins, which in turn become unable to receive a lipid load for as long as aflatoxin continues to be available in the liver.	State Univ Campinas, Dept Food Planning & Nutr, FEA, BR-13083970 Campinas, SP, Brazil	Universidade Estadual de Campinas	Amaya-Farfan, J (corresponding author), State Univ Campinas, Dept Food Planning & Nutr, FEA, CP 6121, BR-13083970 Campinas, SP, Brazil.							Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; DIRR HW, 1986, BIOCHIM BIOPHYS ACTA, V881, P383, DOI 10.1016/0304-4165(86)90030-9; HAMILTON PB, 1977, FED PROC, V36, P1899; MAHLEY RW, 1979, P NATL ACAD SCI USA, V76, P1746, DOI 10.1073/pnas.76.4.1746; MAINIGI KD, 1977, CANCER RES, V37, P4304; MILLER BL, 1985, POULTRY SCI, V64, P1637, DOI 10.3382/ps.0641637; NEWBERNE PM, 1979, CANCER RES, V39, P3986; OHarte FPM, 1996, PEPTIDES, V17, P1323, DOI 10.1016/S0196-9781(96)00231-8; SABBIONI G, 1990, CHEM-BIOL INTERACT, V75, P1, DOI 10.1016/0009-2797(90)90018-I; SABBIONI G, 1987, CARCINOGENESIS, V8, P819, DOI 10.1093/carcin/8.6.819; SHIREMAN RB, 1982, TOXICOL LETT, V14, P213, DOI 10.1016/0378-4274(82)90054-6; TAGGART P, 1986, P SOC EXP BIOL MED, V182, P68, DOI 10.3181/00379727-182-42310; VULOVIC D, 1992, ACTA VET-BEOGRAD, V42, P29; WEISENSBERG BI, 1985, ATHEROSCLEROSIS, V57, P87; WILD CP, 1990, CANCER RES, V50, P245	15	10	10	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 27	1999	353	9154					747	748		10.1016/S0140-6736(98)09261-7	http://dx.doi.org/10.1016/S0140-6736(98)09261-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DR	10073532				2022-12-01	WOS:000078966400046
J	Bachmaier, K; Neu, N; de la Maza, LM; Pal, S; Hessel, A; Penninger, JM				Bachmaier, K; Neu, N; de la Maza, LM; Pal, S; Hessel, A; Penninger, JM			Chlamydia infections and heart disease linked through antigenic mimicry	SCIENCE			English	Article							DEPENDENT DIABETES-MELLITUS; OUTER-MEMBRANE PROTEIN; TRACHOMATIS INFECTION; PNEUMONIAE INFECTION; AUTOIMMUNE-DISEASE; CORONARY-ARTERIES; MYOCARDIAL-INFARCTION; NUCLEOTIDE-SEQUENCE; MOLECULAR MIMICRY; TWAR	Chlamydia infections are epidemiologically Linked to human heart disease. A peptide from the murine heart muscle-specific a myosin heavy chain that has sequence homology to the 60-kilodalton cysteine-rich outer membrane proteins of Chlamydia pneumoniae, C. psittaci, and C. trachomatis was shown to induce autoimmune inflammatory heart disease in mice. Injection of the homologous Chlamydia peptides into mice also induced perivascular inflammation, fibrotic changes, and blood vessel occlusion in the heart, as well as triggering T and B cell reactivity to the homologous endogenous heart muscle-specific peptide. Chlamydia DNA functioned as an adjuvant in the triggering of peptide-induced inflammatory heart disease. Infection with C, trachomatis Led to the production of autoantibodies to heart muscle-specific epitopes, Thus, Chlamydia-mediated heart disease is induced by antigenic mimicry of a heart muscle-specific protein.	Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Innsbruck, Sch Med, Dept Pediat, A-6020 Innsbruck, Austria; Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Innsbruck; University of California System; University of California Irvine	Penninger, JM (corresponding author), Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada.	jpenning@amgen.com	Neu, Nikolaus/AAC-4056-2021; Penninger, Josef M/I-6860-2013; Bachmaier, Kurt/AHC-5491-2022; Bachmaier, Kurt/B-6331-2014	Penninger, Josef M/0000-0002-8194-3777; Bachmaier, Kurt/0000-0002-0299-2707; Bachmaier, Kurt/0000-0002-0299-2707				BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; Bachmaier K, 1997, CIRCULATION, V96, P585; Bachmaier K, 1996, J IMMUNOL, V157, P1752; BACHMAIER K, UNPUB; CAMPBELL LA, 1995, J INFECT DIS, V172, P585, DOI 10.1093/infdis/172.2.585; COLES AM, 1990, NUCLEIC ACIDS RES, V18, P6713, DOI 10.1093/nar/18.22.6713; COMANDUCCI M, 1990, PLASMID, V23, P149, DOI 10.1016/0147-619X(90)90034-A; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Darville T, 1998, Pediatr Rev, V19, P85, DOI 10.1542/pir.19-3-85; DELAMAZA LM, 1991, INFECT IMMUN, V59, P1196, DOI 10.1128/IAI.59.3.1196-1201.1991; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Diaz F, 1997, SCAND J INFECT DIS, V29, P93, DOI 10.3109/00365549709008673; DONERMEYER DL, 1995, J EXP MED, V182, P1291, DOI 10.1084/jem.182.5.1291; Fong IW, 1997, J CLIN MICROBIOL, V35, P48, DOI 10.1128/JCM.35.1.48-52.1997; Gaydos CA, 1996, INFECT IMMUN, V64, P1614, DOI 10.1128/IAI.64.5.1614-1620.1996; GRAYSTON JT, 1993, EUR HEART J, V14, P66; GRAYSTON JT, 1981, JAMA-J AM MED ASSOC, V246, P2823, DOI 10.1001/jama.246.24.2823; Gupta S, 1997, CIRCULATION, V96, P404; Halme S, 1997, EUR HEART J, V18, P1095; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Jackson LA, 1997, AM J PATHOL, V150, P1785; Janeway CA, 1998, IMMUNITY, V8, P391, DOI 10.1016/S1074-7613(00)80544-0; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; Libby P, 1997, CIRCULATION, V96, P4095; Maass M, 1997, ANGIOLOGY, V48, P699, DOI 10.1177/000331979704800805; Maass M, 1998, J AM COLL CARDIOL, V31, P827, DOI 10.1016/S0735-1097(98)00016-3; Maclaren NK, 1997, MOL MED TODAY, V3, P76, DOI 10.1016/S1357-4310(96)10056-3; Matsusaka T, 1996, J CLIN INVEST, V98, P1867, DOI 10.1172/JCI118988; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Miettinen H, 1996, EUR HEART J, V17, P682; Moazed TC, 1996, AM J PATHOL, V148, P667; Moazed TC, 1997, J INFECT DIS, V175, P883, DOI 10.1086/513986; Muhlestein JB, 1998, CIRCULATION, V97, P633, DOI 10.1161/01.CIR.97.7.633; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; Munoz B, 1997, EPIDEMIOL REV, V19, P205, DOI 10.1093/oxfordjournals.epirev.a017953; NEU N, 1987, J IMMUNOL, V139, P3630; ODEH M, 1991, J INTERN MED, V229, P289, DOI 10.1111/j.1365-2796.1991.tb00347.x; Ohashi PS, 1996, CURR OPIN IMMUNOL, V8, P808, DOI 10.1016/S0952-7915(96)80009-4; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; Ossewaarde JM, 1998, EPIDEMIOL INFECT, V120, P93, DOI 10.1017/S0950268897008303; Pal S, 1997, INFECT IMMUN, V65, P3361, DOI 10.1128/IAI.65.8.3361-3369.1997; Pummerer CL, 1996, LAB INVEST, V74, P845; Pummerer CL, 1996, J CLIN INVEST, V97, P2057, DOI 10.1172/JCI118642; Quinn TC, 1996, JAMA-J AM MED ASSOC, V276, P1737, DOI 10.1001/jama.276.21.1737; Ramirez JA, 1996, ANN INTERN MED, V125, P979, DOI 10.7326/0003-4819-125-12-199612150-00008; Ridker PM, 1998, CIRCULATION, V97, P1671, DOI 10.1161/01.CIR.97.17.1671; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SMITH SC, 1992, P NATL ACAD SCI USA, V89, P9131, DOI 10.1073/pnas.89.19.9131; Stiegler H, 1998, LANCET, V351, P143, DOI 10.1016/S0140-6736(05)78113-7; Stokes T, 1997, J PUBLIC HEALTH MED, V19, P222, DOI 10.1093/oxfordjournals.pubmed.a024614; TONG CYW, 1995, LANCET, V346, P710, DOI 10.1016/S0140-6736(95)92327-6; vonHerrath MG, 1996, CURR OPIN IMMUNOL, V8, P878, DOI 10.1016/S0952-7915(96)80019-7; WATSON MW, 1994, MICROBIOL-SGM, V140, P2003, DOI 10.1099/13500872-140-8-2003; WATSON MW, 1990, NUCLEIC ACIDS RES, V18, P5299, DOI 10.1093/nar/18.17.5299; WATSON MW, 1990, NUCLEIC ACIDS RES, V18, P5300, DOI 10.1093/nar/18.17.5300; WESSLEN L, 1992, LANCET, V340, P427, DOI 10.1016/0140-6736(92)91509-7; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; ZABRISKIE JB, 1983, ADV EXP MED BIOL, V161, P457; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	61	322	353	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1999	283	5406					1335	1339		10.1126/science.283.5406.1335	http://dx.doi.org/10.1126/science.283.5406.1335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037605				2022-12-01	WOS:000078839900044
J	Bernstein, MP; Sandford, SA; Allamandola, LJ; Gillette, JS; Clemett, SJ; Zare, RN				Bernstein, MP; Sandford, SA; Allamandola, LJ; Gillette, JS; Clemett, SJ; Zare, RN			UV irradiation of polycyclic aromatic hydrocarbons in ices: Production of alcohols, quinones, and ethers	SCIENCE			English	Article							INTERPLANETARY DUST PARTICLES; INFRARED-SPECTROSCOPY; ABSORPTION FEATURES; MICRON SPECTRA; DENSE CLOUDS; INTERSTELLAR; MOLECULES; METEORITES; ANALOGS	Polycyclic aromatic hydrocarbons (PAHs) in water ice were exposed to ultraviolet (UV) radiation under astrophysical conditions, and the products were analyzed by infrared spectroscopy and mass spectrometry. Peripheral carbon atoms were oxidized, producing aromatic alcohols, ketones; and ethers, and reduced, producing partially hydrogenated aromatic hydrocarbons, molecules that account for the interstellar 3.4-micrometer emission feature. These classes of compounds are all present in carbonaceous meteorites. Hydrogen and deuterium atoms exchange readily between the PAHs and the ice, which may explain the deuterium enrichments found in certain meteoritic molecules. This work has important implications for extraterrestrial organics in biogenesis.	NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; SETI Inst, Mountain View, CA 94043 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Stanford University	Bernstein, MP (corresponding author), NASA, Ames Res Ctr, Mail Stop 245-6, Moffett Field, CA 94035 USA.	mbernstein@mail.arc.nasa.gov	Zare, Richard N./A-8410-2009	Zare, Richard/0000-0001-5266-4253				ALLAMANDOLA LJ, 1987, SCIENCE, V237, P56, DOI 10.1126/science.237.4810.56; ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1998, ASTRON ASTROPHYS, V339, P194; ALLAMANDOLA LJ, 1997, IAU C, V161, P23; Bernstein MP, 1996, ASTROPHYS J, V472, pL127, DOI 10.1086/310376; BERNSTEIN MP, 1995, ASTROPHYS J, V454, P327, DOI 10.1086/176485; Brooke TY, 1996, ASTROPHYS J, V459, P209, DOI 10.1086/176883; BROOKE TY, IN PRESS ASTROPHYS J; Clemett SJ, 1997, IAU SYMP, P305, DOI 10.1017/S0074180900009451; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; CRONIN JR, 1993, GEOCHIM COSMOCHIM AC, V57, P4745, DOI 10.1016/0016-7037(93)90197-5; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; DALGARNO A, 1984, ASTROPHYS J, V287, pL47, DOI 10.1086/184395; Deamer DW, 1997, MICROBIOL MOL BIOL R, V61, P239, DOI 10.1128/.61.2.239-261.1997; Gerakines PA, 1996, ASTRON ASTROPHYS, V312, P289; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; HUDGINS DM, 1995, J PHYS CHEM-US, V99, P3033, DOI 10.1021/j100010a011; Irvine WM, 1998, ORIGINS LIFE EVOL B, V28, P365, DOI 10.1023/A:1006574110907; KERRIDGE JF, 1987, GEOCHIM COSMOCHIM AC, V51, P2527, DOI 10.1016/0016-7037(87)90303-6; McDonald GD, 1996, ICARUS, V122, P107, DOI 10.1006/icar.1996.0112; MCKEEGAN KD, 1985, GEOCHIM COSMOCHIM AC, V49, P1971, DOI 10.1016/0016-7037(85)90091-2; MENDOZAGOMEZ CX, 1995, ASTRON ASTROPHYS, V295, P479; MESSENGER S, 1995, METEORITICS, V30, P546; MESSENGER S, 1996, LPS, V27, P867; MOORE MH, 1983, ICARUS, V54, P388, DOI 10.1016/0019-1035(83)90236-1; MOREELS G, 1994, ASTRON ASTROPHYS, V282, P643; PRASAD SS, 1983, ASTROPHYS J, V267, P603, DOI 10.1086/160896; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; Sandford SA, 1996, METEORIT PLANET SCI, V31, P449, DOI 10.1111/j.1945-5100.1996.tb02088.x; SANDFORD SA, 1993, ASTROPHYS J, V417, P815, DOI 10.1086/173362; SELLGREN K, 1995, ASTROPHYS J, V449, pL69, DOI 10.1086/309627; Sloan GC, 1997, ASTROPHYS J, V474, P735, DOI 10.1086/303484; STERNBERG A, 1987, ASTROPHYS J, V320, P676, DOI 10.1086/165585; STRAZZULLA G, 1995, PLANET SPACE SCI, V43, P1247, DOI 10.1016/0032-0633(95)00040-C; TEGLER SC, 1993, ASTROPHYS J, V411, P260, DOI 10.1086/172825; TIELENS AGGM, 1983, ASTRON ASTROPHYS, V119, P177; TIELENS AGGM, 1984, ASTROPHYS J, V287, P697, DOI 10.1086/162728; TIELENS AGGM, 1992, IAU SYMP, V150, P91; WARNECK P, 1962, APPL OPTICS, V1, P721, DOI 10.1364/AO.1.000721; Wexler AS., 1967, APPL SPECTROSC REV, V1, P29, DOI [DOI 10.1080/05704926708547581, 10.1080/05704926708547581]; WHITTET DCB, 1988, MON NOT R ASTRON SOC, V233, P321, DOI 10.1093/mnras/233.2.321	41	319	325	4	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1135	1138		10.1126/science.283.5405.1135	http://dx.doi.org/10.1126/science.283.5405.1135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024233				2022-12-01	WOS:000078738400042
J	Jenny, C; Hymel, KP; Ritzen, A; Reinert, SE; Hay, TC				Jenny, C; Hymel, KP; Ritzen, A; Reinert, SE; Hay, TC			Analysis of missed cases of abusive head trauma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHAKEN BABY SYNDROME; CHILD-ABUSE; SHAKING; INJURY	Context Abusive head trauma (AHT) is a dangerous form of child abuse that can be difficult to diagnose in young children. Objectives To determine how frequently AHT was previously missed by physicians in a group of abused children with head injuries and to determine factors associated with the unrecognized diagnosis. Design Retrospective chart review of cases of head trauma presenting between January 1, 1990, and December 31, 1995. Setting Academic children's hospital. Patients One hundred seventy-three children younger than 3 years with head injuries caused by abuse. Main Outcome Measures Characteristics of head-injured children in whom diagnosis of AHT was unrecognized and the consequences of the missed diagnoses. Results Fifty-four (31.2%) of 173 abused children with head injuries had been seen by physicians after AHT and the diagnosis was not recognized. The mean time to correct diagnosis among these children was 7 days (range, 0-189 days). Abusive head trauma was more likely to be unrecognized in very young white children from intact families and in children without respiratory compromise or seizures. In 7 of the children with unrecognized AHT, misinterpretation of radiological studies contributed to the delay in diagnosis. Fifteen children (27.8%) were reinjured after the missed diagnosis. Twenty-two (40.7%) experienced medical complications related to the missed diagnosis. Four of 5 deaths in the group with unrecognized AHT might have been prevented by earlier recognition of abuse. Conclusion Although diagnosing head trauma can be difficult in the absence of a history, it is important to consider inflicted head trauma in infants and young children presenting with nonspecific clinical signs.	Brown Univ, Sch Med, Dept Pediat, Providence, RI 02912 USA; Lifespan Med Comp, Providence, RI USA; Natl Naval Med Ctr, Dept Pediat, Bethesda, MD USA; Univ Oregon, Hlth Sci Ctr, Dept Pediat, Portland, OR USA; Univ Colorado, Sch Med, Dept Radiol, Denver, CO USA	Brown University; Walter Reed National Military Medical Center; University of Oregon; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jenny, C (corresponding author), Hasbo Childrens Hosp, MOC-140,593 Eddy St, Providence, RI 02903 USA.			Hymel, Kent/0000-0002-1422-182X				ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; BENZEL EC, 1989, SOUTHERN MED J, V82, P1347, DOI 10.1097/00007611-198911000-00005; Bureau of the Census, 1991, 1990 CENS POP HOUS S; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DIAMOND P, 1994, PEDIATR EMERG CARE, V10, P83, DOI 10.1097/00006565-199404000-00005; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; JACKSON G, 1972, BRIT MED J, V2, P756, DOI 10.1136/bmj.2.5816.756; KORTBEEK LHTS, 1979, CLIN NEUROL NEUROSUR, V81, P265, DOI 10.1016/0303-8467(79)90031-3; Levitt CJ, 1994, CHILD ABUSE MED DIAG, P1; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; RESURRECCION EC, 1972, ANGIOLOGY, V23, P105, DOI 10.1177/000331977202300206; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; SMITH WL, 1992, PEDIATRICS, V89, P332; SPEAR RM, 1992, AM J DIS CHILD, V146, P1415, DOI 10.1001/archpedi.1992.02160240025007; STARLING SP, 1995, PEDIATRICS, V95, P259; WEDGEWOOD J, 1990, PRACTITIONER, V234, P598	22	704	708	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					621	626		10.1001/jama.281.7.621	http://dx.doi.org/10.1001/jama.281.7.621			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029123	Bronze			2022-12-01	WOS:000078548400032
J	Fanto, M; Mlodzik, M				Fanto, M; Mlodzik, M			Asymmetric Notch activation specifies photoreceptors R3 and R4 and planar polarity in the Drosophila eye	NATURE			English	Article							CELL FATES; TISSUE POLARITY; EXPRESSION; GENE; RECEPTOR; COMPLEX; MEMBER	Planar polarity is seen in epidermally derived structures throughout the animal kingdom(1,2). In the Drosophila eye, planar polarity is reflected in the mirror-symmetric arrangement of ommatidia (eye units) across the dorsoventral midline or equator; ommatidia on the dorsal and ventral sides of the equator exhibit opposite chirality(3-5). Photoreceptors R3 and R4 are essential in the establishment of the polarity of ommatidia(6-11). The R3 cell is thought to receive the polarizing signal, through the receptor Frizzled (Fz), before or at higher levels then the R4 cell, generating a difference between neighbouring R3 and R4 cells(6,7,9,10). Both loss-of-function and overexpression of Fz in the R3/R4 pair result in polarity defects and loss of mirror-image symmetry(6,7,9,10,12). Here we identify Notch and Delta (Dl) as dominant enhancers of the phenotypes produced by overexpression of fz and dishevelled (dsh), which encodes a signalling component downstream of Fz, and we show that Dl-mediated activation of Notch is required for establishment of ommatidial polarity. Whereas fz signalling is required to specify R3, Notch signalling induces the R4 fate. Our data indicate that Dl is a transcriptional target of Fz/Dsh signalling in R3, and activates Notch in the neighbouring R4 precursor. This two-tiered mechanism explains how small differences in the level and/or timing of Fz activation reliably generate a binary cell-fate decision, leading to specification of R3 and R4 and ommatidial chirality.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mlodzik, M (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Fanto, Manolis/C-5618-2009					ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Baker NE, 1996, CURR BIOL, V6, P1290, DOI 10.1016/S0960-9822(02)70715-X; BAKER NE, 1995, MECH DEVELOP, V49, P173, DOI 10.1016/0925-4773(94)00314-D; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; Chen CWJ, 1997, DEV BIOL, V188, P181, DOI 10.1006/dbio.1997.8643; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; Fanto M, 1998, MECH DEVELOP, V74, P51, DOI 10.1016/S0925-4773(98)00063-X; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GUBB D, 1993, DEVELOPMENT, P269; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; PARKS AL, 1995, MECH DEVELOP, V50, P201, DOI 10.1016/0925-4773(94)00336-L; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wolff Tanya, 1993, P1277; ZHENG L, 1995, DEVELOPMENT, V121, P3045	29	170	170	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					523	526		10.1038/17389	http://dx.doi.org/10.1038/17389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028968				2022-12-01	WOS:000078574900050
J	Mayers, D				Mayers, D			Maintenance antiretroviral treatment in HIV infection - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ZIDOVUDINE		Henry Ford Hosp, Div Infect Dis, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Mayers, D (corresponding author), Henry Ford Hosp, Div Infect Dis, Detroit, MI 48202 USA.							Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hall DB, 1998, AIDS, V12, pF41, DOI 10.1097/00002030-199807000-00001; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; HAVLIR DV, 1998, 2 INT WORKSH HIV DRU; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MCLEAN AR, 1998, 2 INT WORKSH HIV DRU; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					497	498		10.1001/jama.281.6.497	http://dx.doi.org/10.1001/jama.281.6.497			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022089				2022-12-01	WOS:000078452900003
J	Hinchcliffe, EH; Li, C; Thompson, EA; Maller, JL; Sluder, G				Hinchcliffe, EH; Li, C; Thompson, EA; Maller, JL; Sluder, G			Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts	SCIENCE			English	Article							CELL-FREE-EXTRACTS; SEA-URCHIN EGGS; SPINDLE POLES; DNA-SYNTHESIS; CYCLE; NUCLEAR; REPLICATION; DIVISION	The abnormally high number of centrosomes found in many human tumor cells can lead directly to aneuploidy and genomic instability through the formation of multipolar mitotic spindles. To facilitate investigation of the mechanisms that control centrosome reproduction, a frog egg extract arrested in S phase of the cell cycle that supported repeated assembly of daughter centrosomes was developed, Multiple rounds of centrosome reproduction were blocked by selective inactivation of cyclin-dependent kinase 2-cyclin E (Cdk2-E) and were restored by addition of purified Cdk2-E. Confocal immunomicroscopy revealed that cyclin E was Localized at the centrosome. These results demonstrate that Cdk2-E activity is required for centrosome duplication during S phase and suggest a mechanism that could coordinate centrosome reproduction with cycles of DNA synthesis and mitosis.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sluder, G (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA.	Greenfield.Sluder@ummed.edu						BAILLY E, 1992, J CELL SCI, V101, P529; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hartley RS, 1997, DEV BIOL, V188, P312, DOI 10.1006/dbio.1997.8647; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hinchcliffe EH, 1998, J CELL BIOL, V140, P1417, DOI 10.1083/jcb.140.6.1417; HINCHCLIFFE EH, UNPUB; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; LACEY KR, IN PRESS P NATL ACAD; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MAZIA D, 1984, EXP CELL RES, V153, P1, DOI 10.1016/0014-4827(84)90442-7; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PALAZZO RE, 1992, SCIENCE, V256, P219, DOI 10.1126/science.1566068; REMPEL RE, 1995, J BIOL CHEM, V270, P6842; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1987, J EXP ZOOL, V244, P89, DOI 10.1002/jez.1402440111; SLUDER G, 1985, J CELL BIOL, V100, P887, DOI 10.1083/jcb.100.3.887; Sluder G, 1997, J CELL SCI, V110, P421; Strausfeld UP, 1996, J CELL SCI, V109, P1555; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; TOURNIER F, 1991, P NATL ACAD SCI USA, V88, P9929, DOI 10.1073/pnas.88.22.9929; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5	28	415	428	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					851	854		10.1126/science.283.5403.851	http://dx.doi.org/10.1126/science.283.5403.851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933170				2022-12-01	WOS:000078496800047
J	Kambach, C; Walke, S; Young, R; Avis, JM; de la Fortelle, E; Raker, VA; Luhrmann, R; Li, J; Nagai, K				Kambach, C; Walke, S; Young, R; Avis, JM; de la Fortelle, E; Raker, VA; Luhrmann, R; Li, J; Nagai, K			Crystal structures of two Sm protein complexes and their implications for the assembly of the spliceosomal snRNPs	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; YEAST TFIIA/TBP/DNA COMPLEX; ELECTRON-MICROSCOPY; CORE PROTEIN; U SNRNPS; IN-VITRO; RNA; BINDING; DOMAIN; CAP	The U1, U2, U4/U6, and U5 small nuclear ribonucleoprotein particles (snRNPs) involved in pre-mRNA splicing contain seven Sm proteins (B/B', D-1, D-2, D-3, E, F, and G) in common, which assemble around the Sm site present in four of the major spliceosomal small nuclear RNAs (snRNAs). These proteins share a common sequence motif in two segments, Sm1 and Sm2, separated by a short variable linker. Crystal structures of two Sm protein complexes, D3B and D1D2, show that these proteins have a common fold containing an N-terminal helix followed by a strongly bent five-stranded antiparallel beta sheet, and the D1D2 and D3B dimers superpose closely in their core regions, including the dimer interfaces. The crystal structures suggest that the seven Sm proteins could form a closed ring and the snRNAs may be bound in the positively charged central hole.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	MRC Laboratory Molecular Biology; Philipps University Marburg	Nagai, K (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	kn@mrc-imb.cam.ac.uk						Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Baserga S., 1993, RNA WORLD, P359; Bordonne R, 1996, GENE, V176, P111, DOI 10.1016/0378-1119(96)00230-2; Camasses A, 1998, MOL CELL BIOL, V18, P1956, DOI 10.1128/MCB.18.4.1956; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CECH TR, 1985, CELL, V43, P713; CHU JL, 1991, GENE, V97, P311; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FEENEY RJ, 1989, J BIOL CHEM, V264, P5776; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; FISHER DE, 1985, CELL, V42, P751, DOI 10.1016/0092-8674(85)90271-5; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; Fury MG, 1997, EXP CELL RES, V237, P63, DOI 10.1006/excr.1997.3750; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; Hartmuth K, 1999, J MOL BIOL, V285, P133, DOI 10.1006/jmbi.1998.2300; HEINRICHS V, 1992, J MOL BIOL, V227, P15, DOI 10.1016/0022-2836(92)90678-D; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; IKEMURA T, 1982, J MOL BIOL, V158, P573, DOI 10.1016/0022-2836(82)90250-9; JONES TA, 1994, MANUAL; KASTNER B, 1990, P NATL ACAD SCI USA, V87, P1710, DOI 10.1073/pnas.87.5.1710; KASTNER B, 1992, J CELL BIOL, V116, P839, DOI 10.1083/jcb.116.4.839; LEHMEIER T, 1994, P NATL ACAD SCI USA, V91, P12317, DOI 10.1073/pnas.91.25.12317; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Moore M., 1993, RNA WORLD, P303; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAGAI K, 1994, RNA PROTEIN INTERACT, P150; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Plessel G, 1997, J MOL BIOL, V265, P87, DOI 10.1006/jmbi.1996.0713; PLESSEL G, 1994, MOL CELL BIOL, V14, P4160, DOI 10.1128/MCB.14.6.4160; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VANDAM A, 1989, EMBO J, V8, P3853, DOI 10.1002/j.1460-2075.1989.tb08563.x; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9	57	371	385	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					375	387		10.1016/S0092-8674(00)80550-4	http://dx.doi.org/10.1016/S0092-8674(00)80550-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025403	Bronze			2022-12-01	WOS:000078514600010
J	Roth, WK; Weber, M; Seifried, E				Roth, WK; Weber, M; Seifried, E			Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ALANINE AMINOTRANSFERASE; UNITED-STATES; DONORS; INFECTION; RISK; REPLICATION	Background Despite sensitive antibody-based blood-donor screening, a residual risk of transfusion-transmitted viral infections exists. Only direct monitoring by sensitive nucleic-acid tests would provide data accurately to measure the risk and to assess risk-reduction procedures. We investigated the feasibility and efficacy of routine screening of donors for hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV-1 by PCR. Methods For PCR testing, individual donor plasma samples were pooled (96 x 100 mu L) overnight by two automatic pipetting machines. Viruses were concentrated by centrifugation and nucleic acids were extracted. HCV PCR was done on the Cobas Amplicor system (Hoffmann-La Roche, Mannheim, Germany). HBV and HIV-1 sequences were amplified by single (non-nested) in-house PCRs and detected by agarose-gel electrophoresis. Detection limits were 1000-5000 genome equivalents/mL. in the donor blood. Findings PCR testing was done in parallel to antibody screening with a maximum throughput of 3000 samples in 7-8 h. Positive samples were identified 1-2 days later. 111 of 373423 donations (107 of 4500 pools) were PCR and antibody/antigen-confirmed positive. We found one HCV POP-positive antibody-negative donation with normal alanine aminotransferase and one HCV PCR-positive donation with an elevated alanine aminotransferase (100 IU), which was negative in the AxSYM 2.0 and Matrix 1.0, but positive after control in the Abbott Prism test (Abbott GmbH, Wiesbaden, Germany). Interpretation PCR is a suitable and fast blood-donor screening procedure and contributes to a reduction in viral transmission by transfusion of blood components. In our selected donor population, the yield of detected contaminated donations from donors in the time window in which they are highly infectious but do not have any symptoms or detectable antigen and antibody concentrations (diagnostic window), confirms theoretical estimates.	Red Cross Blood Donor Serv, Inst Transfus Med & Immunohaematol, D-60528 Frankfurt, Germany		Seifried, E (corresponding author), Red Cross Blood Donor Serv, Inst Transfus Med & Immunohaematol, Sandhofstr 1, D-60528 Frankfurt, Germany.							Busch MP, 1995, TRANSFUSION, V35, P903, DOI 10.1046/j.1537-2995.1995.351196110893.x; Diekamp U, 1997, BEITR INFUS, V34, P5; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; Gluck D, 1997, INFUSIONSTHERAPIE, V24, P167; Herrera GA, 1997, TRANSFUSION, V37, P836, DOI 10.1046/j.1537-2995.1997.37897424407.x; Hewlett IK, 1997, TRANSFUSION, V37, P346, DOI 10.1046/j.1537-2995.1997.37397240219.x; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; LIVAK KJ, 1995, PCR METH APPL, V4, P357; *P EHRL I, 1998, BUNDESANZEIGER, V53, P3835; Prince AM, 1997, TRANSFUSION, V37, P211, DOI 10.1046/j.1537-2995.1997.37297203526.x; RUSTER B, 1995, ANAL BIOCHEM, V224, P597, DOI 10.1006/abio.1995.1092; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SHINDO M, 1992, J INFECT DIS, V166, P424, DOI 10.1093/infdis/166.2.424; Vrielink H, 1997, TRANSFUSION, V37, P845, DOI 10.1046/j.1537-2995.1997.37897424409.x; WHETSELL AJ, 1992, J CLIN MICROBIOL, V30, P845, DOI 10.1128/JCM.30.4.845-853.1992; YUKOSUKA O, 1993, DIAGNOSTIC MOL MICRO, P322; ZAYCSCHMIDT EM, 1997, INFUSIONSTHER TRANSF, V24, P195	18	215	233	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					359	363		10.1016/S0140-6736(98)06318-1	http://dx.doi.org/10.1016/S0140-6736(98)06318-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950441				2022-12-01	WOS:000078437000011
J	Wei, M; Gibbons, LW; Mitchell, TL; Kampert, JB; Lee, CD; Blair, SN				Wei, M; Gibbons, LW; Mitchell, TL; Kampert, JB; Lee, CD; Blair, SN			The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus, non-insulin-dependent; physical fitness; blood glucose; age factors; body mass index	ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; MEXICAN-AMERICANS; RISK-FACTORS; CARDIOVASCULAR-DISEASE; EXERCISE; NIDDM; WOMEN; HYPERGLYCEMIA; HYPERTENSION	Background: Several studies show an inverse association between, self-reported physical activity and type 2 diabetes. It is not known whether physical activity or cardiorespiratory fitness is associated with the onset of objectively determined impaired fasting glucose and type 2 diabetes. Objective: To determine whether cardiorespiratory fitness, an objective marker of physical activity, is associated with risk for impaired fasting glucose and type 2 diabetes. Design: Population-based prospective study. Setting: Preventive medicine clinic. Patients: 8633 nondiabetic men (of whom 7511 did not have impaired fasting glucose) who were examined at least twice. Measurements: Cardiorespiratory fitness (determined by a maximal exercise test on a treadmill), fasting plasma glucose level, and other clinical and personal characteristics and incidence of impaired tasting glucose and type 2 diabetes. Results: During an average follow-up of 6 years, 249 patients developed type 2 diabetes and 593 patients developed impaired fasting glucose. After age, cigarette smoking, alcohol consumption, and parental diabetes were considered, men in the low-fitness group (the least fit 20% of the cohort) at baseline had a 1.9-fold risk (95% CI, 1.5- to 2.4-fold) for impaired fasting glucose and a 3.7-fold risk (CI, 2.4- to 5.8-fold) for diabetes compared with those in the high-fitness group (the most fit 40% of the cohort). The risk for impaired fasting glucose was elevated in older men and those with a higher body mass index. Age, body mass index, blood pressure, triglyceride level, and a history of parental diabetes were also directly related to risk for type 2 diabetes. Conclusions: Low cardiorespiratory fitness was associated with increased risk for impaired fasting glucose and type 2 diabetes. A sedentary lifestyle may contribute to the progression from normal fasting glucose to impaired fasting glucose and diabetes. Risk for type 2 diabetes was elevated in older persons and those with higher body mass index, blood pressure, and triglyceride levels and a parental history of diabetes.	Cooper Inst Aerob Res, Dallas, TX 75230 USA; Cooper Clin, Dallas, TX 75230 USA	Cooper Institute; Cooper Institute	Wei, M (corresponding author), Cooper Inst Aerob Res, 12330 Preston Rd, Dallas, TX 75230 USA.	mwei@cooperinst.org			NATIONAL INSTITUTE ON AGING [R37AG006945, R01AG006945] Funding Source: NIH RePORTER; NIA NIH HHS [AG06945] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM COLL SPORTS ME, 1990, MED SCI SPORTS EXERC, V20, P265; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1984, JAMA-J AM MED ASSOC, V252, P487, DOI 10.1001/jama.252.4.487; BLAIR SN, 1989, AM J EPIDEMIOL, V129, P1145, DOI 10.1093/oxfordjournals.aje.a115236; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BOGARDUS C, 1984, DIABETES, V33, P311, DOI 10.2337/diabetes.33.4.311; Bouchard C., 1994, PHYS ACTIVITY FITNES, P106; BURCHFIEL CM, 1995, AM J EPIDEMIOL, V141, P360, DOI 10.1093/aje/141.4.360; CHARLES MA, 1991, DIABETES, V40, P796, DOI 10.2337/diabetes.40.7.796; Charles MA, 1996, LANCET, V348, P1657, DOI 10.1016/S0140-6736(05)65719-4; Eriksson KF, 1996, DIABETOLOGIA, V39, P573, DOI 10.1007/BF00403304; Gavin JR, 1997, DIABETES CARE, V20, P1183; Ghosh S, 1996, DIABETES, V45, P1, DOI 10.2337/diabetes.45.1.1; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Host HH, 1998, J APPL PHYSIOL, V84, P798, DOI 10.1152/jappl.1998.84.3.798; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; LAPORTE RE, 1995, DIABETES AM, P37; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LIPTON RB, 1993, AM J EPIDEMIOL, V138, P826, DOI 10.1093/oxfordjournals.aje.a116786; Lowe LP, 1997, DIABETES CARE, V20, P163, DOI 10.2337/diacare.20.2.163; Lynch J, 1996, ARCH INTERN MED, V156, P1307, DOI 10.1001/archinte.156.12.1307; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; McCance DR, 1997, DIABETOLOGIA, V40, P247, DOI 10.1007/s001250050671; MONTERROSA AE, 1995, DIABETES CARE, V18, P448, DOI 10.2337/diacare.18.4.448; Nyholm B, 1996, DIABETOLOGIA, V39, P813, DOI 10.1007/s001250050515; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PERRY IJ, 1995, BRIT MED J, V310, P560, DOI 10.1136/bmj.310.6979.560; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; *SAS I, 1996, SAS PROC GUID VERS 6; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Wei M, 1996, AM J EPIDEMIOL, V144, P1058, DOI 10.1093/oxfordjournals.aje.a008878; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167; Wei M, 1997, J CLIN EPIDEMIOL, V50, P1137, DOI 10.1016/S0895-4356(97)00150-9; Wei M, 1997, OBES RES, V5, P16, DOI 10.1002/j.1550-8528.1997.tb00278.x; WEI M, 1998, CVD PREV, V1, P123; WILSON JD, 1992, WILLIAMS TXB ENDOCRI, P1255; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801	45	299	307	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					89	+		10.7326/0003-4819-130-2-199901190-00002	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068380				2022-12-01	WOS:000078114200001
J	Wheeler, JG; Sethi, D; Cowden, JM; Wall, PG; Rodrigues, LC; Tompkins, DS; Hudson, MJ; Roderick, PJ				Wheeler, JG; Sethi, D; Cowden, JM; Wall, PG; Rodrigues, LC; Tompkins, DS; Hudson, MJ; Roderick, PJ		Infect Intestinal Dis Study Executive	Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To establish the incidence and aetiology of infectious intestinal disease in the community and presenting to general practitioners. Comparison with incidence and aetiology of cases reaching national laboratory based surveillance. Design Population based community cohort incidence study; general practice based incidence studies, and case linkage to national laboratory surveillance. Setting 70 general practices throughout England. Participants 459975 patients served by the practices. Community surveillance of 9776 randomly selected patients. Main outcome measures Incidence of infectious intestinal disease in community and reported to general practice. Results 781 cases were identified in the community cohort, giving an incidence of 19.4/100 person years (95% confidence interval 18.1 to 20.8). 8770 cases presented to general practice (3/3/100 person years (2.94 to 3.75)). One case was reported to national surveillance for every 1.4 laboratory identifications, 6.2 stools sent for laboratory investigation, 23 cases presenting to general practice, and 136 community cases. The ratio of cases in the community to cases reaching national surveillance was lower for bacterial pathogens (salmonella 3.2:1, campylobacter 7.6:1) than for viruses (rotavirus 35:1, small round structured viruses 1562:1). There were many cases for which no organism was identified. Conclusions Infectious intestinal disease occurs in 1 in 5 people each year, of whom 1 in 6 presents to a general practitioner. The proportion of cases not recorded by national laboratory surveillance is large and varies widely by microorganism. Ways of supplementing die national laboratory surveillance system for infectious intestinal diseases should be considered.	Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Ruchill Hosp, Scottish Ctr Infect & Environm Hlth, Glasgow G20 9NB, Lanark, Scotland; Food Safety Author Ireland, Dublin 1, Ireland; Leeds Publ Hlth Lab, Leeds LS15 7TR, W Yorkshire, England; Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England; Univ Southampton, Southampton SO6 6YD, Hants, England	University of London; London School of Hygiene & Tropical Medicine; University of Southampton	Wheeler, JG (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	j.wheeler@lshtm.ac.uk	RODRIGUES, LAURA CUNHA/AAO-4130-2021	Rodrigues, Laura Cunha/0000-0001-9008-660X				*COMM MICR SAF FOO, 1990, MICR SAF FOOD 1; Cowden J M, 1995, Commun Dis Rep CDR Rev, V5, pR109; Cowden J.M., 1997, Euro Surveill, V2, P1; Diggle P., 2002, ANAL LONGITUDINAL DA; Djuretic T, 1996, Commun Dis Rep CDR Rev, V6, pR78; Evans H S, 1998, Commun Dis Public Health, V1, P165; FELDMAN RA, 1994, EPIDEMIOL INFECT, V113, P41, DOI 10.1017/S095026880005144X; FLEMING DM, 1994, WEEKLY RETURNS SERVI; FRASER RC, 1981, J ROY COLL GEN PRACT, V31, P416; HODGES RG, 1956, AM J HYG, V64, P349, DOI 10.1093/oxfordjournals.aje.a119847; HOOGENBOOMVERDEGAAL AMM, 1994, EPIDEMIOL INFECT, V112, P481, DOI 10.1017/S0950268800051189; KENDALL EJC, 1982, J HYG-CAMBRIDGE, V88, P155, DOI 10.1017/S0022172400070030; MONTO AS, 1980, AM J EPIDEMIOL, V112, P323, DOI 10.1093/oxfordjournals.aje.a112998; Palmer S, 1996, EPIDEMIOL INFECT, V117, P479, DOI 10.1017/S0950268800059148; PAYMENT P, 1991, AM J PUBLIC HEALTH, V81, P703, DOI 10.2105/AJPH.81.6.703; SETHI D, 1998, INT J EPIDEMIOLOGY, V0028; SETHI D, IN PRESS COMM DIS PU; *STAT CORP, 1997, STAT STAT SOFTW REL; TOMPKINS DS, IN PRESS COMM DIS PU; TUCKMAN E, 1962, BRIT MED J, P135, DOI 10.1136/bmj.1.5272.135; Wall P G, 1996, Commun Dis Rep CDR Rev, V6, pR93	21	613	627	0	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1999	318	7190					1046	1050		10.1136/bmj.318.7190.1046	http://dx.doi.org/10.1136/bmj.318.7190.1046			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205103	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000080140000030
J	Sever, S; Muhlberg, AB; Schmid, SL				Sever, S; Muhlberg, AB; Schmid, SL			Impairment of dynamin's GAP domain stimulates receptor-mediated endocytosis	NATURE			English	Article							COATED VESICLE FORMATION; GTPASE-ACTIVATING PROTEINS; MX PROTEINS; GENE; DROSOPHILA; YEAST; MICROTUBULES; ASSEMBLES; SHIBIRE; FORMS	Dynamin is a GTP-hydrolysing protein that is an essential participant in clathrin-mediated endocytosis by cells. It self-assembles into 'collars' in vitro which also form in vivo at the necks of invaginated coated pits. This self-assembly stimulates dynamin's GTPase activity and it has been proposed that dynamin hydrolyses GTP in order to generate the force needed to sever vesicles from the plasma membrane. A mechanism is now described in which self-assembly of dynamin is coordinated by a domain of dynamin with a GTPase-activating function. Unexpectedly, when dynamin mutants defective in self-assembly-stimulated GTPase activity are overexpressed, receptor-mediated endocytosis is accelerated. The results indicate that dynamin, like other members of the GTPase superfamily, functions as a molecular regulator in receptor-mediated endocytosis, rather than as a force-generating GTPase.	Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schmid, SL (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Schmid, Sandra/0000-0002-1690-7024				AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; FERSHT A, 1995, ENZYME STRUCTURE MEC; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; GAMMIE AE, 1995, J CELL BIOL, V130, P553, DOI 10.1083/jcb.130.3.553; Gilbert A, 1997, J CELL SCI, V110, P3105; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Gu XJ, 1996, EMBO J, V15, P695, DOI 10.1002/j.1460-2075.1996.tb00405.x; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; MELEN K, 1992, J BIOL CHEM, V267, P25898; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1993, J BIOL CHEM, V268, P17240; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310	41	308	318	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 8	1999	398	6727					481	486		10.1038/19024	http://dx.doi.org/10.1038/19024			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206643				2022-12-01	WOS:000079662800039
J	Nightingale, SL				Nightingale, SL			Workshop on Medical Device Clinical Trial Development and Design	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1164	1164		10.1001/jama.281.13.1164	http://dx.doi.org/10.1001/jama.281.13.1164			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199413				2022-12-01	WOS:000079464400009
J	Wakasugi, K; Schimmel, P				Wakasugi, K; Schimmel, P			Two distinct cytokines released from a human aminoacyl-tRNA synthetase	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; ACTIVATING POLYPEPTIDE-II; GROWTH-STIMULATORY ACTIVITY; MULTISYNTHETASE COMPLEX; INTERLEUKIN-8 RECEPTORS; HUMAN NEUTROPHILS; PEPTIDE-III; CELL-LINE; IN-VITRO; PROTEIN	Aminoacyl-tRNA synthetases catalyze aminoacylation of transfer RNAs (tRNAs). It is shown that human tyrosyl-tRNA synthetase can be split into two fragments with distinct cytokine activities, The endothelial monocyte-activating polypeptide Ii-Like carboxy-terminal domain has potent leukocyte and monocyte chemotaxis activity and stimulates production of myeloperoxidase, tumor necrosis factor-alpha, and tissue factor. The catalytic amino-terminal domain binds to the interleukin-8 type A receptor and functions as an interleukin-8-like cytokine. Under apoptotic conditions in cell culture, the full-length enzyme is secreted, and the two cytokine activities can be generated by Leukocyte elastase, an extracellular protease. Secretion of this tRNA synthetase may contribute to apoptosis both by arresting translation and producing needed cytokines.	Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, 10555 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu	Wakasugi, Keisuke/AAQ-1642-2020	Wakasugi, Keisuke/0000-0002-8408-5616	NIGMS NIH HHS [GM23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agou F, 1997, EUR J BIOCHEM, V243, P259, DOI 10.1111/j.1432-1033.1997.0259a.x; AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BARKER DG, 1982, FEBS LETT, V150, P419, DOI 10.1016/0014-5793(82)80781-3; BECKER EL, 1977, ARCH PATHOL LAB MED, V101, P509; Bjornland K, 1998, INT J ONCOL, V12, P535; BRANDT E, 1991, CYTOKINE, V3, P311, DOI 10.1016/1043-4666(91)90499-4; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; DALY TJ, 1995, J BIOL CHEM, V270, P23282, DOI 10.1074/jbc.270.40.23282; dePouplana LR, 1996, P NATL ACAD SCI USA, V93, P166, DOI 10.1073/pnas.93.1.166; GHIBELLI L, 1994, FEBS LETT, V344, P35, DOI 10.1016/0014-5793(94)00287-8; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hoch RC, 1996, J LAB CLIN MED, V128, P134, DOI 10.1016/S0022-2143(96)90005-0; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; KORNELYUK AI, 1988, MOL BIOL+, V22, P149; LAZARD M, 1993, GENE, V132, P237, DOI 10.1016/0378-1119(93)90201-D; LEE J, 1992, J BIOL CHEM, V267, P16283; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; MENEGAZZI R, 1992, J LEUKOCYTE BIOL, V52, P619, DOI 10.1002/jlb.52.6.619; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, J BIOL CHEM, V268, P7125; PETERSEN F, 1994, J IMMUNOL, V152, P2467; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; Schraufstatter IU, 1998, BIOCHEM BIOPH RES CO, V244, P243, DOI 10.1006/bbrc.1998.8246; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Tas MPR, 1997, CYTOKINE, V9, P535, DOI 10.1006/cyto.1997.0198; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; WAKASUGI K, UNPUB; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WOLFSON AD, 1990, J CHROMATOGR, V503, P277, DOI 10.1016/S0021-9673(01)81511-9; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403	41	391	448	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1999	284	5411					147	151		10.1126/science.284.5411.147	http://dx.doi.org/10.1126/science.284.5411.147			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102815				2022-12-01	WOS:000079509000054
J	Larkum, ME; Zhu, JJ; Sakmann, B				Larkum, ME; Zhu, JJ; Sakmann, B			A new cellular mechanism for coupling inputs arriving at different cortical layers	NATURE			English	Article							ACTION-POTENTIALS; PYRAMIDAL NEURONS; DENDRITES; HIPPOCAMPUS; INHIBITION; CORTEX	Pyramidal neurons in layer 5 of the neocortex of the brain extend their axons and dendrites into all layers. They are also unusual in having both an axonal and a dendritic zone for the initiation of action potentials(1-6). Distal dendritic inputs, which normally appear greatly attenuated at the axon, must cross a high threshold at the dendritic initiation zone to evoke calcium action potentials(1,7) but can then generate bursts of axonal action potentials. Here we show that a single back-propagating sodium action potential generated in the axons(8) facilitates the initiation of these calcium action potentials when it coincides with distal dendritic input within a time window of several milliseconds. Inhibitory dendritic input can selectively block the initiation of dendritic calcium action potentials, preventing bursts of axonal action potentials. Thus, excitatory and inhibitory postsynaptic potentials arising in the distal dendrites can exert significantly greater control over action potential initiation in the axon than would be expected from their electrotonically isolated locations. The coincidence of a single back-propagating action potential with a subthreshold distal excitatory postsynaptic potential to evoke a burst of axonal action potentials represents a new mechanism by which the main cortical output neurons can associate inputs arriving at different cortical layers.	Max Planck Inst Med Forsch, Zellphysiol Abt, D-69120 Heidelberg, Germany	Max Planck Society	Larkum, ME (corresponding author), Max Planck Inst Med Forsch, Zellphysiol Abt, Jahnstr 29, D-69120 Heidelberg, Germany.			Larkum, Matthew/0000-0001-9799-2656				Buzsaki G, 1996, P NATL ACAD SCI USA, V93, P9921, DOI 10.1073/pnas.93.18.9921; CAULLER LJ, 1991, EXP BRAIN RES, V84, P607; Chen HM, 1997, J NEUROPHYSIOL, V78, P3484, DOI 10.1152/jn.1997.78.6.3484; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; DODT HU, 1993, ADV EXP MED BIOL, V333, P245; Heilman K. M, 1993, CLIN NEUROPSYCHOLOGY; HIRSCH JA, 1995, NATURE, V378, P612, DOI 10.1038/378612a0; Jones EG, 1999, CEREB CORTEX, V13, P139; KIM HG, 1993, J NEUROSCI, V13, P5301, DOI 10.1523/JNEUROSCI.13-12-05301.1993; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; Llinas R, 1994, TEMPORAL CODING BRAI, P251; Magee J, 1998, ANNU REV PHYSIOL, V60, P327, DOI 10.1146/annurev.physiol.60.1.327; MARKRAM H, 1995, J PHYSIOL-LONDON, V485, P1; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Schiller J, 1997, J PHYSIOL-LONDON, V505, P605, DOI 10.1111/j.1469-7793.1997.605ba.x; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; Zhu J. Julius, 1998, Society for Neuroscience Abstracts, V24, P1512; Zhu JJ, 1999, J NEUROPHYSIOL, V81, P1171, DOI 10.1152/jn.1999.81.3.1171; ZHU JJ, 1997, SOC NEUR ABSTR, V23, P2283	22	725	733	2	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 25	1999	398	6725					338	341		10.1038/18686	http://dx.doi.org/10.1038/18686			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DF	10192334				2022-12-01	WOS:000079369600052
J	Paus, T; Zijdenbos, A; Worsley, K; Collins, DL; Blumenthal, J; Giedd, JN; Rapoport, JL; Evans, AC				Paus, T; Zijdenbos, A; Worsley, K; Collins, DL; Blumenthal, J; Giedd, JN; Rapoport, JL; Evans, AC			Structural maturation of neural pathways in children and adolescents: In vivo study	SCIENCE			English	Article							HUMAN BRAIN-DEVELOPMENT; CENTRAL NERVOUS-SYSTEM; MAGNETIC STIMULATION; CORPUS-CALLOSUM; AUDITORY-CORTEX; MOTOR CORTEX; MYELINATION; ADULTHOOD; SPEECH; SCHIZOPHRENIA	Structural maturation of fiber tracts in the human brain, including an increase in the diameter and myelination of axons, may play a role in cognitive development during childhood and adolescence. A computational analysis of structural magnetic resonance images obtained in 111 children and adolescents revealed age-related increases in white matter density in fiber tracts constituting putative corticospinal and frontotemporal pathways. The maturation of the corticospinal tract was bilateral. whereas that of the frontotemporal pathway was found predominantly in the left (speech-dominant) hemisphere. These findings provide evidence for a gradual maturation, during late childhood and adolescence, of fiber pathways presumably supporting motor and speech functions.	McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; NIMH, Clin Psychiat Branch, Bethesda, MD 20892 USA	McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Paus, T (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	tomas@bic.mni.mcgill.ca	Giedd, Jay/J-9644-2015; Collins, D. Louis/ABD-7708-2021; Giedd, Jay N/B-7302-2012; Giedd, Jay N./A-3080-2008	Giedd, Jay/0000-0003-2002-8978; Collins, D. Louis/0000-0002-8432-7021; Giedd, Jay N/0000-0003-0827-3460; 				ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; Armand J., 1996, P125, DOI 10.1016/B978-012759440-8/50010-4; BENES FM, 1994, ARCH GEN PSYCHIAT, V51, P477; BENES FM, 1989, SCHIZOPHRENIA BULL, V15, P585, DOI 10.1093/schbul/15.4.585; BOLLER F, 1978, NEUROPSYCHOLOGIA, V16, P521, DOI 10.1016/0028-3932(78)90078-7; BRODY BA, 1987, J NEUROPATH EXP NEUR, V46, P283, DOI 10.1097/00005072-198705000-00005; Collins DL, 1995, HUM BRAIN MAPP, V3, P190, DOI 10.1002/hbm.460030304; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; CREUTZFELDT O, 1989, EXP BRAIN RES, V77, P476, DOI 10.1007/BF00249601; Evans A., 1998, NEUROIMAGE, V7S, P783; EYRE JA, 1991, J PHYSIOL-LONDON, V434, P441, DOI 10.1113/jphysiol.1991.sp018479; FORSSBERG H, 1991, EXP BRAIN RES, V85, P451; Giedd JN, 1996, CEREB CORTEX, V6, P551, DOI 10.1093/cercor/6.4.551; Giedd JN, 1996, DEV BRAIN RES, V91, P274; HALLGREN B, 1958, J NEUROCHEM, V3, P41, DOI 10.1111/j.1471-4159.1958.tb12607.x; HYDE TM, 1992, ARCH NEUROL-CHICAGO, V49, P401, DOI 10.1001/archneur.1992.00530280095028; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; LAWRENCE DG, 1976, BRAIN, V99, P235, DOI 10.1093/brain/99.2.235; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; MCDONALD WI, 1970, BRAIN, V93, P583, DOI 10.1093/brain/93.3.583; MOORE JK, 1997, ASS RES OTOLARYNGOLO, V20, P28; MULLER K, 1992, NEUROSCI LETT, V144, P57, DOI 10.1016/0304-3940(92)90715-J; MULLER K, 1991, ELECTROEN CLIN NEURO, V81, P63, DOI 10.1016/0168-5597(91)90105-7; MULLERPREUSS P, 1981, BRAIN RES, V215, P61, DOI 10.1016/0006-8993(81)90491-1; Nezu A, 1997, BRAIN DEV-JPN, V19, P176, DOI 10.1016/S0387-7604(96)00552-9; Olivier E, 1997, J NEUROSCI, V17, P267, DOI 10.1523/JNEUROSCI.17-01-00267.1997; OZKAN M, 1993, IEEE T MED IMAGING, V12, P534, DOI 10.1109/42.241881; Paus T, 1996, EUR J NEUROSCI, V8, P2236, DOI 10.1111/j.1460-9568.1996.tb01187.x; Penhune VB, 1996, CEREB CORTEX, V6, P661, DOI 10.1093/cercor/6.5.661; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; SCHALTENBRAND G, 1977, INTRO STEREOTAXIS AT; Sokal R., 1981, BIOMETRY; St-Jean P, 1998, IEEE T MED IMAGING, V17, P672, DOI 10.1109/42.736017; TALLAL P, 1993, ANN NY ACAD SCI, V682, P27, DOI 10.1111/j.1749-6632.1993.tb22957.x; Tournoux P., 1988, COPLANAR STEREOTACTI; Vargha-Khadem F, 1998, P NATL ACAD SCI USA, V95, P12695, DOI 10.1073/pnas.95.21.12695; VERHAART WJC, 1950, J COMP NEUROL, V92, P1, DOI 10.1002/cne.900920102; Vymazal J, 1996, MAGN RESON MED, V36, P61, DOI 10.1002/mrm.1910360111; Vymazal J, 1996, MAGN RESON MED, V35, P56, DOI 10.1002/mrm.1910350108; Wright IC, 1995, NEUROIMAGE, V2, P244, DOI 10.1006/nimg.1995.1032; Yakovlev P., 1967, REGIONAL DEV BRAIN E, P3; ZIJDENBOS AP, 1996, P 4 INT C VIS BIOM C, P439	45	952	964	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1999	283	5409					1908	1911		10.1126/science.283.5409.1908	http://dx.doi.org/10.1126/science.283.5409.1908			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10082463				2022-12-01	WOS:000079228600046
J	Burney, P				Burney, P			Air pollution and asthma: the dog that doesn't always bark	LANCET			English	Editorial Material							OUTBREAKS		Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England	University of London; King's College London	Burney, P (corresponding author), Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England.			Burney, Peter/0000-0001-8635-5678				ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622, DOI 10.2307/3433608; DEVALIA JL, 1998, EUR RESPIR REV, V8, P175; FRY J, 1953, LANCET, V264, P235; Neas LM, 1996, AM J EPIDEMIOL, V143, P797, DOI 10.1093/oxfordjournals.aje.a008818; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; ORDMAN D, 1955, INT ARCH ALLER A IMM, V7, P10, DOI 10.1159/000228201; Roemer W, 1998, EUR RESPIR REV, V8, P125; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; SANDSTROM T, 1998, EUR RESPIR REV, V8, P168; SORIANO JB, 1995, THORAX, V50, P1101, DOI 10.1136/thx.50.10.1101; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; USSETTI P, 1983, LANCET, V2, P280; WICHMANN HE, 1989, ENVIRON HEALTH PERSP, V79, P89, DOI 10.2307/3430534; WILLIAMS PB, 1995, J ALLERGY CLIN IMMUN, V95, P88, DOI 10.1016/S0091-6749(95)70156-7	15	11	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1999	353	9156					859	860		10.1016/S0140-6736(99)00002-1	http://dx.doi.org/10.1016/S0140-6736(99)00002-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BU	10093974				2022-12-01	WOS:000079421400004
J	Avides, MD; Glover, DM				Avides, MD; Glover, DM			Abnormal spindle protein, asp, and the integrity of mitotic centrosomal microtubule organizing centers	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; GAMMA-TUBULIN; SELF-ORGANIZATION; DROSOPHILA; NUCLEATION; MUTATIONS; MUTANT	The product of the abnormal spindle (asp) gene was found to be an asymmetrically Localized component of the centrosome during mitosis, required to focus the poles of the mitotic spindle in vivo. Removing Asp protein function from Drosophila melanogaster embryo extracts, either by mutation or immunodepletion, resulted in Loss of their ability to restore microtubule-organizing center activity to salt-stripped centrosome preparations. This was corrected by addition of purified Asp protein. Thus, Asp appears to hold together the microtubule-nucleating gamma-tubulin ring complexes that organize the mitotic centrosome.	Univ Dundee, Inst Med Sci, Canc Res Campaign, Cell Cycle Genet Lab, Dundee DD1 4HN, Scotland	University of Dundee	Glover, DM (corresponding author), Univ Dundee, Inst Med Sci, Canc Res Campaign, Cell Cycle Genet Lab, Dundee DD1 4HN, Scotland.	d.m.glover@dundee.ac.uk		Glover, David/0000-0003-0956-0103				BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; CASAL J, 1990, DEVELOPMENT, V108, P251; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; GONZALEZ C, 1990, J CELL SCI, V96, P605; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; MITCHISON TJ, 1986, METHOD ENZYMOL, V134, P261; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; RIPOLL P, 1985, CELL, V41, P907, DOI 10.1016/S0092-8674(85)80071-4; Saunders RDC, 1997, J CELL BIOL, V137, P881, DOI 10.1083/jcb.137.4.881; Schnackenberg BJ, 1998, P NATL ACAD SCI USA, V95, P9295, DOI 10.1073/pnas.95.16.9295; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; WhiteCooper H, 1996, GENETICS, V144, P1097, DOI 10.1534/genetics.112.1097.test; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	17	136	139	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	1999	283	5408					1733	1735		10.1126/science.283.5408.1733	http://dx.doi.org/10.1126/science.283.5408.1733			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175PF	10073938				2022-12-01	WOS:000079102800051
J	Meng, WY; Sawasdikosol, S; Burakoff, SJ; Eck, MJ				Meng, WY; Sawasdikosol, S; Burakoff, SJ; Eck, MJ			Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase	NATURE			English	Article							PROTOONCOGENE C-CBL; TYROSINE KINASE; EGF RECEPTOR; V-CBL; PROTEIN; RECOGNITION; ASSOCIATION; REGULATOR; PEPTIDE; PRODUCT	Cbl is an adaptor protein that functions as a negative regulator of many signalling pathways that start from receptors at the cell surface(1-4). The evolutionarily conserved amino-terminal region of Cbl (Cbl-N) binds to phosphorylated tyrosine residues and has cell-transforming activity. Point mutations in Cbl, that disrupt its recognition of phosphotyrosine also interfere with its negative regulatory function and, in the case of v-cbl, with its oncogenic potential(5). In T cells, Cbl-N binds to the tyrosine-phosphorylated inhibitory site of the protein tyrosine kinase ZAP-70(6). Here we describe the crystal structure of Cbl-N, both alone and in complex with a phosphopeptide that represents its binding site in ZAP-70. The structures show that Cbl-N is composed of three interacting domains: a four-helix bundle (4H), an EF-hand(7) calcium-binding domain, and a divergent SH2 domain(8) that was not recognizable from the amino-acid sequence of the protein. The calcium-hound EF hand wedges between the 4H and SH2 domains and roughly determines their relative orientation. In the ligand-occupied structure, the 4H domain packs against the SH2 domain and completes its phosphotyrosine-recognition pocket. Disruption of this binding to ZAP-70 as a result of structure-based mutations in the 4H, EF-hand and SH2 domains confirms that the three domains together form an integrated phosphoprotein-recognition module.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Eck, MJ (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	eck@red.dfci.harvard.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BLAKE TJ, 1991, ONCOGENE, V6, P653; Brunger AT, 1992, X PLOR VERSION 3 0 S; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kretsinger RH, 1997, NAT STRUCT BIOL, V4, P514, DOI 10.1038/nsb0797-514; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; NAVAZA J, 1992, AMORE NEW PACKAGE MO; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/0968-0004(96)10036-0; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	30	238	243	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	1999	398	6722					84	90		10.1038/18050	http://dx.doi.org/10.1038/18050			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174KG	10078535				2022-12-01	WOS:000079033900057
J	Rao, VK; Iademarco, EP; Fraser, VJ; Kollef, MH				Rao, VK; Iademarco, EP; Fraser, VJ; Kollef, MH			Delays in the suspicion and treatment of tuberculosis among hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; DIAGNOSIS; OUTBREAK; INFECTION; CARE; TRANSMISSION; MORTALITY; FAILURE; RISK	Background: Despite increased awareness of tuberculosis, delays in management are common. Objective: To investigate management delays among hospitalized patients with tuberculosis. Design: Retrospective cohort study. Setting: The Barnes-Jewish-Christian Health System, a network of eight community and tertiary-care facilities serving the St. Louis, Missouri, metropolitan area. Patients: All 203 patients with tuberculosis hospitalized in the Barnes-Jewish-Christian Health System from 1988 to 1996. Measurements: Time from admission to first consideration of the diagnosis (suspicion interval), first consideration and treatment initiation (treatment interval), and admission and treatment initiation (overall management interval) were determined. Delays were defined as intervals longer than 24 hours. Results: The overall management interval (median, 6 days [5th and 95th percentiles, 1 and 52 days]) exceeded 24 hours in 152 patients (74.9% [95% CI, 68.9% to 80.9%]). The suspicion interval (median, 1 day [5th and 95th percentiles, 0 and 16 days]) exceeded 24 hours in 54 patients (26.6% [CI, 20.5% to 32.7%]), and the treatment interval (median, 3 days [5th and 95th percentiles, 0 and 51 days]) was prolonged in 130 patients (64.0% [CI, 57.4% to 70.6%]). Overall management delays of more than 10 and 25 days occurred in 33.5% (CI, 27.0% to 40.0%) and 18.7% (CI, 13.3% to 24.1%) of patients, respectively. The 55 patients with smears that were positive for acid-fast bacilli had a median treatment interval of 3 days (5th and 95th percentiles, 0 and 33 days); in 58.2% of patients (CI, 45.2% to 71.2%), this interval exceeded 24 hours. Conclusions: Delays in initiation of treatment were more common than delays in the initial suspicion of tuberculosis. Both types of delays were common even in patients with disease that was confirmed by a positive smear. These data illustrate a need for improved education of physicians about the benefits of early initiation of therapy for tuberculosis.	Washington Univ, Sch Med, Div Pulm & Crit Care, St Louis, MO 63110 USA	Washington University (WUSTL)	Kollef, MH (corresponding author), Washington Univ, Sch Med, Div Pulm & Crit Care, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	mkollef@pulmonary.wustl.edu		Fraser, Victoria/0000-0001-6251-0733	PHS HHS [U50-CCU-710076-04] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Arno P S, 1993, J Law Med Ethics, V21, P317, DOI 10.1111/j.1748-720X.1993.tb01256.x; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Bock NN, 1996, AM J RESP CRIT CARE, V154, P1468, DOI 10.1164/ajrccm.154.5.8912766; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; BYRD RB, 1977, ANN INTERN MED, V86, P799, DOI 10.7326/0003-4819-86-6-799; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; COUNSELL SR, 1989, ARCH INTERN MED, V149, P1274, DOI 10.1001/archinte.149.6.1274; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; ENARSON DA, 1978, CAN MED ASSOC J, V118, P1520; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GORDIN FM, 1989, AM REV RESPIR DIS, V139, P1090, DOI 10.1164/ajrccm/139.5.1090; HEFFNER JE, 1988, ARCH INTERN MED, V148, P1103, DOI 10.1001/archinte.148.5.1103; Kellerman S, 1997, INFECT CONT HOSP EP, V18, P542; LEVY H, 1989, CHEST, V95, P1193, DOI 10.1378/chest.95.6.1193; Liam CK, 1997, INT J TUBERC LUNG D, V1, P326; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; MORAN GJ, 1995, ANN EMERG MED, V26, P290, DOI 10.1016/S0196-0644(95)70074-9; Murray PR., 1995, MANUAL CLIN MICROBIO; PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; *SAS I, 1990, SAS STAT US GUID, V2, P1071; Sumartojo EM, 1997, AM J PUBLIC HEALTH, V87, P2008, DOI 10.2105/AJPH.87.12.2008; Tacconelli E, 1997, INT J TUBERC LUNG D, V1, P582; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; *WHO, 1994, WHO PUBL, P170; 1996, AM J RESP CRIT CARE, V154, P251	36	65	68	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					404	+		10.7326/0003-4819-130-5-199903020-00004	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068414				2022-12-01	WOS:000078898100003
J	Epstein, DS; Lange, JR; Gruber, SB; Mofid, M; Koch, SE				Epstein, DS; Lange, JR; Gruber, SB; Mofid, M; Koch, SE			Is physician detection associated with thinner melanomas?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MALIGNANT-MELANOMA; PREVENTION; CANCER; SKIN	Context In cutaneous melanoma, tumor depth remains the best biologic predictor of patient survival. Detection of prognostically favorable lesions may be associated with improved survival in patients with melanoma. Objective To determine melanoma detection patterns and relate them to tumor thickness. Design interview survey, Setting and Patients All patients with newly detected primary cutaneous melanoma at the Melanoma Center, Johns Hopkins Medical Institutions, between June 1995 and June 1997. Main Outcome Measure Tumor thickness grouped according to detection source. Results Of the 102 patients (47 men, 55 women) in the study, the majority of melanomas were self-detected (55%), followed by detection by physician (24%), spouse (12%), and others (10%), Physicians were more likely to detect thinner lesions than were patients who detected their own melanomas (median thickness, 0.23 mm vs 0.9 mm; P < .001), When grouped according to thickness, 11 (46%) of 24 physician-detected melanomas were in situ, vs only 8 (14%) of 56 patient-detected melanomas. Physician detection was associated with an increase in the probability of detecting thinner (less than or equal to 0.75 mm) melanomas (relative risk, 4.2; 95% confidence interval, 1,4-11.1; P = .01), Conclusions Thinner melanomas are more likely to have been detected by physicians. Increased awareness by all physicians may result in greater detection of early melanomas.	Oregon Hlth Sci Univ, Dept Dermatol, Portland, OR 97201 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Univ Michigan, Dept Med & Mol Genet, Ann Arbor, MI USA	Oregon Health & Science University; Johns Hopkins University; Johns Hopkins University; University of Michigan System; University of Michigan	Koch, SE (corresponding author), Oregon Hlth Sci Univ, Dept Dermatol, Ll468,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							AUSTOKER J, 1994, BRIT MED J, V308, P1682, DOI 10.1136/bmj.308.6945.1682; BALCH CM, 1992, CUTANEOUS MELANOMA, P165; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; HERSEY P, 1991, MED J AUSTRALIA, V154, P583, DOI 10.5694/j.1326-5377.1991.tb121217.x; KOH HK, 1992, J AM ACAD DERMATOL, V26, P914, DOI 10.1016/0190-9622(92)70132-Y; Koh HK, 1996, ARCH DERMATOL, V132, P436, DOI 10.1001/archderm.132.4.436; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Liu TP, 1996, SURG CLIN N AM, V76, P1205, DOI 10.1016/S0039-6109(05)70511-9; Marks R, 1996, CA-CANCER J CLIN, V46, P199, DOI 10.3322/canjclin.46.4.199; Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190-9622(96)90041-9; Schuchter L, 1996, ANN INTERN MED, V125, P369, DOI 10.7326/0003-4819-125-5-199609010-00003	12	132	133	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					640	643		10.1001/jama.281.7.640	http://dx.doi.org/10.1001/jama.281.7.640			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029126	Bronze			2022-12-01	WOS:000078548400035
J	Plotkin, SA; Katz, M; Cordero, JF				Plotkin, SA; Katz, M; Cordero, JF			The eradication of rubella	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VACCINATION STRATEGY; SAO-PAULO; MEASLES; MUMPS; INFECTION; BRAZIL; RISK		Pasteur Merieux Connaught, Swiftwater, PA USA; Pasteur Merieux Connaught, Lyon, France; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; March Dimes Birth Defect Fdn, White Plains, NY USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA	University of Pennsylvania; Centers for Disease Control & Prevention - USA	Plotkin, SA (corresponding author), 4650 Wismer Rd, Doylestown, PA 18901 USA.	splotkin@us.pmc-vacc.com						ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Cooper L.Z., 1995, INFECT DIS FETUS NEW, P268; Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55; GALAZKA A, 1991, EPIDEMIOL INFECT, V107, P43, DOI 10.1017/S0950268800048664; HINMAN A, 1998, PAN AM J PUBLIC HLTH, V4, P156; JUDELSOHN RG, 1973, JAMA-J AM MED ASSOC, V223, P401, DOI 10.1001/jama.223.4.401; KHOURY MJ, 1989, PEDIATRICS, V84, P658; MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281; MASSAD E, 1995, INT J EPIDEMIOL, V24, P842, DOI 10.1093/ije/24.4.842; MillardStafford M, 1997, INT J SPORT NUTR, V7, P26, DOI 10.1123/ijsn.7.1.26; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; PERRY KR, 1993, J MED VIROL, V40, P235, DOI 10.1002/jmv.1890400312; PLOTKIN SA, 1969, AM J DIS CHILD, V118, P178, DOI 10.1001/archpedi.1969.02100040180004; PLOTKIN SA, 1999, RUBELLA VACCINES, P409; Ray P, 1997, JAMA-J AM MED ASSOC, V278, P551, DOI 10.1001/jama.278.7.551; SCHEIE HG, 1967, ARCH OPHTHALMOL-CHIC, V77, P440, DOI 10.1001/archopht.1967.00980020442005; Schluter WW, 1998, J INFECT DIS, V178, P636, DOI 10.1086/515384; SCHOUB BD, 1990, PEDIATR INFECT DIS J, V9, P263, DOI 10.1097/00006454-199004000-00008; *WHO, IN PRESS B WORLD HLT; WILLIAMS NM, 1983, MMWR-MORBID MORTAL W, V33, pS1; Yamamoto L, 1995, TROP GEOGR MED, V47, P235; ZgorniakNowosielska I, 1996, EUR J EPIDEMIOL, V12, P303, DOI 10.1007/BF00145421	23	17	20	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					561	562		10.1001/jama.281.6.561	http://dx.doi.org/10.1001/jama.281.6.561			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022114				2022-12-01	WOS:000078452900036
J	Kramer, U; Heinrich, J; Wjst, M; Wichmann, HE				Kramer, U; Heinrich, J; Wjst, M; Wichmann, HE			Age of entry to day nursery and allergy in later childhood	LANCET			English	Article							DAY-CARE ATTENDANCE; RESPIRATORY ILLNESS; INFECTIONS; ATOPY; CHILDREN; SENSITIZATION; PREVALENCE; INFANCY; DISEASE	Background Infections in early childhood may prevent allergies in later life. If this hypothesis is true, early exposure to childcare, outside the home would protect against atopy by promotion of cross infections. We investigated whether children who attend a nursery at a young age have a lower rate of atopy and fewer allergies than children who attend from an older age. Methods In a cross-sectional study carried out in 1992-93, we examined 2471 children in three age-groups (5-7, 8-10, and 11-14 years) from the towns of Bitterfeld, Hettstedt, and Zerbst in eastern Germany. The children's parents answered a questionnaire about allergies and symptoms, attendance at day care, and related factors. Sensitisation was assessed by shin-prick tests and measurement of allergen-specific IgE antibodies in serum. Findings In 669 children from small families (up to three people), the prevalance of atopy was higher among children who started to attend day nursery at an older age than in those who started to attend at a younger age (p < 0.05). Compared with children who first attended at age 6-11 months, the adjusted odds ratios for a positive skin-prick test were 1.99 (95% CI 1.08-3.66) for children who attended at age 12-23 months and 2.72 (1.37-5.40) for those who attended at age 24 months and older. In 1761 children from large families (more than three people), age of entry to day nursery had no effect on atopy. Interpretation Our findings accord with the hypothesis that early infection may protect against allergies in later life.	GSF, Res Ctr Environm & Hlth, Inst Epidemiol Neuherberg, D-85764 Oberschleissheim, Germany; Univ Dusseldorf, Med Inst Environm Hyg, D-4000 Dusseldorf, Germany; Univ Munich, Dept Epidemiol, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Heinrich Heine University Dusseldorf; University of Munich	Heinrich, J (corresponding author), GSF, Res Ctr Environm & Hlth, Inst Epidemiol Neuherberg, D-85764 Oberschleissheim, Germany.		Wichmann, Heinz Erich/AAA-5695-2022; Heinrich, Joachim/N-1720-2013; Annesi-Maesano, Isabella/D-9173-2016	Heinrich, Joachim/0000-0002-9620-1629; Annesi-Maesano, Isabella/0000-0002-6340-9300				Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; BACKMAN A, 1984, ALLERGY, V39, P309, DOI 10.1111/j.1398-9995.1984.tb00867.x; CAUGHY MO, 1994, CHILD DEV, V65, P457, DOI 10.1111/j.1467-8624.1994.tb00763.x; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Heinrich J, 1998, AM J PUBLIC HEALTH, V88, P1319, DOI 10.2105/AJPH.88.9.1319; HOLBERG CJ, 1993, PEDIATRICS, V91, P885; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; HURWITZ ES, 1991, PEDIATRICS, V87, P62; Kopjar B, 1996, PEDIATRICS, V97, P43; Marbury MC, 1997, AM J RESP CRIT CARE, V155, P156, DOI 10.1164/ajrccm.155.1.9001305; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; NIEBSCH G, 1989, HEILBERUFE, V41, P383; OSTERHOLM MT, 1994, PEDIATRICS, V94, P987; Passauer I, 1991, Padiatr Grenzgeb, V30, P311; PICKERING LK, 1992, SOZIALPADIATRIE, V14, P235; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; SCHWARTZ B, 1994, PEDIATRICS, V94, P1018; Shaheen S, 1997, BRIT MED J, V314, P987, DOI 10.1136/bmj.314.7086.987; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WALD ER, 1988, J PEDIATR-US, V112, P540, DOI 10.1016/S0022-3476(88)80164-1; Woolcock AJ, 1995, PROG ALLER CLIN IMM, V3, P167	26	332	340	0	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					450	454		10.1016/S0140-6736(98)06329-6	http://dx.doi.org/10.1016/S0140-6736(98)06329-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989715				2022-12-01	WOS:000078572800011
J	Jakob, U; Muse, W; Eser, M; Bardwell, JCA				Jakob, U; Muse, W; Eser, M; Bardwell, JCA			Chaperone activity with a redox switch	CELL			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; IN-VIVO; MOLECULAR CHAPERONES; DENATURED PROTEINS; OXIDATIVE STRESS; DISULFIDE BONDS; INDUCTION; DEGRADATION; CYTOPLASM	Hsp33, a member of a newly discovered heal shock protein family, was found to be a very potent molecular chaperone. Hsp33 is distinguished from all other known molecular chaperones by its mode of functional regulation. Its activity is redox regulated, Hsp33 is a cytoplasmically localized protein with highly reactive cysteines that respond quickly to changes in the redox environment. Oxidizing conditions like H2O2 cause disulfide bonds to form in Hsp33, a process that leads to the activation of its chaperone function. In vitro and in vivo experiments suggest that Hsp33 protects cells from oxidants, leading us to conclude that we have found a protein family that plays an important role in the bacterial defense system toward oxidative stress.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Jakob, U (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	ujakob@biology.lsa.umich.edu						BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BENOV L, 1995, J BACTERIOL, V177, P3344, DOI 10.1128/jb.177.11.3344-3346.1995; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CHUANG SE, 1993, J BACTERIOL, V175, P5242, DOI 10.1128/JB.175.16.5242-5252.1993; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P215, DOI 10.1016/0891-5849(88)90015-9; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUNT JB, 1984, J BIOL CHEM, V259, P4793; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Korber P, 1999, J BIOL CHEM, V274, P249, DOI 10.1074/jbc.274.1.249; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; McDuffee AT, 1997, J CELL PHYSIOL, V171, P143, DOI 10.1002/(SICI)1097-4652(199705)171:2<143::AID-JCP4>3.0.CO;2-O; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; Sherman M Y, 1996, EXS, V77, P57; Takemoto T, 1998, FREE RADICAL BIO MED, V24, P556, DOI 10.1016/S0891-5849(97)00287-6; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; Thorstenson YR, 1997, J BACTERIOL, V179, P5333, DOI 10.1128/jb.179.17.5333-5339.1997; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	39	422	431	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					341	352		10.1016/S0092-8674(00)80547-4	http://dx.doi.org/10.1016/S0092-8674(00)80547-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025400	Bronze			2022-12-01	WOS:000078514600007
J	Zheleznova, EE; Markham, PN; Neyfakh, AA; Brennan, RG				Zheleznova, EE; Markham, PN; Neyfakh, AA; Brennan, RG			Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter	CELL			English	Article							DNA-BINDING; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; ALPHA-HELIX; PROTEIN; EFFLUX; DOMAIN; RESISTANCE; REPRESSOR; REGULATOR	Multidrug-efflux transporters demonstrate an unusual ability to recognize multiple structurally dissimilar toxins. A comparable ability to bind diverse hydrophobic cationic drugs is characteristic of the Bacillus subtilis transcription regulator BmrR, which upon drug binding activates expression of the multidrug transporter Bmr. Crystal structures of the multidrug-binding domain of BmrR (2.7 Angstrom resolution) and of its complex with the drug tetraphenylphosphonium (2.8 Angstrom resolution) revealed a drug-induced unfolding and relocation of an alpha helix, which exposes an internal drug-binding pocket. Tetraphenylphosphonium binding is mediated by stacking and van der Waals contacts with multiple hydrophobic residues of the pocket and by an electrostatic interaction between the positively charged drug and a buried glutamate residue, which is the key to cation selectivity. Similar binding principles may be used by other multidrug-binding proteins.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA	Oregon Health & Science University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Brennan, RG (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	brennanr@ohsu.edu		Brennan, Richard/0000-0001-7647-485X; Heldwein, Ekaterina/0000-0003-3113-6958	NIGMS NIH HHS [GM49819, GM49244] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049244] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED M, 1994, J BIOL CHEM, V269, P28506; ANSARI AZ, 1995, NATURE, V374, P371; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Chen X, 1998, J MOL BIOL, V278, P641, DOI 10.1006/jmbi.1998.1734; Constantine KL, 1998, BIOCHEMISTRY-US, V37, P7965, DOI 10.1021/bi980203o; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Flomer WA, 1996, ACTA CRYSTALLOGR C, V52, P2445, DOI 10.1107/S0108270196005847; Flower DR, 1996, BIOCHEM J, V318, P1; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMES DJ, 1993, EMBO J, V12, P3183, DOI 10.1002/j.1460-2075.1993.tb05987.x; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LALONDE JM, 1994, FASEB J, V8, P1240, DOI 10.1096/fasebj.8.15.8001736; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; LOMOVSKAYA O, 1995, J BACTERIOL, V177, P2328, DOI 10.1128/jb.177.9.2328-2334.1995; Ma D, 1996, MOL MICROBIOL, V19, P101, DOI 10.1046/j.1365-2958.1996.357881.x; Markham PN, 1997, BIOCHEM BIOPH RES CO, V239, P269, DOI 10.1006/bbrc.1997.7467; MARKHAM PN, 1996, J BACTERIOL, V178, P473; NAGADOI A, 1995, STRUCTURE, V3, P1217, DOI 10.1016/S0969-2126(01)00257-X; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; Zheleznova EE, 1997, PROTEIN SCI, V6, P2465	48	162	169	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					353	362		10.1016/S0092-8674(00)80548-6	http://dx.doi.org/10.1016/S0092-8674(00)80548-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025401	Bronze			2022-12-01	WOS:000078514600008
J	Moshfegh, K; Wuillemin, WA; Redondo, M; Lammle, B; Beer, JH; Liechti-Gallati, S; Meyer, BJ				Moshfegh, K; Wuillemin, WA; Redondo, M; Lammle, B; Beer, JH; Liechti-Gallati, S; Meyer, BJ			Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study	LANCET			English	Article							CORONARY-THROMBOSIS; WHOLE-BLOOD; SMOKING; IIIA; NOREPINEPHRINE; AGGREGATION; PREVENTION; DISEASE; STROKE; GENE	Background The platelet membrane glycoprotein Ia/IIa plays a major part in platelet function as a primary receptor for collagen. A previous report showed a Variation of glycoprotein Ia/IIa receptor density and function associated with two silent and linked polymorphisms (807C/T and 873G/A) within the glycoprotein la gene; Because platelet thrombus formation is implicated in the pathogenesis of acute myocardial infarction, we investigated these polymorphisms among patients who had had a myocardial infarction. Methods We did a 2/1 case-control study including 177 patients (median age 57.0 [range 32-72] years) and 89 controls with same age and sex. Distributions of the 807C/T and 873G/A polymorphisms were investigated by genotyping DNA by PCR, single-strand conformation polymorphism analysis, and sequencing. Findings The prevalence of the homozygous 807T/873A genotype was 2.9 times higher among patients with myocardial infarction than among controls (16.4% vs 5.6%, p = 0.022). There was an association between patients homozygous for the 807T/873A allele and myocardial infarction (odds ratio 3.3 [95% CI 1.2-8.8]), which was strongest in a subgroup of smokers. The homozygous 807T/873A genotype remained an independent risk factor for myocardial infarction (p = 0.005) when age, sex, smoking, hypertension, diabetes, body-mass index, LDL-cholesterol and HDL-cholesterol, and fibrinogen were adjusted for by logistic regression. Interpretation The 807T/873A homozygosity of the platelet glycoprotein Ia/IIa gene polymorphism, associated with differences in surface collagen receptor density and activity, appears to be an independent risk factor for acute myocardial infarction. Our findings need to be confirmed in a larger, prospective study that includes patients from different populations and cardiovascular risk groups.	Univ Hosp Bern, Inselspital, Dept Med, Div Cardiol, CH-3010 Bern, Switzerland; Univ Hosp Bern, Inselspital, Cent Haematol Lab, CH-3010 Bern, Switzerland; Univ Hosp Bern, Inselspital, Dept Mol Genet, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Meyer, BJ (corresponding author), Univ Hosp Bern, Inselspital, Dept Med, Div Cardiol, CH-3010 Bern, Switzerland.	bmeyer@insel.ch	Laemmle, Bernhard/AAJ-1216-2020	Laemmle, Bernhard/0000-0003-4538-5154; Beer, Jurg Hans/0000-0002-7199-0406				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BEUTLER E, 1990, HUM GENET, V85, P9; BEUTLER E, 1992, GENOMICS, V12, P795, DOI 10.1016/0888-7543(92)90311-F; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Carroll VA, 1997, ARTERIOSCL THROM VAS, V17, P114, DOI 10.1161/01.ATV.17.1.114; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; Davies MJ, 1995, EUR HEART J, V16, P3, DOI 10.1093/eurheartj/16.suppl_L.3; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; *EFF PLAT GLYC IIB, 1997, CIRCULATION, V96, P1445; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; HUANG EM, 1981, BLOOD, V57, P685; KIRCHHOFER D, 1995, BLOOD, V86, P3815, DOI 10.1182/blood.V86.10.3815.bloodjournal86103815; Kunicki TJ, 1997, BLOOD, V89, P1939, DOI 10.1182/blood.V89.6.1939; KUNICKI TJ, 1993, BLOOD, V82, P2693; Newman PJ, 1997, LANCET, V349, P370, DOI 10.1016/S0140-6736(97)80002-5; NURDEN AT, 1995, THROMB HAEMOSTASIS, V74, P345; Nurden AT, 1997, LANCET, V350, P1189, DOI 10.1016/S0140-6736(05)63447-2; RICHARD I, 1995, NAT GENET, V10, P259, DOI 10.1038/ng0795-259; Ridker PM, 1997, LANCET, V349, P385, DOI 10.1016/S0140-6736(97)80010-4; SHARP DS, 1995, THROMB HAEMOSTASIS, V74, P730; SIESS W, 1982, CIRCULATION, V66, P44, DOI 10.1161/01.CIR.66.1.44; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Walter DH, 1997, LANCET, V350, P1217, DOI 10.1016/S0140-6736(97)05399-3; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	30	178	195	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					351	354		10.1016/S0140-6736(98)06448-4	http://dx.doi.org/10.1016/S0140-6736(98)06448-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950439				2022-12-01	WOS:000078437000009
J	Viola, A; Schroeder, S; Sakakibara, Y; Lanzavecchia, A				Viola, A; Schroeder, S; Sakakibara, Y; Lanzavecchia, A			T lymphocyte costimulation mediated by reorganization of membrane microdomains	SCIENCE			English	Article							CELL ACTIVATION; ANTIGEN RECEPTORS; CAVEOLAE; DOMAINS; KINASE; PURIFICATION; LOCALIZATION; PROTEIN; BINDING; CD28	Although dispensable, costimulation through CD28 facilitates activation of naive T lymphocytes. CD28 engagement Led to the redistribution and clustering of membrane and intracellular kinase-rich raft microdomains at the site of T cell receptor (TCR) engagements. Although not affecting TCR down-regulation, this process Led to higher and more stable tyrosine phosphorylation of several substrates and higher consumption of Lck. These results may provide a general mechanism for amplifying receptor signaling by reorganization of membrane microdomains.	Basel Inst Immunol, CH-4005 Basel, Switzerland		Viola, A (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.	viola@bii.ch	Agatea, Lisa/L-8267-2016; Viola, Antonella/A-4321-2015	Viola, Antonella/0000-0002-0125-9271				Bachmann MF, 1997, IMMUNITY, V7, P549, DOI 10.1016/S1074-7613(00)80376-3; Beeson C, 1996, J EXP MED, V184, P777, DOI 10.1084/jem.184.2.777; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CINEK T, 1992, J IMMUNOL, V149, P2262; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Hudrisier D, 1998, J IMMUNOL, V161, P553; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Lowin-Kropf B, 1998, J CELL BIOL, V140, P861, DOI 10.1083/jcb.140.4.861; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tuosto L, 1998, EUR J IMMUNOL, V28, P2131, DOI 10.1002/(SICI)1521-4141(199807)28:07<2131::AID-IMMU2131>3.0.CO;2-Q; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1997, J EXP MED, V186, P1775, DOI 10.1084/jem.186.10.1775; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1987, J IMMUNOL, V138, P2169; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	41	822	847	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1999	283	5402					680	682		10.1126/science.283.5402.680	http://dx.doi.org/10.1126/science.283.5402.680			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924026				2022-12-01	WOS:000078324400040
J	Rodionov, O; Lobocka, M; Yarmolinsky, M				Rodionov, O; Lobocka, M; Yarmolinsky, M			Silencing of genes flanking the P1 plasmid centromere	SCIENCE			English	Article							INTEGRATION HOST FACTOR; COLI F-PLASMID; ESCHERICHIA-COLI; PARTITION COMPLEX; NEGATIVE CONTROL; MINI-F; PROTEIN; REPLICATION; CHROMOSOME; REGION	Partition modules stabilize bacterial plasmids and chromosomes by actively promoting their segregation into daughter cells. The partition module of plasmid P1 is typical and consists of a centromere site, parS, and genes that encode proteins ParA and ParB. We show that ParB can silence genes flanking parS (to which ParB binds), apparently by polymerizing along the DNA from a nucleation site at parS. Wild-type ParB contacts an extensive region of P1 DNA; silencing-defective ParB proteins, which were found to be partition-defective, are Less able to spread. Hence, the silenced structure appears to function in partitioning.	NCI, Biochem Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yarmolinsky, M (corresponding author), NCI, Biochem Lab, 37 Convent Dr, Bethesda, MD 20892 USA.	myarmo@helix.nih.gov	B, Łobocka Małgorzata/I-3844-2019; Lobocka, Malgorzata/K-4496-2019	Lobocka, Malgorzata/0000-0003-0679-5193	DIVISION OF BASIC SCIENCES - NCI [Z01BC005267] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; ABELES AL, 1986, J MOL BIOL, V189, P387; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; BIEK DP, 1994, P NATL ACAD SCI USA, V91, P8027, DOI 10.1073/pnas.91.17.8027; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CHATTORAJ D, 1984, P NATL ACAD SCI-BIOL, V81, P6456, DOI 10.1073/pnas.81.20.6456; DARN M, 1994, J MOL BIOL, V236, P1289; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; FUMMELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1994, BIOCHIMIE, V76, P924, DOI 10.1016/0300-9084(94)90017-5; GALLIE DR, 1987, J MOL BIOL, V193, P465, DOI 10.1016/0022-2836(87)90260-9; GERDES K, UNPUB; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; HAYES F, 1993, P NATL ACAD SCI USA, V90, P9228, DOI 10.1073/pnas.90.19.9228; HELSBERG M, 1986, J BACTERIOL, V165, P1043, DOI 10.1128/jb.165.3.1043-1045.1986; Jensen RB, 1998, P NATL ACAD SCI USA, V95, P8550, DOI 10.1073/pnas.95.15.8550; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Kim SK, 1998, P NATL ACAD SCI USA, V95, P1523, DOI 10.1073/pnas.95.4.1523; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Lobocka M, 1996, J MOL BIOL, V259, P366, DOI 10.1006/jmbi.1996.0326; LOBOCKA M, UNPUB; LYNCH AS, 1995, P NATL ACAD SCI USA, V92, P1896, DOI 10.1073/pnas.92.6.1896; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; MILLER JH, 1975, METHOD ENZYMOL, V43, P737; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; NICHOLS BP, 1983, METHOD ENZYMOL, V101, P155; PAPP PP, 1994, J BIOL CHEM, V269, P23563; RODIONOV O, UNPUB; RUSSO EA, 1996, EPIGENETIC MECHANISM; SOM T, 1982, MOL GEN GENET, V187, P375, DOI 10.1007/BF00332615; TAKANO T, 1976, VIROLOGY, V70, P198, DOI 10.1016/0042-6822(76)90252-X; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6	39	195	195	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1999	283	5401					546	549		10.1126/science.283.5401.546	http://dx.doi.org/10.1126/science.283.5401.546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915704	Green Submitted			2022-12-01	WOS:000078203300040
J	Hofmann, T; Obukhov, AG; Schaefer, M; Harteneck, C; Gudermann, T; Schultz, G				Hofmann, T; Obukhov, AG; Schaefer, M; Harteneck, C; Gudermann, T; Schultz, G			Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol	NATURE			English	Article							CAPACITATIVE CALCIUM-ENTRY; STORE DEPLETION; MAST-CELLS; G-PROTEIN; RECEPTOR; EXPRESSION; CA2+; CLONING	Eukaryotic cells respond to many hormones and neurotransmitters with increased activity of the enzyme phospholipase C and a subsequent rise in the concentration of intracellular free calcium ([Ca2+](i))(1). The increase in [Ca2+](i) occurs as a result of the release of Ca2+ from intracellular stores and an influx of Ca2+ through the plasma membrane(2-4); this influx of Ca2+ may(5) or may not(6) be store-dependent. Drosophila transient receptor potential (TRP) proteins and some mammalian homologues (TRPC proteins) are thought to mediate capacitative Ca2+ entry(7-9). Here we describe the molecular mechanism of store-depletion-independent activation of a subfamily of mammalian TRPC channels. We find that hTRPC6 is a non-selective cation channel that is activated by diacylglycerol in a membrane-delimited fashion, independently of protein kinases C activated by diacylglycerol, Although hTRPC3, the closest structural relative of hTRPC6, is activated in the same way, TRPCs i, 4 and 5 and the vanilloid receptor subtype 1 are unresponsive to the lipid mediator. Thus, hTRPC3 and hTRPC6 represent the first members of a new functional family of second-messenger-operated cation channels, which are activated by diacylglycerol.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schultz, G (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	gschultz@zedat.fu-berlin.de	Obukhov, Alexander G/C-7246-2008	Obukhov, Alexander G/0000-0002-3862-6004				BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; Helliwell RM, 1997, J PHYSIOL-LONDON, V499, P417, DOI 10.1113/jphysiol.1997.sp021938; Hille B., 1992, IONIC CHANNELS EXCIT; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Migas I, 1996, AM J PHYSIOL-CELL PH, V271, pC1194; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Mori Y, 1998, NEUROREPORT, V9, P507; NEHER E, 1977, ANNU REV BIOPHYS BIO, V6, P345, DOI 10.1146/annurev.bb.06.060177.002021; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6296	27	1174	1209	1	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					259	263		10.1038/16711	http://dx.doi.org/10.1038/16711			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930701				2022-12-01	WOS:000078184800054
J	Rivera, C; Voipio, J; Payne, JA; Ruusuvuori, E; Lahtinen, H; Lamsa, K; Pirvola, U; Saarma, M; Kaila, K				Rivera, C; Voipio, J; Payne, JA; Ruusuvuori, E; Lahtinen, H; Lamsa, K; Pirvola, U; Saarma, M; Kaila, K			The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation	NATURE			English	Article							K-CL COTRANSPORTER; HIPPOCAMPAL-NEURONS; PYRAMIDAL NEURONS; MESSENGER-RNAS; IONIC BASIS; RAT; INHIBITION; GANGLIA; CELLS; BRAIN	GABA (gamma-aminobutyric acid) is the main inhibitory transmitter in the adult brain, and it exerts its fast hyperpolarizing effect through activation of anion (predominantly Cl-)-permeant GABA(A) receptors(1), However, during early neuronal development, GABA(A)-receptor-mediated responses are often depolarizing(2,3), which may be a key factor in the control of several Ca2+-dependent developmental phenomena, including neuronal proliferation, migration and targeting(4-6). To date, however, the molecular mechanism underlying this shift in neuronal electrophysiological phenotype is unknown. Here we show that, in pyramidal neurons of the rat hippocampus, the ontogenetic change in GABA(A)-mediated responses from depolarizing to hyperpolarizing is coupled to a developmental induction of the expression of the neuronal Cl--extruding K+/Cl- co-transporter, KCC2 (ref. 7). Antisense oligonucleotide inhibition of KCC2 expression produces a marked positive shift in the reversal potential of GABA, responses in functionally mature hippocampal pyramidal neurons. These data support the conclusion that KCC2 is the main Cl- extruder to promote fast hyperpolarizing postsynaptic inhibition in the brain.	Univ Helsinki, Dept Biosci, Div Anim Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland; Univ Calif Davis, Sch Med, Dept Human Physiol, Davis, CA 95616 USA	University of Helsinki; University of Helsinki; University of California System; University of California Davis	Kaila, K (corresponding author), Univ Helsinki, Dept Biosci, Div Anim Physiol, FIN-00014 Helsinki, Finland.	kai.kaila@helsinki.fi	Lamsa, Karri/T-2025-2019; Rivera, Claudio/ABE-2499-2021; Kaila, Kai/R-8528-2016	Rivera, Claudio/0000-0003-2462-6561; Voipio, Juha/0000-0001-7096-1286; Kaila, Kai/0000-0003-0668-5955; Lamsa, Karri/0000-0002-4609-1337				BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BENGTSTROM M, 1991, NUCLEIC ACIDS RES S, V24, P288; Bevensee Mark O., 1998, P211; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clayton GH, 1998, DEV BRAIN RES, V108, P307, DOI 10.1016/S0165-3806(98)00045-5; Clayton GH, 1998, DEV BRAIN RES, V109, P281, DOI 10.1016/S0165-3806(98)00078-9; DESCHENES M, 1976, BRAIN RES, V118, P486, DOI 10.1016/0006-8993(76)90318-8; GILLEN C, 1993, J BIOL CHEM, V271, P16237; KAILA K, 1994, PROG NEUROBIOL, V42, P489, DOI 10.1016/0301-0082(94)90049-3; KAILA K, 1993, J PHYSIOL-LONDON, V464, P273, DOI 10.1113/jphysiol.1993.sp019634; LoTurco JJ, 1995, NEURON, V15, P1287, DOI 10.1016/0896-6273(95)90008-X; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; Moshnyakov M, 1996, MOL BRAIN RES, V43, P141, DOI 10.1016/S0169-328X(96)00168-4; Pasternack M, 1996, NEUROPHARMACOLOGY, V35, P1279, DOI 10.1016/S0028-3908(96)00075-5; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1997, AM J PHYSIOL, V42, pC1516; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; RIVERA C, 1997, SOC NEUROSCI ABSTR, V23; SERAFINI R, 1995, J PHYSIOL-LONDON, V488, P371, DOI 10.1113/jphysiol.1995.sp020973; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; SUTOR B, 1995, PERSPECT DEV NEUROBI, V2, P409; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512, DOI 10.1152/jn.1989.61.3.512; vandenPol AN, 1996, J NEUROSCI, V16, P4283; WU WI, 1992, J NEUROSCI, V12, P3935; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S; ZHANG L, 1991, J PHYSIOL-LONDON, V444, P25, DOI 10.1113/jphysiol.1991.sp018864	28	1566	1610	1	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1999	397	6716					251	255		10.1038/16697	http://dx.doi.org/10.1038/16697			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930699				2022-12-01	WOS:000078184800052
J	Perrier, A; Desmarais, S; Miron, MJ; de Moerloose, P; Lepage, R; Slosman, D; Didier, D; Unger, PF; Patenaude, JV; Bounameaux, H				Perrier, A; Desmarais, S; Miron, MJ; de Moerloose, P; Lepage, R; Slosman, D; Didier, D; Unger, PF; Patenaude, JV; Bounameaux, H			Non-invasive diagnosis of venous thromboembolism in outpatients	LANCET			English	Article							DEEP-VEIN THROMBOSIS; SUSPECTED PULMONARY-EMBOLISM; SERIAL IMPEDANCE PLETHYSMOGRAPHY; D-DIMER LEVELS; LUNG-SCAN; ULTRASONOGRAPHY; MANAGEMENT; PLASMA; ANGIOGRAPHY; PROBABILITY	Background We designed a simple and integrated diagnostic algorithm for acute venous thromboembolism based on clinical probability assessment of deep-vein thrombosis (DVT) or pulmonary embolism (PE), plasma D-dimer measurement, lower-limb venous compression ultrasonography, and lung scan to reduce the need for phlebography and pulmonary angiography. Methods 918 consecutive patients presenting at the emergency ward of the Geneva University Hospital, Geneva, Switzerland, and Hopital Saint-Luc, Montreal, Canada, with clinically suspected venous thromboembolism were entered into a sequential diagnostic protocol. Patients in whom venous thromboembolism was deemed absent were not given anticoagulants and were followed up for 3 months. Findings A normal D-dimer concentration (<500 mu g/L by a rapid ELISA) ruled out venous thromboembolism in 286 (31%) members of the study cohort, whereas DVT by ultrasonography established the diagnosis in 157 (17%). Lung scan was diagnostic in 80 (9%) of the remaining patients. Venous thromboembolism was also deemed absent in patients with low to intermediate clinical probability of DVT and a normal venous ultrasonography (236 [26%] patients), and in patients with a low clinical probability of PE and a non-diagnostic result on lung scan (107 [12%] patients). Pulmonary angiography and phlebography were done in only 50 (5%) and 2 (<1%) of the patients, respectively. Hence, a non-invasive diagnosis was possible in 866 (94%) members of the entire cohort. The 3-month thromboembolic risk in patients not given anticoagulants, based on the results of the diagnostic protocol, was 1.8% (95% CI 0.9-3.1). Interpretation A diagnostic strategy combining clinical assessment, D-dimer, ultrasonography, and lung scan gave a non-invasive diagnosis in the vast majority of outpatients with suspected venous thromboembolism, and appeared to be safe.	Univ Hosp Geneva, Med Clin 1, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Angiol, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Haemostasis, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Radiodiagnost & Intervent Radiol, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Med & Surg Emergency, CH-1211 Geneva 14, Switzerland; Univ Montreal, Hop St Luc, Dept Internal & Vasc Med, Quebec City, PQ, Canada; Univ Montreal, Hop St Luc, Haematol Lab, Quebec City, PQ, Canada	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; Universite de Montreal; Universite de Montreal	Perrier, A (corresponding author), Univ Hosp Geneva, Med Clin 1, 24 Rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.	arnaud.perrier@medecine.unige.ch	Perrier, Arnaud/M-2263-2014					ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BARRITT DW, 1960, LANCET, V1, P1309; BECKER DM, 1989, ARCH INTERN MED, V149, P1731, DOI 10.1001/archinte.149.8.1731; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; Borg JY, 1997, THROMB HAEMOSTASIS, V77, P602; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; Bounameaux H, 1997, QJM-INT J MED, V90, P437, DOI 10.1093/qjmed/90.7.437; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; DAngelo A, 1996, THROMB HAEMOSTASIS, V75, P412; deMoerloose P, 1996, THROMB HAEMOSTASIS, V75, P11; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; GOLDHABER SZ, 1993, JAMA-J AM MED ASSOC, V270, P2819, DOI 10.1001/jama.270.23.2819; GOODMAN LR, 1995, AM J ROENTGENOL, V164, P1369, DOI 10.2214/ajr.164.6.7754875; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; Janssen MCH, 1997, THROMB HAEMOSTASIS, V77, P262; KAKKAR VV, 1969, LANCET, V2, P230; LAGERSTEDT CI, 1985, LANCET, V2, P515; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MIRON MJ, 1998, J GEN INTERN MED, V13, P205; MORABIA A, 1994, J GEN INTERN MED, V9, P496, DOI 10.1007/BF02599219; MOSER KM, 1994, BRIT MED J, V309, P1525, DOI 10.1136/bmj.309.6968.1525; Perrier A, 1997, ARCH INTERN MED, V157, P2309, DOI 10.1001/archinte.157.20.2309; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; Perrier A, 1997, AM J RESP CRIT CARE, V156, P492, DOI 10.1164/ajrccm.156.2.9702032; PERRIER A, 1998, J GEN INTERN MED, V13, P235; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; RAIMONDI P, 1993, THROMB RES, V69, P125, DOI 10.1016/0049-3848(93)90009-D; RemyJardin M, 1996, RADIOLOGY, V200, P699, DOI 10.1148/radiology.200.3.8756918; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; Turkstra F, 1997, ANN INTERN MED, V126, P775, DOI 10.7326/0003-4819-126-10-199705150-00005; vanRossum AB, 1996, THORAX, V51, P23, DOI 10.1136/thx.51.1.23; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008; WORSLEY DF, 1994, ARCH INTERN MED, V154, P2737, DOI 10.1001/archinte.1994.00420230134016	44	634	641	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	1999	353	9148					190	195		10.1016/S0140-6736(98)05248-9	http://dx.doi.org/10.1016/S0140-6736(98)05248-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923874				2022-12-01	WOS:000078175600011
J	Van Beneden, CA; Keene, WE; Strang, RA; Werker, DH; King, AS; Mahon, B; Hedberg, K; Bell, A; Kelly, MT; Balan, VK; Mac Kenzie, WR; Fleming, D				Van Beneden, CA; Keene, WE; Strang, RA; Werker, DH; King, AS; Mahon, B; Hedberg, K; Bell, A; Kelly, MT; Balan, VK; Mac Kenzie, WR; Fleming, D			Multinational outbreak of Salmonella enterica serotype newport infections due to contaminated alfalfa sprouts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MICROBIAL HAZARDS; SEEDS; EPIDEMIOLOGY	Context In December 1995, reported Salmonella enterica serotype Newport (SN) infections increased sharply in Oregon and British Columbia but not elsewhere in North America. Similar unexplained increases had been noted in 6 other states in the fall of 1995. Objective To determine the source of the outbreak(s). Design Case-control studies, environmental investigations, bacterial subtyping, and surveillance information review. Settings Oregon and British Columbia communities (winter 1995-1996) and Georgia, Oklahoma, Pennsylvania, Vermont, Virginia, and West Virginia (fall 1995). Participants Oregon and British Columbia residents with culture-confirmed SN infections and onset from December 1, 1995, through February 29, 1996, and healthy community controls. Main Outcome Measures Odds ratio (OR) of illness associated with exposures; distribution patterns and culture of alfalfa seeds and sprouts; subtyping of SN isolates. Results We identified 133 cases in Oregon and British Columbia; 124 (93%) occurred in patients older than 18 years; 87 (65%) were female. Case patients were more likely than community control subjects to report having eaten alfalfa sprouts in the 5 days preceding illness (41% [17/41] vs 4% [3/75]; OR, 17.0; 95% confidence interval, 4.3-96.0). Case isolates shared a distinctive pulsed-field gel electrophoresis (PFGE) pattern. The SN was grown from seeds and alfalfa sprouts. The distribution of 1 seed lot to multiple growers corresponded to the distribution of cases. Distribution of a second seed lot from the same European wholesaler corresponded to the location of the fall outbreak, which was characterized by a similar demographic profile. The PFGE pattern of fall outbreak isolates and confiscated sprouts and seeds was indistinguishable from the Oregon and British Columbia outbreak and differed from background isolates. Conclusions The SN-contaminated alfalfa seeds were distributed to multiple growers across North America in 1995 and resulted in a protracted international outbreak scattered over many months. Current sprouting methods are inadequate to protect consumers from such events. Alfalfa sprouts may be an elusive but important vehicle for salmonellosis and other enteric infections.	Oregon Hlth Div, Acute & Communicable Dis Program, Portland, OR 97212 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA USA; Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada; British Columbia Ctr Dis Control, Epidemiol Serv, Vancouver, BC, Canada; Hlth Canada, Lab Ctr Dis Control, Field Epidemiol Training Program, Ottawa, ON K1A 0L2, Canada; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; British Columbia Ctr Dis Control, Prov Lab, Vancouver, BC, Canada; Oregon State Publ Hlth Lab, Portland, OR USA	Oregon Health & Science University; Centers for Disease Control & Prevention - USA; University of British Columbia; Health Canada; Centers for Disease Control & Prevention - USA	Van Beneden, CA (corresponding author), Oregon Hlth Div, Acute & Communicable Dis Program, 800 NE Oregon St,Suite 772, Portland, OR 97212 USA.		Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				ANDERSON ES, 1956, J CLIN PATHOL, V9, P94, DOI 10.1136/jcp.9.2.94; ANDREWS WH, 1982, J ASSOC OFF ANA CHEM, V65, P241; [Anonymous], 1995, EP INF COMP PROGR VE; *AOAC, 1995, OFF METH AN AOAC ITN, pCH17; BENENSON AS, 1995, CONTROL COMMUNICABLE, P412; Bennett J., 1987, CLOSING GAP BURDEN U; Beuchat LR, 1997, INT J FOOD MICROBIOL, V34, P329, DOI 10.1016/S0168-1605(96)01202-0; BRYAN FL, 1968, J MILK FOOD TECHNOL, V31, P131, DOI 10.4315/0022-2747-31.5.131; Buck P., 1998, 47 ANN EP INT SERV C; *CDC, 1974, FOODB WAT DIS OUTB A, P23; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P741; CHALKER RB, 1988, REV INFECT DIS, V10, P111; *FDA, 1992, BACT AN MAN, pCH5; GLYNN MK, 1998, 47 ANN EP INT SERV C; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; Herwaldt BL, 1997, NEW ENGL J MED, V336, P1548, DOI 10.1056/NEJM199705293362202; *HLTH PROT BRANCH, 1978, COMP ANAL METHODS, V2; Itoh Y, 1998, APPL ENVIRON MICROB, V64, P1532; Jaquette CB, 1996, APPL ENVIRON MICROB, V62, P2212, DOI 10.1128/AEM.62.7.2212-2215.1996; Lehmacher A, 1995, EPIDEMIOL INFECT, V115, P501, DOI 10.1017/S0950268800058660; Mahon BE, 1997, J INFECT DIS, V175, P876, DOI 10.1086/513985; MOUZIN E, 1997, 6 ANN EP INT SERV C; PONKA A, 1995, LANCET, V345, P462, DOI 10.1016/S0140-6736(95)90451-4; Puohiniemi R, 1997, J CLIN MICROBIOL, V35, P2487, DOI 10.1128/JCM.35.10.2487-2491.1997; Tauxe R, 1997, J FOOD PROTECT, V60, P1400, DOI 10.4315/0362-028X-60.11.1400; TAYLOR DE, 1992, J BACTERIOL, V174, P2332, DOI 10.1128/JB.174.7.2332-2337.1992; WEGENER HC, 1997, P ABSTR INT S SALM S, P587	27	128	131	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					158	162		10.1001/jama.281.2.158	http://dx.doi.org/10.1001/jama.281.2.158			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917119	Bronze			2022-12-01	WOS:000077966800036
J	Desai, A; Verma, S; Mitchison, TJ; Walczak, CE				Desai, A; Verma, S; Mitchison, TJ; Walczak, CE			Kin I kinesins are microtubule-destabilizing enzymes	CELL			English	Article							DYNAMIC INSTABILITY; SACCHAROMYCES-CEREVISIAE; GTP HYDROLYSIS; EGG EXTRACTS; CELL-CYCLE; REAL-TIME; PROTEIN; MOTOR; IDENTIFICATION; ENDS	Using in vitro assays with purified proteins, we show that XKCM1 and XKIF2, two distinct members of the internal catalytic domain (Kin I) kinesin subfamily, catalytically destabilize microtubules using a novel mechanism. Both XKCM1 and XKIF2 influence microtubule stability by targeting directly to microtubule ends where they induce a destabilizing conformational change. ATP hydrolysis recycles XKCM1/XKIF2 for multiple rounds of action by dissociating a XKCM1/ XKIF2-tubulin dimer complex released upon microtubule depolymerization. These results establish Kin I kinesins as microtubule-destabilizing enzymes, distinguish them mechanistically from kinesin superfamily members that use ATP hydrolysis to translocate along microtubules, and have important implications for the regulation of microtubule dynamics and for the intracellular functions and evolution of the kinesin superfamily.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Desai, A (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	arshad.desai@embl-heidelberg.de						BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CASSIMERIS L, 1993, CELL MOTIL CYTOSKEL, V26, P275, DOI 10.1002/cm.970260402; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; COHN SA, 1993, METHOD CELL BIOL, V39, P75, DOI 10.1016/S0091-679X(08)60162-4; Cottingham FR, 1997, J CELL BIOL, V138, P1041, DOI 10.1083/jcb.138.5.1041; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DeZwaan TM, 1997, J CELL BIOL, V138, P1023, DOI 10.1083/jcb.138.5.1023; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.biophys.21.1.145; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; Huyett A, 1998, J CELL SCI, V111, P295; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Morfini G, 1997, J CELL BIOL, V138, P657, DOI 10.1083/jcb.138.3.657; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; Pierce DW, 1997, NATURE, V388, P338, DOI 10.1038/41009; Saunders W, 1997, J CELL BIOL, V137, P417, DOI 10.1083/jcb.137.2.417; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Tran PT, 1997, J STRUCT BIOL, V118, P107, DOI 10.1006/jsbi.1997.3844; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Waters JC, 1996, CURR BIOL, V6, P361, DOI 10.1016/S0960-9822(02)00495-5; Wein H, 1996, J CELL BIOL, V133, P595, DOI 10.1083/jcb.133.3.595; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95	46	560	579	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					69	78		10.1016/S0092-8674(00)80960-5	http://dx.doi.org/10.1016/S0092-8674(00)80960-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989498	Bronze			2022-12-01	WOS:000078023200009
J	Niklason, LE; Gao, J; Abbott, WM; Hirschi, KK; Houser, S; Marini, R; Langer, R				Niklason, LE; Gao, J; Abbott, WM; Hirschi, KK; Houser, S; Marini, R; Langer, R			Functional arteries grown in vitro	SCIENCE			English	Article							SMOOTH-MUSCLE CELLS; BLOOD-VESSEL; CONSCIOUS DOGS; COLLAGEN; ELASTIN; VEIN; DIFFERENTIATION; PATHOGENESIS; DENSITY	A tissue engineering approach was developed to produce arbitrary lengths of vascular graft material from smooth muscle and endothelial cells that were derived from a biopsy of vascular tissue. Bovine vessels cultured under pulsatile conditions had rupture strengths greater than 2000 millimeters of mercury, suture retention strengths of up to 90 grams, and collagen contents of up to 50 percent. Cultured vessels also showed contractile responses to pharmacological agents and contained smooth muscle cells that displayed markers of differentiation such as calponin and myosin heavy chains. Tissue-engineered arteries were implanted in miniature swine, with patency documented up to 24 days by digital angiography.	Duke Univ, Dept Anesthesia, Durham, NC 27710 USA; Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA; MIT, Dept Comparat Med, Cambridge, MA 02139 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Duke University; Duke University; Case Western Reserve University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Baylor College of Medicine; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Niklason, LE (corresponding author), Duke Univ, Dept Anesthesia, Durham, NC 27710 USA.	nikla001@mc.duke.edu			NHLBI NIH HHS [K08HL03492, HL60435] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060435, K08HL003492] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMENTANO RL, 1991, AM J PHYSIOL, V260, pH1870, DOI 10.1152/ajpheart.1991.260.6.H1870; *ASS ADV MED INSTR, 1994, AM NAT STAND CARD IM; BARRA JG, 1993, CIRC RES, V73, P1040, DOI 10.1161/01.RES.73.6.1040; Caro C., 1978, MECH CIRCULATION, P44; COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I; CROSS KS, 1994, BRIT J SURG, V81, P699, DOI 10.1002/bjs.1800810524; Davidson JM, 1997, J BIOL CHEM, V272, P345, DOI 10.1074/jbc.272.1.345; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DODGE AB, 1993, J CELL BIOCHEM, V53, P21, DOI 10.1002/jcb.240530104; FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689; Gao JM, 1998, J BIOMED MATER RES, V42, P417, DOI 10.1002/(SICI)1097-4636(19981205)42:3<417::AID-JBM11>3.0.CO;2-D; Greisler HP, 1996, BIOMATERIALS, V17, P329, DOI 10.1016/0142-9612(96)85571-2; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; LLTALIEN GJ, 1994, AM J PHYSIOL, V267, pH574; Niklason LE, 1997, TRANSPL IMMUNOL, V5, P303; Owens GK, 1996, CIRC RES, V79, P1054, DOI 10.1161/01.RES.79.5.1054; OWENS GK, 1995, PHYSIOL REV, V75, P487; Rao SK, 1996, ANN NY ACAD SCI, V800, P131; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sayers RD, 1998, BRIT J SURG, V85, P934; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; TINKER D, 1985, PHYSIOL REV, V65, P607, DOI 10.1152/physrev.1985.65.3.607; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	30	1307	1436	4	255	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					489	493		10.1126/science.284.5413.489	http://dx.doi.org/10.1126/science.284.5413.489			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205057				2022-12-01	WOS:000079792200048
J	Koch, C; Laurent, G				Koch, C; Laurent, G			Complexity and the nervous system	SCIENCE			English	Editorial Material							NEURAL ASSEMBLIES; NEURONS; NETWORKS; BRAIN	Advances in the neurosciences have revealed the staggering complexity of even "simple" nervous systems. This is reflected in their function, their evolutionary history, their structure, and the coding schemes they use to represent information. These four viewpoints need all play a role in any future science of "brain complexity."	CALTECH, Div Biol, Computat & Neural Syst Program, Pasadena, CA 91125 USA; CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Koch, C (corresponding author), CALTECH, Div Biol, Computat & Neural Syst Program, Pasadena, CA 91125 USA.	koch@klab.caltech.edu	Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Koch, Christof/0000-0001-6482-8067				ABBOTT LF, 1994, Q REV BIOPHYS, V27, P291, DOI 10.1017/S0033583500003024; Allman J. M., 1998, EVOLVING BRAINS; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Bennett C. H., 1987, EMERGING SYNTHESIS S; Bialek W., 1996, SPIKES EXPLORING NEU; CONRAD M, 1990, BIOSYSTEMS, V24, P61, DOI 10.1016/0303-2647(90)90030-5; Crick F, 1998, CEREB CORTEX, V8, P97, DOI 10.1093/cercor/8.2.97; DALE N, 1993, P NATL ACAD SCI USA, V90, P7163, DOI 10.1073/pnas.90.15.7163; DURBIN R, 1987, THESIS CAMBRIDGE U; GELLMAN M, 1994, QUARK JAGUAR; Gerhart J., 1997, EMBRYOS EVOLUTION; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; HARRISWARRICK RM, 1991, ANNU REV NEUROSCI, V14, P39, DOI 10.1146/annurev.ne.14.030191.000351; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Koch Christof, 1999, P1; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MacLeod K, 1998, NATURE, V395, P693, DOI 10.1038/27201; McCann K, 1998, NATURE, V395, P794, DOI 10.1038/27427; MCCANN K, 1972, NATURE, V238, P413; MOBBS PG, 1982, PHILOS T ROY SOC B, V298, P309, DOI 10.1098/rstb.1982.0086; Murphy GG, 1997, SCIENCE, V278, P467, DOI 10.1126/science.278.5337.467; Shadlen MN, 1998, J NEUROSCI, V18, P3870; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Stavenga D.G., 1989, FACETS VISION; Stopfer M, 1997, NATURE, V390, P70, DOI 10.1038/36335; Strausfeld N.J., 1980, HDB SENSORY PHYSL, P1; Strausfeld NJ., 1976, ATLAS INSECT BRAIN, DOI 10.1007/978-3-642-66179-2; Tononi G, 1998, TRENDS COGN SCI, V2, P474, DOI 10.1016/S1364-6613(98)01259-5; Tononi G, 1996, P NATL ACAD SCI USA, V93, P3422, DOI 10.1073/pnas.93.8.3422; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; TURRIGIANO G, 1995, J NEUROSCI, V15, P3640; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; von Frisch K, 1969, DANCE LANGUAGE ORIEN; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	37	217	228	3	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1999	284	5411					96	98		10.1126/science.284.5411.96	http://dx.doi.org/10.1126/science.284.5411.96			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102826				2022-12-01	WOS:000079509000039
J	Khattak, S; Moghtader, GK; McMartin, K; Barrera, M; Kennedy, D; Koren, G				Khattak, S; Moghtader, GK; McMartin, K; Barrera, M; Kennedy, D; Koren, G			Pregnancy outcome following gestational exposure to organic solvents - A prospective controlled study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR MALFORMATIONS; SPONTANEOUS-ABORTIONS; FINLAND; WOMEN	Context Numerous women of childbearing age are exposed occupationally to organic solvents. Previous retrospective studies have reported conflicting results regarding teratogenic risk. Objective To evaluate pregnancy and fetal outcome following maternal occupational exposure to organic solvents. Design A prospective, observational, controlled study, Setting An antenatal counseling service in Toronto, Ontario. Patients One hundred twenty-five pregnant women who were exposed occupationally to organic solvents and seen during the first trimester between 1987 and 1996. Each pregnant woman who was exposed to organic solvents was matched to a pregnant woman who was exposed to a nonteratogenic agent on age (+/-4 years), gravidity (+/-1), and smoking and drinking status. Main Outcome Measure Occurrence of major congenital malformations. Results Significantly more major malformations occurred among fetuses of women exposed to organic solvents than controls (13 vs 1; relative risk, 13.0; 95% confidence interval, 1.8-99.5). Twelve malformations occurred among the 75 women who had symptoms temporally associated with their exposure, while none occurred among 43 asymptomatic exposed women (P<.001), (One malformation occurred in a woman for whom such information was missing.) More of these exposed women had previous miscarriage while working with organic solvents than controls (54/117 [46.2%] vs 24/125 [19.2%]; P < .001). However, exposed women who had a previous miscarriage had rates of major malformation that were similar to exposed women who had no previous miscarriage. Conclusions Occupational exposure to organic solvents during pregnancy is associated with an increased risk of major fetal malformations, This risk appears to be increased among women who report symptoms associated with organic solvent exposure. Women's exposure to organic solvents should be minimized during pregnancy. Symptomatic exposure appears to predict higher fetal risk for malformations.	Hosp Sick Children, Div Clin Pharmacol & Toxicol, Motherisk Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Koren, G (corresponding author), Hosp Sick Children, Div Clin Pharmacol & Toxicol, Motherisk Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				ANDREW FD, 1979, TOXICOL APPL PHARM, V48, pA27; ANDREW FD, 1981, TOXICOLOGIST, V1, P30; DOE J, 1983, TOXICOL APPL PHARM, V3, P70; GREEN JD, 1978, TOXICOL APPL PHARM, V46, P9, DOI 10.1016/0041-008X(78)90132-1; HANSON JW, 1976, JAMA-J AM MED ASSOC, V236, P1010; HEMMINKI K, 1983, AM J IND MED, V4, P293, DOI 10.1002/ajim.4700040122; HEMSWORTH BN, 1968, J REPROD FERTIL, V17, P325; HOLMBERG PC, 1979, LANCET, V2, P177; HUDAK A, 1978, TOXICOLOGY, V11, P55, DOI 10.1016/S0300-483X(78)90439-0; JOHN JA, 1980, TOXICOL APPL PHARM, V49, pA88; Koren G, 1998, NEW ENGL J MED, V338, P1128, DOI 10.1056/NEJM199804163381607; LINDBOHM ML, 1990, AM J IND MED, V17, P449, DOI 10.1002/ajim.4700170404; McMartin KI, 1998, AM J IND MED, V34, P288, DOI 10.1002/(SICI)1097-0274(199809)34:3<288::AID-AJIM12>3.0.CO;2-Q; Schardein J., 1993, CHEM INDUCED BIRTH D, V2nd, P751; SILBERG SL, 1979, SOUTHERN MED J, V72, P1170, DOI 10.1097/00007611-197909000-00027; TIKKANEN J, 1988, AM J IND MED, V14, P197, DOI 10.1002/ajim.4700140210; TIKKANEN J, 1988, AM J IND MED, V14, P1, DOI 10.1002/ajim.4700140102; VALCIUKAS JA, 1994, DEV CONSEQUENCES, P213	18	113	118	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1999	281	12					1106	1109		10.1001/jama.281.12.1106	http://dx.doi.org/10.1001/jama.281.12.1106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	177EP	10188661				2022-12-01	WOS:000079197100032
J	Warzecha, AK; Egelhaaf, M				Warzecha, AK; Egelhaaf, M			Variability in spike trains during constant and dynamic stimulation	SCIENCE			English	Article							VISUAL CORTICAL-NEURONS; RESPONSE VARIABILITY; INFORMATION; RELIABILITY; SYSTEM; FLY; MONKEYS; INPUTS	In a recent study, it was concluded that natural time-varying stimuli are represented more reliably in the brain than constant stimuli are. The results presented here disagree with this conclusion, although they were obtained from the same identified neuron (H1) in the fly's visual system. For large parts of the neuron's activity range, the variability of the responses was very similar for constant and time-varying stimuli and was considerably smaller than that in many visual interneurons of vertebrates.	Univ Bielefeld, Fak Biol, Lehrstuhl Neurobiol, D-33501 Bielefeld, Germany	University of Bielefeld	Warzecha, AK (corresponding author), Univ Bielefeld, Fak Biol, Lehrstuhl Neurobiol, Postfach 10 01 31, D-33501 Bielefeld, Germany.		Egelhaaf, Martin/A-9824-2010	Egelhaaf, Martin/0000-0002-9336-4270				Berry MJ, 1997, P NATL ACAD SCI USA, V94, P5411, DOI 10.1073/pnas.94.10.5411; Berry MJ, 1998, J NEUROSCI, V18, P2200; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; Buracas GT, 1998, NEURON, V20, P959, DOI 10.1016/S0896-6273(00)80477-8; ECKERT H, 1980, J COMP PHYSIOL, V135, P29, DOI 10.1007/BF00660179; EGELHAAF M, 1987, BIOL CYBERN, V56, P69, DOI 10.1007/BF00317982; EGELHAAF M, 1989, J OPT SOC AM A, V6, P1070, DOI 10.1364/JOSAA.6.001070; EGELHAAF M, 1993, J NEUROSCI, V13, P4563; Geisler WS, 1997, VISUAL NEUROSCI, V14, P897, DOI 10.1017/S0952523800011627; Gershon ED, 1998, J NEUROPHYSIOL, V79, P1135, DOI 10.1152/jn.1998.79.3.1135; Gur M, 1997, J NEUROSCI, V17, P2914; Haag J, 1997, J NEUROSCI, V17, P4809; Haag J, 1996, NATURE, V379, P639, DOI 10.1038/379639a0; Hausen K., 1981, Verhandlungen der Deutschen Zoologischen Gesellschaft, V74, P49; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MILLER JP, 1991, J NEUROPHYSIOL, V66, P1680, DOI 10.1152/jn.1991.66.5.1680; Nowak LG, 1997, CEREB CORTEX, V7, P487, DOI 10.1093/cercor/7.6.487; Shadlen MN, 1998, J NEUROSCI, V18, P3870; TOLHURST DJ, 1981, EXP BRAIN RES, V41, P414; VANSTEVENINCK RD, 1995, PHILOS T R SOC B, V348, P321; vanSteveninck RRD, 1997, SCIENCE, V275, P1805, DOI 10.1126/science.275.5307.1805; VOGELS R, 1989, EXP BRAIN RES, V77, P432, DOI 10.1007/BF00275002; Warzecha AK, 1997, EUR J NEUROSCI, V9, P1365, DOI 10.1111/j.1460-9568.1997.tb01491.x; Warzecha AK, 1998, CURR BIOL, V8, P359, DOI 10.1016/S0960-9822(98)70154-X	25	55	55	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1927	1930		10.1126/science.283.5409.1927	http://dx.doi.org/10.1126/science.283.5409.1927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10082467	Green Submitted			2022-12-01	WOS:000079228600051
J	Ninomiya-Tsuji, J; Kishimoto, K; Hiyama, A; Inoue, J; Cao, ZD; Matsumoto, K				Ninomiya-Tsuji, J; Kishimoto, K; Hiyama, A; Inoue, J; Cao, ZD; Matsumoto, K			The kinase TAK1 can activate the NIK-I kappa B as well as the MAP kinase cascade in the IL-1 signalling pathway	NATURE			English	Article							BETA; FAMILY; IDENTIFICATION; TRANSDUCTION; ALPHA; TNF	Interleukin-1 (IL-1) is a proinflammatory cytokine that has several effects in the inflammation profess. When it binds to its cell-surface receptor, H-l initiates a signalling cascade that leads to activation of the transcription factor NF-kappa B and is relayed through the protein TRAF6 and a succession of kinase enzymes, including NF-kappa B-inducing kinase (NIK) and I kappa B kinases (IKKs)(1-7). However, the molecular mechanism by which NIK is activated is not understood. Here we show that the MAPKK kinase TAK1 (ref. 8) acts upstream of NIK in the IL-1-activated signalling pathway and that TAK1 associates with TRAF6 during IL-1 signalling. Stimulation of TAK1 causes activation of NF-kappa B, which is blocked by dominant-negative mutants of NIK, and an inactive TAK1 mutant prevents activation of NF-kappa B that is mediated by IL-1 but not by NIK Activated TAK1 phosphorylates NIK, which stimulates IKK-alpha activity. Our results indicate that TAK1 links TRAF6 to the MIK-IKK cascade in the IL-1 signalling pathway.	Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 46401, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 108, Japan; Tularik Inc, S San Francisco, CA 94080 USA	Nagoya University; Japan Science & Technology Agency (JST); University of Tokyo	Matsumoto, K (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan.	g44177a@nucc.cc.na-goya-u.ac.jp		Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; TAKAKAWA M, 1997, EMBO J, V16, P4973; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	25	963	1011	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	1999	398	6724					252	256		10.1038/18465	http://dx.doi.org/10.1038/18465			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UA	10094049				2022-12-01	WOS:000079228400056
J	Hoeper, MM; Niedermeyer, J; Hoffmeyer, F; Flemming, P; Fabel, H				Hoeper, MM; Niedermeyer, J; Hoffmeyer, F; Flemming, P; Fabel, H			Pulmonary hypertension after splenectomy?	ANNALS OF INTERNAL MEDICINE			English	Article								Background: A high prevalence of asplenia has been observed in patients with unexplained pulmonary hypertension. Objective: To describe the clinical and histopathologic characteristics of patients with postsplenectomy pulmonary hypertension and to compare the prevalence of surgical asplenia in patients with idiopathic pulmonary hypertension and patients with other pulmonary diseases. Design: Case series and case-control study. Setting: University hospital in Hannover, Germany. Patients: 61 patients with pulmonary hypertension and 151 lung transplant recipients. Results: The prevalence of asplenia in patients with pulmonary hypertension was 11.5% (95% CI, 4.7% to 22.2%) compared with 0% (CI, 0% to 3.2%) in those without pulmonary hypertension (P < 0.001). Histopathologic examination of lung specimens from patients with postsplenectomy pulmonary hypertension showed intimal fibrosis, plexiform lesions, and abundant thrombotic lesions. Conclusion: Patients who have had splenectomy may be at increased risk for developing pulmonary hypertension.	Hannover Med Sch, Dept Resp Med, D-30623 Hannover, Germany	Hannover Medical School	Hoeper, MM (corresponding author), Hannover Med Sch, Dept Resp Med, D-30623 Hannover, Germany.		Hoeper, Marius C/Z-1546-2019	Hoeper, Marius C/0000-0001-9086-2293; Hoffmeyer, Frank/0000-0002-0870-4171				Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; AESSOPOS A, 1995, CHEST, V107, P50, DOI 10.1378/chest.107.1.50; Kisanuki A, 1997, THROMB RES, V85, P95, DOI 10.1016/S0049-3848(96)00226-5; MCDONNELL PJ, 1983, AM REV RESPIR DIS, V127, P437, DOI 10.1164/arrd.1983.127.4.437; PHILPOTT GW, 1981, TXB SURG BIOL BASIS, P1311; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; Rosner B., 2011, FUNDAMENTALS BIOSTAT, P352; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; Sonakul D, 1992, Southeast Asian J Trop Med Public Health, V23 Suppl 2, P25; SPEICH R, 1991, CHEST, V100, P1268, DOI 10.1378/chest.100.5.1268; Stewart GW, 1996, BRIT J HAEMATOL, V93, P303, DOI 10.1046/j.1365-2141.1996.4881033.x; Sumiyoshi A, 1992, Southeast Asian J Trop Med Public Health, V23 Suppl 2, P29	12	124	131	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	1999	130	6					506	509		10.7326/0003-4819-130-6-199903160-00014	http://dx.doi.org/10.7326/0003-4819-130-6-199903160-00014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	176RL	10075618				2022-12-01	WOS:000079165500006
J	Robertson, RG				Robertson, RG			Sherry and Richard	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1999	281	10					874	874		10.1001/jama.281.10.874-a	http://dx.doi.org/10.1001/jama.281.10.874-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172XH	10078463				2022-12-01	WOS:000078950600001
J	Passner, JM; Ryoo, HD; Shen, LY; Mann, RS; Aggarwal, AK				Passner, JM; Ryoo, HD; Shen, LY; Mann, RS; Aggarwal, AK			Structure of a DNA-bound Ultrabithorax-Extradenticle homeodomain complex	NATURE			English	Article							CRYSTAL-STRUCTURE; HOMEOTIC GENE; SPECIFICITY; HOX; DROSOPHILA; PROTEINS; BINDING; MODEL; RECOGNITION; HETERODIMER	During the development of multicellular organisms, gene expression must be tightly regulated, both spatially and temporally, One set of transcription factors that are important in animal development is encoded by the homeotic (Hox) genes, which govern the choice between alternative developmental pathways along the anterior-posterior axis(1,2). Hox proteins, such as Drosophila Ultrabithorax, have low DNA-binding specificity by themselves but gain affinity and specificity when they bind together with the homeoprotein Extradenticle (or Pbx1 in mammals)(3,4). To understand the structural basis of Hox-Extradenticle pairing, we determine here the crystal structure of an Ultrabithorax-Extradenticle-DNA complex at 2.4 Angstrom resolution, using the minimal polypeptides that form a cooperative heterodimer. The Ultrabithorax and Extradenticle homeodomains bind opposite faces of the DNA, with their DNA-recognition helices almost touching each other. However, most of the cooperative interactions arise from the YPWM amino-acid motif of Ultrabithorax-located amino-terminally to its homeodomain-which forms a reverse turn and inserts into a hydrophobic pocket on the Extradenticle homeodomain surface. Together, these protein-DNA and protein-protein interactions define the general principles by which homeotic proteins interact with Extradenticle (or Pbx1) to affect development along the anterior-posterior axis of animals.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University	Aggarwal, AK (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, Box 1677,1425 Madison Ave, New York, NY 10029 USA.	aggarwal@inka.mssm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Chan SK, 1996, EMBO J, V15, P2476, DOI 10.1002/j.1460-2075.1996.tb00605.x; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1996, MOL CELL BIOL, V16, P1734; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fraenkel E, 1998, NAT STRUCT BIOL, V5, P692, DOI 10.1038/1382; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lu Q, 1996, MOL CELL BIOL, V16, P1632; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Wolberger C, 1996, CURR OPIN STRUC BIOL, V6, P62, DOI 10.1016/S0959-440X(96)80096-0	30	256	262	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1999	397	6721					714	719		10.1038/17833	http://dx.doi.org/10.1038/17833			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067897				2022-12-01	WOS:000078840100055
J	Schreiber, S; Nikolaus, S; Hampe, J; Hamling, J; Koop, I; Groessner, B; Lochs, H; Raedler, A				Schreiber, S; Nikolaus, S; Hampe, J; Hamling, J; Koop, I; Groessner, B; Lochs, H; Raedler, A			Tumour necrosis factor a and interleukin 1 beta in relapse of Crohn's disease	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; CHIMERIC MONOCLONAL-ANTIBODY; FACTOR-ALPHA; MAINTENANCE TREATMENT; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; PLACEBO; INDEX; CA2	Background Concentrations of proinflammatory cytokines are increased in the intestinal mucosa of patients with active Crohn's disease. Experimental immunotherapeutic interventions with anticytokine agents in refractory Crohn's disease show that tumour necrosis factor cw (TNF alpha) may be an important mediator,of inflammation. We investigated the relation between production of TNF alpha and interleukin 1 beta by mononuclear cells of the colonic lamina propria in patients with remitting Crohn's disease and the risk of relapse. Methods We followed up 137 patients with Crohn's disease in steroid-induced remission for 1 year. Secretion of proinflammatory cytokines (tumour necrosis factor alpha [TNF alpha] and interleukin 1 beta) was assessed after short-term culture of human lamina propria mononuclear cells. Findings Increased secretion of TNF alpha and interleukin 1 beta were predictive for acute relapses within the next year. Site and extent of disease, baseline demographics, and serum acute-phase proteins had little predictive value. Interpretation TNF alpha is important as a target molecule for immune interventions in Crohn's disease. The capacity to produce TNFa or interleukin 1 beta may identify patients who would benefit from anti-inflammatory remission maintenance.	Univ Kiel, Dept Med 1, D-24105 Kiel, Germany; Univ Kiel, Dept Conservat Dent & Paradontol, D-24105 Kiel, Germany; Humboldt Univ, Charite Univ Hosp, 4th Med Dept, Berlin, Germany; Tabea Ctr Inflammatory Bowel Dis, Hamburg, Germany	University of Kiel; University of Kiel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schreiber, S (corresponding author), Univ Kiel, Dept Med 1, D-24105 Kiel, Germany.	s.schreiber@mucosa.de	Hampe, Jochen/A-2555-2010	Hampe, Jochen/0000-0002-2421-6127				BELLUZI A, 1996, NEW ENGL J MED, V334, P1567; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRIGNOLA C, 1986, GASTROENTEROLOGY, V91, P1490, DOI 10.1016/0016-5085(86)90206-4; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; GENDRE JP, 1993, GASTROENTEROLOGY, V104, P435, DOI 10.1016/0016-5085(93)90411-5; Greenberg GR, 1996, GASTROENTEROLOGY, V110, P45, DOI 10.1053/gast.1996.v110.pm8536887; Hanauer SB, 1996, NEW ENGL J MED, V334, P841, DOI 10.1056/NEJM199603283341307; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MUNKHOLM P, 1995, SCAND J GASTROENTERO, V30, P699, DOI 10.3109/00365529509096316; REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174; RILEY SA, 1991, GUT, V32, P174, DOI 10.1136/gut.32.2.174; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P1434, DOI 10.1016/0016-5085(95)90692-4; Stack WA, 1997, LANCET, V349, P521, DOI 10.1016/S0140-6736(97)80083-9; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; WRIGHT JP, 1987, DIGEST DIS SCI, V32, P164, DOI 10.1007/BF01297104; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H	19	239	246	1	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 6	1999	353	9151					459	461		10.1016/S0140-6736(98)03339-X	http://dx.doi.org/10.1016/S0140-6736(98)03339-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989717				2022-12-01	WOS:000078572800013
J	Nightingale, SL				Nightingale, SL			Journal editors act to enhance reporting of public health hazards	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					408	408		10.1001/jama.281.5.408	http://dx.doi.org/10.1001/jama.281.5.408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952188				2022-12-01	WOS:000078318500009
J	Chapman, CR				Chapman, CR			Planetary science - Probing Europa's third dimension	SCIENCE			English	Editorial Material									SW Res Inst, Space Studies Dept, Boulder, CO 80302 USA		Chapman, CR (corresponding author), SW Res Inst, Space Studies Dept, Boulder, CO 80302 USA.							*AM ASTR SOC, 1998, M GEOL SOC AM TOR CA; Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; KUIPER GP, 1966, JET PROPULS LAB TECH, V32, P35; Moore JM, 1998, ICARUS, V135, P127, DOI 10.1006/icar.1998.5973; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; SHOEMAKER EM, 1996, EUR OC C SAN JUAN CA; 1998, ICARUS, V135	9	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					338	339		10.1126/science.283.5400.338	http://dx.doi.org/10.1126/science.283.5400.338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925494				2022-12-01	WOS:000078067000030
J	England, PM; Zhang, YN; Dougherty, DA; Lester, HA				England, PM; Zhang, YN; Dougherty, DA; Lester, HA			Backbone mutations in transmembrane domains of a ligand-gated ion channel: Implications for the mechanism of gating	CELL			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; FROG NEUROMUSCULAR-JUNCTION; SITE-SPECIFIC INCORPORATION; UNNATURAL AMINO-ACIDS; END-PLATE CURRENTS; ALPHA-SUBUNIT; LINING RESIDUES; BINDING-SITE; M2 DOMAIN; PROTEINS	An approach to identify backbone conformational changes underlying nicotinic acetylcholine receptor (nAChR) gating was developed. Specific backbone peptide bonds were replaced with an ester, which disrupts backbone hydrogen bonds at the site of mutation. At a conserved proline residue (alpha Pro221) in the first transmembrane (M1) domain, the amide-to-ester mutation provides receptors with near-normal sensitivity, although the natural amino acids tested other than Pro produce receptors that gate with a much larger EC50 than normal. Therefore, a backbone hydrogen bond at this site may interfere with normal gating. In the alpha M2 domain, the amide-to-ester mutation yielded functional receptors at 15 positions, 3 of which provided receptors with >10-fold lower EC50 than wild type. These results support a model for gating that includes significant changes of backbone conformation within the M2 domain.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Lester, HA (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	lester@caltech.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756, R01NS034407, R37NS034407] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34407, NS11756] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS PR, 1981, J MEMBRANE BIOL, V58, P161, DOI 10.1007/BF01870902; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; Auerbach A, 1996, J PHYSIOL-LONDON, V494, P155, DOI 10.1113/jphysiol.1996.sp021482; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Chapman E, 1997, J AM CHEM SOC, V119, P7151, DOI 10.1021/ja970826+; CHARNET P, 1990, NEURON, V2, P87; COLQUHOUN D, 1977, PROC R SOC SER B-BIO, V199, P231, DOI 10.1098/rspb.1977.0137; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; DOYKLE D, 1998, SCIENCE, V280, P69; Edelstein SJ, 1998, ADV PROTEIN CHEM, V51, P121; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; HERZ JM, 1989, J BIOL CHEM, V264, P12439; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kearney PC, 1996, NEURON, V17, P1221, DOI 10.1016/S0896-6273(00)80252-4; Kearney PC, 1996, MOL PHARMACOL, V50, P1401; Koh JT, 1997, BIOCHEMISTRY-US, V36, P11314, DOI 10.1021/bi9707685; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LIDE DR, 1990, HDB CHEM PHYSICS, P7; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P173, DOI 10.1113/jphysiol.1972.sp009840; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P151, DOI 10.1113/jphysiol.1972.sp009839; NEHER E, 1975, P NATL ACAD SCI USA, V72, P2140, DOI 10.1073/pnas.72.6.2140; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; Nowak MW, 1998, METHOD ENZYMOL, V293, P504; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Saks ME, 1996, J BIOL CHEM, V271, P23169, DOI 10.1074/jbc.271.38.23169; SANKARARAMAKRISHNAN R, 1992, INT J PEPT PROT RES, V39, P356; SHERIDAN RE, 1977, J GEN PHYSIOL, V70, P187; SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; Zhang H, 1997, BIOCHEMISTRY-US, V36, P15856, DOI 10.1021/bi972357u; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	41	111	149	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					89	98		10.1016/S0092-8674(00)80962-9	http://dx.doi.org/10.1016/S0092-8674(00)80962-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989500	Bronze			2022-12-01	WOS:000078023200011
J	HSIEH, LC; YONKOVICH, S; KOCHERSPERGER, L; SCHULTZ, PG				HSIEH, LC; YONKOVICH, S; KOCHERSPERGER, L; SCHULTZ, PG			CONTROLLING CHEMICAL-REACTIVITY WITH ANTIBODIES	SCIENCE			English	Article							ENANTIOSELECTIVE REDUCTION; ORGANIC-SYNTHESIS; KETONES; MANDELATE	The remarkable specificity of an antibody molecule has been used to accomplish highly selective functional group transformations not attainable by current chemical methods. An antibody raised against an amine-oxide hapten catalyzes the reduction of a diketone to a hydroxyketone with greater than 75:1 regioselectivity for one of two nearly equivalent ketone moieties. The antibody-catalyzed reaction is highly stereoselective, affording the hydroxyketone in high enantiomeric excess. Similarly, the reduction of ketones containing branched and aryl substituents, including the highly symmetrical 1-nitrophenyl-3-phenyl-2-propanone, was enantioselective. The simple strategy presented herein may find general applicability to the regio- and stereoselective reduction of a broad range of compounds.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; AFFYMAX RES INST,DEPT BIOORGAN CHEM,PALO ALTO,CA 94304	University of California System; University of California Berkeley								COREY EJ, 1990, TETRAHEDRON LETT, V31, P611, DOI 10.1016/S0040-4039(00)94581-7; COREY EJ, 1987, J AM CHEM SOC, V109, P5551, DOI 10.1021/ja00252a056; DALE JA, 1973, J AM CHEM SOC, V95, P512, DOI 10.1021/ja00783a034; Finn MG, 1985, ASYMMETRIC SYNTHESIS, P247; GLADYSZ JA, 1992, ENANTIOSELECTIVE SYN, V92, P739; GONG B, 1992, J AM CHEM SOC, V114, P1486, DOI 10.1021/ja00030a056; GREENE TW, 1991, PROTECTIVE GROUPS OR; HUMMEL W, 1989, EUR J BIOCHEM, V184, P1, DOI 10.1111/j.1432-1033.1989.tb14983.x; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KAGAN HB, 1982, COMPREHENSIVE ORGANO, V8, P463; KATSUKI T, 1980, J AM CHEM SOC, V102, P5974, DOI 10.1021/ja00538a077; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAYAMA GR, 1992, J AM CHEM SOC, V114, P780, DOI 10.1021/ja00028a066; NOYORI R, 1989, MOD SYN MET, V5, P115; OJIMA I, 1985, ASYMMETRIC SYNTHESIS, V5, P104; SANTANIELLO E, 1992, CHEM REV, V92, P1071, DOI 10.1021/cr00013a016; SEEBACH D, 1990, ANGEW CHEM INT EDIT, V29, P1320, DOI 10.1002/anie.199013201; SIH CJ, 1984, ANGEW CHEM INT EDIT, V23, P570, DOI 10.1002/anie.198405701; SUH JH, 1991, B KOR CHEM SOC, V12, P352; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; WAI JSM, 1989, J AM CHEM SOC, V111, P1123, DOI 10.1021/ja00185a050; WANG L, 1992, J AM CHEM SOC, V114, P7568, DOI 10.1021/ja00045a042; WONG CH, 1989, SCIENCE, V244, P1145, DOI 10.1126/science.2658059; XU DQ, 1992, J AM CHEM SOC, V114, P7570, DOI 10.1021/ja00045a043; ZASSINOVICH G, 1992, CHEM REV, V92, P1051, DOI 10.1021/cr00013a015	26	63	67	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					337	339		10.1126/science.10049109	http://dx.doi.org/10.1126/science.10049109			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	10049109				2022-12-01	WOS:A1993KX80000033
J	Nakashima, K; Yanagisawa, M; Arakawa, H; Kimura, N; Hisatsune, T; Kawabata, M; Miyazono, K; Taga, T				Nakashima, K; Yanagisawa, M; Arakawa, H; Kimura, N; Hisatsune, T; Kawabata, M; Miyazono, K; Taga, T			Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; FIBRILLARY ACIDIC PROTEIN; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; TUMOR-SUPPRESSOR; SMAD PROTEINS; STEM-CELLS; DIFFERENTIATION; EXPRESSION; CBP/P300	The cytokines LIF (leukemia inhibitor factor) and BMP2 (bone morphogenetic protein-2) signal through different receptors and transcription factors, namely STATs (signal transducers and activators of transcription) and Smads. LIF and BMP2 were found to act in synergy on primary fetal neural progenitor cells to induce astrocytes. The transcriptional coactivator p300 interacts physically with STAT3 at its amino terminus in a cytokine stimulation-independent manner, and with Smad1 at its carboxyl terminus in a cytokine stimulation-dependent manner. The formation of a complex between STAT3 and Smad1, bridged by p300, is involved in the cooperative signaling of LIF and BMP2 and the subsequent induction of astrocytes from neural progenitors.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cell Biol, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Med Res Inst, Cell Fate Modulat Res Unit, Tokyo 1010062, Japan; Univ Tokyo, Dept Appl Biol Chem, Tokyo 1138857, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Tokyo 1708455, Japan; Japan Soc Promot Sci, Res Future Program, Tokyo 1708455, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Tokyo; Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science	Taga, T (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cell Biol, Tokyo 1010062, Japan.		Hisatsune, Tatsuhiro/Q-7583-2019					Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kahn MA, 1997, J NEUROCHEM, V68, P1413; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nakashima K, 1997, FEBS LETT, V401, P49, DOI 10.1016/S0014-5793(96)01430-5; NAKASHIMA K, UNPUB; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Rajan P, 1998, J NEUROSCI, V18, P3620; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	27	698	726	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					479	482		10.1126/science.284.5413.479	http://dx.doi.org/10.1126/science.284.5413.479			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205054				2022-12-01	WOS:000079792200045
J	Trotter, Y; Celebrini, S				Trotter, Y; Celebrini, S			Gaze direction controls response gain in primary visual-cortex neurons	NATURE			English	Article							POSTERIOR PARIETAL NEURONS; EYE POSITION; PRESTRIATE CORTEX; VIEWING DISTANCE; MACAQUE MONKEY; GENICULATE; ACTIVATION; MODULATION; STRIATE; MST	To localize objects in space, the brain needs to combine information about the position of the stimulus on the retinae with information about the location of the eyes in their orbits. Interaction between these two types of information occurs in several cortical areas(1-12), but the role of the primary visual cortex (area V1) in this process has remained unclear. Here we show that, for half the cells recorded in area V1 of behaving monkeys, the classically described visual responses are strongly modulated by gaze direction, Specifically, we find that selectivity for horizontal retinal disparity-the difference in the position of a stimulus on each retina which relates to relative object distance-and for stimulus orientation may be present at a given gaze direction, but be absent or poorly expressed at another direction. Shifts in preferred disparity also occurred in several neurons. These neural changes were most often present at the beginning of the visual response, suggesting a feedforward gain control by eye position signals. Cortical neural processes for encoding information about the three-dimensional position of a stimulus in space therefore start as early as area V1.	Univ Toulouse 3, Fac Med Rangueil, Ctr Rech Cerveau & Cognit, F-31062 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Trotter, Y (corresponding author), Univ Toulouse 3, Fac Med Rangueil, Ctr Rech Cerveau & Cognit, 133 Route Narbonne, F-31062 Toulouse, France.	trotter@cerco.ups-tlse.fr	Trotter, Yves/G-7333-2011; celebrini, simona/H-2169-2011					ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; BOUSSAOUD D, 1993, EXP BRAIN RES, V93, P423; DONALDSON IML, 1980, EXP BRAIN RES, V38, P245; Duhamel JR, 1997, NATURE, V389, P845, DOI 10.1038/39865; GALLETTI C, 1989, J NEUROSCI, V9, P1112; Galletti C, 1995, EUR J NEUROSCI, V7, P2486, DOI 10.1111/j.1460-9568.1995.tb01047.x; GIBLERT CD, 1998, PHYSIOL REV, V78, P467; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; Guo K, 1997, NEUROREPORT, V8, P1405, DOI 10.1097/00001756-199704140-00017; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; LAL R, 1989, SCIENCE, V243, P93, DOI 10.1126/science.2911723; Lamme VAF, 1998, CURR OPIN NEUROBIOL, V8, P529, DOI 10.1016/S0959-4388(98)80042-1; MOLOTCHNIKOFF S, 1985, J NEUROSCI RES, V14, P105, DOI 10.1002/jnr.490140110; MORRISON LC, 1977, AM J OPTOM PHYSL OPT, V54, P536; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; NEWSOME WT, 1988, J NEUROPHYSIOL, V60, P604, DOI 10.1152/jn.1988.60.2.604; OGLE KN, 1962, PROBLEM HOROPTER, P325; OGLE KN, 1962, SPATIAL LOCALIZATION, P271; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; Squatrito S, 1996, VISUAL NEUROSCI, V13, P385, DOI 10.1017/S0952523800007628; Trotter Y, 1996, J NEUROPHYSIOL, V76, P2872, DOI 10.1152/jn.1996.76.5.2872; TROTTER Y, 1992, SCIENCE, V257, P1279, DOI 10.1126/science.1519066; WEYAND TG, 1993, J NEUROPHYSIOL, V69, P2258, DOI 10.1152/jn.1993.69.6.2258; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0; Zipser K, 1996, J NEUROSCI, V16, P7376	28	141	143	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	1999	398	6724					239	242		10.1038/18444	http://dx.doi.org/10.1038/18444			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UA	10094046				2022-12-01	WOS:000079228400053
J	Westphal, CH; Muller, L; Zhou, A; Zhu, XR; Bonner-Weir, S; Schambelan, M; Steiner, DF; Lindberg, I; Leder, P				Westphal, CH; Muller, L; Zhou, A; Zhu, XR; Bonner-Weir, S; Schambelan, M; Steiner, DF; Lindberg, I; Leder, P			The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease	CELL			English	Article							PROHORMONE CONVERTASE PC2; DOPAMINERGIC REGULATION; PROPROTEIN CONVERTASES; GENE-EXPRESSION; POLYPEPTIDE 7B2; TRANSGENIC MICE; RAT PITUITARY; GROWTH-FACTOR; CELLS; PROOPIOMELANOCORTIN	The neuroendocrine protein 7B2 has been implicated in activation of prohormone convertase 2 (PC2), an important neuroendocrine precursor processing endoprotease. To test this hypothesis, we created a null mutation in 7B2 employing a novel transposon-facilitated technique and compared the phenotypes of 7B2 and PC2 nulls. 7B2 null mice have no demonstrable PC2 activity, are deficient in processing islet hormones, and display hypoglycemia, hyperproinsulinemia, and hypoglucagonemia. In contrast to the PC2 null phenotype, these mice show markedly elevated circulating ACTH and corticosterone levels, with adrenocortical expansion. They die before 9 weeks of severe Cushing's syndrome arising from pituitary intermediate lobe ACTH hypersecretion. We conclude that 7B2 is indeed required for activation of PC2 in vivo but has additional important functions in regulating pituitary hormone secretion.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem, Chicago, IL 60637 USA; Joslin Diabet Ctr 535, Boston, MA 02215 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Louisiana State University System; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; University of Chicago; University of Chicago; Harvard University; Joslin Diabetes Center, Inc.; University of California System; University of California San Francisco	Lindberg, I (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	ilindb@lsumc.edu; leder@rascal.med.harvard.edu	Lindberg, Iris/Q-3825-2019; muller, laurent/S-1990-2016	muller, laurent/0000-0001-9634-4323; Bonner-Weir, Susan/0000-0003-4682-0656	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00204, R56 DA005084, DA05084] Funding Source: Medline; NIDDK NIH HHS [R01 DK049703, DK49703] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUTELITANO DJ, 1989, ANNU REV PHYSIOL, V51, P715, DOI 10.1146/annurev.ph.51.030189.003435; Benjannet S, 1998, FEBS LETT, V428, P37, DOI 10.1016/S0014-5793(98)00480-3; BENJANNET S, 1995, FEBS LETT, V362, P151, DOI 10.1016/0014-5793(95)00228-2; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BORRELLI E, 1992, P NATL ACAD SCI USA, V89, P2764, DOI 10.1073/pnas.89.7.2764; Bosse R, 1997, NEURON, V19, P127, DOI 10.1016/S0896-6273(00)80353-0; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Braks JAM, 1996, EUR J BIOCHEM, V236, P60, DOI 10.1111/j.1432-1033.1996.00060.x; CASTRO MG, 1989, MOL CELL ENDOCRINOL, V65, P165, DOI 10.1016/0303-7207(89)90177-9; CHRONWALL BM, 1987, ENDOCRINOLOGY, V120, P1201, DOI 10.1210/endo-120-3-1201; Collini P, 1998, VIRCHOWS ARCH, V432, P505, DOI 10.1007/s004280050198; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DEVINE SE, 1994, NUCLEIC ACIDS RES, V22, P3765, DOI 10.1093/nar/22.18.3765; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; HU NP, 1994, ONCOGENE, V9, P1021; IGUCHI H, 1984, NEUROENDOCRINOLOGY, V39, P453, DOI 10.1159/000124020; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; Johanning K, 1996, J BIOL CHEM, V271, P27871, DOI 10.1074/jbc.271.44.27871; Kelly MA, 1997, NEURON, V19, P103, DOI 10.1016/S0896-6273(00)80351-7; LAMBERTS SWJ, 1980, J CLIN ENDOCR METAB, V51, P307, DOI 10.1210/jcem-51-2-307; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; MARCINKIEWICZ M, 1994, NEUROSCI LETT, V177, P91, DOI 10.1016/0304-3940(94)90052-3; MCANDREW J, 1995, ENDOCRINOLOGY, V136, P4479, DOI 10.1210/en.136.10.4479; Meier CA, 1997, ENDOCRIN METAB CLIN, V26, P741, DOI 10.1016/S0889-8529(05)70280-2; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; OHASHI M, 1990, HORM METAB RES, V22, P114, DOI 10.1055/s-2007-1004862; ORTH DN, 1982, ENDOCRINOLOGY, V111, P559, DOI 10.1210/endo-111-2-559; Oyarce AM, 1996, J NEUROCHEM, V67, P229; ROEBROEK AJM, 1989, CANCER RES, V49, P4154; Rosenfeld MG, 1996, RECENT PROG HORM RES, V51, P217; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Saiardi A, 1998, MOL ENDOCRINOL, V12, P1133, DOI 10.1210/me.12.8.1133; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Seidel B, 1998, DNA CELL BIOL, V17, P1017, DOI 10.1089/dna.1998.17.1017; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STENZELPOORE MP, 1992, ENDOCRINOLOGY, V130, P3378, DOI 10.1210/en.130.6.3378; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; Van Horssen AM, 1998, MOL CELL ENDOCRINOL, V137, P7, DOI 10.1016/S0303-7207(97)00237-2; VIEAU D, 1992, CLIN ENDOCRINOL, V36, P597, DOI 10.1111/j.1365-2265.1992.tb02271.x; Wang CC, 1997, GENOMICS, V39, P303, DOI 10.1006/geno.1996.4519; Westphal GH, 1997, CURR BIOL, V7, P530, DOI 10.1016/S0960-9822(06)00224-7; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1998, J BIOL CHEM, V273, P1158, DOI 10.1074/jbc.273.2.1158; Zhu XR, 1996, J BIOL CHEM, V271, P23582, DOI 10.1074/jbc.271.38.23582	55	154	159	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	1999	96	5					689	700		10.1016/S0092-8674(00)80579-6	http://dx.doi.org/10.1016/S0092-8674(00)80579-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	174TB	10089884	Bronze			2022-12-01	WOS:000079050100012
J	Wilde, A; Beattie, EC; Lem, L; Riethof, DA; Liu, SH; Mobley, WC; Soriano, P; Brodsky, FM				Wilde, A; Beattie, EC; Lem, L; Riethof, DA; Liu, SH; Mobley, WC; Soriano, P; Brodsky, FM			EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; COATED PIT FORMATION; PROTEIN TYROSINE KINASE; SYMPATHETIC NEURONS; SURFACE-MORPHOLOGY; FAMILY KINASES; RAPID CHANGES; C-SRC; ENDOCYTOSIS; CELLS	Epidermal growth factor (EGF) binding to its receptor causes rapid phosphorylation of the clathrin heavy chain at tyrosine 1477, which lies in a domain controlling clathrin assembly. EGF-mediated clathrin phosphorylation is followed by clathrin redistribution to the cell periphery and is the product of downstream activation of SRC kinase by EGF receptor (EGFR) signaling. In cells lacking SRC kinase, or cells treated with a specific SRC family kinase inhibitor, EGF stimulation of clathrin phosphorylation and redistribution does not occur, and EGF endocytosis is delayed. These observations demonstrate a role for SRC kinase in modification and recruitment of clathrin during ligand-induced EGFR endocytosis and thereby define a novel effector mechanism for regulation of endocytosis by receptor signaling.	Univ Calif San Francisco, Dept Immunol & Microbiol, GW Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Fred Hutchinson Cancer Center	Brodsky, FM (corresponding author), Univ Calif San Francisco, Dept Immunol & Microbiol, GW Hooper Fdn, San Francisco, CA 94143 USA.	fmarbro@itsa.ucsf.edu	Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Brodsky, Frances/0000-0002-1334-9258	NIGMS NIH HHS [GM57657, GM38093] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057657, R01GM038093] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BLANK GS, 1987, J CELL BIOL, V105, P2011, DOI 10.1083/jcb.105.5.2011; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; CADENA DL, 1994, J BIOL CHEM, V269, P260; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; CONNOLLY JL, 1981, J CELL BIOL, V90, P176, DOI 10.1083/jcb.90.1.176; CORVERA S, 1990, J BIOL CHEM, V265, P2413; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FEDER D, 1990, J BIOL CHEM, V265, P8205; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/cjpp-74-10-1095; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; FREEDMAN NJ, 1996, RECENT PROG HORM RES, V51, P352; GEISOW MJ, 1985, EUR J CELL BIOL, V38, P51; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Grimes ML, 1996, J NEUROSCI, V16, P7950; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HOLEN I, 1995, J BIOL CHEM, V270, P12823, DOI 10.1074/jbc.270.21.12823; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LIN PH, 1995, ONCOGENE, V10, P401; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MARTINPEREZ J, 1989, J CELL BIOL, V109, P577, DOI 10.1083/jcb.109.2.577; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Stenberg PE, 1997, BLOOD, V89, P2384, DOI 10.1182/blood.V89.7.2384; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	289	292	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	1999	96	5					677	687		10.1016/S0092-8674(00)80578-4	http://dx.doi.org/10.1016/S0092-8674(00)80578-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	174TB	10089883	Bronze			2022-12-01	WOS:000079050100011
J	Costigan, DJ				Costigan, DJ			Trying to let go	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Costigan, DJ (corresponding author), 10007 Kennerly Rd, St Louis, MO 63128 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					446	446		10.7326/0003-4819-130-5-199903020-00006	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068422				2022-12-01	WOS:000078898100011
J	Schulman, KA; Berlin, JA; Harless, W; Kerner, JF; Sistrunk, S; Gersh, BJ; Dube, R; Taleghani, CK; Burke, JE; Williams, S; Eisenberg, JM; Escarce, JJ				Schulman, KA; Berlin, JA; Harless, W; Kerner, JF; Sistrunk, S; Gersh, BJ; Dube, R; Taleghani, CK; Burke, JE; Williams, S; Eisenberg, JM; Escarce, JJ			The effect of race and sex on physicians' recommendations for cardiac catheterization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; IN-HOSPITAL MORTALITY; OF-VETERANS-AFFAIRS; RACIAL-DIFFERENCES; REVASCULARIZATION PROCEDURES; CARDIOVASCULAR PROCEDURES; RHEUMATOID-ARTHRITIS; REFERRAL PATTERNS; CLINICAL JUDGMENT	Background Epidemiologic studies have reported differences in the use of cardiovascular procedures according to the race and sex of the patient. Whether the differences stem from differences in the recommendations of physicians remains uncertain. Methods We developed a computerized survey instrument to assess physicians' recommendations for managing chest pain. Actors portrayed patients with particular characteristics in scripted interviews about their symptoms. A total of 720 physicians at two national meetings of organizations of primary care physicians participated in the survey. Each physician viewed a recorded interview and was given other data about a hypothetical patient. He or she then made recommendations about that patient's care. We used multivariate logistic-regression analysis to assess the effects of the race and sex of the patients on treatment recommendations, while controlling for the physicians' assessment of the probability of coronary artery disease as well as for the age of the patient, the level of coronary risk, the type of chest pain, and the results of an exercise stress test. Results The physicians' mean (+/-SD) estimates of the probability of coronary artery disease were tower for women (probability, 64.1+/-19.3 percent, vs. 69.2+/-18.2 percent for men; P<0.001), younger patients (63.8+/-19.5 percent for patients who were 55 years old, vs. 69.5+/-17.9 percent for patients who were 70 years old; P<0.001), and patients with non-anginal pain (58.3+/-19.0 percent, vs. 64.4+/-18.3 percent for patients with possible angina and 77.1+/-14.0 percent for those with definite angina; P<0.001). Logistic-regression analysis indicated that women (odds ratio, 0.60; 95 percent confidence interval, 0.4 to 0.9; P=0.02) and blacks (odds ratio, 0.60; 95 percent confidence interval, 0.4 to 0.9; P=0.02) were less likely to be referred for cardiac catheterization than men and whites, respectively. Analysis of race-sex interactions showed that black women were significantly less likely to be referred for catheterization than white men (odds ratio, 0.4; 95 percent confidence interval, 0.2 to 0.7; P=0.004). Conclusions Our findings suggest that the race and sex of a patient independently influence how physicians manage chest pain. (N Engl J Med 1999;340:618-26.) (C)1999, Massachusetts Medical Society.	Georgetown Univ, Med Ctr, Clin Econ Res Unit, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Div Gen Internal Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Div Cardiol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; Interact Drama, Bethesda, MD USA; RAND Hlth Program, Santa Monica, CA USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University; Georgetown University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; RAND Corporation	Schulman, KA (corresponding author), Georgetown Univ, Med Ctr, Clin Econ Res Unit, 2233 Wisconsin Ave NW,Suite 440, Washington, DC 20007 USA.			Kerner, Jon/0000-0002-8792-3830	AHRQ HHS [HS07315] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Abbott RD, 1987, NIH PUBLICATION, V87-2703; ADES PA, 1992, AM J CARDIOL, V69, P1422, DOI 10.1016/0002-9149(92)90894-5; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BEERY TA, 1995, HEART LUNG, V24, P427, DOI 10.1016/S0147-9563(95)80020-4; BEGG MD, 1993, J AM STAT ASSOC, V88, P166, DOI 10.2307/2290710; BELL MR, 1993, JAMA-J AM MED ASSOC, V269, P2091, DOI 10.1001/jama.269.16.2091; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BLUSTEIN J, 1995, AM J PUBLIC HEALTH, V85, P345, DOI 10.2105/AJPH.85.3.345; Carlisle DM, 1997, AM J PUBLIC HEALTH, V87, P263, DOI 10.2105/AJPH.87.2.263; DEVINE PG, 1989, J PERS SOC PSYCHOL, V56, P5, DOI 10.1037/0022-3514.56.1.5; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; DIAMOND GA, 1983, J AM COLL CARDIOL, V1, P474; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; Ferguson JA, 1997, J AM COLL CARDIOL, V30, P1707, DOI 10.1016/S0735-1097(97)00365-3; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KIMMEL SE, 1995, J AM COLL CARDIOL, V26, P931, DOI 10.1016/0735-1097(95)00294-4; KIRWAN JR, 1983, ANN RHEUM DIS, V42, P644, DOI 10.1136/ard.42.6.644; KIRWAN JR, 1983, J RHEUMATOL, V10, P901; Laouri M, 1997, J AM COLL CARDIOL, V29, P891, DOI 10.1016/S0735-1097(96)00434-2; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MCNUTT RA, 1992, MED DECIS MAKING, V12, P342; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; SCHULMAN KA, 1992, MED DECIS MAKING, V12, P109, DOI 10.1177/0272989X9201200203; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WIGTON RS, 1990, ACAD MED, V65, pS5, DOI 10.1097/00001888-199009000-00017	40	1361	1366	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					618	626		10.1056/NEJM199902253400806	http://dx.doi.org/10.1056/NEJM199902253400806			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	169NP	10029647				2022-12-01	WOS:000078755700006
J	Okada, Y; Hirokawa, N				Okada, Y; Hirokawa, N			A processive single-headed motor: Kinesin superfamily protein KIF1A	SCIENCE			English	Article							STIMULATED ATP HYDROLYSIS; MICROTUBULE INTERACTION; MOLECULES; MECHANISM; MOVEMENT; DOMAINS; NECK; MICROSCOPY; KINETICS; MYOSIN	A single kinesin molecule can move "processively" along a microtubule for more than 1 micrometer before detaching from it. The prevailing explanation far this processive movement is the "walking model," which envisions that each of two motor domains (heads) of the kinesin molecule binds coordinately to the microtubule. This implies that each kinesin molecule must have two heads to "walk" and that a single-headed kinesin could not move processively. Here, a motor-domain construct of KIF1A, a single-headed kinesin superfamily protein, was shown to move processively along the microtubule for more than 1 micrometer. The movement along the microtubules was stochastic and fitted a biased Brownian-movement model.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Hongo, Tokyo 1130033, Japan.		Okada, Yasushi/N-5067-2015	Okada, Yasushi/0000-0003-2601-3689				Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Chandrasekhar S, 1943, REV MOD PHYS, V15, P0001, DOI 10.1103/RevModPhys.15.1; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Inoue Y, 1997, P NATL ACAD SCI USA, V94, P7275, DOI 10.1073/pnas.94.14.7275; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; NAKATA T, 1993, BIOPHYS J, V65, P2504, DOI 10.1016/S0006-3495(93)81304-3; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; Tripet B, 1997, J BIOL CHEM, V272, P8946; Tucker C, 1997, J BIOL CHEM, V272, P9481; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	34	349	355	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1152	1157		10.1126/science.283.5405.1152	http://dx.doi.org/10.1126/science.283.5405.1152			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024239				2022-12-01	WOS:000078738400048
J	Wood, ER; Dudchenko, PA; Eichenbaum, H				Wood, ER; Dudchenko, PA; Eichenbaum, H			The global record of memory in hippocampal neuronal activity	NATURE			English	Article							UNIT-ACTIVITY; SAMPLE PERFORMANCE; RECOGNITION MEMORY; DELAYED-NONMATCH; RATS; TASK; RESPONSES	In humans the hippocampal region of the brain is crucial for declarative(1) or episodic(2) memory for a broad range of materials. In contrast, there has been controversy over whether the hippocampus mediates a similarly general memory function in other species, or whether it is dedicated to spatial memory processing(3-6). Evidence for the spatial view is derived principally from the observations of 'place cells'-hippocampal neurons that fire whenever the animal is in a particular location in its environment(7,8), or when it perceives a specific stimulus or per forms a specific behaviour in a particular place(3,4). We trained rats to perform the same recognition memory task in several distinct locations in a rich spatial environment and found that the activity of many hippocampal neurons was related consistently to perceptual, behavioural or cognitive events, regardless of the location where these events occurred. These results indicate that nonspatial events are fundamental elements of hippocampal representation, and support the view that, across species, the hippocampus has a broad role in information processing associated with memory.	Boston Univ, Dept Psychol, Lab Cognit Neurobiol, Boston, MA 02215 USA	Boston University	Eichenbaum, H (corresponding author), Boston Univ, Dept Psychol, Lab Cognit Neurobiol, 64 Cummington St, Boston, MA 02215 USA.	hbe@bu.edu						BERGER TW, 1983, J NEUROPHYSIOL, V50, P1197, DOI 10.1152/jn.1983.50.5.1197; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; Cohen, 1993, MEMORY AMNESIA HIPPO, DOI 10.1136/jnnp.58.1.128-a; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; Deadwyler SA, 1996, J NEUROSCI, V16, P354; EICHENBAUM H, 1987, J NEUROSCI, V7, P716; Gothard KM, 1996, J NEUROSCI, V16, P8027; Gothard KM, 1996, J NEUROSCI, V16, P823; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136; MULLER RU, 1987, J NEUROSCI, V7, P1935; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; NADEL L., 1991, HIPPOCAMPUS, V1, P230; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKeefe J, 1996, NATURE, V381, P425, DOI 10.1038/381425a0; OTTO T, 1992, HIPPOCAMPUS, V2, P323, DOI 10.1002/hipo.450020310; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; ROLLS ET, 1993, EXP BRAIN RES, V93, P299; SAKURAI Y, 1994, J NEUROSCI, V14, P2606; Tanila H, 1997, J NEUROSCI, V17, P5155; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Weiss C, 1996, HIPPOCAMPUS, V6, P192, DOI 10.1002/(SICI)1098-1063(1996)6:2<192::AID-HIPO9>3.0.CO;2-R; WIBLE CG, 1986, BRAIN RES, V399, P97, DOI 10.1016/0006-8993(86)90604-9; WIENER SI, 1989, J NEUROSCI, V9, P2737; WILSON FAW, 1990, BEHAV BRAIN RES, V40, P7, DOI 10.1016/0166-4328(90)90038-G; YOUNG BJ, 1994, J NEUROSCI, V14, P6553	27	490	494	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1999	397	6720					613	616		10.1038/17605	http://dx.doi.org/10.1038/17605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050854				2022-12-01	WOS:000078738500049
J	Rich-Edwards, JW; Colditz, GA; Stampfer, MJ; Willett, WC; Gillman, MW; Hennekens, CH; Speizer, FE; Manson, JE				Rich-Edwards, JW; Colditz, GA; Stampfer, MJ; Willett, WC; Gillman, MW; Hennekens, CH; Speizer, FE; Manson, JE			Birthweight and the risk for type 2 diabetes mellitus in adult women	ANNALS OF INTERNAL MEDICINE			English	Article						birth weight; diabetes mellitus, non-insulin-dependent; infant, low birth weight; body weight; diabetes, gestational	IMPAIRED GLUCOSE-TOLERANCE; LOW-PROTEIN-DIET; BIRTH-WEIGHT; FETAL GROWTH; CARDIOVASCULAR-DISEASE; THRIFTY PHENOTYPE; HEART-DISEASE; HYPERTENSION; LIFE; HISTORY	Background: Previous reports have suggested an association between birthweight and type 2 diabetes mellitus. Objective: To investigate the association between birthweight and type 2 diabetes in a large cohort of adult women, taking into account potential explanatory factors in childhood and adult life. Design: Cohort study. Birthweight was ascertained at the end of follow-up. Setting: The Nurses' Health Study, a cohort of 121701 U.S. women born from 1921 to 1946 who have been followed since 1976. Participants: 69526 women in the Nurses' Health Study who were free of diabetes at baseline and reported their own birthweight on the 1992 questionnaire. Measurement: 2123 cases of confirmed type 2 diabetes diagnosed from 1976 to 1992. Results: Low birthweight was associated with increased risk for type 2 diabetes. Age-adjusted relative risks suggested a reverse J-shape association between birthweight and risk for type 2 diabetes. However, after adjustment for adult body mass index and maternal history of diabetes, an inverse association across the entire range of birthweight became apparent; compared with the reference group, relative risks by ascending birthweight category were 1.83 (95% CI, 1.55 to 2.16) for birthweight less than 5.0 Ib, 1.76 (CI, 1.49 to 2.07) for birthweight 5.0 to 5.5 Ib, 1.23 (CI, 1.11 to 1.37) for birthweight 5.6 to 7.0 Ib, 0.95 (Ct, 0.82 to 1.10) for birthweight 8.6 to 10.0 Ib, and 0.83 (CI, 0.63 to 1.07) for birthweight of more than 10 lb (P for trend < 0.001). Adjustment for ethnicity, childhood socioeconomic status, and adult lifestyle factors did not substantially alter this association. The association between birthweight and risk for type 2 diabetes was strongest among women whose mothers had no history of diabetes. Conclusions: Birthweight is inversely associated with risk for type 2 diabetes during adulthood. Examination of prenatal nutrition and other potential in utero determinants of both birthweight and risk for type 2 diabetes may yield new means to prevent type 2 diabetes.			Rich-Edwards, JW (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK36798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALCOLADO JC, 1991, BRIT MED J, V302, P1178, DOI 10.1136/bmj.302.6786.1178; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; DAHRI S, 1995, P NUTR SOC, V54, P345, DOI 10.1079/PNS19950003; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; Forrester TE, 1996, BRIT MED J, V312, P156; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS M, 1979, DIABETES, V28, P1039; Kleinbaum D.G., 1988, STUDENTS PARTIAL SOL; LANGFORD K, 1994, EUR J CLIN INVEST, V24, P851, DOI 10.1111/j.1365-2362.1994.tb02030.x; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; MITCHELL BD, 1993, DIABETES CARE, V16, P1262, DOI 10.2337/diacare.16.9.1262; NEEL JV, 1962, AM J HUM GENET, V14, P353; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; VANASSCHE FA, 1975, CARBOHYD METABOL, P68; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	33	345	358	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	1999	130	4	1				278	+		10.7326/0003-4819-130-4_Part_1-199902160-00005	http://dx.doi.org/10.7326/0003-4819-130-4_Part_1-199902160-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166PY	10068385				2022-12-01	WOS:000078587200004
J	Hedges, SB; Poling, LL				Hedges, SB; Poling, LL			A molecular phylogeny of reptiles	SCIENCE			English	Article							TURTLES; ORIGIN; SEQUENCES; POSITION; BIRDS	The classical phylogeny of Living reptiles pairs crocodilians with birds, tuataras with squamates, and places turtles at the base of the tree. New evidence from two nuclear genes, and analyses of mitochondrial DNA and 22 additional nuclear genes, join crocodilians with turtles and place squamates at the base of the tree. Morphological and paleontological evidence for this molecular phylogeny is unclear. Molecular time estimates support a Triassic origin for the major groups of Living reptiles.	Penn State Univ, Inst Mol Evolut Genet, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Penn State Univ, Astrobiol Res Ctr, Mueller Lab 208, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hedges, SB (corresponding author), Penn State Univ, Inst Mol Evolut Genet, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA.							[Anonymous], 1993, MEGA MOL EVOLUTIONAR; Benton MJ, 1997, VERTEBRATE PALEONTOL; BENTON MJ, 1993, FOSSIL RECORD, V2; deBraga M, 1997, ZOOL J LINN SOC-LOND, V120, P281, DOI 10.1111/j.1096-3642.1997.tb01280.x; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Fushitani K, 1996, MOL BIOL EVOL, V13, P1039, DOI 10.1093/oxfordjournals.molbev.a025654; Gaffney E. S., 1990, B AM MUS NAT HIST, V194, P1; GAFFNEY ES, 1988, PHYLOGENY CLASSIFICA, V1, P157; GOODMAN M, 1987, MOL MORPHOLOGY EVOLU; Gorr TA, 1998, J MOL EVOL, V47, P471, DOI 10.1007/PL00006404; Gu X, 1997, MOL BIOL EVOL, V14, P1106, DOI 10.1093/oxfordjournals.molbev.a025720; HEDGES SB, 1990, MOL BIOL EVOL, V7, P607; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; HEDGES SB, 1994, P NATL ACAD SCI USA, V91, P2621, DOI 10.1073/pnas.91.7.2621; JAMIESON BGM, 1992, PHILOS T ROY SOC B, V335, P207, DOI 10.1098/rstb.1992.0019; Kirsch JAW, 1998, PHILOS T R SOC B, V353, P1221, DOI 10.1098/rstb.1998.0278; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Kumar S., 1996, PHYLTEST PROGRAM TES; LAURIN M, 1995, ZOOL J LINN SOC-LOND, V113, P165, DOI 10.1111/j.1096-3642.1995.tb00932.x; LAURIN M, 1997, COMPLETING TRANSITIO, P9; Lee MSY, 1997, ZOOL J LINN SOC-LOND, V120, P197; Lee MSY, 1996, NATURE, V379, P812, DOI 10.1038/379812a0; Lee MSY, 1997, NATURE, V389, P245, DOI 10.1038/38422; Mannen H, 1997, MOL BIOL EVOL, V14, P1081, DOI 10.1093/oxfordjournals.molbev.a025717; Platz JE, 1997, NATURE, V389, P246, DOI 10.1038/38425; Rieppel O, 1996, NATURE, V384, P453, DOI 10.1038/384453a0; Romer A.S., 1956, OSTEOLOGY REPTILES; Romer AS, 1966, VERTEBRATE PALEONTOL; RZHETSKY A, 1995, MOL BIOL EVOL, V12, P163, DOI 10.1093/oxfordjournals.molbev.a040185; Saita A., 1987, B ZOOL, V4, P307; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wilkinson M, 1997, NATURE, V387, P466, DOI 10.1038/387466a0; Zardoya R, 1998, P NATL ACAD SCI USA, V95, P14226, DOI 10.1073/pnas.95.24.14226; [No title captured]; [No title captured]	37	264	287	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					998	1001		10.1126/science.283.5404.998	http://dx.doi.org/10.1126/science.283.5404.998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974396				2022-12-01	WOS:000078574800053
J	Bradbury, A; Evans, C; Allan, P; Lee, A; Ruckley, CV; Fowkes, FGR				Bradbury, A; Evans, C; Allan, P; Lee, A; Ruckley, CV; Fowkes, FGR			What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE	Objective To define the relations between age, sex, lower limb symptoms, and the presence of trunk varicose veins on clinical examination. Design Cross sectional population study. Setting 12 general practices with catchment areas geographically and socioeconomically distributed throughout Edinburgh. Participants An age stratified random sample of 1566 people (699 men and 867 women) aged 18-64 selected from the computerised age-sex registers of participating practices. Main outcome measures Self administered questionnaire on the presence of lower limb symptoms and physical examination to determine the presence and severity of varicose veins. Results Women were significantly mole likely than men to report lower limb symptoms such as heaviness or tension, swelling, aching, restless legs, cramps, and itching. The prevalence of symptoms tended to increase with age in both sexes. In men, only itching was significantly related to the presence and severity of trunk varices (linear test for trend, P = 0.011). In women there was a significant relation between trunk varices and the symptoms of heaviness or tension (P less than or equal to 0.001), aching (P less than or equal to 0.001), and itching (P less than or equal to 0.005). However, the level of agreement between the presence of symptoms and trunk varices was too low to be of clinical value, especially in men. Conclusions Even in the presence of trunk varices, most lower limb symptoms probably have a non-venous cause. Surgical extirpation of trunk varices is unlikely to ameliorate such symptoms in most patients.	Univ Edinburgh, Wolfson Unit Prevent Peripheral Vasc Dis, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Royal Infirm, Dept Surg & Clin Sci, Vasc Surg Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm, Dept Med Imaging, Edinburgh, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh	Fowkes, FGR (corresponding author), Univ Edinburgh, Wolfson Unit Prevent Peripheral Vasc Dis, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	gerry.fowkes@ed.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER DM, 1995, EUR J VASC ENDOVASC, V9, P299, DOI 10.1016/S1078-5884(05)80134-0; CALLAM MJ, 1994, BRIT J SURG, V81, P167, DOI 10.1002/bjs.1800810204; *DEP HLTH SOC SEC, 1988, HOSP EP STAT 1987 88; Evans CJ, 1997, PHLEBOLOGY, V12, P127, DOI 10.1177/026835559701200403; EVANS CJ, IN PRESS J EPIDEMIOL; EVANS CJ, IN PRESS J VASC SURG; FORREST APM, 1995, PRINCIPLES PRACTICE, P289; FOWKES FGR, 1996, PHLEBOLOGY, V41, P2; JOHNSON G, 1995, VASCULAR SURG, P1825; JONES HJS, 1997, EUR J VASC ENDOVASC, V14, P130; Nelzen O, 1996, BRIT J SURG, V83, P255, DOI 10.1046/j.1365-2168.1996.02099.x; Nelzen O, 1996, PHLEBOLOGY, V11, P50, DOI 10.1177/026835559601100204; Peripheral Venous Disorders LK, 1978, PREVALENCE SOCIO MED, P1; ROYLE JP, 1992, SURG MANAGEMENT VASC, P1239; Ruckley CV, 1997, ANGIOLOGY, V48, P67, DOI 10.1177/000331979704800111; TIBBS DT, 1994, OXFORD TXB SURG, P503	16	216	229	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					353	356		10.1136/bmj.318.7180.353	http://dx.doi.org/10.1136/bmj.318.7180.353			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933194	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000078572600022
J	Wang, C; Stewart, RJ; Kopecek, J				Wang, C; Stewart, RJ; Kopecek, J			Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains	NATURE			English	Article							PHASE-TRANSITION; GEL; HETERODIMER; SWITCH	Stimuli-sensitive polymer hydrogels, which swell or shrink in response to changes in the environmental conditions, have been extensively investigated and used as 'smart' biomaterials and drug-delivery systems(1,2). Most of these responsive hydrogels are prepared from a limited number of synthetic polymers and their derivatives, such as copolymers of (meth)acrylic acid, acrylamide and N-isopropyl acrylamide(3-12). Water-soluble synthetic polymers have also been crosslinked with molecules of biological origin, such as oligopeptides(13) and oligodeoxyribonudeotides(14), or with intact native proteins(15). Very often there are several factors influencing the relationship between structure and properties in these systems, making it difficult to engineer hydrogels with specified responses to particular stimuli. Here we report a hybrid hydrogel system assembled from water-soluble synthetic polymers and a well-defined protein-folding motif, the coiled coil. These hydrogels undergo temperature-induced collapse owing to the cooperative conformational transition of the coiled-coil protein domain. This system shows that well-characterized water-soluble synthetic polymers can be combined with well-defined folding motifs of proteins in hydrogels with engineered volume-change properties(16,17).	Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kopecek, J (corresponding author), Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.	Jindrich.Kopecek@m.cc.utah.edu						Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P510, DOI 10.1038/nsb0696-510; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Ho CH, 1998, LANGMUIR, V14, P3889, DOI 10.1021/la980148k; HOCHULI H, 1990, GENET ENG, V12, P87; Holtz JH, 1997, NATURE, V389, P829, DOI 10.1038/39834; Hu ZB, 1998, NATURE, V393, P149, DOI 10.1038/30205; ISER PF, 1998, NATURE, V394, P459; KOKUFATA E, 1991, NATURE, V351, P302, DOI 10.1038/351302a0; KOPECEK J, 1971, J POLYM SCI A1, V9, P2801, DOI 10.1002/pol.1971.150091005; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; Langer R, 1998, NATURE, V392, P5; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)10052-9; Nagahara S, 1996, POLYM GELS NETW, V4, P111, DOI 10.1016/0966-7822(96)00001-9; NG K, 1995, LANGMUIR, V11, P4048, DOI 10.1021/la00010a069; Obaidat AA, 1996, PHARM RES-DORDR, V13, P989, DOI 10.1023/A:1016090103979; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Peppas NA, 1997, CURR OPIN COLLOID IN, V2, P531, DOI 10.1016/S1359-0294(97)80103-3; Petka WA, 1998, SCIENCE, V281, P389, DOI 10.1126/science.281.5375.389; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; SUBR V, 1990, Journal of Biomaterials Science Polymer Edition, V1, P261; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; WANG C, 1998, ACS POLYM PREPRINTS, V39, P194; WANG C, 1998, P INT S CONTR REL BI, V25, P54; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	30	500	521	11	281	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					417	420		10.1038/17092	http://dx.doi.org/10.1038/17092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989405				2022-12-01	WOS:000078461700042
J	Dimitrakopoulos, AN; Kordossis, T; Hatzakis, A; Moutsopoulos, HM				Dimitrakopoulos, AN; Kordossis, T; Hatzakis, A; Moutsopoulos, HM			Mixed cryoglobulinemia in HIV-1 infection: The role of HIV-1	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATITIS-C VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; RED FINGERS SYNDROME; LYMPHOMA; RNA	Background: Cryoglobulins are associated with chronic infections. Objective: To investigate the prevalence of mixed cryoglobulinemia in patients with HIV-1 infection, the clinical spectrum of cryoglobulinemia in these patients, and the possible role of HIV-1 in cryoglobulin formation. Design: Prospective cohort study. Setting: Laiko Hospital, Athens, Greece. Patients: 89 patients with HIV-1 infection. Measurements: Serum and cryoglobulins were evaluated for antibodies to HIV and hepatitis C virus (HCV), HIV-1, and HCV viral load. Results: Mixed cryoglobulins were detected in 24 patients with HIV-1 infection (27% [95% CI, 18% to 36%]). The HIV-1 viral load was higher in cryoglobulin-positive patients (median, 38.25 x 10(3) copies/mL [25th, 75th percentiles: 13.8 x 10(3) copies/mL, 78.55 x 10(3) copies/mL]) than in cryoglobulin-negative patients (median, 5.3 x 10(3) copies/mL [25th, 75th percentiles: 0.7 x 10(3) copies/mL, 27.2 x 10(3) copies/mL]) (P = 0.001). Antibodies to HIV were detected in all cryoprecipitates, and HIV-1 RNA sequences were identified in 22 of the 23 cryoprecipitates examined. Nine cryoglobulin-positive patients (38% [CI, 19% to 54%]) had clinical manifestations compatible with cryoglobulinemia. Conclusions: Mixed cryoglobulinemia is common in patients with HIV-1 infection.	Natl & Kapodistrian Univ, Sch Med, Dept Pathophysiol, Athens 11527, Greece; Natl & Kapodistrian Univ, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens	Moutsopoulos, HM (corresponding author), Natl & Kapodistrian Univ, Sch Med, Dept Pathophysiol, 75 Mikras Asias St, Athens 11527, Greece.							Battegay M, 1996, LANCET, V348, P763, DOI 10.1016/S0140-6736(05)65682-6; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; DAgati V, 1997, J AM SOC NEPHROL, V8, P138; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; ELLAURIE M, 1990, AIDS RES HUM RETROV, V6, P1437, DOI 10.1089/aid.1990.6.1437; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LELOSTEC Z, 1994, AIDS, V8, P1351, DOI 10.1097/00002030-199409000-00026; MATSUDA J, 1994, CLIN INFECT DIS, V18, P832, DOI 10.1093/clinids/18.5.832; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; PAPADOPOULOS NM, 1985, CLIN IMMUNOL IMMUNOP, V35, P43, DOI 10.1016/0090-1229(85)90076-5; Pechere M, 1996, LANCET, V348, P196, DOI 10.1016/S0140-6736(05)66142-9; Straus DJ, 1997, MED CLIN N AM, V81, P495, DOI 10.1016/S0025-7125(05)70528-9; STRICKER RB, 1992, NEUROLOGY, V42, P2103, DOI 10.1212/WNL.42.11.2103; TAILLAN B, 1993, CLIN EXP RHEUMATOL, V11, P350; Tzioufas AG, 1996, ARTHRITIS RHEUM, V39, P767, DOI 10.1002/art.1780390508; Zignego AL, 1997, ARCH VIROL, V142, P545, DOI 10.1007/s007050050100	19	47	48	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					226	230		10.7326/0003-4819-130-3-199902020-00027	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00027			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049201				2022-12-01	WOS:000078355000007
J	Kalra, PA; Kumwenda, M; MacDowall, P; Roland, MO				Kalra, PA; Kumwenda, M; MacDowall, P; Roland, MO			Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ARTERY STENOSIS; HEART-FAILURE; CAPTOPRIL	Objectives To determine the current pattern of use of angiotensin converting enzyme inhibitor and monitoring of renal function in general practice and to audit all admissions to a regional renal unit for. uraemia related to use of these drugs. Design Postal questionnaire sent to 400 general practitioners; audit of clinical notes of all patients receiving these drugs in one large general practice; audit of all cases of uraemia (creatinine concentration > 500 mu mol/l) related to treatment presenting to hospital renal services over 12 months. Setting General practices in the North Wales health authority and one in central Manchester. Regional renal unit in Salfold. Main outcome measures Proportion of general practitioners who regular ly monitored renal function before and after initiation of angiotensin converting enzyme inhibitors. Indications for treatment and details of monitoring of renal function in patients receiving these drugs. Incidence of related uraemia and evidence of comorbid disease, other aetiological factors, delayed detection, and patient outcome. Results 277 (69%) general practitioners replied; 235 (85%) checked renal function before but only 93 (34%) after the start of treatment, and 42 (15%) never checked renal function. Angiotensin converting enzyme inhibitors were prescribed for 162 patients from a total of 3625 aged >35 years (mean age 66.4 (SD 15.9) years). Monitoring of renal function occurred before treatment in 55 (45%) and after start of treatment in 35 (29%) of the 122 patients treated in general practice. Angiotensin converting enzyme inhibitors could be causally implicated in 9 (7%) of 135 admissions for uraemia (mean age 74.2 (7.2) v 62.1 (2.1) years; P < 0.01). 3 patients had renovascular disease and 6 had congestive cardiac failure with another intercurrent illness. Renal function had not been checked in any patient after the start of treatment; mean duration of illness before admission was 10.5 (3.2) days. Mean length of hospital stay was 20.9 (10.4) days; there were 8 survivors. Conclusion cases of uraemia related to treatment with angiotensin converting enzyme inhibitors are still encountered and are often detected late because of lack of judicious monitoring of renal function in vulnerable, often elderly, patients, especially at times of intercurrent illness. guidelines for appropriate monitoring of renal function may help to minimise the problem.	Hope Hosp, Dept Renal Med, Salford M6 8HD, Lancs, England; Glan Clwyd Hosp, Dept Renal Med, Rhyl LL18 5UJ, Wales; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England	University of Manchester	Kalra, PA (corresponding author), Hope Hosp, Dept Renal Med, Salford M6 8HD, Lancs, England.	phil@ren.srth.nwest.nhs.uk						CHOUDHRI AH, 1990, BRIT MED J, V301, P1197, DOI 10.1136/bmj.301.6762.1197; DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; Eccles M, 1998, BMJ-BRIT MED J, V316, P1369, DOI 10.1136/bmj.316.7141.1369; HARDING MB, 1992, J AM SOC NEPHROL, V2, P1608; Hart W, 1993, BR J MED EC, V6, P91; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; KALRA PS, 1990, Q J MED, V282, P1013; MacDowall P, 1998, LANCET, V352, P13, DOI 10.1016/S0140-6736(97)11060-1; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; SCHWARTZ CJ, 1964, BRIT MED J, V2, P1415, DOI 10.1136/bmj.2.5422.1415; STRUTHERS AD, 1996, CLIN CARDIOL, V19, P2; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	12	38	40	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	1999	318	7178					234	237						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915733				2022-12-01	WOS:000078292300026
J	Magistretti, PJ; Pellerin, L; Rothman, DL; Shulman, RG				Magistretti, PJ; Pellerin, L; Rothman, DL; Shulman, RG			Neuroscience - Energy on demand	SCIENCE			English	Editorial Material							HUMAN BRAIN; ASTROCYTES		Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Diagnost Radiol, New Haven, CT 06520 USA	University of Lausanne; Yale University; Yale University	Magistretti, PJ (corresponding author), Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland.	pierre.magistretti@iphysiol.unil.ch	Pellerin, Luc/A-8912-2017	Pellerin, Luc/0000-0002-1016-1970; Magistretti, Pierre Julius/0000-0002-6678-320X				Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; MASON GF, 1995, J CEREBR BLOOD F MET, V15, P12, DOI 10.1038/jcbfm.1995.2; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; ROTHMAN DL, 1993, P NATL ACAD SCI USA, V90, P5662, DOI 10.1073/pnas.90.12.5662; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; Shulman RG, 1998, P NATL ACAD SCI USA, V95, P11993, DOI 10.1073/pnas.95.20.11993; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; TAKAHASHI S, 1995, P NATL ACAD SCI USA, V92, P4616, DOI 10.1073/pnas.92.10.4616	9	907	937	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1999	283	5401					496	497		10.1126/science.283.5401.496	http://dx.doi.org/10.1126/science.283.5401.496			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9988650				2022-12-01	WOS:000078203300024
J	Hateboer, N; Dijk, MAV; Bogdanova, N; Coto, E; Saggar-Malik, AK; San Millan, JL; Torra, R; Breuning, M; Ravine, D				Hateboer, N; Dijk, MAV; Bogdanova, N; Coto, E; Saggar-Malik, AK; San Millan, JL; Torra, R; Breuning, M; Ravine, D		European PDK1-PDK2 Study Grp	Comparison of phenotypes of polycystic kidney disease types 1 and 2	LANCET			English	Article							RENAL-FAILURE; CLINICAL-FEATURES; HETEROGENEITY; PROGRESSION; PROGNOSIS; FAMILIES; PKD2; INSUFFICIENCY; ENCODES; PROTEIN	Background Although autosomal dominant polycystic kidney disease type 2 (PKD2) is known to have a milder clinical phenotype than PKD1, neither disorder has been compared with an unaffected control population in terms of survival. We report the findings;of a multicentre survey that aimed to define more precisely;Phe survival and clinical expression of PKD1 and PKD2. Methods Clinical data from 333 people with PKD1 (31 families) were compared with data from 291 people with PKD2(31 families) and 398 geographically matched controls. Survival analysis was used to compare age-at-event data. Differences in the prevalence of complications were assessed by logistic regression. Findings Median age at death or onset of end-stage renal disease, was 53.0 years (95% CI 51.2-54.8) in individuals with PKD1, 69.1 years (66.9-71.3) in those with PKD2, and 78.0 years (73.8-82.2) in controls. Women with PKD2 had a significantly longer median survival than men (71.0 [67.4-74.8] vs 67.3 [64.9-69.7] years), but no sex influence was apparent in PKD1. Age at presentation with kidney failure was later in PKD2 than in PKD1 (median age 74.0 [67.2-80.8] vs 54.3 [52.7-55.9] years). PKD2 patients were less likely to have hypertension (odds ratio 0.25 [95% CI 0.15-0.42]), a history of urinary-tract infection (0.50 [0.31-0.83]), or haematuria (0.59 [0.35-0.98]). Interpretation Although PKD2 is clinically milder than PKD1, it has a deleterious impact on overall life expectancy and cannot be regarded as a benign disorder.	Univ Wales Hosp, Inst Med Genet, Cardiff CF4 4XN, S Glam, Wales; Acad Hosp Leiden, Leiden, Netherlands; Univ Munster, Inst Human Genet, D-4400 Munster, Germany; Univ Oviedo, Hosp Cent Asturias, Inst Reine Sofia Invest Nefrol, E-33080 Oviedo, Spain; Univ London St Georges Hosp, Sch Med, Med Genet Unit, London SW17 0RE, England; Hosp Ramon & Cajal, Unidad Genet Mol, E-28034 Madrid, Spain; Hosp Clin Barcelona, Serv Nefrol, Barcelona, Spain; Leiden Univ, Afdeling Anthropogenet, Leiden, Netherlands	Cardiff University; Leiden University; Leiden University Medical Center (LUMC); University of Munster; Central University Hospital Asturias; University of Oviedo; St Georges University London; Hospital Universitario Ramon y Cajal; University of Barcelona; Hospital Clinic de Barcelona; Leiden University; Leiden University - Excl LUMC	Hateboer, N (corresponding author), Univ Wales Hosp, Inst Med Genet, Hlth Pk, Cardiff CF4 4XN, S Glam, Wales.	hateboer@cardiff.ac.uk	Torra, Roser/A-9983-2008; San-Millán, José L./F-9944-2015; Ravine, David/A-6797-2008; Breuning, Martijn H/E-3429-2010	Torra, Roser/0000-0001-8714-2332; 				BEAR JC, 1992, AM J MED GENET, V43, P548, DOI 10.1002/ajmg.1320430309; BRAZY PC, 1989, KIDNEY INT, V35, P670, DOI 10.1038/ki.1989.37; COTO E, 1995, J MED GENET, V32, P442, DOI 10.1136/jmg.32.6.442; DALGAARD O Z, 1957, Acta Med Scand Suppl, V328, P1; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; FLORIJN KW, 1995, AM J KIDNEY DIS, V25, P370, DOI 10.1016/0272-6386(95)90096-9; GABOW PA, 1992, AM J KIDNEY DIS, V20, P140, DOI 10.1016/S0272-6386(12)80541-5; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GABOW PA, 1992, KIDNEY INT, V41, P1311, DOI 10.1038/ki.1992.195; Gonzalo A, 1996, NEPHRON, V72, P225, DOI 10.1159/000188846; GRETZ N, 1989, AM J KIDNEY DIS, V14, P178, DOI 10.1016/S0272-6386(89)80068-X; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KANNEL WB, 1976, STROKE, V7, P327, DOI 10.1161/01.STR.7.4.327; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; NAROD S, 1991, CLIN GENET, V39, P125; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; RAVINE D, 1994, LANCET, V343, P824, DOI 10.1016/S0140-6736(94)92026-5; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; Sandhu S, 1997, KIDNEY INT, V51, P1535, DOI 10.1038/ki.1997.211; SANMILLAN JL, 1995, AM J HUM GENET, V56, P248; Simon P, 1996, NEPHROLOGIE, V17, P123; STEWART JH, 1994, AM J KIDNEY DIS, V24, P181, DOI 10.1016/S0272-6386(12)80179-X; Torra R, 1996, J AM SOC NEPHROL, V7, P2142; VANDERMEY AGL, 1989, LANCET, V2, P1291; WARD CJ, 1994, CELL, V77, P881; ZEIER M, 1994, NEPHROL DIAL TRANSPL, V9, P1734; ZERRES K, 1993, J MED GENET, V30, P583, DOI 10.1136/jmg.30.7.583	29	407	431	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					103	107		10.1016/S0140-6736(98)03495-3	http://dx.doi.org/10.1016/S0140-6736(98)03495-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023895				2022-12-01	WOS:000078087200011
J	Schulz, HN; Brinkhoff, T; Ferdelman, TG; Marine, MH; Teske, A; Jorgensen, BB				Schulz, HN; Brinkhoff, T; Ferdelman, TG; Marine, MH; Teske, A; Jorgensen, BB			Dense populations of a giant sulfur bacterium in Namibian shelf sediments	SCIENCE			English	Article							THIOPLOCA-ARAUCAE; BEGGIATOA; NITRATE; CHILEAE; MARINE; COAST	A previously unknown giant sulfur bacterium is abundant in sediments underlying the oxygen minimum zone of the Benguela Current upwelling system. The bacterium has a spherical cell that exceeds by up to 100-fold the biovolume of the largest known prokaryotes. On the basis of 16S ribosomal DNA sequence data, these bacteria are closely related to the marine filamentous sulfur bacteria Thioploca, abundant in the upwelling area off Chile and Peru. Similar to Thioploca, the giant bacteria oxidize sulfide with nitrate that is accumulated to less than or equal to 800 millimolar in a central vacuole.	Max Planck Inst Marine Microbiol, D-28359 Bremen, Germany; Univ Oldenburg, Inst Chem & Biol Marine Environm, D-26111 Oldenburg, Germany; Univ Barcelona, Fac Farm, E-08028 Barcelona, Spain; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Max Planck Society; Carl von Ossietzky Universitat Oldenburg; University of Barcelona; Woods Hole Oceanographic Institution	Schulz, HN (corresponding author), Max Planck Inst Marine Microbiol, Celsiusstr, D-28359 Bremen, Germany.		Ferdelman, Timothy G/A-3758-2013; Teske, Andreas/AAQ-9577-2021; Jorgensen, Bo B/C-2214-2013; Schulz-Vogt, Heide/I-1397-2012	Ferdelman, Timothy G/0000-0002-9701-3793; Jorgensen, Bo B/0000-0001-9398-8027; Schulz-Vogt, Heide/0000-0003-1445-0291				ANGERT ER, 1993, NATURE, V362, P239, DOI 10.1038/362239a0; Bremner J.M., 1983, COASTAL UPWELLING IT, P73; BRONGERSMASANDE.M, 1983, COASTAL UPWELLING IT, P421; Ferdelman TG, 1997, GEOCHIM COSMOCHIM AC, V61, P3065, DOI 10.1016/S0016-7037(97)00158-0; FOSSING H, 1995, NATURE, V374, P713, DOI 10.1038/374713a0; GALLARDO VA, 1977, NATURE, V268, P331, DOI 10.1038/268331a0; Hart T. J., 1960, Discovery Reports, V31, P123; Huettel M, 1996, APPL ENVIRON MICROB, V62, P1863, DOI 10.1128/AEM.62.6.1863-1872.1996; LARKIN J, 1989, Microbios Letters, V42, P69; MAIER S, 1984, INT J SYST BACTERIOL, V34, P414, DOI 10.1099/00207713-34-4-414; MAIER S, 1990, CAN J MICROBIOL, V36, P438, DOI 10.1139/m90-077; MAIER S, 1965, CAN J MICROBIOL, V11, P635; MANZ W, 1992, SYST APPL MICROBIOL, V15, P593, DOI 10.1016/S0723-2020(11)80121-9; McHatton SC, 1996, APPL ENVIRON MICROB, V62, P954, DOI 10.1128/AEM.62.3.954-958.1996; MOLLER MM, 1985, APPL ENVIRON MICROB, V50, P373; NELSON DC, 1989, APPL ENVIRON MICROB, V55, P2909, DOI 10.1128/AEM.55.11.2909-2917.1989; NELSON DC, 1986, APPL ENVIRON MICROB, V52, P161, DOI 10.1128/AEM.52.1.161-168.1986; OTTE S, UNPUB; SCHUETTE G, 1981, COASTAL UPWELLING, P373; Schulz HN, 1996, APPL ENVIRON MICROB, V62, P1855, DOI 10.1128/AEM.62.6.1855-1862.1996; STROTMANN B, UNPUB; Teske Andreas, 1995, Systematic and Applied Microbiology, V18, P517	22	321	336	2	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					493	495		10.1126/science.284.5413.493	http://dx.doi.org/10.1126/science.284.5413.493			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205058				2022-12-01	WOS:000079792200049
J	Delhase, M; Hayakawa, M; Chen, Y; Karin, M				Delhase, M; Hayakawa, M; Chen, Y; Karin, M			Positive and negative regulation of I kappa B kinase activity through IKK beta subunit phosphorylation	SCIENCE			English	Article							TRANSCRIPTION FACTOR; ACTIVATION; COMPLEX; ALPHA; IDENTIFICATION; CLONING; FAMILY; SITES; MEKK1	I kappa B [inhibitor of nuclear factor kappa B (NF-kappa B)] kinase (IKK) phosphorylates I kappa B inhibitory proteins, causing their degradation and activation of transcription factor NF-KB, a master activator of inflammatory responses. IKK is composed of three subunits-IKK alpha and IKK beta, which are highly similar protein kinases, and IKK gamma, a regulatory subunit. In mammalian cells, phosphorylation of two sites at the activation Loop of IKK beta was essential for activation of IKK by tumor necrosis factor and interleukin-1. Elimination of equivalent sites in IKK alpha, however, did not interfere with IKK activation. Thus, IKK beta, not IKK alpha, is the target for proinflammatory stimuli. Once activated, IKK beta autophosphorylated at a carboxyl-terminal serine cluster. Such phosphorylation decreased IKK activity and may prevent prolonged activation of the inflammatory response.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Delhase, Mireille/ABE-5256-2021	Delhase, Mireille/0000-0003-2312-1051	NIAID NIH HHS [R01 AI43477] Funding Source: Medline; NIEHS NIH HHS [R37 ES04151] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DELHASE M, UNPUB; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOEDDEL D, COMMUNICATION; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; KARIN M, P NATL ACAD SCI US, P9067; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li Z.B., UNPUB; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANO H, P NATL ACAD SCI US, P3537; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	33	719	775	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					309	313		10.1126/science.284.5412.309	http://dx.doi.org/10.1126/science.284.5412.309			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195894				2022-12-01	WOS:000079636400040
J	De Strooper, B; Annaert, W; Cupers, P; Saftig, P; Craessaerts, K; Mumm, JS; Schroeter, EH; Schrijvers, V; Wolfe, MS; Ray, WJ; Goate, A; Kopan, R				De Strooper, B; Annaert, W; Cupers, P; Saftig, P; Craessaerts, K; Mumm, JS; Schroeter, EH; Schrijvers, V; Wolfe, MS; Ray, WJ; Goate, A; Kopan, R			A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE GENE; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; BETA; CLEAVAGE; PROTEOLYSIS; INHIBITION; EXPRESSION; RECEPTOR	Signalling through the receptor protein Notch, which is involved in crucial cell-fate decisions during development, requires ligand-induced cleavage of Notch. This cleavage occurs within the predicted transmembrane domain, releasing the Notch intracellular domain (MCD), and is reminiscent of gamma-secsretase-mediated cleavage of beta-amyloid precursor protein (APP), a critical event in the pathogenesis of Alzheimer's disease. a deficiency in presenilin-1 (PS1) inhibits processing of APP by gamma-secretase in mammalian cells, and genetic interactions between Notch and PS1 homologues in Caenorhabditis elegans indicate that the presenilins may modulate the Notch signalling pathway(1-4). Here we report that, in mammalian cells, PS1 deficiency also reduces the proteolytic release of NICD from a truncated Notch construct, thus identifying the specific biochemical step of the Notch signalling pathway that is affected by PS1. Moreover, several gamma-secretase inhibitors block this same step in Notch processing indicating that related protease activities are responsible for cleavage within the predicted transmembrane domains of Notch and APP. Thus the targeting of gamma-secretase for the treatment of Alzheimer's disease may risk toxicity caused by reduced Notch signalling.	Katholieke Univ Leuven VIB, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, B-3000 Louvain, Belgium; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Washington Univ, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Tennessee, Dept Pharmaceut Sci, Memphis, TN 38138 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; University of Gottingen; Washington University (WUSTL); Washington University (WUSTL); University of Tennessee System; University of Tennessee Health Science Center; Washington University (WUSTL); Washington University (WUSTL)	De Strooper, B (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, B-3000 Louvain, Belgium.	Bart.Destrooper@med.kuleuven.ac.be; Kopan@Pharmsun.Wustl.Edu	De Strooper, Bart/F-6507-2012; de+Strooper, Bart/Z-1638-2019; Kopan, Raphael/AFG-3275-2022; Saftig, Paul/A-7966-2010; Ray, William J/E-9834-2016; Kopan, Raphael/AAF-1357-2022; Mumm, Jeff S/F-3125-2013	De Strooper, Bart/0000-0001-5455-5819; Mumm, Jeff/0000-0002-2575-287X				Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Levitan D, 1998, DEVELOPMENT, V125, P3599; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Robey E, 1998, CURR OPIN IMMUNOL, V10, P181, DOI 10.1016/S0952-7915(98)80247-1; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; Saftig P, 1998, MOL PSYCHIATR, V3, P287, DOI 10.1038/sj.mp.4000408; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; WOLFE MS, IN PRESS BIOCHEMISTR; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; XIA W, 1997, P NATL ACAD SCI USA, V94, P8206; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y	30	1486	1551	3	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 8	1999	398	6727					518	522		10.1038/19083	http://dx.doi.org/10.1038/19083			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206645				2022-12-01	WOS:000079662800049
J	Bradke, F; Dotti, CG				Bradke, F; Dotti, CG			The role of local actin instability in axon formation	SCIENCE			English	Article							GROWTH CONE; HIPPOCAMPAL-NEURONS; STRESS FIBERS; RHO-PROTEINS; CELL-GROWTH; ORGANIZATION; FILOPODIA; POLARITY; CULTURE; CDC42	The role of localized instability of the actin network in specifying axonal fate was examined with the use of rat hippocampal neurons in culture. During normal neuronal development, actin dynamics and instability polarized to a single growth cone before axon formation. Consistently, global application of actin-depolymerizing drugs and of the Rho-signaling inactivator toxin B to nonpolarized cells produced neurons with multiple axons. Moreover, disruption of the actin network in one individual growth cone induced its neurite to become the axon. Thus, local instability of the actin network restricted to a single growth cone is a physiological signal specifying neuronal polarization.	European Mol Biol Lab, Cell Biol Programme, D-69012 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Dotti, CG (corresponding author), European Mol Biol Lab, Cell Biol Programme, Meyerhofstr 1, D-69012 Heidelberg, Germany.	dotti@embl-heidelberg.de	Dotti, Carlos G/I-5533-2015	Dotti, Carlos G/0000-0003-4052-1719; Bradke, Frank/0000-0002-0345-3772				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; BENTLEY D, 1986, NATURE, V323, P712, DOI 10.1038/323712a0; Bradke F, 1997, NEURON, V19, P1175, DOI 10.1016/S0896-6273(00)80410-9; BRADKE F, 1997, MICROINJECTION TRANS, P81; BRIDGMAN PC, 1989, J CELL BIOL, V108, P95, DOI 10.1083/jcb.108.1.95; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHIEN CB, 1993, NEURON, V11, P237, DOI 10.1016/0896-6273(93)90181-P; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.neuro.17.1.267; de Hoop MJ, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P154; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1991, J CELL SCI, P75; EDSON K, 1993, DEVELOPMENT, V117, P689; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; HEIDEMANN SR, 1990, J CELL BIOL, V111, P1949, DOI 10.1083/jcb.111.5.1949; Jareb M, 1997, J NEUROSCI, V17, P8955; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; LAMOUREUX P, 1989, NATURE, V340, P156, DOI 10.1038/340159a0; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Mandell JW, 1996, J NEUROSCI, V16, P5727; MARSH L, 1984, J CELL BIOL, V99, P2041, DOI 10.1083/jcb.99.6.2041; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Suter DM, 1998, J CELL BIOL, V141, P227, DOI 10.1083/jcb.141.1.227; Suter DM, 1998, CURR OPIN NEUROBIOL, V8, P106, DOI 10.1016/S0959-4388(98)80014-7; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; ZHENG J, 1994, J CELL BIOL, V127, P2049, DOI 10.1083/jcb.127.6.2049	36	410	419	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1999	283	5409					1931	1934		10.1126/science.283.5409.1931	http://dx.doi.org/10.1126/science.283.5409.1931			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10082468				2022-12-01	WOS:000079228600052
J	Brunet, A; Bonni, A; Zigmond, MJ; Lin, MZ; Juo, P; Hu, LS; Anderson, MJ; Arden, KC; Blenis, J; Greenberg, ME				Brunet, A; Bonni, A; Zigmond, MJ; Lin, MZ; Juo, P; Hu, LS; Anderson, MJ; Arden, KC; Blenis, J; Greenberg, ME			Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor	CELL			English	Article							PROTEIN-KINASE AKT; CAENORHABDITIS-ELEGANS; INDUCED APOPTOSIS; GENE; BINDING; DEATH; SITE; SPECIFICITY; EXPRESSION; CLONING	Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase Akt, which then phosphorylates and inactivates components of the apoptotic machinery, including BAD and Caspase 9. In this study, we demonstrate that Akt also regulates the activity of FKHRL1, a member of the Forkhead family of transcription factors. In the presence of survival factors, Akt phosphorylates FKHRL1, leading to FKHRL1's association with 14-3-3 proteins and FKHRL1's retention in the cytoplasm. Survival factor withdrawal leads to FKHRL1 dephosphorylation, nuclear translocation, and target gene activation. Within the nucleus, FKHRL1 triggers apoptosis most likely by inducing the expression of genes that are critical for cell death, such as the Fas ligand gene.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif San Diego, Ludwig Inst Canc Res, San Diego, CA 92093 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Greenberg, ME (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.	greenberg@a1.tch.harvard.edu	Roszak, Joanna/F-4003-2010; Li, Chia Cheng/D-9906-2015; Juo, Peter/CJY-3695-2022	Juo, Peter/0000-0002-3039-2266; Lin, Michael/0000-0002-0492-1961	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043855, R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595, CA43855] Funding Source: Medline; NICHD NIH HHS [HD 18655] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Datta SR, 1998, HORM SIGNALING, V1, P257; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Faris M, 1998, J IMMUNOL, V160, P134; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KAUFMANN E, 1995, J MOL BIOL, V248, P239, DOI 10.1006/jmbi.1995.0218; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KHANNA KK, 1993, ONCOGENE, V8, P3307; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; MIYASHITA T, 1995, CELL, V80, P293; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Sakamaki K, 1998, EUR J BIOCHEM, V253, P399, DOI 10.1046/j.1432-1327.1998.2530399.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUNG SSJ, 1991, J IMMUNOL, V147, P2047; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	44	5207	5383	13	246	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	1999	96	6					857	868		10.1016/S0092-8674(00)80595-4	http://dx.doi.org/10.1016/S0092-8674(00)80595-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102273	Bronze			2022-12-01	WOS:000079300100012
J	Vetter, IR; Nowak, C; Nishimoto, T; Kuhlmann, J; Wittinghofer, A				Vetter, IR; Nowak, C; Nishimoto, T; Kuhlmann, J; Wittinghofer, A			Structure of a Ran-binding domain complexed with Ran bound to a GTP analogue: implications for nuclear transport	NATURE			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PROTEIN IMPORT; PORE COMPLEX; RAN/TC4 GTPASE; CRYSTAL-STRUCTURE; PH DOMAIN; EF-TU; GDP; MOTIF; IDENTIFICATION	The protein Ran is a small GTP-binding protein that binds to two types of effector inside the cell: Ran-binding proteins, which have a role in terminating export processes from the nucleus to the cytoplasm, and importin-beta-like molecules that bind cargo proteins during nuclear transport. The Ran-binding domain is a conserved sequence motif found in several proteins that participate in these transport processes. The Ran-binding protein RanBP2 contains four of these domains and constitutes a large part of the cytoplasmic fibrils that extend from the nuclear-pore complex. The structure of Ran bound to a non-hydrolysable GTP analogue (Ran.GppNHp) in oomplex with the first Ran-binding domain (RanBD1) of human RanRP2 reveals not only that RanBD1 has a pleckstrin-homology domain fold, but also that the switch-I region of Ran.GppNHp resembles the canonical Ras.GppNHp structure and that the carboxy terminus of Ran is wrapped around RanBD1, contacting a basic patch on RanBD1 through its acidic end. This molecular 'embrace' enables RanBDs to sequester the Ran carboxy terminus, triggering the dissociation of Ran.GTP from importin-beta-related transport factors and facilitating GTP hydrolysis by the GTPase-activating protein ranGAP. Such a mechanism represents a new type of switch mechanism and regulatory protein-protein interaction for a Ras-related protein.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44026 Dortmund, Germany; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 81282, Japan	Max Planck Society; Kyushu University	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Postfach 102664, D-44026 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de						Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HARTMANN E, 1995, TRENDS CELL BIOL, V5, P192, DOI 10.1016/S0962-8924(00)88992-8; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WILKEN N, 1995, EUR J CELL BIOL, V68, P211; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	50	241	245	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	1999	398	6722					39	46		10.1038/17969	http://dx.doi.org/10.1038/17969			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174KG	10078529				2022-12-01	WOS:000079033900044
J	Nightingale, SL				Nightingale, SL			Warning on abbokinase	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					786	786		10.1001/jama.281.9.786	http://dx.doi.org/10.1001/jama.281.9.786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10070983				2022-12-01	WOS:000078804300005
J	Bremser, M; Nickel, W; Schweikert, M; Ravazzola, M; Amherdt, M; Hughes, CA; Sollner, TH; Rothman, JE; Wieland, FT				Bremser, M; Nickel, W; Schweikert, M; Ravazzola, M; Amherdt, M; Hughes, CA; Sollner, TH; Rothman, JE; Wieland, FT			Coupling of coat assembly and vesicle budding to packaging of putative cargo receptors	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GOLGI MEMBRANES REQUIRES; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; PROTEIN-TRANSPORT; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-EXCHANGE; BREFELDIN-A; ARF; BINDING	COPI-coated vesicle budding from lipid bilayers whose composition resembles mammalian Golgi membranes requires coatomer, ARF, GTP, and cytoplasmic tails of putative cargo receptors (p24 family proteins) or membrane cargo proteins (containing the KKXX retrieval signal) emanating from the bilayer surface. Liposome-derived COPI-coated vesicles are similar to their native counterparts with respect to diameter, buoyant density, morphology, and the requirement for an elevated temperature for budding. These results suggest that a bivalent interaction of coatomer with membrane-bound ARF[GTP] and with the cytoplasmic tails of cargo or putative cargo receptors is the molecular basis of COPI coat assembly and provide a simple mechanism to couple uptake of cargo to transport vesicle formation.	Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva 4, Switzerland	Ruprecht Karls University Heidelberg; Memorial Sloan Kettering Cancer Center; University of Geneva	Wieland, FT (corresponding author), Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany.	felix.wieland@urz.uni-heidelberg.de			NIGMS NIH HHS [GM19079-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FLEISCHER B, 1974, Journal of Supramolecular Structure, V2, P737, DOI 10.1002/jss.400020517; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KEENAN TW, 1970, BIOCHEMISTRY-US, V9, P19, DOI 10.1021/bi00803a003; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, MOL CELL, V2, P703, DOI 10.1016/S1097-2765(00)80168-9; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nickel W, 1998, SEMIN CELL DEV BIOL, V9, P493, DOI 10.1006/scdb.1998.0256; Nickel W, 1997, FEBS LETT, V413, P395, DOI 10.1016/S0014-5793(97)00939-3; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; REINHARD C, 1999, IN PRESS P NATL ACAD; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; SPINGER S, 1998, SCIENCE, V281, P698; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	61	234	240	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					495	506		10.1016/S0092-8674(00)80654-6	http://dx.doi.org/10.1016/S0092-8674(00)80654-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052452	Bronze			2022-12-01	WOS:000078718600001
J	Patapoutian, A; Backus, C; Kispert, A; Reichardt, LF				Patapoutian, A; Backus, C; Kispert, A; Reichardt, LF			Regulation of neurotrophin-3 expression by epithelial mesenchymal interactions: The role of Wnt factors	SCIENCE			English	Article							NEURONS; SURVIVAL; DEATH; MICE; NT-3	Neurotrophins regulate survival, axonal growth, and target innervation of sensory and other neurons. Neurotrophin-3 (NT-3) is expressed specifically in cells adjacent to extending axons of dorsal root ganglia neurons, and its absence results in loss of most of these neurons before their axons reach their targets. However, axons are not required for NT-3 expression in limbs; instead, Local signals from ectoderm induce NT-3 expression in adjacent mesenchyme. Wnt factors expressed in Limb ectoderm induce NT-3 in the underlying mesenchyme. Thus, epithelial-mesenchymal interactions mediated by Wnt factors control NT-3 expression and may regulate axonal growth and guidance.	Univ Calif San Francisco, Dept Psychol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Max Planck Inst Immunbiol, Dept Mol Embryol, D-79108 Freiburg, Germany	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Max Planck Society	Patapoutian, A (corresponding author), Univ Calif San Francisco, Dept Psychol, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48200] Funding Source: Medline; NINDS NIH HHS [P01 NS016033-190014, P01 NS016033] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; ElShamy WM, 1996, NEURON, V16, P963, DOI 10.1016/S0896-6273(00)80119-1; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Farinas I, 1998, NEURON, V21, P325, DOI 10.1016/S0896-6273(00)80542-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; Farinas I, 1996, NEURON, V17, P1065, DOI 10.1016/S0896-6273(00)80240-8; FRANZ T, 1993, ANAT EMBRYOL, V187, P371; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kispert A, 1998, DEVELOPMENT, V125, P4225; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; PARR BA, 1993, DEVELOPMENT, V119, P247; PATAPOUTIAN A, UNPUB; Reichardt L. F., 1997, MOL CELLULAR APPROAC, P220; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; Wilkinson GA, 1996, J NEUROSCI, V16, P7661	19	57	57	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1180	1183		10.1126/science.283.5405.1180	http://dx.doi.org/10.1126/science.283.5405.1180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024246	Green Accepted			2022-12-01	WOS:000078738400055
J	Richman, LK; Montali, RJ; Garber, RL; Kennedy, MA; Lehnhardt, J; Hildebrandt, T; Schmitt, D; Hardy, D; Alcendor, DJ; Hayward, GS				Richman, LK; Montali, RJ; Garber, RL; Kennedy, MA; Lehnhardt, J; Hildebrandt, T; Schmitt, D; Hardy, D; Alcendor, DJ; Hayward, GS			Novel endotheliotropic herpesviruses fatal for Asian and African elephants	SCIENCE			English	Article							INFECTION; MAXIMUS	A highly fatal hemorrhagic disease has been identified in 10 young Asian and African elephants at North American toes. In the affected animals there was ultrastructural evidence for herpesvirus-like particles in endothelial cells of the heart, liver, and tongue. Consensus primer polymerase chain reaction combined with sequencing yielded molecular evidence that confirmed the presence of two novel but rotated herpesviruses associated with the disease, one in Asian elephants and another in African elephants. Otherwise healthy African elephants with external herpetic Lesions yielded herpesvirus sequences identical to that found in Asian elephants with endothelial disease. This finding suggests that the Asian elephant deaths were caused by cross-species infection with a herpesvirus that is naturally latent in, but normally not lethal to, African elephants, A reciprocal relationship may exist for the African elephant disease.	Smithsonian Inst, Natl Zool Pk, Washington, DC 20008 USA; Johns Hopkins Sch Med, Baltimore, MD 21205 USA; PathoGenesis Corp, Seattle, WA 98119 USA; Univ Tennessee, Knoxville, TN 37901 USA; Inst Zoo Biol & Wildlife Res, D-10305 Berlin, Germany; SW Missouri State Univ, Springfield, MO 65804 USA; Dickerson Pk Zoo, Springfield, MO 65803 USA	Smithsonian Institution; Smithsonian National Zoological Park & Conservation Biology Institute; Johns Hopkins University; Johns Hopkins Medicine; University of Tennessee System; University of Tennessee Knoxville; Missouri State University	Richman, LK (corresponding author), Smithsonian Inst, Natl Zool Pk, Washington, DC 20008 USA.			Alcendor, Donald/0000-0002-4568-8158; Kennedy, Melissa/0000-0001-6237-1104	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001526] Funding Source: NIH RePORTER; NIAID NIH HHS [1 K08 AI01526-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		HARGIS AM, IN P0RESS VET DERM; JACOBSON ER, 1986, J AM VET MED ASSOC, V189, P1075; KARLIN S, 1994, J VIROL, V68, P1886, DOI 10.1128/JVI.68.3.1886-1902.1994; METZLER AE, 1990, J WILDLIFE DIS, V26, P41, DOI 10.7589/0090-3558-26.1.41; Munson L, 1995, J ZOO WILDLIFE MED, V26, P353; OSSENT P, 1990, VET PATHOL, V27, P131, DOI 10.1177/030098589002700212; Persoons MCJ, 1998, J PATHOL, V184, P103, DOI 10.1002/(SICI)1096-9896(199801)184:1<103::AID-PATH964>3.0.CO;2-C; RICHMAN L, UNPUB; SCHMITT DL, 1998, J ELEPHANT MANAGERS, V9, P103; VanDevanter DR, 1996, J CLIN MICROBIOL, V34, P1666, DOI 10.1128/JCM.34.7.1666-1671.1996	10	136	140	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1171	1176		10.1126/science.283.5405.1171	http://dx.doi.org/10.1126/science.283.5405.1171			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024244				2022-12-01	WOS:000078738400053
J	Johnson, RE; Prakash, S; Prakash, L				Johnson, RE; Prakash, S; Prakash, L			Efficient bypass of a thymine-thymine dimer by yeast DNA polymerase, Pol eta	SCIENCE			English	Article							SIMPLE REPETITIVE SEQUENCES; PIGMENTOSUM VARIANT CELLS; SACCHAROMYCES-CEREVISIAE; PROTEIN; PHOTOPRODUCTS; REPLICATION	The RAD30 gene of the yeast Saccharomyces cerevisiae is required for the error-free postreplicational repair of DNA that has been damaged by ultraviolet irradiation. Here, RAD30 is shown to encode a DNA polymerase that can replicate efficiently past a thymine-thymine cis-syn cyclobutane dimer, a lesion that normally blocks DNA polymerases. When incubated in vitro with all four nucleotides, Rad30 incorporates two adenines opposite the thymine-thymine dimer. Rad30 is the seventh eukaryotic DNA polymerase to be described and hence is named DNA polymerase eta.	Univ Texas, Med Branch, Sealy Branch Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Branch Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NIGMS NIH HHS [GM19261] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1988, J BIOL CHEM, V263, P925; Friedberg EC, 1995, DNA REPAIR MUTAGENES; Goodman MF, 1998, NATURE, V395, P221, DOI 10.1038/26111; Johnson R. M., UNPUB; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; JOHNSON RE, 1994, J BIOL CHEM, V269, P28259; McDonald JP, 1997, GENETICS, V147, P1557; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Svoboda DL, 1998, CANCER RES, V58, P2445; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006; Walker GC, 1998, P NATL ACAD SCI USA, V95, P10348, DOI 10.1073/pnas.95.18.10348; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276	17	675	685	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					1001	1004		10.1126/science.283.5404.1001	http://dx.doi.org/10.1126/science.283.5404.1001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974380				2022-12-01	WOS:000078574800054
J	Bezard, B; Encrenaz, T; Lellouch, E; Feuchtgruber, H				Bezard, B; Encrenaz, T; Lellouch, E; Feuchtgruber, H			Planetary science - A new look at the Jovian planets	SCIENCE			English	Editorial Material									Observ Paris, Dept Rech Spatiale, F-92195 Meudon, France; Max Planck Inst Extraterr Phys, D-85748 Garching, Germany	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Max Planck Society	Bezard, B (corresponding author), Observ Paris, Dept Rech Spatiale, F-92195 Meudon, France.	Bruno.Bezard@obspm.fr		Bezard, Bruno/0000-0002-5433-5661				*AM ASTR SOC DIV P, 1998, B AM ASTRON SOC, V30; Bezard B, 1998, ASTRON ASTROPHYS, V334, pL41; BEZARD B, 1999, ASTROPHYS J, V515; Bockelee-Morvan D, 1998, ICARUS, V133, P147, DOI 10.1006/icar.1998.5916; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; DEGRAAUW T, 1997, ASTRON ASTROPHYS, V321, P613; Feuchtgruber H, 1999, ASTRON ASTROPHYS, V341, pL17; Feuchtgruber H, 1997, NATURE, V389, P159, DOI 10.1038/38236; Griffin MJ, 1996, ASTRON ASTROPHYS, V315, pL389; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; KIM SJ, 1985, ICARUS, V64, P233, DOI 10.1016/0019-1035(85)90088-0; LELLOUCH E, 1996, B AM ASTRON SOC, V28, P1148; Mahaffy PR, 1998, SPACE SCI REV, V84, P251, DOI 10.1023/A:1005091806594; MOSES JI, 1996, COLLISION COMET SHOE, P243; *UNESCO, 1998, EUR SPAC AG SPEC PUB	16	8	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					800	801		10.1126/science.283.5403.800	http://dx.doi.org/10.1126/science.283.5403.800			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	10049124				2022-12-01	WOS:000078496800028
J	Gao, F; Bailes, E; Robertson, DL; Chen, YL; Rodenburg, CM; Michael, SF; Cummins, LB; Arthur, LO; Peeters, M; Shaw, GM; Sharp, PM; Hahn, BH				Gao, F; Bailes, E; Robertson, DL; Chen, YL; Rodenburg, CM; Michael, SF; Cummins, LB; Arthur, LO; Peeters, M; Shaw, GM; Sharp, PM; Hahn, BH			Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes	NATURE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; WILD-CAPTURED CHIMPANZEE; TANTALUS MONKEYS; LENTIVIRUS; SEQUENCE; ORGANIZATION; GENOME; TYPE-2; AFRICA; GABON	The human AIDS viruses human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) represent cross-species (zoonotic) infections(1-4). Although the primate reservoir of HIV-2 has been clearly identified as the sooty mangabey (Cercocebus atys)(2,4-7), the origin of HIV-1 remains uncertain. Viruses related to HIV-1 have been isolated from the common chimpanzee (Pan troglodytes)(8,9), but only three such SIVcpz infections have been documented(1,10,11), one of which involved a virus so divergent(11) that it might represent a different primate lentiviral lineage. In a search for the HIV-1 reservoir, rye have now sequenced the genome of a new SIVcpz strain (SIVcpzUS) and have determined, by mitochondrial DNA analysis, the subspecies identity of all known SIVcpz-infected chimpanzees. We find that two chimpanzee subspecies in Africa, the central P. t. troglodytes and the eastern P. t. schweinfurthii, harbour SIVcpz and that their respective viruses form two highly divergent (but subspecies-specific) phylogenetic lineages. All HIV-1 strains known to infect man, including HIV-1 groups M, N and O, are closely related to just one of these SIVcpz lineages, that found in P. t. troglodytes. Moreover, we find that HIV-1 group N is a mosaic of SIVcpzUS- and HTV-1-related sequences, indicating an ancestral recombination event in a chimpanzee host. These results, together with the observation that the natural range of P. t. troglodytes coincides uniquely with areas of HIV-1 group M, N and O endemicity, indicate that P. t. troglodytes is the primary reservoir for HIV-I and has been the source of at least three independent introductions of SIVcpz into the human population.	Univ Alabama Birmingham, Dept Med & Microbiol, Birmingham, AL 35294 USA; Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England; CNRS, Lab Struct & Genet Informat, F-13402 Marseille, France; SW Fdn Biomed Res, San Antonio, TX 78245 USA; NCI, AIDS Vaccine Program, Frederick Canc Res & Dev Ctr, SAIC Frederick, Ft Detrick, MD 21702 USA; ORSTOM, Retrovirus Lab, F-34032 Rennes, France; Univ Alabama Birmingham, Howard Hughes Med Inst, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Nottingham; Centre National de la Recherche Scientifique (CNRS); Texas Biomedical Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Institut de Recherche pour le Developpement (IRD); Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham	Hahn, BH (corresponding author), Univ Alabama Birmingham, Dept Med & Microbiol, 701 S 19th St,LHRB 613, Birmingham, AL 35294 USA.	bhahn@uab.edu	Sharp, Paul M/F-5783-2010; Sharp, Paul/Y-3787-2019; Sharp, Paul M/GPX-1497-2022	Sharp, Paul M/0000-0001-9771-543X; Sharp, Paul M/0000-0001-9771-543X; Hahn, Beatrice/0000-0002-9400-9887				ADACHI J, 1994, I STAT MATH; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Chen ZW, 1997, J VIROL, V71, P3953, DOI 10.1128/JVI.71.5.3953-3960.1997; Chen ZW, 1996, J VIROL, V70, P3617, DOI 10.1128/JVI.70.6.3617-3627.1996; GAO F, 1994, J VIROL, V68, P7433, DOI 10.1128/JVI.68.11.7433-7447.1994; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; GILDEN RV, 1986, LANCET, V1, P678; Gonder MK, 1997, NATURE, V388, P337, DOI 10.1038/41005; Groves Colin P., 1993, P243; Gurtler LG, 1996, ARCH VIROL, P195; HIRSCH VM, 1993, VIROLOGY, V197, P426, DOI 10.1006/viro.1993.1606; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HUET T, 1990, NATURE, V345, P356, DOI 10.1038/345356a0; JANSSENS W, 1994, AIDS RES HUM RETROV, V10, P1191, DOI 10.1089/aid.1994.10.1191; JIN MJ, 1994, EMBO J, V13, P2935, DOI 10.1002/j.1460-2075.1994.tb06588.x; KOBER B, 1997, HUMAN RETROVIRUSES A; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; MULLER MC, 1993, J VIROL, V67, P1227; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; PEETERS M, 1992, AIDS, V6, P447, DOI 10.1097/00002030-199205000-00002; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHARMA KD, 1994, HYDROL PROCESS, V8, P27, DOI 10.1002/hyp.3360080103; SHARP PM, 1995, PHILOS T R SOC B, V349, P41, DOI 10.1098/rstb.1995.0089; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Teleki G., 1989, P312; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VandenHaesevelde MM, 1996, VIROLOGY, V221, P346, DOI 10.1006/viro.1996.0384; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	28	1019	1056	2	219	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 4	1999	397	6718					436	441		10.1038/17130	http://dx.doi.org/10.1038/17130			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989410				2022-12-01	WOS:000078461700049
J	Nightingale, SL				Nightingale, SL			Lyme disease vaccine approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					408	408		10.1001/jama.281.5.408	http://dx.doi.org/10.1001/jama.281.5.408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952188				2022-12-01	WOS:000078318500007
J	Luttrell, LM; Ferguson, SSG; Daaka, Y; Miller, WE; Maudsley, S; Della Rocca, GJ; Lin, FT; Kawakatsu, H; Owada, K; Luttrell, DK; Caron, MG; Lefkowitz, RJ				Luttrell, LM; Ferguson, SSG; Daaka, Y; Miller, WE; Maudsley, S; Della Rocca, GJ; Lin, FT; Kawakatsu, H; Owada, K; Luttrell, DK; Caron, MG; Lefkowitz, RJ			beta-arrestin-dependent formation of beta(2) adrenergic receptor Src protein kinase complexes	SCIENCE			English	Article							COUPLED THROMBIN RECEPTOR; HETEROTRIMERIC G-PROTEINS; BETA(2)-ADRENERGIC RECEPTOR; TYROSINE-KINASE; GAMMA-SUBUNITS; MAP KINASE; C-SRC; SIGNAL-TRANSDUCTION; ACTIVATION; PHOSPHORYLATION	The Pas-dependent activation of mitogen-activated protein (MAP) kinase pathways by many receptors coupled to heterotrimeric guanine nucleotide binding proteins (G proteins) requires the activation of Src family tyrosine kinases. Stimulation of beta(2) adrenergic receptors resulted in the assembly of a protein complex containing activated c-Src and the receptor. Src recruitment was mediated by beta-arrestin, which functions as an adapter protein, binding both c-Src and the agonist-occupied receptor. beta-Arrestin 1 mutants, impaired either in c-Src binding or in the ability to target receptors to clathrin-coated pits, acted as dominant negative inhibitors of beta(2) adrenergic receptor-mediated activation of the MAP kinases Erk1 and Erk2. These data suggest that beta-arrestin binding, which terminates receptor-C protein;coupling, also initiates a second wave of signal transduction in which the "desensitized" receptor functions as a critical structural component of a mitogenic signaling complex.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; Kyoto Pharmaceut Univ, Inst Mol & Cellular Biol, Yamashina Ku, Kyoto 607, Japan; Glaxo Wellcome Res & Dev, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Duke University; Western University (University of Western Ontario); University of California System; University of California San Francisco; Kyoto Pharmaceutical University; GlaxoSmithKline	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Maudsley, Stuart/Q-4782-2019; Lefkowitz, Robert/AAW-2649-2021; Maudsley, Stuart/AAV-9929-2021; Della Rocca, Gregory/AAM-5281-2021	Maudsley, Stuart/0000-0002-1868-184X; Miller, William/0000-0001-6900-4884; Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK55524, DK02352] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK055524, K08DK002352, R01DK055524] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GARANOVSKAYA MN, 1996, BIOCHEMISTRY-US, V35, P13716; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; LUTTRELL LM, UNPUB; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SATOH T, 1992, J BIOL CHEM, V267, P24149; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WINITZ S, 1993, J BIOL CHEM, V268, P19196; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	47	1193	1224	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					655	661		10.1126/science.283.5402.655	http://dx.doi.org/10.1126/science.283.5402.655			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924018				2022-12-01	WOS:000078324400032
J	Hutloff, A; Dittrich, AM; Beier, KC; Eljaschewitsch, B; Kraft, R; Anagnostopoulos, I; Kroczek, RA				Hutloff, A; Dittrich, AM; Beier, KC; Eljaschewitsch, B; Kraft, R; Anagnostopoulos, I; Kroczek, RA			ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28	NATURE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; DIFFERENTIATION FACTORS; GERMINAL-CENTERS; CTLA-4; ACTIVATION; ANTIGEN; COSTIMULATION; RECOGNITION; EXPRESSION; LIGATION	The T-cell-specific cell-surface receptors CD28 and CTLA-4 are important regulators of the immune system. CD28 potently enhances those T-cell functions that are essential for an effective antigen-specific immune response(1-5), and the homologous CTLA-4 counterbalances the CD28-mediated signals and thus prevents an otherwise fatal overstimulation of the lymphoid system(6-9). Here we report the identification of a third member of this family of molecules, inducible co-stimulator (ICOS), which is a homodimeric protein of relative molecular mass 55,000-60,000 (M-r 55K-60K). Matching CD28 in potency, ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, upregulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B cells. Unlike the constitutively expressed CD28, ICOS has to be de novo induced on the T-cell surface, does not upregulate the production of interleukin-2, but superinduces the synthesis of interleukin-10, a B-cell-differentiation factor. In vivo, ICOS is highly expressed on tonsillar T cells, which are closely associated with B cells in the apical light zone of germinal centres, the site of terminal B-cell maturation. Our results indicate that ICOS is another major regulator of the adaptive immune system.	Robert Koch Inst, D-13353 Berlin, Germany; Max Delbruck Centrum, Dept Prot Chem, D-13122 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pathol, D-12200 Berlin, Germany	Robert Koch Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kroczek, RA (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.		Dittrich, Anna/GRY-6738-2022; Hutloff, Andreas/D-1781-2014; Dittrich, Anna Maria/M-5640-2013	Hutloff, Andreas/0000-0002-0572-8151; 				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Choe J, 1998, EUR J IMMUNOL, V28, P508, DOI 10.1002/(SICI)1521-4141(199802)28:02<508::AID-IMMU508>3.0.CO;2-I; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; HARA T, 1985, J EXP MED, V161, P1513, DOI 10.1084/jem.161.6.1513; JACOBS KA, 1988, NUCLEIC ACIDS RES, V16, P4637, DOI 10.1093/nar/16.10.4637; JUNG LKL, 1984, J EXP MED, V160, P1597, DOI 10.1084/jem.160.5.1597; Kindler V, 1997, J IMMUNOL, V159, P2085; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LUCAS PJ, 1995, J IMMUNOL, V154, P5757; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; NAKANISHI K, 1984, J EXP MED, V160, P1605, DOI 10.1084/jem.160.6.1605; NUNES J, 1993, INT IMMUNOL, V5, P311, DOI 10.1093/intimm/5.3.311; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Truneh A, 1996, MOL IMMUNOL, V33, P321, DOI 10.1016/0161-5890(95)00077-1; Tsiagbe VK, 1996, CRIT REV IMMUNOL, V16, P381; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	30	1107	1339	1	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					263	266		10.1038/16717	http://dx.doi.org/10.1038/16717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930702				2022-12-01	WOS:000078184800055
J	Cole, DEC; Peltekova, VD; Rubin, LA; Hawker, GA; Vieth, R; Liew, CC; Hwang, DM; Evrovski, J; Hendy, GN				Cole, DEC; Peltekova, VD; Rubin, LA; Hawker, GA; Vieth, R; Liew, CC; Hwang, DM; Evrovski, J; Hendy, GN			A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations	LANCET			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; PORTABLE CLINICAL ANALYZER; CA2+-SENSING RECEPTOR; SECONDARY HYPERPARATHYROIDISM; EXTRACELLULAR CALCIUM; GENE; MUTATIONS; CLONING; HEALTH	Background The regulation of extracellular calcium concentration by parathyroid hormone is mediated by a calcium-sensing, G-protein-coupled cell-surface receptor (CASR). Mutations of the CASR gene alter the set-point for extracellular ionised calcium [Ca2+](o) and cause familial hypercalcaemia or hypocalcaemia. The CASR missense polymorphism, A986S, is common in the general population and is, therefore, a prime candidate as a genetic determinant of extracellular calcium concentration. Methods We genotyped the CASR A986S variant (S allele frequency of 16.3%) in 163 healthy adult women and tested samples of their serum for total calcium, albumin, total protein, creatinine, phosphate, pH, and parathyroid hormone. A prospectively generated, random subset of 84 of these women provided a whole blood sample for assay of [Ca2+](o). Findings The A986S genotype showed no association with total serum concentration of calcium, until corrected for albumin. In a multivariate regression model, biochemical and genetic variables accounted for 74% of the total variation in calcium. The significant predictors of serum calcium were: albumin (p<0.001), phosphate (p=0.02), parathyroid hormone (p=0.007), pH (p=0.001), and A986S genotype (p=0.009). Fasting whole-blood [Ca2+](o) also showed an independent positive association with the 986S variant (p=0.013). Interpretation The CASR A986S variant has a significant effect on extracellular calcium. The CASR A986S polymorphism is a likely candidate locus for genetic predisposition to various bone and mineral disorders in which extracellular calcium concentrations have a prominent part.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Genet, Toronto, ON, Canada; McGill Univ, Dept Med Physiol & Human Genet, Montreal, PQ, Canada	University of Toronto; University of Toronto; University of Toronto; McGill University	Cole, DEC (corresponding author), Banting Inst, Room 402,100 Coll St, Toronto, ON M5G 1L5, Canada.	davidec.cole@utoronto.ca						Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bai M, 1997, J CLIN INVEST, V99, P88, DOI 10.1172/JCI119137; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1997, BONE, V20, P303, DOI 10.1016/S8756-3282(97)00002-1; Butters RR, 1997, J BONE MINER RES, V12, P568, DOI 10.1359/jbmr.1997.12.4.568; Cole DEC, 1997, AM J MED GENET, V71, P202, DOI 10.1002/(SICI)1096-8628(19970808)71:2<202::AID-AJMG16>3.0.CO;2-I; Diaz R, 1997, AM J PHYSIOL-REG I, V273, pR1008, DOI 10.1152/ajpregu.1997.273.3.R1008; ERICKSON KA, 1993, CLIN CHEM, V39, P283; GARETT JE, 1995, J BIOL CHEM, V270, P12919; HAVLIK R, 1977, CLIN CHEM, V23, P659; Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323; JACOBS E, 1993, CLIN CHEM, V39, P1069; JANICIC N, 1995, AM J HUM GENET, V56, P880; KALOUSDIAN S, 1987, GENET EPIDEMIOL, V4, P1, DOI 10.1002/gepi.1370040102; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Michelangeli VP, 1997, ANN CLIN BIOCHEM, V34, P97, DOI 10.1177/000456329703400115; NORDIN BEC, 1989, CLIN CHEM, V35, P14; Pearce SHS, 1997, J ENDOCRINOL, V154, P371, DOI 10.1677/joe.0.1540371; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Rubin LA, 1997, SCAND J CLIN LAB INV, V57, P122; RUBIN LA, 1997, J BONE MINER RES  S1, V12, pS374; Sherwood Edith, 1994, Clinical Chemistry, V40, P1057; THODE J, 1989, SCAND J CLIN LAB INV, V49, P217, DOI 10.3109/00365518909089086; WHITE TF, 1986, CLIN CHIM ACTA, V157, P199, DOI 10.1016/0009-8981(86)90226-3; WHITFIELD JB, 1984, ANN CLIN BIOCHEM, V21, P176, DOI 10.1177/000456328402100303; WILLIAMS PD, 1992, CLIN SCI, V82, P493, DOI 10.1042/cs0820493	30	142	151	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					112	115		10.1016/S0140-6736(98)06434-4	http://dx.doi.org/10.1016/S0140-6736(98)06434-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023897				2022-12-01	WOS:000078087200013
J	Lloyd-Jones, DM; Larson, MG; Beiser, A; Levy, D				Lloyd-Jones, DM; Larson, MG; Beiser, A; Levy, D			Lifetime risk of developing coronary heart disease	LANCET			English	Article							GLOBAL BURDEN; POSTMENOPAUSAL WOMEN; MORTALITY; THERAPY; HEALTH; HYPERTENSION; DISABILITY; CANCER	Background The lifetime risk of developing coronary heart disease has not been estimated in a general population. We investigated the lifetime risks of initial coronary events at different ages. Methods We assessed data for 7733 participants in the Framingham Heart Study, who had been examined at least once at age 40-94 years between 1971 and 1975, found to be free of coronary heart disease, and then followed up. We estimated the lifetime risks of coronary heart disease (angina pectoris, coronary insufficiency, myocardia[ infarction, or death from coronary heart disease) by multiple-decrement life-table methods. Findings The 7733 patients were followed up for a total of 109 948 person-years. Overall, 1157 participants developed coronary heart disease. 1312 died from noncoronary heart disease causes. Lifetime risk of coronary heart disease at age 40 years was 48.6% (95% CI 45.8-51.3) for men and 31.7% (29.2-34.2) for women. At age 70 years, lifetime risk was 34.9% (31.2-38.7) for men and 24.2% (21.4-27.0) for women. After we excluded isolated angina pectoris as an initial event, the lifetime risk of coronary artery disease events at age 40 years was 42.4% for men and 24.9% for women. Interpretation Lifetime risk at age 40 years is one in two for men and one in three for women. Even at age 70 years it is one in three for men and one in four for women. This knowledge may promote efforts in education, screening, and treatment for prevention of coronary heart disease in younger and alder patients.	NHLBI, Framingham Heart Study, NIH, Framingham, MA 01702 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Unit, Boston, MA USA; Boston Univ, Sch Med, Div Cardiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Epidemiol & Prevent Med, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02118 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Med, Sch Med, Boston, MA 02115 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Harvard Medical School; Massachusetts General Hospital; Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Levy, D (corresponding author), NHLBI, Framingham Heart Study, NIH, 5 Thurber St, Framingham, MA 01702 USA.	dan@fram.nhlbi.nih.gov	Lloyd-Jones, Donald M/C-5899-2009; Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Levy, Daniel/0000-0003-1843-8724; Lloyd-Jones, Donald/0000-0003-0847-6110; Beiser, Alexa/0000-0001-8551-7778; Larson, Martin/0000-0002-9631-1254				Abbott RD, 1987, FRAMINGHAM STUDY EPI; *AM HEART ASS, 1998, 1998 HEART STROK STA; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.157.21.2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FRASER GE, 1995, AM J EPIDEMIOL, V142, P746, DOI 10.1093/oxfordjournals.aje.a117706; Garfinkel L, 1995, Stat Bull Metrop Insur Co, V76, P31; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; *NAT CTR HLTH STAT, 1997, HLTH US 1996 97; *NAT HEART LUNG BL, 1996, MORB MORT 1996 CHART; National Center for Health Statistics, 1996, HLTH PEOPL 2000 REV; Pearson TA, 1998, J AM COLL CARDIOL, V31, p88A, DOI 10.1016/S0735-1097(97)84091-0; SCHOUTEN LJ, 1994, J EPIDEMIOL COMMUN H, V48, P596, DOI 10.1136/jech.48.6.596; Seshadri S, 1997, NEUROLOGY, V49, P1498, DOI 10.1212/WNL.49.6.1498; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P	28	606	633	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					89	92		10.1016/S0140-6736(98)10279-9	http://dx.doi.org/10.1016/S0140-6736(98)10279-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023892				2022-12-01	WOS:000078087200008
J	Jin, XW; Shearman, LP; Weaver, DR; Zylka, MJ; De Vries, GJ; Reppert, SM				Jin, XW; Shearman, LP; Weaver, DR; Zylka, MJ; De Vries, GJ; Reppert, SM			A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock	CELL			English	Article							VASOPRESSIN-DEFICIENT RATS; DROSOPHILA PERIOD GENE; MESSENGER-RNA; ENDOGENOUS VASOPRESSIN; NEUROSPORA-CRASSA; IN-VITRO; EXPRESSION; NUCLEUS; NEURONS; CLONING	We examined the transcriptional regulation of the clock-controlled arginine vasopressin gene in the suprachiasmatic nuclei (SCN). A core clock mechanism in mouse SCN appears to involve a transcriptional feedback loop in which CLOCK and BMAL1 are positive regulators and three mPeriod (mPer) genes are involved in negative feedback. We show that the RNA rhythm of each mPer gene is severely blunted in Clock/ Clock mice. The vasopressin RNA rhythm is abolished in the SCN of Clock/Clock animals, leading to markedly decreased peptide levels. Luciferase reporter gene assays show that CLOCK-BMAL1 heterodimers act through an E box enhancer in the vasopressin gene to activate transcription; this activation can be inhibited by the mPER and mTIM proteins. These data indicate that the transcriptional machinery of the core clockwork directly regulates a clock-controlled output rhythm.	Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Univ Massachusetts, Dept Psychol, Ctr Neuroendocrine Studies, Amherst, MA 01003 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Amherst	Reppert, SM (corresponding author), Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA.	reppert@helix.mgh.harvard.edu	Jansen, Heiko T./A-5770-2008; Weydahl, Andi/C-6391-2008	Jansen, Heiko T./0000-0003-0178-396X; Weaver, David/0000-0001-7941-6719; de Vries, Geert/0000-0002-1263-3775	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011547, F32MH012067] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD14427] Funding Source: Medline; NIMH NIH HHS [MH12067, MH11547] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BROWN MH, 1989, PHYSIOL BEHAV, V46, P759, DOI 10.1016/0031-9384(89)90364-8; CARTER DA, 1992, MOL BRAIN RES, V12, P315, DOI 10.1016/0169-328X(92)90133-V; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1998, CURR OPIN GENET DEV, V8, P400, DOI 10.1016/S0959-437X(98)80109-3; FERRIS CF, 1984, SCIENCE, V224, P521, DOI 10.1126/science.6538700; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GROBLEWSKI TA, 1981, BRAIN RES BULL, V6, P125, DOI 10.1016/S0361-9230(81)80036-6; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARA Y, 1990, MOL BRAIN RES, V8, P319, DOI 10.1016/0169-328X(90)90045-F; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Ingram CD, 1996, NEUROSCIENCE, V75, P635, DOI 10.1016/0306-4522(96)00274-6; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki Y, 1997, ENDOCRINOLOGY, V138, P5266, DOI 10.1210/en.138.12.5266; Kalsbeek A, 1996, J NEUROSCI, V16, P5555, DOI 10.1523/jneurosci.16-17-05555.1996; Kalsbeek A, 1996, J NEUROENDOCRINOL, V8, P299, DOI 10.1046/j.1365-2826.1996.04597.x; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; LOROS JJ, 1991, MOL CELL BIOL, V11, P558, DOI 10.1128/MCB.11.1.558; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; MIHAI R, 1994, NEUROSCIENCE, V62, P783, DOI 10.1016/0306-4522(94)90476-6; MIHAI R, 1994, NEUROSCI LETT, V179, P95, DOI 10.1016/0304-3940(94)90943-1; NINKINA NN, 1995, MOL BRAIN RES, V33, P233; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; REPPERT SM, 1987, TRENDS NEUROSCI, V10, P76, DOI 10.1016/0166-2236(87)90029-4; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; RIVKEES SA, 1992, BRAIN RES, V598, P332, DOI 10.1016/0006-8993(92)90203-L; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; SCHRIER RW, 1985, VASOPRESSIN; SCHWARTZ WJ, 1987, P NATL ACAD SCI USA, V84, P1694, DOI 10.1073/pnas.84.6.1694; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SHEARMAN LP, IN PRESS NEUROSCIENC; Shipley MT, 1989, NEUROANATOMICAL TRAC, V2, P331, DOI [10.1007/978-1-4757-2055-6, DOI 10.1007/978-1-4757-2055-6]; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; TOMINAGA K, 1992, NEUROREPORT, V3, P809, DOI 10.1097/00001756-199209000-00022; UHL GR, 1986, SCIENCE, V232, P390, DOI 10.1126/science.3961487; VanGelder RN, 1995, CURR BIOL, V5, P1424, DOI 10.1016/S0960-9822(95)00280-6; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; ZHOU L, 1994, ENDOCRINOLOGY, V134, P2622, DOI 10.1210/en.134.6.2622; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	61	738	755	0	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					57	68		10.1016/S0092-8674(00)80959-9	http://dx.doi.org/10.1016/S0092-8674(00)80959-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989497	Bronze			2022-12-01	WOS:000078023200008
J	Ng, T; Squire, A; Hansra, G; Bornancin, F; Prevostel, C; Hanby, A; Harris, W; Barnes, D; Schmidt, S; Mellor, H; Bastiaens, PIH; Parker, PJ				Ng, T; Squire, A; Hansra, G; Bornancin, F; Prevostel, C; Hanby, A; Harris, W; Barnes, D; Schmidt, S; Mellor, H; Bastiaens, PIH; Parker, PJ			Imaging protein kinase C alpha activation in cells	SCIENCE			English	Article							MICROSCOPY; ASSOCIATION	Spatially resolved fluorescence resonance energy transfer (FRET) measured by fluorescence lifetime imaging microscopy (FLIM), provides a method for tracing the catalytic activity of fluorescently tagged proteins inside live cell cultures and enables determination of the functional state of proteins in fixed cells and tissues. Here, a dynamic marker of protein kinase C alpha (PKC alpha) activation is identified and exploited. Activation of PKC alpha is detected through the binding of fluorescently tagged phosphorylation site-specific antibodies; the consequent FRET is measured through the donor fluorophore on PKC alpha by FLIM. This approach enabled the imaging of PKC alpha activation in live and fixed cultured cells and was also applied to pathological samples.	Imperial Canc Res Fund, Cell Biophys Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; Guys Hosp, Imperial Canc Res Fund, Hedley Atkins Lab, London SE1 9RT, England	Cancer Research UK; Cancer Research UK; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Bastiaens, PIH (corresponding author), Imperial Canc Res Fund, Cell Biophys Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	bastiaen@icrf.icnet.uk; parkerp@icrf.icnet.uk	Parker, Peter j/D-5192-2013; Bornancin, Frederic/AAA-2888-2021; Prevostel, Corinne/AAO-1433-2020	Bornancin, Frederic/0000-0002-0152-6720; Mellor, Harry/0000-0003-3894-0623; PREVOSTEL, Corinne/0000-0002-7553-087X; parker, peter/0000-0002-6218-2933; Ng, Tony/0000-0003-3894-5619				Bastiaens PIH, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P136; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Carlsson K, 1997, J MICROSC-OXFORD, V185, P37, DOI 10.1046/j.1365-2818.1997.1450705.x; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dong CY, 1995, BIOPHYS J, V69, P2234, DOI 10.1016/S0006-3495(95)80148-7; Gadella T. W. J.  Jr., 1994, Bioimaging, V2, P139, DOI 10.1002/1361-6374(199409)2:3<139::AID-BIO4>3.3.CO;2-K; GADELLA TWJ, 1993, BIOPHYS CHEM, V48, P221, DOI 10.1016/0301-4622(93)85012-7; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P221; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAKOWICZ JR, 1991, REV SCI INSTRUM, V62, P1727, DOI 10.1063/1.1142413; NG TK, UNPUB; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; SANDERS R, 1995, ANAL BIOCHEM, V227, P302, DOI 10.1006/abio.1995.1285; Schneider PC, 1997, REV SCI INSTRUM, V68, P4107, DOI 10.1063/1.1148354; SO PTC, 1995, BIOIMAGING, V3, P1; Squire A, 1999, J MICROSC-OXFORD, V193, P36, DOI 10.1046/j.1365-2818.1999.00427.x	21	256	267	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2085	2089		10.1126/science.283.5410.2085	http://dx.doi.org/10.1126/science.283.5410.2085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10092232				2022-12-01	WOS:000079369800047
J	Ji, Q; Luo, ZX; Ji, SA				Ji, Q; Luo, ZX; Ji, SA			A Chinese triconodont mammal and mosaic evolution of the mammalian skeleton	NATURE			English	Article							SHOULDER	Here we describe a new triconodont mammal from the Late Jurassic/Early Cretaceous period of Liaoning, China. This new mammal is represented by the best-preserved skeleton known so far for triconodonts which form one of the earliest Mesozoic mammalian groups with high diversity. The postcranial skeleton of this new triconodont shows a mosaic of characters, including a primitive pelvic girdle and hindlimb but a very derived pectoral girdle that is closely comparable to those of derived therians. Given the basal position of this taxon in mammalian phylogeny, its derived pectoral girdle indicates that homoplasies (similarities resulting from independent evolution among unrelated lineages) are as common in the postcranial skeleton as they are in the skull and dentition in the evolution of Mesozoic mammals. Limb structures of the new triconodont indicate that it was probably a ground-dwelling animal.	Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, Pittsburgh, PA 15213 USA; China Univ Geosci, Beijing 100083, Peoples R China; Natl Geol Museum China, Beijing 100034, Peoples R China	China University of Geosciences	Luo, ZX (corresponding author), Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, Pittsburgh, PA 15213 USA.	louz@clpgh.org	Luo, Zhe-XI/AAU-2263-2021					Chen PJ, 1998, NATURE, V391, P147, DOI 10.1038/34356; Cifelli RL, 1998, J VERTEBR PALEONTOL, V18, P237, DOI 10.1080/02724634.1998.10011048; Crompton A.W., 1974, Bulletin Br Mus nat Hist (Geol), V24, P399; FOX RC, 1976, CAN J EARTH SCI, V13, P1105, DOI 10.1139/e76-113; Hopson James A., 1994, Short Courses in Paleontology, V7, P190; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; Hu YM, 1997, NATURE, V390, P137, DOI 10.1038/36505; Jenkins F.A., 1971, B PEABODY MUS NAT HI, V36, P1, DOI DOI 10.1671/0272-4634(2008)28[445:NMOMBC]2.0CO;2; Jenkins F.A. Jr, 1979, P74; JENKINS FA, 1976, PHILOS T ROY SOC B, V273, P387, DOI 10.1098/rstb.1976.0022; JENKINS FA, 1979, J ZOOL, V188, P379; JENKINS FA, 1988, J VERTEBR PALEONTOL, V6, P1; Ji Q, 1998, NATURE, V393, P753, DOI 10.1038/31635; Ji Q., 1996, CHINESE GEOL, V233, P30; KEMP TS, 1983, ZOOL J LINN SOC-LOND, V77, P353, DOI 10.1111/j.1096-3642.1983.tb00859.x; KERMACK KA, 1973, ZOOL J LINN SOC-LOND, V53, P87, DOI 10.1111/j.1096-3642.1973.tb00786.x; Kielan-Jaworowska Z, 1998, ACTA PALAEONTOL POL, V43, P413; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; KIELANJAWOROWSK.Z, 1997, LETHAIA, V29, P249; Klima M., 1973, Advances Anat Embryol Cell Biol, V47, P1; KRAUSE D W, 1983, Bulletin of the Museum of Comparative Zoology, V150, P199; LUO Z, 1994, SHADOW DINOSAURS EAR, P980; MCLEOD N, 1993, AM J SCI, V293, P300; Rougier Guillermo W., 1996, American Museum Novitates, V3183, P1; ROUGIER GW, 1993, THESIS U NACIONAL BU; ROUGLER GW, 1993, THESIS U NACIONAL BU; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; SERENO PC, 1995, NATURE, V377, P144, DOI 10.1038/377144a0; Sigogneau-Russell Denise, 1995, Acta Palaeontologica Polonica, V40, P149; SIMPSON G. G., 1928, CATALOGUE MESOZOIC M; SUN A, 1985, VERTEBRAT PALASIATIC, V23, P136	31	153	182	7	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	1999	398	6725					326	330						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DF	10192332				2022-12-01	WOS:000079369600049
J	Supattapone, S; Bosque, P; Muramoto, T; Wille, H; Aagaard, C; Peretz, D; Nguyen, HOB; Heinrich, C; Torchia, M; Safar, J; Cohen, FE; DeArmond, SJ; Prusiner, SB; Scott, M				Supattapone, S; Bosque, P; Muramoto, T; Wille, H; Aagaard, C; Peretz, D; Nguyen, HOB; Heinrich, C; Torchia, M; Safar, J; Cohen, FE; DeArmond, SJ; Prusiner, SB; Scott, M			Prion protein of 106 residues creates an artificial transmission barrier for prion replication in transgenic mice	CELL			English	Article							SCRAPIE ISOFORM; CULTURED-CELLS; BIOCHEMICAL-PROPERTIES; SECONDARY STRUCTURE; CELLULAR PRP; N-TERMINUS; PROPAGATION; INFECTIVITY; DISEASE; MUTANT	A redacted prion protein (PrP) of 106 amino acids with two large deletions was expressed in transgenic (Tg) mice deficient for wild-type (wt) PrP (Prnp(0/0)) and supported prion propagation. RML prions containing full-length PrPSc produced disease in Tg(PrP106)Prnp(0/0) mice after similar to 300 days, while transmission of RML106 prions containing PrP(Sc)106 created disease in Tg(PrP106) Prnp(0/0) mice after only similar to 65 days on repeated passage. This artificial transmission barrier for the passage of RML prions was diminished by the coexpression of wt MoPrPC in Tg(PrP106)Prnp(+/0) mice that developed scrapie in similar to 165 days, suggesting that wt MoPrP acts in trans to accelerate replication of RML106 prions. Purified PrP(Sc)106 was protease resistant, formed filaments, and was insoluble in nondenaturing detergents. The unique features of RML106 prions offer insights into the mechanism of prion replication, and the small size of PrP(Sc)106 should facilitate structural analysis.	Univ Calif San Francisco, Inst Neurodegenerat Dis, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Scott, M (corresponding author), Univ Calif San Francisco, Inst Neurodegenerat Dis, Dept Neurol, San Francisco, CA 94143 USA.		Safar, Jiri G/G-6512-2013; Wille, Holger/C-2280-2008	Wille, Holger/0000-0001-5102-8706				BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BUELER H, 1994, MOL MED, V1, P19; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; CHANDLER RL, 1961, LANCET, V1, P1378; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; MASTERS CL, 1978, BRAIN, V101, P333, DOI 10.1093/brain/101.2.333; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Riesner D, 1996, J VIROL, V70, P1714, DOI 10.1128/JVI.70.3.1714-1722.1996; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; Scott MR, 1997, J VIROL, V71, P9032, DOI 10.1128/JVI.71.12.9032-9044.1997; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Wille H, 1999, BIOPHYS J, V76, P1048, DOI 10.1016/S0006-3495(99)77270-X; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998	39	181	185	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	1999	96	6					869	878		10.1016/S0092-8674(00)80596-6	http://dx.doi.org/10.1016/S0092-8674(00)80596-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102274	Bronze			2022-12-01	WOS:000079300100013
J	Hamada, F; Tomoyasu, Y; Takatsu, Y; Nakamura, M; Nagai, S; Suzuki, A; Fujita, F; Shibuya, H; Toyoshima, K; Ueno, N; Akiyama, T				Hamada, F; Tomoyasu, Y; Takatsu, Y; Nakamura, M; Nagai, S; Suzuki, A; Fujita, F; Shibuya, H; Toyoshima, K; Ueno, N; Akiyama, T			Negative regulation of Wingless signaling by D-axin, a Drosophila homolog of axin	SCIENCE			English	Article							BETA-CATENIN; LIMB DEVELOPMENT; CELL FATES; EXPRESSION; MELANOGASTER; ARMADILLO; PROTEIN; MOSAICS; ABDOMEN; CANCER	Wnt/Wingless directs many cell fates during development. Wnt/Wingless signaling increases the amount of beta-catenin/Armadillo, which in turn activates gene transcription. Here the Drosophila protein D-Axin was shown to interact with Armadillo and D-APC. Mutation of d-axin resulted in the accumulation of cytoplasmic Armadillo and one of the Wingless target gene products, Distal-less. Ectopic expression of d-axin inhibited Wingless signaling. Hence, D-Axin negatively regulates Wingless signaling by down-regulating the Level of Armadillo. These results establish the importance of the Axin family of proteins in Wnt/Wingless signaling in Drosophila.	Osaka Univ, Res Inst Microbial Dis, Dept Oncogene Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, PRESTO, Inheritance & Variat Precursory Res Embryon Sci &, Kyoto, Japan; Natl Inst Basic Biol, Dept Dev Biol, Okazaki, Aichi 4448585, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari Ku, Osaka 5378511, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Dept Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan	Osaka University; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Osaka Medical Center for Cancer & Cardiovascular Diseases; University of Tokyo	Akiyama, T (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Oncogene Res, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		Tomoyasu, Yoshinori/D-3061-2017	Tomoyasu, Yoshinori/0000-0001-9824-3454; Ueno, Naoto/0000-0002-8375-2317				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chou TB, 1996, GENETICS, V144, P1673; HAMADA F, UNPUB; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Neumann CJ, 1997, DEVELOPMENT, V124, P871; PEIFER M, 1994, DEVELOPMENT, V120, P369; Penton A, 1996, NATURE, V382, P162, DOI 10.1038/382162a0; ROBERTSON HM, 1988, GENETICS, V118, P461; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Shiga Y, 1996, DEV GROWTH DIFFER, V38, P99; Shirras AD, 1996, DEV BIOL, V175, P24, DOI 10.1006/dbio.1996.0092; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; XU T, 1993, DEVELOPMENT, V117, P1223; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	34	168	173	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	1999	283	5408					1739	1742		10.1126/science.283.5408.1739	http://dx.doi.org/10.1126/science.283.5408.1739			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175PF	10073940				2022-12-01	WOS:000079102800053
J	Lu, PJ; Zhou, XZ; Shen, MH; Lu, KP				Lu, PJ; Zhou, XZ; Shen, MH; Lu, KP			Function of WW domains as phosphoserine- or phosphothreonine-binding modules	SCIENCE			English	Article							PROTEIN-PROTEIN RECOGNITION; SACCHAROMYCES-CEREVISIAE; SIGNALING PROTEINS; CDC25 PHOSPHATASE; TYROSINE KINASES; SH3 DOMAINS; M-PHASE; UBIQUITIN; PHOSPHORYLATION; DEGRADATION	Protein-interacting modules help determine the specificity of signal transduction events, and protein phosphorylation can modulate the assembly of such modules into specific signaling complexes. Although phosphotyrosine-binding modules have been well-characterized, phosphoserine- or phosphothreonine-binding modules have not been described. WW domains are small protein modules found in various proteins that participate in cell signaling or regulation, WW domains of the essential mitotic prolyl isomerase Pin1 and the ubiquitin ligase Nedd4 bound to phosphoproteins, including physiological substrates of enzymes, in a phosphorylation-dependent manner. The Pin1 WW domain functioned as a phosphoserine- or phosphothreonine-binding module, with properties similar to those of SRC homology 2 domains, Phosphoserine- or phosphothreonine-binding activity was required for Pin1 to interact with its substrates in vitro and to perform its essential function in vivo.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.				NIGMS NIH HHS [R01GM58556, R01GM56230] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230, R01GM058556] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COPLEY RR, 1994, J MOL BIOL, V242, P321; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JANIN J, 1990, J BIOL CHEM, V265, P16027; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; YOUNG L, 1994, PROTEIN SCI, V3, P717; Zhou X., UNPUB	53	579	596	2	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1325	1328		10.1126/science.283.5406.1325	http://dx.doi.org/10.1126/science.283.5406.1325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037602				2022-12-01	WOS:000078839900041
J	Fazel, S; Hope, T; Jacoby, R				Fazel, S; Hope, T; Jacoby, R			Assessment of competence to complete advance directives: validation of a patient centred approach	BRITISH MEDICAL JOURNAL			English	Article							CAPACITY; CONSENT	Objective To develop a patient centred approach for the assessment of competence to complete advance directives ("living wills") of elderly people with cognitive impairment Design Semistructured interviews. Setting Oxfordshire. Subjects 50 elderly volunteers living in the community, and 50 patients with dementia on first referral from primary care. Main outcome measures Psychometric properties of competence assessment. Results This patient centred approach for assessing competence to complete advance directives can discriminate between elderly persons living in the community and elderly patients with dementia, The procedure has good interrater (r = 0.95) and test-retest (r = 0.97) reliability Validity was examined by relating this approach with a global assessment of competence to complete an advance directive made by two of us (both specialising in old age psychiatry). The data were also used to determine the best threshold score for discriminating between those competent and those incompetent to complete an advance directive, Conclusion A patient centred approach to assess competence to complete advance directives can be reliably and validly used in routine clinical practice.	Univ Oxford, Warneford Hosp, Old Age Psychiat Sect, Oxford OX3 7JX, England	University of Oxford	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Old Age Psychiat Sect, Oxford OX3 7JX, England.	seena.fazel@psychiatry.ox.ac.uk	Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLEBAUM PS, 1995, LAW HUMAN BEHAV, V19, P149; APPLEBAUM PS, 1988, NEW ENGL J MED, V319, P1635; *BRIT MED ASS, 1994, STAT ADV DIR; Buchanan AE., 1989, DECIDING OTHERS ETHI; FITTEN LJ, 1990, J AM GERIATR SOC, V38, P1097, DOI 10.1111/j.1532-5415.1990.tb01372.x; GILLICK MR, 1995, ANN INTERN MED, V123, P621, DOI 10.7326/0003-4819-123-8-199510150-00009; HOPE T, 1992, BRIT MED J, V304, P398, DOI 10.1136/bmj.304.6824.398; JACOBY R, 1997, PSYCHIAT ELDERLY; JANOFSKY JS, 1992, HOSP COMMUNITY PSYCH, V43, P132; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; MARSON DC, 1994, ALZ DIS ASSOC DIS, V8, P5, DOI 10.1097/00002093-199400000-00002; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P949, DOI 10.1001/archneur.1995.00540340029010; SILBERFELD M, 1993, J AM GERIATR SOC, V41, P1141, DOI 10.1111/j.1532-5415.1993.tb06464.x	13	57	58	2	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1999	318	7182					493	+		10.1136/bmj.318.7182.493	http://dx.doi.org/10.1136/bmj.318.7182.493			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	170QT	10024254	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000078818100022
J	Lorch, Y; Zhang, M; Kornberg, RD				Lorch, Y; Zhang, M; Kornberg, RD			Histone octamer transfer by a chromatin-remodeling complex	CELL			English	Article							NUCLEOSOMAL DNA; BINDING; PROTEIN	RSC, an abundant, essential chromatin-remodeling complex related to SWI/SNF complex, catalyzes the transfer of a histone octamer from a nucleosome core particle to naked DNA. The newly formed octamer-DNA complex is identical with a nucleosome in all respects. The reaction requires ATP and involves an activated RSC-nucleosome intermediate. The mechanism may entail formation of a duplex displacement loop on the nucleosome, facilitating the entry of exogeneous DNA and the release of the endogenous molecule.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S	13	227	244	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					389	392		10.1016/S0092-8674(00)80551-6	http://dx.doi.org/10.1016/S0092-8674(00)80551-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025404	Bronze			2022-12-01	WOS:000078514600011
J	Susin, SA; Lorenzo, HK; Zamzami, N; Marzo, I; Snow, BE; Brothers, GM; Mangion, J; Jacotot, E; Costantini, P; Loeffler, M; Larochette, N; Goodlett, DR; Aebersold, R; Siderovski, DP; Penninger, JM; Kroemer, G				Susin, SA; Lorenzo, HK; Zamzami, N; Marzo, I; Snow, BE; Brothers, GM; Mangion, J; Jacotot, E; Costantini, P; Loeffler, M; Larochette, N; Goodlett, DR; Aebersold, R; Siderovski, DP; Penninger, JM; Kroemer, G			Molecular characterization of mitochondrial apoptosis-inducing factor	NATURE			English	Article							CYTOCHROME-C; FRAGMENTATION; PROTEASE; BCL-2; DNA; REQUIREMENT; ACTIVATION; PROTEINS; RELEASE; CELLS	Mitochondria play a key part in the regulation of apoptosis (cell death)(1,2). Their intermembrane space contains several proteins that are liberated through the outer membrane in order to participate in the degradation phase of apoptosis(3-9). Here we report the identification and cloning of an apoptosis-inducing factor, AIF(5), which is sufficient to induce apoptosis of isolated nuclei. AIF is a flavoprotein of relative molecular mass 57,000 which shares homology with the bacterial oxidoreductases; it is normally confined to mitochondria but translocates to the nucleus when apoptosis is induced. Recombinant AIF causes chromatin condensation in isolated nuclei and large-scale fragmentation of DNA. It induces purified mitochondria to release the apoptogenic proteins cytochrome c and caspase-9. Microinjection of AIF into the cytoplasm of intact cells induces condensation of chromatin, dissipation of the mitochondrial transmembrane potential, and exposure of phosphatidylserine in the plasma membrane. None of these effects is prevented by the wide-ranging caspase inhibitor known as Z-VAD.fmk. Overexpression of Bcl-2, which controls the opening of mitochondrial permeability transition pores, prevents the release of AIF from the mitochondrion but does not affect its apoptogenic activity. These results indicate that AIF is a mitochondrial effector of apoptotic cell death.	CNRS, UPR 420, F-94801 Villejuif, France; Inst Pasteur, Unite Biochim Struct, F-75724 Paris 15, France; Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Washington; University of Washington Seattle	Kroemer, G (corresponding author), CNRS, UPR 420, 19 Rue Guy Moquet, F-94801 Villejuif, France.		Marzo, Isabel/E-6918-2016; Susin, Santos A/Q-6754-2017; LAROCHETTE, Nathanael/R-4298-2017; Penninger, Josef M/I-6860-2013; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Siderovski, David Peter/AAA-9603-2019; Lorenzo, Hans-Kristian/GLR-5785-2022	Marzo, Isabel/0000-0002-2315-9079; Susin, Santos A/0000-0002-3366-1628; LAROCHETTE, Nathanael/0000-0002-7936-678X; Penninger, Josef M/0000-0002-8194-3777; KROEMER, Guido/0000-0002-9334-4405; Siderovski, David Peter/0000-0002-0688-8210; /0000-0002-5301-1569; Lorenzo, Hans Kristian/0000-0002-7921-177X				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Cedano J, 1997, J MOL BIOL, V266, P594, DOI 10.1006/jmbi.1996.0804; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAGARKOVA MA, 1995, J BIOL CHEM, V270, P20239, DOI 10.1074/jbc.270.35.20239; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Robinson KM, 1996, J BIOL CHEM, V271, P4061; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Trbovich AM, 1998, CELL DEATH DIFFER, V5, P38, DOI 10.1038/sj.cdd.4400299; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wada J, 1998, P NATL ACAD SCI USA, V95, P144, DOI 10.1073/pnas.95.1.144; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHU W, 1996, EMBO J, V15, P4139	30	3266	3451	8	301	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					441	446		10.1038/17135	http://dx.doi.org/10.1038/17135			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989411				2022-12-01	WOS:000078461700050
J	Nightingale, SL				Nightingale, SL			FDA conference on human subject protection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					408	408		10.1001/jama.281.5.408	http://dx.doi.org/10.1001/jama.281.5.408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952188				2022-12-01	WOS:000078318500008
J	Daumit, GL; Hermann, JA; Coresh, J; Powe, NR				Daumit, GL; Hermann, JA; Coresh, J; Powe, NR			Use of cardiovascular procedures among black persons and white persons: A 7-year nationwide study in patients with renal disease	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY HEART-DISEASE; INVASIVE CARDIAC PROCEDURES; BYPASS GRAFT-SURGERY; NON-HISPANIC WHITES; UNITED-STATES; HEALTH-CARE; REVASCULARIZATION PROCEDURES; RACIAL-DIFFERENCES; ETHNIC-DIFFERENCES	Background: Black persons historically undergo fewer invasive cardiovascular procedures than white persons. Objective: To determine whether acquisition of Medicare health insurance and comprehensive care for severe illness reduce ethnic disparity in use of cardiovascular procedures. Design: 7-year longitudinal analyses in a cohort from the United States Renal Data System. Setting: Health care institutions in the United States. Patients: Nationwide random sample of 4987 adult black and white patients with incident end-stage renal disease (ESRD) from 303 dialysis facilities in 1986 to 1987. Measurements: Medical history and service use records, physical examination, and laboratory data. Main outcome measures were receipt of a coronary catheterization or revascularization procedure before (baseline) and after (follow-up) development of ESRD and acquisition of Medicare, adjusted for clinical and socioeconomic variables. Results: At baseline, 9.9% of white patients and 2.8% of black patients had had a cardiac procedure; the odds were almost three times greater in white than in black patients (adjusted odds ratio, 2.92 [95% CI, 2.04 to 4.18]). During follow-up, white patients were only 1.4 times more likely than black patients to have a procedure (adjusted relative risk, 1.41 [CI, 1.13 to 1.77]); rates were 7.8% for white persons and 8.5% for black persons. In patients with Medicare coverage before development of ESRD, the initial threefold difference in procedure use was eliminated over follow-up (odds ratio, 1.05 [CI, 0.56 to 1.60]). For procedures after hospital admission for myocardial infarction or coronary disease, no difference between ethnic groups was seen during follow-up (relative risk, 1.12 [CI, 0.68 to 1.85]). Conclusions: Differences between ethnic groups in use of cardiovascular procedures narrowed markedly once a serious illness (ESRD) developed and adequate insurance coverage was ensured; the disparity was eliminated in patients with previous Medicare insurance or a stronger indication for a procedure. These findings suggest that almost equal access to care is attainable by combining insurance with delivery of comprehensive, clinically appropriate rare.	Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Powe, NR (corresponding author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-641, Baltimore, MD 21205 USA.	npowe@jhsmi.edu			NHLBI NIH HHS [5T32HLO7024] Funding Source: Medline; NIDDK NIH HHS [R01DK47797] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047797] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aday L A, 1974, Health Serv Res, V9, P208; ANDERSEN R, 1978, MED CARE, V16, P533, DOI 10.1097/00005650-197807000-00001; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Bender FH, 1996, AM J KIDNEY DIS, V28, P67, DOI 10.1016/S0272-6386(96)90132-8; BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; BLOOM B, 1997, VITAL HLTH STAT, V10, P1; BLUSTEIN J, 1995, AM J PUBLIC HEALTH, V85, P345, DOI 10.2105/AJPH.85.3.345; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; Carlisle DM, 1997, AM J PUBLIC HEALTH, V87, P263, DOI 10.2105/AJPH.87.2.263; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DAVIS K, 1987, MILBANK Q, V65, P213, DOI 10.2307/3349956; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DRACUP K, 1991, HEART LUNG, V20, P570; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; EVANS RW, 1981, JAMA-J AM MED ASSOC, V245, P487, DOI 10.1001/jama.245.5.487; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; FORD ES, 1995, HEALTH SERV RES, V30, P237; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; Gillum RF, 1997, ANN INTERN MED, V127, P111, DOI 10.7326/0003-4819-127-2-199707150-00003; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; Gillum RF, 1997, J AM COLL CARDIOL, V29, P1557, DOI 10.1016/S0735-1097(97)00089-2; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; HUBBELL FA, 1989, AM J MED, V87, P127; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; *INT CLASS DIS, 1994, CLIN MOD; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; Lee H O, 1997, Am J Crit Care, V6, P7; LEVY P, 1998, ENCY BIOSTATISTICS, P2635; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MCBEAN AM, 1994, AM HEART J, V127, P287, DOI 10.1016/0002-8703(94)90115-5; Mickelson JK, 1997, J AM COLL CARDIOL, V29, P915, DOI 10.1016/S0735-1097(97)00034-X; MORT EA, 1994, ARCH INTERN MED, V154, P761, DOI 10.1001/archinte.154.7.761; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PUGH JA, 1994, AM J KIDNEY DIS, V23, P803; Ramsey DJ, 1997, J CLIN EPIDEMIOL, V50, P603, DOI 10.1016/S0895-4356(97)80002-9; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; STAFFORD RS, 1991, JAMA-J AM MED ASSOC, V265, P59, DOI 10.1001/jama.265.1.59; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US REN DAT SYST, 1994, USRDS ANN DAT REP; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WEISSMAN JS, 1993, ANNU REV PUBL HEALTH, V14, P243; Weissman JS., 1994, FALLING SAFETY NET I; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wild Sarah H., 1995, Annals of Epidemiology, V5, P432, DOI 10.1016/1047-2797(95)00058-5	59	81	82	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					173	+		10.7326/0003-4819-130-3-199902020-00002	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	162PD	10049195				2022-12-01	WOS:000078355000001
J	DeVries, SH; Schwartz, EA				DeVries, SH; Schwartz, EA			Kainate receptors mediate synaptic transmission between cones and "off" bipolar cells in a mammalian retina	NATURE			English	Article							GANGLION-CELLS; RESPONSES; NEURONS; AMPA; PHOTORECEPTORS; TERMINALS; SQUIRREL; TURTLE; LIGHT	Light produces a graded hyperpolarization in retinal photoreceptors(1,2) that decreases their release of synaptic neurotransmitter(3,4). Cone photoreceptors use glutamate(5,6) as a neurotransmitter with which to communicate with two types of bipolar cell. Activation of metabotropic glutamate receptors in 'On' bipolar cells(7,8) initiates a second-messenger cascade that can amplify small synaptic inputs from cones. In contrast, it is not known how the ionotropic glutamate receptors that are activated in 'Off' bipolar cells(9,10) are optimized for transmitting small, graded signals. Here we show, by recording from a cone and a synaptically connected 'Off' bipolar cell in slices of retina from the ground squirrel, that transmission is mediated by glutamate receptors of the kainate-preferring subtype. In the dark, a cone releases sufficient neurotransmitter to desensitize most postsynaptic kainate receptors. The small postsynaptic current that persists (<5% of maximum) is quickly modulated by changes in presynaptic voltage. Since recovery from desensitization is slow (the decay time constant is roughly 500 milliseconds), little recovery can occur during the brief (roughly 100-millisecond) hyperpolarization that is produced in cones by a flash of light. By limiting the postsynaptic current, receptor desensitization prevents saturation of the 'Off' bipolar cell's voltage response and allows the synapse to operate over the cone's entire physiological voltage range.	Univ Texas, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA	University of Texas System; University of Texas Health Science Center Houston; University of Chicago	DeVries, SH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA.							ATTWELL D, 1987, J PHYSIOL-LONDON, V387, P125, DOI 10.1113/jphysiol.1987.sp016567; BAYLOR DA, 1970, J PHYSIOL-LONDON, V207, P77, DOI 10.1113/jphysiol.1970.sp009049; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; DOWLING JE, 1973, NATURE, V242, P101, DOI 10.1038/242101a0; Falk G., 1988, Progress in Retinal Research, V8, P255, DOI 10.1016/0278-4327(88)90028-4; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; KRAFT TW, 1988, J PHYSIOL-LONDON, V404, P199, DOI 10.1113/jphysiol.1988.sp017286; LEEPER HF, 1985, J NEUROPHYSIOL, V54, P1157, DOI 10.1152/jn.1985.54.5.1157; LINDBERG KA, 1996, J COMP NEUROL, V365, P173; LUKASIEWICZ P, 1988, J NEUROSCI, V8, P4470; MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Mennerick S, 1996, NEURON, V17, P1241, DOI 10.1016/S0896-6273(00)80254-8; MILLER AM, 1983, J PHYSIOL-LONDON, V334, P325, DOI 10.1113/jphysiol.1983.sp014497; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0; Rice SO, 1944, BELL SYST TECH J, V23, P282, DOI 10.1002/j.1538-7305.1944.tb00874.x; SAITO T, 1983, J GEN PHYSIOL, V81, P589, DOI 10.1085/jgp.81.4.589; TRIFONOV Y A, 1968, Biofizika, V13, P809; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; WEST RW, 1976, J COMP NEUROL, V168, P355, DOI 10.1002/cne.901680304	26	177	183	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					157	160		10.1038/16462	http://dx.doi.org/10.1038/16462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923677				2022-12-01	WOS:000078085000045
J	Freedman, MS; Lucas, RJ; Soni, B; von Schantz, M; Munoz, M; David-Gray, Z; Foster, R				Freedman, MS; Lucas, RJ; Soni, B; von Schantz, M; Munoz, M; David-Gray, Z; Foster, R			Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors	SCIENCE			English	Article							GANGLION-CELLS; LIGHT; MICE; RHYTHMS; PIGMENT; RETINA; SYSTEM; OPSIN; RD/RD; CLOCK	Circadian rhythms of mammals are entrained by light to follow the daily solar cycle (photoentrainment). To determine whether retinal rods and cones are required for this response, the effects of light on the regulation of circadian wheel-running behavior were examined in mice lacking these photoreceptors. Mice without cones (cl) or without both rods and cones (rdta/cl) showed unattenuated phase-shifting responses to light. Removal of the eyes abolishes this behavior. Thus, neither rods nor cones are required for photoentrainment, and the murine eye contains additional photoreceptors that regulate the circadian clock.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England; Univ Oviedo, Dept Morfol & Biol Celular, Oviedo 33072, Spain	Imperial College London; University of Oviedo	Foster, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Alexander Fleming Bldg, London SW7 2AZ, England.		Llamosas, Marta Muñoz/A-7667-2008; von Schantz, Malcolm/C-5962-2014; Jansen, Heiko T./A-5770-2008	Llamosas, Marta Muñoz/0000-0002-9832-3523; von Schantz, Malcolm/0000-0002-9911-9436; Jansen, Heiko T./0000-0003-0178-396X; Lucas, Robert/0000-0002-1088-8029				BAEHR W, 1988, FEBS LETT, V238, P253, DOI 10.1016/0014-5793(88)80490-3; David-Gray ZK, 1998, NAT NEUROSCI, V1, P655, DOI 10.1038/3656; FOSTER RG, 1993, J BIOL RHYTHM, V8, pS17; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; GARCIAFERNANDEZ JM, 1995, NEUROSCI LETT, V187, P33; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Lupi D, 1999, NEUROSCIENCE, V89, P363, DOI 10.1016/S0306-4522(98)00353-4; McCall MA, 1996, EXP EYE RES, V63, P35, DOI 10.1006/exer.1996.0089; MOORE RY, 1995, J COMP NEUROL, V352, P351, DOI 10.1002/cne.903520304; Oren DA, 1998, SCIENCE, V279, P333, DOI 10.1126/science.279.5349.333; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; PROVENCIO I, 1995, BRAIN RES, V694, P183, DOI 10.1016/0006-8993(95)00694-L; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7; Sun H, 1997, P NATL ACAD SCI USA, V94, P8860, DOI 10.1073/pnas.94.16.8860; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; vonSchantz M, 1997, BRAIN RES, V770, P131, DOI 10.1016/S0006-8993(97)00791-9; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C	23	570	590	3	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					502	504		10.1126/science.284.5413.502	http://dx.doi.org/10.1126/science.284.5413.502			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205061				2022-12-01	WOS:000079792200052
J	Pittenger, MF; Mackay, AM; Beck, SC; Jaiswal, RK; Douglas, R; Mosca, JD; Moorman, MA; Simonetti, DW; Craig, S; Marshak, DR				Pittenger, MF; Mackay, AM; Beck, SC; Jaiswal, RK; Douglas, R; Mosca, JD; Moorman, MA; Simonetti, DW; Craig, S; Marshak, DR			Multilineage potential of adult human mesenchymal stem cells	SCIENCE			English	Article							HUMAN MARROW; IN-VIVO; PRECURSOR CELLS; STROMAL CELLS; BONE; DIFFERENTIATION; TRANSPLANTATION; DEXAMETHASONE; CARTILAGE; INVITRO	Human mesenchymal stem cells are thought to be multipotent cells, which are present in adult marrow, that can replicate as undifferentiated cells and that have the potential to differentiate to Lineages of mesenchymal tissues, including bone; cartilage, fat, tendon, muscle, and marrow stroma. Cells that have the characteristics of human mesenchymal stem cells were isolated from marrow aspirates of volunteer donors. These cells displayed a stable phenotype and remained as a monolayer in vitro. These adult stem cells could be induced to differentiate exclusively into the adipocytic, chondrocytic, or osteocytic Lineages. Individual stem cells were identified that, when expanded to colonies, retained their multilineage potential.	Osiris Therapeut, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Osiris Therapeutics; Johns Hopkins University	Pittenger, MF (corresponding author), Osiris Therapeut, 2001 Aliceanna St, Baltimore, MD 21231 USA.	mpittenger@osiristx.com						ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; BAB I, 1984, CLIN ORTHOP RELAT R, P243; BELLOWS CG, 1989, DEV BIOL, V133, P8, DOI 10.1016/0012-1606(89)90291-1; Bergman RJ, 1996, J BONE MINER RES, V11, P568; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; Bruder SP, 1998, CLIN ORTHOP RELAT R, pS247; Bruder SP, 1998, J BONE JOINT SURG AM, V80A, P985, DOI 10.2106/00004623-199807000-00007; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Cassiede P, 1996, J BONE MINER RES, V11, P1264; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; CIVIN CI, 1984, J IMMUNOL, V133, P157; Cui Q, 1997, J BONE JOINT SURG AM, V79A, P1054, DOI 10.2106/00004623-199707000-00012; Dennis JE, 1996, CONNECT TISSUE RES, V35, P93, DOI 10.3109/03008209609029179; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; FRIEDENSTEIN AJ, 1976, INT REV CYTOL, V47, P327, DOI 10.1016/S0074-7696(08)60092-3; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756-3282(92)90364-3; HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756-3282(92)90363-2; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kadiyala S, 1997, CELL TRANSPLANT, V6, P125, DOI 10.1016/S0963-6897(96)00279-5; Kuznetsov SA, 1997, J BONE MINER RES, V12, P1335, DOI 10.1359/jbmr.1997.12.9.1335; LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306; Lennon DP, 1996, IN VITRO CELL DEV-AN, V32, P602; LORD BI, 1996, STEM CELLS, P401; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; MAUJUDAR MK, 1998, J CELL PHYSL, V176, P57; OWEN M, 1988, CIBA F SYMP, V136, P42, DOI 10.1002/9780470513637.ch4; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Pittenger M.F., 1998, U.S. Patent, Patent No. [5,827,740, 5827740]; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SRINIVAS GR, 1993, J IMMUNOL METHODS, V159, P53, DOI 10.1016/0022-1759(93)90141-S; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; WAKITANI S, 1994, J BONE JOINT SURG AM, V76A, P579, DOI 10.2106/00004623-199404000-00013; Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623-199812000-00004; Young RG, 1998, J ORTHOPAED RES, V16, P406, DOI 10.1002/jor.1100160403	39	16038	18520	48	2588	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1999	284	5411					143	147		10.1126/science.284.5411.143	http://dx.doi.org/10.1126/science.284.5411.143			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102814				2022-12-01	WOS:000079509000053
J	Tsiantis, M; Schneeberger, R; Golz, JF; Freeling, M; Langdale, JA				Tsiantis, M; Schneeberger, R; Golz, JF; Freeling, M; Langdale, JA			The maize rough sheath2 gene and leaf development programs in monocot and dicot plants	SCIENCE			English	Article							HOMEO BOX GENE; ECTOPIC EXPRESSION; ARABIDOPSIS; KNOTTED-1; MERISTEM; MUTATION; LEAVES; BARLEY; MUTANT; FATES	Leaves of higher plants develop in a sequential manner from the shoot apical meristem. previously it was determined that perturbed Leaf development in maize rough sheath2 (rs2) mutant plants results from ectopic expression of knotted1-like (knox) homeobox genes. Here, the rs2 gene sequence was found to be similar to the Antirrhinum PHANTASTICA (PHAN) gene sequence, which encodes a Myb-Like transcription factor. RS2 and PHAN are both required to prevent the accumulation of knox gene products in maize and Antirrhinum leaves, respectively. However, rs2 and phan mutant phenotypes differ, highlighting fundamental differences in monocot and dicot leaf development programs.	Univ Oxford, Dept Plant Sci, Oxford OX1 3BR, England; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland	University of Oxford; University of California System; University of California Berkeley; University of Edinburgh	Langdale, JA (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3BR, England.		Langdale, Jane A./AAE-8343-2019; Golz, John F./H-4290-2019	Golz, John F./0000-0001-9478-5459; Langdale, Jane/0000-0001-7648-3924	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014578] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42610, GM14578] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chuck G, 1996, PLANT CELL, V8, P1277, DOI 10.1105/tpc.8.8.1277; Eichler A. W., 1861, ENTWICKELUNGSGESCHIC; FREELING M, 1992, DEV BIOL, V153, P44, DOI 10.1016/0012-1606(92)90090-4; HARAVEN D, 1996, CELL, V84, P735; JACKSON D, 1994, DEVELOPMENT, V120, P404; KAPLAN DR, 1973, Q REV BIOL, V48, P437, DOI 10.1086/407703; Kerstetter RA, 1997, DEVELOPMENT, V124, P3045; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; Muehlbauer GJ, 1997, DEVELOPMENT, V124, P5097; MULLER KJ, 1995, NATURE, V374, P727, DOI 10.1038/374727a0; POETHIG S, 1984, CONT PROBLEMS PLANT, P235; Scanlon MJ, 1996, DEVELOPMENT, V122, P1683; Schneeberger R, 1998, DEVELOPMENT, V125, P2857; SCHNEEBERGER RG, 1995, GENE DEV, V9, P2292, DOI 10.1101/gad.9.18.2292; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1992, DEVELOPMENT, V116, P21; TSIANTIS M, UNPUB; WAITES R, 1995, DEVELOPMENT, V121, P2143; Waites R, 1998, CELL, V93, P779, DOI 10.1016/S0092-8674(00)81439-7; WAITES R, UNPUB; WilliamsCarrier RE, 1997, DEVELOPMENT, V124, P3737	21	242	255	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	1999	284	5411					154	156		10.1126/science.284.5411.154	http://dx.doi.org/10.1126/science.284.5411.154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102817				2022-12-01	WOS:000079509000056
J	Wei, Y; Yu, LL; Bowen, J; Gorovsky, MA; Allis, CD				Wei, Y; Yu, LL; Bowen, J; Gorovsky, MA; Allis, CD			Phosphorylation of histone H3 is required for proper chromosome condensation and segregation	CELL			English	Article							TETRAHYMENA-THERMOPHILA; LINKER HISTONES; SACCHAROMYCES-CEREVISIAE; CHROMATIN CONDENSATION; PROTEIN COMPLEXES; 13S CONDENSIN; OKADAIC ACID; BETA-TUBULIN; CELL-CYCLE; IN-VITRO	Phosphorylation of histone H3 at serine 10 occurs during mitosis in diverse eukaryotes and correlates closely with mitotic and meiotic chromosome condensation. To better understand the function of H3 phosphorylation in vivo, we created strains of Tetrahymena in which a mutant H3 gene (S10A) was the only gene encoding the major H3 protein. Although both micronuclei and macronuclei contain H3 in typical nucleosomal structures, defects in nuclear divisions were restricted to mitotically dividing micronuclei; macronuclei, which are amitotic, showed no defects. Strains lacking phosphorylated H3 showed abnormal chromosome segregation, resulting in extensive chromosome loss during mitosis. During meiosis, micronuclei underwent abnormal chromosome condensation and failed to faithfully transmit chromosomes. These results demonstrate that H3 serine 10 phosphorylation is causally linked to chromosome condensation and segregation in vivo and is required for proper chromosome dynamics.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Gorovsky, MA (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	micro@dialup.rochester.edu; allis@virginia.edu			NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM21793, GM40922] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Ajiro K, 1996, EUR J BIOCHEM, V241, P923, DOI 10.1111/j.1432-1033.1996.00923.x; ALLEN SL, 1967, SCIENCE, V155, P575, DOI 10.1126/science.155.3762.575; ALLIS CD, 1982, DEV BIOL, V93, P519, DOI 10.1016/0012-1606(82)90139-7; ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; ALLIS CD, 1980, CELL, V20, P55; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CassidyHanley D, 1997, GENETICS, V146, P135; DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91; DOERDER FP, 1980, DEV GENET, V1, P205; GAERTIG J, 1994, P NATL ACAD SCI USA, V91, P4549, DOI 10.1073/pnas.91.10.4549; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GOROVSKY MA, 1977, COLD SPRING HARB SYM, V42, P493; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; MERRIAM EV, 1988, GENETICS, V120, P389; MIZZEN CM, 1999, IN RPESS COLD SPRING, V63; Murray AW, 1998, SCIENCE, V282, P425, DOI 10.1126/science.282.5388.425; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; Patterton HG, 1998, J BIOL CHEM, V273, P7268, DOI 10.1074/jbc.273.13.7268; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Strunnikov AV, 1998, TRENDS CELL BIOL, V8, P454, DOI 10.1016/S0962-8924(98)01370-1; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Sweet MT, 1997, J BIOL CHEM, V272, P916, DOI 10.1074/jbc.272.2.916; SWEET MT, 1993, CHROMOSOMA, V102, P637, DOI 10.1007/BF00352312; VACQUIER VD, 1989, DEV BIOL, V133, P111, DOI 10.1016/0012-1606(89)90302-3; Van Hooser A, 1998, J CELL SCI, V111, P3497; Vignali M, 1998, NAT STRUCT BIOL, V5, P1025, DOI 10.1038/4133; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1998, TRENDS CELL BIOL, V8, P266; WENKERT D, 1984, J CELL BIOL, V98, P2107, DOI 10.1083/jcb.98.6.2107; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; Wolffe AP., 1998, CHROMATIN STRUCTURE; Yanagida M, 1998, TRENDS CELL BIOL, V8, P144, DOI 10.1016/S0962-8924(98)01236-7; Yu LL, 1997, MOL CELL BIOL, V17, P6303, DOI 10.1128/MCB.17.11.6303	64	560	581	2	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					99	109		10.1016/S0092-8674(00)80718-7	http://dx.doi.org/10.1016/S0092-8674(00)80718-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199406	Bronze			2022-12-01	WOS:000079843900012
J	Petitou, M; Herault, LP; Bernat, A; Driguez, PA; Duchaussoy, P; Lormeau, JC; Herbert, JM				Petitou, M; Herault, LP; Bernat, A; Driguez, PA; Duchaussoy, P; Lormeau, JC; Herbert, JM			Synthesis of thrombin-inhibiting heparin mimetics without side effects	NATURE			English	Article							ANTITHROMBIN-III; FACTOR-XA; PENTASACCHARIDE; OLIGOSACCHARIDES; ANALOGS	Unwanted side effects of pharmacologically active compounds can usually be eliminated by structural modifications. But the complex heterogeneous structure of the polysaccharide heparin(1) has limited this approach to fragmentation, leading to slightly better-tolerated heparin preparations of low molecular mass(2). Despite this improvement, heparin-induced thrombocytopaenia(3) (HIT), related to an interaction with platelet factor 4 (PF4) and, to a lesser extent, haemorrhages(4), remain significant side effects of heparinotherapy. Breakthroughs in oligosaccharide chemistry(5) made possible the total synthesis of the pentasaccharide antithrombin-binding site of heparin(6,7). This pentasaccharide represents a new family of potential antithrombotic drugs, devoid of thrombin inhibitory properties, and free of undesired interactions with blood and vessel components. To obtain more potent and well-tolerated antithrombotic drugs, we wished to synthesize heparin mimetics able to inhibit thrombin, that is, longer oligosaccharides. Like thrombin inhibition, undesired interactions are directly correlated to the charge and the size of the molecules(8), so we had to design structures that were able to discriminate between thrombin and other proteins, particularly PF4. Here we describe the use of multistep converging synthesis to obtain sulphated oligosaccharides that meet these requirements.	Sanofi Rech, F-31036 Toulouse, France	Sanofi-Aventis; Sanofi France	Herbert, JM (corresponding author), Sanofi Rech, 195 Route Espagne, F-31036 Toulouse, France.	jean-marc.herbert@sanofi.com						ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BASTEN J, 1992, BIOORG MED CHEM LETT, V2, P905, DOI 10.1016/S0960-894X(00)80585-5; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; GROOTENHUIS PDJ, 1995, NAT STRUCT BIOL, V2, P736, DOI 10.1038/nsb0995-736; Herbert JM, 1996, CIRC RES, V79, P590, DOI 10.1161/01.RES.79.3.590; JIN J, 1997, P NATL ACAD SCI USA, V94, P14683; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LANE DA, 1989, HEPARIN; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; PAULSEN H, 1982, ANGEW CHEM INT EDIT, V21, P155, DOI 10.1002/anie.198201553; Petitou M, 1997, J MED CHEM, V40, P1600, DOI 10.1021/jm960726z; Petitou M, 1998, ANGEW CHEM INT EDIT, V37, P3009, DOI 10.1002/(SICI)1521-3773(19981116)37:21<3009::AID-ANIE3009>3.0.CO;2-F; SACHE E, 1982, THROMB RES, V25, P443, DOI 10.1016/0049-3848(82)90086-X; SHERIDAN D, 1986, BLOOD, V67, P27; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Thomas DP, 1997, THROMB HAEMOSTASIS, V78, P1422; UMETSU T, 1978, THROMB HAEMOSTASIS, V39, P74; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; VERSTRAETE M, 1990, DRUGS, V40, P498, DOI 10.2165/00003495-199040040-00003; Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1; Westerduin P, 1994, Bioorg Med Chem, V2, P1267, DOI 10.1016/S0968-0896(00)82078-7	27	278	291	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					417	422		10.1038/18877	http://dx.doi.org/10.1038/18877			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201371				2022-12-01	WOS:000079508200051
J	Aldridge, J; Measham, F				Aldridge, J; Measham, F			Sildenafil (Viagra) is used as a recreational drug in England	BRITISH MEDICAL JOURNAL			English	Letter									Appl Res Ctr, Social Policy Social Problems SPARC, Manchester M13 9PL, Lancs, England	University of Manchester	Aldridge, J (corresponding author), Appl Res Ctr, Social Policy Social Problems SPARC, Manchester M13 9PL, Lancs, England.			Measham, Fiona/0000-0002-9322-1931				KIRBY R, 1999, STUDENT BMJ, V7, P11; Parker HowardJ., 1998, ILLEGAL LEISURE NORM	2	57	58	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					669	669		10.1136/bmj.318.7184.669	http://dx.doi.org/10.1136/bmj.318.7184.669			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066221	Green Published			2022-12-01	WOS:000079089200049
J	Nightingale, SL				Nightingale, SL			Cerebyx labels changed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					786	786		10.1001/jama.281.9.786	http://dx.doi.org/10.1001/jama.281.9.786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10070983				2022-12-01	WOS:000078804300007
J	Augustsson, K; Skog, K; Jagerstad, M; Dickman, PW; Steineck, G				Augustsson, K; Skog, K; Jagerstad, M; Dickman, PW; Steineck, G			Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study	LANCET			English	Article							MEAT-PRODUCTS; HUMAN TISSUES; PAN RESIDUES; RISK; FISH	Background Heterocyclic amines formed in cooked meat and fish are carcinogenic in animal models and form DNA adducts in human beings. We undertook a study to assess whether these substances are related to the risks of cancer in the large bowel and urinary tract. Methods In a population-based case-control study, cases were identified from the Swedish cancer registry. Controls were randomly selected from the population register. Information on intake of various foods and was assessed by questionnaire, with photographs of foods cooked at various temperatures. We measured the content of heterocyclic amines in foods cooked under these conditions. Findings Information was retrieved from 553 controls, 352 cases of colon cancer, 249 cases of rectal cancer, 273 cases of bladder cancer, and 138 cases of kidney cancer. The response rate was 80% for controls and 70% for cases. The estimated daily median intake of heterocyclic amines was 77 ng for controls, and 66 ng, 63 ng, 96 ng, and 84 ng for cases with cancer of the colon, rectum, bladder, and kidney, respectively. The relative risk for the intake of heterocyclic amines (highest vs lowest quintile) was 0.6 (95% CI 0.4-1.0) for colon cancer, 0.7 (0.4-1.1) for rectal cancer, 1.2 (0.7-2.1) for bladder cancer, and 1.0 (0.5-1.9) for kidney cancer. Seven cases, but no controls, had an estimated daily intake of heterocyclic amines above 1900 ng. Interpretation Intake of heterocyclic amines, within the usual dietary range in this study population, is unlikely to increase the incidence of cancer in the colon, rectum, bladder, or kidney. For daily intakes above 1900 ng, our data are consistent with human carcinogenicity, but the precision was extremely low.	Karolinska Inst, Stockholm, Sweden; Swedish Univ Agr Sci, Dept Food Sci, Uppsala, Sweden; Swedish Univ Agr Sci, Ctr Chem & Chem Engn, Dept Appl Nutr & Food Chem, Uppsala, Sweden	Karolinska Institutet; Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences	Augustsson, K (corresponding author), Karolinska Univ Hosp, Norrbacka 5 Tr, SE-17176 Stockholm, Sweden.	Gunnar.Steineck@onkpat.ki.se	Dickman, Paul W/B-4572-2013; Steineck, Gunnar/W-1515-2019	Dickman, Paul W/0000-0002-5788-3380; Steineck, Gunnar/0000-0002-0787-3969				Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931; AUGUSTSSON K, IN PRESS FOOD ADDIT; Becker W., 1994, FOOD HABITS NUTR INT; BENITO E, 1990, INT J CANCER, V45, P69, DOI 10.1002/ijc.2910450114; DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408; FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004; Gaard M, 1996, EUR J CANCER PREV, V5, P445; Hsing AW, 1998, INT J CANCER, V77, P549, DOI 10.1002/(SICI)1097-0215(19980812)77:4&lt;549::AID-IJC13&gt;3.0.CO;2-1; IARC, 1993, IARC MON EV CARC RIS, V56, P165; JAGERSTAD M, 1983, ACS SYM SER, V215, P507; JAGERSTAD M, 1991, ADV EXP MED BIOL, V289, P83; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; MAUGH TH, 1978, SCIENCE, V202, P37, DOI 10.1126/science.694517; NAGAO M, 1977, CANCER LETT, V2, P221, DOI 10.1016/S0304-3835(77)80025-6; NORELL SE, 1986, AM J EPIDEMIOL, V124, P894, DOI 10.1093/oxfordjournals.aje.a114479; OVERVIK E, 1984, MUTAT RES, V135, P149, DOI 10.1016/0165-1218(84)90115-0; REUTERSWARD AL, 1987, FOOD CHEM TOXICOL, V25, P755, DOI 10.1016/0278-6915(87)90230-4; RobertsThomson IC, 1996, LANCET, V347, P1372, DOI 10.1016/S0140-6736(96)91012-0; SADRIEH N, 1995, CARCINOGENESIS, V16, P1549, DOI 10.1093/carcin/16.7.1549; SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861; Skog K, 1997, FOOD CHEM TOXICOL, V35, P555, DOI 10.1016/S0278-6915(97)00021-5; SKOG K, 1993, FOOD CHEM TOXICOL, V31, P655, DOI 10.1016/0278-6915(93)90049-5; STEINECK G, 1990, INT J CANCER, V45, P1006, DOI 10.1002/ijc.2910450604; Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6; SUGIMURA T, 1977, ORIGINS HUMAN CANCER, P1561; Totsuka Y, 1996, CARCINOGENESIS, V17, P1029, DOI 10.1093/carcin/17.5.1029; *WHO, 1977, INT CLASS DIS INJ CA; WILLETT W, 1990, MONOGRAPHS EPIDEMIOL; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; YOUNG TB, 1988, INT J CANCER, V42, P167, DOI 10.1002/ijc.2910420205	30	207	212	1	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 27	1999	353	9154					703	707		10.1016/S0140-6736(98)06099-1	http://dx.doi.org/10.1016/S0140-6736(98)06099-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DR	10073512				2022-12-01	WOS:000078966400010
J	Behr, MA; Warren, SA; Salamon, H; Hopewell, PC; de Leon, AP; Daley, CL; Small, PM				Behr, MA; Warren, SA; Salamon, H; Hopewell, PC; de Leon, AP; Daley, CL; Small, PM			Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli	LANCET			English	Article							EPIDEMIOLOGY; DIAGNOSIS; IMPACT; HIV	Background The microscopic examination of sputum for acid-fast bacilli, is a simple and rapid test that is used to provide a presumptive diagnosis of infectious tuberculosis. While patients with tuberculosis with sputum smears negative for acid-fast bacilli are less infectious than those with positive smears, both theoretical and empirical evidence suggest that they can still transmit Mycobacterium tuberculosis. We aimed to estimate the risk of transmission from smear-negative individuals. Methods As part of an ongoing study of the molecular epidemiology of tuberculosis in San Francisco, patients with tuberculosis with mycobacterial isolates with the same DNA fingerprint were assigned to clusters that were assumed to have involved recent transmission. Secondary cases with tuberculosis, whose mycobacterial isolates had the same DNA, were linked to their presumed source case to estimate transmission from smear-negative patients. Sensitivity analyses were done to assess potential bias due to misclassification of source cases, unidentified source cases, and HIV-1 co-infection. Findings 1574 patients with culture-positive tuberculosis were reported and DNA fingerprints were available for 1359 (86%) of these patients. Of the 71 clusters of patients infected with strains that had matching fingerprints, 28 (39% [95% CI 28-52]) had a smear-negative putative source. There were 183 secondary cases in these 71 clusters, of whom a minimum of 32 were attributed to infection by smear-negative patients (17% [12-24]), The relative transmission rate of smear-negative compared with smear-positive patients was calculated as 0.22 (95% CI 0.16-0.32). Sensitivity analyses and stratification for HIV-1 status had no impact on these estimates. Interpretation In San Francisco, the acid-fast-bacilli smear identifies the most infectious patients, but patients with smear-negative culture-positive tuberculosis appear responsible for about 17% of tuberculosis transmission.	McGill Univ, Ctr Hlth, Dept Med, Div Infect Dis, Montreal, PQ, Canada; Stanford Univ, Sch Med, Dept Med, Div Infect Dis & Geog Med, Stanford, CA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA; Inst Nacl Nutr Salvador Zubiran, Div Infect Dis, Mexico City 14000, DF, Mexico	McGill University; Stanford University; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico	Behr, MA (corresponding author), Montreal Gen Hosp, Div Infect Dis, Room A5-156, Montreal, PQ H3G 1A4, Canada.	marcel@molepi.stanford.edu	Daley, Charles L./AAC-3231-2021	Ponce-de-Leon, Alfredo/0000-0003-2640-2916; Salamon, Hugh/0000-0003-1472-5785	PHS HHS [A101137, A134238] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Behr MA, 1998, AM J RESP CRIT CARE, V158, P465, DOI 10.1164/ajrccm.158.2.9801062; Braden CR, 1997, CLIN INFECT DIS, V24, P35, DOI 10.1093/clinids/24.1.35; Bradford WZ, 1998, J INFECT DIS, V177, P1104, DOI 10.1086/517405; Burman WJ, 1997, AM J RESP CRIT CARE, V155, P1140, DOI 10.1164/ajrccm.155.3.9117000; Casper C, 1996, AM J PUBLIC HEALTH, V86, P551, DOI 10.2105/AJPH.86.4.551; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P15; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; Chin DP, 1998, AM J RESP CRIT CARE, V158, P1797, DOI 10.1164/ajrccm.158.6.9804029; DANIEL WW, 1991, BIOSTATISTICS FDN AN, P589; ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U; ENARSON DA, 1996, TUBERCULOSIS GUIDE L, P5; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HERTZBERG GERH, 1957, AN EPIDEMIOLOGICAL INVESTIGATION ACTA TUBERC SCAND SUPPL, V38, P1; HOBBY GL, 1973, ANTIMICROB AGENTS CH, V4, P954; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JACOBSEN E, 1994, J HOSP INFECT, V30, P75; JOHNSTON RF, 1974, AM REV RESPIR DIS, V109, P636; LINCOLN EDITH M., 1965, ADVANCES TUBERC RES, V14, P157; LONG R, 1991, AM J PUBLIC HEALTH, V81, P1326, DOI 10.2105/AJPH.81.10.1326; LOUDON RG, 1958, AM REV TUBERC PULM, V77, P623; McPhedran FM, 1935, AM J HYG, V22, P565, DOI 10.1093/oxfordjournals.aje.a118191; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P114; *NAT TUB I, 1974, B WORLD HEALTH ORGAN, V51, P473; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; SKINNER C, 1990, BRIT MED J, V300, P995; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STRUMPF IJ, 1979, AM REV RESPIR DIS, V119, P599; van Geuns H A, 1975, Bull Int Union Tuberc, V50, P107; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANZWANENBERG D, 1960, AM REV RESPIR DIS, V82, P31; Vidal R, 1997, MED CLIN-BARCELONA, V108, P361; YEAGER H, 1967, AM REV RESPIR DIS, V95, P998	37	568	588	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1999	353	9151					444	449		10.1016/S0140-6736(98)03406-0	http://dx.doi.org/10.1016/S0140-6736(98)03406-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989714				2022-12-01	WOS:000078572800010
J	Williams, NW				Williams, NW			Serpents, staffs, and the emblems of medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Williams, NW (corresponding author), Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA.							BUNN JT, 1967, J AMER MED ASSOC, V202, P615, DOI 10.1001/jama.202.7.615; GEELHOED GW, 1988, SOUTHERN MED J, V81, P1155, DOI 10.1097/00007611-198809000-00020; MERRILL JM, 1991, J LAB CLIN MED, V117, P431; METZER WS, 1989, SOUTHERN MED J, V82, P743, DOI 10.1097/00007611-198906000-00017; Parry Donald W., 1994, TEMPLES ANCIENT WORL; RUSSEL FE, 1980, SNAKE VENOM POISONIN	6	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					475	475		10.1001/jama.281.5.475	http://dx.doi.org/10.1001/jama.281.5.475			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952211	hybrid			2022-12-01	WOS:000078318500041
J	Jardine, E; O'Toole, M; Paton, JY; Wallis, C				Jardine, E; O'Toole, M; Paton, JY; Wallis, C			Current status of long term ventilation of children in the United Kingdom: questionnaire survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To identify the number and current location of children, aged 0 to 16 years, requiring long term ventilation in the United Kingdom, and to establish their underlying diagnoses and ventilatory needs. Design Postal questionnaires sent to consultant respiratory paediatricians and all lead clinicians of intensive care and special care baby units in the United Kingdom. Subjects AU children in the United Kingdom who, when medically stable, continue to need a mechanical aid for breathing. Results 141 children requiring long term ventilation were identified from the initial questionnaire. Detailed information was then obtained on 136 children from 30 units. Thirty three children (24%) required continuous positive pressure ventilation by tracheostomy over 24 hours, and 103 received ventilation when asleep by a non-invasive mask (n = 62; 46%), tracheostomy (n = 32; 24%), or negative pressure ventilation (n = 9; 7%). Underlying conditions included neuromuscular disease (n = 62; 46%), congenital central hypoventilation syndrome (n = 18; 13%), spinal injury (n = 16; 12%), craniofacial syndromes (n = 9; 7%), bronchopulmonary dysplasia (n = 6; 4%), and others (n = 25; 18%). 93 children were cared for ar home. 43 children remained in hospital because of home circumstances, inadequate funding, or lack of provision of home carers. 96 children were of school age and 43 were attending mainstream school. Conclusions A significant increase in the number of children requiring long term ventilation in the United Kingdom has occurred over the past decade. Contributing factors include improved technology, developments in paediatric non-invasive ventilatory support, and a change in attitude towards home care. Successful discharge home and return to school is occurring even for severely disabled patients. Funding and home carers are common obstacles to discharge.	Inst Child Hlth, London WC1N 3JH, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Glasgow	Wallis, C (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 3JH, England.	c.wallis@ich.ucl.ac.uk	Paton, James/B-9541-2008						0	97	101	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	1999	318	7179					295	299		10.1136/bmj.318.7179.295	http://dx.doi.org/10.1136/bmj.318.7179.295			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924054	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000078436700022
J	Brouqui, P; Lascola, B; Roux, V; Raoult, D				Brouqui, P; Lascola, B; Roux, V; Raoult, D			Chronic Bartonella quintana bacteremia in homeless patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAT-SCRATCH DISEASE; ROCHALIMAEA QUINTANA; BACILLARY ANGIOMATOSIS; HENSELAE; ENDOCARDITIS; SEROPREVALENCE; INFECTION	Background Infection with Bartonella quintana can cause french fever, endocarditis, bacillary angiomatosis, and peliosis. An outbreak of bacteremia due to B. quintana has been reported among homeless people in Seattle, and the seroprevalence is high among homeless people in both the United States and Europe. Body lice are known to be the vectors of B. quintana. Methods We studied all the homeless people who presented in 1997 to the emergency departments of the University Hospital, Marseiiles, France. Blood was collected for microimmunofluorescence testing for antibodies against B. quintana and for culture of the bacterium. Body lice were collected and analyzed by the polymerase chain reaction and sequencing of a portion of the citrate synthase gene of B. quintana. Results in 10 of 71 homeless patients (14 percent), blood cultures were positive for B. quintana, and 21 of the patients (30 percent) had high titers of antibody against the organism. A total of 17 patients (24 percent) had evidence of recent infection (bacteremia or seroconversion). Tests of lice from 3 of the 15 patients from whom they were collected were positive for B. quintana. The homeless people with B. quintana bacteremia were more likely to have been exposed to lice (P=0.002), were more likely to have headaches (P=0.03) and severe leg pain (P<0.001), and had lower platelet counts (P=0.006) than the homeless people who were seronegative for B. quintana and did not have bacteremia; 8 of the 10 patients with bacteremia were afebrile. Five patients had chronic bacteremia, as indicated by positive blood cultures over a period of several weeks. Conclusions in an outbreak of urban trench fever among homeless people in Marseiiles, B. quintana infections were associated with body lice in patients with nonspecific symptoms or no symptoms. (N Engl J Med 1999;340:184-9.) (C) 1999, Massachusetts Medical Society.	Fac Med Marseille, Unite Rickettsies, CNRS, UPRES A 6020, F-13885 Marseille, France; Assistance Publ Hop Marseille, Ctr Hosp Univ Felix Houphouet Boigny, Serv Malad Infect & Trop, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Brouqui, P (corresponding author), Fac Med Marseille, Unite Rickettsies, CNRS, UPRES A 6020, 27 Blvd J Moulin, F-13885 Marseille, France.		LA SCOLA, Bernard/P-6477-2016; RAOULT, Didier/A-8434-2008; Brouqui, Philippe/P-5771-2016	LA SCOLA, Bernard/0000-0001-8006-7704; RAOULT, Didier/0000-0002-0633-5974; 				AZAD AF, 1992, P NATL ACAD SCI USA, V89, P43, DOI 10.1073/pnas.89.1.43; Birtles RJ, 1996, INT J SYST BACTERIOL, V46, P891, DOI 10.1099/00207713-46-4-891; Brenner SA, 1997, J CLIN MICROBIOL, V35, P544, DOI 10.1128/JCM.35.3.544-547.1997; Brouqui P, 1996, CLIN INFECT DIS, V23, P756, DOI 10.1093/clinids/23.4.756; Byam W, 1919, TRENCH FEVER LOUSE B; CHOMEL BB, 1995, J CLIN MICROBIOL, V33, P2445, DOI 10.1128/JCM.33.9.2445-2450.1995; Comer JA, 1996, ARCH INTERN MED, V156, P2491, DOI 10.1001/archinte.156.21.2491; Drancourt M, 1996, J CLIN MICROBIOL, V34, P1158, DOI 10.1128/JCM.34.5.1158-1160.1996; DRANCOURT M, 1995, NEW ENGL J MED, V332, P419, DOI 10.1056/NEJM199502163320702; Drancourt M, 1996, LANCET, V347, P441, DOI 10.1016/S0140-6736(96)90012-4; DRANCOURT M, 1996, LANCET, V347, P842; Jackson LA, 1996, J INFECT DIS, V173, P1023, DOI 10.1093/infdis/173.4.1023; Koehler JE, 1997, NEW ENGL J MED, V337, P1876, DOI 10.1056/NEJM199712253372603; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; KORDICK DL, 1995, J CLIN MICROBIOL, V33, P1655, DOI 10.1128/JCM.33.6.1655-1656.1995; KORDICK DL, 1995, J CLIN MICROBIOL, V33, P3245, DOI 10.1128/JCM.33.12.3245-3251.1995; KOSTRZEWSKI J, 1949, Bull Int Acad Pol Sci Let Cl Med, V7, P233; LARSON AM, 1994, J CLIN MICROBIOL, V32, P1492, DOI 10.1128/JCM.32.6.1492-1496.1994; LaScola B, 1996, J CLIN MICROBIOL, V34, P2270, DOI 10.1128/JCM.34.9.2270-2274.1996; Maurin M, 1996, CLIN MICROBIOL REV, V9, P273, DOI 10.1128/CMR.9.3.273; MCNEE JW, 1916, BRIT MED J, V225, P34; MOOSER H, 1959, P 6 INT C TROP MED M, V5, P631; Raoult D, 1998, LANCET, V352, P353, DOI 10.1016/S0140-6736(97)12433-3; RAOULT D, 1994, LANCET, V343, P977, DOI 10.1016/S0140-6736(94)90102-3; Raoult D, 1996, ANN INTERN MED, V125, P646, DOI 10.7326/0003-4819-125-8-199610150-00004; RAOULT D, 1997, ANN INTERN MED, V127, P249; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; STEIN A, 1995, LANCET, V345, P450, DOI 10.1016/S0140-6736(95)90430-1; Swift HF, 1920, ARCH INTERN MED, V26, P76, DOI 10.1001/archinte.1920.00100010079006; VINSON JW, 1969, AM J TROP MED HYG, V18, P713, DOI 10.4269/ajtmh.1969.18.713; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992	32	202	212	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					184	189		10.1056/NEJM199901213400303	http://dx.doi.org/10.1056/NEJM199901213400303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895398				2022-12-01	WOS:000078202900003
J	Hasdai, D; Lerman, A; Grill, DE; Rihal, CS; Holmes, DR				Hasdai, D; Lerman, A; Grill, DE; Rihal, CS; Holmes, DR			Medical therapy after successful percutaneous coronary revascularization	ANNALS OF INTERNAL MEDICINE			English	Article						angioplasty, transluminal percutaneous coronary; angina pectoris; calcium channel blockers; adrenergic beta-antagonists; nitrates	TERM FOLLOW-UP; SINGLE-VESSEL; ARTERY DISEASE; RANDOMIZED TRIAL; ANGINA-PECTORIS; ANGIOPLASTY; WITHDRAWAL; SURVIVAL; ISCHEMIA; OUTCOMES	Background: Percutaneous coronary revascularization frequently relieves angina in patients with ischemic heart disease and may obviate the need for antianginal medications. Objective: To examine the use of antianginal medications after successful percutaneous coronary revascularization. Design: Retrospective cohort study of the Mayo Clinic PTCA [percutaneous transluminal coronary angioplasty] Registry. Setting: Tertiary care center. Patients: 3831 patients who underwent successful percutaneous coronary revascularization from September 1979 through August 1997 and had not had myocardial infarction within the year before the intervention. Measurements: Use of antianginal medications (beta-adrenergic blockers, nitrates, and calcium-channel blockers) before the intervention, at hospital discharge, and 6 months after the intervention. Results: 99% of patients reported improvement in their symptoms at hospital discharge. At 6 months, 87% of patients were free of myocardial infarction, coronary bypass surgery, or additional percutaneous intervention. Co mpa red with 66% of patients before the index intervention, only 12% of patients had severe angina at 6 months and 69% were completely free of angina. Nonetheless, at 6 months, 39% of patients were receiving beta-adrenergic blockers (preprocedure proportion, 43%; P < 0.001), 36% were receiving nitrates (preprocedure proportion, 41%; P < 0.001), and 57% were receiving calcium-channel blockers (preprocedure proportion, 50%; P < 0.001). These trends persisted for patients without hypertension and those who had complete revascularization. Conclusions: Successful percutaneous coronary revascularization did not substantially supplant the use of antianginal medications, which were commonly used despite the marked improvement in anginal status. This may reflect reluctance to alter therapy once symptoms of angina subside. Guidelines on continued medical therapy after percutaneous coronary revascularization are needed.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Holmes, DR (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	holmes.david@mayo.edu						BELL MR, 1990, J AM COLL CARDIOL, V16, P553, DOI 10.1016/0735-1097(90)90342-M; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOURASSA MG, 1989, EUR HEART J, V10, P36, DOI 10.1093/eurheartj/10.suppl_G.36; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; BRITTEN N, 1995, J CLIN PHARM THER, V20, P199, DOI 10.1111/j.1365-2710.1995.tb00649.x; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Chamberlain DA, 1997, LANCET, V350, P461; COHEN DJ, 1994, CIRCULATION, V89, P1859, DOI 10.1161/01.CIR.89.4.1859; Davies RF, 1997, CIRCULATION, V95, P2037, DOI 10.1161/01.CIR.95.8.2037; Folland ED, 1997, J AM COLL CARDIOL, V29, P1505, DOI 10.1016/S0735-1097(97)00097-1; GERSH BJ, 1997, HEART DIS TXB CARDIO, P1289; GRUNTZIG A, 1978, LANCET, V1, P263, DOI 10.1016/s0140-6736(78)90500-7; Hasdai D, 1997, NEW ENGL J MED, V336, P755, DOI 10.1056/NEJM199703133361103; Hasdai D, 1997, ARCH INTERN MED, V157, P677, DOI 10.1001/archinte.157.6.677; Hasdai D, 1997, AM J CARDIOL, V79, P1005, DOI 10.1016/S0002-9149(97)00038-6; HENDERSON RA, 1992, EUR HEART J, V13, P781, DOI 10.1093/oxfordjournals.eurheartj.a060256; HILLEMAN DE, 1994, CLIN THER, V16, P88; HOLMES DR, 1987, PERCUTANEOUS TRANSLU, P35; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; JOHANSSON SR, 1990, AM J CARDIOL, V66, P915, DOI 10.1016/0002-9149(90)90925-Q; KADEL C, 1992, AM HEART J, V124, P1159, DOI 10.1016/0002-8703(92)90395-C; King SB, 1993, J AM COLL CARDIOL, V22, P353, DOI 10.1016/0735-1097(93)90037-2; MILLER RR, 1975, NEW ENGL J MED, V293, P416, DOI 10.1056/NEJM197508282930902; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PRZYBOJEWSKI JZ, 1983, S AFR MED J, V64, P101; RYAN TJ, 1993, CIRCULATION, V88, P2987, DOI 10.1161/01.CIR.88.6.2987; Vahanian A, 1996, DRUGS, V52, P9, DOI 10.2165/00003495-199600524-00005; vanHout BA, 1995, EUR HEART J, V16, P81, DOI 10.1093/eurheartj/16.suppl_L.81; WARNER MF, 1992, AM HEART J, V124, P1169, DOI 10.1016/0002-8703(92)90396-D; WEINTRAUB WS, 1995, J AM COLL CARDIOL, V26, P142, DOI 10.1016/0735-1097(95)00136-N; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	31	14	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					108	+		10.7326/0003-4819-130-2-199901190-00004	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068356				2022-12-01	WOS:000078114200003
J	Kohn, MJ				Kohn, MJ			Biochemistry - You are what you eat	SCIENCE			English	Editorial Material							DIET		Univ S Carolina, Dept Geol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Kohn, MJ (corresponding author), Univ S Carolina, Dept Geol Sci, Columbia, SC 29208 USA.		Kohn, Matthew/A-2562-2012	Kohn, Matthew/0000-0002-7202-4525				BRYANT JD, 1995, GEOCHIM COSMOCHIM AC, V59, P4523; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; DANSGAARD W, 1964, TELLUS, V16, P436; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; FOLEY RA, 1993, SEASONALITY HUMAN EC, P7; Fricke HC, 1996, PALAEOGEOGR PALAEOCL, V126, P91, DOI 10.1016/S0031-0182(96)00072-7; HAYES JM, 1990, ORG GEOCHEM, V16, P1115, DOI 10.1016/0146-6380(90)90147-R; Koch P.L., 1994, P63; Kohn MJ, 1996, GEOCHIM COSMOCHIM AC, V60, P4811, DOI 10.1016/S0016-7037(96)00240-2; SCHWARCZ HP, 1991, YEARB PHYS ANTHROPOL, V34, P283; 1998, 58 ANN M SOC VERT PA; 1998, APPL STABLE ISOTOPE	12	50	63	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					335	336		10.1126/science.283.5400.335	http://dx.doi.org/10.1126/science.283.5400.335			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925492				2022-12-01	WOS:000078067000028
J	McDermott, MF; Aksentijevich, I; Galon, J; McDermott, EM; Ogunkolade, BW; Centola, M; Mansfield, E; Gadina, M; Karenko, L; Pettersson, T; McCarthy, J; Frucht, DM; Aringer, M; Torosyan, Y; Teppo, AM; Wilson, M; Karaarslan, HM; Wan, Y; Todd, I; Wood, G; Schlimgen, R; Kumarajeewa, TR; Cooper, SM; Vella, JP; Amos, CI; Mulley, J; Quane, KA; Molloy, MG; Ranki, A; Powell, RJ; Hitman, GA; O'Shea, JJ; Kastner, DL				McDermott, MF; Aksentijevich, I; Galon, J; McDermott, EM; Ogunkolade, BW; Centola, M; Mansfield, E; Gadina, M; Karenko, L; Pettersson, T; McCarthy, J; Frucht, DM; Aringer, M; Torosyan, Y; Teppo, AM; Wilson, M; Karaarslan, HM; Wan, Y; Todd, I; Wood, G; Schlimgen, R; Kumarajeewa, TR; Cooper, SM; Vella, JP; Amos, CI; Mulley, J; Quane, KA; Molloy, MG; Ranki, A; Powell, RJ; Hitman, GA; O'Shea, JJ; Kastner, DL			Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes	CELL			English	Article							TUMOR-NECROSIS-FACTOR; PERIODIC-FEVER; LYMPHOPROLIFERATIVE SYNDROME; ERYTHROPOIETIN RECEPTOR; RHEUMATOID-ARTHRITIS; MEDITERRANEAN FEVER; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; HUMAN NEUTROPHILS; CHROMOSOME 12P13	Autosomal dominant periodic fever syndromes are characterized by unexplained episodes of fever and severe localized inflammation. In seven affected families, we found six different missense mutations of the 55 kDa tumor necrosis factor receptor (TNFR1), five of which disrupt conserved extracellular disulfide bonds. Soluble plasma TNFR1 levels in patients were approximately half normal. Leukocytes bearing a C52F mutation showed increased membrane TNFR1 and reduced receptor cleavage following stimulation. We propose that the autoinflammatory phenotype results from impaired downregulation of membrane TNFR1 and diminished shedding of potentially antagonistic soluble receptor. TNFR1-associated periodic syndromes (TRAPS) establish an important class of mutations in TNF receptors. Detailed analysis of one such mutation suggests impaired cytokine receptor clearance as a novel mechanism of disease.	St Bartholomews & Royal London Hosp Sch Med & Den, Med Unit, London E1 1BB, England; NIAMSD, Genet Sect, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA; NIAMSD, Lymphocyte Cell Biol Sect, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA; NIAMSD, Clin Invest Sect, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA; Univ Nottingham, Queens Med Ctr, Sch Clin Lab Sci, Div Mol & Clin Immunol, Nottingham NG7 2UH, England; Univ Helsinki, Cent Hosp, Dept Dermatol, Helsinki 00029, Finland; Univ Helsinki, Cent Hosp, Dept Med, Div Internal Med, Helsinki 00029, Finland; Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol, Helsinki 00029, Finland; Natl Univ Ireland Univ Coll Cork, Dept Med, Cork, Ireland; Natl Univ Ireland Univ Coll Cork, Dept Rheumatol, Cork, Ireland; New Childrens Hosp, Dept Clin Genet, Westmead, NSW, Australia; Univ Vermont, Coll Med, Rheumatol & Clin Immunol Unit, Burlington, VT 05405 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Nottingham; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University College Cork; University College Cork; University of Sydney; University of Vermont; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Womens & Childrens Hospital Australia	Kastner, DL (corresponding author), St Bartholomews & Royal London Hosp Sch Med & Den, Med Unit, London E1 1BB, England.	m.f.mcdermott@mds.qmw.ac.uk; kastnerd@arb.niams.nih.gov	Galon, Jerome/G-9838-2019; Gadina, Massimo/R-4195-2019; McDermott, Michael Francis/GZM-5330-2022; McDermott, Michael/S-8490-2019; Aksentijevich, Ivona/AAF-1335-2019	Galon, Jerome/0000-0001-9635-1339; McDermott, Michael/0000-0002-1015-0745; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041123, R01AR044422, ZIAAR041123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052607] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44422] Funding Source: Medline; NIGMS NIH HHS [GM52607] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ADERKA D, 1996, CYTOKINE GROWTH F R, V7, P2331; Aksentijevich I, 1997, CELL, V90, P797; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Bernot A, 1997, NAT GENET, V17, P25; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Centola M, 1998, HUM MOL GENET, V7, P1581, DOI 10.1093/hmg/7.10.1581; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Douni E, 1998, J EXP MED, V188, P1343, DOI 10.1084/jem.188.7.1343; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; DRENTH JPH, 1994, HUM GENET, V94, P616, DOI 10.1007/BF00206953; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GARCIA I, 1995, EUR J IMMUNOL, V25, P2401, DOI 10.1002/eji.1830250841; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; KARENKO L, 1992, J INTERN MED, V232, P365, DOI 10.1111/j.1365-2796.1992.tb00600.x; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; McDermott EM, 1997, MAYO CLIN PROC, V72, P806, DOI 10.4065/72.9.806; MCDERMOTT EM, 1997, FAMILIAL MEDITERRANE, P24; McDermott MF, 1998, AM J HUM GENET, V62, P1446, DOI 10.1086/301886; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Mulley J, 1998, AM J HUM GENET, V62, P884, DOI 10.1086/301793; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Peschon JJ, 1998, J IMMUNOL, V160, P943; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PORTEU F, 1994, J BIOL CHEM, V269, P2834; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Valimaki M, 1985, Duodecim, V101, P2428; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WILLIAMSON LM, 1982, Q J MED, V51, P469; ZAKS N, 1997, FAMILIAL MEDITERRANE, P211	51	952	993	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					133	144		10.1016/S0092-8674(00)80721-7	http://dx.doi.org/10.1016/S0092-8674(00)80721-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199409	Bronze			2022-12-01	WOS:000079843900015
J	Yamaguchi, Y; Takagi, T; Wada, T; Yano, K; Furuya, A; Sugimoto, S; Hasegawa, J; Handa, H				Yamaguchi, Y; Takagi, T; Wada, T; Yano, K; Furuya, A; Sugimoto, S; Hasegawa, J; Handa, H			NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation	CELL			English	Article							C-TERMINAL DOMAIN; ACCURATE TRANSCRIPTION INITIATION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; ACTIVATED TRANSCRIPTION; LARGEST SUBUNIT; P-TEFB; PHOSPHORYLATION; PURIFICATION; PROTEIN	DRB is a classic inhibitor of transcription elongation by RNA polymerase II (pol II). Since DRB generally affects class II genes, factors involved in this process must play fundamental roles in pol II elongation. Recently, two elongation factors essential for DRB action were identified, namely DSIF and P-TEFb. Here we describe the identification and purification from HeLa nuclear extract of a third protein factor required for DRB-sensitive transcription. This factor, termed negative elongation factor (NELF), cooperates with DSIF and strongly represses pol II elongation. This repression is reversed by P-TEFb-dependent phosphorylation of the pol II C-terminal domain. NELF is composed of five polypeptides, the smallest of which is identical to RD, a putative RNA-binding protein of unknown function. This study reveals a molecular mechanism for DRB action and a regulatory network of positive and negative elongation factors.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan	Tokyo Institute of Technology; Kyowa Kirin Ltd	Handa, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		Yamaguchi, Yuki/B-9390-2015	Yamaguchi, Yuki/0000-0002-0197-614X				Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Ausubel F.M., 1995, CURRENT PROTOCOLS MO; Chadwick GA., 1989, MET MATER, V5, P6; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHENG JH, 1993, BIOCHEM J, V294, P589, DOI 10.1042/bj2940589; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 1996, MOL CELL BIOL, V16, P2848; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KIM WY, 1988, J BIOL CHEM, V263, P18880; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; LEVISTRAUSS M, 1988, SCIENCE, V240, P201, DOI 10.1126/science.3353717; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; Thompson NE, 1996, METHOD ENZYMOL, V274, P513; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WADA T, 1991, J VIROL, V65, P557, DOI 10.1128/JVI.65.2.557-564.1991; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WATAMORI TS, 1990, APHASIOLOGY, V4, P9, DOI 10.1080/02687039008249051; WINSTON F, 1992, TRANSCRIPTIONAL REGU, P1271; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Yamaguchi Y, 1998, GENES CELLS, V3, P9, DOI 10.1046/j.1365-2443.1998.00162.x; YAMAGUCHI Y, 1999, IN PRESS J BIOL CHEM; YUE Z, 1997, P NATL ACAD SCI USA, V94, P12989; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	55	547	567	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					41	51		10.1016/S0092-8674(00)80713-8	http://dx.doi.org/10.1016/S0092-8674(00)80713-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199401	Bronze			2022-12-01	WOS:000079843900007
J	Rudge, P				Rudge, P			Are clinical trials of therapeutic agents for MS long enough?	LANCET			English	Editorial Material							REMITTING MULTIPLE-SCLEROSIS; PLACEBO-CONTROLLED TRIAL; RELAPSE RATE; DOUBLE-BLIND; DISABILITY		UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Rudge, P (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.							DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; JACOBS LD, 1996, ANN NEUROL, V39, P254; Johnson KP, 1998, NEUROLOGY, V50, P701, DOI 10.1212/WNL.50.3.701; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; NOTEWORTHY JH, 1998, NEUROLOGY, V52, P1342; RUDGE P, 1989, J NEUROL NEUROSUR PS, V52, P559, DOI 10.1136/jnnp.52.5.559; SIPE JC, 1994, LANCET, V344, P9, DOI 10.1016/S0140-6736(94)91046-4; YUDKIN PL, 1991, LANCET, V338, P1051, DOI 10.1016/0140-6736(91)91909-E	12	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1033	1034		10.1016/S0140-6736(98)00407-3	http://dx.doi.org/10.1016/S0140-6736(98)00407-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199348				2022-12-01	WOS:000079614000007
J	Brown, CB; Boyer, AS; Runyan, RB; Barnett, JV				Brown, CB; Boyer, AS; Runyan, RB; Barnett, JV			Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart	SCIENCE			English	Article							GROWTH-FACTOR-BETA; GENE-EXPRESSION; EMBRYONIC HEART; BETAGLYCAN; LIGAND; ANTIBODIES; ACTIVATION; TGF-BETA-2; CLONING; PROTEIN	Transforming growth factor-beta (TGF-beta) signaling is mediated by a complex of type I (TBRI) and type II (TBRII) receptors. The type III receptor (TBRIII) Lacks a recognizable signaling domain and has no clearly defined role in TGF-beta signaling. Cardiac endothelial cells that undergo epithelial-mesenchymal transformation express TBRIII, and here TBRIII-specific antisera were found to inhibit mesenchyme formation and migration in atrioventricular cushion explants. Misexpression of TBRIII in nontransforming ventricular endothelial cells conferred transformation in response to TGF-beta 2. These results support a model where TBRIII localizes transformation in the heart and plays an essential, nonredundant role in TGF-beta signaling.	Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med & Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Univ Arizona, Univ Heart Ctr, Dept Cell Biol & Anat, Tucson, AZ 85724 USA	Vanderbilt University; Vanderbilt University; University of Arizona	Barnett, JV (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med & Pharmacol, 2200 Pierce Ave, Nashville, TN 37232 USA.	joey.barnett@mcmail.vanderbilt.edu	Runyan, Raymond B/B-6977-2012	Runyan, Raymond B/0000-0002-7410-916X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052922] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL052922, R01 HL052922-05, HL52922] Funding Source: Medline; PHS HHS [42266, 38649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARNETT JV, 1994, DEV DYNAM, V199, P12, DOI 10.1002/aja.1001990103; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; Brown CB, 1996, DEV BIOL, V174, P248, DOI 10.1006/dbio.1996.0070; BROWN CM, UNPUB; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DICKSON MC, 1993, DEVELOPMENT, V117, P625; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Fishman MC, 1997, DEVELOPMENT, V124, P2099; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; JOHNSON DW, 1995, GENOMICS, V28, P356, DOI 10.1006/geno.1995.1157; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; POTTS JD, 1989, DEV BIOL, V134, P392, DOI 10.1016/0012-1606(89)90111-5; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; RUNYAN RB, 1983, DEV BIOL, V95, P108, DOI 10.1016/0012-1606(83)90010-6; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; Sheffield VC, 1997, HUM MOL GENET, V6, P117, DOI 10.1093/hmg/6.1.117; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	31	302	312	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2080	2082		10.1126/science.283.5410.2080	http://dx.doi.org/10.1126/science.283.5410.2080			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10092230				2022-12-01	WOS:000079369800045
J	Simini, B				Simini, B			Preoperative fasting	LANCET			English	Editorial Material									Osped Lucca, Anaesthesia Intens Care & Pain Management Unit, I-55100 Lucca, Italy		Simini, B (corresponding author), Osped Lucca, Anaesthesia Intens Care & Pain Management Unit, I-55100 Lucca, Italy.							Harter RL, 1998, ANESTH ANALG, V86, P147, DOI 10.1097/00000539-199801000-00030; LISTER J, 1993, HOLMES SYSTEM SURG, V3; Lydon A, 1998, BRIT J ANAESTH, V81, P522, DOI 10.1093/bja/81.4.522; MACFIE AG, 1991, BRIT J ANAESTH, V67, P54, DOI 10.1093/bja/67.1.54; SELLICK BA, 1961, LANCET, V2, P404; Smith AF, 1997, BRIT MED J, V314, P1486, DOI 10.1136/bmj.314.7092.1486a; SNOW J, 1847, INHALATION VAPOUR ET, P43; SOREIDE E, 1995, ACTA ANAESTH SCAND, V39, P738, DOI 10.1111/j.1399-6576.1995.tb04162.x; Soreide E, 1996, ACTA ANAESTH SCAND, V40, P549, DOI 10.1111/j.1399-6576.1996.tb04486.x	9	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 13	1999	353	9156					862	862		10.1016/S0140-6736(99)00081-1	http://dx.doi.org/10.1016/S0140-6736(99)00081-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BU	10093976				2022-12-01	WOS:000079421400006
J	Buchel, C; Coull, JT; Friston, KJ				Buchel, C; Coull, JT; Friston, KJ			The predictive value of changes in effective connectivity for human learning	SCIENCE			English	Article							SPATIAL LOCATION; OBJECT-LOCATION; EPISODIC MEMORY; REGIONS; HIPPOCAMPUS; MECHANISMS; RETRIEVAL; ATTENTION; NETWORKS; TERM	During learning, neural responses decrease over repeated exposure to identical stimuli. This repetition suppression is thought to reflect a progressive optimization of neuronal responses elicited by the task. Functional magnetic resonance imaging was used to study the neural basis of associative learning of visual objects and their locations. As expected, activation in specialized cortical areas decreased with time. However, with path analysis it was shown that, in parallel to this adaptation, increases in effective connectivity occurred between distinct cortical systems specialized for spatial and object processing. The time course of these plastic changes was highly correlated with individual learning performance, suggesting that interactions between brain areas underlie associative learning.	Inst Neurol, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England	University of London; University College London	Buchel, C (corresponding author), Inst Neurol, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England.	c.buechel@fil.ion.ucl.ac.uk	Coull, Jennifer T/M-4243-2015; Friston, Karl/D-9230-2011	Coull, Jennifer T/0000-0002-8790-5835; Friston, Karl/0000-0001-7984-8909				Aertsen A., 1991, DYNAMICS ACTIVITY CO; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; Buchel C, 1997, CEREB CORTEX, V7, P768, DOI 10.1093/cercor/7.8.768; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Damasio A., 1994, LARGE SCALE NEURONAL, P61; Desimone R, 1996, P NATL ACAD SCI USA, V93, P13494, DOI 10.1073/pnas.93.24.13494; DISTLER C, 1993, J COMP NEUROL, V334, P125, DOI 10.1002/cne.903340111; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Friston K, 1995, HUM BRAIN MAPP, V2, P1; Friston KJ, 1995, HUM BRAIN MAPP, V3, P302, DOI 10.1002/hbm.460030405; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GERSTEIN GL, 1969, SCIENCE, V164, P828, DOI 10.1126/science.164.3881.828; Holmes AP, 1997, NEUROIMAGE, V5, pS480; HORWITZ B, 1992, J COGNITIVE NEUROSCI, V4, P311, DOI 10.1162/jocn.1992.4.4.311; Jouve B, 1998, CEREB CORTEX, V8, P28, DOI 10.1093/cercor/8.1.28; Kohler S, 1998, NEUROPSYCHOLOGIA, V36, P129, DOI 10.1016/S0028-3932(97)00098-5; Kohler S, 1998, CEREB CORTEX, V8, P451, DOI 10.1093/cercor/8.5.451; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; McIntosh A. R., 1994, Human Brain Mapping, V2, P2; McIntosh AR, 1998, J NEUROPHYSIOL, V80, P2790, DOI 10.1152/jn.1998.80.5.2790; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Milner B, 1997, PHILOS T R SOC B, V352, P1469, DOI 10.1098/rstb.1997.0133; MOSCOVITCH M, 1995, P NATL ACAD SCI USA, V92, P3721, DOI 10.1073/pnas.92.9.3721; Owen AM, 1996, J COGNITIVE NEUROSCI, V8, P588, DOI 10.1162/jocn.1996.8.6.588; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; Wiggs CL, 1998, CURR OPIN NEUROBIOL, V8, P227, DOI 10.1016/S0959-4388(98)80144-X; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023	34	340	347	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1538	1541		10.1126/science.283.5407.1538	http://dx.doi.org/10.1126/science.283.5407.1538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066177				2022-12-01	WOS:000078959200049
J	Asturias, FJ; Jiang, YW; Myers, LC; Gustafsson, CM; Kornberg, RD				Asturias, FJ; Jiang, YW; Myers, LC; Gustafsson, CM; Kornberg, RD			Conserved structures of mediator and RNA polymerase II holoenzyme	SCIENCE			English	Article							YEAST; TRANSCRIPTION; ACTIVATION; DOMAIN	Single particles of the mediator of transcriptional regulation (Mediator) and of RNA polymerase II holoenzyme were revealed by electron microscopy and image processing. Mediator alone appeared compact, but at high pH or in the presence of RNA polymerase II it displayed an extended conformation. Holoenzyme contained Mediator in a fully extended state, partially enveloping the globular polymerase, with points of apparent contact in the vicinity of the polymerase carboxyl-terminal domain and the DNA-binding channel. A similarity in appearance and conformational behavior of yeast and murine complexes indicates a conservation of Mediator structure among eukaryotes.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Asturias, FJ (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Bldg, Stanford, CA 94305 USA.			Gustafsson, Claes/0000-0003-3531-8468; Myers, Lawrence/0000-0002-6537-6856	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTURIAS FJ, UNPUB; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T	12	193	203	5	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					985	987		10.1126/science.283.5404.985	http://dx.doi.org/10.1126/science.283.5404.985			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974391				2022-12-01	WOS:000078574800048
J	de Lange, T; DePinho, RA				de Lange, T; DePinho, RA			Cell proliferation - Unlimited mileage from telomerase?	SCIENCE			English	Editorial Material							IMMORTAL CELLS; FIBROBLASTS; SENESCENCE; RNA; P53; RB		Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Rockefeller University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.		de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X; DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [R01CA076027] Funding Source: NIH RePORTER; NCI NIH HHS [CA76027] Funding Source: Medline; NICHD NIH HHS [HD 348880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KARSLEDER J, IN PRESS SCIENCE; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	25	52	53	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					947	949		10.1126/science.283.5404.947	http://dx.doi.org/10.1126/science.283.5404.947			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	10075559				2022-12-01	WOS:000078574800036
J	Livnah, O; Stura, EA; Middleton, SA; Johnson, DL; Jolliffe, LK; Wilson, LA				Livnah, O; Stura, EA; Middleton, SA; Johnson, DL; Jolliffe, LK; Wilson, LA			Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation	SCIENCE			English	Article							NECROSIS-FACTOR RECEPTOR; HUMAN GROWTH-HORMONE; X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; EPO RECEPTOR; EXTRACELLULAR DOMAIN; MOLECULAR REPLACEMENT; TRANSMEMBRANE SEGMENT; PROTEIN HORMONE; HIGH-AFFINITY	Erythropoietin receptor (EPOR) is thought to be activated by Ligand-induced homodimerization. However, structures of agonist and antagonist peptide complexes of EPOR, as well as an EPO-EPOR complex, have shown that the actual dimer configuration is critical for the biological response and signal efficiency. The crystal structure of the extracellular domain of EPOR in its unliganded form at 2.4 angstrom resolution has revealed a dimer in which the individual membrane-spanning and intracellular domains would be too far apart to permit phosphorylation by JAK2. This unliganded EPOR dimer is formed from self-association of the same key binding site residues that interact with EPO-mimetic peptide and EPO Ligands. This model for a preformed dimer on the cell surface provides insights into the organization, activation, and plasticity of recognition of hematopoietic cell surface receptors.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA	Scripps Research Institute; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA	Jolliffe, LK (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Stura, Enrico A./A-2793-2010; fathi, mazyar/H-1722-2016	Stura, Enrico A./0000-0001-6718-2118; 	NIGMS NIH HHS [GM49497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Barbone FP, 1997, J BIOL CHEM, V272, P4985, DOI 10.1074/jbc.272.8.4985; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Brosig B, 1998, PROTEIN SCI, V7, P1052; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1991, ACTA CRYSTALLOGR A, V47, P195, DOI 10.1107/S0108767390011795; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Huang MD, 1998, J MOL BIOL, V275, P873, DOI 10.1006/jmbi.1997.1512; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Johnson DL, 1998, BIOCHEMISTRY-US, V37, P3699, DOI 10.1021/bi971956y; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; JOLLIFFE LK, 1995, NEPHROL DIAL TRANSPL, V10, P28, DOI 10.1093/ndt/10.supp2.28; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRANTZ SB, 1991, BLOOD, V77, P419; Laage R, 1997, EUR J BIOCHEM, V249, P540, DOI 10.1111/j.1432-1033.1997.00540.x; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MIDDLETON SA, UNPUB; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; Naismith JH, 1996, J MOL RECOGNIT, V9, P113, DOI 10.1002/(SICI)1099-1352(199603)9:2<113::AID-JMR253>3.0.CO;2-H; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; SAWADA K, 1987, J CLIN INVEST, V80, P357, DOI 10.1172/JCI113080; Schneider H, 1997, BLOOD, V89, P473, DOI 10.1182/blood.V89.2.473; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Thompson NL, 1997, PHOTOCHEM PHOTOBIOL, V65, P39, DOI 10.1111/j.1751-1097.1997.tb01875.x; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	53	494	518	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1999	283	5404					987	990		10.1126/science.283.5404.987	http://dx.doi.org/10.1126/science.283.5404.987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974392				2022-12-01	WOS:000078574800049
J	Jacobs, TW; Byrne, C; Colditz, G; Connolly, JL; Schnitt, SJ				Jacobs, TW; Byrne, C; Colditz, G; Connolly, JL; Schnitt, SJ			Radial scars in benign breast-biopsy specimens and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEMALE BREAST; ATYPICAL HYPERPLASIA; SCLEROSING LESION; CARCINOMA; WOMEN; DISEASE; FEATURES	Background Radial scars are benign breast lesions of uncertain clinical significance. In particular, it is not known whether these lesions alter the risk of breast cancer in women with benign breast disease. We conducted a case-control study of women who had benign breast lesions with or without radial scars. Methods We reviewed benign breast-biopsy specimens from 1396 women enrolled in the Nurses' Health Study, including 255 women in whom breast cancer subsequently developed and 1141 women without subsequent breast cancer (controls). The controls were matched to the women with subsequent breast cancer according to age and the year when the benign lesion was identified. The median followup after biopsy of the benign lesions was 12 years. Results Radial scars were identified in biopsy specimens from 99 women (71 percent). Most biopsy specimens with radial scars had only one radial scar (60.6 percent), and they tended to be incidental microscopical findings (median size, 4.0 mm). The women with radial scars had a risk of breast cancer that was almost twice the risk of the women without scars, regardless of the histologic type of benign breast disease (relative risk, 1.8; 95 percent confidence interval, 1.1 to 2.9). Among women who had proliferative disease without atypia as compared with women who had nonproliferative disease, the relative risk of breast cancer was 3.0 (95 percent confidence interval, 1.7 to 5.5) for those with radial scars and 1.5 (95 percent confidence interval, 1.1 to 2.1) for those without radial scars. Among women with atypical hyperplasia as compared with women with nonproliferative disease, the relative risk of breast cancer was 5.8 (95 percent confidence interval, 2.7 to 12.7) for those with radial scars and 3.8 (95 percent confidence interval, 2.4 to 5.9) for those without radial scars. Conclusions Radial scars are an independent histologic risk factor for breast cancer. (N Engl J Med 1999;340:430-6.) (C) 1999, Massachusetts Medical Society.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Schnitt, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, East Campus,330 Brookline Ave, Boston, MA 02215 USA.		Colditz, Graham/A-3963-2009; Byrne, Celia/K-2964-2015	Colditz, Graham/0000-0002-7307-0291; Byrne, Celia/0000-0001-8289-4252	NATIONAL CANCER INSTITUTE [R01CA050385, R01CA040356, R37CA040356, R01CA046475] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356, CA 46475, CA 50385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN JA, 1986, PATHOL ANNU, V21, P145; ANDERSEN JA, 1984, CANCER, V53, P2557, DOI 10.1002/1097-0142(19840601)53:11<2557::AID-CNCR2820531131>3.0.CO;2-D; ANDERSON TJ, 1985, J PATHOL, V147, P23, DOI 10.1002/path.1711470104; BLOODGOOD JC, 1932, AM J CANCER, V16, P103; Breslow NE., 1980, IARC SCI PUBLICATION, V32; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; DELATORRE M, 1993, HUM PATHOL, V24, P1294, DOI 10.1016/0046-8177(93)90262-F; DouglasJones AG, 1997, HISTOPATHOLOGY, V30, P214, DOI 10.1046/j.1365-2559.1997.d01-600.x; DUPONT WD, 1993, CANCER, V71, P1258, DOI 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1994, NEW ENGL J MED, V331, P10, DOI 10.1056/NEJM199407073310103; FENOGLIO C, 1974, CANCER, V33, P691, DOI 10.1002/1097-0142(197403)33:3<691::AID-CNCR2820330313>3.0.CO;2-L; FISHER ER, 1979, AM J CLIN PATHOL, V71, P240; FISHER ER, 1983, BREAST CANCER RES TR, V3, P39, DOI 10.1007/BF01806233; FROUGE C, 1995, RADIOLOGY, V195, P623, DOI 10.1148/radiology.195.3.7753984; JENSEN RA, 1989, CANCER, V64, P1977, DOI 10.1002/1097-0142(19891115)64:10<1977::AID-CNCR2820641002>3.0.CO;2-N; Linell F, 1980, Acta Pathol Microbiol Scand Suppl, P1; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P1780; Marshall LM, 1997, CANCER EPIDEM BIOMAR, V6, P297; NIELSEN M, 1985, HISTOPATHOLOGY, V9, P287, DOI 10.1111/j.1365-2559.1985.tb02446.x; NIELSEN M, 1987, CANCER, V59, P1019, DOI 10.1002/1097-0142(19870301)59:5<1019::AID-CNCR2820590528>3.0.CO;2-N; Page DL, 1996, CANCER, V78, P258, DOI 10.1002/(SICI)1097-0142(19960715)78:2<258::AID-CNCR11>3.0.CO;2-V; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; PALLI D, 1991, INT J CANCER, V47, P703, DOI 10.1002/ijc.2910470513; RICKERT RR, 1981, CANCER, V47, P561, DOI 10.1002/1097-0142(19810201)47:3<561::AID-CNCR2820470323>3.0.CO;2-0; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; *SAS I, 1989, SAS STAT US GUID VER, V2; SAS Institute, 1990, SAS PROC GUID VERS 6; Semb C, 1928, ACTA CHIR SCAND    S, V10, P1; SLOANE JP, 1993, HISTOPATHOLOGY, V23, P225, DOI 10.1111/j.1365-2559.1993.tb01194.x; TREMBLAY G, 1977, AM J SURG PATHOL, V1, P155, DOI 10.1097/00000478-197706000-00006; WEIDNER N, 1990, SEMIN DIAGN PATHOL, V7, P90; WELLINGS SR, 1984, HUM PATHOL, V15, P475, DOI 10.1016/S0046-8177(84)80083-0	33	202	209	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					430	436		10.1056/NEJM199902113400604	http://dx.doi.org/10.1056/NEJM199902113400604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971867				2022-12-01	WOS:000078571000004
J	George, KM; Chatterjee, D; Gunawardana, G; Welty, D; Hayman, J; Lee, R; Small, PLC				George, KM; Chatterjee, D; Gunawardana, G; Welty, D; Hayman, J; Lee, R; Small, PLC			Mycolactone: A polyketide toxin from Mycobacterium ulcerans required for virulence	SCIENCE			English	Article								Mycobacterium ulcerans is the causative agent of Buruli ulcer, a severe human skin disease that occurs primarily in Africa and Australia, Infection with M. ulcerans results in persistent severe necrosis without an acute inflammatory response. The presence of histopathological changes distant from the site of infection suggested that pathogenesis might be toxin mediated. A polyketide-derived macrolide designated mycolactone was isolated that causes cytopathicity and cell cycle arrest in cultured L929 murine fibroblasts. Intradermal inoculation of purified toxin into guinea pigs produced a lesion similar to that of Buruli ulcer in humans. This toxin may represent one of a family of virulence factors associated with pathology in mycobacterial diseases such as leprosy and tuberculosis.	NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Abbott Labs, Abbott Pk, IL 60064 USA; Box Hill Hosp, Box Hill, Vic 3128, Australia; NIAID, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Colorado State University; Abbott Laboratories; Box Hill Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Small, PLC (corresponding author), NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.		Lee, Richard/AAX-3996-2021; Lee, Richard/J-4997-2013	Lee, Richard/0000-0002-2397-0443; Lee, Richard/0000-0002-2397-0443; HAYMAN, John/0000-0002-4174-2639				Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CONNOR DH, 1966, ARCH PATHOL, V81, P183; George KM, 1998, INFECT IMMUN, V66, P587, DOI 10.1128/IAI.66.2.587-593.1998; HAYMAN J, 1993, J CLIN PATHOL, V46, P5, DOI 10.1136/jcp.46.1.5; HOCKMEYER WT, 1978, INFECT IMMUN, V21, P124, DOI 10.1128/IAI.21.1.124-128.1978; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUDSON AT, 1970, BIOCHEMISTRY-US, V9, P3988, DOI 10.1021/bi00822a018; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KRIEG RE, 1974, ARCH DERMATOL, V110, P783, DOI 10.1001/archderm.110.5.783; Labro MT, 1998, INT J ANTIMICROB AG, V10, P11, DOI 10.1016/S0924-8579(98)00012-0; MAPLESTONE RA, 1992, GENE, V115, P151, DOI 10.1016/0378-1119(92)90553-2; PIMSLER M, 1988, J INFECT DIS, V157, P577, DOI 10.1093/infdis/157.3.577; Portaels F, 1997, J CLIN MICROBIOL, V35, P1097, DOI 10.1128/JCM.35.5.1097-1100.1997; READ JK, 1974, INFECT IMMUN, V9, P1114, DOI 10.1128/IAI.9.6.1114-1122.1974; Ross BC, 1997, APPL ENVIRON MICROB, V63, P4135, DOI 10.1128/AEM.63.10.4135-4138.1997; [No title captured]	16	473	489	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					854	857		10.1126/science.283.5403.854	http://dx.doi.org/10.1126/science.283.5403.854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933171	Green Submitted			2022-12-01	WOS:000078496800048
J	Thanos, CD; Goodwill, KE; Bowie, JU				Thanos, CD; Goodwill, KE; Bowie, JU			Oligomeric structure of the human EphB2 receptor SAM domain	SCIENCE			English	Article							MAXIMUM-LIKELIHOOD; CRYSTAL-STRUCTURES; TYROSINE KINASES; PROTEIN; FUSION; TEL; LEUKEMIA; GENE; ASSOCIATION; REFINEMENT	The sterile alpha motif (SAM) domain is a protein interaction module that is present in diverse signal-transducing proteins. SAM domains are known to form homo- and hetero-oligomers. The crystal structure of the SAM domain from an Eph receptor tyrosine kinase, EphB2, reveals two Large interfaces. In one interface, adjacent monomers exchange amino-terminal peptides that insert into a hydrophobic groove on each neighbor. A second interface is composed of the carboxyl-terminal helix and a nearby Loop. A possible oligomer, constructed from a combination of these binding modes, may provide a platform for the formation of larger protein complexes.	Univ Calif Los Angeles, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Bowie, JU (corresponding author), Univ Calif Los Angeles, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA.	bowie@mbi.ucla.edu						Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Barr MM, 1996, MOL CELL BIOL, V16, P5597; Bornemann D, 1996, DEVELOPMENT, V122, P1621; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PAWSON T, 1995, NATURE, V373, P575; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SHULTZ J, 1997, PROTEIN SCI, V6, P249; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THANOS CD, UNPUB; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Tosi S, 1998, GENE CHROMOSOME CANC, V21, P223, DOI 10.1002/(SICI)1098-2264(199803)21:3<223::AID-GCC6>3.3.CO;2-B; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0	44	194	202	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					833	836		10.1126/science.283.5403.833	http://dx.doi.org/10.1126/science.283.5403.833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933164	Green Submitted			2022-12-01	WOS:000078496800041
J	Ness, RB; Grisso, JA; Hirschinger, N; Markovic, N; Shaw, LM; Day, NL; Kline, J				Ness, RB; Grisso, JA; Hirschinger, N; Markovic, N; Shaw, LM; Day, NL; Kline, J			Cocaine and tobacco use and the risk of spontaneous abortion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; HAIR ANALYSIS; PREGNANCY; EXPOSURE; ABUSE; CONSUMPTION; PREVALENCE; FETUS	Background Cigarette smoking and cocaine use may be risk factors for spontaneous abortion, but data supporting such a link are limited. Methods We studied the associations between cocaine and tobacco use and spontaneous abortion among pregnant adolescents and women (age range, 14 to 40 years) who sought care at an inner-city emergency department. A total of 400 adolescents and women had spontaneous abortions either at study entry or during follow-up (which lasted until 22 weeks' gestation), and 570 adolescents and women remained pregnant past 22 weeks' gestation. Cocaine use was measured at base line by self-reports and analysis of urine and hair samples, Cigarette smoking was measured by self-reports and urine analysis. Results The adolescents and women in both groups were predominantly black and of lower socioeconomic status. Among those who had spontaneous abortions, 28.9 percent used cocaine on the basis of hair analysis and 34.6 percent smoked on the basis of a urine cotinine assay, as compared with 20.5 percent and 21.8 percent, respectively, of the adolescents and women who did not have spontaneous abortions. The presence of cocaine in hair samples was independently associated with an increase in the occurrence of spontaneous abortion (odds ratio, 1.4; 95 percent confidence interval, 1.0 to 2.1) after adjustment for demographic and drug-use variables. However, the use of cocaine as measured by self-reports and by urine analysis was not. The presence of cotinine in urine was also independently associated with an increased risk of spontaneous abortion (odds ratio, 1.8; 95 percent confidence interval, 1.3 to 2.6). Twenty-four percent of the risk of spontaneous abortion could be related to cocaine or tobacco use. Conclusions Cocaine use and tobacco use were common in our study population and were associated with a significant risk of spontaneous abortion, (N Engl J Med 1999;340:333-9.) (C) 1999, Massachusetts Medical Society.	Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA; New York State Psychiat Inst, New York, NY 10032 USA; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA; Columbia Univ, Sch Publ Hlth, New York, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; New York State Psychiatry Institute; Columbia University; Columbia University	Ness, RB (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, 130 DeSoto St,517 Parran Hall, Pittsburgh, PA 15261 USA.		Day, Nancy L/H-3171-2016		AHRQ HHS [R01 HS08358] Funding Source: Medline; NIDA NIH HHS [R01 DA08252] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008252] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARMSTRONG BG, 1992, AM J PUBLIC HEALTH, V82, P85, DOI 10.2105/AJPH.82.1.85; BINGOL N, 1987, J PEDIATR-US, V110, P350; BRUMGARTNER WA, 1992, RECENT DEV THERAPEUT, P577; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CHURCH MW, 1990, NEUROTOXICOL TERATOL, V12, P327, DOI 10.1016/0892-0362(90)90051-D; FRANK DA, 1988, PEDIATRICS, V82, P888; GRANT T, 1994, OBSTET GYNECOL, V83, P524, DOI 10.1097/00006250-199404000-00007; HADDOW JE, 1987, BRIT J OBSTET GYNAEC, V94, P678, DOI 10.1111/j.1471-0528.1987.tb03174.x; HIMMELBERGER DU, 1978, AM J EPIDEMIOL, V108, P470, DOI 10.1093/oxfordjournals.aje.a112645; KEITH LG, 1989, OBSTET GYNECOL, V73, P715; Klebanoff MA, 1998, AM J EPIDEMIOL, V148, P259; KLINE J, 1995, AM J EPIDEMIOL, V141, P417, DOI 10.1093/oxfordjournals.aje.a117444; Kline J, 1997, AM J PUBLIC HEALTH, V87, P352, DOI 10.2105/AJPH.87.3.352; Kline J.S., 1989, CONCEPTION BIRTH EPI; KOREN G, 1992, J CLIN PHARMACOL, V32, P671, DOI 10.1002/j.1552-4604.1992.tb05780.x; MACGREGOR SN, 1989, OBSTET GYNECOL, V74, P882; MAGURA S, 1992, INT J ADDICT, V27, P51; MCNAGNY SE, 1992, JAMA-J AM MED ASSOC, V267, P1106, DOI 10.1001/jama.267.8.1106; MOORE TR, 1986, AM J OBSTET GYNECOL, V155, P883, DOI 10.1016/S0002-9378(86)80044-8; RAMOSKA EA, 1989, ANN EMERG MED, V18, P48, DOI 10.1016/S0196-0644(89)80310-5; RYAN L, 1987, NEUROTOXICOL TERATOL, V9, P295, DOI 10.1016/0892-0362(87)90018-3; SAITOH M, 1969, ADV BIOL SKIN, V9, P183; Sozio J, 1998, Infect Dis Obstet Gynecol, V6, P8, DOI 10.1155/S1064744998000039; WALSH RA, 1994, HUM BIOL, V66, P1059; WILCOX AJ, 1984, AM J EPIDEMIOL, V120, P727, DOI 10.1093/oxfordjournals.aje.a113940; WINDHAM GC, 1992, AM J EPIDEMIOL, V135, P1394, DOI 10.1093/oxfordjournals.aje.a116250; WOODS JR, 1987, JAMA-J AM MED ASSOC, V257, P957, DOI 10.1001/jama.257.7.957	27	195	197	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1999	340	5					333	339		10.1056/NEJM199902043400501	http://dx.doi.org/10.1056/NEJM199902043400501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163WC	9929522				2022-12-01	WOS:000078428500001
J	Bjornson, CRR; Rietze, RL; Reynolds, BA; Magli, MC; Vescovi, AL				Bjornson, CRR; Rietze, RL; Reynolds, BA; Magli, MC; Vescovi, AL			Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo	SCIENCE			English	Article							MOUSE BRAIN; MICE	Stem cells are found in various organs where they participate in tissue homeostasis by replacing differentiated cells Lost to physiological turnover or injury. An investigation was performed to determine whether stem cells are restricted to produce specific cell types, namely, those from the tissue in which they reside. After transplantation into irradiated hosts; genetically labeled neural stem cells were found to produce a variety of blood cell types including myeloid and lymphoid cells as well as early hematopoietic cells. Thus, neural stem cells appear to have a wider differentiation potential than previously thought.	NeuroSpheres Ltd, Calgary, AB T2N 4N1, Canada; CNR, Ist Mutagenesi, I-56124 Pisa, Italy; Ist Nazl Neurol C Besta, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituto Neurologico Besta	Bjornson, CRR (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.		Vescovi, Angelo Luigi/A-4919-2015	Vescovi, Angelo Luigi/0000-0002-1742-4112	Telethon [A.116] Funding Source: Medline	Telethon(Fondazione Telethon)		BARTLETT PF, 1982, P NATL ACAD SCI-BIOL, V79, P2722, DOI 10.1073/pnas.79.8.2722; DIBERARDINO MA, 1997, GENOMIC POTENTIAL DI, P1; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gritti A, 1996, J NEUROSCI, V16, P1091; Loeffler Markus, 1997, P1, DOI 10.1016/B978-012563455-7/50002-7; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; TARBELL NJ, 1987, INT J RADIAT ONCOL, V13, P1065, DOI 10.1016/0360-3016(87)90046-0; VALTZ NLM, 1991, NEW BIOL, V3, P364; VESCOVI AL, IN PRESS EXP NEUROL; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581	14	1112	1261	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					534	537		10.1126/science.283.5401.534	http://dx.doi.org/10.1126/science.283.5401.534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915700				2022-12-01	WOS:000078203300036
J	Huntsman, MM; Porcello, DM; Homanics, GE; DeLorey, TM; Huguenard, JR				Huntsman, MM; Porcello, DM; Homanics, GE; DeLorey, TM; Huguenard, JR			Reciprocal inhibitory connections and network synchrony in the mammalian thalamus	SCIENCE			English	Article							SPINDLE RHYTHMICITY; RETICULAR NEURONS; RELAY NEURONS; IN-VITRO; NUCLEUS; RAT; SUBUNIT; BRAIN	Neuronal rhythmic activities within thalamocortical circuits range from partially synchronous oscillations during normal sleep to hypersynchrony associated with absence epilepsy. It has been proposed that recurrent inhibition within the thalamic reticular nucleus serves to reduce synchrony and thus prevents seizures, Inhibition and synchrony in slices from mice devoid of the gamma-aminobutyric acid type-A (GABA(A)) receptor beta(3) subunit were examined, because in rodent thalamus, beta(3) is largely restricted to reticular nucleus. in beta(3) knockout mice, GABA(A)-mediated inhibition was nearly abolished in reticular nucleus, but was unaffected in relay cells. In addition, oscillatory synchrony was dramatically intensified. Thus, recurrent inhibitory connections within reticular nucleus act as "desynchronizers."	Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15261 USA; Mol Res Inst, Palo Alto, CA 94304 USA	Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Huguenard, JR (corresponding author), Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.		Huguenard, John/I-5016-2012; Huguenard, John/K-6429-2019	Huguenard, John/0000-0002-6950-1191; Huguenard, John/0000-0002-6950-1191; Homanics, Gregg/0000-0003-3641-8153	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034774, R37NS034774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010422] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10422] Funding Source: Medline; NINDS NIH HHS [NS34774, NS06477] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLSEN G, 1982, BRAIN RES, V236, P482, DOI 10.1016/0006-8993(82)90731-4; Cox CL, 1996, J COMP NEUROL, V366, P416; DeLorey TM, 1998, J NEUROSCI, V18, P8505; DESTEXHE A, 1994, J NEUROPHYSIOL, V72, P803, DOI 10.1152/jn.1994.72.2.803; Homanics GE, 1997, P NATL ACAD SCI USA, V94, P4143, DOI 10.1073/pnas.94.8.4143; HUGUENARD JR, 1994, J NEUROSCI, V14, P5485; HUGUENARD JR, 1994, J NEUROPHYSIOL, V71, P2576, DOI 10.1152/jn.1994.71.6.2576; JONES EG, 1975, J COMP NEUROL, V162, P285, DOI 10.1002/cne.901620302; Jones MV, 1997, J NEUROSCI, V17, P7626; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; KONIG P, 1994, J NEUROSCI METH, V54, P31, DOI 10.1016/0165-0270(94)90157-0; Krasowski MD, 1998, NEUROSCI LETT, V240, P81, DOI 10.1016/S0304-3940(97)00929-4; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; Pinault D, 1997, J NEUROSCI, V17, P3215; SanchezVives MV, 1997, J NEUROSCI, V17, P8894; SCHEIBEL MADGE E., 1966, BRAIN RES, V1, P43, DOI 10.1016/0006-8993(66)90104-1; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; ULRICH D, 1995, NEURON, V15, P909, DOI 10.1016/0896-6273(95)90181-7; Ulrich D, 1997, J NEUROPHYSIOL, V78, P1748, DOI 10.1152/jn.1997.78.3.1748; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; WARREN RA, 1994, J NEUROPHYSIOL, V72, P1993, DOI 10.1152/jn.1994.72.4.1993; WISDEN W, 1992, J NEUROSCI, V12, P1040; Zhang SLJ, 1997, J NEUROPHYSIOL, V78, P2280, DOI 10.1152/jn.1997.78.5.2280	25	273	275	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					541	543		10.1126/science.283.5401.541	http://dx.doi.org/10.1126/science.283.5401.541			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915702				2022-12-01	WOS:000078203300038
J	Jacobs, JJL; Kieboom, K; Marino, S; DePinho, RA; van Lohuizen, M				Jacobs, JJL; Kieboom, K; Marino, S; DePinho, RA; van Lohuizen, M			The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus	NATURE			English	Article							TRANSGENIC MICE; TUMOR SUPPRESSION; AXIAL SKELETON; LYMPHOMAGENESIS; IDENTIFICATION; TRANSFORMATION; PROTOONCOGENE; FIBROBLASTS; EXPRESSION; P16(INK4A)	The bmi-1 gene was first isolated as an oncogene that cooperates with c-myc in the generation of mouse lymphomas(1,2). We subsequently identified Bmi-1 as a transcriptional repressor belonging to the mouse Polycomb group(3-6). The Polycomb group comprises an important, conserved set of proteins that are required to maintain stable repression of specific target genes, such as homeobox-cluster genes, during development(7-9). In mice, the absence of bmi-1 expression results in neurological defects and severe proliferative defects in lymphoid cells, whereas bmi-1 overexpression induces lymphomas(4,10). Here we show that bmi-1-deficient primary mouse embryonic fibroblasts are impaired in progression into the S phase of the cell cycle and undergo premature senescence. In these fibroblasts and in bmi-1-deficient: lymphocytes, the expression of the tumour suppressors p16 and p19(Arf), which are encoded by ink4a, is raised markedly. Conversely, overexpression of bmi-1 allows fibroblast immortalization, downregulates expression of p16 and p19(Arf) and, in combination with H-ras, leads to neoplastic transformation. Removal of ink4a dramatically reduces the lymphoid and neurological defects seen in bmi-1-deficient mice, indicating that ink4a is a critical in vivo target for Bmi-1. Our results connect transcriptional repression by Polycomb-group proteins with cell-cycle control and senescence.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	lohuizen@nki.nl	Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795; Marino, Silvia/0000-0002-9612-2883; DePinho, Ronald/0000-0002-5625-577X				Akasaka T, 1996, DEVELOPMENT, V122, P1513; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BLYTH K, 1995, ONCOGENE, V10, P1717; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; PARO R, 1995, TRENDS GENET, V11, P295, DOI 10.1016/S0168-9525(00)89081-2; PIROTTA V, 1997, CURR OPIN GENET DEV, V7, P249; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; van Lohuizen M, 1998, CELL MOL LIFE SCI, V54, P71, DOI 10.1007/s000180050126; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VANLOHUIZEN M, 1991, CELL, V65, P735; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	30	1289	1365	2	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 14	1999	397	6715					164	168		10.1038/16476	http://dx.doi.org/10.1038/16476			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923679				2022-12-01	WOS:000078085000047
J	Hawton, K; Simkin, S; Deeks, J; O'Connor, S; Keen, A; Altman, DG; Philo, G; Bulstrode, C				Hawton, K; Simkin, S; Deeks, J; O'Connor, S; Keen, A; Altman, DG; Philo, G; Bulstrode, C			Effects of a drug overdose in a television drama on presentations to hospital for self poisoning: time series and questionnaire study	BRITISH MEDICAL JOURNAL			English	Article							NEWS STORIES; SUICIDE; IMITATION; PARACETAMOL; FILMS	Objectives To determine whether a serious paracetamol overdose in the medical television drama Casualty altered the incidence and nature of general hospital presentations for deliberate self poisoning. Design Interrupted time series analysis of presentations for self poisoning at accident and emergency departments during three week periods before and after the broadcast. Questionnaire responses collected from self poisoning patients during the same periods. Setting 49 accident and emergency departments and psychiatric services in United Kingdom collected incidence data; 25 services collected questionnaire data Subjects 4403 self poisoning patients; questionnaires completed for 1047. Main outcome measures Change in presentation rates for self poisoning in the three weeks after the broadcast compared with the three weeks before, use of paracetamol and other drugs for self poisoning, and the nature of overdoses in viewers of the broadcast compared with non-viewers. Results Presentations for self poisoning increased by 17% (95% confidence interval 7% to 28%) in the week after the broadcast and by 9% (0 to 19%) in the second week. Increases in paracetamol overdoses were more marked than increases in non-paracetamol overdoses. Thirty two patients who presented in the week after the broadcast and were interviewed had seen the episode-20% said that it had influenced their decision to take an overdose, and 17% said it had influenced their choice of drug. The use of paracetamol for overdose doubled among viewers of Casualty after the episode (rise of 106%; 28% to 232%). Conclusions Broadcast of popular television dramas depicting self poisoning may have a short term influence in terms of increases in hospital presentation for overdose and changes in the choice Of drug taken. This raises serious questions about the advisability of the media portraying suicidal behaviour.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Imperial Canc Res Fund, NHS Ctr Stat Med, Inst Hlth Sci, Oxford OX3 7LF, England; Barrow Hosp, Directorate Mental Hlth, United Bristol Healthcare Trust, Bristol BS19 3SG, Avon, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Orthopaed Surg, Oxford OX3 9DU, England; Univ Glasgow, Media Unit, Glasgow G12 8LF, Lanark, Scotland	University of Oxford; University of Oxford; University of Oxford; University of Glasgow	Hawton, K (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.		Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971				BERMAN AL, 1988, AM J PSYCHIAT, V145, P982; BERO L, 1998, COCHRANE LIB; BOLLEN KA, 1982, AM SOCIOL REV, V47, P802, DOI 10.2307/2095217; *CMA MED DAT, 1996, DIR EM SPEC CAR UN 1; Dean AG, 1994, EPIINFO VERSION 6 WO; DIGGLE RJ, 1994, ANAL LOGITUDINAL DAT; GOULD MS, 1986, NEW ENGL J MED, V315, P690, DOI 10.1056/NEJM198609113151107; *GOV STAT SERV, 1998, REG TRENDS 33 1998 E; Gunnell D, 1997, J EPIDEMIOL COMMUN H, V51, P175, DOI 10.1136/jech.51.2.175; Gunnell D., 1994, BMJ-BRIT MED J, V308, P1446, DOI DOI 10.1136/BMJ.308.6941.1446; HAFNER H, 1989, SUICIDE YOUTH PERSPE, P117; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Hughes T., 1998, PSYCHIAT B, V22, P88; Kapur N, 1998, BRIT MED J, V316, P831, DOI 10.1136/bmj.316.7134.831; KESSLER RC, 1989, J NERV MENT DIS, V177, P551, DOI 10.1097/00005053-198909000-00006; O'Connor S, 1999, BRIT MED J, V318, P978, DOI 10.1136/bmj.318.7189.978; OSTROFF RB, 1985, AM J PSYCHIAT, V142, P989; PHILLIPS DP, 1974, AM SOCIOL REV, V39, P340, DOI 10.2307/2094294; PHILLIPS DP, 1986, NEW ENGL J MED, V315, P685, DOI 10.1056/NEJM198609113151106; PLATT S, 1987, BRIT MED J, V294, P954, DOI 10.1136/bmj.294.6577.954; PLATT S, 1994, PREVENTION SUICIDE, P125; SCHMIDTKE A, 1988, PSYCHOL MED, V18, P665, DOI 10.1017/S0033291700008345; Simkin S, 1995, BRIT J PSYCHIAT, V167, P754, DOI 10.1192/bjp.167.6.754; *STAT, 1997, STAT STAT SOFTW REL; WASSERMAN IM, 1984, AM SOCIOL REV, V49, P427, DOI 10.2307/2095285	25	111	114	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					972	977		10.1136/bmj.318.7189.972	http://dx.doi.org/10.1136/bmj.318.7189.972			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	186VU	10195966	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000079751500018
J	Minor, DL; Masseling, SJ; Jan, YN; Jan, LY				Minor, DL; Masseling, SJ; Jan, YN; Jan, LY			Transmembrane structure of an inwardly rectifying potassium channel	CELL			English	Article							RECTIFIER K+ CHANNEL; NEGATIVELY CHARGED RESIDUE; 2 PORE DOMAINS; MEMBRANE-PROTEINS; FUNCTIONAL EXPRESSION; SUBUNIT STOICHIOMETRY; LACTOSE PERMEASE; ESCHERICHIA-COLI; HELIX PACKING; FAMILY	Inwardly rectifying potassium channels (K-ir), comprising four subunits each with two transmembrane domains, M1 and M2, regulate many important physiological processes. We employed a yeast genetic screen to identify functional channels from libraries of K-ir 2.1 containing mutagenized M1 or M2 domains. Patterns in the allowed sequences indicate that M1 and M2 are helices. Protein-lipid and protein-water interaction surfaces identified by the patterns were verified by sequence minimization experiments. Second-site suppressor analyses of helix packing indicate that the M2 pore-lining inner helices are surrounded by the M1 lipid-facing outer helices, arranged such that the M1 helices participate in subunit-subunit interactions. This arrangement is distinctly different from the structure of a bacterial potassium channel with the same topology and identifies helix-packing residues as hallmark sequences common to all K-ir superfamily members.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Jan, LY (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA.	gkw@itsa.ucsf.edu						Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; DONNELLY D, 1993, PROTEIN SCI, V2, P55; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Imredy JP, 1998, BIOCHEMISTRY-US, V37, P14867, DOI 10.1021/bi980929k; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jin WL, 1998, BIOCHEMISTRY-US, V37, P13291, DOI 10.1021/bi981178p; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; KERJAN P, 1986, NUCLEIC ACIDS RES, V14, P7861, DOI 10.1093/nar/14.20.7861; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Krapivinsky G, 1998, NEURON, V20, P995, DOI 10.1016/S0896-6273(00)80480-8; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; Lemmon MA., 1992, CURR OPIN STRUC BIOL, V2, P511; Lesage F, 1996, J BIOL CHEM, V271, P4183; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; Lu Z, 1997, BIOCHEMISTRY-US, V36, P6936, DOI 10.1021/bi9702849; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Raab-Graham KF, 1998, J BIOL CHEM, V273, P19699, DOI 10.1074/jbc.273.31.19699; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; Reuveny E, 1996, BIOPHYS J, V70, P754, DOI 10.1016/S0006-3495(96)79615-7; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Smith BC, 1996, REAL-TIME IMAGING, V2, P3, DOI 10.1006/rtim.1996.0002; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; TANG WM, 1995, MOL BIOL CELL, V6, P1231, DOI 10.1091/mbc.6.9.1231; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; Wallin E, 1997, PROTEIN SCI, V6, P808; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Wen JA, 1996, NAT STRUCT BIOL, V3, P141, DOI 10.1038/nsb0296-141; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7; ZERANGUE N, 1999, IN PRESS NEURON; Zhou YF, 1997, NAT STRUCT BIOL, V4, P986, DOI 10.1038/nsb1297-986; [No title captured]	70	131	134	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	1999	96	6					879	891		10.1016/S0092-8674(00)80597-8	http://dx.doi.org/10.1016/S0092-8674(00)80597-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102275	Bronze			2022-12-01	WOS:000079300100014
J	Stein, K; Allen, N				Stein, K; Allen, N			Cross sectional survey of cervical cancer screening in women with learning disability	BRITISH MEDICAL JOURNAL			English	Article									Southampton & SW Hants Hlth Author, Southampton SO16 4GX, Hants, England		Stein, K (corresponding author), Univ Southampton, Inst Hlth Res & Dev, Boldrewood, Southampton SO15 2GS, Hants, England.							ALLEN N, 1994, ANN REPORT DIRECTOR; BEAIL N, 1995, J INTELL DISABIL RES, V39, P382, DOI 10.1111/j.1365-2788.1995.tb00542.x; HAIRE AR, 1992, BR J FAM PLAN, V17, P120; Reid D, 1995, BR J LEARN DISABIL, V23, P56; *ROYAL COLL GEN PR, 1990, 47 RCGP	5	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					641	641		10.1136/bmj.318.7184.641	http://dx.doi.org/10.1136/bmj.318.7184.641			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066206	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000079089200029
J	Nightingale, SL				Nightingale, SL			Celecoxib for arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					786	786		10.1001/jama.281.9.786	http://dx.doi.org/10.1001/jama.281.9.786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10070983				2022-12-01	WOS:000078804300006
J	Dries, DL; Exner, DV; Gersh, BJ; Cooper, HA; Carson, PE; Domanski, MJ				Dries, DL; Exner, DV; Gersh, BJ; Cooper, HA; Carson, PE; Domanski, MJ			Racial differences in the outcome of left ventricular dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-FAILURE; CARVEDILOL	Background Population-based studies have found that black patients with congestive heart failure have a higher mortality rate than white patients with the same condition. This finding has been attributed to differences in the severity, causes, and management of heart failure, the prevalence of coexisting conditions, and socioeconomic factors. Although these factors probably account for some of the higher mortality due to congestive heart failure among blacks, we hypothesized that racial differences in the natural history of left ventricular dysfunction might also have a role. Methods Using data from the Studies of Left Ventricular Dysfunction (SOLVD) prevention and treatment trials, in which all patients received standardized therapy and follow-up, we conducted a retrospective analysis of the outcomes of asymptomatic and symptomatic left ventricular systolic dysfunction among black and white participants. The mean (+/-SD) follow-up was 34.2+/-14.0 months in the prevention trial and 32.3+/-14.8 months in the treatment trial among the black and white participants. Results The overall mortality rates in the prevention trial were 8.1 per 100 person-years for blacks and 5.1 per 100 person years for whites. In the treatment trial, the rates were 16.7 per 100 person-years and 13.4 per 100 person-years, respectively. After adjustment for age, coexisting conditions, severity and causes of heart failure, and use of medications, blacks had a higher risk of death from all causes in both the SOLVD prevention trial (relative risk, 1.36; 95 percent confidence interval, 1.06 to 1.74; P=0.02) and the treatment trial (relative risk, 1.25; 95 percent confidence interval, 1.04 to 1.50; P=0.02). In both trials blacks were also at higher risk for death due to pump failure and for the combined end point of death from any cause or hospitalization for heart failure, our two predefined indicators of the progression of left ventricular systolic dysfunction. Conclusions Blacks with mild-to-moderate left ventricular systolic dysfunction appear to be at higher risk for progression of heart failure and death from any cause than similarly treated whites. These results suggest that there may be racial differences in the outcome of asymptomatic and symptomatic left ventricular systolic dysfunction. (N Engl J Med 1999;340:609-16.) (C)1999, Massachusetts Medical Society.	NHLBI, Clin Trials Sci Res Grp, Div Epidemiol & Clin Applicat, Rockledge Ctr 2, Bethesda, MD 20892 USA; Georgetown Univ Hosp, Div Cardiol, Washington, DC 20007 USA; Dept Vet Affairs, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University	Dries, DL (corresponding author), NHLBI, Clin Trials Sci Res Grp, Div Epidemiol & Clin Applicat, Rockledge Ctr 2, 6701 Rockledge Dr,Rm 8149, Bethesda, MD 20892 USA.	ddries@aol.com	E, D/AAH-1638-2020		NHLBI NIH HHS [TA-HL-1002] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AHCPR, 1994, AHCPR PUBL; ALEXANDER M, 1995, JAMA-J AM MED ASSOC, V274, P1037, DOI 10.1001/jama.274.13.1037; Benedict CR, 1996, CIRCULATION, V94, P690, DOI 10.1161/01.CIR.94.4.690; Chatterjee K, 1996, CIRCULATION, V94, P2689, DOI 10.1161/01.CIR.94.11.2689; Colucci WS, 1996, CIRCULATION, V94, P2800, DOI 10.1161/01.CIR.94.11.2800; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; MATERSON BJ, 1994, NEW ENGL J MED, V330, P1689, DOI 10.1056/NEJM199406093302316; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2344; Packer M, 1996, CIRCULATION, V94, P2793, DOI 10.1161/01.CIR.94.11.2793; PAPPAS G, 1993, NEW ENGL J MED, V329, P1139; Philbin EF, 1998, AM J CARDIOL, V82, P76, DOI 10.1016/S0002-9149(98)00233-1; SOLVD Investigators, 1990, AM J CARDIOL, V66, P1026; WEIR MR, 1995, HYPERTENSION, V26, P124, DOI 10.1161/01.HYP.26.1.124; WILLIAMS DR, 1990, SOC PSYCHOL QUART, V53, P81, DOI 10.2307/2786672; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1990, AM J CARDIOL, V66, P315; 1994, MMWR MORB MORTAL WKL, V43, P77	20	266	270	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					609	616		10.1056/NEJM199902253400804	http://dx.doi.org/10.1056/NEJM199902253400804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169NP	10029645				2022-12-01	WOS:000078755700004
J	Jazwinska, A; Kirov, N; Wieschaus, E; Roth, S; Rushlow, C				Jazwinska, A; Kirov, N; Wieschaus, E; Roth, S; Rushlow, C			The Drosophila gene brinker reveals a novel mechanism of Dpp target gene regulation	CELL			English	Article							DORSAL-VENTRAL PATTERN; ORGANIZING ACTIVITY; MORPHOGEN GRADIENT; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; WING DEVELOPMENT; PROTEIN; EMBRYO; RECEPTOR; HEDGEHOG	decapentaplegic (dpp), a Drosophila member of the TGF beta family of secreted molecules, functions as a long-range morphogen in patterning of the embryo and the adult appendages. Dpp signals via the SMAD proteins Mad and Medea. Here we show that in the absence of brinker (brk), Mad is not required for the activation of Dpp target genes that depend on low levels of Dpp. brk encodes a novel protein with features of a transcriptional repressor. brk itself is negatively regulated by Dpp. Dpp signaling might relieve brk's repression of low-level target genes either by transcriptional repression of brk or by antagonizing a repressor function of brk at the target gene promoters.	Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany; NYU, Dept Biol, New York, NY 10003 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Max Planck Society; New York University; Princeton University	Roth, S (corresponding author), Max Planck Inst Entwicklungsbiol, Spemannstr 35-2, D-72076 Tubingen, Germany.	roth@bio.tuebingen.mpg.de; rushlow@is.nyu.edu	Jazwinska, Anna/M-8705-2016; Roth, Siegfried/E-8241-2010	Jazwinska, Anna/0000-0003-3881-9284; Roth, Siegfried/0000-0001-5772-3558				ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Burke R, 1996, DEVELOPMENT, V122, P2261; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Das P, 1998, DEVELOPMENT, V125, P1519; De Celis JF, 1998, INT J DEV BIOL, V42, P335; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dosch R, 1997, DEVELOPMENT, V124, P2325; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Hudson JB, 1998, DEVELOPMENT, V125, P1407; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Lecuit T, 1998, DEVELOPMENT, V125, P4901; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; RAFTERY LA, 1995, GENETICS, V139, P241; ROBERTS DB, 1998, DROSOPHILA, V191; Rushlow C., 1996, ADV DEV BIO, V4, P27, DOI 10.1016/s1566-3116(08)60016-x; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Singer MA, 1997, DEVELOPMENT, V124, P79; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TERRACOL R, 1994, GENETICS, V138, P165; TOWER J, 1993, GENETICS, V133, P347; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; WHARTON KA, 1993, DEVELOPMENT, V117, P807; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; XU T, 1993, DEVELOPMENT, V117, P1223; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265	62	225	232	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					563	573		10.1016/S0092-8674(00)80660-1	http://dx.doi.org/10.1016/S0092-8674(00)80660-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052458	Bronze			2022-12-01	WOS:000078718600007
J	Simmen, MW; Leitgeb, S; Charlton, J; Jones, SJM; Harris, BR; Clark, VH; Bird, A				Simmen, MW; Leitgeb, S; Charlton, J; Jones, SJM; Harris, BR; Clark, VH; Bird, A			Nonmethylated transposable elements and methylated genes in a chordate genome	SCIENCE			English	Article							TRANSCRIPTIONAL INTERFERENCE; GLOBIN GENE; DNA METHYLATION; PROMOTER; UPSTREAM; REPEATS; CPG; INACTIVATION; RNA	The genome of the invertebrate chordate Ciona intestinalis was found to be a stable mosaic of methylated and nonmethylated domains. Multiple copies of an apparently active long terminal repeat retrotransposon and a long interspersed element are nonmethylated and a Large fraction of abundant short interspersed elements are also methylation free. Genes, by contrast, are predominantly methylated. These data are incompatible with the genome defense model which proposes that DNA methylation in animals is primarily targeted to endogenous transposable elements. Cytosine methylation in this urochordate may be preferentially directed to genes.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Sanger Ctr, Cambridge CB10 1SA, England	University of Edinburgh; Wellcome Trust Sanger Institute	Simmen, MW (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.		Jones, Steven J/C-3621-2009	Jones, Steven J/0000-0003-3394-2208; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; ALLAN M, 1983, CELL, V35, P187; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], UNPUB; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bird A, 1997, TRENDS GENET, V13, P469, DOI 10.1016/S0168-9525(97)01310-3; BIRD AP, 1979, CELL, V17, P889, DOI 10.1016/0092-8674(79)90329-5; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Boeke J. D., 1997, P343; BRODERS F, 1990, P NATL ACAD SCI USA, V87, P503, DOI 10.1073/pnas.87.2.503; CALABI F, 1985, EMBO J, V4, P667, DOI 10.1002/j.1460-2075.1985.tb03681.x; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; ELLEDGE SJ, 1989, GENE DEV, V3, P185, DOI 10.1101/gad.3.2.185; FREEDMAN T, 1993, GENETICS, V135, P357; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Goyon C, 1996, NUCLEIC ACIDS RES, V24, P3348, DOI 10.1093/nar/24.17.3348; Greger IH, 1998, NUCLEIC ACIDS RES, V26, P1294, DOI 10.1093/nar/26.5.1294; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KRICKER MC, 1992, P NATL ACAD SCI USA, V89, P1075, DOI 10.1073/pnas.89.3.1075; LEY TJ, 1983, BIOCHEM BIOPH RES CO, V112, P1041, DOI 10.1016/0006-291X(83)91723-0; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; Regev A, 1998, MOL BIOL EVOL, V15, P880, DOI 10.1093/oxfordjournals.molbev.a025992; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; Selker EU, 1997, TRENDS GENET, V13, P296, DOI 10.1016/S0168-9525(97)01201-8; Simmen MW, 1998, P NATL ACAD SCI USA, V95, P4437, DOI 10.1073/pnas.95.8.4437; SONNHAMMER ELL, 1994, COMPUT APPL BIOSCI, V10, P301; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tweedie S, 1997, MOL CELL BIOL, V17, P1469, DOI 10.1128/MCB.17.3.1469; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WHITTAKER PA, 1981, NUCLEIC ACIDS RES, V9, P801, DOI 10.1093/nar/9.4.801; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	35	110	114	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1164	1167		10.1126/science.283.5405.1164	http://dx.doi.org/10.1126/science.283.5405.1164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024242				2022-12-01	WOS:000078738400051
J	Chakravarti, D; Ogryzko, V; Kao, HY; Nash, A; Chen, HW; Nakatani, Y; Evans, RM				Chakravarti, D; Ogryzko, V; Kao, HY; Nash, A; Chen, HW; Nakatani, Y; Evans, RM			A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity	CELL			English	Article							STEROID-RECEPTOR COACTIVATOR-1; HISTONE ACETYLTRANSFERASE; TRANSCRIPTIONAL ADAPTER; RNA-POLYMERASE; CELL-CYCLE; ACTIVATION; ACETYLATION; BINDING; CBP; PROTEINS	Nucleosomal histone modification is believed to be a critical step in the activation of RNA polymerase II-dependent transcription. p300/CBP and PCAF histone acetyltransferases (HATs) are coactivators for several transcription factors, including nuclear hormone receptors, p53, and Stat1 alpha, and participate in transcription by forming an activation complex and by promoting histone acetylation. The adenoviral E1A oncoprotein represses transcriptional signaling by binding to p300/CBP and displacing PCAF and p/CIP proteins from the complex. Here, we show that E1A directly represses the HAT activity of both p300/CBP and PCAF in vitro and p300-dependent transcription in vivo. Additionally, E1A inhibits nucleosomal histone modifications by the PCAF complex and blocks p53 acetylation. These results demonstrate the modulation of HAT activity as a novel mechanism of transcriptional regulation.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; Salk Institute	Chakravarti, D (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Ogryzko, Vasily/M-6665-2015; Evans, Ronald/AAF-4001-2019	Ogryzko, Vasily/0000-0002-8548-1389; Evans, Ronald/0000-0002-9986-5965; Chakravarti, Debabrata/0000-0001-8446-8599				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STURHL K, 1998, GENE DEV, V12, P599; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	44	297	306	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					393	403		10.1016/S0092-8674(00)80552-8	http://dx.doi.org/10.1016/S0092-8674(00)80552-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025405	Bronze			2022-12-01	WOS:000078514600012
J	Schmitz, JE; Kuroda, MJ; Santra, S; Sasseville, VG; Simon, MA; Lifton, MA; Racz, P; Tenner-Racz, K; Dalesandro, M; Scallon, BJ; Ghrayeb, J; Forman, MA; Montefiori, DC; Rieber, EP; Letvin, NL; Reimann, KA				Schmitz, JE; Kuroda, MJ; Santra, S; Sasseville, VG; Simon, MA; Lifton, MA; Racz, P; Tenner-Racz, K; Dalesandro, M; Scallon, BJ; Ghrayeb, J; Forman, MA; Montefiori, DC; Rieber, EP; Letvin, NL; Reimann, KA			Control of viremia in simian immunodeficiency virus infection by CD8(+) lymphocytes	SCIENCE			English	Article							CELL DEPLETION; DISEASE	Clinical evidence suggests that cellular immunity is involved in controlling human immunodeficiency virus-1 (HIV-1) replication. An animal model of acquired immune deficiency syndrome (AIDS), the simian immunodeficiency virus (SIV)-infected rhesus monkey, was used to show that virus replication is not controlled in monkeys depleted of CD8(+) Lymphocytes during primary SIV infection. Eliminating CD8(+) lymphocytes from monkeys during chronic SIV infection resulted in a rapid and marked increase in viremia that was again suppressed coincident with the reappearance of SIV-specific CD8(+) T cells. These results confirm the importance of cell-mediated immunity in controlling HIV-1 infection and support the exploration of vaccination approaches for preventing infection that will elicit these immune responses.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Viral Pathogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Centocor Inc, Malvern, PA 19355 USA; Beckman Coulter, Miami, FL 33196 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; Tech Univ Dresden, Inst Immunol, D-01101 Dresden, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Bernhard Nocht Institut fur Tropenmedizin; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Beckman Coulter Inc.; Duke University; Technische Universitat Dresden	Schmitz, JE (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Viral Pathogenesis, Boston, MA 02215 USA.		Schmitz, Joern/A-4929-2018	Schmitz, Joern/0000-0001-8803-0922	NCRR NIH HHS [RR-13150, P51 RR000168, RR-00168] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013150, P51RR000168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CASTRO BA, 1992, CLIN IMMUNOL IMMUNOP, V65, P227, DOI 10.1016/0090-1229(92)90151-D; CHAKRABARTI L, 1994, J VIROL, V68, P6634, DOI 10.1128/JVI.68.10.6634-6643.1994; *COMM AN HARV MED, 1996, GUID CAR US LAB AN; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KURODA M, UNPUB; Kuroda MJ, 1998, J EXP MED, V187, P1373, DOI 10.1084/jem.187.9.1373; Langlois AJ, 1998, J VIROL, V72, P6950, DOI 10.1128/JVI.72.8.6950-6955.1998; LETVIN NL, 1994, CURRENT TOPICS MICRO, V188; Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; SCHMITZ J, UNPUB; Seth A, 1998, P NATL ACAD SCI USA, V95, P10112, DOI 10.1073/pnas.95.17.10112; Tenner-Racz K, 1998, J EXP MED, V187, P949, DOI 10.1084/jem.187.6.949; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484	16	1852	1910	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					857	860		10.1126/science.283.5403.857	http://dx.doi.org/10.1126/science.283.5403.857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933172				2022-12-01	WOS:000078496800049
J	Falvo, MR; Taylor, RM; Helser, A; Chi, V; Brooks, FP; Washburn, S; Superfine, R				Falvo, MR; Taylor, RM; Helser, A; Chi, V; Brooks, FP; Washburn, S; Superfine, R			Nanometre-scale rolling and sliding of carbon nanotubes	NATURE			English	Article							ATOMIC-SCALE; FRICTION; NANOTRIBOLOGY; MICROSCOPE; ANISOTROPY; MOTION; C-60	Understanding the relative motion of objects in contact is essential for controlling macroscopic lubrication and adhesion, for comprehending biological macromolecular interfaces, and for developing submicrometre-scale electromechanical devices(1,2) An object undergoing lateral motion while in contact with a second object can either roll or slide. The resulting energy loss and mechanical wear depend largely on which mode of motion occurs. At the macroscopic scale, rolling(3) is preferred over sliding, and it is expected to have an equally important role in the microscopic domain. Although progress has been made in our understanding of the dynamics of sliding at the atomic level(4), we have no comparable insight into rolling owing to a lack of experimental data on microscopic length scales. Here we produce controlled rolling of carbon nanotubes on graphite surfaces using an atomic force microscope. We measure the accompanying energy loss and compare this with sliding. Moreover, by reproducibly rolling a nanotube to expose different faces to the substrate and to an external probe, we are able to study the object over its complete surface.	Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, N Carolina Ctr Nanoscale Mat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Superfine, R (corresponding author), Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA.		Superfine, Richard/A-1968-2012	Superfine, Richard/0000-0002-2569-071X				Baur C, 1997, J VAC SCI TECHNOL B, V15, P1577, DOI 10.1116/1.589404; BHUSHAN B, 1995, NATURE, V374, P607, DOI 10.1038/374607a0; BHUSHAN B, 1993, APPL PHYS LETT, V62, P3253, DOI 10.1063/1.109090; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Chaudhury MK, 1996, J APPL PHYS, V80, P30, DOI 10.1063/1.362819; EBBESEN TW, 1995, CARBON, V33, P973, DOI 10.1016/0008-6223(95)00025-9; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; Falvo MR, 1997, NATURE, V389, P582, DOI 10.1038/39282; FINCH M, 1995, ACM S INT 3D GRAPH; Hertel T, 1998, J PHYS CHEM B, V102, P910, DOI 10.1021/jp9734686; HIRANO M, 1991, PHYS REV LETT, V67, P2642, DOI 10.1103/PhysRevLett.67.2642; ISRAELACHVILI J, 1991, INTERMOLECULAR SURFA; Johnson KL, 1994, CONTACT MECH; JOHNSON KL, 1997, MICRONANOTRIBOLOGY I, P157; KENDALL K, 1975, WEAR, V33, P351, DOI 10.1016/0043-1648(75)90288-4; LUTHI R, 1994, SCIENCE, V266, P1979, DOI 10.1126/science.266.5193.1979; Mason M., 1985, ROBOT HANDS MECH MAN; MATE CM, 1987, PHYS REV LETT, V59, P1942, DOI 10.1103/PhysRevLett.59.1942; OVERNEY RM, 1994, PHYS REV LETT, V72, P3546, DOI 10.1103/PhysRevLett.72.3546; Persson B. N. J., 1998, SLIDING FRICTION PHY; PRESCOTT J, 1936, MECH PARTICLES RIGID; Rapoport L, 1997, NATURE, V387, P791, DOI 10.1038/42910; Schwarz UD, 1997, PHYS REV B, V56, P6987, DOI 10.1103/PhysRevB.56.6987; Sheehan PE, 1996, SCIENCE, V272, P1158, DOI 10.1126/science.272.5265.1158; TAYLOR RM, 1993, SIGGRAPH 93	25	406	427	2	141	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					236	238		10.1038/16662	http://dx.doi.org/10.1038/16662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930698				2022-12-01	WOS:000078184800046
J	Whittle, HC; Aaby, P; Samb, B; Jensen, H; Bennett, J; Simondon, F				Whittle, HC; Aaby, P; Samb, B; Jensen, H; Bennett, J; Simondon, F			Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa	LANCET			English	Article							RURAL SENEGAL; MORTALITY; EFFICACY; IMMUNIZATION; COVERAGE; EXPOSURE; DURATION; ANTIBODY; GAMBIA; RATES	Background Despite a high coverage with measles vaccines in parts of west Africa, epidemics of measles occur with reduced severity in an increasing proportion of older children who have been vaccinated. We examined the effect of exposure to natural measles on immunity in vaccinated children. Methods Our study was carried out in 1992 during an epidemic of measles in Niakhar, a rural area of Senegal with about 27 000 inhabitants who mostly live in compounds that include several households; within each household people live in different huts. Vaccine coverage in Niakhar was 81% at the time of our study. We measured haemagglutinin-inhibiting antibody at exposure and twice thereafter (after 4-5 weeks and at 6 months) in 36 vaccinated and 87 unvaccinated children. The frequency of measles and subclinical measles-defined as a four-fold or greater rise in antibody titre without clinical signs or symptoms-was related to intensity of exposure according to whether the index case was in the same hut, household, or compound. Findings Clinical measles occurred in 20 (56%) of 36 unvaccinated children and in one (1%) of 87 vaccinated children. Subclinical measles occurred in 39 (45%) of 86 vaccinated children who were exposed to measles and in four (25%) of 16 unvaccinated children. The frequency was inversely related to pre-exposure antibody concentration (p<0.001 for trend) and directly related to intensity of exposure (p=0.002 for trend), Antibody concentrations in subclinical cases increased on average by 45-fold and remained raised for at least 6 months. Interpretation Increased antibody titre after subclinical measles may be common in vaccinated children in West Africa where the intensity of exposure is high. As measles vaccination coverage increases, the circulation of wild measles will decrease, and vaccine-induced antibody is less likely to be boosted. Thus, new epidemics, albeit milder in form, may occur in vaccinated areas which should be recognised in campaigns to eradicate measles.	MRC Labs, Banjul, Gambia; ORSTOM, Dakar, Senegal; Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol, DK-2300 Copenhagen, Denmark; INSERM, U13, Paris, France; Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA	MRC Laboratory Molecular Biology; Institut de Recherche pour le Developpement (IRD); Aarhus University; Statens Serum Institut; Institut National de la Sante et de la Recherche Medicale (Inserm); Emory University; Rollins School Public Health	Whittle, HC (corresponding author), MRC Labs, POB 273, Banjul, Gambia.			Aaby, Peter/0000-0001-8331-1389; Simondon, Francois/0000-0003-0395-1314				AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1984, AM J EPIDEMIOL, V120, P49, DOI 10.1093/oxfordjournals.aje.a113874; Anders JF, 1996, PEDIATR INFECT DIS J, V15, P62, DOI 10.1097/00006454-199601000-00014; BENNETT J, IN PRESS INT J EPIDE; BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415; CHABNAZARIAN A, 1992, POPULATION SANTE NIA; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; CISSE B, IN PRESS AM J EPIDEM; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; FORSTER SO, 1971, AFR J MED SCI, V2, P151; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; KRUGMAN S, 1983, REV INFECT DIS, V5, P477; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; McMurray D N, 1979, Bull Pan Am Health Organ, V13, P52; MULHOLLAND K, 1995, LANCET, V345, P305, DOI 10.1016/S0140-6736(95)90282-1; NORRBY E, 1995, CURR TOP MICROBIOL, V191, P167; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Outlaw MC, 1997, VIRUS RES, V48, P125, DOI 10.1016/S0168-1702(96)01434-7; Panum, 1940, OBSERVATIONS MADE EP; RIMA BK, 1995, J GEN VIROL, V76, P1173, DOI 10.1099/0022-1317-76-5-1173; SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007; SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6; Samb B, 1997, AM J EPIDEMIOL, V145, P51, DOI 10.1093/oxfordjournals.aje.a009031; STETLER HC, 1986, PEDIATRICS, V77, P471; WHITTLE H, 1988, LANCET, V2, P811; WHITTLE HC, 1998, LANCET, V351, P866; WHITTLE HC, IN PRESS PEDIAT INFE	30	101	105	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					98	102		10.1016/S0140-6736(98)02364-2	http://dx.doi.org/10.1016/S0140-6736(98)02364-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023894				2022-12-01	WOS:000078087200010
J	Steiner, JF				Steiner, JF			Talking about treatment: The language of populations and the language of individuals	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RANDOMIZED CLINICAL-TRIALS; PHYSICIANS; RISK; PRESCRIBE; DECISIONS; DISEASE; GUIDE; CARE		Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Steiner, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Box B-180,4200 E 9th Ave, Denver, CO 80262 USA.							[Anonymous], 1991, JAMA, V265, P3255; Atkins CD, 1997, J GEN INTERN MED, V12, P500, DOI 10.1046/j.1525-1497.1997.00089.x; BERWICK DM, 1981, AM J MED, V71, P991, DOI 10.1016/0002-9343(81)90325-9; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; BROWNER WS, 1987, JAMA-J AM MED ASSOC, V257, P2459, DOI 10.1001/jama.257.18.2459; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; CASSELL EJ, 1997, DOCTORING NATURE PRI; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Detsky A S, 1995, ACP J Club, V122, pA12; ELSON RB, 1995, PRIMARY CARE, V22, P365; FEINSTEIN AR, 1992, AM J MED, V92, P117, DOI 10.1016/0002-9343(92)90099-W; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GLOSSARY ACP, 1997, J CLUB, V126, P28; GREENLICK MR, 1992, JAMA-J AM MED ASSOC, V267, P1645, DOI 10.1001/jama.267.12.1645; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; KALET A, 1994, J GEN INTERN MED, V9, P402, DOI 10.1007/BF02629523; Katz Jay, 1984, SILENT WORLD DOCTOR; LARSON EB, 1993, JAMA-J AM MED ASSOC, V270, P2708, DOI 10.1001/jama.270.22.2708; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Logan RL, 1996, LANCET, V347, P595, DOI 10.1016/S0140-6736(96)91284-2; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; REISER SJ, 1980, ANN INTERN MED, V92, P837, DOI 10.7326/0003-4819-92-6-837; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SACKETT DL, 1991, ACP J CLUB, V114, pA12; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	35	28	31	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	1999	130	7					618	622		10.7326/0003-4819-130-7-199904060-00029	http://dx.doi.org/10.7326/0003-4819-130-7-199904060-00029			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183BG	10189345				2022-12-01	WOS:000079533300027
J	Quinn, M; Babb, P; Jones, J; Allen, E				Quinn, M; Babb, P; Jones, J; Allen, E			Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics	BRITISH MEDICAL JOURNAL			English	Article							WALES; WOMEN	Objective To assess die impact of screening on the incidence of and mortality from cervical cancer. Design Comparison of age specific incidence and mortality before and after the introduction of the national call and recall system in 1988 Setting England. Subjects Women aged over 19 years. Results From the mid-1960s, the number of smears taken rose continuously to 4.5 million at the end of the 1980s. Between 1988 and 1994, coverage of the larger group doubled to around 85%, Registrations of in situ disease increased broadly in parallel with the numbers of smears taken. The overall incidence of invasive disease remained stable up to the end of the 1980s, although there were strong cohort effects; from 1990 incidence fell continuously and in 1995 was 35% lower than in the 1980s. The fall in overall mortality since 1950 accelerated at the end of the 1980s; there were strong cohort effects. Mortality in women under 55 was much lower in the 1990s than would have been expected. Conclusions The national call and recall system and incentive payments to general practitioners increased coverage to around 85%. This resulted in falls in incidence of in invasive disease in all regions of England and in all age groups from 30 to 74. The falls in mortality in older women were largely unrelated to screening, but without screening there might have been 800 more deaths from cervical cancer in women under 55 in 1997.	Natl Canc Registrat Bur, Off Natl Stat, Demog & Hlth Div, London SW1V 2QQ, England		Quinn, M (corresponding author), Natl Canc Registrat Bur, Off Natl Stat, Demog & Hlth Div, London SW1V 2QQ, England.		Allen, Liz/AAK-3137-2020; Allen, Liz/B-2625-2012	Allen, Liz/0000-0002-9298-3168; Allen, Liz/0000-0002-9298-3168				AUSTOKER J, 1994, BRIT MED J, V309, P241, DOI 10.1136/bmj.309.6949.241; CHAMBERLAIN J, 1988, ONCOLOGY NURSES HLTH, V1, P155; COLEMAN MP, 1993, IARC SCI PUBLICATION, V121; COOK GA, 1984, BRIT J CANCER, V50, P367, DOI 10.1038/bjc.1984.185; DAY NE, 1989, J EPIDEMIOL COMMUN H, V43, P103, DOI 10.1136/jech.43.2.103; *DEP HLTH, 1989, GEN PRACT NHS NEW CO; *DEP HLTH, 1996, STAT B, V3; *DEP HLTH, 1989, CERV CYT 1988 89 199; *DEP HLTH, 1996, STAT B, V26; *DEP HLTH, 1997, STAT B, V27; *DEP HLTH SOC SEC, 1988, HLTH SERV MAN CERV C; *DEP HLTH SOC SEC, 1981, CERV CYT 1980 1987 8; Esteve J., 1994, IARC SCI PUBLICATION, V128; FARMERY E, 1994, REPORT FIRST 5 YEARS; Herbert A, 1996, J Med Screen, V3, P23; HUGGETT C, 1995, REV QUALITY COMPARAB; JOHNSON J, 1997, BRIT MED J, V314, P1630; LANCASTER G, 1992, J PUBLIC HEALTH MED, V16, P50; MILLER AB, 1990, INT J CANCER, V46, P761, DOI 10.1002/ijc.2910460502; MOSS S, 1996, EVALUATION CNC SCREE, P15; MURPHY MFG, 1987, J EPIDEMIOL COMM HLT, V42, P49; *NAT AUD OFF, 1998, PERF NHS CERV SCREEN; *OFF POP CENS SURV, 1979, CANC STAT REG EN MB1; OSMOND C, 1982, BRIT MED J, V284, P1005, DOI 10.1136/bmj.284.6321.1005; PARKIN DM, 1985, BRIT J OBSTET GYNAEC, V92, P150, DOI 10.1111/j.1471-0528.1985.tb01067.x; QUINN M, 1995, BRIT MED J, V311, P1391, DOI 10.1136/bmj.311.7017.1391; Raffle AE, 1997, BRIT MED J, V315, P953; RAFFLE AE, 1995, LANCET, V345, P1469, DOI 10.1016/S0140-6736(95)91036-0; ROBERTS A., 1982, Health Trends, V14, P41; SASIENI P, 1995, LANCET, V346, P1566, DOI 10.1016/S0140-6736(95)92099-4; Sasieni PD, 1996, BRIT J CANCER, V73, P1001, DOI 10.1038/bjc.1996.196; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; Wilson J., 1968, 34 WHO	33	365	383	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1999	318	7188					904	+		10.1136/bmj.318.7188.904	http://dx.doi.org/10.1136/bmj.318.7188.904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185GV	10102852	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000079660500024
J	Caterina, MJ; Rosen, TA; Tominaga, M; Brake, AJ; Julius, D				Caterina, MJ; Rosen, TA; Tominaga, M; Brake, AJ; Julius, D			A capsaicin-receptor homologue with a high threshold for noxious heat	NATURE			English	Article							SENSORY NEURONS; CHANNELS; TRANSDUCTION; ACTIVATION; PROTEIN; CALCIUM; INVITRO; TRP	Pain-producing heat is detected by several classes of nociceptive sensory neuron that differ in their thermal response thresholds(1-3). The cloned capsaicin receptor, also known as the vanilloid receptor subtype 1 (VR1), is a heat-gated ion channel that has been proposed to mediate responses of small-diameter sensory neurons to moderate (43 degrees C) thermal stimuli(4,5). VR1 is also activated by protons, indicating that it may participate in the detection of noxious thermal and chemical stimuli in vivo. Here we identify a structurally related receptor, VRL-1, that does not respond to capsaicin, acid or moderate heat. Instead, VRL-1 is activated by high temperatures, with a threshold of similar to 52 degrees C. Within sensory ganglia, VRL-1 is most prominently expressed by a subset of medium- to large-diameter neurons, making it a candidate receptor for transducing high-threshold heat responses in this dass of cells. VRL-1 transcripts are not restricted to the sensory nervous system, indicating that this channel may be activated by stimuli other than heat. We propose that responses to noxious heat involve these related, but distinct, ion-channel subtypes that together detect a range of stimulus intensities.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Julius, D (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.							BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CMAPBELL JN, 1986, SPINAL AFFERENT PROC, P59; Colbert HA, 1997, J NEUROSCI, V17, P8259; DRAY A, 1990, NEUROSCI LETT, V110, P52, DOI 10.1016/0304-3940(90)90786-9; DUBNER R, 1977, PAIN TRIGEMINAL REGI, P57; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; Helliwell RJA, 1998, NEUROSCI LETT, V250, P177, DOI 10.1016/S0304-3940(98)00475-3; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; LAWSON SN, 1985, J PHYSL, V371, pP59; LEEM JW, 1993, J NEUROPHYSIOL, V69, P1684, DOI 10.1152/jn.1993.69.5.1684; LIGHT AR, 1979, J COMP NEUROL, V186, P117, DOI 10.1002/cne.901860202; MARSH SJ, 1987, NEUROSCIENCE, V23, P275, DOI 10.1016/0306-4522(87)90289-2; McCarthy PW, 1997, J COMP NEUROL, V388, P541; MEYER RA, 1994, TXB PAIN, P13; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Nagy I, 1999, NEUROSCIENCE, V88, P995, DOI 10.1016/S0306-4522(98)00535-1; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; Reichling DB, 1997, P NATL ACAD SCI USA, V94, P7006, DOI 10.1073/pnas.94.13.7006; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Snider WD, 1998, NEURON, V20, P629, DOI 10.1016/S0896-6273(00)81003-X; Todd AJ, 1998, NEUROSCIENCE, V85, P459, DOI 10.1016/S0306-4522(97)00669-6; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; WINTER J, 1993, NEUROSCIENCE, V57, P747, DOI 10.1016/0306-4522(93)90021-7; WOOD JN, 1988, J NEUROSCI, V8, P3208; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	30	1130	1196	8	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					436	441		10.1038/18906	http://dx.doi.org/10.1038/18906			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201375				2022-12-01	WOS:000079508200055
J	Hsieh, JC; Kodjabachian, L; Rebbert, ML; Rattner, A; Smallwood, PM; Samos, CH; Nusse, R; Dawid, IB; Nathans, J				Hsieh, JC; Kodjabachian, L; Rebbert, ML; Rattner, A; Smallwood, PM; Samos, CH; Nusse, R; Dawid, IB; Nathans, J			A new secreted protein that binds to Wnt proteins and inhibits their activities	NATURE			English	Article							XENOPUS EMBRYOS	The Wnt proteins constitute a large family of extracellular signalling molecules that are found throughout the animal kingdom and are important for a wide variety of normal and pathological developmental processes(1,2). Here we describe Wnt-inhibitory factor-1 (WIF-1), a secreted protein that binds to Wnt proteins and inhibits their activities. WIF-1 is present in fish, amphibia and mammals, and is expressed during Xenopus and zebrafish development in a Complex pattern that includes paraxial presomitic mesoderm, notochord, branchial arches and neural crest derivatives. We use Xenopus embryos to show that WIF-1 overexpression affects somitogenesis (the generation of trunk mesoderm segments), in agreement with its normal expression in paraxial mesoderm. In vitro, WIF-1 binds to Drosophila Wingless and Xenopus Wnt8 produced by Drosophila S2 cells. Together with earlier results obtained with the secreted Frizzled-related proteins(1.2), our results indicate that Wnt proteins interact with structurally diverse extracellular inhibitors, presumably to fine-tune the spatial and temporal patterns of Wnt activity.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; NICHHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA; Stanford Univ, Med Ctr, Sch Med, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; Stanford University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.		Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284; Rattner, Amir/0000-0001-9542-6212; Nathans, Jeremy/0000-0001-8106-5460; Kodjabachian, Laurent/0000-0002-4000-612X				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; MOON RT, 1993, DEVELOPMENT, P85; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; PEIFER M, 1993, DEVELOPMENT, V118, P1191; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	17	558	607	2	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					431	436		10.1038/18899	http://dx.doi.org/10.1038/18899			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201374				2022-12-01	WOS:000079508200054
J	Carlson, RW; Anderson, MS; Johnson, RE; Smythe, WD; Hendrix, AR; Barth, CA; Soderblom, LA; Hansen, GB; McCord, TB; Dalton, JB; Clark, RN; Shirley, JH; Ocampo, AC; Matson, DL				Carlson, RW; Anderson, MS; Johnson, RE; Smythe, WD; Hendrix, AR; Barth, CA; Soderblom, LA; Hansen, GB; McCord, TB; Dalton, JB; Clark, RN; Shirley, JH; Ocampo, AC; Matson, DL			Hydrogen peroxide on the surface of Europa	SCIENCE			English	Article							SPECTROMETER EXPERIMENT; INFRARED SPECTROSCOPY; GALILEAN SATELLITES; OPTICAL-CONSTANTS; ULTRAVIOLET; ATMOSPHERE; JUPITER; ICES	Spatially resolved infrared and ultraviolet wavelength spectra of Europa's Leading, anti-jovian quadrant observed from the Galileo spacecraft show absorption features resulting from hydrogen peroxide. Comparisons with laboratory measurements indicate surface hydrogen peroxide concentrations of about 0.13 percent, by number, relative to water ice. The inferred abundance is consistent with radiolytic production of hydrogen peroxide by intense energetic particle bombardment and demonstrates that Europa's surface chemistry is dominated by radiolysis.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Virginia, Charlottesville, VA 22903 USA; Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; US Geol Survey, Flagstaff, AZ 86001 USA; Univ Hawaii, Planetary Geosci Div, Honolulu, HI 96822 USA; US Geol Survey, Denver, CO 80225 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Virginia; University of Colorado System; University of Colorado Boulder; United States Department of the Interior; United States Geological Survey; University of Hawaii System; United States Department of the Interior; United States Geological Survey	Carlson, RW (corresponding author), CALTECH, Jet Prop Lab, Mail Stop 183-601,4800 Oak Grove Dr, Pasadena, CA 91109 USA.	rcarlson@lively.jpl.nasa.gov	Shirley, James/AAR-1264-2020					BAIN O, 1955, CAN J CHEM, V33, P527, DOI 10.1139/v55-063; BERTIE JE, 1969, J CHEM PHYS, V50, P4501, DOI 10.1063/1.1670922; Brown ME, 1996, NATURE, V380, P229, DOI 10.1038/380229a0; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; CARLSON RW, 1993, ANTARCT J US, V28, P256; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CLARK RN, 93592 US GEOL SURV; COOPER JF, UNPUB ICARUS; COTTIN M, 1955, J CHIM PHYS PCB, V52, P545; Domingue DL, 1998, GEOPHYS RES LETT, V25, P4421, DOI 10.1029/1998GL900209; Gerakines PA, 1996, ASTRON ASTROPHYS, V312, P289; GHORMLEY JA, 1956, J AM CHEM SOC, V78, P2934, DOI 10.1021/ja01594a004; GIGUERE PA, 1959, J MOL SPECTROSC, V3, P36, DOI 10.1016/0022-2852(59)90005-0; Greeley R, 1998, ICARUS, V135, P4, DOI 10.1006/icar.1998.5969; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HAPKE B, 1993, THEORY REFLECTANCE E, P197; Hendrix AR, 1998, ICARUS, V135, P79, DOI 10.1006/icar.1998.5983; HORD CW, 1992, SPACE SCI REV, V60, P503, DOI 10.1007/BF00216866; HUDGINS DM, 1993, ASTROPHYS J SUPPL S, V86, P713, DOI 10.1086/191796; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; Ip WH, 1998, GEOPHYS RES LETT, V25, P829, DOI 10.1029/98GL00472; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; Johnson RE, 1998, GEOPHYS RES LETT, V25, P3257, DOI 10.1029/98GL02565; Johnson RE., 1990, ENERGETIC CHARGED PA, DOI 10.1007/978-3-642-48375-2; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LIN CL, 1978, GEOPHYS RES LETT, V5, P113, DOI 10.1029/GL005i002p00113; McCord TB, 1998, J GEOPHYS RES-PLANET, V103, P8603, DOI 10.1029/98JE00788; McCord TB, 1997, SCIENCE, V278, P271, DOI 10.1126/science.278.5336.271; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; MCCORD TB, IN PRESS J GEOPHYS R; MILLER RL, 1961, J CHEM PHYS, V34, P265, DOI 10.1063/1.1731575; NOLL KS, 1997, J GEOPHYS RES, V102, P19057; SCHRIEVER R, 1991, J PHYS CHEM-US, V95, P6124, DOI 10.1021/j100169a016; Sieger MT, 1998, NATURE, V394, P554, DOI 10.1038/29015; SMYTHE WD, 1998, 29 LUN PLAN SCI C HO; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206	38	220	223	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2062	2064		10.1126/science.283.5410.2062	http://dx.doi.org/10.1126/science.283.5410.2062			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10092224				2022-12-01	WOS:000079369800039
J	Goldberg, J				Goldberg, J			Structural and functional analysis of the ARF1-ARFGAP complex reveals a role for coatomer in GTP hydrolysis	CELL			English	Article							ADP-RIBOSYLATION FACTOR-1; NUCLEOTIDE EXCHANGE FACTOR; TRANSITION-STATE ANALOG; COP-COATED VESICLES; ACTIVATING PROTEINS; GUANINE-NUCLEOTIDE; TRANSPORT VESICLES; CRYSTAL-STRUCTURE; BINDING-PROTEIN; ARF PROTEIN	The crystal structure of the complex of ARF1 GTPase bound to GDP and the catalytic domain of ARF GTPase-activating protein (ARFGAP) has been determined at 1.95 Angstrom resolution. The ARFGAP molecule binds to switch 2 and helix alpha 3 to orient ARF1 residues for catalysis, but it supplies neither arginine nor other amino acid side chains to the GTPase active site. In the complex, the effector-binding region appears to be unobstructed, suggesting that ARFGAP could stimulate GTP hydrolysis while ARF1 maintains an interaction with its effector, the coatomer complex of COPI-coated vesicles. Biochemical experiments show that coatomer directly participates in the GTPase reaction, accelerating GTP hydrolysis a further 1000-fold in an ARFGAP-dependent manner. Thus, a tripartite complex controls the GTP hydrolysis reaction triggering disassembly of COPI vesicle coats.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	jonathan@ximpact4.ski.mskcc.org						Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Brunger A.T., 1992, X PLOR VERSION 3 1 M; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, EMBO J, V17, P4313, DOI 10.1093/emboj/17.15.4313; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vitale N, 1998, J BIOL CHEM, V273, P2553, DOI 10.1074/jbc.273.5.2553; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; ZHAO L, 1999, IN PRESS J BIOL CHEM; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	49	246	250	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	1999	96	6					893	902		10.1016/S0092-8674(00)80598-X	http://dx.doi.org/10.1016/S0092-8674(00)80598-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102276	Bronze			2022-12-01	WOS:000079300100015
J	Brewer, T; Colditz, GA				Brewer, T; Colditz, GA			Postmarketing surveillance and adverse drug reactions - Current perspectives and future needs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; FENFLURAMINE-PHENTERMINE; MYOCARDIAL-INFARCTION; ACTIVE SURVEILLANCE; BREAST-CANCER; EVENTS; THERAPY; SAFETY; RISK; MORTALITY	Spontaneous reporting systems like MEDWATCH can be effective in revealing unusual or rare adverse events that occur with the use of medications, and such reports may often be sufficient to assign causality. However, spontaneous reports do not reliably detect adverse drug reactions (ADRs) that occur widely separated in time from the original use of the drug or that represent an increased risk of an adverse event that occurs commonly in populations not exposed to the drug. In these situations, spontaneous reports alone do not provide sufficient evidence to conclude that the adverse event was an ADR, identification of ADRs associated with long-term administration of drugs for chronic diseases also remains problematic. Methods to evaluate ADRs using data from clinical trials, medical records, and computerized databases of medication users and nonusers must be developed to complement spontaneous reporting systems. Without these methods, potentially important ADRs will remain undetected, and spurious associations between adverse outcomes and medications or devices will remain unchallenged.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Technol Assessment Grp, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Brewer, T (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NIAID NIH HHS [1 KO8 AI01444-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001444] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anello C, 1996, CLIN RES REGUL AFF, V13, P13, DOI 10.3109/10601339609019625; [Anonymous], 1995, J Clin Epidemiol, V48, P1441; AURICHE M, 1993, DRUG SAFETY, V9, P230, DOI 10.2165/00002018-199309030-00008; BLUM MD, 1994, CLIN INFECT DIS, V18, P946, DOI 10.1093/clinids/18.6.946; BROWN RB, 1986, ARCH INTERN MED, V146, P2159, DOI 10.1001/archinte.146.11.2159; Capella D, 1998, EUR J CLIN PHARMACOL, V53, P299, DOI 10.1007/s002280050382; CASE B, 1991, AM J HOSP PHARM, V48, P121, DOI 10.1093/ajhp/48.1.121; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; CHEN RT, 1995, LANCET, V345, P1369, DOI 10.1016/S0140-6736(95)92568-6; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; EIRIS JM, 1995, NEUROLOGY, V45, P1155, DOI 10.1212/WNL.45.6.1155; Ellenberg SS, 1997, PUBLIC HEALTH REP, V112, P10; ENAS GG, 1995, STAT MED, V14, P1099, DOI 10.1002/sim.4780140930; FARRINGTON P, 1995, LANCET, V345, P567, DOI 10.1016/S0140-6736(95)90471-9; FEELY J, 1990, BRIT MED J, V300, P22, DOI 10.1136/bmj.300.6716.22; FRAZIER HS, 1995, MED WORTH PAYING FOR, P212; Graham DJ, 1997, NEW ENGL J MED, V337, P635, DOI 10.1056/NEJM199708283370911; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HALVORSEN KT, 1992, MED USES STAT, P413; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HELDENBERG D, 1983, NEUROLOGY, V33, P510, DOI 10.1212/WNL.33.4.510; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HORWITZ RI, 1985, ARCH INTERN MED, V145, P1873, DOI 10.1001/archinte.145.10.1873; INMAN W, 1993, LANCET, V342, P658, DOI 10.1016/0140-6736(93)91763-C; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; KOCH KE, 1990, AM J HOSP PHARM, V47, P1314, DOI 10.1093/ajhp/47.6.1314; LABARTHE DR, 1979, J CHRON DIS, V32, P95, DOI 10.1016/0021-9681(79)90021-3; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LORTIE FM, 1986, CAN MED ASSOC J, V135, P27; MIREMONT G, 1994, EUR J CLIN PHARMACOL, V46, P285; MITCHELL AS, 1988, BRIT MED J, V297, P891, DOI 10.1136/bmj.297.6653.891; MUURONEN A, 1985, BRIT MED J, V291, P1481, DOI 10.1136/bmj.291.6507.1481; NASH JQ, 1995, EPIDEMIOL INFECT, V114, P475, DOI 10.1017/S0950268800052183; PIAZZAHEPP TD, 1995, AM J HEALTH-SYST PH, V52, P1436, DOI 10.1093/ajhp/52.13.1436; PINI L-G, 1990, Acta Physiologica Hungarica, V75, P237; ROSSI AC, 1983, JAMA-J AM MED ASSOC, V249, P2226, DOI 10.1001/jama.249.16.2226; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SCOTT HD, 1990, JAMA-J AM MED ASSOC, V263, P1785, DOI 10.1001/jama.263.13.1785; SENEKJIAN EK, 1988, AM J OBSTET GYNECOL, V158, P493, DOI 10.1016/0002-9378(88)90012-9; SILLS JM, 1986, AM J HOSP PHARM, V43, P2764, DOI 10.1093/ajhp/43.11.2764; STOLLEY PD, 1982, J CLIN PHARMACOL, V22, P499, DOI 10.1002/j.1552-4604.1982.tb02642.x; Strom B L, 1991, Ann Ist Super Sanita, V27, P235; TUBERT P, 1992, J CLIN EPIDEMIOL, V45, P283, DOI 10.1016/0895-4356(92)90088-5; VENNING GR, 1983, BRIT MED J, V286, P544, DOI 10.1136/bmj.286.6364.544; VENULET J, 1992, INT J CLIN PHARM RES, V12, P61; White GG, 1998, J TOXICOL-CLIN TOXIC, V36, P145, DOI 10.3109/15563659809162609; Wise RP, 1997, JAMA-J AM MED ASSOC, V278, P1176, DOI 10.1001/jama.278.14.1176	50	233	238	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					824	829		10.1001/jama.281.9.824	http://dx.doi.org/10.1001/jama.281.9.824			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071004				2022-12-01	WOS:000078804300033
J	Nichol, KL; Baken, L; Nelson, A				Nichol, KL; Baken, L; Nelson, A			Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE RESPIRATORY-DISEASE; PREVENTING HOSPITALIZATION; COST-EFFECTIVENESS; EPIDEMIC; EFFICACY; PNEUMONIA; COMMUNITY; IMPACT; RISK	Background: Influenza Vaccine is underused in groups targeted for vaccination. Objective: To define the effects of influenza and the benefits of influenza Vaccination in elderly persons with chronic lung disease. Design: Retrospective, multiseason cohort study. Setting: Large managed care organization. Patients: All elderly members of a managed care organization who had a previous diagnosis of chronic lung disease. Measurements: Outcomes in vaccinated and unvaccinated persons for the 1993-1994, 1994-1995, and 1995-1996 influenza seasons were compared after adjustment for baseline demographic and health characteristics. All data were obtained from administrative databases. Results: Vaccination rates were greater than 70% for each season. Among unvaccinated persons, hospitalization rates for pneumonia and influenza were twice as high in the influenza seasons as they were in the interim (non-influenza) periods. Influenza vaccination was associated with fewer hospitalizations for pneumonia and influenza (adjusted risk ratio, 0.48 [95% CI, 0.28 to 0.82]) and with lower risk for death (adjusted odds ratio, 0.30 [Cl, 0.21 to 0.43]) during the influenza seasons. It was also associated with fewer outpatient visits for pneumonia and influenza and for all respiratory conditions. Conclusions: For elderly persons with chronic lung disease, influenza is associated with significant adverse health effects and influenza vaccination is associated with substantial health benefits, including fewer outpatient visits, fewer hospitalizations, and fewer deaths. Health care providers should take advantage of all opportunities to immunize these high-risk patients.	Vet Affairs Med Ctr 111, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Hlth Partners & Grp Hlth Fdn, Bloomington, MN USA	University of Minnesota System; University of Minnesota Twin Cities	Nichol, KL (corresponding author), Vet Affairs Med Ctr 111, 1 Vet Dr, Minneapolis, MN 55417 USA.							Ahmed AH, 1997, EPIDEMIOL INFECT, V118, P27, DOI 10.1017/S0950268896007121; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; BEYER WEP, 1989, VACCINE, V7, P385, DOI 10.1016/0264-410X(89)90150-3; COUCH RB, 1993, ANN NY ACAD SCI, V685, P803, DOI 10.1111/j.1749-6632.1993.tb35946.x; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; Fleming DM, 1995, EPIDEMIOL INFECT, V115, P581, DOI 10.1017/S095026880005874X; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; FOX R, 1995, RESP MED, V89, P559, DOI 10.1016/0954-6111(95)90158-2; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1989, VACCINE, V7, P303, DOI 10.1016/0264-410X(89)90190-4; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P1; Kelsey JL., 1996, METHODS OBSERVATIONA; LUI KJ, 1987, AM J PUBLIC HEALTH, V77, P712, DOI 10.2105/AJPH.77.6.712; MACDONALD R, IN PRESS AM J PREV M; MARGOLIS KL, 1992, J AM GERIATR SOC, V40, P1021, DOI 10.1111/j.1532-5415.1992.tb04480.x; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Ohmit SE, 1995, INT J EPIDEMIOL, V24, P1240, DOI 10.1093/ije/24.6.1240; PAUL WS, 1988, J INFECT DIS, V157, P633, DOI 10.1093/infdis/157.4.633; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; Rothenberg RB, 1996, PREVENTION EFFECTIVE, P193; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P285; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; 1995, MMWR MORB MORTAL WKL, V44, P561; 1998, MMWR MORB MORTAL WKL, V47, P797	31	253	262	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					397	+		10.7326/0003-4819-130-5-199903020-00003	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068413	Green Submitted			2022-12-01	WOS:000078898100002
J	Morrison, A; Stone, DH; Redpath, A; Campbell, H; Norrie, J				Morrison, A; Stone, DH; Redpath, A; Campbell, H; Norrie, J			Trend analysis of socioeconomic differentials in deaths from injury in childhood in Scotland, 1981-95	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland; Scottish Hlth Serv, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Publ Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Edinburgh; University of Glasgow	Morrison, A (corresponding author), Univ Glasgow, Dept Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland.		Campbell, Harry/E-2959-2010	Campbell, Harry/0000-0002-6169-6262				Carstairs V., 1991, DEPRIVATION HLTH SCO; JARVIS S, 1995, HLTH OUR CHILDREN S; LINDSEY J., 1995, MODELLING FREQUENCY; Roberts I, 1996, BRIT MED J, V313, P784; SMITH GD, 1997, PROGR PUBLIC HLTH	5	22	22	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					567	568		10.1136/bmj.318.7183.567	http://dx.doi.org/10.1136/bmj.318.7183.567			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037632	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000078966300027
J	Rodriguez, LAG; Ruigomez, A				Rodriguez, LAG; Ruigomez, A			Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Ctr Espanol Invest Farmacoepidemiol, E-28004 Madrid, Spain		Rodriguez, LAG (corresponding author), Ctr Espanol Invest Farmacoepidemiol, E-28004 Madrid, Spain.		rodriguez, luis a garcia/B-1980-2010; Ruigomez, Ana/HDN-8290-2022					Barber R, 1997, BRIT MED J, V314, P1903; MCKENDRICK MW, 1994, J INFECTION, V29, P1, DOI 10.1016/S0163-4453(94)94871-2; Neal KR, 1997, BRIT MED J, V314, P779, DOI 10.1136/bmj.314.7083.779; Rodriguez LAG, 1997, EPIDEMIOLOGY, V8, P571; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419	5	259	278	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					565	566		10.1136/bmj.318.7183.565	http://dx.doi.org/10.1136/bmj.318.7183.565			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037630	Green Published			2022-12-01	WOS:000078966300025
J	Remy, I; Wilson, IA; Michnick, SW				Remy, I; Wilson, IA; Michnick, SW			Erythropoietin receptor activation by a ligand-induced conformation change	SCIENCE			English	Article							RESONANCE ENERGY-TRANSFER; DIHYDROFOLATE-REDUCTASE; PROTEIN HORMONE; CELLS; DIMERIZATION; COMPLEX	Erythropoietin and other cytokine receptors are thought to be activated through hormone-induced dimerization and autophosphorylation of JAK kinases associated with the receptor intracellular domains, An in vivo protein fragment complementation assay was used to obtain evidence for an alternative mechanism in which unliganded erythropoietin receptor dimers exist in a conformation that prevents activation of JAK2 but then undergo a ligand-induced conformation change that allows JAK2 to be activated, These results are consistent with crystallographic evidence of distinct dimeric configurations for unliganded and ligand-bound forms of the erythropoietin receptor.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Universite de Montreal; Scripps Research Institute	Michnick, SW (corresponding author), Univ Montreal, Dept Biochim, Casier Postal 6128,Succursale Ctrville, Montreal, PQ H3C 3J7, Canada.				NIGMS NIH HHS [GM49497] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CODY V, 1992, ANTI-CANCER DRUG DES, V7, P483; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GUO CM, 1995, J BIOL CHEM, V270, P27562, DOI 10.1074/jbc.270.46.27562; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; ISRAEL DI, 1993, P NATL ACAD SCI USA, V90, P4290, DOI 10.1073/pnas.90.9.4290; Johnson DL, 1998, BIOCHEMISTRY-US, V37, P3699, DOI 10.1021/bi971956y; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KAUFMAN RJ, 1978, J BIOL CHEM, V253, P5852; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Pelletier JN, 1997, PROTEIN ENG, V10, P89; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; REMY I, UNPUB; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Wrighton NC, 1997, NAT BIOTECHNOL, V15, P1261, DOI 10.1038/nbt1197-1261	24	498	528	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					990	993		10.1126/science.283.5404.990	http://dx.doi.org/10.1126/science.283.5404.990			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974393				2022-12-01	WOS:000078574800050
J	Eisenberg, L				Eisenberg, L			Would cloned humans really be like sheep?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PLASTICITY; BRAIN		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Eisenberg, L (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Ashworth D, 1998, NATURE, V394, P329, DOI 10.1038/28521; BENES FM, 1994, ARCH GEN PSYCHIAT, V51, P477; Berg P, 1998, SCIENCE, V282, P413, DOI 10.1126/science.282.5388.413; BLACK FL, 1975, SCIENCE, V187, P515, DOI 10.1126/science.163483; BLACK FL, 1992, SCIENCE, V258, P1739, DOI 10.1126/science.1465610; Catalano SM, 1998, SCIENCE, V281, P559, DOI 10.1126/science.281.5376.559; EISENBERG L, 1995, AM J PSYCHIAT, V152, P1563, DOI 10.1176/ajp.152.11.1563; EISENBERG L, 1972, SCIENCE, V176, P123, DOI 10.1126/science.176.4031.123; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; GROBSTEIN C, 1964, SCIENCE, V143, P643, DOI 10.1126/science.143.3607.643; Hamdy S, 1998, NAT NEUROSCI, V1, P64, DOI 10.1038/264; HARLAN JR, 1975, SCIENCE, V188, P618, DOI 10.1126/science.188.4188.617; Hughes JB, 1997, SCIENCE, V278, P689, DOI 10.1126/science.278.5338.689; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; National Research Council, 1972, GEN VULN MAJ CROPS; Needham JHA., 1959, HIST EMBRYOLOGY; Nelson CA, 1997, CHILD DEV, V68, P970, DOI 10.1111/j.1467-8624.1997.tb01974.x; ORMEROD WE, 1976, SCIENCE, V191, P815, DOI 10.1126/science.2977; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; SCHLAUG G, 1995, SCIENCE, V267, P699, DOI 10.1126/science.7839149; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; Signer EN, 1998, NATURE, V394, P329, DOI 10.1038/28524; Sterr A, 1998, J NEUROSCI, V18, P4417; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0; WIESEL TN, 1982, 1981 NOB PRIZ LECT S; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wilmut I, 1997, NATURE, V386, P200, DOI 10.1038/386200a0; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	29	19	19	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					471	475		10.1056/NEJM199902113400612	http://dx.doi.org/10.1056/NEJM199902113400612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971875				2022-12-01	WOS:000078571000012
J	Holmes, AM; Haber, JE				Holmes, AM; Haber, JE			Double-strand break repair in yeast requires both leading and lagging strand DNA polymerases	CELL			English	Article							CELL NUCLEAR ANTIGEN; ALPHA-PRIMASE COMPLEX; REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; MATING-TYPE; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL REPLICATION; ESCHERICHIA-COLI; GENE CONVERSION; MISMATCH REPAIR	Mitotic double-strand break (DSB)-induced gene conversion at MAT in Saccharomyces cerevisiae was analyzed molecularly in mutant strains thermosensitive for essential replication factors. The processivity cofactors PCNA and RFC are essential even to synthesize as little as 30 nucleotides following strand invasion. Both PCNA-associated DNA polymerases delta and epsilon are important for gene conversion, though a temperature-sensitive Pol epsilon mutant is more severe than one in Pol delta. Surprisingly, mutants of lagging strand replication, DNA polymerase alpha (pol1-17), DNA primase (pri2-1), and Rad27p (rad27 Delta) also greatly inhibit completion of DSB repair, even in G1-arrested cells. We propose a novel model for DSB-induced gene conversion in which a strand invasion creates a modified replication fork, involving leading and lagging strand synthesis from the donor template. Replication is terminated by capture of the second end of the DSB.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA	Brandeis University; Brandeis University	Holmes, AM (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.			Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM20056, GM01722] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020056, R01GM020056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ASAI T, 1993, EMBO J, V12, P3287, DOI 10.1002/j.1460-2075.1993.tb05998.x; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bosco G, 1998, GENETICS, V150, P1037; BROOKS M, 1989, J BIOL CHEM, V264, P3602; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BUDD ME, 1989, MOL CELL BIOL, V9, P365, DOI 10.1128/MCB.9.2.365; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; COLAIACOVO M, 1999, IN PRESS GENETICS; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dillin A, 1998, SCIENCE, V279, P1733, DOI 10.1126/science.279.5357.1733; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; FABRE F, 1991, MOL GEN GENET, V229, P353, DOI 10.1007/BF00267455; Ferguson DO, 1996, P NATL ACAD SCI USA, V93, P5419, DOI 10.1073/pnas.93.11.5419; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; FOLANI M, 1995, MOL CELL BIOL, V15, P883; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; George JW, 1996, GENETICS, V143, P1507; GIOT L, 1995, MOL GEN GENET, V246, P212, DOI 10.1007/BF00294684; GORDON JE, 1992, GEOMORPHOLOGY, V6, P89, DOI 10.1016/0169-555X(92)90051-O; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; HASTINGS PJ, 1988, BIOESSAYS, V9, P61, DOI 10.1002/bies.950090206; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KLAR AJS, 1984, COLD SPRING HARB SYM, V49, P77, DOI 10.1101/SQB.1984.049.01.011; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LONGHESE MP, 1993, GENETICS, V133, P183; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MCGILL C, 1989, CELL, V57, P459, DOI 10.1016/0092-8674(89)90921-5; Morrow DM, 1997, GENETICS, V147, P371; Mueller JE, 1996, GENE DEV, V10, P351, DOI 10.1101/gad.10.3.351; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; Paques F, 1998, MOL CELL BIOL, V18, P2045, DOI 10.1128/MCB.18.4.2045; PAQUES F, 1995, J MOL EVOL, V41, P615; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; RAVEH D, 1989, MOL GEN GENET, V220, P33; RAY BL, 1991, MOL CELL BIOL, V11, P5372, DOI 10.1128/MCB.11.10.5372; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Shcherbakova PV, 1996, GENETICS, V142, P717; Sherman DA, 1998, MOL BIOL CELL, V9, P1833, DOI 10.1091/mbc.9.7.1833; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1995, GENETICS, V140, P965; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VOELKELMEIMAN K, 1990, GENETICS, V124, P561; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WU XH, 1995, GENE DEV, V9, P1922, DOI 10.1101/gad.9.15.1922; ZEHFUS BR, 1990, GENETICS, V126, P41	72	217	221	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					415	424		10.1016/S0092-8674(00)80554-1	http://dx.doi.org/10.1016/S0092-8674(00)80554-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025407	Bronze			2022-12-01	WOS:000078514600014
J	Keys, DN; Lewis, DL; Selegue, JE; Pearson, BJ; Goodrich, LV; Johnson, RL; Gates, J; Scott, MP; Carroll, SB				Keys, DN; Lewis, DL; Selegue, JE; Pearson, BJ; Goodrich, LV; Johnson, RL; Gates, J; Scott, MP; Carroll, SB			Recruitment of a hedgehog regulatory circuit in butterfly eyespot evolution	SCIENCE			English	Article							CUBITUS-INTERRUPTUS; IMAGINAL DISKS; TARGET GENES; DROSOPHILA; EXPRESSION; PATTERN; WINGS; PLASTICITY; PROTEINS; SIGNAL	The origin of new morphological characters is a long-standing problem in evolutionary biology. Novelties arise through changes in development, but the nature of these changes is largely unknown. In butterflies, eyespots have evolved as new pattern elements that develop from special organizers called foci. Formation of these foci is associated with novel expression patterns of the Hedgehog signaling protein, its receptor Patched, the transcription factor Cubitus interruptus, and the engrailed target gene that break the conserved compartmental restrictions on this regulatory circuit in insect wings. Redeployment of preexisting regulatory circuits may be a general mechanism underlying the evolution of novelties.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Stanford Univ, Med Ctr, Howard Hughes Med Inst, Beckman Ctr, Palo Alto, CA 94304 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; Stanford University	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, 1525 Linden Dr, Madison, WI 53706 USA.			Pearson, Bret/0000-0002-3473-901X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018162] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [F32 GM18162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BLAIR S, 1992, DEVELOPMENT, V119, P339; BRAKEFIELD PM, 1991, ECOL ENTOMOL, V16, P291, DOI 10.1111/j.1365-2311.1991.tb00220.x; Brakefield PM, 1996, NATURE, V384, P236, DOI 10.1038/384236a0; BRAKEFIELD PM, 1995, DEV BIOL, V168, P98, DOI 10.1006/dbio.1995.1064; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FRENCH V, 1995, DEV BIOL, V168, P112, DOI 10.1006/dbio.1995.1065; Hepker J, 1997, DEVELOPMENT, V124, P549; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; KEYS DN, UNPUB; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MONTEIRO A, 1995, EVOLUTION, V48, P1147; MULLER GB, 1991, ANNU REV ECOL SYST, V22, P229, DOI 10.1146/annurev.es.22.110191.001305; Mullor JL, 1997, DEVELOPMENT, V124, P1227; NIJHOUT HF, 1980, DEV BIOL, V80, P267, DOI 10.1016/0012-1606(80)90403-0; NIJHOUT HF, 1994, DEVELOPMENT, P225; Nijhout HF, 1991, DEV EVOLUTION BUTTER; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; SLUSARSKI DC, 1995, GENETICS, V139, P229; Strigini M, 1997, DEVELOPMENT, V124, P4697; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8	26	229	230	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					532	534		10.1126/science.283.5401.532	http://dx.doi.org/10.1126/science.283.5401.532			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915699				2022-12-01	WOS:000078203300035
J	Unwin, C; Blatchley, N; Coker, W; Ferry, S; Hotopf, M; Hull, L; Ismail, K; Palmer, I; David, A; Wessely, S				Unwin, C; Blatchley, N; Coker, W; Ferry, S; Hotopf, M; Hull, L; Ismail, K; Palmer, I; David, A; Wessely, S			Health of UK servicemen who served in Persian Gulf War	LANCET			English	Article							POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS HEALTH; SELF-REPORTED HEALTH; US VETERANS; EXPOSURE; POPULATION; PREVALENCE; COMBAT; RECALL; SCALE	Background Various symptoms in military personnel in the Persian Gulf War 1990-91 have caused international speculation and concern. We investigated UK servicemen. Methods We did a cross-sectional postal survey on a random sample of Gulf War veterans (Gulf War cohort, n=4248) and, stratified for age and rank, servicemen deployed to the Bosnia conflict (Bosnia cohort, n=4250) and those serving during the Gulf War but not deployed there (Era cohort, n=4246). We asked about deployment, exposures, symptoms, and illnesses. We analysed men only. Our outcome measures were physical health, functional capacity (SF-36), the general health questionnaire, the Centers for Disease Control and Prevention (CDC) multisymptom criteria for Gulf war illness, and post-traumatic stress reactions. Findings There were 8195 (65.1%) valid responses. The Gulf War cohort reported symptoms and disorders significantly more frequently than those in the Bosnia and Era cohorts, which were similar. Perception of physical health and ability were significantly worse in the Gulf War cohort than in the other cohorts, even after adjustment for confounders. Gulf War veterans were more likely than the Bosnia cohort to have substantial fatigue (odds ratio 22 [95% CI 1.9-2.6]), symptoms of post-traumatic stress (2.6 [1.9-3.4]), and psychological distress (1.6 [1/.4-1.8]), and were nearly twice as likely to reach the CDC case definition (25 [2.2-2.8]). In the Gulf War, Bosnia, and Era cohorts, respectively, 61.9%, 36.8%, and 36.4% met the CDC criteria, which fell to 25.3%, 11.8%, and 12.2% for severe symptoms. Potentially harmful exposures were reported most frequently by the Gulf War cohort. All exposures showed associations with all of the outcome measures in the three cohorts. Exposures specific to the Gulf were associated with all outcomes. Vaccination against biological warfare and multiple routine vaccinations were associated with the CDC multisymptom syndrome in the Gulf War cohort. Interpretation Service in the Gulf War was associated with various health problems over and above those associated with deployment to an unfamiliar hostile environment. Since associations of ill health with adverse events and exposures were found in all cohorts, however, they may not be unique and causally implicated in Gulf-War-related illness. A specific mechanism may link vaccination against biological warfare agents and later ill health, but the risks of illness must be considered against the protection of servicemen.	Guys Kings & St Thomas Med Sch, Gulf War Illness Res Unit, London SE5 8AF, England; USAF, Med Operat Agcy, Washington, DC 20330 USA; Off Natl Stat, London, England; Royal Def Med Coll, London, England	University of London; King's College London; United States Department of Defense; United States Air Force	Wessely, S (corresponding author), Guys Kings & St Thomas Med Sch, Gulf War Illness Res Unit, London SE5 8AF, England.	s.wessely@iop.bpmf.ac.uk	David, Anthony S/C-1315-2011; David, Anthony/O-1750-2019; Hotopf, Matthew/E-4971-2010; Wessely, Simon C/A-8713-2008	David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X; Wessely, Simon Charles/0000-0002-6743-9929; Ismail, Khalida/0000-0001-6084-449X				Andreski P, 1998, PSYCHIAT RES, V79, P131, DOI 10.1016/S0165-1781(98)00026-2; Baker DG, 1997, ARCH INTERN MED, V157, P2076, DOI 10.1001/archinte.157.18.2076; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Coker W J, 1996, J R Nav Med Serv, V82, P141; DAVIDSON LM, 1986, J CONSULT CLIN PSYCH, V54, P303, DOI 10.1037/0022-006X.54.3.303; DECOUFLE P, 1992, AM J EPIDEMIOL, V135, P312, DOI 10.1093/oxfordjournals.aje.a116285; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; Eaker S, 1998, AM J EPIDEMIOL, V147, P74; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Goldberg DP., 1972, DETECTION PSYCHIAT I; Gray GC, 1996, NEW ENGL J MED, V335, P1505, DOI 10.1056/NEJM199611143352007; Gray GC, 1998, AM J EPIDEMIOL, V148, P328; Haley RW, 1998, AM J EPIDEMIOL, V148, P315, DOI 10.1093/oxfordjournals.aje.a009645; HOPWOOD DG, 1988, ARCH ENVIRON HEALTH, V43, P234, DOI 10.1080/00039896.1988.9934939; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; Hynes Samuel, 1992, WAR IMAGINED 1 WORLD; Joseph SC, 1997, MIL MED, V162, P149; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; KIPEN HM, 1995, AM J PUBLIC HEALTH, V85, P574, DOI 10.2105/AJPH.85.4.574; KORGESKI GP, 1983, AM J PSYCHIAT, V140, P1443; Leed E., 1979, MANS LAND COMBAT IDE; *NAT SURV RES TEAM, 1998, C FED SPONS GULF WAR; OToole BI, 1996, INT J EPIDEMIOL, V25, P319, DOI 10.1093/ije/25.2.319; OToole BI, 1996, INT J EPIDEMIOL, V25, P307, DOI 10.1093/ije/25.2.307; PITMAN RK, 1989, AM J PSYCHIAT, V146, P667; Rook GAW, 1997, LANCET, V349, P1831, DOI 10.1016/S0140-6736(97)01164-1; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; SIMON GE, 1995, EPIDEMIOL REV, V17, P221, DOI 10.1093/oxfordjournals.epirev.a036180; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WHITEMAN DC, 1995, ARCH ENVIRON HEALTH, V50, P281, DOI 10.1080/00039896.1995.9935955; WRIGHT K, 1995, OPERAETION DESERT SH; Wynn ML, 1997, NEUROLOGY, V48, P2044; 1997, PRESIDENTIAL ADVISOR	35	442	443	0	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					169	178		10.1016/S0140-6736(98)11338-7	http://dx.doi.org/10.1016/S0140-6736(98)11338-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	159LW	9923871				2022-12-01	WOS:000078175600008
J	Mao, CD; Sun, WQ; Shen, ZY; Seeman, NC				Mao, CD; Sun, WQ; Shen, ZY; Seeman, NC			A nanomechanical device based on the B-Z transition of DNA	NATURE			English	Article							DOUBLE-CROSSOVER MOLECULES; RESONANCE ENERGY-TRANSFER; JUNCTION; SHUTTLE	The assembly of synthetic, controllable molecular mechanical systems(1-7) is one of the goals of nanotechnology. Protein-based molecular machines, often driven by an energy source such as ATP, are abundant in biology(8,9). It has been shown previously that branched motifs of DNA can provide components for the assembly of nanoscale objects(10), links(11) and arrays(12). Here we show that such structures can also provide the basis for dynamic assemblies: switchable molecular machines. We have constructed a supramolecular device consisting of two rigid DNA 'double-crossover' (DX) molecules connected by 4.5 double-helical turns. One domain of each DX molecule is attached to the connecting helix. To effect switchable motion in this assembly, we use the transition between the B and Z(13,14) forms of DNA. In conditions that favour B-DNA, the two unconnected domains of the DX molecules lie on the same side of the central helix, In Z-DNA-promoting conditions, however, these domains switch to opposite sides of the helix. This relative repositioning is detected by means of fluorescence resonance energy transfer spectroscopy, which measures the relative proximity of two dye molecules attached fa the free ends of the DX molecules, The switching event induces atomic displacements of 20-60 Angstrom.	NYU, Dept Chem, New York, NY 10003 USA	New York University	Seeman, NC (corresponding author), NYU, Dept Chem, New York, NY 10003 USA.		Mao, Chengde/GPP-1546-2022					Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; CHATTOPADHYAYA R, 1990, J MOL BIOL, V211, P189, DOI 10.1016/0022-2836(90)90020-M; CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; DADO GP, 1993, J AM CHEM SOC, V115, P12609, DOI 10.1021/ja00079a060; FU TJ, 1993, BIOCHEMISTRY-US, V32, P3211, DOI 10.1021/bi00064a003; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; JaresErijman EA, 1996, J MOL BIOL, V257, P597, DOI 10.1006/jmbi.1996.0188; Li XJ, 1996, J AM CHEM SOC, V118, P6131, DOI 10.1021/ja960162o; Livoreil A, 1997, J AM CHEM SOC, V119, P12114, DOI 10.1021/ja9720826; MA RI, 1986, NUCLEIC ACIDS RES, V14, P9745, DOI 10.1093/nar/14.24.9745; Mao CD, 1997, NATURE, V386, P137, DOI 10.1038/386137b0; Murakami H, 1997, J AM CHEM SOC, V119, P7605, DOI 10.1021/ja971438a; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SEEMAN NC, 1988, J BIOMOL STRUCT DYN, V5, P997, DOI 10.1080/07391102.1988.10506445; SEEMAN NC, 1993, MATER RES SOC SYMP P, V292, P123; Seeman NC, 1998, ANNU REV BIOPH BIOM, V27, P225, DOI 10.1146/annurev.biophys.27.1.225; SHEARDY RD, 1993, J MOL BIOL, V231, P475, DOI 10.1006/jmbi.1993.1295; Smith SS, 1997, P NATL ACAD SCI USA, V94, P2162, DOI 10.1073/pnas.94.6.2162; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; Yang XP, 1998, BIOPOLYMERS, V45, P69, DOI 10.1002/(SICI)1097-0282(199801)45:1<69::AID-BIP6>3.3.CO;2-W; Zahn S, 1998, ANGEW CHEM INT EDIT, V37, P305, DOI 10.1002/(SICI)1521-3773(19980216)37:3<305::AID-ANIE305>3.0.CO;2-T; ZELKOVICH L, 1995, NATURE, V374, P790	27	685	723	10	204	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					144	146		10.1038/16437	http://dx.doi.org/10.1038/16437			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923675				2022-12-01	WOS:000078085000040
J	Goulis, J; Patch, D; Burroughs, AK				Goulis, J; Patch, D; Burroughs, AK			Bacterial infection in the pathogenesis of variceal bleeding	LANCET			English	Article							NITRIC-OXIDE PATHWAY; ENDOTHELIN RECEPTORS; PORTAL-HYPERTENSION; CIRRHOTIC-PATIENTS; HYPERDYNAMIC CIRCULATION; PLATELET-AGGREGATION; ESOPHAGEAL-VARICES; STELLATE CELLS; RAT-LIVER; PRESSURE	Variceal bleeding is a life-threatening complication of cirrhosis. Potential risk factors include clinical, endoscopic, and haemodynamic factors, but why bleeding occurs unpredictably in individual patients is not known. We postulate that bacterial infections in patients with variceal haemorrhage may be the critical factor that triggers bleeding. In patients with large varices and a high wall tension, the release of endotoxin into the systemic circulation during episodes of bacterial infection results in a further increase in portal pressure through the induction endothelin and possibly vasoconstrictive cyclo-oxygenase products. The Subsequent. contraction of hepatic stellate cells causes a rise in intrahepatic vascular resistance., furthermore, endotoxin-induced nitric oxide and postacyclin, and prostacyclin induced by endothelin could inhibit platelet aggregation, which may result in a further deterioration of primary haemostasis at the level of varix. We propose that the combination of these two effects leads to the onset of variceal haemorrhage.	Royal Free Hosp, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Burroughs, AK (corresponding author), Royal Free Hosp, Pond St, London NW3 2QG, England.		Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X				Armonis A, 1997, HEPATOLOGY, V25, P245, DOI 10.1053/jhep.1997.v25.ajhep0250245; BENARI Z, 1996, J HEPATOL, V20, P92; BERNARD B, 1995, GASTROENTEROLOGY, V108, P1828, DOI 10.1016/0016-5085(95)90146-9; BERNARD B, 1996, GUT S3, V39, pA186; BLEICHNER G, 1986, BRIT J SURG, V73, P724, DOI 10.1002/bjs.1800730916; BURROUGHS AK, 1989, HEPATOLOGY, V9, P801, DOI 10.1002/hep.1840090602; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; DESAI K, 1989, LANCET, V1, P693; Eakes AT, 1997, AM J PHYSIOL-GASTR L, V272, pG605, DOI 10.1152/ajpgi.1997.272.3.G605; Gandhi CR, 1998, LIVER, V18, P39; GERBES AL, 1995, HEPATOLOGY, V21, P735, DOI 10.1002/hep.1840210321; Gines P, 1998, J HEPATOL, V29, P490, DOI 10.1016/S0168-8278(98)80072-X; Goulis J, 1998, HEPATOLOGY, V27, P1207, DOI 10.1002/hep.510270504; GRATTON JP, 1995, J CARDIOVASC PHARM, V26, pS88; GUARNER C, 1993, HEPATOLOGY, V18, P1139; HOUSSET C, 1993, P NATL ACAD SCI USA, V90, P9266, DOI 10.1073/pnas.90.20.9266; HUGHES AK, 1995, KIDNEY INT, V47, P53, DOI 10.1038/ki.1995.6; Laffi G, 1995, HEPATOLOGY, V22, P1666, DOI 10.1002/hep.1840220609; MCCORMICK PA, 1995, GUT, V36, P100, DOI 10.1136/gut.36.1.100; MOLLER S, 1995, J HEPATOL, V23, P135, DOI 10.1016/0168-8278(95)80327-0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; OKUDA K, 1984, GASTROENTEROLOGY, V86, P600; Pannen BHJ, 1996, AM J PHYSIOL-HEART C, V271, pH1953, DOI 10.1152/ajpheart.1996.271.5.H1953; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; POLIO J, 1986, SEMIN LIVER DIS, V6, P318, DOI 10.1055/s-2008-1040614; Preneta E, 1998, HEPATOLOGY, V28, p453A; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; READY JB, 1991, GASTROENTEROLOGY, V100, P1403; Riddell DR, 1997, J BIOL CHEM, V272, P89; Rockey DC, 1998, HEPATOLOGY, V27, P472, DOI 10.1002/hep.510270222; Rockey DC, 1996, HEPATOLOGY, V24, P233; Rocky D, 1997, HEPATOLOGY, V25, P2, DOI 10.1002/hep.510250102; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; Sogni P, 1998, HEPATOLOGY, V28, P655, DOI 10.1002/hep.510280308; SPENCE RAJ, 1984, SURG GYNECOL OBSTET, V159, P253; SUTTORP N, 1987, AM J PHYSIOL, V253, pC384, DOI 10.1152/ajpcell.1987.253.3.C384; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; YAMAMOTO S, 1997, AM J PHYSIOL, V272, pH1; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001	41	196	202	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1999	353	9147					139	142		10.1016/S0140-6736(98)06020-6	http://dx.doi.org/10.1016/S0140-6736(98)06020-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023916				2022-12-01	WOS:000078087200044
J	Mohlke, KL; Purkayastha, AA; Westrick, RJ; Smith, PL; Petryniak, B; Lowe, JB; Ginsburg, D				Mohlke, KL; Purkayastha, AA; Westrick, RJ; Smith, PL; Petryniak, B; Lowe, JB; Ginsburg, D			Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase	CELL			English	Article							DOLICHOS-BIFLORUS AGGLUTININ; VONWILLEBRAND DISEASE; TRANSGENIC MICE; FACTOR-VIII; MOUSE CHROMOSOME-11; BINDING-SITES; FACTOR GENE; BLOOD-GROUP; FACTOR-IX; CELLS	We have identified altered lineage-specific expression of an N-acetylgalactosaminyltransferase gene, Galgt2, as the gain-of-function mechanism responsible for the action of the Mvwf locus, a major modifier of plasma von Willebrand factor (VWF) level in RIIIS/J mice. A switch of Galgt2 gene expression from intestinal epithelial cell-specific to a pattern restricted to the vascular endothelial cell bed leads to aberrant posttranslational modification and rapid clearance of WVF from plasma. Transgenic expression of Galgt2 directed to vascular endothelial cells reproduces the low VWF phenotype, confirming this switch in lineage-specific gene expression as the likely molecular mechanism for Mvwf. These findings identify alterations in glycosyltransferase function as a potential general mechanism for the genetic modification of plasma protein levels.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ginsburg, D (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.	ginsburg@umich.edu			NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039693, R37HL039693] Funding Source: NIH RePORTER; NCI NIH HHS [CA71932] Funding Source: Medline; NHLBI NIH HHS [HL39693] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; BEDELL MA, 1995, GENE DEV, V9, P455, DOI 10.1101/gad.9.4.455; Bedell MA, 1996, NAT GENET, V12, P229, DOI 10.1038/ng0396-229; Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; Cunningham JM, 1996, SEMIN HEMATOL, V33, P9; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; GILL JC, 1987, BLOOD, V69, P1691; GINSBURG D, 1992, BLOOD, V79, P2507; Ihara Y, 1998, P NATL ACAD SCI USA, V95, P2526, DOI 10.1073/pnas.95.5.2526; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; Kornfeld S, 1998, J CLIN INVEST, V101, P1293, DOI 10.1172/JCI3140; Lip GYH, 1997, CARDIOVASC RES, V34, P255, DOI 10.1016/S0008-6363(97)00039-4; LYONS SE, 1992, J BIOL CHEM, V267, P4424; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mohlke KL, 1998, GENOMICS, V54, P19, DOI 10.1006/geno.1998.5553; Mohlke KL, 1997, J LAB CLIN MED, V130, P252, DOI 10.1016/S0022-2143(97)90019-6; Mohlke KL, 1996, P NATL ACAD SCI USA, V93, P15352, DOI 10.1073/pnas.93.26.15352; Nichols WC, 1997, MEDICINE, V76, P1, DOI 10.1097/00005792-199701000-00001; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; NICHOLS WC, 1994, BLOOD, V83, P3225; NICHOLS WC, 1991, P NATL ACAD SCI USA, V88, P3857, DOI 10.1073/pnas.88.9.3857; ORSTAVIK KH, 1985, AM J HUM GENET, V37, P89; ORSTAVIK KH, 1989, BLOOD, V73, P990; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; PONDER BAJ, 1983, DEV BIOL, V96, P535, DOI 10.1016/0012-1606(83)90191-4; PONDER BAJ, 1985, J EMBRYOL EXP MORPH, V87, P229; RAND JH, 1987, ARTERIOSCLEROSIS, V7, P287, DOI 10.1161/01.ATV.7.3.287; RODEGHIERO F, 1987, BLOOD, V69, P454; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; Schwarz HP, 1997, THROMB HAEMOSTASIS, V78, P571; SMITH PL, 1994, J BIOL CHEM, V269, P15162; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SODETZ JM, 1979, J BIOL CHEM, V254, P754; Stoddart JH, 1996, BLOOD, V88, P1692; SWEENEY JD, 1990, BLOOD, V76, P2258; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; UITERDIJK HG, 1986, GENET RES, V47, P125, DOI 10.1017/S0016672300022953; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WatkinsChow D, 1996, MAMM GENOME, V6, pS201	49	131	134	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					111	120		10.1016/S0092-8674(00)80964-2	http://dx.doi.org/10.1016/S0092-8674(00)80964-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989502	Bronze			2022-12-01	WOS:000078023200013
J	Lucas, RJ; Freedman, MS; Munoz, M; Garcia-Fernandez, JM; Foster, RG				Lucas, RJ; Freedman, MS; Munoz, M; Garcia-Fernandez, JM; Foster, RG			Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors	SCIENCE			English	Article							SEROTONIN N-ACETYLTRANSFERASE; BLUE-LIGHT PHOTORECEPTORS; RETINOHYPOTHALAMIC TRACT; CGMP-PHOSPHODIESTERASE; RETINAL DEGENERATION; BETA-SUBUNIT; RD MOUSE; PHOTOENTRAINMENT; MUTATION; PIGMENT	In mammals, ocular photoreceptors mediate an acute inhibition of pineal melatonin by light. The effect of rod and cone loss on this response was assessed by combining the rd mutation with a transgenic ablation of cones (cl) to produce mice lacking both photoreceptor classes. Despite the loss of all known retinal photoreceptors, rd/rd cl mice showed normal suppression of pineal melatonin in response to monochromatic light of wavelength 509 nanometers. These data indicate that mammals have additional ocular photoreceptors that they use in the regulation of temporal physiology.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England; Univ Oviedo, Dept Morfol & Biol Celular, Oviedo 33072, Spain	Imperial College London; University of Oviedo	Lucas, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Sir Alexander Fleming Bldg, London SW7 2AZ, England.		Llamosas, Marta Muñoz/A-7667-2008	Llamosas, Marta Muñoz/0000-0002-9832-3523; Garcia-Fernandez, Jose M./0000-0003-1347-8305; Lucas, Robert/0000-0002-1088-8029				Arendt J., 1995, MELATONIN MAMMALIAN; BAEHR W, 1988, FEBS LETT, V238, P253, DOI 10.1016/0014-5793(88)80490-3; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2547, DOI 10.1073/pnas.69.9.2547; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2208, DOI 10.1073/pnas.69.8.2208; EBIHARA S, 1986, SCIENCE, V231, P491, DOI 10.1126/science.3941912; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; KLEIN DC, 1979, BRAIN RES, V174, P245, DOI 10.1016/0006-8993(79)90848-5; LUCAS RJ, IN PRESS ENDOCRINOLO; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Provencio I, 1998, J COMP NEUROL, V395, P417, DOI 10.1002/(SICI)1096-9861(19980615)395:4<417::AID-CNE1>3.0.CO;2-4; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Rodieck R, 1998, 1 STEPS SEEING; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7; Sun H, 1997, P NATL ACAD SCI USA, V94, P8860, DOI 10.1073/pnas.94.16.8860; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; vonSchantz M, 1997, BRAIN RES, V770, P131, DOI 10.1016/S0006-8993(97)00791-9; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WETTERBERG L, 1993, LIGHT BIOL RHYTHMS M, V62	27	389	397	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					505	507		10.1126/science.284.5413.505	http://dx.doi.org/10.1126/science.284.5413.505			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205062				2022-12-01	WOS:000079792200053
J	Goldberg, RJ; Samad, NA; Yarzebski, J; Gurwitz, J; Bigelow, C; Gore, JM				Goldberg, RJ; Samad, NA; Yarzebski, J; Gurwitz, J; Bigelow, C; Gore, JM			Temporal trends in cardiogenic shock complicating acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMMUNITY-WIDE PERSPECTIVE; WORCESTER-HEART-ATTACK; AORTIC BALLOON COUNTERPULSATION; TISSUE-PLASMINOGEN-ACTIVATOR; CORONARY-CARE UNIT; GUSTO-I TRIAL; ANGIOPLASTY THERAPY; GENDER DIFFERENCES; SURVIVAL RATES; MORTALITY	Background Limited information is available on trends in the incidence of and mortality due to cardiogenic shock complicating acute myocardial infarction. We studied the incidence of cardiogenic shock complicating acute myocardial infarction and in-hospital death rates among patients with this condition in a single community from 1975 through 1997. Methods We conducted an observational study of 9076 residents of metropolitan Worcester, Massachusetts, who were hospitalized with confirmed acute myocardial infarction in all local hospitals during 11 one-year periods between 1975 and 1997. Our study included periods before and after the advent of reperfusion therapy. Results The incidence of cardiogenic shock remained relatively stable over time, averaging 7.1 percent among patients with acute myocardial infarction. The results of a multivariable regression analysis indicated that the patients hospitalized during recent study years were not at a substantially lower risk for shock than patients hospitalized in the mid-to-late 1970s. Patients in whom cardiogenic shock developed had a significantly greater risk of dying during hospitalization (71.7 percent) than those who did not have cardiogenic shock (12.0 percent, P<0.001). A significant trend toward an increase in in-hospital survival among patients with cardiogenic shock in the mid-to-late 1990s was found in crude and adjusted analyses. Conclusions Our findings indicate no significant change in the incidence of cardiogenic shock complicating acute myocardial infarction over a 23-year period. However, the short-term survival rate has increased in recent years at the same time as the use of coronary reperfusion strategies has increased. (N Engl J Med 1999;340:1162-8.) (C)1999, Massachusetts Medical Society.	Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA 01655 USA; Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Biostat & Epidemiol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Amherst	Goldberg, RJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, 55 Lake Ave N, Worcester, MA 01655 USA.	roberr.goldberg@ummc.ummed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035434] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL35434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1986, LANCET, V1, P397; BENGTSON JR, 1992, J AM COLL CARDIOL, V20, P1482, DOI 10.1016/0735-1097(92)90440-X; Berger PB, 1997, CIRCULATION, V96, P122; BOLOOKI H, 1989, CIRCULATION, V79, P137; CALIFF RM, 1994, NEW ENGL J MED, V330, P1724, DOI 10.1056/NEJM199406163302406; CHEITLIN MD, 1988, JAMA-J AM MED ASSOC, V260, P2894, DOI 10.1001/jama.260.19.2894; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; COL NF, 1994, AM J CARDIOL, V73, P149, DOI 10.1016/0002-9149(94)90206-2; DEWOOD MA, 1980, CIRCULATION, V61, P1105, DOI 10.1161/01.CIR.61.6.1105; DOMANSKI MJ, 1994, AM J CARDIOL, V74, P724, DOI 10.1016/0002-9149(94)90318-2; GACIOCH GM, 1992, J AM COLL CARDIOL, V19, P647, DOI 10.1016/S0735-1097(10)80286-4; GHEORGHIADE M, 1988, AM HEART J, V116, P1212; GOLDBERG R, 1979, JOHNS HOPKINS MED J, V144, P73; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDBERG RJ, 1986, JAMA-J AM MED ASSOC, V255, P2774, DOI 10.1001/jama.255.20.2774; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GOLDBERG RJ, 1989, CIRCULATION, V79, P1369, DOI 10.1161/01.CIR.79.6.1369; GURWITZ JH, 1994, ARCH INTERN MED, V154, P2202; HANDS ME, 1989, J AM COLL CARDIOL, V14, P40, DOI 10.1016/0735-1097(89)90051-X; HIBBARD MD, 1992, J AM COLL CARDIOL, V19, P639, DOI 10.1016/S0735-1097(10)80285-2; HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; Holmes DR, 1997, LANCET, V349, P75, DOI 10.1016/S0140-6736(96)03031-0; KILLIP T, 1989, J AM COLL CARDIOL, V14, P47, DOI 10.1016/0735-1097(89)90052-1; KOBAYASHI M, 1984, JPN CIRC J, V48, P650, DOI 10.1253/jcj.48.650; KUHN LA, 1967, AM HEART J, V74, P578, DOI 10.1016/0002-8703(67)90019-1; LEE L, 1991, J AM COLL CARDIOL, V17, P599, DOI 10.1016/S0735-1097(10)80171-8; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LEOR J, 1993, AM J MED, V94, P265, DOI 10.1016/0002-9343(93)90058-W; Moscucci Mauro, 1995, Cardiology Clinics, V13, P391; ONEILL WW, 1992, J AM COLL CARDIOL, V19, P915, DOI 10.1016/0735-1097(92)90270-W; PAGLEY PR, 1993, ARCH INTERN MED, V153, P625, DOI 10.1001/archinte.153.5.625; Peterson ED, 1997, ANN INTERN MED, V126, P561, DOI 10.7326/0003-4819-126-7-199704010-00012; SCHEIDT S, 1973, NEW ENGL J MED, V288, P979, DOI 10.1056/NEJM197305102881901; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	37	404	424	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1162	1168		10.1056/NEJM199904153401504	http://dx.doi.org/10.1056/NEJM199904153401504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202167	Green Published			2022-12-01	WOS:000079687700004
J	Wang, HG; Pathan, N; Ethell, IM; Krajewski, S; Yamaguchi, Y; Shibasaki, F; McKeon, F; Bobo, T; Franke, TF; Reed, JC				Wang, HG; Pathan, N; Ethell, IM; Krajewski, S; Yamaguchi, Y; Shibasaki, F; McKeon, F; Bobo, T; Franke, TF; Reed, JC			Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD	SCIENCE			English	Article							CELL-DEATH; BCL-2 FAMILY; PERMEABILITY TRANSITION; NEURON SURVIVAL; CYCLOSPORINE-A; PHOSPHORYLATION; PROTEIN; AKT; ACTIVATION; MITOCHONDRIA	The Ca2+-activated protein phosphatase calcineurin induces apoptosis, but the mechanism is unknown. Calcineurin was found to dephosphorylate BAD, a pro-apoptotic member of the Bcl-2 family, thus enhancing BAD heterodimerization with Bcl-x(L) and promoting apoptosis. The Ca2+-induced dephosphorylation of BAD correlated with its dissociation from 14-3-3 in the cytosol and translocation to mitochondria where Bcl-x(L) resides. In hippocampal neurons, L-glutamate, an inducer of Ca2+ influx and calcineurin activation, triggered mitochondrial targeting of BAD and apoptosis, which were both suppressible by coexpression of a dominant-inhibitory mutant of calcineurin or pharmacological inhibitors of this phosphatase. Thus, a Ca2+-inducible mechanism for apoptosis induction operates by regulating BAD phosphorylation and Localization in cells.	Burnham Inst, La Jolla, CA 92037 USA; Univ S Florida, Dept Pharmacol & Therapeut, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Sanford Burnham Prebys Medical Discovery Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Harvard University; Harvard Medical School; Columbia University	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-institute.org	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Ethell, Iryna/0000-0002-1324-6611	NCI NIH HHS [CA-69381] Funding Source: Medline; NIA NIH HHS [AG-1593] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Ethell IM, 1999, J CELL BIOL, V144, P575, DOI 10.1083/jcb.144.3.575; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; FURUYA Y, 1994, CANCER RES, V54, P6167; HARADA H, IN PRESS MOL CELL; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kitada S, 1998, AM J PATHOL, V152, P51; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; PATHAN N, UNPUB; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Schinder AF, 1996, J NEUROSCI, V16, P6125; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WANG H, UNPUB; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wood AM, 1998, J NEUROCHEM, V70, P677; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	37	977	1022	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					339	343		10.1126/science.284.5412.339	http://dx.doi.org/10.1126/science.284.5412.339			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195903				2022-12-01	WOS:000079636400049
J	Kosslyn, SM; Pascual-Leone, A; Felician, O; Camposano, S; Keenan, JP; Thompson, WL; Ganis, G; Sukel, KE; Alpert, NM				Kosslyn, SM; Pascual-Leone, A; Felician, O; Camposano, S; Keenan, JP; Thompson, WL; Ganis, G; Sukel, KE; Alpert, NM			The role of Area 17 in visual imagery: Convergent evidence from PET and rTMS	SCIENCE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; POSITRON EMISSION TOMOGRAPHY; OCCIPITAL CORTEX; PERCEPTION; CONNECTIVITY	Visual imagery is used in a wide range of mental activities, ranging from memory to reasoning, and also plays a role in perception proper. The contribution of early visual cortex, specifically Area 17, to Visual mental imagery was examined by the use of two convergent techniques. In one, subjects closed their eyes during positron emission tomography (PET) while they visualized and compared properties (for example, relative length) of sets of stripes. The results showed that when people perform this task, Area 17 is activated. In the other, repetitive transcranial magnetic stimulation (rTMS) was applied to medial occipital cortex before presentation of the same task. Performance was impaired after rTMS compared with a sham control condition; similar results were obtained when the subjects performed the task by actually Looking at the stimuli. In sum, the PET results showed that when patterns of stripes are visualized, Area 17 is activated, and the rTMS results showed that such activation underlies information processing.	Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Lab Magnet Brain Stimulat,Behav Neurol Unit, Boston, MA 02215 USA	Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kosslyn, SM (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.	smk@wjh.harvard.edu	Pascual-Leone, Alvaro/AAC-5101-2019; Felician, Olivier/F-1212-2011; Pascual-Leone, Alvaro/G-6566-2011	Pascual-Leone, Alvaro/0000-0001-8975-0382; Felician, Olivier/0000-0002-1481-1846; Ganis, Giorgio/0000-0001-6175-2618	NATIONAL EYE INSTITUTE [R01EY012091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057980] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY12091] Funding Source: Medline; NIMH NIH HHS [R01 MH57980] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMASSIAN VE, 1989, ELECTROEN CLIN NEURO, V74, P458, DOI 10.1016/0168-5597(89)90036-1; ARNASSIAN VE, 1998, J CLIN NEUROPHYSIOL, V15, P288; BECKERS G, 1995, BRAIN, V118, P49, DOI 10.1093/brain/118.1.49; BECKERS G, 1991, EXP BRAIN RES, V87, P421; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; DEsposito M, 1997, NEUROPSYCHOLOGIA, V35, P725, DOI 10.1016/S0028-3932(96)00121-2; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; Kosslyn S., 1980, IMAGE MIND; Kosslyn S.M., 1994, IMAGE BRAIN RESOLUTI; Kosslyn SM, 1998, PSYCHOPHYSIOLOGY, V35, P151, DOI 10.1111/1469-8986.3520151; KOSSLYN SM, IN PRESS MEM COGNIT; MARSOLEK CJ, 1997, CERBRAL ASYMMETRIES; Mellet E, 1998, NEUROIMAGE, V8, P129, DOI 10.1006/nimg.1998.0355; MELLET E, 1995, J COGNITIVE NEUROSCI, V7, P433, DOI 10.1162/jocn.1995.7.4.433; MELLET E, IN PRESS NEUROIMAGE; PASCUALLEONE A, 1994, NEW HORIZONS COGNITI; PASCUALLEONE A, 1996, HDB NEUROPSYCHOLOGY, V11; Paus T, 1997, J NEUROSCI, V17, P3178; Potts GF, 1998, J CLIN NEUROPHYSIOL, V15, P344, DOI 10.1097/00004691-199807000-00006; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; THOMPSON WL, IN PRESS BRAIN MAPPI; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; Tye M., 1991, THE IMAGERY DEBATE; Walsh V, 1998, TRENDS COGN SCI, V2, P103, DOI 10.1016/S1364-6613(98)01134-6; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127	29	508	526	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1999	284	5411					167	170		10.1126/science.284.5411.167	http://dx.doi.org/10.1126/science.284.5411.167			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102821				2022-12-01	WOS:000079509000060
J	Bhat, MA; Izaddoost, S; Lu, Y; Cho, KO; Choi, KW; Bellen, HJ				Bhat, MA; Izaddoost, S; Lu, Y; Cho, KO; Choi, KW; Bellen, HJ			Discs lost, a novel multi-PDZ domain protein, establishes and maintains epithelial polarity	CELL			English	Article							DROSOPHILA-MELANOGASTER; CELL POLARITY; ZONULA ADHERENS; MUTATIONS; JUNCTIONS; CRUMBS; EXPRESSION; ARMADILLO; ADHESION; SEPTATE	Polarization of epithelial cells depends on a hierarchical process whereby specific membrane-associated proteins become targeted to specialized membrane domains. Here, we describe a novel Drosophila protein, Discs Lost (DLT), that plays a crucial role in the polarization of embryonic epithelia during cellular blastoderm formation. At subsequent stages of development, DLT interacts with the apical determinant Crumbs (CRB) and the laterally localized protein Neurexin IV (NRX IV). Mutations in dlt or double-stranded RNA interference lead to aberrant localization of CRB and NRX IV and cause a concomitant loss of epithelial cell polarity. Hence, DLT is required to establish and maintain cell polarity and participates in different molecular complexes that define apical and lateral membrane domains.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Bellen, HJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.	hbellen@bcm.tmc.edu	Choi, Kwang-Wook/C-1707-2011; Cho, Kyung-Ok/C-1705-2011; BHAT, MANZOOR/S-9273-2018	Choi, Kwang-Wook/0000-0002-8997-3065; Cho, Kyung-Ok/0000-0002-0760-2560; Bellen, Hugo/0000-0001-5992-5989; BHAT, MANZOOR/0000-0003-0989-1498				Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Balda MS, 1998, J CELL SCI, V111, P541; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bellen HJ, 1998, TRENDS NEUROSCI, V21, P444, DOI 10.1016/S0166-2236(98)01267-3; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1993, BIOESSAYS, V15, P383, DOI 10.1002/bies.950150604; CHOU TB, 1992, GENETICS, V131, P643; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LEE JK, 1993, J CELL BIOL, V123, P1797, DOI 10.1083/jcb.123.6.1797; Littleton JT, 1997, J CELL BIOL, V137, P793, DOI 10.1083/jcb.137.4.793; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Salzberg A, 1997, GENETICS, V147, P1723; SCHEJTER ED, 1993, ANNU REV CELL BIOL, V9, P67, DOI 10.1146/annurev.cb.09.110193.000435; SLITER TJ, 1989, GENETICS, V123, P327; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Tepass U, 1997, BIOESSAYS, V19, P673, DOI 10.1002/bies.950190807; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; WANG M, 1994, MOL GEN GENET, V245, P598, DOI 10.1007/BF00282222; Ward RE, 1998, J CELL BIOL, V140, P1463, DOI 10.1083/jcb.140.6.1463; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WODARZ A, 1993, MECH DEVELOP, V44, P175, DOI 10.1016/0925-4773(93)90066-7; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; [No title captured]	43	232	238	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	1999	96	6					833	845		10.1016/S0092-8674(00)80593-0	http://dx.doi.org/10.1016/S0092-8674(00)80593-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102271	Bronze			2022-12-01	WOS:000079300100010
J	Ruiz-Trillo, I; Riutort, M; Littlewood, DTJ; Herniou, EA; Baguna, J				Ruiz-Trillo, I; Riutort, M; Littlewood, DTJ; Herniou, EA; Baguna, J			Acoel flatworms: Earliest extant bilaterian metazoans, not members of Platyhelminthes	SCIENCE			English	Article							18S RDNA SEQUENCES; MAXIMUM-LIKELIHOOD; MOLECULAR CLOCK; RIBOSOMAL-RNA; DNA-SEQUENCES; EVOLUTION; PHYLA; LIFE; TREE	Because of their simple organization the Acoela have been considered to be either primitive bilaterians or descendants of coelomates through secondary loss of derived features. Sequence data of 18S ribosomal DNA genes from non-fast evolving species of acoels and other metazoans reveal that this group does not belong to the Platyhelminthes but represents the extant members of the earliest divergent Bilateria, an interpretation that is supported by recent studies on the embryonic cleavage pattern and nervous system of acoels. This study has implications for understanding the evolution of major body plans, and for perceptions of the Cambrian evolutionary explosion.	Nat Hist Museum, Dept Zool, London SW7 5BD, England; Univ Barcelona, Fac Biol, Dept Genet, E-08028 Barcelona, Spain	Natural History Museum London; University of Barcelona	Baguna, J (corresponding author), Nat Hist Museum, Dept Zool, Cromwell Rd, London SW7 5BD, England.	bagunya@porthos.bio.ub.es	Ruiz-Trillo, Iñaki/C-1360-2008; Littlewood, Tim/B-5230-2008; Ruiz-Trillo, Iñaki/H-3217-2019; Herniou, Elisabeth/B-3786-2016; Riutort, Marta/B-6441-2009	Ruiz-Trillo, Iñaki/0000-0001-6547-5304; Littlewood, Tim/0000-0002-2718-4001; Ruiz-Trillo, Iñaki/0000-0001-6547-5304; Herniou, Elisabeth/0000-0001-5362-6056; Riutort, Marta/0000-0002-2134-7674	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Ax P, 1996, MULTICELLULAR ANIMAL; AX P, 1963, LOWER METAZOA, P191; Ax P., 1987, PHYLOGENETIC SYSTEM; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Boyer BC, 1998, AM ZOOL, V38, P621; BOYER BC, 1971, J EXP ZOOL, V176, P97, DOI 10.1002/jez.1401760110; BRORNHARN L, 1998, P NATL ACAD SCI USA, V95, P12386; Brusca R.C., 1990, INVERTEBRATES; Carranza S, 1997, MOL BIOL EVOL, V14, P485, DOI 10.1093/oxfordjournals.molbev.a025785; Carranza S, 1996, MOL BIOL EVOL, V13, P824, DOI 10.1093/oxfordjournals.molbev.a025643; Conway-Morris S., 1998, CRUCIBLE CREATION; Ehlers U, 1985, PHYLOGENETISCHE SYST; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; Hadzi J, 1963, EVOLUTION METAZOA; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Haszprunar G, 1996, J ZOOL SYST EVOL RES, V34, P41; HENRY JE, COMMUNICATION; Hyman L.H., 1951, ACOELOMATE BILATERIA, P550; Jagersten G, 1972, EVOLUTION METAZOAN L; Karling T.G., 1974, P1; KATAYAMA T, 1993, ZOOL SCI, V10, P529; LI WH, 1987, NATURE, V326, P93, DOI 10.1038/326093a0; Littlewood DTJ, 1999, BIOL J LINN SOC, V66, P75, DOI 10.1111/j.1095-8312.1999.tb01918.x; Morris SC, 1998, BIOESSAYS, V20, P676, DOI 10.1002/(SICI)1521-1878(199808)20:8<676::AID-BIES11>3.0.CO;2-W; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; Nielsen C, 2012, ANIMAL EVOLUTION: INTERRELATIONSHIPS OF THE LIVING PHYLA, 3RD EDITION, P1; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; PHILIPPE H, 1994, DEVELOPMENT, P15; RAFF RA, 1994, ANNU REV ECOL SYST, V25, P351, DOI 10.1146/annurev.es.25.110194.002031; Raikova OI, 1998, ZOOMORPHOLOGY, V118, P69, DOI 10.1007/s004350050058; REISINGER E, 1972, Zeitschrift fuer Zoologische Systematik und Evolutionsforschung, V10, P1; Reuter M, 1998, TISSUE CELL, V30, P57, DOI 10.1016/S0040-8166(98)80006-2; Rieger R, 1985, ORIGINS RELATIONSHIP, P101; RIEGER RM, 1994, AM ZOOL, V34, P484; Rieger RM, 1991, MICROSCOPIC ANATOMY, V3, P7; SALVINIPLAWEN LV, 1978, Z ZOOL SYST EVOL, V16, P40; Siewing R., 1980, Zoologische Jahrbuecher Abteilung fuer Anatomie und Ontogenie der Tiere, V103, P439; SMITH MR, 1986, IEEE T MED IMAGING, V5, P132, DOI 10.1109/TMI.1986.4307762; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815; Tyler S, 1985, ORIGINS RELATIONSHIP, P123; Valentine JW, 1997, P NATL ACAD SCI USA, V94, P8001, DOI 10.1073/pnas.94.15.8001; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; WINNEPENNINCKX B, 1995, MOL BIOL EVOL, V12, P641; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; Zrzavy J, 1998, CLADISTICS, V14, P249, DOI 10.1111/j.1096-0031.1998.tb00338.x	48	353	366	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1999	283	5409					1919	1923		10.1126/science.283.5409.1919	http://dx.doi.org/10.1126/science.283.5409.1919			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10082465				2022-12-01	WOS:000079228600049
J	Winkleby, MA; Robinson, TN; Sundquist, J; Kraemer, HC				Winkleby, MA; Robinson, TN; Sundquist, J; Kraemer, HC			Ethnic variation in cardiovascular disease risk factors among children and young adults - Findings from the Third National Health and Nutrition Examination Survey, 1988-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HISPANIC WHITE-CHILDREN; BODY-MASS INDEX; SOCIOECONOMIC-STATUS; DIABETES-MELLITUS; RACIAL-DIFFERENCES; MEXICAN-AMERICANS; BLOOD-PRESSURE; INSULIN; ADOLESCENTS; GROWTH	Context Knowledge about ethnic differences in cardiovascular disease (CVD) risk factors among children and young adults from national samples is limited. Objective To evaluate ethnic differences in CVD risk factors, the age at which differences were first apparent, and whether differences remained after accounting for socioeconomic status (SES). Design Third National Health and Nutrition Examination Survey, 1988-1994, Setting Eighty-nine mobile examination centers, Participants A total of 2769 black, 2854 Mexican American, and 2063 white (non-Hispanic) children and young adults aged 6 to 24 years. Main Outcome Measures Ethnicity and household level of education (SES) in relation to body mass index (BMI), percentage of energy from dietary fat, cigarette smoking, systolic blood pressure, glycosylated hemoglobin (HbA(1c)), and non-high-density lipoprotein cholesterol (non-HDL-C [the difference between total cholesterol and HDL-C]). Results The BMI levels were significantly higher for black and Mexican American girls than for white girls, with ethnic differences evident by the age of 6 to 9 years (a difference of approximately 0.5 BMI units) and widening thereafter (a difference of >2 BMI units among 18- to 24-year-olds). Percentages of energy from dietary fat paralleled these findings and were also significantly higher for black than for white boys. Blood pressure levels were higher for black girls than for white girls in every age group, and glycosylated hemoglobin levels were highest for black and Mexican American girls and boys in every age group. In contrast, smoking prevalence was highest for white girls and boys, especially for those from low-SES homes (77% of young men and 61% of young women, aged 18-24 years, from low-SES homes were current smokers). All ethnic differences remained significant after accounting for SES and age. Conclusion These findings show strong ethnic differences in CVD risk factors among youths of comparable age and SES from a large national sample. The differences highlight the need for heart disease prevention programs to begin early in childhood and continue throughout young adulthood to reduce the risk of atherosclerosis.	Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Dept Med, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA	Stanford University; Stanford University	Winkleby, MA (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Dept Med, 1000 Welch Rd, Palo Alto, CA 94304 USA.	Marilyn_Winkleby@SCRDP.Stanford.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL057100] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-RO3-HL-57100] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Andersen RE, 1998, JAMA-J AM MED ASSOC, V279, P938, DOI 10.1001/jama.279.12.938; [Anonymous], 1994, VITAL HLTH STAT, V1, P1; Bao WH, 1997, JAMA-J AM MED ASSOC, V278, P1749, DOI 10.1001/jama.278.21.1749; Batey LS, 1997, CIRCULATION, V96, P4319; BELCHER JD, 1993, PREV MED, V22, P143, DOI 10.1006/pmed.1993.1012; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; *BOG HEART STUD, 1995, AM J MED SCI, V310, pS1; BOYKO EJ, 1991, DIABETES, V40, P509, DOI 10.2337/diabetes.40.4.509; CUMMINGS SR, 1988, AM J PUBLIC HEALTH, V78, P574, DOI 10.2105/AJPH.78.5.574; Daniels SR, 1996, J PEDIATR-US, V129, P208, DOI 10.1016/S0022-3476(96)70244-5; Dietz WH, 1998, J PEDIATR-US, V132, P191; Dwyer JT, 1998, AM J CLIN NUTR, V67, P602, DOI 10.1093/ajcn/67.4.602; Ezzati T M, 1992, Vital Health Stat 2, P1; FOLSOM AR, 1989, AM J EPIDEMIOL, V130, P911, DOI 10.1093/oxfordjournals.aje.a115424; FORREST RD, 1987, DIABETIC MED, V4, P254, DOI 10.1111/j.1464-5491.1987.tb00875.x; GOFF DC, 1994, AM J EPIDEMIOL, V139, P474; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAFFNER SM, 1986, INT J OBESITY, V10, P493; HAVEL RJ, 1995, NEW ENGL J MED, V332, P1491, DOI 10.1056/NEJM199506013322207; HENDEE WR, 1991, JAMA-J AM MED ASSOC, V265, P248; JIANG XZ, 1995, ARCH INTERN MED, V155, P190, DOI 10.1001/archinte.155.2.190; JUDSON JJ, 1971, J AMER MED ASSOC, V216, P1185; Kaufman JS, 1997, EPIDEMIOLOGY, V8, P621, DOI 10.1097/00001648-199710000-00002; Kington RS, 1997, AM J PUBLIC HEALTH, V87, P805, DOI 10.2105/AJPH.87.5.805; KRIEGER N, 1993, AM J PUBLIC HEALTH, V83, P1086, DOI 10.2105/AJPH.83.8.1086; Liu K, 1996, CIRCULATION, V93, P60, DOI 10.1161/01.CIR.93.1.60; Lowry R, 1996, JAMA-J AM MED ASSOC, V276, P792, DOI 10.1001/jama.276.10.792; LYNCH J, 1995, CIRCULATION, V92, P1786, DOI 10.1161/01.CIR.92.7.1786; McNutt SW, 1997, J ADOLESCENT HEALTH, V20, P27, DOI 10.1016/S1054-139X(96)00176-0; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; NIETO FJ, 1992, AM J EPIDEMIOL, V136, P201, DOI 10.1093/oxfordjournals.aje.a116486; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; PinhasHamiel O, 1996, J PEDIATR-US, V128, P608, DOI 10.1016/S0022-3476(96)80124-7; RESNICOW K, 1990, AM J EPIDEMIOL, V132, P1083, DOI 10.1093/oxfordjournals.aje.a115751; Rockett HRH, 1997, AM J CLIN NUTR, V65, P1116; SHEA S, 1991, AM J EPIDEMIOL, V134, P567, DOI 10.1093/oxfordjournals.aje.a116130; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Srinivasan SR, 1996, METABOLISM, V45, P235, DOI 10.1016/S0026-0495(96)90060-8; STRONG JP, 1995, CLIN CHEM, V41, P134; Tortolero SR, 1997, CIRCULATION, V96, P418; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; US Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; *US PHS, 1994, HLTH US; Wagenknecht LE, 1998, ANN EPIDEMIOL, V8, P301, DOI 10.1016/S1047-2797(97)00211-1; Webber LS, 1996, PREV MED, V25, P432, DOI 10.1006/pmed.1996.0075; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; Winkleby MA, 1998, JAMA-J AM MED ASSOC, V280, P356, DOI 10.1001/jama.280.4.356; WINKLEBY MA, 1998, BIOMEDICINA, V1, P321	50	227	229	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1999	281	11					1006	1013		10.1001/jama.281.11.1006	http://dx.doi.org/10.1001/jama.281.11.1006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	175EE	10086435	Bronze			2022-12-01	WOS:000079079400027
J	Kampf, JP; Frank, CW; Malmstrom, EE; Hawker, CJ				Kampf, JP; Frank, CW; Malmstrom, EE; Hawker, CJ			Adaptation of bulk constitutive equations to insoluble monolayer collapse at the air-water interface	SCIENCE			English	Article							DENDRITIC MACROMOLECULES; ORIENTED POLYETHYLENE; PHASE-TRANSITIONS; LIGHT-SCATTERING; BEHAVIOR; CREEP; RELAXATION; NUCLEATION; POLYMER; SURFACE	A constitutive equation based on stress-strain models of bulk solids was adapted to relate the surface pressure, compression rate, and temperature of an insoluble monolayer of monodendrons during collapse at the air-water interface. power Law relation between compression rate and surface pressure and an Arrhenius temperature dependence of the steady-state creep rate were observed in data from compression rate and creep experiments in the collapse region. These relations were combined into a single constitutive equation to calculate the temperature dependence of the collapse pressure with a maximum error of 5 percent for temperatures ranging from 10 degrees to 25 degrees C.	Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; IBM Corp, Almaden Res Ctr, San Jose, CA 95120 USA	Stanford University; International Business Machines (IBM)	Frank, CW (corresponding author), Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.		Hawker, Craig J/G-4971-2011; Malmström, Eva E/G-3026-2010	Hawker, Craig J/0000-0001-9951-851X; Malmström, Eva E/0000-0002-8348-2273; Kampf, James/0000-0003-3050-3998				ADAMS J, 1993, MACROMOLECULES, V26, P2871, DOI 10.1021/ma00063a036; Ashby M. F., 1982, DEFORMATION MECH MAP; BAGLIONI P, 1980, J COLLOID INTERF SCI, V78, P347, DOI 10.1016/0021-9797(80)90573-1; CARDENASVALERA AE, 1993, COLLOID SURFACE A, V79, P115, DOI 10.1016/0927-7757(93)80166-C; Cheung CY, 1997, J RHEOL, V41, P45, DOI 10.1122/1.550858; Copeland LE, 1942, J CHEM PHYS, V10, P357, DOI 10.1063/1.1723735; EARNSHAW JC, 1993, J PHYS-CONDENS MAT, V5, P1769, DOI 10.1088/0953-8984/5/12/005; EARNSHAW JC, 1990, J PHYS-CONDENS MAT, V2, P8499, DOI 10.1088/0953-8984/2/42/026; Edwards D. A., 1991, INTERFACIAL TRANSPOR; EVANS WJ, 1983, J MATER SCI, V18, P3449, DOI 10.1007/BF00544173; FINDLEY WN, 1989, CREE RELAXATION NONL; Forrest JA, 1997, PHYS REV E, V56, P5705, DOI 10.1103/PhysRevE.56.5705; Fried J.R., 1995, POLYM SCI TECHNOLOGY, P4; Friedenberg MC, 1996, MACROMOLECULES, V29, P705, DOI 10.1021/ma9507812; Gaines Jr. G. L., 1966, INSOLUBLE MONOLAYERS; GOVAERT LE, 1995, POLYMER, V36, P4425, DOI 10.1016/0032-3861(95)96848-3; GOVAERT LE, 1993, POLYMER, V34, P534, DOI 10.1016/0032-3861(93)90546-M; HALPERIN K, 1989, LANGMUIR, V5, P161, DOI 10.1021/la00085a030; HAWKER CJ, 1995, J AM CHEM SOC, V117, P4409, DOI 10.1021/ja00120a028; Hawker CJ, 1997, J AM CHEM SOC, V119, P9903, DOI 10.1021/ja972027x; HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/ja00177a027; Kampf JP, 1999, LANGMUIR, V15, P227, DOI 10.1021/la980808l; KATO T, 1990, LANGMUIR, V6, P870, DOI 10.1021/la00094a027; KEDDIE JL, 1994, FARADAY DISCUSS, V98, P219, DOI 10.1039/fd9949800219; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; Krasowsky AJ, 1997, METALL MATER TRANS A, V28, P1831, DOI 10.1007/s11661-997-0113-7; KURI T, 1994, B CHEM SOC JPN, V67, P942, DOI 10.1246/bcsj.67.942; LEE WK, 1995, COLLOID SURFACE A, V102, P191, DOI 10.1016/0927-7757(95)03255-C; Maruyama T, 1998, LANGMUIR, V14, P1836, DOI 10.1021/la971047+; Maruyama T, 1996, SCIENCE, V274, P233, DOI 10.1126/science.274.5285.233; MEAGHER S, 1992, ACTA METALL MATER, V40, P159, DOI 10.1016/0956-7151(92)90209-W; NELSON DR, 1979, PHYS REV B, V19, P2457, DOI 10.1103/PhysRevB.19.2457; OBRIEN KC, 1985, LANGMUIR, V1, P453, DOI 10.1021/la00064a009; OIKAWA H, 1992, MAT SCI ENG A-STRUCT, V153, P427, DOI 10.1016/0921-5093(92)90232-P; PRAKASH O, 1992, ACTA METALL MATER, V40, P3443, DOI 10.1016/0956-7151(92)90058-M; Prucker O, 1998, MACROMOL CHEM PHYSIC, V199, P1435, DOI 10.1002/(SICI)1521-3935(19980701)199:7<1435::AID-MACP1435>3.0.CO;2-#; RAPP B, 1990, PHYS REV A, V42, P2215, DOI 10.1103/PhysRevA.42.2215; RETTER U, 1992, LANGMUIR, V8, P1693, DOI 10.1021/la00043a001; SEITZ M, 1996, THIN SOLID FILMS, V285, P304; Skarlupka R, 1998, POLYMER, V39, P387, DOI 10.1016/S0032-3861(97)00275-9; SPERLING LH, 1992, INTRO PHYSICALA POLY; TOMALIA DA, 1994, ADV MATER, V6, P529, DOI 10.1002/adma.19940060703; TOMOAIACOTISEL M, 1983, J COLLOID INTERF SCI, V94, P390, DOI 10.1016/0021-9797(83)90278-3; Uppuluri S, 1998, MACROMOLECULES, V31, P4498, DOI 10.1021/ma971199b; VOLLHARDT D, 1991, J PHYS CHEM-US, V95, P3723, DOI 10.1021/j100162a052; VOLLHARDT D, 1991, THIN SOLID FILMS, V199, P189, DOI 10.1016/0040-6090(91)90065-6; VOLLHARDT D, 1992, LANGMUIR, V8, P309, DOI 10.1021/la00037a056; Wagner J, 1996, LANGMUIR, V12, P2807, DOI 10.1021/la950962x; WANG LF, 1995, MATER CHEM PHYS, V40, P197, DOI 10.1016/0254-0584(94)01469-W; YOUNG AP, 1979, PHYS REV B, V19, P1855, DOI 10.1103/PhysRevB.19.1855	50	32	33	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	1999	283	5408					1730	1733		10.1126/science.283.5408.1730	http://dx.doi.org/10.1126/science.283.5408.1730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175PF	10073937				2022-12-01	WOS:000079102800050
J	Tomoda, K; Kubota, Y; Kato, J				Tomoda, K; Kubota, Y; Kato, J			Degradation of the cyclin-dependent-kinase inhibitor p27(Kip1) is instigated by Jab1	NATURE			English	Article							CELL-CYCLE; CDK INHIBITOR; PROTEIN; PHOSPHORYLATION; GENE; BINDING; ARREST; CRM1; BETA; P27	The proliferation of mammalian cells is under strict control, and the cyclin-dependent-kinase inhibitory protein p27(Kip1) is an essential participant in this regulation both in vitro and in vivo(1). Although mutations in p27(Kip1) are rarely found in human tumours, reduced expression of the protein correlates well with poor survival among patients with breast or colorectal carcinomas(2), suggesting that disruption of the p27(Kip1) regulatory mechanisms contributes to neoplasia. The abundance of p27(Kip1) in the cell is determined either at or after translation(3), for example as a result of phosphorylation by cyclinE/Cdk2 complexes(4,5), degradation by the ubiquitin/proteasome pathway(6), sequestration by unknown Myc-inducible proteins(7), binding to cyclinD/Cdk4 complexes(8), or inactivation by the viral ElA oncoprotein(9). We have found that a mouse 38K protein (p38) encoded by the Jab1 gene(10) interacts specifically with p27(Kip1) and show here that ol overexpression of p38 in mammalian cells causes the translocation of p27(Kip1) from the nucleus to the cytoplasm, decreasing the amount of p27(Kip1) in the cell by accelerating its degradation. Ectopic expression of p38 in mouse fibroblasts partially overcomes p27(Kip1)-mediated arrest in the G1 phase of the cell cycle and markedly reduces their dependence on serum. Our findings indicate that p38 functions as a negative regulator of p27(Kip1) by promoting its degradation.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Nara Institute of Science & Technology	Kato, J (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	jkata@bs.aist-nara.ac.jp						Akamatsu E, 1998, J BIOL CHEM, V273, P16494, DOI 10.1074/jbc.273.26.16494; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; KATO J, 1993, GENE DEV, V7, P331; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NISHI K, 1994, J BIOL CHEM, V269, P6320; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Steeg PS, 1997, NAT MED, V3, P152, DOI 10.1038/nm0297-152; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7	30	550	584	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	1999	398	6723					160	165		10.1038/18230	http://dx.doi.org/10.1038/18230			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176DG	10086358				2022-12-01	WOS:000079135200047
J	Hutin, YJF; Pool, V; Cramer, EH; Nainan, OV; Weth, J; Williams, IT; Goldstein, ST; Gensheimer, KF; Bell, BP; Shapiro, CN; Alter, MJ; Margolis, HS				Hutin, YJF; Pool, V; Cramer, EH; Nainan, OV; Weth, J; Williams, IT; Goldstein, ST; Gensheimer, KF; Bell, BP; Shapiro, CN; Alter, MJ; Margolis, HS		Natl Hepatitis A Invest Team	A multistate, foodborne outbreak of hepatitis A	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							A VIRUS; FROZEN RASPBERRIES; SEQUENCE-ANALYSIS; AMPLIFICATION; PROGRAMS; STRAINS	Background We investigated a large, foodborne outbreak of hepatitis A that occurred in February and March 1997 in Michigan and then extended the investigation to determine whether it was related to sporadic cases reported in other states among persons who had consumed frozen strawberries, the food suspected of causing the outbreak. Methods The cases of hepatitis A were serologically confirmed. Epidemiologic studies were conducted in the two states with sufficient numbers of cases, Michigan and Maine. Hepatitis A virus RNA detected in clinical specimens was sequenced to determine the relatedness of the virus from outbreak-related cases and other cases. Results A total of 213 cases of hepatitis A were reported from 23 schools in Michigan and 29 cases from 13 schools in Maine, with the median rate of attack ranging from 0.2 to 14 percent. Hepatitis A was associated with the consumption of frozen strawberries in a case-control study (odds ratio for the disease, 8.3; 95 percent confidence interval, 2.1 to 33) and a cohort study (relative risk of infection, 7.5; 95 percent confidence interval, 1.1 to 53) in Michigan and in a case-control study in Maine (odds ratio for infection, 3.4; 95 percent confidence interval, 1.0 to 14). The genetic sequences of viruses from 126 patients in Michigan and Maine were identical to one another and to those from 5 patients in Wisconsin and 7 patients in Arizona, all of whom attended schools where frozen strawberries from the same processor had been served, and to those in 2 patients from Louisiana, both of whom had consumed commercially prepared products containing frozen strawberries from the same processor. Conclusions We describe a large outbreak of hepatitis A in Michigan that was associated with the consumption of frozen strawberries. We found apparently sporadic cases in other states that could be linked to the same source by viral genetic analysis. (N Engl J Med 1999;340:595-602.) (C)1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Hepatitis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA 30333 USA; Calhoun Cty Dept Hlth, Battle Creek, MI USA; Maine State Bur Hlth, Augusta, ME USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Hutin, YJF (corresponding author), Ctr Dis Control & Prevent, Hepatitis Branch, Mailstop G37, Atlanta, GA 30333 USA.							Bell BP, 1998, J INFECT DIS, V178, P1579, DOI 10.1086/314518; Bender JB, 1997, NEW ENGL J MED, V337, P388, DOI 10.1056/NEJM199708073370604; BROWN VK, 1990, BIOTECHNIQUES, V8, P262; CARL M, 1983, J INFECT DIS, V148, P1133, DOI 10.1093/infdis/148.6.1133; *CDCP, 1996, 56 CDCP, P25; COHEN JI, 1987, J VIROL, V61, P50, DOI 10.1128/JVI.61.1.50-59.1987; Dean A.G., 1994, EPI INFO VERSION 6 W; DESENCLOS JCA, 1991, AM J PUBLIC HEALTH, V81, P1268, DOI 10.2105/AJPH.81.10.1268; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; *ENV PROT AG, 1997, FOOD SAF FARM TABL N; Killalea D, 1996, BMJ-BRIT MED J, V313, P1105, DOI 10.1136/bmj.313.7065.1105; MCCAUSTLAND KA, 1982, J CLIN MICROBIOL, V16, P957, DOI 10.1128/JCM.16.5.957-958.1982; Nainan OV, 1996, J VIROL METHODS, V61, P127, DOI 10.1016/0166-0934(96)02077-0; NAINAN OV, 1991, J GEN VIROL, V72, P1685, DOI 10.1099/0022-1317-72-7-1685; NIU MT, 1992, J INFECT DIS, V166, P518, DOI 10.1093/infdis/166.3.518; Noah N. D., 1981, MED LAB SCI, V38, P428; PORTNOY BL, 1975, JAMA-J AM MED ASSOC, V233, P1065, DOI 10.1001/jama.233.10.1065; RAMSAY CN, 1989, LANCET, V1, P43; REID TMS, 1987, EPIDEMIOL INFECT, V98, P109, DOI 10.1017/S095026880006177X; ROBERTSON BH, 1992, J GEN VIROL, V73, P1365, DOI 10.1099/0022-1317-73-6-1365; ROSENBLUM LS, 1990, AM J PUBLIC HEALTH, V80, P1075, DOI 10.2105/AJPH.80.9.1075; Rushing J. W., 1996, Dairy, Food and Environmental Sanitation, V16, P549; SCHUCHAT A, 1991, CLIN MICROBIOL REV, V4, P396, DOI 10.1128/CMR.4.3.396-.1991; SIEGL G, 1984, HEPATITIS A, P9; 1997, MMWR MORB MORTAL WKL, V46, P288	25	251	268	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					595	602		10.1056/NEJM199902253400802	http://dx.doi.org/10.1056/NEJM199902253400802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169NP	10029643				2022-12-01	WOS:000078755700002
J	Shibahara, K; Stillman, B				Shibahara, K; Stillman, B			Replication-dependent marking of DNA by PCNA facilitates CAF-1-coupled inheritance of chromatin	CELL			English	Article							CELL NUCLEAR ANTIGEN; ASSEMBLY FACTOR-I; NUCLEOTIDE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; SACCHAROMYCES-CEREVISIAE; POLYMERASE-DELTA; FACTOR-C; AUXILIARY PROTEINS; ACCESSORY PROTEINS; INVITRO	Chromatin assembly factor 1 (CAF-1) is required for inheritance of epigenetically determined chromosomal states in vivo and promotes assembly of chromatin during DNA replication in vitro. Herein, we demonstrate that after DNA replication, replicated, but not unreplicated, DNA is also competent for CAF-1-dependent chromatin assembly. The proliferating cell nuclear antigen (PCNA), a DNA polymerase clamp, is a component of the replication-dependent marking of DNA for chromatin assembly. The clamp loader, replication factor C (RFC), can reverse this mark by unloading PCNA from the replicated DNA. PCNA binds directly to p150, the largest subunit of CAF-1, and the two proteins colocalize at sites of DNA replication in cells. We suggest that PCNA and CAF-1 connect DNA replication to chromatin assembly and the inheritance of epigenetic chromosome states.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	stillman@cshl.org		Stillman, Bruce/0000-0002-9453-4091	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DEPAMPHILIS ML, 1980, ANNU REV BIOCHEM, V49, P627, DOI 10.1146/annurev.bi.49.070180.003211; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FOTEDAR R, 1989, P NATL ACAD SCI USA, V86, P6459, DOI 10.1073/pnas.86.17.6459; Gaillard PHL, 1997, EMBO J, V16, P6281, DOI 10.1093/emboj/16.20.6281; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grewal SIS, 1998, GENETICS, V150, P563; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HUBSCHER U, 1996, DNA REPLICATION EUKA, P525; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kaufman PD, 1998, MOL CELL BIOL, V18, P4793, DOI 10.1128/MCB.18.8.4793; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Klar AJS, 1998, CIBA F SYMP, V214, P87; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; LEE SH, 1991, J BIOL CHEM, V266, P594; Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; MILLER AM, 1984, COLD SPRING HARB SYM, V49, P105, DOI 10.1101/SQB.1984.049.01.014; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Qian ZJ, 1998, MOL CELL BIOL, V18, P4783, DOI 10.1128/MCB.18.8.4783; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE AP, 1991, J CELL SCI, V99, P201; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385	69	535	540	21	61	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					575	585		10.1016/S0092-8674(00)80661-3	http://dx.doi.org/10.1016/S0092-8674(00)80661-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052459	Bronze			2022-12-01	WOS:000078718600008
J	Maron, BJ; Casey, SA; Poliac, LC; Gohman, TE; Almquist, AK; Aeppli, DM				Maron, BJ; Casey, SA; Poliac, LC; Gohman, TE; Almquist, AK; Aeppli, DM			Clinical course of hypertrophic cardiomyopathy in a regional United States cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE CARDIOMYOPATHY; SUBAORTIC STENOSIS; PROGNOSIS; POPULATION; ECHOCARDIOGRAPHY; SPECTRUM; HISTORY	Context Hypertrophic cardiomyopathy (HCM) has been regarded as a disease that causes substantial disability, with annual mortality rates of up to 6%, based largely on reports from tertiary referral centers. Objective To assess the clinical course of HCM in a patient cohort more closely resembling the true disease state. Design Retrospective cohort study. Setting A regional cohort from Minnesota and adjoining regions, free of referral center bias, studied at Minneapolis Heart Institute. Patients Two hundred seventy-seven consecutively studied HCM patients, none referred for specialized HCM care, managed clinically in a standard fashion. Main Outcome Measures Mortality and clinical course of HCM. Results During a mean (SD) follow-up of 8.1 (6.6) years, 45 patients died and 29 of these deaths were directly related to HCM; however, 8 of the 29 HCM deaths were not premature (occurring >75 years of age). Annual HCM mortality rate was 1.3% (0.7% for sudden cardiac death). Patients identified in adulthood (n = 234) showed no statistically significant difference in mortality when compared with expected mortality, as calculated for the general US or Minnesota populations (P = .17). Patients identified as children (n = 43) showed decreased survival compared with the general population (P < .001). At most recent clinical evaluation, 192 patients (69%) had no or mild symptoms and 69 (25%) experienced incapacitating symptoms or HCM-related death; 53 (19%) of the patients had achieved estimated life expectancy of 75 years or older. More advanced symptoms at diagnosis-occurrence of atrial fibrillation (often associated with stroke), the presence of basal outflow obstruction of at least 30 mm Hg, and marked left ventricular wall thickness of more than 25 mm-were clinically important independent predictors of HCM mortality. Conclusions In a regionally selected patient population most closely resembling the true disease state, HCM did not significantly increase the risk of premature death or adversely affect overall life expectancy. Prevailing misconceptions of HCM as a generally unfavorable condition may largely be related to the skewed patient referral patterns characteristic of tertiary care centers. Hypertrophic cardiomyopathy is nevertheless a highly complex disease capable of serious clinical consequences and premature death in some patients.	Minneapolis Heart Inst Fdn, Cardiovasc Res Div, Minneapolis, MN 55407 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA	Minneapolis Heart Institute Foundation; University of Minnesota System; University of Minnesota Twin Cities	Maron, BJ (corresponding author), Minneapolis Heart Inst Fdn, Cardiovasc Res Div, 920 E 28th St,Suite 40, Minneapolis, MN 55407 USA.							ADELMAN AG, 1972, ANN INTERN MED, V77, P515, DOI 10.7326/0003-4819-77-4-515; CANNAN CR, 1995, CIRCULATION, V92, P2488, DOI 10.1161/01.CIR.92.9.2488; CECCHI F, 1995, J AM COLL CARDIOL, V26, P1529, DOI 10.1016/0735-1097(95)00353-3; *DEP HLTH HUM SERV, 1992, VIT STAT US A, V2; Eland-Johnson RC, 1980, SURVIVAL MODELS DATA; FAY WP, 1990, J AM COLL CARDIOL, V16, P321; FIDDLER GI, 1978, AM J CARDIOL, V42, P793, DOI 10.1016/0002-9149(78)90099-1; FRANK S, 1968, CIRCULATION, V37, P759, DOI 10.1161/01.CIR.37.5.759; HARDARSON T, 1973, LANCET, V2, P1462; Kappenberger L, 1997, EUR HEART J, V18, P1249; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; Knight C, 1997, CIRCULATION, V95, P2075, DOI 10.1161/01.CIR.95.8.2075; KOFFLARD MJ, 1993, AM J CARDIOL, V72, P939, DOI 10.1016/0002-9149(93)91111-T; Maki S, 1998, AM J CARDIOL, V82, P774, DOI 10.1016/S0002-9149(98)00455-X; MARON BJ, 1976, CIRCULATION, V53, P9, DOI 10.1161/01.CIR.53.1.9; Maron BJ, 1998, CIRCULATION, V98, P1460, DOI 10.1161/01.CIR.98.14.1460; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; MARON BJ, 1994, BR HEART J S, V72, P13; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1984, ARCH DIS CHILD, V59, P971, DOI 10.1136/adc.59.10.971; *MINN DEP HLTH, 1992, MENN HLTH STAT, P29; MORROW AG, 1975, CIRCULATION, V52, P88, DOI 10.1161/01.CIR.52.1.88; PANZA JA, 1992, J AM COLL CARDIOL, V19, P91, DOI 10.1016/0735-1097(92)90057-T; SHAH PM, 1974, CIRC RES, V35, P179; SHAPIRO LM, 1983, BRIT HEART J, V50, P530; Sherrid MV, 1998, CIRCULATION, V97, P41, DOI 10.1161/01.CIR.97.1.41; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; SWAN DA, 1971, BRIT HEART J, V33, P671; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680	31	372	389	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					650	655		10.1001/jama.281.7.650	http://dx.doi.org/10.1001/jama.281.7.650			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029128	Bronze			2022-12-01	WOS:000078548400037
J	Daviglus, ML; Liao, YL; Greenland, P; Dyer, AR; Liu, K; Xie, XY; Huang, CF; Prineas, RJ; Stamler, J				Daviglus, ML; Liao, YL; Greenland, P; Dyer, AR; Liu, K; Xie, XY; Huang, CF; Prineas, RJ; Stamler, J			Association of nonspecific minor ST-T abnormalities with cardiovascular mortality - The Chicago Western Electric study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; ELECTROCARDIOGRAPHIC FINDINGS; DEATH; RISK	Context Minor electrocardiographic (ECG) ST-T abnormalities are common, but their prognostic importance has not been fully determined, Objective To examine associations of single (1 time only) and multiple (2 times only and greater than or equal to 3 times) nonspecific minor ST-T abnormalities in 5 years with long-term mortality due to myocardial infarction (MI), coronary heart disease (CHD), cardiovascular disease (CVD), and ail causes in middle-aged men. Design Prospective cohort study (29-year follow-up after 5 annual examinations). Setting and Participants A total of 1673 men employed at the Western Electric Company in Chicago, ill, aged 40 to 55 years at entry, with no evidence of CHD and no major ECC abnormalities throughout the first 5-year period. Main Outcome Measures Minor ST-T abnormalities identified from annual resting ECGs and mortality ascertained from death certificates. Results Of the 1673 men, 173 had evidence of isolated nonspecific minor ST-T segment abnormalities. During the follow-up period, there were 234 deaths due to MI, 352 deaths due to CHD, 463 deaths due to CVD, and 889 deaths due to all causes. For men with 3 or more annual recordings of minor ST-T abnormalities, risk of death due to Mi, CHD, CVD, and all causes was significantly greater than for those with normal ECG findings. For men with 3 or more ECGs with minor ST-T abnormalities, relative risks (and 95% confidence intervals) adjusted for cardiovascular and other risk factors were 2.28 (1.16-4.49), 2.39 (1.39-4.12), 2.30 (1.44-3.68), and 1.60 (1.06-2.42), respectively, with a graded relationship between frequency of occurrence of ST-T abnormalities and mortality risk (linear trend, P less than or equal to.007). Conclusions Persistent, minor, nonspecific ST-T abnormalities are associated with increased long-term risk of mortality due to MI, CHD, CVD, and all causes; the higher the frequency of occurrence of minor ST-T abnormalities, the greater the risk, These data underscore the potential value of including nonspecific ECC findings in the overall assessment of cardiovascular risk.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA	Northwestern University; Loyola University Chicago; University of Minnesota System; University of Minnesota Twin Cities	Daviglus, ML (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.		Greenland, Philip/ABD-5528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021010, K14HL003387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 15174, HL 21010, HL 03387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTERHOG JH, 1981, ACTA MED SCAND, V209, P75; BARTEL A, 1971, ARCH INTERN MED, V128, P929, DOI 10.1001/archinte.128.6.929; BLACKBURN H, 1970, Circulation Research Supplement, V41, P154; *COR DRUG PROJ RES, 1972, ANN INTERN MED, V77, P677; COX DR, 1972, J R STAT SOC B, V34, P187; CULLEN K, 1982, BRIT HEART J, V47, P209; DEBACQUER D, 1994, EUR HEART J, V15, P1604, DOI 10.1093/oxfordjournals.eurheartj.a060441; FURBERG C, 1967, ACTA MED SCAND, V181, P21; GARRISON RJ, 1993, INT J OBESITY, V17, P417; GOLDBARG AN, 1970, CIRCULATION, V41, P257, DOI 10.1161/01.CIR.41.2.257; GREIG M, 1980, J EPIDEMIOL COMMUN H, V34, P23, DOI 10.1136/jech.34.1.23; GUAZZI M, 1975, CARDIOVASC RES, V9, P342, DOI 10.1093/cvr/9.3.342; HARLAN WR, 1967, J CHRON DIS, V20, P853, DOI 10.1016/0021-9681(67)90023-9; HIGGINS ITT, 1965, BRIT J PREV SOC MED, V19, P53; *INT CLASS DIS, 1967, NATL CTR HLTH STAT, V49, P522; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KANNEL WB, 1987, AM HEART J, V113, P370, DOI 10.1016/0002-8703(87)90280-8; KEMP GL, 1968, ARCH INTERN MED, V121, P518, DOI 10.1001/archinte.121.6.518; KIESSLING CHARLES E., 1964, AMER J CARDIOL, V13, P598, DOI 10.1016/0002-9149(64)90193-6; KNUTSEN R, 1988, J CLIN EPIDEMIOL, V41, P293, DOI 10.1016/0895-4356(88)90134-5; LIAO YL, 1987, CIRCULATION, V75, P347, DOI 10.1161/01.CIR.75.2.347; MATHEWSON FAL, 1960, CIRCULATION, V21, P196, DOI 10.1161/01.CIR.21.2.196; OSTOR E, 1981, EUR HEART J, V2, P317; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; OSTRANDER LD, 1966, CIRCULATION, V34, P1069, DOI 10.1161/01.CIR.34.6.1069; OSTRANDER LD, 1970, AM J CARDIOL, V25, P325, DOI 10.1016/S0002-9149(70)80010-8; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; Prineas R.J., 1982, MINNESOTA CODE MANUA; RABKIN SW, 1982, BRIT HEART J, V47, P546; Reunanen A, 1978, Adv Cardiol, V21, P310; ROSE G, 1978, BRIT HEART J, V40, P636; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; Sigurdsson E, 1996, J AM COLL CARDIOL, V27, P1140, DOI 10.1016/0735-1097(95)00614-1; Singer R B, 1982, Trans Assoc Life Insur Med Dir Am, V65, P180; STAMLER J, 1991, HYPERTENSION S, V18, P195; SURAWICZ B, 1977, CARDIOVASC MED, V2, P629; TAGGART P, 1978, PROGR CARDIOLOGY, P103; UNGERLEIDER HE, 1960, AM J CARDIOL, V6, P35, DOI 10.1016/0002-9149(60)90033-3	39	129	132	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					530	536		10.1001/jama.281.6.530	http://dx.doi.org/10.1001/jama.281.6.530			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022109	Bronze			2022-12-01	WOS:000078452900031
J	Laumann, EO; Paik, A; Rosen, RC				Laumann, EO; Paik, A; Rosen, RC			Sexual dysfunction in the United States - Prevalence and predictors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LATENT CLASS ANALYSIS; ERECTILE DYSFUNCTION; SATISFACTION	Context While recent pharmacological advances have generated increased public interest and demand for clinical services regarding erectile dysfunction, epidemiologic data on sexual dysfunction are relatively scant for both women and men. Objective To assess the prevalence and risk of experiencing sexual dysfunction across various social groups and examine the determinants and health consequences of these disorders. Design Analysis of data from the National Health and Social Life Survey, a probability sample study of sexual behavior in a demographically representative, 1992 cohort of US adults. Participants A national probability sample of 1749 women and 1410 men aged 18 to 59 years at the time of the survey. Main Outcome Measures Risk of experiencing sexual dysfunction as well as negative concomitant outcomes. Results Sexual dysfunction is more prevalent for women (43%) than men (31%) and is associated with various demographic characteristics, including age and educational attainment. Women of different racial groups demonstrate different patterns of sexual dysfunction. Differences among men are not as marked but generally consistent with women. Experience of sexual dysfunction is more likely among women and men with poor physical and emotional health. Moreover, sexual dysfunction is highly associated with negative experiences in sexual relationships and overall wellbeing. Conclusions The results indicate that sexual dysfunction is an important public health concern, and emotional problems likely contribute to the experience of these problems.	Univ Chicago, Dept Sociol, Chicago, IL 60637 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA	University of Chicago; Rutgers State University New Brunswick; Rutgers State University Medical Center	Laumann, EO (corresponding author), Univ Chicago, Dept Sociol, 5848 S Univ Ave, Chicago, IL 60637 USA.	ob01@midway.uchicago.edu	Paik, Anthony/ABE-5953-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028356] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD28356] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P493; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; Browning CR, 1997, AM SOCIOL REV, V62, P540, DOI 10.2307/2657425; BURNETT AL, 1995, BIOL REPROD, V52, P485, DOI 10.1095/biolreprod52.3.485; CLOGG CC, 1977, UNRESTRICTED RESTRIC; Clogg CC., 1995, HDB STAT MODELING SO, P311, DOI [DOI 10.1007/978-1-4899-1292-3_6, 10.1007/978-1-4899-1292-3_6]; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; EATON WW, 1989, SOCIOL METHOD RES, V18, P104, DOI 10.1177/0049124189018001004; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; FRANK E, 1978, NEW ENGL J MED, V299, P111, DOI 10.1056/NEJM197807202990302; FuglMeyer AR, 1997, INT J IMPOT RES, V9, P141, DOI 10.1038/sj.ijir.3900269; HEATON JPW, 1995, UROLOGY, V45, P200, DOI 10.1016/0090-4295(95)80005-0; Kinsey A.C., 1953, SEXUAL BEHAV HUMAN F; Kinsey AC, 1948, SEXUAL BEHAV HUMAN F; Laumann E.O., 2000, SOCIAL ORG SEXUALITY; McCutheon A.L., 1987, LATENT CLASS ANAL; MORALES A, 1995, UROL CLIN N AM, V22, P879; MOROKOFF PJ, 1993, J SEX RES, V30, P43, DOI 10.1080/00224499309551677; Park K, 1997, INT J IMPOT RES, V9, P27, DOI 10.1038/sj.ijir.3900258; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; RINDSKOPF D, 1986, STAT MED, V5, P21, DOI 10.1002/sim.4780050105; ROSEN RC, 1993, ARCH SEX BEHAV, V22, P521, DOI 10.1007/BF01543299; ROSEN RC, 1993, J SEX MARITAL THER, V19, P171; SEGRAVES RT, 1993, J SEX MARITAL THER, V19, P198; SPECTOR IP, 1990, ARCH SEX BEHAV, V19, P389, DOI 10.1007/BF01541933; *STATA, 1997, STATA REL 5; UEBERSAX JS, 1990, STAT MED, V9, P559, DOI 10.1002/sim.4780090509; YOUNG MA, 1982, J NERV MENT DIS, V170, P443, DOI 10.1097/00005053-198208000-00001; YOUNG MA, 1983, J PSYCHIATR RES, V17, P285, DOI 10.1016/0022-3956(82)90007-3; [No title captured]	30	3422	3566	1	115	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					537	544		10.1001/jama.281.6.537	http://dx.doi.org/10.1001/jama.281.6.537			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	164FQ	10022110	Bronze			2022-12-01	WOS:000078452900032
J	Strauss, JH; Strauss, EG				Strauss, JH; Strauss, EG			Viral RNA replication - With a little help from the host	SCIENCE			English	Editorial Material							VIRUS-RNA; SACCHAROMYCES-CEREVISIAE; NONSTRUCTURAL PROTEINS; EXPRESSION; TRANSCRIPTION; POLYMERASE; REPLICONS; SEQUENCE		CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Strauss, JH (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.							AHLQUIST P, 1985, J VIROL, V53, P536, DOI 10.1128/JVI.53.2.536-542.1985; Ahlquist P, COMMUNICATION; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; Das T, 1998, P NATL ACAD SCI USA, V95, P1449, DOI 10.1073/pnas.95.4.1449; HASELOFF J, 1984, P NATL ACAD SCI-BIOL, V81, P4358, DOI 10.1073/pnas.81.14.4358; Ishikawa M, 1997, P NATL ACAD SCI USA, V94, P13810, DOI 10.1073/pnas.94.25.13810; Ishikawa M, 1997, J VIROL, V71, P7781, DOI 10.1128/JVI.71.10.7781-7790.1997; Janda M, 1998, P NATL ACAD SCI USA, V95, P2227, DOI 10.1073/pnas.95.5.2227; JANDA M, 1993, CELL, V72, P961, DOI 10.1016/0092-8674(93)90584-D; Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; Price BD, 1996, P NATL ACAD SCI USA, V93, P9465, DOI 10.1073/pnas.93.18.9465; QUADT R, 1995, P NATL ACAD SCI USA, V92, P4892, DOI 10.1073/pnas.92.11.4892; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994	16	28	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					802	804		10.1126/science.283.5403.802	http://dx.doi.org/10.1126/science.283.5403.802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	10049125				2022-12-01	WOS:000078496800030
J	Bringuier, V; Chavane, F; Glaeser, L; Fregnac, Y				Bringuier, V; Chavane, F; Glaeser, L; Fregnac, Y			Horizontal propagation of visual activity in the synaptic integration field of area 17 neurons	SCIENCE			English	Article							RECEPTIVE-FIELDS; POSTSYNAPTIC POTENTIALS; STRIATE CORTEX; CAT; CONNECTIONS; RAT; ORGANIZATION; EXCITATION; INHIBITION; RESPONSES	The receptive field of a visual neuron is classically defined as the region of space (or retina) where a visual stimulus evokes a change in its firing activity. At the cortical Level, a challenging issue concerns the roles of feedforward, Local recurrent, intracortical, and cortico-cortical feedback connectivity in receptive field properties. Intracellular recordings in cat area 17 showed that the visually evoked synaptic integration field extends over a much Larger area than that established on the basis of spike activity. Synaptic depolarizing responses to stimuli flashed at increasing distances from the center of the receptive field decreased in strength, whereas their onset Latency increased. These findings suggest that subthreshold responses in the unresponsive region surrounding the classical discharge field result from the integration of visual activation waves spread by slowly conducting horizontal axons within primary visual cortex.	CNRS, Inst Alfred Fessard, Equipe Cognisci, F-98118 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Fregnac, Y (corresponding author), CNRS, Inst Alfred Fessard, Equipe Cognisci, Ave Terresse, F-98118 Gif Sur Yvette, France.		Chavane, Frederic/ABB-1487-2021	Chavane, Frederic/0000-0001-7916-2640				ALBUS K, 1975, EXP BRAIN RES, V24, P181, DOI 10.1007/BF00234062; BISHOP PO, 1971, J PHYSIOL-LONDON, V219, P625, DOI 10.1113/jphysiol.1971.sp009681; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; Borg-Graham LJ, 1998, NATURE, V393, P369, DOI 10.1038/30735; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; CREUTZFELDT O, 1968, EXP BRAIN RES, V6, P324; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1994, J NEUROSCI, V14, P2545; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HOFFMANN KP, 1971, BRAIN RES, V32, P460, DOI 10.1016/0006-8993(71)90340-4; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUMPHREY AL, 1985, J COMP NEUROL, V233, P159, DOI 10.1002/cne.902330203; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; KISVARDAY ZF, 1993, EUR J NEUROSCI, V5, P1558, DOI 10.1111/j.1460-9568.1993.tb00226.x; LI CY, 1994, VISION RES, V34, P2337, DOI 10.1016/0042-6989(94)90280-1; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; MURAKOSHI T, 1993, NEUROSCI LETT, V163, P211, DOI 10.1016/0304-3940(93)90385-X; NELSON DA, 1995, NEURON, V15, P23, DOI 10.1016/0896-6273(95)90061-6; ORBAN G, 1984, STUD BRAIN FUNCT, V11, P365; PEI X, 1994, J NEUROSCI, V14, P7130; Rosenquist AC., 1985, CEREB CORTEX, P81; Salin PA, 1996, J NEUROPHYSIOL, V75, P1589, DOI 10.1152/jn.1996.75.4.1589; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SHULZ D, 1993, SOC NEUR ABSTR, V19, P638; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; TUSA RJ, 1978, J COMP NEUROL, V177, P213, DOI 10.1002/cne.901770204	30	404	406	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					695	699		10.1126/science.283.5402.695	http://dx.doi.org/10.1126/science.283.5402.695			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924031				2022-12-01	WOS:000078324400045
J	Miyoshi, H; Smith, KA; Mosier, DE; Verma, IM; Torbett, BE				Miyoshi, H; Smith, KA; Mosier, DE; Verma, IM; Torbett, BE			Transduction of human CD34(+) cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors	SCIENCE			English	Article							LENTIVIRAL VECTOR; GENE-TRANSFER; HEMATOPOIETIC-CELLS; NONDIVIDING CELLS; CORD-BLOOD; IN-VIVO; EFFICIENT; THERAPY; STEM; EXPRESSION	Efficient gene transfer into human hematopoietic stem cells (HSCs) is an important goal in the study of the hematopoietic system as well as for gene therapy of hematopoietic disorders. A Lentiviral vector based on the human immunodeficiency virus (HIV) was able to transduce human CD34(+) cells capable of stable, Long-term reconstitution of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. High-efficiency transduction occurred in the absence of cytokine stimulation and resulted in transgene expression in multiple Lineages of human hematopoietic cells for up to 22 weeks after transplantation.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Salk Institute; Scripps Research Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Miyoshi, Hiroyuki/G-9808-2013		NCI NIH HHS [CA44360] Funding Source: Medline; NHLBI NIH HHS [HL53670] Funding Source: Medline; NIDDK NIH HHS [DK49886] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044360] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049886] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bhatia M, 1997, J EXP MED, V186, P619, DOI 10.1084/jem.186.4.619; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Blomer U, 1997, J VIROL, V71, P6641; Cheng LZ, 1998, BLOOD, V92, P83, DOI 10.1182/blood.V92.1.83.413k09_83_92; Conneally E, 1998, BLOOD, V91, P3487, DOI 10.1182/blood.V91.9.3487.3487_3487_3493; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; Hao QL, 1996, BLOOD, V88, P3306, DOI 10.1182/blood.V88.9.3306.bloodjournal8893306; Havenga M, 1997, STEM CELLS, V15, P162, DOI 10.1002/stem.150162; Hogan CJ, 1997, BLOOD, V90, P85; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; Kiem HP, 1998, BLOOD, V92, P1878, DOI 10.1182/blood.V92.6.1878.418k39_1878_1886; Kim VN, 1998, J VIROL, V72, P811, DOI 10.1128/JVI.72.1.811-816.1998; Kohn DB, 1996, BONE MARROW TRANSPL, V18, pS55; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Marandin A, 1998, HUM GENE THER, V9, P1497, DOI 10.1089/hum.1998.9.10-1497; MCNIECE IK, 1989, BLOOD, V74, P609; METCALF D, 1979, CLIN HAEMATOL, V8, P263; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nienhuis AW, 1997, STEM CELLS, V15, P123, DOI 10.1002/stem.5530150816; Poeschla E, 1996, P NATL ACAD SCI USA, V93, P11395, DOI 10.1073/pnas.93.21.11395; REINHARDT B, 1994, AIDS RES HUM RETROV, V10, P131, DOI 10.1089/aid.1994.10.131; Reiser J, 1996, P NATL ACAD SCI USA, V93, P15266, DOI 10.1073/pnas.93.26.15266; Schilz AJ, 1998, BLOOD, V92, P3163, DOI 10.1182/blood.V92.9.3163.421k25_3163_3171; SHULTZ LD, 1995, J IMMUNOL, V154, P180; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; Sutton RE, 1998, J VIROL, V72, P5781, DOI 10.1128/JVI.72.7.5781-5788.1998; Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939; van Hennik PB, 1998, BLOOD, V92, P4013, DOI 10.1182/blood.V92.11.4013.423k53_4013_4022; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; WILLIAMS DA, 1993, BLOOD, V81, P3169; Wu Q, 1995, NUCLEIC ACIDS RES, V23, P5087, DOI 10.1093/nar/23.24.5087; Zanjani ED, 1998, EXP HEMATOL, V26, P353; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	39	539	590	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					682	686		10.1126/science.283.5402.682	http://dx.doi.org/10.1126/science.283.5402.682			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924027				2022-12-01	WOS:000078324400041
J	Gomez, TM; Spitzer, NC				Gomez, TM; Spitzer, NC			In vivo regulation of axon extension and pathfinding by growth-cone calcium transients	NATURE			English	Article							MIGRATION; DYNAMICS; BEHAVIOR	Growth cones at the tips of extending neurites migrate through complex environments in the developing nervous system and guide axons to appropriate target regions using local cues(1,2). The intracellular calcium concentration ([Ca2+](i)) of growth cones correlates with motility in vitro(3-7), but the physiological links between environmental cues and axon growth in vivo are unknown. Here we report that growth cones generate transient elevations of [Ca2+](i) as they migrate within the embryonic spinal cord and that the rate of axon outgrowth is inversely proportional to the frequency of transients. Suppressing Ca2+ transients by photorelease of a Ca2+ chelator accelerates axon extension, whereas mimicking transients with photorelease of Ca2+ slows otherwise rapid axonal growth. The frequency of Ca2+ transients is cell-type specific and depends on the position of growth cones along their pathway. Furthermore, growth-cone stalling and axon retraction, which are two important aspects of pathfinding(8-10), are associated with high frequencies of Ca2+ transients. Our results indicate that environmentally regulated growth-cone Ca2+ transients control axon growth in the developing spinal cord.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Gomez, TM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.			Spitzer, Nicholas/0000-0002-3523-1103; Gomez, Timothy/0000-0002-1515-8228				BOVOLENTA P, 1987, J NEUROSCI, V7, P1447; CHIEN CB, 1993, NEURON, V11, P237, DOI 10.1016/0896-6273(93)90181-P; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; GHOSH A, 1992, J NEUROSCI, V12, P39; GODEMENT P, 1994, J NEUROSCI, V14, P7024; GOMEZ TM, 1995, NEURON, V14, P1233, DOI 10.1016/0896-6273(95)90270-8; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GU XN, 1994, J NEUROSCI, V14, P6325; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hagg T, 1997, BRAIN RES, V764, P17, DOI 10.1016/S0006-8993(97)00419-8; KATER SB, 1991, J NEUROSCI, V11, P891; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; Komuro H, 1996, NEURON, V17, P275, DOI 10.1016/S0896-6273(00)80159-2; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MYERS PZ, 1993, J NEUROSCI, V13, P127; NIEUWKOOP JM, 1967, NORMAL TABLE XENOPUS; ROBERTS A, 1982, PHILOS T R SOC B, V296, P195, DOI 10.1098/rstb.1982.0002; SNOW DM, 1994, DEV BIOL, V166, P87, DOI 10.1006/dbio.1994.1298; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; Tymianski M, 1997, CELL CALCIUM, V21, P175, DOI 10.1016/S0143-4160(97)90042-7; Tymianski M, 1997, CELL CALCIUM, V22, P111, DOI 10.1016/S0143-4160(97)90111-1; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	25	401	412	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					350	355		10.1038/16927	http://dx.doi.org/10.1038/16927			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950427				2022-12-01	WOS:000078324600050
J	Pecoul, B; Chirac, P; Trouiller, P; Pinel, J				Pecoul, B; Chirac, P; Trouiller, P; Pinel, J			Access to essential drugs in poor countries - A lost battle?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Drugs offer a simple, cost-effective solution to many health problems, provided they are available, affordable, and properly used. However, effective treatment is lacking in poor countries for many diseases, including African trypanosomiasis, Shigella dysentery, leishmaniasis, tuberculosis, and bacterial meningitis, Treatment may be precluded because no effective drug exists, it is too expensive, or it has been withdrawn from the market. Moreover, research and development in tropical diseases have come to a near standstill. This article focuses on the problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world: (1) poor-quality and counterfeit drugs; (2) lack of availability of essential drugs due to fluctuating production or prohibitive cost; (3) need to develop field-based drug research to determine optimum utilization and remotivate research and development for new drugs for the developing world; and (4) potential consequences of recent World Trade Organization agreements on the availability of old and new drugs, These problems are not independent and unrelated but are a result of the fundamental nature of the pharmaceutical market and the way it is regulated.	Fdn Med Sans Frontieres, F-75011 Paris, France		Pecoul, B (corresponding author), Fdn Med Sans Frontieres, 8 Rue St Sabin, F-75011 Paris, France.	office@paris.msf.org						*CDCP, 1993, MORT DYS AFR FOLL UP; COLLSECK A, 1998, 12 INT C AIDS JUN 28; Correa CM, 1997, URUGUAY ROUND DRUGS; CROFTON J, 1997, WHOTB6210; DOUA F, 1987, AM J TROP MED HYG, V37, P525, DOI 10.4269/ajtmh.1987.37.525; Grabowski H, 1997, PHARMACOECONOMICS, V11, P389, DOI 10.2165/00019053-199711050-00002; *HARV SCH PUBL HLT, 1996, INT STRAT TROP DIS T; *INT FED PHARM MAN, 1997, INT PROP PAT PHARM; KADDAR M, 1995, REV PRECRIRE, V157, P844; LANJOUW JO, 1998, INTRO PHARM PROD PAT; LEGROS D, 1997, 24 INT SCI COUNC TRY; O'Brien KL, 1998, JAMA-J AM MED ASSOC, V279, P1175, DOI 10.1001/jama.279.15.1175; Olliario P, 1997, TROP MED INT HEALTH, V2, P113, DOI 10.1046/j.1365-3156.1997.d01-234.x; PAQUET C, 1994, LANCET, V344, P823, DOI 10.1016/S0140-6736(94)92381-7; PAQUET C, 1993, LANCET, V342, P175, DOI 10.1016/0140-6736(93)91378-Y; Paquet C, 1995, Sante, V5, P181; PECOUL B, 1991, LANCET, V338, P862, DOI 10.1016/0140-6736(91)91511-R; PINEL J, 1997, MED MALADIES INFECT, V27, P1; ROZEK RP, 1998, EFF PAT PROT PRIC PH; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; TANDON BN, 1996, EPIDEMIOL INFECT, V117, P313; *TROP DIS RES, 1995, INV ER TROP DIS RES, P9; Trouiller P, 1996, Sante, V6, P299; TROUILLER P, 1998, 8 INT C INF DIS MAY; *UNICEF SUPPL DIV, 1995, ESS DRUGS PRIC LIST; VARAINE F, 1998, 8 INT C INF DIS MAY; Velasquez German, 1998, HLTH EC DRUGS DAP SE, P25; *WHO, 1997, B WKLY EPIDEMIOL REC, V72, P313; WHO, 1996, WHO TECHN REP SER, V863; *WHO, 1996, WHO DRUG INFORMATION, V4, P182; *WHO, 1992, WHODMPCFD92; World Health Organization, 1995, WHO DRUG INF, V9, P127; World Health Organization, 1998, WORLD HLTH STAT ANN	33	217	221	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					361	367		10.1001/jama.281.4.361	http://dx.doi.org/10.1001/jama.281.4.361			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929090				2022-12-01	WOS:000078111300036
J	Kitamura, K; Tokunaga, M; Iwane, AH; Yanagida, T				Kitamura, K; Tokunaga, M; Iwane, AH; Yanagida, T			A single myosin head moves along an actin filament with regular steps of 5.3 nanometres	NATURE			English	Article							RABBIT SKELETAL-MUSCLE; MOLECULE ANALYSIS; SLIDING DISTANCE; ACTOMYOSIN MOTOR; FORCE MICROSCOPY; STRIATED-MUSCLE; SMOOTH-MUSCLE; F-ACTIN; ONE ATP; MOVEMENT	Actomyosin, a complex of actin filaments and myosin motor proteins, is responsible for force generation during muscle contraction. To resolve the individual mechanical events of force generation by actomyosin, we have developed a new Instrument with which we can capture and directly manipulate individual myosin subfragment-1 molecules using a scanning probe. Single subfragment-1 molecules can be visualized by using a fluorescent label. The data that we obtain using this technique are consistent with myosin moving along an actin filament with single mechanical steps of approximately 5.3 nanometres; groups of two to five rapid steps In succession often produce displacements of 11 to 30 nanometres. This multiple stepping is produced by a single myosin head during just one biochemical cycle of ATP hydrolysis.	JST, ERATO, Yanagida BioMotron Project, Osaka 5620035, Japan; Osaka Univ, Dept Biophys Engn, Osaka 5608531, Japan; Osaka Univ, Sch Med, Dept Physiol 1, Osaka 5650871, Japan; Natl Inst Genet, Struct Biol Ctr, Shizuoka 4118540, Japan; JST, Single Mol Proc Project, ICORP, Osaka 5620035, Japan	Japan Science & Technology Agency (JST); Osaka University; Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Japan Science & Technology Agency (JST)	Yanagida, T (corresponding author), JST, ERATO, Yanagida BioMotron Project, 2-4-14 Senba Higashi, Osaka 5620035, Japan.	yanagida@phys1.med.osaka-u.ac.jp	Yanagida, Toshio/D-1919-2009; Kitamura, Kazuo/F-3379-2013	Kitamura, Kazuo/0000-0002-8956-4122; Tokunaga, Makio/0000-0003-4586-8922				Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; Bevington P. R., 2002, DATA REDUCTION ERROR, V3rd; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; CRAIG SW, 1982, METHOD ENZYMOL, V85, P316; EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Huxley AF, 1996, J MUSCLE RES CELL M, V17, P507, DOI 10.1007/BF00123366; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1967, J MOL BIOL, V30, P383, DOI 10.1016/S0022-2836(67)80046-9; HUXLEY HE, 1969, SCIENCE, V164, P1355; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; Iwane AH, 1997, BIOCHEM BIOPH RES CO, V230, P76, DOI 10.1006/bbrc.1996.5861; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KADO H, 1992, REV SCI INSTRUM, V63, P3330, DOI 10.1063/1.1142548; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KITANO M, 1990, J CRYST GROWTH, V102, P965, DOI 10.1016/0022-0248(90)90867-K; KLIBANOV AM, 1995, NATURE, V374, P596, DOI 10.1038/374596a0; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mehta AD, 1997, P NATL ACAD SCI USA, V94, P7927, DOI 10.1073/pnas.94.15.7927; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Saito K, 1997, J MICROSC-OXFORD, V188, P255, DOI 10.1046/j.1365-2818.1997.2580814.x; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Tanaka H, 1998, BIOPHYS J, V75, P1886, DOI 10.1016/S0006-3495(98)77629-5; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V231, P566, DOI 10.1006/bbrc.1997.6144; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; Wand M.P., 1995, KERNEL SMOOTHING; WOLEDGE RC, 1985, ENERGETIC ASPECTS MU, pCH3; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	50	446	459	2	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					129	134		10.1038/16403	http://dx.doi.org/10.1038/16403			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923673				2022-12-01	WOS:000078085000035
J	Agarwal, SK; Guru, SC; Heppner, C; Erdos, MR; Collins, RM; Park, SY; Saggar, S; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL				Agarwal, SK; Guru, SC; Heppner, C; Erdos, MR; Collins, RM; Park, SY; Saggar, S; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL			Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription	CELL			English	Article							ENDOCRINE NEOPLASIA TYPE-1; C-JUN; PARATHYROID TUMORS; FOS PROTEINS; GENE; CELLS; AP-1; ONCOPROTEIN; MUTATIONS; DOMAIN	MEN1 is a tumor suppressor gene that encodes a 610 amino acid nuclear protein (menin) of previously unknown function. Using a yeast two-hybrid screen with menin as the bait, we have identified the transcription factor JunD as a direct menin-interacting partner. Menin did not interact directly with other Jun and Fos family members. The menin-JunD interaction was confirmed in vitro and in vive. Menin repressed transcriptional activation mediated by JunD fused to the Gal4 DNA-binding domain from a Gal4 responsive reporter, or by JunD from an AP1-responsive reporter. Several naturally occurring and clustered MEN1 missense mutations disrupted menin interaction with JunD. These observations suggest that menin's tumor suppressor function involves direct binding to JunD and inhibition of JunD activated transcription.	NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Agarwal, SK (corresponding author), NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA.		Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043006, Z01DK043009, ZIEDK043006, ZIEDK043009] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1994, FOS JUN FAMILIES TRA, P3; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BERGER I, 1991, ONCOGENE, V6, P561; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FEARON ER, 1998, GENETIC BASIS HUMAN, P229; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Marx S, 1998, GENETIC BASIS HUMAN, P489; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; METIVIER C, 1993, ONCOGENE, V8, P2311; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Rahmsdorf HJ, 1996, J MOL MED, V74, P725, DOI 10.1007/s001090050077; RYSECK RP, 1991, ONCOGENE, V6, P533; SAMUELS HH, 1974, J CLIN INVEST, V54, P853, DOI 10.1172/JCI107825; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; Zhuang ZP, 1997, CANCER RES, V57, P4682	36	474	489	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					143	152		10.1016/S0092-8674(00)80967-8	http://dx.doi.org/10.1016/S0092-8674(00)80967-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989505	Bronze			2022-12-01	WOS:000078023200016
J	Zhu, MH; John, S; Berg, M; Leonard, WJ				Zhu, MH; John, S; Berg, M; Leonard, WJ			Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFN gamma-mediated signaling	CELL			English	Article							RECEPTOR-BETA-CHAIN; DNA-BINDING ACTIVITY; GENE-EXPRESSION; INTERFERON-ALPHA; T-LYMPHOCYTES; TRANSCRIPTION; PROTEINS; CBP; ACTIVATION; P300/CBP	Using the coiled-coil region of Stat5b as the bait in a yeast two-hybrid screen, we identified the association of Nmi, a protein of unknown function previously reported as an N-Myc interactor. We further show that Nmi interacts with all STATs except Stat2. We evaluated two cytokine systems, IL-2 and lFN gamma, and demonstrate that Nmi augments STAT-mediated transcription in response to these cytokines. Interestingly, Nmi lacks an intrinsic transcriptional activation domain; instead, Nmi enhances the association of CBP/p300 coactivator proteins with Stall and Stat5, and together with CBP/p300 can augment IL-2- and IFN gamma-dependent transcription. Therefore, our data not only reveal that Nmi can potentiate STAT-dependent transcription, but also suggest that it can augment coactivator protein recruitment to at least some members of a group of sequence-specific transcription factors.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	wjl@helix.nih.gov	Leonard, Warren/AAA-1397-2022	John, Susan/0000-0002-5620-1982				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bao JX, 1996, ONCOGENE, V12, P2171; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; JOHN S, 1999, IN PRESS MOL CELL BI; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NIELSEN M, 1994, EUR J IMMUNOL, V24, P3082, DOI 10.1002/eji.1830241225; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	62	247	254	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					121	130		10.1016/S0092-8674(00)80965-4	http://dx.doi.org/10.1016/S0092-8674(00)80965-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989503	Bronze			2022-12-01	WOS:000078023200014
J	Bodenheimer, T				Bodenheimer, T			Disease management - Promises and pitfalls	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHRONIC ILLNESS; DIABETES MANAGEMENT; CARE; POPULATION		Univ Calif San Francisco, Sch Med, San Francisco, CA 94110 USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94110 USA.							ANDERSON D, 1996, BUSINESS HLTH SA, V14, P19; Burns H, 1996, LANCET, V347, P1021, DOI 10.1016/S0140-6736(96)90151-8; Ellrodt G, 1997, JAMA-J AM MED ASSOC, V278, P1687, DOI 10.1001/jama.278.20.1687; Epstein RS, 1996, ANN INTERN MED, V124, P832, DOI 10.7326/0003-4819-124-9-199605010-00008; Gerson V, 1996, Bus Health, V14, P29; Harris JM, 1996, ANN INTERN MED, V124, P838, DOI 10.7326/0003-4819-124-9-199605010-00009; HERZLINGER R, 1997, MARKET DRIVEN HLTH C; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Homer CJ, 1997, NEW ENGL J MED, V337, P1461, DOI 10.1056/NEJM199711133372010; Hunter DJ, 1997, BRIT MED J, V315, P50, DOI 10.1136/bmj.315.7099.50; Lucas J, 1995, Manag Care Q, V3, P14; McCulloch D K, 1998, Eff Clin Pract, V1, P12; MCCULLOCH DK, 1994, DIABETES CARE, V17, P765, DOI 10.2337/diacare.17.7.765; NICHOLS NA, 1994, MED MANAGEMENT MERGE, P105; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rubin RJ, 1998, J CLIN ENDOCR METAB, V83, P2635, DOI 10.1210/jc.83.8.2635; SADUR C, 1997, DIABETES S1, V46, pA61; SPALDING J, 1996, FAMILY PRACTICE MAR, P71; STOCKWELL DH, 1994, AM J PUBLIC HEALTH, V84, P1768, DOI 10.2105/AJPH.84.11.1768; The Boston Consulting Group, 1995, PROM DIS MAN; TODD W, 1997, DIS MANAGEMENT SYSTE; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wagner EH, 1997, HEALTH SERV RES, V32, P702; WAGNER EH, 1995, PATIENT EDUC COUNS, V26, P225, DOI 10.1016/0738-3991(95)00761-N; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; 1998, HEALTHCARE DEMAND DI, V4, P120; 1997, MED HLTH PERSPE 0707, P1	28	132	132	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1202	1205		10.1056/NEJM199904153401511	http://dx.doi.org/10.1056/NEJM199904153401511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202174				2022-12-01	WOS:000079687700011
J	Fletcher, LC; Brand, U; Running, MP; Simon, R; Meyerowitz, EM				Fletcher, LC; Brand, U; Running, MP; Simon, R; Meyerowitz, EM			Signaling of cell fate decisions by CLAVATA3 in Arabidopsis shoot meristems	SCIENCE			English	Article							FLOWER DEVELOPMENT; APICAL MERISTEM; THALIANA; REGULATOR; SITES	In higher plants, organogenesis occurs continuously from self-renewing apical meristems. Arabidopsis thaliana plants with loss-of-function mutations in the CLAVATA (CLV1, 2, and 3) genes have enlarged meristems and generate extra floral organs. Genetic analysis indicates that CLV1, which encodes a receptor kinase, acts with CLV3 to control the balance between meristem cell proliferation and differentiation. CLV3 encodes a small, predicted extracellular protein. CLV3 ads nonautonomously in meristems and is expressed at the meristem surface overlying the CLV1 domain. These proteins may act as a ligand-receptor pair in a signal transduction pathway, coordinating growth between adjacent meristematic regions.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; Univ Cologne, Inst Entwicklungsbiol, D-50923 Cologne, Germany	California Institute of Technology; University of Cologne	Meyerowitz, EM (corresponding author), CALTECH, Div Biol 156 29, 1200 E Calif Blvd, Pasadena, CA 91125 USA.		Running, Mark P./R-8950-2019; Meyerowitz, Elliot M/A-7118-2009					ALVAREZ J, 1994, ARABIDOPSIS ATLAS MO; [Anonymous], COMMUNICATION; BARTON MK, 1993, DEVELOPMENT, V119, P823; Becraft PW, 1998, TRENDS PLANT SCI, V3, P384, DOI 10.1016/S1360-1385(98)01301-6; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CLARK SE, 1993, DEVELOPMENT, V119, P397; CLARK SE, 1995, DEVELOPMENT, V121, P2057; Clark SE, 1996, SEMIN CELL DEV BIOL, V7, P873, DOI 10.1006/scdb.1996.0107; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; FELDMANN KA, 1987, MOL GEN GENET, V208, P1, DOI 10.1007/BF00330414; Kayes JM, 1998, DEVELOPMENT, V125, P3843; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Laufs P, 1998, PLANT CELL, V10, P1375, DOI 10.1105/tpc.10.8.1375; LEYSER HMO, 1992, DEVELOPMENT, V116, P397; Long JA, 1998, DEVELOPMENT, V125, P3027; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Steeves TA, 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STEWART RN, 1978, CLONAL BASIS DEV; Tilney-Bassett RA., 1986, PLANT CHIMERAS; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wisman E, 1998, PLANT MOL BIOL, V37, P989, DOI 10.1023/A:1006082009151	24	947	1003	1	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1911	1914		10.1126/science.283.5409.1911	http://dx.doi.org/10.1126/science.283.5409.1911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10082464				2022-12-01	WOS:000079228600047
J	Logan, M; Tabin, CJ				Logan, M; Tabin, CJ			Role of Pitx1 upstream of Tbx4 in specification of hindlimb identity	SCIENCE			English	Article							T-BOX GENES; LIMB DEVELOPMENT; ADDITIONAL LIMB; CHICK-EMBRYOS; EXPRESSION; INITIATION; PATTERN; FLANK; PTX1; BUD	In spite of recent breakthroughs in understanding Limb patterning, the genetic factors determining the differences between the forelimb and the hindlimb have not been understood. The genes Pitx1 and Tbx4 encode transcription factors that are expressed throughout the developing hindlimb but not forelimb buds. Misexpression of Pitx1 in the chick wing bud induced distal expression of Tbx4, as well as HoxC10 and HoxC11, which are normally restricted to hindlimb expression domains. Wing buds in which Pitx1 was misexpressed developed into Limbs with some morphological characteristics of hindlimbs: the flexure was altered to that normally observed in legs, the digits were more toe-like in their relative size and shape, and the muscle pattern was transformed to that of a Leg.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.							Bao ZZ, 1997, J NEUROSCI, V17, P1425; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Isaac A, 1998, DEVELOPMENT, V125, P1867; Kardon G, 1998, DEVELOPMENT, V125, P4019; Klymkowsky M. W., 1991, WHOLE MOUNT STAINING; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lanctot C, 1997, DEVELOPMENT, V124, P2807; LANSER ME, 1987, ANAT RECORD, V217, P61, DOI 10.1002/ar.1092170110; Logan M, 1998, METHODS, V14, P407, DOI 10.1006/meth.1998.0595; Logan M, 1998, DEVELOPMENT, V125, P2825; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Ohuchi H, 1998, DEVELOPMENT, V125, P51; OHUCHI H, 1995, BIOCHEM BIOPH RES CO, V209, P809, DOI 10.1006/bbrc.1995.1572; PAUTOU MP, 1982, ARCH ANAT MICROSC MO, V71, P193; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Shang J, 1997, GENOMICS, V40, P108, DOI 10.1006/geno.1996.4558; SHELLSWELL GB, 1977, PATTERN MUSCLE TENDO; Simon HG, 1997, DEVELOPMENT, V124, P1355; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; Vogel A, 1996, DEVELOPMENT, V122, P1737; WORTHAM RA, 1948, J MORPHOL, V83, P105, DOI 10.1002/jmor.1050830106	26	223	231	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	1999	283	5408					1736	1739		10.1126/science.283.5408.1736	http://dx.doi.org/10.1126/science.283.5408.1736			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175PF	10073939				2022-12-01	WOS:000079102800052
J	El-Serag, HB; Mason, AC				El-Serag, HB; Mason, AC			Rising incidence of hepatocellular carcinoma in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HEPATITIS-B; VIRUS-INFECTION; ALPHA	Background and Methods Clinical observations have suggested that the number of cases of hepatocellular carcinoma has increased in the United States. We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) data base to determine the age-adjusted incidence of hepatocellular carcinoma from 1976 to 1995, data from the U.S, vital-statistics data base to determine age-adjusted mortality rates from 1981 to 1995, and data from the Department of Veterans Affairs to determine age-adjusted rates of hospitalization for the disease from 1983 to 1997. Results The incidence of histologically proved hepatocellular carcinoma increased from 1.4 per 100,000 population (95 percent confidence interval, 1.3 to 1.4) for the period from 1976 to 1980 to 2.4 per 100,000 (95 percent confidence interval, 2.3 to 2.4) for the period from 1991 to 1995. Among black men, the incidence was 6.1 per 100,000 for the period from 1991 to 1995, and among white men, it was 2.8 per 100,000. There was a 41 percent increase in the mortality rate from primary liver cancer and a 46 percent increase in the proportion of hospitalizations attributable to this disease during the periods studied. The incidence increased significantly among younger persons (40 to 60 years old) during the period from 1991 to 1995 as compared with earlier periods. Conclusions An increase in the number of cases of hepatocellular carcinoma has occurred in the United States over the past two decades. The age-specific incidence of this cancer has progressively shifted toward younger people. (N Engl J Med 1999;340:745-50.) (C)1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Gastroenterol Sect, Albuquerque, NM 87108 USA; Univ New Mexico, Albuquerque, NM 87131 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico	El-Serag, HB (corresponding author), Vet Affairs Med Ctr, Gastroenterol Sect, 111F,1501 San Pedro SE, Albuquerque, NM 87108 USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; BISCEGLIE AM, 1991, HEPATOLOGY, V14, P969; Breslow NE, 1987, STAT METHODS CANC RE, P58; CASTELLS L, 1995, LIVER, V15, P159; Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DiBisceglie AM, 1997, HEPATOLOGY, V26, pS34, DOI 10.1002/hep.510260706; DUFOUR MC, 1994, NIH PUBLICATION, P615; GODLEY PA, DIGESTIVE DIS US EPI; GRANT B, 1989, 11 NAT I ALC AB ALC; GRANT BFD, 1990, LIVER CIRRHOSIS MORT; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12, P87; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; Kew MC, 1998, SLEISENGER FORDTRANS, V1, P1364; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; MCQUILLAN GM, 1989, AM J MED, V87, pS5; MCQUILLAN GM, 1994, NIH PUBLICATION, P127; *NAT CANC I, 1998, SURV EP END RES PROG; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; OKUDA K, 1987, CANCER RES, V47, P4967; Percy C., 1990, INT CLASSIFICATION D; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; SHERLOCK S, 1994, GUT, V35, P828, DOI 10.1136/gut.35.6.828; TAKANO S, 1995, HEPATOLOGY, V21, P650; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; U.S. Department of Health and Human Services, 1989, DHHS PUBL; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WONG JB, 1995, ANN INTERN MED, V122, P664, DOI 10.7326/0003-4819-122-9-199505010-00004; YARRISH RL, 1980, INT J CANCER, V26, P711, DOI 10.1002/ijc.2910260603	30	2379	2439	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1999	340	10					745	750		10.1056/NEJM199903113401001	http://dx.doi.org/10.1056/NEJM199903113401001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	174KJ	10072408				2022-12-01	WOS:000079034100001
J	Moran, JV; DeBerardinis, RJ; Kazazian, HH				Moran, JV; DeBerardinis, RJ; Kazazian, HH			Exon shuffling by L1 retrotransposition	SCIENCE			English	Article							HUMAN TRANSPOSABLE ELEMENT; HUMAN GENOME; SEQUENCE; LINE-1; GENE; INSERTION; EVOLUTION; ORIGIN	Long interspersed nuclear elements (LINE-1s or L1s) are the most abundant retrotransposons in the human genome, and they serve as major sources of reverse transcriptase activity. Engineered L1s retrotranspose at high frequency in cultured human cells. Here it is shown that L1s insert into transcribed genes and retrotranspose sequences derived from their 3' flanks to new genomic Locations. Thus, retrotransposition-competent L1s provide a vehicle to mobilize non-L1 sequences, such as exons or promoters, into existing genes and may represent a general mechanism for the evolution of new genes.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Moran, JV (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [GM45398] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045398] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; CONWAY L, 1985, P NATL ACAD SCI USA, V82, P3949, DOI 10.1073/pnas.82.12.3949; DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FANNING T, 1987, NUCLEIC ACIDS RES, V15, P2251, DOI 10.1093/nar/15.5.2251; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Gilbert W, 1997, P NATL ACAD SCI USA, V94, P7698, DOI 10.1073/pnas.94.15.7698; Hohjoh H, 1997, EMBO J, V16, P6034, DOI 10.1093/emboj/16.19.6034; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; Leder P, 1982, Natl Cancer Inst Monogr, V60, P49; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; LUNQUE T, 1997, MOL BIOL EVOL, V14, P1316; Lupski JR, 1998, MOL MED, V4, P3, DOI 10.1007/BF03401724; MARTIN SL, 1995, GENE, V153, P261, DOI 10.1016/0378-1119(94)00785-Q; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; McNaughton JC, 1997, GENOMICS, V40, P294, DOI 10.1006/geno.1996.4543; MIKI Y, 1992, CANCER RES, V52, P643; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; MORAN JV, UNPUB; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Rozmahel R, 1997, GENOMICS, V45, P554, DOI 10.1006/geno.1997.4968; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; YANDELL M, COMMUNICATION	30	457	465	4	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1530	1534		10.1126/science.283.5407.1530	http://dx.doi.org/10.1126/science.283.5407.1530			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066175				2022-12-01	WOS:000078959200047
J	Staab, JF; Bradway, SD; Fidel, PL; Sundstrom, P				Staab, JF; Bradway, SD; Fidel, PL; Sundstrom, P			Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1	SCIENCE			English	Article							TRANSAMIDATING ENZYMES; EXPRESSION; MECHANISM; PROTEINS; PROLINE	The pathogenesis of candidiasis involves invasion of host tissues by filamentous forms of the opportunistic yeast Candida albicans. Morphology-specific gene products may confer proinvasive properties. A hypha-specific surface protein, Hwp1, with similarities to mammalian small proline-rich proteins was shown to serve as a substrate for mammalian transglutaminases. Candida albicans strains lacking Hwp1 were unable to form stable attachments to human buccal epithelial cells and had a reduced capacity to cause systemic candidiasis in mice. This represents a paradigm for microbial adhesion that implicates essential host enzymes.	Ohio State Univ, Coll Med & Publ Hlth, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Ohio State Univ, Coll Dent, Dept Periodontol, Columbus, OH 43210 USA; Louisiana State Univ, Med Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Louisiana State University System	Sundstrom, P (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Med Microbiol & Immunol, 333 W 10th Ave, Columbus, OH 43210 USA.	sundstrom.1@osu.edu			NIAID NIH HHS [AI32556] Funding Source: Medline; NIDCR NIH HHS [1 R01 DE11375-05A2] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032556, R01AI032556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011375] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Austin SJ, 1996, J BIOL CHEM, V271, P3737, DOI 10.1074/jbc.271.7.3737; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BRADWAY SD, 1993, CRIT REV ORAL BIOL M, V4, P293, DOI 10.1177/10454411930040030601; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHILDS WC, 1988, J DENT RES, V67, P826, DOI 10.1177/00220345880670050601; DESBUQUOIS B, 1975, EUR J BIOCHEM, V60, P335, DOI 10.1111/j.1432-1033.1975.tb21008.x; Fichtenbaum CJ, 1998, CLIN INFECT DIS, V26, P556, DOI 10.1086/514571; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FONZI WA, 1993, GENETICS, V134, P717; Kaartinen MT, 1997, J BIOL CHEM, V272, P22736, DOI 10.1074/jbc.272.36.22736; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; LORAND L, 1971, ANAL BIOCHEM, V44, P221, DOI 10.1016/0003-2697(71)90363-0; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; POSTLETHWAIT P, 1995, J BACTERIOL, V177, P1772, DOI 10.1128/jb.177.7.1772-1779.1995; Reichert Uwe, 1993, P107; Rex J H, 1998, Adv Intern Med, V43, P321; Sambrook J., 1989, MOL CLONING LAB MANU; Staab JF, 1998, YEAST, V14, P681, DOI 10.1002/(SICI)1097-0061(199805)14:7&lt;681::AID-YEA256&gt;3.0.CO;2-8; Staab JF, 1996, J BIOL CHEM, V271, P6298, DOI 10.1074/jbc.271.11.6298; STAAB JF, UNPUB; Tarcsa E, 1998, J BIOL CHEM, V273, P23297, DOI 10.1074/jbc.273.36.23297; VELASCO PT, 1988, BIOCHEM BIOPH RES CO, V152, P505, DOI 10.1016/S0006-291X(88)80066-4	25	451	470	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1535	1538		10.1126/science.283.5407.1535	http://dx.doi.org/10.1126/science.283.5407.1535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066176				2022-12-01	WOS:000078959200048
J	Garris, PA; Kilpatrick, M; Bunin, MA; Michael, D; Walker, QD; Wightman, RM				Garris, PA; Kilpatrick, M; Bunin, MA; Michael, D; Walker, QD; Wightman, RM			Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation	NATURE			English	Article							INVIVO MICRODIALYSIS; BRAIN-STIMULATION; RAT-BRAIN; REWARD; STRIATUM; RECOVERY	Mesolimbic dopamine-releasing neurons appear to be important in the brain reward system(1,2). One behavioural paradigm that supports this hypothesis is intracranial self-stimulation (ICS), during which animals repeatedly press a lever to stimulate their own dopamine-releasing neurons electrically(3-6). Here we study dopamine release from dopamine terminals in the nucleus accumbens core and shell in the brain by using rapid-responding voltammetric microsensors(7) during electrical stimulation of dopamine cell bodies in the ventral tegmental area/substantia nigra brain regions. In rats in which stimulating electrode placement failed to elicit dopamine release in the nucleus accumbens, ICS behaviour was not learned In contrast, ICS was acquired when stimulus trains evoked extracellular dopamine in either the core or the shell of the nucleus accumbens. In animals that could learn ICS, experimenter-delivered stimulation always elicited dopamine release. In contrast, extracellular dopamine was rarely observed during ICS itself. Thus, although activation of mesolimbic dopamine-releasing neurons seems to be a necessary condition for ICS, evoked dopamine release is actually diminished during ICS. Dopamine may therefore be a neural substrate for novelty(8) or reward expectation(9) rather than reward itself.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC 27599 USA; Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Illinois State University	Wightman, RM (corresponding author), Univ N Carolina, Dept Chem, CB 3290,Venable Hall, Chapel Hill, NC 27599 USA.							BLAHA CD, 1990, J NEUROSCI METH, V34, P125, DOI 10.1016/0165-0270(90)90050-P; Cahill PS, 1996, ANAL CHEM, V68, P3180, DOI 10.1021/ac960347d; DIORINO DF, 1993, BEHAV BRAIN RES, V55, P131; FIBIGER HC, 1987, J NEUROSCI, V7, P3888; GALLISTEL CR, 1987, PHARMACOL BIOCHEM BE, V26, P731, DOI 10.1016/0091-3057(87)90605-8; GARRIS PA, 1994, J NEUROSCI, V14, P6084; Garris PA, 1997, J NEUROCHEM, V68, P152; Jones SR, 1996, SYNAPSE, V23, P224, DOI 10.1002/(SICI)1098-2396(199607)23:3<224::AID-SYN12>3.3.CO;2-6; Kruk ZL, 1998, J NEUROSCI METH, V79, P9, DOI 10.1016/S0165-0270(97)00156-8; MARSDEN CA, 1988, NEUROSCIENCE, V25, P389, DOI 10.1016/0306-4522(88)90247-3; MICHAEL AC, 1987, BRAIN RES, V421, P325, DOI 10.1016/0006-8993(87)91302-3; Michael D, 1998, ANAL CHEM, V70, p586A, DOI 10.1021/ac9819640; MILIARESSIS E, 1991, BEHAV BRAIN RES, V46, P43, DOI 10.1016/S0166-4328(05)80095-6; Mirenowicz J, 1996, NATURE, V379, P449, DOI 10.1038/379449a0; MURRAY B, 1994, BEHAV BRAIN RES, V63, P47, DOI 10.1016/0166-4328(94)90050-7; NAKAHARA D, 1992, BRAIN RES, V574, P164, DOI 10.1016/0006-8993(92)90813-O; Nirenberg MJ, 1997, J NEUROSCI, V17, P6899; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775; PARSONS LH, 1992, J NEUROCHEM, V58, P212, DOI 10.1111/j.1471-4159.1992.tb09298.x; Phillips AG, 1989, NEUROPHARMACOLOGICAL, P66; Pich EM, 1997, SCIENCE, V275, P83; REVEC GV, 1997, NEUROSCIENCE, V76, P707; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Shizgal P., 1989, NEUROPHARMACOLOGICAL, P106; STELLAR JR, 1989, NEUROPHARMACOLOGICAL, P14; Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535; WISE RA, 1983, NEUROBIOLOGY OPIATE, P405	30	256	264	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 4	1999	398	6722					67	69		10.1038/18019	http://dx.doi.org/10.1038/18019			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174KG	10078530				2022-12-01	WOS:000079033900052
J	Karlseder, J; Broccoli, D; Dai, YM; Hardy, S; de Lange, T				Karlseder, J; Broccoli, D; Dai, YM; Hardy, S; de Lange, T			p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2	SCIENCE			English	Article							ATAXIA-TELANGIECTASIA; CELLS; DNA; PROTEIN; PATHWAY; ARREST; MICE	Although broken chromosomes can induce apoptosis, natural chromosome ends (telomeres) do not trigger this response. It is shown that this suppression of apoptosis involves the telomeric-repeat binding factor 2 (TRF2), Inhibition of TRF2 resulted in apoptosis in a subset of mammalian cell types, The response was mediated by p53 and the ATM (ataxia telangiectasia mutated) kinase, consistent with activation of a DNA damage checkpoint. Apoptosis was not due to rupture of dicentric chromosomes formed by end-to-end fusion, indicating that telomeres Lacking TRF2 directly signal apoptosis, possibly because they resemble damaged DNA. Thus, in some cells, telomere shortening may signal cell death rather than senescence.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA; Cell Genesys, Foster City, CA 94405 USA	Rockefeller University; Cell Genesys Inc	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, 1230 York Ave, New York, NY 10021 USA.		de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NIGMS NIH HHS [GM49046] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049046, R01GM049046] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; SMOGORZEWSKA A, UNPUB; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	29	870	911	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1321	1325		10.1126/science.283.5406.1321	http://dx.doi.org/10.1126/science.283.5406.1321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037601				2022-12-01	WOS:000078839900040
J	Lowe, TM; Eddy, SR				Lowe, TM; Eddy, SR			A computational screen for methylation guide snoRNAs in yeast	SCIENCE			English	Article							SMALL NUCLEOLAR RNAS; HIDDEN MARKOV-MODELS; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; GENES; ELEMENTS; SEQUENCE; INTRON	Small nucleolar RNAs (snoRNAs) are required for ribose 2'-O-methylation of eukaryotic ribosomal RNA. Many of the genes for this snoRNA family have remained unidentified in Saccharomyces cerevisiae, despite the availability of a complete genome sequence. Probabilistic modeling methods akin to those used in speech recognition and computational linguistics were used to computationally screen the yeast genome and identify 22 methylation guide snoRNAs, snR50 to snR71. Gene disruptions and other experimental characterization confirmed their methylation guide function. in total, 51 of the 55 ribose methylated sites in yeast ribosomal RNA were assigned to 41 different guide snoRNAs.	Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL)	Lowe, TM (corresponding author), Washington Univ, Sch Med, Dept Genet, 4566 Scott Ave, St Louis, MO 63110 USA.		Lowe, Todd Michael/ABJ-5261-2022	Eddy, Sean/0000-0001-6676-4706	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001363] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01-HG01363] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bachellerie JP, 1997, TRENDS BIOCHEM SCI, V22, P257, DOI 10.1016/S0968-0004(97)01057-8; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Barrett C, 1997, COMPUT APPL BIOSCI, V13, P191; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Cavaille J, 1998, NUCLEIC ACIDS RES, V26, P1576, DOI 10.1093/nar/26.7.1576; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; EDDY SR, 1994, NUCLEIC ACIDS RES, V22, P2079, DOI 10.1093/nar/22.11.2079; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; GANNOT P, 1997, CELL, V89, P799; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HADJICHRISTODOULOU A, 1985, Cyprus Agricultural Research Institute Technical Bulletin, P1; JARMOLOWSKI A, 1990, EMBO J, V9, P4503, DOI 10.1002/j.1460-2075.1990.tb07901.x; Kiss-Laszlo Z, 1998, EMBO J, V17, P797, DOI 10.1093/emboj/17.3.797; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KLOOTWIJK J, 1973, EUR J BIOCHEM, V39, P325, DOI 10.1111/j.1432-1033.1973.tb03130.x; Lange TS, 1998, EMBO J, V17, P3176, DOI 10.1093/emboj/17.11.3176; Leader DJ, 1997, EMBO J, V16, P5742, DOI 10.1093/emboj/16.18.5742; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; NI JS, COMMUNICATION; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; Qu LH, 1999, MOL CELL BIOL, V19, P1144; RAUE HA, 1988, PROG BIOPHYS MOL BIO, V51, P77, DOI 10.1016/0079-6107(88)90011-9; Richard Durbin., 1998, BIOL SEQUENCE ANAL P; SAKAKIBARA Y, 1994, NUCLEIC ACIDS RES, V22, P5112, DOI 10.1093/nar/22.23.5112; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; SINGH H, 1964, CAN J BIOCHEM PHYS, V42, P1011, DOI 10.1139/o64-112; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; VELDMAN GM, 1981, NUCLEIC ACIDS RES, V9, P6935, DOI 10.1093/nar/9.24.6935; Watkins NJ, 1998, RNA, V4, P582, DOI 10.1017/S1355838298980128	37	373	407	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1168	1171		10.1126/science.283.5405.1168	http://dx.doi.org/10.1126/science.283.5405.1168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10024243				2022-12-01	WOS:000078738400052
J	Chin, AE; Hedberg, K; Higginson, GK; Fleming, DW				Chin, AE; Hedberg, K; Higginson, GK; Fleming, DW			Legalized physician-assisted suicide in Oregon - The first year's experience	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; ATTITUDES	Background and Methods On October 27, 1997, Oregon legalized physician-assisted suicide. We collected data on all terminally ill Oregon residents who received prescriptions for lethal medications under the Oregon Death with Dignity Act and who died in 1998. The data were obtained from physicians' reports, death certificates, and interviews with physicians. We compared persons who took lethal medications prescribed under the act with those who died from similar illnesses but did not receive prescriptions for lethal medications. Results Information on 23 persons who received prescriptions for lethal medications was reported to the Oregon Health Division; 15 died after taking the lethal medications, 6 died from underlying illnesses, and 2 were alive as of January 1, 1999. The median age of the 15 patients who died after taking lethal medications was 69 years; 8 were male, and all 15 were white. Thirteen of the 15 patients had cancer. The case patients and controls were similar with regard to sex, race, urban or rural residence, level of education, health insurance coverage, and hospice enrollment. No case patients or control patients expressed concern about the financial impact of their illness. One case patient and 15 control patients expressed concern about inadequate control of pain (P=0.10). The case patients were more likely than the control patients to have never married (P=0.04) and were more likely to be concerned about loss of autonomy due to illness (P=0.01) and loss of control of bodily functions (P=0.02). At death, 21 percent of the case patients and 84 percent of the control patients were completely disabled (P<0.001). Conclusions During the first year of legalized physician-assisted suicide in Oregon, the decision to request and use a prescription for lethal medication was associated with concern about loss of autonomy or control of bodily functions, not with fear of intractable pain or concern about financial loss. In addition, we found that the choice of physician-assisted suicide was not associated with level of education or health insurance coverage. (N Engl J Med 1999;340:577-83.) (C)1999, Massachusetts Medical Society.	Oregon Hlth Div, Portland, OR 97232 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA	Oregon Health & Science University; Centers for Disease Control & Prevention - USA	Hedberg, K (corresponding author), Oregon Hlth Div, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA.							ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; *CTR HLTH STAT OR, 1997, OR VIT STAT COUNTY D; DEAN A, 1995, EPI INFO VERSION 6 W; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; *DRUG ENF AG DRUG, 1998, 4 DEP JUST DRUG ENF, P43; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; HALEY K, 1998, OREGON DEATH DIGNITY, P40; HEDBERG K, 1998, OREGON DEATH DIGNITY, P43; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; O'Keefe Mark, 1997, OREGONIAN       1019, pA1; OKEEFE M, 1994, OREGONIAN       1204, pA1; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PELLEGRINO ED, 1998, REGULATING WE DIE ET, P71; Preston T. A., 1996, J PHARM CARE PAIN SY, V4, P183; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009	20	211	211	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					577	583		10.1056/NEJM199902183400724	http://dx.doi.org/10.1056/NEJM199902183400724			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021482				2022-12-01	WOS:000078680100039
J	Wechsler, E; D'Aleo, C; Hill, VA; Hopper, J; Myers-Wiley, D; O'Keefe, E; Jacobs, J; Guido, F; Huang, A; Dodt, SN; Rowan, B; Sherman, M; Greenberg, A; Schneider, D; Noone, B; Fanella, L; Williamson, BR; Dinda, E; Mayer, M; Backer, M; Agasan, A; Kornstein, L; Stavinsky, F; Neal, B; Edwards, D; Haroon, M; Hurley, D; Colbert, L; Miller, J; Mojica, B; Carloni, E; Devine, B; Cambridge, M; Root, T; Schoonmaker, D; Shayegani, M; Hastback, W; Wallace, B; Kondracki, S; Smith, P; Matiuck, S; Pilot, K; Acharya, M; Wolf, G; Manley, W; Genese, C; Brooks, J; Dembek, Z; Hadler, J				Wechsler, E; D'Aleo, C; Hill, VA; Hopper, J; Myers-Wiley, D; O'Keefe, E; Jacobs, J; Guido, F; Huang, A; Dodt, SN; Rowan, B; Sherman, M; Greenberg, A; Schneider, D; Noone, B; Fanella, L; Williamson, BR; Dinda, E; Mayer, M; Backer, M; Agasan, A; Kornstein, L; Stavinsky, F; Neal, B; Edwards, D; Haroon, M; Hurley, D; Colbert, L; Miller, J; Mojica, B; Carloni, E; Devine, B; Cambridge, M; Root, T; Schoonmaker, D; Shayegani, M; Hastback, W; Wallace, B; Kondracki, S; Smith, P; Matiuck, S; Pilot, K; Acharya, M; Wolf, G; Manley, W; Genese, C; Brooks, J; Dembek, Z; Hadler, J			Outbreak of Vibrio parahaemolyticus infection associated with eating raw oysters and clams harvested from Long Island Sound - Connecticut, New Jersey, and New York, 1998 (Reprinted from MMWR, vol 48, pg 48, 1999)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint									Westchester Cty Hlth Dept, New Rochelle, NY USA; Nassau Cty Dept Hlth, Div Dis Control, Mineola, NY USA; Suffolk Cty Dept Hlth Serv, Hauppauge, NY USA; New York City Bur Labs, Enter Pathogens Lab, New York, NY USA; New York City Bur Labs, Environm Microbiol Lab, New York, NY USA; New York City Dept Hlth, New York, NY USA; Bur Community Sanitat & Food Protect, New York, NY USA; Wadsworth Ctr Labs & Res, Albany, NY USA; New York State Dept Hlth, Albany, NY 12237 USA; New York State Dept Environm Conservat, New York, NY USA; Bur Communicable Dis Control, New York, NY USA; Bur Labs, New York, NY USA; New Jersey State Dept Hlth, Trenton, NJ 08625 USA; Connecticut Dept Publ Hlth, US FDA, Hartford, CT USA; US Fish & Wildlife Serv, USDA, Washington, DC USA; CDC, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Foodborne & Diarrheal Dis Branch, Atlanta, GA 30333 USA; CDC, Epidemiol Program Off, Div Appl Publ Hlth Training, State Branch, Atlanta, GA 30333 USA	New York City Department of Health & Mental Hygiene; Wadsworth Center; State University of New York (SUNY) System; New Jersey Department of Health & Senior Services; US Food & Drug Administration (FDA); United States Department of Agriculture (USDA); United States Department of the Interior; US Fish & Wildlife Service; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Wechsler, E (corresponding author), Westchester Cty Hlth Dept, New Rochelle, NY USA.							1999, MMWR, V48, P48	1	12	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					603	604						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029109				2022-12-01	WOS:000078548400010
J	Johnson, SA; Ollivier, PJ; Mallouk, TE				Johnson, SA; Ollivier, PJ; Mallouk, TE			Ordered mesoporous polymers of tunable pore size from colloidal silica templates	SCIENCE			English	Article							POLYFURFURYL ALCOHOL; POLYVINYL ACETATE; MOLECULAR-SIEVES; LAMELLAE; MONTMORILLONITE; NANOSTRUCTURES; CARBONIZATION; NANOMATERIALS; REPLICATION; FILM	Ordered mesoporous polymers have been prepared by replication of colloidal crystals made from silica spheres 35 nanometers in diameter. The pores in the colloidal crystals were filled with divinylbenzene (DVB), ethyleneglycol dimethacrylate (EDMA), or a mixture of the two. Polymerization and subsequent dissolution of the silica template Leaves a polycrystalline network of interconnected pores. When mixtures of DVB and EDMA are used, the pore size of the polymer replicas can be varied continuously between 35 and 15 nanometers because the polymer shrinks when the silica template is removed.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Mallouk, TE (corresponding author), Penn State Univ, Dept Chem, 152 Davey Lab, University Pk, PA 16802 USA.	tom@chem.psu.edu	Mallouk, Thomas E/K-7391-2012	Mallouk, Thomas E/0000-0003-4599-4208	NIGMS NIH HHS [GM-43844] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGSHAW SA, 1995, SCIENCE, V269, P1242, DOI 10.1126/science.269.5228.1242; Bandosz TJ, 1996, CHEM MATER, V8, P2023, DOI 10.1021/cm960233i; BLATTER F, 1988, SURF SCI, V203, P571, DOI 10.1016/0039-6028(88)90099-4; Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; DHAL PK, 1991, J AM CHEM SOC, V113, P7417, DOI 10.1021/ja00019a046; Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; Johnson SA, 1998, J MATER CHEM, V8, P13, DOI 10.1039/a706791g; Johnson SA, 1997, CHEM MATER, V9, P2448, DOI 10.1021/cm9703278; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; KYOTANI T, 1994, CARBON, V32, P627, DOI 10.1016/0008-6223(94)90082-5; KYOTANI T, 1988, NATURE, V331, P331, DOI 10.1038/331331a0; KYOTANI T, 1994, CHEM MATER, V6, P2138, DOI 10.1021/cm00047a039; Lakshmi BB, 1997, CHEM MATER, V9, P857, DOI 10.1021/cm9605577; MARTIN CR, 1995, ACCOUNTS CHEM RES, V28, P61, DOI 10.1021/ar00050a002; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Martin CR, 1996, CHEM MATER, V8, P1739, DOI 10.1021/cm960166s; MASUDA H, 1995, SCIENCE, V268, P1466, DOI 10.1126/science.268.5216.1466; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; OLIVIER JP, 1993, CHARACTERIZATION POR; OSSEOASARE K, 1990, COLLOID SURFACE, V50, P321, DOI 10.1016/0166-6622(90)80273-7; Ozin GA, 1997, ACCOUNTS CHEM RES, V30, P17, DOI 10.1021/ar960021r; Park SH, 1998, ADV MATER, V10, P1045, DOI 10.1002/(SICI)1521-4095(199809)10:13<1045::AID-ADMA1045>3.3.CO;2-U; ROY DM, 1974, NATURE, V247, P220, DOI 10.1038/247220a0; SCHIRATO BS, 1995, SCIENCE, V267, P369, DOI 10.1126/science.267.5196.369; Sokol PE, 1996, NATURE, V379, P616, DOI 10.1038/379616a0; SONOBE N, 1990, CARBON, V28, P483, DOI 10.1016/0008-6223(90)90042-W; SONOBE N, 1991, CARBON, V29, P61, DOI 10.1016/0008-6223(91)90095-Z; SONOBE N, 1988, CARBON, V26, P573, DOI 10.1016/0008-6223(88)90158-3; SONOBE N, 1988, J PHYS CHEM-US, V92, P7029, DOI 10.1021/j100335a037; van Blaaderen A, 1998, SCIENCE, V282, P887; Velev OD, 1997, NATURE, V389, P447, DOI 10.1038/38921; WEBER JN, 1971, NATURE, V233, P337, DOI 10.1038/233337a0; WHITE RL, 1972, SCIENCE, V176, P1922; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; WU CG, 1994, SCIENCE, V266, P1013, DOI 10.1126/science.266.5187.1013; WU CG, 1994, SCIENCE, V264, P1757, DOI 10.1126/science.264.5166.1757; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Zakhidov AA, 1998, SCIENCE, V282, P897, DOI 10.1126/science.282.5390.897; Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i	40	595	656	3	297	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1999	283	5404					963	965		10.1126/science.283.5404.963	http://dx.doi.org/10.1126/science.283.5404.963			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974384				2022-12-01	WOS:000078574800041
J	Rodriguez, FI; Esch, JJ; Hall, AE; Binder, BM; Schaller, GE; Bleecker, AB				Rodriguez, FI; Esch, JJ; Hall, AE; Binder, BM; Schaller, GE; Bleecker, AB			A copper cofactor for the ethylene receptor ETR1 from Arabidopsis	SCIENCE			English	Article							BINDING; GENE; SIMILARITY; COMPLEXES; PLANTS	The ETR1 receptor from Arabidopsis binds the gaseous hormone ethylene, A copper ion associated with the ethylene-binding domain is required for high-affinity ethylene-binding activity. A missense mutation in the domain that renders the plant insensitive to ethylene eliminates both ethylene binding and the interaction of topper with the receptor. A sequence from the genome of the cyanobacterium Synechocystis sp, strain 6803 that shows homology to the ethylene-binding domain of ETR1 encodes a functional ethylene-binding protein. On the basis of sequence conservation between the Arabidopsis and the cyanobacterial ethylene-binding domains and on in vitro mutagenesis of ETR1, a structural model for this copper-based ethylene sensor domain is presented.	Univ Wisconsin, Dept Bot, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bleecker, AB (corresponding author), Univ Wisconsin, Dept Bot, 430 Lincoln Dr, Madison, WI 53706 USA.			Binder, Brad/0000-0002-8172-2034				Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BENGOCHEA T, 1980, PLANTA, V148, P397, DOI 10.1007/BF00388129; BEYER EM, 1976, PLANT PHYSIOL, V58, P268, DOI 10.1104/pp.58.3.268; BURG SP, 1965, SCIENCE, V148, P1190, DOI 10.1126/science.148.3674.1190; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; HALL AJ, UNPUB; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; MUNAKATA M, 1986, INORG CHEM, V25, P2622, DOI 10.1021/ic00235a027; RODRIGUEZ FJM, UNPUB; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SISLER EC, 1979, PLANT PHYSIOL, V64, P538, DOI 10.1104/pp.64.4.538; Smith P. M., 1988, Technical Services Quarterly, V6, P3, DOI 10.1300/J124v06n01_02; THOMPSON JS, 1983, J AM CHEM SOC, V105, P3522, DOI 10.1021/ja00349a026; Wilde A, 1997, FEBS LETT, V406, P89, DOI 10.1016/S0014-5793(97)00248-2; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; Wilmotte A., 1994, MOL BIOL CYANOBACTER, P1, DOI DOI 10.1007/978-94-011-0227-8_1; YU JP, 1995, PLANT MOL BIOL, V29, P331, DOI 10.1007/BF00043656; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	21	466	501	2	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					996	998		10.1126/science.283.5404.996	http://dx.doi.org/10.1126/science.283.5404.996			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974395				2022-12-01	WOS:000078574800052
J	Carlson, RW				Carlson, RW			A tenuous carbon dioxide atmosphere on Jupiter's moon Callisto	SCIENCE			English	Article							GALILEAN SATELLITES; GANYMEDE; SPECTROSCOPY; SURFACE; OXYGEN	An off-limb scan of Callisto was conducted by the Galileo near-infrared mapping spectrometer to search for a carbon dioxide atmosphere. Airglow in the carbon dioxide nu(3) band was observed up to 100 kilometers above the surface and indicates the presence of a tenuous carbon dioxide atmosphere with surface pressure of 7.5 x 10(-12) bar and a temperature of about 150 kelvin, close to the surface temperature. A lifetime on the order of 4 years is suggested, based on photoionization and magnetospheric sweeping. Either the atmosphere is transient and was formed recently or some process is currently supplying carbon dioxide to the atmosphere.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Carlson, RW (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr,Mail Stop 183-601, Pasadena, CA 91109 USA.							Barth CA, 1997, GEOPHYS RES LETT, V24, P2147, DOI 10.1029/97GL01927; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; CARLSON RW, 1976, JUPITER, P433; deGraauw T, 1997, ASTRON ASTROPHYS, V321, pL13; Delitsky ML, 1997, J GEOPHYS RES-PLANET, V102, P16385, DOI 10.1029/97JE01250; DONAHUE TM, 1967, J GEOPHYS RES, V72, P2803, DOI 10.1029/JZ072i011p02803; DUSHMAN S, 1962, SCI FDN VACUUM TECHN, P726; ENCRENAZ T, 1998, JOV SYST GAL SAT SYS; Feuchtgruber H, 1997, NATURE, V389, P159, DOI 10.1038/38236; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; Hall DT, 1998, ASTROPHYS J, V499, P475, DOI 10.1086/305604; HANEL R, 1979, SCIENCE, V206, P952, DOI 10.1126/science.206.4421.952; HAPKE B, 1981, J GEOPHYS RES, V86, P3039, DOI 10.1029/JB086iB04p03039; HERZBERG G, 1945, MOL SPECTRA MOL STRU, V2, P422; HOLSTEIN T, 1947, PHYS REV, V72, P1212, DOI 10.1103/PhysRev.72.1212; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; Johnson RE, 1998, GEOPHYS RES LETT, V25, P3257, DOI 10.1029/98GL02565; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; McCord TB, 1998, J GEOPHYS RES-PLANET, V103, P8603, DOI 10.1029/98JE00788; McCord TB, 1997, SCIENCE, V278, P271, DOI 10.1126/science.278.5336.271; MOORE JS, UNPUB; PLACZEK G, 1934, HDB RADIOLOGIE, V2, P209; Rothman LS, 1998, J QUANT SPECTROSC RA, V60, P665, DOI 10.1016/S0022-4073(98)00078-8; SHOCK EL, 1993, ICARUS, V106, P464, DOI 10.1006/icar.1993.1185; SMYTHE WD, 1998, 29 LUN PLAN SCI C HO; SPENCER JR, 1987, ICARUS, V69, P297, DOI 10.1016/0019-1035(87)90107-2; TOHMATSU T, 1966, REP IONOS SPACE RES, V20, P418; ZAHNLE K, 1992, ICARUS, V95, P1, DOI 10.1016/0019-1035(92)90187-C	30	79	79	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					820	821		10.1126/science.283.5403.820	http://dx.doi.org/10.1126/science.283.5403.820			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933159				2022-12-01	WOS:000078496800036
J	Glynn, RJ; Beckett, LA; Hebert, LE; Morris, MC; Scherr, PA; Evans, DA				Glynn, RJ; Beckett, LA; Hebert, LE; Morris, MC; Scherr, PA; Evans, DA			Current and remote blood pressure and cognitive decline	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY PEOPLE; ALZHEIMERS-DISEASE; LONGITUDINAL DATA; IMPAIRMENT; MORTALITY; NONRESPONSE; ASSOCIATION; COMMUNITY; MEMORY; MODELS	Context Previous studies raise the possibility that blood pressure (BP) in middle age predicts later cognitive decline. Objective To examine prospectively the relationship of BP with level of and change in cognitive function in the elderly. Design Longitudinal, population-based study comprising subjects enrolled in the East Boston component of the Established Populations for the Epidemiologic Study of the Elderly (EPESE) (1982-1983) and the Hypertension Detection and Follow-Up Program (HDFP) (1973-1974). Setting East Boston, Mass. Participants Of the 3657 participants in the EPESE with baseline BP measurements, 2068 also participated in the HDFP. Subjects were aged 65 to 102 years at baseline in the EPESE and had mental status and memory assessed at baseline and 3 and 6 years. Main Outcome Measures Numbers of errors on the Short Portable Mental Status Questionnaire and the East Boston Memory Test and rates of change in these numbers of errors. Subjects had BP measured both at baseline in the EPESE and 9 years before, as part of the HDFP. Results In analyses adjusted for age, sex, and education, there was no strong linear association between BP and cognition. The associations found were fairly small in magnitude, and varied according to which test was used to measure cognition. There was little evidence for an effect of BP on change in cognitive function with either test, or for an effect on level of function on the memory test. In analyses of level of mental status questionnaire performance, however, elevated systolic BP (greater than or equal to 160 mm Hg)9 years before baseline was associated with a 14% (95% confidence interval [CI], 4%-25%) increase in error rate, relative to the referent (130-139 mm Hg). Baseline systolic BP had a U-shaped association with the number of errors; error rates were 9% higher compared with the referent group among those with systolic BP lower than 130 mm Hg (95% CI, 1%-17%) and 7% greater (95% CI, 0%-15%) among those with elevated systolic BP. Diastolic BP 9 years before baseline also had a U-shaped association with errors on the mental status questionnaire. Conclusion The findings do not suggest a linear association of BP with cognitive decline, but they are consistent with a more complex relationship between BP and cognition than previously appreciated.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Rush Univ, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA; Rush Univ, Rush Inst Healthy Aging, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Rush University; Rush University; Rush University; Centers for Disease Control & Prevention - USA	Glynn, RJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	rglynn@rics.bwh.harvard.edu			NATIONAL INSTITUTE ON AGING [P30AG010161, R01AG012106] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERT M, 1991, INT J NEUROSCI, V57, P167, DOI 10.3109/00207459109150691; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1978, J Chronic Dis, V31, P651; [Anonymous], 1991, JAMA, V265, P3255; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; Evans D A, 1993, Ann Epidemiol, V3, P71; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Gale CR, 1996, BRIT MED J, V312, P608; Gfeller JD, 1996, J CLIN PSYCHOL, V52, P191, DOI 10.1002/(SICI)1097-4679(199603)52:2<191::AID-JCLP10>3.0.CO;2-F; GLYNN RJ, 1993, AM J EPIDEMIOL, V138, P365, DOI 10.1093/oxfordjournals.aje.a116869; GLYNN RJ, 1993, J AM STAT ASSOC, V88, P984, DOI 10.2307/2290790; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; GLYNN RJ, 1995, ARCH INTERN MED, V155, P1855; GLYNN RJ, 1995, LANCET, V345, P825, DOI 10.1016/S0140-6736(95)92964-9; Guo ZC, 1997, AM J EPIDEMIOL, V145, P1106; Kilander L, 1998, HYPERTENSION, V31, P780, DOI 10.1161/01.HYP.31.3.780; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; LAUNER LJ, 1994, AM J EPIDEMIOL, V139, P803, DOI 10.1093/oxfordjournals.aje.a117077; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; SAS Institute Inc, 1997, SAS STAT SOFTW CHANG, P247; SCHERR PA, 1991, AM J EPIDEMIOL, V134, P1303, DOI 10.1093/oxfordjournals.aje.a116033; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.1997.03540340047031; Sturmer T, 1996, AM J EPIDEMIOL, V143, P683; VENABLES WN, 1997, MODERN APPL STAT S P; WALLACE RB, 1985, J CHRON DIS, V38, P475, DOI 10.1016/0021-9681(85)90031-1; White H, 1996, J AM GERIATR SOC, V44, P265, DOI 10.1111/j.1532-5415.1996.tb00912.x; WHITE L, 1994, J CLIN EPIDEMIOL, V47, P363, DOI 10.1016/0895-4356(94)90157-0; WILKIE F, 1971, SCIENCE, V172, P959, DOI 10.1126/science.172.3986.959; [No title captured]; [No title captured]	34	194	203	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					438	445		10.1001/jama.281.5.438	http://dx.doi.org/10.1001/jama.281.5.438			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952204	Bronze			2022-12-01	WOS:000078318500032
J	Nishino, I; Spinazzola, A; Hirano, M				Nishino, I; Spinazzola, A; Hirano, M			Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder	SCIENCE			English	Article							CELL GROWTH-FACTOR; GASTROINTESTINAL ENCEPHALOPATHY SYNDROME; TISSUE DISTRIBUTION; EXPRESSION; DNA; DELETIONS	Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive human disease associated with multiple deletions of skeletal muscle mitochondrial DNA (mtDNA), which have been ascribed to a defect in communication between the nuclear and mitochondrial genomes. Examination of 12 MNGIE probands revealed homozygous or compound-heterozygous mutations in the gene specifying thymidine phosphorylase (TP), Located on chromosome 22q13.32-qter. TP activity in Leukocytes from MNGIE patients was Less than 5 percent of controls, indicating that Loss-of-function mutations in TP cause the disease. The pathogenic mechanism may be related to aberrant thymidine metabolism, leading to impaired replication or maintenance of mtDNA, or both.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA	Columbia University	Hirano, M (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, 630 W 168th St,P&S 4-443, New York, NY 10032 USA.	mh29@columbia.edu	Spinazzola, Antonella/P-5298-2017; Spinazzola, Antonella/P-5791-2019; Nishino, Ichizo/G-2676-2010	Spinazzola, Antonella/0000-0003-4242-8091; Spinazzola, Antonella/0000-0003-4242-8091; Nishino, Ichizo/0000-0001-9452-112X; Hirano, Michio/0000-0002-7070-7402	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059657] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL59657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREU AL, COMMUNICATION; ASAI K, 1992, J NEUROCHEM, V59, P307, DOI 10.1111/j.1471-4159.1992.tb08905.x; BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189; BERK AJ, 1973, J BIOL CHEM, V248, P2722; BESTWICK RK, 1982, J BIOL CHEM, V257, P9305; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown NS, 1998, BIOCHEM J, V334, P1; Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; DiMauro S, 1998, BBA-BIOENERGETICS, V1366, P199, DOI 10.1016/S0005-2728(98)00113-3; ECCLESTON PA, 1995, NEUROSCI LETT, V192, P137, DOI 10.1016/0304-3940(95)11622-4; FOX SB, 1995, J PATHOL, V176, P183, DOI 10.1002/path.1711760212; FRIEDKIN M, 1954, J BIOL CHEM, V207, P245; GALLO RC, 1967, J BIOL CHEM, V242, P5059; Griffiths L, 1997, BRIT J CANCER, V76, P689, DOI 10.1038/bjc.1997.447; HAGIWARA K, 1991, MOL CELL BIOL, V11, P2125, DOI 10.1128/MCB.11.4.2125; Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979; JOHNS DR, 1993, AM J OPHTHALMOL, V115, P108, DOI 10.1016/S0002-9394(14)73533-0; Julias JG, 1998, J VIROL, V72, P7941, DOI 10.1128/JVI.72.10.7941-7949.1998; Kim UJ, 1996, P NATL ACAD SCI USA, V93, P6297, DOI 10.1073/pnas.93.13.6297; MARSH JC, 1964, J CLIN INVEST, V43, P267, DOI 10.1172/JCI104911; Matsukawa K, 1996, BBA-MOL CELL RES, V1314, P71, DOI 10.1016/S0167-4889(96)00078-X; MORAES CT, 1991, AM J HUM GENET, V48, P492; MORRIS NR, 1963, BIOCHIM BIOPHYS ACTA, V68, P93; Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086; Pugmire WJ, 1998, J MOL BIOL, V281, P285, DOI 10.1006/jmbi.1998.1941; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; THRELKELD AB, 1992, AM J OPHTHALMOL, V114, P322, DOI 10.1016/S0002-9394(14)71799-4; USUKI K, 1992, BIOCHEM BIOPH RES CO, V184, P1311, DOI 10.1016/S0006-291X(05)80025-7; WALTENBERGER J, 1992, FEBS LETT, V313, P129, DOI 10.1016/0014-5793(92)81428-O; YOSHIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P107, DOI 10.1016/0304-4165(90)90160-X	33	661	679	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1999	283	5402					689	692		10.1126/science.283.5402.689	http://dx.doi.org/10.1126/science.283.5402.689			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924029				2022-12-01	WOS:000078324400043
J	Santini, JT; Cima, MJ; Langer, R				Santini, JT; Cima, MJ; Langer, R			A controlled-release microchip	NATURE			English	Article							DELIVERY SYSTEMS; DRUG DELIVERY	Much previous work in methods of achieving complex drug-release patterns has focused on pulsatile release from polymeric materials in response to specific stimuli(1), such as electric(2-5) or magnetic(6,7) fields, exposure to ultrasound(7,8), light(9) or enzymes(10), and changes in pH(11) or temperature(12-14), An alternative method for achieving pulsatile release involves using microfabrication technology to develop active devices that incorporate micrometre-scale pumps, valves and flow channels to deliver liquid solutions(15,16). Here we report a solid-state silicon microchip that can provide controlled release of single or multiple chemical substances on demand. The release mechanism is based on the electrochemical dissolution of thin anode membranes covering microreservoirs filled with chemicals in solid, liquid or gel form. We have conducted proof-of-principle release studies with a prototype microchip using gold and saline solution as a model electrode material and release medium, and we have demonstrated controlled, pulsatile release of chemical substances with this device.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Langer, R (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; BAE YH, 1994, POLYM DRUGS DRUG ADM, P98; EDELMAN ER, 1985, J BIOMED MATER RES, V19, P67, DOI 10.1002/jbm.820190107; FISCHELGHODSIAN F, 1988, P NATL ACAD SCI USA, V85, P2403, DOI 10.1073/pnas.85.7.2403; FRANKENTHAL RP, 1982, J ELECTROCHEM SOC, V129, P1192, DOI 10.1149/1.2124085; Gravesen P., 1993, Journal of Micromechanics and Microengineering, V3, P168, DOI 10.1088/0960-1317/3/4/002; HEPEL M, 1994, POLYM DRUGS DRUG ADM, P79; HOFFMAN A S, 1986, Journal of Controlled Release, V4, P213; Jaeger RC, 1988, INTRO MICROELECTRONI; JIRAN E, 1992, THIN SOLID FILMS, V208, P23, DOI 10.1016/0040-6090(92)90941-4; KOST J, 1989, P NATL ACAD SCI USA, V86, P7663, DOI 10.1073/pnas.86.20.7663; KOST J, 1991, ADV DRUG DELIVER REV, V6, P19; Kost J, 1990, PULSED SELF REGULATE, P3; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; MATHIOWITZ E, 1989, J MEMBRANE SCI, V40, P67, DOI 10.1016/S0376-7388(00)80913-8; Merchant B, 1998, BIOLOGICALS, V26, P49, DOI 10.1006/biol.1997.0123; MILLER LL, 1988, MOL CRYST LIQ CRYST, V160, P297, DOI 10.1080/15421408808083024; Okano K, 1990, PULSED SELF REGULATE, P17; SHOJI S, 1994, J MICROMECH MICROENG, V4, P157, DOI 10.1088/0960-1317/4/4/001; SIEGEL RA, 1988, J CONTROL RELEASE, V8, P179, DOI 10.1016/0168-3659(88)90044-2; Wolf S, 1986, SILICON PROCESSING V, V1, P531; WU BM, 1997, THESIS MIT, P25	22	702	747	3	184	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					335	338		10.1038/16898	http://dx.doi.org/10.1038/16898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9988626	Green Submitted			2022-12-01	WOS:000078324600045
J	Harding, HP; Zhang, YH; Ron, D				Harding, HP; Zhang, YH; Ron, D			Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase	NATURE			English	Article							GLUCOSE-REGULATED PROTEINS; INITIATION-FACTOR 2-ALPHA; TRANSMEMBRANE PROTEIN; CULTURED-CELLS; PHOSPHORYLATION; ACTIVATION; INDUCTION; DEPLETION; SIGNALS; NUCLEUS	Protein synthesis and the folding of the newly synthesized proteins into the correct three-dimensional structure are coupled in cellular compartments of the exocytosis pathway by a process that modulates the phosphorylation level of eukaryotic initiation factor-2 alpha (eIF2 alpha) in response to a stress signal from the endoplasmic reticulum (ER)(1,2). Activation of this process leads to reduced rates of initiation of protein translation during ER stress(3). Here we describe the cloning of perk, a gene encoding a type I transmembrane ER-resident protein. PERK has a lumenal domain that is similar to the ER-stress-sensing lumenal domain of the ER-resident kinase Irel, and a cytoplasmic portion that contains a protein-kinase domain most similar to that of the known eIF2 alpha kinases, PKR and HRI. ER stress increases PERK's protein-kinase activity and PERK phosphorylates eIF2 alpha on serine residue 51, inhibiting translation of messenger RNA into protein. These properties implicate PERK in a signalling pathway that attenuates protein translation in response to ER stress.	NYU, Sch Med, Dept Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University; New York University	Ron, D (corresponding author), NYU, Sch Med, Dept Med, Skirball Inst Biomol Med, New York, NY 10016 USA.	ron@saturn.med.nyu.edu	Longo, Kenneth A/A-5631-2010	Harding, Heather P/0000-0002-7359-7974; Ron, David/0000-0002-3014-5636				BERRY MJ, 1985, J BIOL CHEM, V260, P1240; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127; CHEN YS, 1995, IEEE SIGNAL PROC LET, V2, P105, DOI 10.1109/97.388909; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE A, 1993, CURR BIOL, V4, P267; MORI K, 1993, CELL, V74, P743; PRICE BD, 1992, CANCER RES, V52, P3814; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Savinova O, 1997, METHODS, V11, P419, DOI 10.1006/meth.1996.0438; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shamu CE, 1997, CURR BIOL, V7, pR67, DOI 10.1016/S0960-9822(06)00038-8; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291	26	2404	2486	4	160	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1999	397	6716					271	274		10.1038/16729	http://dx.doi.org/10.1038/16729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930704				2022-12-01	WOS:000078184800057
J	Braverman, IM				Braverman, IM			Protective effects of erythema nodosum in coccidioidomycosis	LANCET			English	Editorial Material							BCG		Yale Sch Med, Dept Dermatol, New Haven, CT 06520 USA	Yale University	Braverman, IM (corresponding author), Yale Sch Med, Dept Dermatol, New Haven, CT 06520 USA.							Arsura EL, 1998, CLIN INFECT DIS, V27, P1201, DOI 10.1086/514985; Bertolli J, 1997, INT J EPIDEMIOL, V26, P888, DOI 10.1093/ije/26.4.888; BRAVERMAN IM, 1998, SKIN SIGNS SYSTEMIC, P349; FAVOUR CB, 1947, ARCH INTERN MED, V80, P435, DOI 10.1001/archinte.1947.00220160014002; Kelly P, 1997, EUR RESPIR J, V10, P619; REA TH, 1997, ARCH DERMATOL, V113, P345; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; TEMPLETON AC, 1975, J NATL CANCER I, V55, P1301, DOI 10.1093/jnci/55.6.1301	8	5	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					168	168		10.1016/S0140-6736(05)77213-5	http://dx.doi.org/10.1016/S0140-6736(05)77213-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923870				2022-12-01	WOS:000078175600007
J	Ismail, K; Everitt, B; Blatchley, N; Hull, L; Unwin, C; David, A; Wessely, S				Ismail, K; Everitt, B; Blatchley, N; Hull, L; Unwin, C; David, A; Wessely, S			Is there a Gulf War syndrome?	LANCET			English	Article							SYMPTOMS	Background UK veterans of the Gulf War report more ill health than servicemen who were not deployed to the Gulf War. We investigated whether the pattern of symptom reporting by veterans of the Gulf War differed from that in active servicemen who had not fought in the Gulf War or who had fought in other conflicts. Methods We used a population-based cross-sectional design. We sent a standardised survey that ashed about 50 physical symptoms to three UK military cohorts; men who had served in the Gulf War, those who had served in the Bosnia conflict, and men who had been in active service but not deployed to the Gulf War (Era cohort). We used exploratory factor analysis to identify underlying factors and describe the factor structure of the symptoms reported in the Gulf War cohort. Confirmatory factor analysis was used to test the fit of this factor structure in the Bosnia and Era cohorts. Findings Three factors in the Gulf War cohort together accounted for about 20% of the common variance. We labelled the factors mood, respiratory system, and peripheral nervous system, according to the symptoms that loaded on to them. In the confirmatory factor analysis, the factor structure identified in the Gulf War cohort fitted reasonably well in the Bosnia and Era cohorts. Interpretation Although results from complex modelling procedures need to be interpreted with caution, our findings do not support a unique Gulf War syndrome. The mechanisms behind increased self-reporting of symptoms need further investigation.	Guys Kings & St Thomas Med Sch, Gulf War Illness Res Unit, London SE5 8AF, England; Inst Psychiat, Dept Biostat, London, England; Minist Def, Off Natl Stat, London, England	University of London; King's College London; University of London; King's College London	Ismail, K (corresponding author), Guys Kings & St Thomas Med Sch, Gulf War Illness Res Unit, London SE5 8AF, England.		David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011; Wessely, Simon C/A-8713-2008	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; Everitt, Barry/0000-0003-4431-6536; Wessely, Simon Charles/0000-0002-6743-9929				Cowan DN, 1998, AM J EPIDEMIOL, V148, P326; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Dunn G, 1993, COVARIANCES LATENT V; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Gray GC, 1998, AM J EPIDEMIOL, V148, P328; Haley RW, 1998, AM J EPIDEMIOL, V148, P315, DOI 10.1093/oxfordjournals.aje.a009645; Haley RW, 1998, AM J EPIDEMIOL, V148, P334; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P215, DOI 10.1001/jama.277.3.215; Kang HK, 1998, AM J EPIDEMIOL, V148, P324; Simon G, 1996, PSYCHOSOM MED, V58, P481, DOI 10.1097/00006842-199609000-00010; Wegman DH, 1997, AM J EPIDEMIOL, V146, P704	12	114	114	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					179	182		10.1016/S0140-6736(98)11339-9	http://dx.doi.org/10.1016/S0140-6736(98)11339-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923872				2022-12-01	WOS:000078175600009
J	Singer, PA; Martin, DK; Kelner, M				Singer, PA; Martin, DK; Kelner, M			Quality end-of-life care - Patients' perspectives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCE DIRECTIVES; FAMILY MEMBERS; PREFERENCES	Context Quality end-of-life care is increasingly recognized as an ethical obligation of health care providers, both clinicians and organizations. However, this concept has not been examined from the perspective of patients. Objective To identify and describe elements of quality end-of-life care from the patient's perspective. Design Qualitative study using in-depth, open-ended, face-to-face interviews and content analysis. Setting Toronto, Ontario. Participants A total of 126 participants from 3 patient groups: dialysis patients (n = 48), people with human immunodeficiency virus infection (n = 40), and residents of a long-term care facility (n = 38). Outcome Measures Participants' views on end-of-life issues. Results Participants identified 5 domains of quality end-of-life care: receiving adequate pain and symptom management, avoiding inappropriate prolongation of dying, achieving a sense of control, relieving burden, and strengthening relationships with loved ones. Conclusion These domains, which characterize patients' perspectives on end-of-life care, can serve as focal points for improving the quality of end-of-life care.	Univ Toronto, Joint Ctr Bioeth, Dept Med, Toronto, ON M5G 1L4, Canada; Univ Toronto, Inst Human Dev Life Course & Aging, Toronto, ON M5G 1L4, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Singer, PA (corresponding author), Univ Toronto, Joint Ctr Bioeth, Dept Med, 88 Coll St, Toronto, ON M5G 1L4, Canada.	peter.singer@utoronto.ca						Ahronheim JC, 1996, ARCH INTERN MED, V156, P2094, DOI 10.1001/archinte.156.18.2094; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; BLUSTEIN J, 1993, HASTINGS CTR REP MAY, P6; Byock Ira, 1998, DYING WELL PEACE POS; CLEARY PD, 1997, JAMA-J AM MED ASSOC, V278, P608; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; Feinstein AR., 1967, CLIN JUDGMENT; Field MJ, 1997, APPROACHING DEATH IM; Fischer GS, 1997, ARCH INTERN MED, V157, P801, DOI 10.1001/archinte.157.7.801; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; HARDWIG J, 1990, HASTINGS CENT REP, P5; HIGH DM, 1994, HASTINGS CENT REP, V24, pS16, DOI 10.2307/3563476; KELNER MJ, 1995, SOC SCI MED, V4, P537; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lindemann Nelson H, 1995, PATIENT FAMILY; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Manning P. K., 1998, COLLECTING INTERPRET, P463; MARTIN DK, IN PRESS ARCH INTERN; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; SINGER PA, 1995, J AM SOC NEPHROL, V6, P1410; Singer PA, 1997, J GEN INTERN MED, V12, P729, DOI 10.1046/j.1525-1497.1997.07157.x; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Singer PA, 1998, CAN MED ASSOC J, V159, P159; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Strauss A., 1998, BASICS QUALITATIVE R; Strauss A., 1994, HDB QUALITATIVE RES, V17, P273, DOI DOI 10.1007/BF00988593; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709	31	796	804	2	95	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					163	168		10.1001/jama.281.2.163	http://dx.doi.org/10.1001/jama.281.2.163			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	155VJ	9917120				2022-12-01	WOS:000077966800037
J	Li, QT; Van Antwerp, D; Mercurio, F; Lee, KF; Verma, IM				Li, QT; Van Antwerp, D; Mercurio, F; Lee, KF; Verma, IM			Severe liver degeneration in mice lacking the I kappa B kinase 2 gene	SCIENCE			English	Article							INDUCED APOPTOSIS; IKK-ALPHA; ACTIVATION; PHOSPHORYLATION; COMPLEX; DEGRADATION; BETA; DISSOCIATION; EXPRESSION; COMPONENT	Phosphorylation of inhibitor of kappa B (I kappa B) proteins is an important step in the activation of the transcription nuclear factor kappa B (NF-kappa B) and requires two I kappa B kinases, IKK1 (IKK alpha) and IKK2 (IKK beta). Mice that are devoid of the IKK2 gene had extensive Liver damage from apoptosis and died as embryos, but these mice could be rescued by the inactivation of the gene encoding tumor necrosis factor receptor 1. Mouse embryonic fibroblast cells that were isolated from IKK2(-/-) embryos showed a marked reduction in tumor necrosis factor-alpha (TNF-alpha)- and interleukin-1 alpha-induced NF-kappa B activity and an enhanced apoptosis in response to TNF-alpha. IKK1 associated with NF-kappa B essential modulator (IKK gamma/IKKAP1), another component of the IKK complex. These results show that IKK2 is essential for mouse development and cannot be substituted with IKK1.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Signal Pharmaceut, San Diego, CA 92121 USA	Salk Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1996, CELL, V87, P565; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HUNT JS, 1992, CYTOKINE, V4, P340, DOI 10.1016/1043-4666(92)90076-4; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	24	816	860	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					321	325		10.1126/science.284.5412.321	http://dx.doi.org/10.1126/science.284.5412.321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195897				2022-12-01	WOS:000079636400043
J	Sherman, SI; Gopal, J; Haugen, BR; Chiu, AC; Whaley, K; Nowlakha, P; Duvic, M				Sherman, SI; Gopal, J; Haugen, BR; Chiu, AC; Whaley, K; Nowlakha, P; Duvic, M			Central hypothyroidism associated with retinoid X receptor-selective ligands	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	5th International Pituitary Congress	JUN 28-30, 1998	FT MYERS, FL				THYROTROPIN-BETA PROMOTER; THYROID-HORMONE; MYCOSIS-FUNGOIDES; LGD1069 TARGRETIN; MAMMARY-CARCINOMA; DIFFERENTIATION; AGONISTS; SUBUNIT; THERAPY; CELLS	Background The occurrence of symptomatic central hypothyroidism (characterized by low serum thyrotropin and thyroxine concentrations) in a patient with cutaneous T-cell lymphoma during therapy with the retinoid X receptor-selective ligand bexarotene led us to hypothesize that such ligands could reversibly suppress thyrotropin production by a thyroid hormone-independent mechanism and thus cause central hypothyroidism. Methods We evaluated thyroid function in 27 patients with cutaneous T-cell lymphoma who were enrolled in trials of high-dose oral bexarotene at one institution. in addition, we evaluated the in vitro effect of triiodothyronine, 9-cis-retinoic acid, and the retinoid X receptor-selective ligand LGD346 on the activity of the thyrotropin beta-subunit gene promoter. Results The mean serum thyrotropin concentration declined from 2.2 mU per liter at base line to 0.05 mU per liter during treatment with bexarotene (P<0.001), and the mean serum free thyroxine concentration declined from 1.0 ng per deciliter (12.9 pmol per liter) at base line to 0.45 ng per deciliter (5.8 pmol per liter) (P<0.001) during treatment. The degree of suppression of thyrotropin secretion tended to be greater in patients treated with higher doses of bexarotene (>300 mg per square meter of body-surface area per day) and in those with a history of treatment with interferon alfa. Nineteen patients had symptoms or signs of hypothyroidism, particularly fatigue and cold intolerance. The symptoms improved after the initiation of thyroxine therapy, and all patients became euthyroid after treatment with bexarotene was stopped. In vitro, LGD346 suppressed the activity of the thyrotropin beta-subunit gene promoter in thyrotrophs by as much as 50 percent, an effect similar to that of triiodothyronine and 9-cis-retinoic acid. Conclusions Hypothyroidism may develop in patients with cutaneous T-cell lymphoma who are treated with high-dose bexarotene, most likely because the retinoid X receptor-selective ligand suppresses thyrotropin secretion. (N Engl J Med 1999;340:1075-9.) (C) 1999, Massachusetts Medical Society.	Univ Texas, MD Anderson Canc Ctr, Sect Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dermatol Sect, Houston, TX 77030 USA; Univ Colorado, Hlth Sci Ctr, Div Endocrinol, Denver, CO USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sherman, SI (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sect Endocrine Neoplasia & Hormonal Disorders, 1515 Holcombe Blvd, Houston, TX 77030 USA.	sisherma@mdanderson.org		Gopal, Jayashree/0000-0001-8951-4726; Sherman, Steven/0000-0002-3079-5153				ABEL EA, 1993, CA-CANCER J CLIN, V43, P93, DOI 10.3322/canjclin.43.2.93; Bischoff ED, 1998, CANCER RES, V58, P479; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Breen JJ, 1997, MOL CELL ENDOCRINOL, V131, P137, DOI 10.1016/S0303-7207(97)00099-3; BREEN JJ, 1995, ENDOCRINOLOGY, V136, P543, DOI 10.1210/en.136.2.543; BUNN PA, 1994, ANN INTERN MED, V121, P592, DOI 10.7326/0003-4819-121-8-199410150-00007; Coya R, 1997, LIFE SCI, V60, pPL247, DOI 10.1016/S0024-3205(97)00091-X; Duvic M, 1996, J AM ACAD DERMATOL, V34, P1022, DOI 10.1016/S0190-9622(96)90282-0; Duvic M, 1996, J AM ACAD DERMATOL, V35, P587; Fitzgerald P, 1997, CANCER RES, V57, P2642; Gottardis MM, 1996, CANCER RES, V56, P5566; Haugen BR, 1997, MOL ENDOCRINOL, V11, P481, DOI 10.1210/me.11.4.481; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HEYMAN RA, 1998, 80 ANN M END SOC NEW, P22; Kakizawa T, 1997, J BIOL CHEM, V272, P23799, DOI 10.1074/jbc.272.38.23799; Kizaki M, 1996, BLOOD, V87, P1977; Koh LKH, 1997, THYROID, V7, P891, DOI 10.1089/thy.1997.7.891; LANGLOIS MF, 1997, THYROID S, V7, pS40; Lee HY, 1996, CELL GROWTH DIFFER, V7, P997; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Mukherjee R, 1998, ARTERIOSCL THROM VAS, V18, P272, DOI 10.1161/01.ATV.18.2.272; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; WOOD WM, 1989, J BIOL CHEM, V264, P14840	23	183	211	9	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1999	340	14					1075	1079		10.1056/NEJM199904083401404	http://dx.doi.org/10.1056/NEJM199904083401404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	184AK	10194237				2022-12-01	WOS:000079587000004
J	Gritsman, K; Zhang, JJ; Cheng, S; Heckscher, E; Talbot, WS; Schier, AF				Gritsman, K; Zhang, JJ; Cheng, S; Heckscher, E; Talbot, WS; Schier, AF			The EGF-CFC protein one-eyed pinhead is essential for nodal signaling	CELL			English	Article							ZEBRAFISH ORGANIZER; MESODERM INDUCTION; DROSOPHILA EMBRYO; MOUSE EMBRYO; FLOOR PLATE; RECEPTOR; AXIS; GENE; GASTRULATION; MUTATIONS	The zebrafish EGF-CFC gene one-eyed pinhead (oep) is required zygotically for the formation of the ventral neuroectoderm, endoderm, and prechordal plate. Here we report that embryos lacking both maternal and zygotic Oep activity are defective in germ layer formation, organizer development, and the positioning of the anterior-posterior axis. An identical phenotype is displayed by double mutants for the nodal-related genes squint and cyclops. Mutations in oep eliminate the response to Squint and Cyclops overexpression but are suppressed by expression of Activin and activated forms of the type I receptor ActRIB and Smad2. Expression of the murine EGF-CFC gene cripto rescues oep mutants. These results suggest a conserved role for EGF-CFC proteins as essential extracellular cofactors for Nodal signaling during vertebrate development.	NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med,Dev Genet Program, New York, NY 10016 USA	New York University	Schier, AF (corresponding author), NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med,Dev Genet Program, New York, NY 10016 USA.		Gritsman, Kira/J-8644-2019	Gritsman, Kira/0000-0002-1367-1167; Schier, Alexander Franz/0000-0001-7645-5325	NIGMS NIH HHS [R01GM57825, R01GM56211] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056211, R01GM057825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Chang CB, 1997, DEVELOPMENT, V124, P827; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; Dodd J, 1998, SCIENCE, V282, P1654, DOI 10.1126/science.282.5394.1654; Dyson S, 1997, CURR BIOL, V7, P81, DOI 10.1016/S0960-9822(06)00030-3; Erter CE, 1998, DEV BIOL, V204, P361, DOI 10.1006/dbio.1998.9097; Fekany K, 1999, DEVELOPMENT, V126, P1427; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511; JIMENEZ F, 1982, ROUX ARCH DEV BIOL, V191, P191, DOI 10.1007/BF00848335; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; Salomon DS, 1999, BIOESSAYS, V21, P61, DOI 10.1002/(SICI)1521-1878(199901)21:1&lt;61::AID-BIES8&gt;3.0.CO;2-H; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; Schier AF, 1996, DEVELOPMENT, V123, P165; Schier AF, 1997, DEVELOPMENT, V124, P327; Schier AF, 1998, CURR OPIN GENET DEV, V8, P464, DOI 10.1016/S0959-437X(98)80119-6; Shen MM, 1997, DEVELOPMENT, V124, P429; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Strahle U, 1997, Genes Funct, V1, P131; TOYAMA R, 1995, DEVELOPMENT, V121, P383; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Varlet I, 1997, COLD SPRING HARB SYM, V62, P105; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Yamanaka Y, 1998, GENE DEV, V12, P2345, DOI 10.1101/gad.12.15.2345; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	47	588	597	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					121	132		10.1016/S0092-8674(00)80720-5	http://dx.doi.org/10.1016/S0092-8674(00)80720-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199408	Bronze			2022-12-01	WOS:000079843900014
J	Velankar, SS; Soultanas, P; Dillingham, MS; Subramanya, HS; Wigley, DB				Velankar, SS; Soultanas, P; Dillingham, MS; Subramanya, HS; Wigley, DB			Crystal structures of complexes of PcrA DNA helicase with a DNA substrate indicate an inchworm mechanism	CELL			English	Article							COLI REP HELICASE; HEPATITIS-C VIRUS; RNA HELICASE; INDUCED DIMERIZATION; DUPLEX DNA; DOMAIN; REPLICATION; PROTEIN	We have determined two different structures of PcrA DNA helicase complexed with the same single strand tailed DNA duplex, providing snapshots of different steps on the catalytic pathway. One of the structures is of a complex with a nonhydrolyzable analog of ATP and is thus a "substrate" complex. The other structure contains a bound sulphate ion that sits in a position equivalent to that occupied by the phosphate ion produced after ATP hydrolysis, thereby mimicking a "product" complex. In both complexes, the protein is monomeric. Large and distinct conformational changes occur on binding DNA and the nucleotide cofactor. Taken together, these structures provide evidence against an "active rolling" model for helicase action but are instead consistent with an "inchworm" mechanism.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Wigley, DB (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	wigley@eric.path.ox.ac.uk		Soultanas, Panos/0000-0003-3578-5699; Dillingham, Mark/0000-0002-4612-7141; Velankar, Sameer/0000-0002-8439-5964	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; GORBALENYA AE, 1991, FEBS LETT, V291, P277, DOI 10.1016/0014-5793(91)81301-N; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LEE MS, 1990, J BIOL CHEM, V265, P17078; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Soultanas P, 1999, NUCLEIC ACIDS RES, V27, P1421, DOI 10.1093/nar/27.6.1421; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	25	654	659	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					75	84		10.1016/S0092-8674(00)80716-3	http://dx.doi.org/10.1016/S0092-8674(00)80716-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199404	Bronze			2022-12-01	WOS:000079843900010
J	Wise, RJS; Greene, J; Buchel, C; Scott, SK				Wise, RJS; Greene, J; Buchel, C; Scott, SK			Brain regions involved in articulation	LANCET			English	Article							HUMAN AUDITORY-CORTEX; COORDINATING SPEECH ARTICULATION; ANATOMY	Background The left inferior frontal gyrus (Broca's area) is generally believed to be critical for the motor act of speech. A lesion-based analysis has, however, shown that the left anterior insula is necessary for accurate articulation. We used functional imaging in normal people to show the neural systems involved in speech during different speech tasks. Methods 12 normal people underwent positron emission tomography with oxygen-15-labelled water as tracer. We measured cerebral activity while participants performed three different tasks: repetition of heard nouns at different rates; listening to single nouns at different rates; and anticipation of listening or repetition. We analysed the data with imaging software. Findings Repetition of single words did not activate Broca's area but activity in three left-lateralised regions was seen: the anterior insula, a localised region in the lateral premotor cortex, and the posterior pallidum. The left anterior insula and lateral premotor cortex showed a conjunction of activity for hearing and articulation. In addition, articulation modulated the response to hearing words in the left dorsolateral temporal cortex, the physiological expression of the speaker's auditory attention being directed towards the stimuli and not his or her articulated responses. Interpretation The formulation of an articulatory plan is a function of the left anterior insula and lateral premotor cortex and not of Broca's area. The left basal ganglia seem to be dominant for speech, although the axial muscles involved receive their motor output from both cerebral hemispheres.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0NN, England; Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; MRC, Appl Psychol Unit, Cambridge CB2 2EF, England	Imperial College London; University of London; University College London; University of Cambridge	Wise, RJS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0NN, England.	richard@wren.rpms.ac.uk	Scott, Sophie K/A-1843-2010	Scott, Sophie K/0000-0001-7510-6297	Wellcome Trust [090961] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMANN H, 1992, J NEUROL, V239, P223, DOI 10.1007/BF00839144; ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; BARTH A, 1993, ANN NEUROL, V33, P451, DOI 10.1002/ana.410330507; BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; Bregman A. S, 1990, AUDITORY SCENE ANAL; BUCHMAN AS, 1986, J NEUROL NEUROSUR PS, V49, P489, DOI 10.1136/jnnp.49.5.489; Caplan D., 1987, NEUROLINGUISTICS LIN; CREUTZFELDT O, 1989, EXP BRAIN RES, V77, P476, DOI 10.1007/BF00249601; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Dhankhar A, 1997, J NEUROPHYSIOL, V77, P476, DOI 10.1152/jn.1997.77.1.476; Donnan GA, 1997, LANCET, V349, P221, DOI 10.1016/S0140-6736(05)64855-6; Dronkers NF, 1996, NATURE, V384, P159, DOI 10.1038/384159a0; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Fitch RH, 1997, ANNU REV NEUROSCI, V20, P331, DOI 10.1146/annurev.neuro.20.1.331; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; KIM JS, 1994, STROKE, V25, P1994, DOI 10.1161/01.STR.25.10.1994; LEVELT WJM, 1999, IN PRESS BEHAV BRAIN; MCFARLAND DH, 1995, NEURAL CONTROL SKILL, P61; Miller G., 1951, LANGUAGE COMMUNICATI; MOHR JP, 1978, NEUROLOGY, V28, P311, DOI 10.1212/WNL.28.4.311; MULLERPREUSS P, 1981, BRAIN RES, V215, P61, DOI 10.1016/0006-8993(81)90491-1; PANTEV C, 1995, ELECTROEN CLIN NEURO, V94, P26, DOI 10.1016/0013-4694(94)00209-4; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PRICE C, 1992, NEUROSCI LETT, V146, P179, DOI 10.1016/0304-3940(92)90072-F; Price CJ, 1996, BRAIN, V119, P919, DOI 10.1093/brain/119.3.919; Tohgi H, 1996, EUR NEUROL, V36, P338, DOI 10.1159/000117290; WOOTEN GF, 1993, NEUROLOGY, V43, P1764, DOI 10.1212/WNL.43.9.1764; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767	30	403	407	0	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1999	353	9158					1057	1061		10.1016/S0140-6736(98)07491-1	http://dx.doi.org/10.1016/S0140-6736(98)07491-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199354				2022-12-01	WOS:000079614000013
J	Ogawa, T; Tomita, K; Ueda, T; Watanabe, K; Uozumi, T; Masaki, H				Ogawa, T; Tomita, K; Ueda, T; Watanabe, K; Uozumi, T; Masaki, H			A cytotoxic ribonuclease targeting specific transfer RNA anticodons	SCIENCE			English	Article							ESCHERICHIA-COLI; POLYNUCLEOTIDE KINASE; RIBOSOMAL-RNA; BIOSYNTHESIS; COLICIN-E3; QUEUOSINE; SEQUENCE; PROTEIN; GENES; ACID	The carboxyl-terminal domain of colicin E5 was shown to inhibit protein synthesis of Escherichia coli. Its target, as revealed through in vivo and in vitro experiments, was not ribosomes as in the case of E3, but the transfer RNAs (tRNAs) for Tyr, His, Asn, and Asp, which contain a modified base, queuine, at the wobble position of each anticodon. The E5 carboxyl-terminal domain hydrolyzed these tRNAs just on the 3' side of this nucleotide. Tight correlation was observed between the toxicity of E5 and the cleavage of intracellular tRNAs of this group, implying that these tRNAs are the primary targets of colicin E5.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138654, Japan	University of Tokyo; University of Tokyo	Masaki, H (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.		Ogawa, Tetsuhiro/AAO-2961-2021; Ueda, Takuya/K-5217-2014; Tomita, Kozo/J-5746-2013; Tomita, Kozo/E-9390-2017	Ueda, Takuya/0000-0002-7760-8271; Tomita, Kozo/0000-0002-7374-3898				AKUTSU A, 1989, J BACTERIOL, V171, P6430, DOI 10.1128/jb.171.12.6430-6436.1989; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; BAAN RA, 1976, FEBS LETT, V71, P351, DOI 10.1016/0014-5793(76)80968-4; Blackburn P, 1982, ENZYMES, VXV, P317; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLBERG AE, 1975, P NATL ACAD SCI USA, V72, P2940, DOI 10.1073/pnas.72.8.2940; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; Gerlt J. A., 1993, NUCLEASES, P1; Jakes KS., 1982, MOL ACTION TOXINS VI, P131; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KEITH G, 1995, BIOCHIMIE, V77, P142, DOI 10.1016/0300-9084(96)88118-1; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; LAU PCK, 1989, MOL GEN GENET, V217, P269, DOI 10.1007/BF02464892; LAU PCK, 1992, BACTERIOCINS MICROCI, P353; MASAKI H, 1991, GENE, V107, P133; MASAKI H, 1985, J MOL BIOL, V182, P217, DOI 10.1016/0022-2836(85)90340-7; MASAKI H, 1992, BACTERIOCINS MICROCI, P379; Masaki H, 1997, NUCL ACIDS S SER, V37, P287; MOCK M, 1982, J BACTERIOL, V150, P1069, DOI 10.1128/JB.150.3.1069-1076.1982; Morse DP, 1997, BIOCHEMISTRY-US, V36, P8429, DOI 10.1021/bi9709607; Nakamura Y, 1996, CELL, V87, P147, DOI 10.1016/S0092-8674(00)81331-8; NIRENBERG MW, 1963, METHOD ENZYMOL, V6, P17, DOI 10.1016/0076-6879(63)06142-5; NISHIMURA S, 1983, PROG NUCLEIC ACID RE, V28, P49, DOI 10.1016/S0079-6603(08)60082-3; NOGUCHI S, 1982, J BIOL CHEM, V257, P6544; OGAWA T, UNPUB; OHNO S, 1978, J BIOCHEM-TOKYO, V84, P1637, DOI 10.1093/oxfordjournals.jbchem.a132291; Pugsley A, 1987, METHODS STUDYING COL; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; Sagara JI, 1998, NUCLEIC ACIDS RES, V26, P1974, DOI 10.1093/nar/26.8.1974; SAXENA SK, 1992, J BIOL CHEM, V267, P21982; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; 24 S NUCL AC CHEM TO	36	143	148	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2097	2100		10.1126/science.283.5410.2097	http://dx.doi.org/10.1126/science.283.5410.2097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10092236				2022-12-01	WOS:000079369800051
J	Berry, MJ; Brivanlou, IH; Jordan, TA; Meister, M				Berry, MJ; Brivanlou, IH; Jordan, TA; Meister, M			Anticipation of moving stimuli by the retina	NATURE			English	Article							CONTRAST GAIN-CONTROL; MOTION EXTRAPOLATION; ATTENTION SHIFT; GANGLION-CELLS; LATENCY; SIGNALS; CORTEX; MAPS	A flash of light evokes neural activity in the brain with a delay of 30-100 milliseconds', much of which is due to the slow process of visual transduction in photoreceptors(2,3). A moving object can cover a considerable distance in this time, and should therefore be seen noticeably behind its actual location. As this conflicts with everyday experience, it has been suggested that the visual cortex uses the delayed visual data from the eye to extrapolate the trajectory of a moving object, so that it is perceived at its actual location(4-7). Here we report that such anticipation of moving stimuli begins in the retina. A moving bar elicits a moving wave of spiking activity in the population of retinal ganglion cells. Rather than lagging behind the visual image, the population activity travels near the leading edge of the moving bar. This response is observed over a wide range of speeds and apparently compensates for the visual response latency. We show how this anticipation follows from known mechanisms of retinal processing.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Berry, MJ (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.			Meister, Markus/0000-0003-2136-6506				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; BALDO MVC, 1995, NATURE, V378, P565, DOI 10.1038/378565a0; BENARDETE EA, 1992, VISUAL NEUROSCI, V8, P483, DOI 10.1017/S0952523800004995; Carandini M, 1997, J NEUROSCI, V17, P8621; COREY DP, 1979, BIOPHYS J, V26, P499, DOI 10.1016/S0006-3495(79)85267-4; Crevier DW, 1998, J NEUROPHYSIOL, V79, P1869, DOI 10.1152/jn.1998.79.4.1869; DEVALOIS RL, 1991, VISION RES, V31, P1619, DOI 10.1016/0042-6989(91)90138-U; DeVries SH, 1997, J NEUROPHYSIOL, V78, P2048, DOI 10.1152/jn.1997.78.4.2048; HUNTER IW, 1986, BIOL CYBERN, V55, P135; Jacobs AL, 1998, J NEUROPHYSIOL, V80, P447, DOI 10.1152/jn.1998.80.1.447; KHURANA B, 1995, NATURE, V378, P566, DOI 10.1038/378566a0; KNUDSEN EI, 1987, ANNU REV NEUROSCI, V10, P41, DOI 10.1146/annurev.ne.10.030187.000353; KNUDSEN EI, 1982, J NEUROSCI, V2, P1177; LENNIE P, 1981, VISION RES, V21, P815, DOI 10.1016/0042-6989(81)90180-2; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; MERIGAN WH, 1993, ANNU REV NEUROSCI, V16, P369, DOI 10.1146/annurev.ne.16.030193.002101; Nijhawan R, 1997, NATURE, V386, P66, DOI 10.1038/386066a0; NIJHAWAN R, 1994, NATURE, V370, P256, DOI 10.1038/370256b0; Purushothaman G, 1998, NATURE, V396, P424, DOI 10.1038/24766; RODIECK R. W., 1965, VISION RES, V5, P583, DOI 10.1016/0042-6989(65)90033-7; SAKAI HM, 1995, J GEN PHYSIOL, V105, P815, DOI 10.1085/jgp.105.6.815; SCHNAPF JL, 1987, NATURE, V325, P439, DOI 10.1038/325439a0; SHAPLEY RM, 1978, J PHYSIOL-LONDON, V285, P275, DOI 10.1113/jphysiol.1978.sp012571; Smirnakis SM, 1997, NATURE, V386, P69, DOI 10.1038/386069a0; SPARKS DL, 1986, PHYSIOL REV, V66, P118, DOI 10.1152/physrev.1986.66.1.118; VICTOR JD, 1987, J PHYSIOL-LONDON, V386, P219, DOI 10.1113/jphysiol.1987.sp016531; Warland DK, 1997, J NEUROPHYSIOL, V78, P2336, DOI 10.1152/jn.1997.78.5.2336; Whitney D, 1998, NAT NEUROSCI, V1, P656, DOI 10.1038/3659	29	316	322	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 25	1999	398	6725					334	338		10.1038/18678	http://dx.doi.org/10.1038/18678			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DF	10192333				2022-12-01	WOS:000079369600051
J	Neuzil, KM; Reed, GW; Mitchel, EF; Griffin, MR				Neuzil, KM; Reed, GW; Mitchel, EF; Griffin, MR			Influenza-associated morbidity and mortality in young and middle-aged women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RESPIRATORY-DISEASE; EPIDEMIC INFLUENZA; UNITED-STATES; VACCINATION; INFECTION; HOSPITALIZATION; PNEUMONIA; COMMUNITY; IMPACT; ADULTS	Context Data are limited on rates of influenza-associated hospitalizations and deaths among adults younger than 65 years. Objective To quantify serious morbidity and mortality from influenza for women younger than 65 years with and without certain chronic medical conditions, including human immunodeficiency virus infection. Design Retrospective cohort study. Setting and Population Women aged 15 to 64 years enrolled in the Tennessee Medicaid program from 1974 to 1993, Main Outcome Measure All hospitalizations for and deaths from pneumonia, influenza, and other selected acute cardiopulmonary conditions for women with and without selected chronic medical conditions during 19 consecutive years. Influenza-attributable risk was calculated by subtracting event rates during peri-influenza season (November through April of each year when influenza virus was not circulating) from adjusted rates during influenza season (November through April when influenza virus was circulating). Results During the 19 years of the study, we identified 53 607 acute cardiopulmonary hospitalizations and deaths, Rates of such events were consistently higher during influenza seasons than peri-influenza seasons, Among high-risk women, the estimated annual excess was 23 hospitalizations and deaths per 10 000 women aged 15 to 44 years and 58 such events per 10 000 women aged 45 to 64 years, The estimated annual excess mortality due to influenza was 2 deaths per 10 000 high-risk women for both age groups combined. Among women with no identified high-risk conditions, estimated annual excess hospitalizations and deaths were 4 and 6 per 10 000 women aged 15 to 44 and 45 to 64 years, respectively. Conclusions Women younger than 65 years with certain chronic medical conditions experience substantial morbidity and mortality from acute cardiopulmonary events during influenza season. More effective targeting of these populations for annual influenza immunization is warranted.	Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; New England Res Inst, Watertown, MA 02172 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University; Vanderbilt University; HealthCore, Inc	Griffin, MR (corresponding author), Vanderbilt Univ, Dept Prevent Med, A-1124 Med Ctr N, Nashville, TN 37232 USA.	marie.griffin@mcmail.vanderbilt.edu						AHMED AEH, 1995, LANCET, V346, P591, DOI 10.1016/S0140-6736(95)91434-X; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Armitage P, 1994, STAT METHODS MED RES; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; Bishop YMM., 2007, DISCRETE MULTIVARIAT; BOUTER KP, 1991, DIABETES RES CLIN PR, V12, P61, DOI 10.1016/0168-8227(91)90131-V; *CDCP, 1994, VIT HLTH STAT, V10, P89; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P797; *EP INT SERV, 1998, 47 ANN EP INT SERV C; EVANS KD, 1995, PEDIATR INFECT DIS J, V14, P332, DOI 10.1097/00006454-199504000-00022; FALSEY AR, 1996, J INFECT DIS, V174, P456; Fisher RG, 1997, PEDIATRICS, V99, pE71, DOI 10.1542/peds.99.2.e7; FOX JP, 1982, AM J EPIDEMIOL, V116, P212, DOI 10.1093/oxfordjournals.aje.a113407; Glesby MJ, 1996, J INFECT DIS, V174, P1332, DOI 10.1093/infdis/174.6.1332; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; HANCKOM WA, 1998, PEDIATR RES, P43; HOUSWORTH J, 1974, AM J EPIDEMIOL, V100, P40, DOI 10.1093/oxfordjournals.aje.a112007; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; *NAT CTR HLTH STAT, 1995, HLTH PEOPL 2000 MIDC; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Osborne ML, 1996, CHEST, V110, P1458, DOI 10.1378/chest.110.6.1458; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; Piper J M, 1991, Paediatr Perinat Epidemiol, V5, P402, DOI 10.1111/j.1365-3016.1991.tb00726.x; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SAFRIN S, 1990, CHEST, V98, P33, DOI 10.1378/chest.98.1.33; Simonsen L, 1997, EPIDEMIOLOGY, V8, P390, DOI 10.1097/00001648-199707000-00007; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; THUM JR, 1989, CHEST, V95, P807; YERLY S, 1994, AIDS, V8, P1503, DOI 10.1097/00002030-199410000-00022	33	168	178	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1999	281	10					901	907		10.1001/jama.281.10.901	http://dx.doi.org/10.1001/jama.281.10.901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172XH	10078486				2022-12-01	WOS:000078950600034
J	Limburg, J; Vrettos, JS; Liable-Sands, LM; Rheingold, AL; Crabtree, RH; Brudvig, GW				Limburg, J; Vrettos, JS; Liable-Sands, LM; Rheingold, AL; Crabtree, RH; Brudvig, GW			A functional model for O-O bond formation by the O-2-evolving complex in photosystem II	SCIENCE			English	Article							PHOTOSYNTHETIC OXYGEN EVOLUTION; WATER-OXIDATION; MANGANESE CLUSTER; EVOLVING COMPLEX; EPOXIDATION; DIOXYGEN; RELEVANT; PLANTS; DIMER; ION	The formation of molecular oxygen from water in photosynthesis is catalyzed by photosystem II at an active site containing four manganese ions that are arranged in di-mu-oxo dimanganese units (where mu is a bridging mode). The complex [H2O(terpy)Mn(O)(2)Mn(terpy)OH2](NO3)(3) (terpy is 2,2':6',2 "-terpyridine), which was synthesized and structurally characterized, contains a di-mu-oxo manganese dimer and catalyzes the conversion of sodium hypochlorite to molecular oxygen. Oxygen-18 isotope labeling showed that water is the source of the oxygen atoms in the molecular oxygen evolved, and so this system is a functional model for photosynthetic water oxidation.	Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Delaware, Dept Chem, Crystallog Lab, Newark, DE 19716 USA	Yale University; University of Delaware	Crabtree, RH (corresponding author), Yale Univ, Dept Chem, POB 208107, New Haven, CT 06520 USA.	robert.crabtree@yale.edu; gary.bruvig@yale.edu	Rheingold, Arnold/U-4735-2019	Rheingold, Arnold/0000-0003-4472-8127	NIGMS NIH HHS [GM32715] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032715] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin MJ, 1996, J AM CHEM SOC, V118, P11325, DOI 10.1021/ja9626906; Bernadou J, 1998, CHEM COMMUN, P2167, DOI 10.1039/a802734j; BERNADOU J, 1994, J AM CHEM SOC, V116, P9375, DOI 10.1021/ja00099a083; Blomberg MRA, 1997, J AM CHEM SOC, V119, P8285, DOI 10.1021/ja9642323; BRITT RD, 1996, ADV PHOTOSYNTH, V4, P137; BRUICE TC, 1983, J AM CHEM SOC, V105, P2452, DOI 10.1021/ja00346a057; COLLINS TJ, 1989, J AM CHEM SOC, V111, P4511, DOI 10.1021/ja00194a063; COLLINS TJ, 1990, J AM CHEM SOC, V112, P899, DOI 10.1021/ja00158a077; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0167-4838(92)90520-N; DINER BA, 1996, ADV PHOTOSYNTHESIS, V4, P214; Finney NS, 1997, ANGEW CHEM INT EDIT, V36, P1720, DOI 10.1002/anie.199717201; GAMELIN DR, 1994, J AM CHEM SOC, V116, P2392, DOI 10.1021/ja00085a019; GERSTEN SW, 1982, J AM CHEM SOC, V104, P4029, DOI 10.1021/ja00378a053; GESELOWITZ D, 1990, INORG CHEM, V29, P3894, DOI 10.1021/ic00344a048; GILCHRIST ML, 1995, P NATL ACAD SCI USA, V92, P9545, DOI 10.1073/pnas.92.21.9545; Groves JT, 1997, J AM CHEM SOC, V119, P6269, DOI 10.1021/ja962605u; GROVES JT, 1988, J AM CHEM SOC, V110, P8628, DOI 10.1021/ja00234a009; Halfen JA, 1996, SCIENCE, V271, P1397, DOI 10.1126/science.271.5254.1397; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; HURST JK, 1992, INORG CHEM, V31, P1010, DOI 10.1021/ic00032a017; Limburg J, 1997, J AM CHEM SOC, V119, P2761, DOI 10.1021/ja963899m; LIMBURG J, IN PRESS J CHEM S DA; LIMBURG J, IN PRESS BIOMIMETIC; MACDONNELL FM, 1994, J AM CHEM SOC, V116, P7431, DOI 10.1021/ja00095a066; MANCHANDA R, 1995, COORDIN CHEM REV, V144, P1, DOI 10.1016/0010-8545(95)01147-H; MESSINGER J, 1995, P NATL ACAD SCI USA, V92, P3209, DOI 10.1073/pnas.92.8.3209; NARUTA Y, 1994, ANGEW CHEM INT EDIT, V33, P1839, DOI 10.1002/anie.199418391; Pecoraro VL, 1998, PURE APPL CHEM, V70, P925, DOI 10.1351/pac199870040925; RANDALL DW, 1995, J AM CHEM SOC, V117, P11780, DOI 10.1021/ja00152a021; Ruttinger W, 1997, CHEM REV, V97, P1, DOI 10.1021/cr950201z; Siegbahn PEM, 1999, J AM CHEM SOC, V121, P117, DOI 10.1021/ja982290d; THORP HH, 1991, NEW J CHEM, V15, P479; Tommos C, 1998, CURR OPIN CHEM BIOL, V2, P244, DOI 10.1016/S1367-5931(98)80066-5; Yachandra VK, 1996, CHEM REV, V96, P2927, DOI 10.1021/cr950052k; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177	35	617	622	1	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1524	1527		10.1126/science.283.5407.1524	http://dx.doi.org/10.1126/science.283.5407.1524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066173				2022-12-01	WOS:000078959200045
J	Campbell, G; Tomlinson, A				Campbell, G; Tomlinson, A			Transducing the Dpp morphogen gradient in the wing of Drosophila: Regulation of Dpp targets by brinker	CELL			English	Article							OPTOMOTOR-BLIND; DNA-BINDING; GENE; PROTEIN; RECEPTORS; EXPRESSION; PATTERN; MELANOGASTER; DOWNSTREAM; MECHANISMS	Dpp, a TGF beta, organizes pattern in the Drosophila wing by acting as a graded morphogen, activating different targets above distinct threshold concentrations. Like other TGF beta s, Dpp appears to induce transcription directly via activation of a SMAD, Mad. However, here we demonstrate that Dpp can also control gene expression indirectly by downregulating the expression of the brinker gene, which encodes a putative transcription factor that functions to repress Dpp targets. The medial-to-lateral Dpp gradient along the anterior-posterior axis is complemented by a lateral-to-medial gradient of Drinker, and the presence of these two opposing gradients may function to allow cells to detect small differences in Dpp concentration and respond by activating different target genes.	Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Campbell, G (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	camp+@pitt.edu		Campbell, Gerard/0000-0002-7631-4394				BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; Chen YJ, 1998, DEVELOPMENT, V125, P1759; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Haerry TE, 1998, DEVELOPMENT, V125, P3977; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HARTL DL, 1994, P NATL ACAD SCI USA, V91, P6824, DOI 10.1073/pnas.91.15.6824; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Khalsa O, 1998, DEVELOPMENT, V125, P2723; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Kuhnlein RP, 1997, MECH DEVELOP, V66, P107, DOI 10.1016/S0925-4773(97)00103-2; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lecuit T, 1998, DEVELOPMENT, V125, P4901; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Nguyen M, 1998, CELL, V95, P495, DOI 10.1016/S0092-8674(00)81617-7; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; ROBERTSON HM, 1988, GENETICS, V118, P461; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WILLIAMS JA, 1990, MOL GEN GENET, V221, P8, DOI 10.1007/BF00280361; XU T, 1993, DEVELOPMENT, V117, P1223; Yu K, 1996, DEVELOPMENT, V122, P4033; ZECCA M, 1995, DEVELOPMENT, V121, P2265	43	232	240	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					553	562		10.1016/S0092-8674(00)80659-5	http://dx.doi.org/10.1016/S0092-8674(00)80659-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052457	Bronze			2022-12-01	WOS:000078718600006
J	O'Connor, GT; Quinton, HB; Traven, ND; Ramunno, LD; Dodds, TA; Marciniak, TA; Wennberg, JE				O'Connor, GT; Quinton, HB; Traven, ND; Ramunno, LD; Dodds, TA; Marciniak, TA; Wennberg, JE			Geographic variation in the treatment of acute myocardial infarction - The cooperative cardiovascular project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; HEALTH-CARE; PRACTICE GUIDELINES; CLINICAL-TRIALS; HEART-DISEASE; TASK-FORCE; MANAGEMENT; IMPROVEMENT; MEDICARE; MASSACHUSETTS	Context. Quality indicators for the treatment of acute myocardial infarction include pharmacologic therapy, reperfusion, and smoking cessation advice, but these therapies may not be administered to all patients who could benefit from them. Objective To assess geographic variation in adherence to quality indicators for treatment of acute myocardial infarction, Design Inception cohort using data from the Health Care Financing Administration Cooperative Cardiovascular Project. Setting Acute care hospitals in the United States. Patients A total of 186 800 Medicare beneficiaries hospitalized for treatment of confirmed acute myocardial infarction from February 1994 through July 1995. Main Outcome Measures Adherence to quality indicators for pharmacologic therapy, reperfusion, and smoking cessation advice for patients judged to be ideal candidates for these therapies. The mean rates of adherence to these quality indicators for the entire United States were determined, and the 20th and 80th percentiles of the age- and sex-adjusted rates for each of 306 hospital referral regions were contrasted (mean rate [20th-80th percentiles]), Results Aspirin was used frequently both during hospitalization (86.2% [82.6% 90.1%]) and at discharge (77.8% [72.5%-83.9%]). Calcium channel blockers were with held from most patients with impaired left Ventricular function (81.9% [73.6%-90.8%]). Lower rates were seen in the use of angiotensin-converting enzyme inhibitors at discharge (59.3% [49.2%-69.2%]); reperfusion, using thrombolytic therapy or coronary angioplasty. (67.2% [59.8%-75.1%]); prescription of beta-blockers at discharge (49.5% [35.8%-61.5%]); and for smoking cessation advice (41.9% [32.8%-51.3%]). Conclusions Substantial geographic Variation exists in the treatment of patients with acute myocardial infarction, and these gaps between knowledge and practice have important consequences. Therapies with proven benefit for AMI are underused despite strong evidence that their use will result in better patient outcomes.	Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH 03755 USA; NE Hlth Care Qual Fdn, Dover, NH USA; Hlth Care Financing Adm, Dept Hlth & Human Serv, Baltimore, MD USA	Dartmouth College	O'Connor, GT (corresponding author), Dartmouth Med Sch, Ctr Evaluat Clin Sci, 330 Strasenburgh Hall, Hanover, NH 03755 USA.	gerald.t.oconnor@dartmouth.edu						*AM HEART ASS, 1996, HEART STROK FACTS 19, P1; [Anonymous], 1988, BRIT MED J, V296, P320; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BATALDEN PB, 1994, JOINT COMM J QUAL IM, V20, P167, DOI 10.1016/S1070-3241(16)30059-1; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CORNFIELD J, 1960, B INT STATIST INST, V38, P97; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; Huff ED, 1997, J CLIN EPIDEMIOL, V50, P1395, DOI 10.1016/S0895-4356(97)00218-7; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; Kanigel Robert, 1997, 1 BEST WAY FW TAYLOR; LAMBERTHUBER DA, 1994, CLIN PERFORMANCE QUA, V2, P219; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEE TH, 1997, HEART DIS TXB CARDIO, P1939; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; NELSON EC, 1994, HLTH CARE FORUM J, V34, P25; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; Rogers E., 1995, DIFFUSION INNOVATION, VFourth; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; *STAT CORP, 1997, STAT COMP PROGR REL; Tukey J.W., 1977, EXPLORATORY DATA ANA, P61, DOI 10.1007/978-0-387-32833-1_136; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; *US DEP HHS, 1988, INT CLASS DIS 9 REV; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Wennberg JE, 1996, DARTMOUTH ATLAS HLTH; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; ZYZANSKI SJ, 1994, J FAM PRACTICE, V39, P140	37	259	262	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					627	633		10.1001/jama.281.7.627	http://dx.doi.org/10.1001/jama.281.7.627			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029124	Bronze			2022-12-01	WOS:000078548400033
J	Mintova, S; Olson, NH; Valtchev, V; Bein, T				Mintova, S; Olson, NH; Valtchev, V; Bein, T			Mechanism of zeolite a nanocrystal growth from colloids at room temperature	SCIENCE			English	Article							MOLECULAR-SIEVE CRYSTALS; LIGHT-SCATTERING; ELECTRON-MICROSCOPY; TPA-SILICALITE-1; FILMS; CRYSTALLIZATION; SPECTROSCOPY; NUCLEATION; LAYERS; NMR	The formation and growth of crystal nuclei of zeolite A from clear solutions at room temperature were studied with Low-dose, high-resolution transmission electron microscopy in field emission mode and with in situ dynamic Light scattering. Single zeolite A crystals nucleated in amorphous gel particles of 40 to 80 nanometers within 3 days at room temperature. The resulting nanoscale single crystals (10 to 30 nanometers) were embedded in the amorphous gel particles. The gel particles were consumed during further crystal growth at room temperature, forming a colloidal suspension of zeolite A nanocrystals of 40 to 80 nanometers, On heating this suspension at 80 degrees C, solution-mediated transport resulted in additional substantial crystal growth.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol, W Lafayette, IN 47907 USA; Bulgarian Acad Sci, Cent Lab Mineral & Crystallog, Sofia 1000, Bulgaria	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Bulgarian Academy of Sciences	Bein, T (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.		Mintova, Svetlana/N-7933-2018; Bein, Thomas/G-7686-2014	Mintova, Svetlana/0000-0002-0738-5244; Bein, Thomas/0000-0001-7248-5906	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033050, R37GM033050] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baerlocher C., 1996, ATLAS ZEOLITE STRUCT; BEHRENS P, 1996, COMPREHENSIVE SUPRAM, V7, P721; Bein T, 1996, CHEM MATER, V8, P1636, DOI 10.1021/cm960148a; Breck D. W., 1974, ZEOLITE MOL SIEVES; BURKETT SL, 1994, J PHYS CHEM-US, V98, P4647, DOI 10.1021/j100068a027; BURKETT SL, 1996, COMPREHENSIVE SUPRAM, V7, P465; Corkery RW, 1997, ZEOLITES, V18, P379, DOI 10.1016/S0144-2449(97)81256-0; CUNDY CS, 1995, ZEOLITES, V15, P342, DOI 10.1016/0144-2449(94)00042-Q; DAVIS ME, 1992, CHEM MATER, V4, P756, DOI 10.1021/cm00022a005; DOKTER WH, 1995, ANGEW CHEM INT EDIT, V34, P73, DOI 10.1002/anie.199500731; DOUGHERTY J, 1995, ZEOLITES, V15, P640, DOI 10.1016/0144-2449(95)00045-8; FENG S, 1994, SCIENCE, V265, P1839, DOI 10.1126/science.265.5180.1839; FENG S, 1994, NATURE, V368, P834, DOI 10.1038/368834a0; GIER TE, 1991, NATURE, V349, P508, DOI 10.1038/349508a0; Gora L, 1997, ZEOLITES, V18, P119, DOI 10.1016/S0144-2449(96)00144-3; Gora L, 1997, ZEOLITES, V18, P132, DOI 10.1016/S0144-2449(96)00163-7; KESSLER H, 1996, COMPREHENSIVE SUPRAM, V7, P425; Mintova S, 1997, ADV MATER, V9, P585; OZIN GA, 1992, ADV MATER, V4, P612, DOI 10.1002/adma.19920041003; PERSSON AE, 1994, ZEOLITES, V14, P557, DOI 10.1016/0144-2449(94)90191-0; Ravishankar R, 1998, J PHYS CHEM B, V102, P2633, DOI 10.1021/jp973147u; REGEV O, 1994, ZEOLITES, V14, P314, DOI 10.1016/0144-2449(94)90103-1; SAND LB, 1987, ZEOLITES, V7, P387, DOI 10.1016/0144-2449(87)90001-7; SCHOEMAN BJ, 1994, ZEOLITES, V14, P110, DOI 10.1016/0144-2449(94)90004-3; Schoeman BJ, 1997, ZEOLITES, V18, P97, DOI 10.1016/S0144-2449(96)00134-0; Tsapatsis M, 1996, MICROPOROUS MATER, V5, P381, DOI 10.1016/0927-6513(95)00069-0; TWOMEY TAM, 1994, ZEOLITES, V14, P162, DOI 10.1016/0144-2449(94)90150-3; YAN YA, 1995, J AM CHEM SOC, V117, P9990, DOI 10.1021/ja00145a008; Zhu GS, 1998, CHEM MATER, V10, P1483, DOI 10.1021/cm980061k	29	539	555	13	450	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					958	960		10.1126/science.283.5404.958	http://dx.doi.org/10.1126/science.283.5404.958			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974382				2022-12-01	WOS:000078574800039
J	Meikle, PJ; Hopwood, JJ; Clague, AE; Carey, WF				Meikle, PJ; Hopwood, JJ; Clague, AE; Carey, WF			Prevalence of lysosomal storage disorders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL PROTEIN THIOESTERASE; DISEASES; DIAGNOSIS; MUTATIONS; GENE	Context Lysosomal storage disorders represent a group of at least 41 genetically distinct, biochemically related, inherited diseases. Individually. these disorders are con considered rare, although high prevalence values have been reported in some populations. These disorders are devastating for individuals and their families and result in considerable use of resources from health care systems; however, the magnitude of the problem is not well defined. To date, no comprehensive study has been performed on the prevalence of these disorders as a group. Objective To determine the prevalence of lysosomal storage disorders individually and as a group in the Australian population. Design Retrospective case studies. Setting Australia, from January 1, 1980, through December 31, 1996. Main Outcome Measure Enzymatic diagnosis of a lysosomal storage disorder. Results Twenty-seven different lysosomal storage disorders were diagnosed in 545 individuals. The prevalence ranged from 1 per 57 000 live births for Gaucher disease to 1 per 4.2 million live births for sialidosis. Eighteen of 27 disorders had more than 10 diagnosed cases. As a group of disorders, the combined prevalence was 1 per 7700 live births. There was no significant increase in the rate of either clinical diagnoses or prenatal diagnoses of lysosomal storage disorders during the study period. Conclusions Individually, lysosomal storage disorders are rare genetic diseases. However. as a group, they are relatively common and represent an important health problem in Australia.	Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Dis Res Unit, Adelaide, SA, Australia; Womens & Childrens Hosp, Dept Chem Pathol, Natl Referal Lab, Adelaide, SA, Australia; Queensland Hlth Pathol Serv, Div Chem Pathol, Brisbane, Qld, Australia	Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; Queensland Health	Meikle, PJ (corresponding author), Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Dis Res Unit, 72 King William Rd, N Adelaide, SA 5006, Australia.		Meikle, Peter J/B-4023-2009	Meikle, Peter/0000-0002-2593-4665				ARVIO M, 1993, ACTA PAEDIATR, V82, P587, DOI 10.1111/j.1651-2227.1993.tb12761.x; Beutler E, 1995, METABOLIC MOL BASES, P2641; CLAUSSEN M, 1992, AM J MED GENET, V42, P536, DOI 10.1002/ajmg.1320420422; Coelho JC, 1997, EUR J PEDIATR, V156, P650, DOI 10.1007/s004310050685; CZARTORYSKA B, 1993, PEDIATR NEUROL, V11, P295; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; Hopwood JJ, 1997, ORGANELLE DIS, P7; KRASNOPOLSKAYA KD, 1993, J INHERIT METAB DIS, V16, P994, DOI 10.1007/BF00711517; LOWRY RB, 1990, HUM GENET, V85, P389; Meikle PJ, 1997, CLIN CHEM, V43, P1325; Michelakakis H., 1995, Genetic Counseling, V6, P43; NEUFELD EF, 1995, METABOLIC MOL BASES, V2, P2465; OZAND PT, 1990, J INHERIT METAB DIS, V13, P849, DOI 10.1007/BF01800209; PETERSEN GM, 1983, AM J HUM GENET, V35, P1258; Rider J A, 1988, Am J Med Genet Suppl, V5, P21; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; VANDEKAMP JJP, 1981, CLIN GENET, V20, P152; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0	20	1488	1590	0	123	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1999	281	3					249	254		10.1001/jama.281.3.249	http://dx.doi.org/10.1001/jama.281.3.249			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157GK	9918480	Bronze			2022-12-01	WOS:000078052800030
J	Fleck, BW				Fleck, BW			Therapy for retinopathy of prematurity	LANCET			English	Editorial Material							DIODE-LASER PHOTOCOAGULATION; THRESHOLD RETINOPATHY		Univ Edinburgh, Royal Infirm, Dept Ophthalmol, Edinburgh EH3 9HA, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh	Fleck, BW (corresponding author), Univ Edinburgh, Royal Infirm, Dept Ophthalmol, Edinburgh EH3 9HA, Midlothian, Scotland.							CAPONE A, 1993, AM J OPHTHALMOL, V116, P444, DOI 10.1016/S0002-9394(14)71402-3; CUNNINGHAM S, 1995, LANCET, V346, P1464, DOI 10.1016/S0140-6736(95)92475-2; Elsas FJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P417; GARNER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1130; Matsuo T, 1997, JPN J OPHTHALMOL, V41, P428, DOI 10.1016/S0021-5155(97)00077-4; McGregor M L, 1998, J AAPOS, V2, P360, DOI 10.1016/S1091-8531(98)90035-0; MCNAMARA JA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1714, DOI 10.1001/archopht.1992.01080240054029; Nagata M, 1968, JPN J OPHTHALMOL, V22, P419; O'Keefe M, 1998, BRIT J OPHTHALMOL, V82, P1246, DOI 10.1136/bjo.82.11.1246; Pearce IA, 1998, BRIT J OPHTHALMOL, V82, P1254, DOI 10.1136/bjo.82.11.1254; White JE, 1997, J PEDIAT OPHTH STRAB, V34, P83	11	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					166	167		10.1016/S0140-6736(05)77211-1	http://dx.doi.org/10.1016/S0140-6736(05)77211-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923868				2022-12-01	WOS:000078175600005
J	Nelken, I; Rotman, Y; Bar Yosef, O				Nelken, I; Rotman, Y; Bar Yosef, O			Responses of auditory-cortex neurons to structural features of natural sounds	NATURE			English	Article							COMODULATION MASKING RELEASE; MODULATION; REPRESENTATION; CAT	Sound-processing strategies that use the highly non-random structure off natural sounds may confer evolutionary advantage to many species. Auditory processing of natural sounds has been studied almost exclusively in the context of species-specific vocalizations(1-4), although these form only a small part of the acoustic biotope(5), To study the relationships between properties of natural soundscapes and neuronal processing mechanisms in the auditory system, we analysed sound from a range of different environments. Here we show that for many non-animal sounds and background mixtures of animal sounds, energy in different frequency bands is coherently modulated. Co-modulation of different frequency bands in background noise facilitates the detection of tones in noise by humans, a phenomenon known as co-modulation masking release (CMR)(6,7). We show that comodulation also improves the ability of auditory-cortex neurons to detect tones in noise, and we propose that this property of auditory neurons may underlie behavioural CMR. This correspondence may represent an adaptation of the auditory system for the use of an attribute of natural sounds to facilitate real-world processing tasks.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Nelken, I (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, POB 12272, IL-91120 Jerusalem, Israel.	israel@music.md.huji.ac.il	Nelken, Israel/B-7753-2011; Rotman, Yaron/AAK-8032-2020	Nelken, Israel/0000-0002-6645-107X; Rotman, Yaron/0000-0002-7549-8216				AERTSEN AMHJ, 1979, BIOL CYBERN, V32, P175, DOI 10.1007/BF00337394; CARLYON RP, 1989, HEARING RES, V42, P37, DOI 10.1016/0378-5955(89)90116-0; EGGERMONT JJ, 1994, HEARING RES, V74, P51, DOI 10.1016/0378-5955(94)90175-9; HALL JW, 1984, J ACOUST SOC AM, V76, P50, DOI 10.1121/1.391005; KLUMP GM, 1995, HEARING RES, V87, P157, DOI 10.1016/0378-5955(95)00087-K; Pelleg-Toiba R., 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P257; RAUSCHECKER JP, 1995, SCIENCE, V268, P111, DOI 10.1126/science.7701330; RHODE WS, 1995, 18 ASS RES OT M ST P, P127; RICHARDS DG, 1980, AM NAT, V115, P381, DOI 10.1086/283568; RUDERMAN DL, 1994, PHYS REV LETT, V73, P814, DOI 10.1103/PhysRevLett.73.814; SCHOONEVELDT GP, 1989, J ACOUST SOC AM, V85, P273, DOI 10.1121/1.397734; SCHREINER CE, 1988, HEARING RES, V32, P49, DOI 10.1016/0378-5955(88)90146-3; STEINSCHNEIDER M, 1990, BRAIN RES, V519, P158, DOI 10.1016/0006-8993(90)90074-L; SUGA N, 1992, PHILOS T ROY SOC B, V336, P423, DOI 10.1098/rstb.1992.0078; Wang XQ, 1995, J NEUROPHYSIOL, V74, P2685, DOI 10.1152/jn.1995.74.6.2685	15	243	247	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 14	1999	397	6715					154	157		10.1038/16456	http://dx.doi.org/10.1038/16456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923676				2022-12-01	WOS:000078085000044
J	Shaw, PJ				Shaw, PJ			Stiff-man syndrome and its variants	LANCET			English	Editorial Material							AUTOANTIBODIES; RIGIDITY		Univ Newcastle Upon Tyne, Royal Victoria Infirm, Dept Med Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Shaw, PJ (corresponding author), Univ Newcastle Upon Tyne, Royal Victoria Infirm, Dept Med Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.		Shaw, Pamela J/A-7620-2010; Shaw, Pamela J/A-5215-2009	Shaw, Pamela/0000-0002-8925-2567				Barker RA, 1998, J NEUROL NEUROSUR PS, V65, P633, DOI 10.1136/jnnp.65.5.633; BLUM P, 1991, MOVEMENT DISORD, V6, P12, DOI 10.1002/mds.870060104; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; LEIGH PN, 1980, J NEUROL NEUROSUR PS, V43, P1125, DOI 10.1136/jnnp.43.12.1125; Marsden CD, 1994, MOVEMENT DISORD, V3, P373; MOERSCH FP, 1956, P STAFF M MAYO CLIN, V31, P421; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; WHITELEY AM, 1976, BRAIN, V99, P27, DOI 10.1093/brain/99.1.27	8	31	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 9	1999	353	9147					86	87		10.1016/S0140-6736(05)76151-1	http://dx.doi.org/10.1016/S0140-6736(05)76151-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XP	10023890				2022-12-01	WOS:000078087200006
J	Bilwes, AM; Alex, LA; Crane, BR; Simon, MI				Bilwes, AM; Alex, LA; Crane, BR; Simon, MI			Structure of CheA, a signal-transducing histidine kinase	CELL			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DNA GYRASE; INTERMOLECULAR COMPLEMENTATION; MULTISTEP PHOSPHORELAY; BACTERIAL CHEMOTAXIS; PROTEIN STRUCTURES; BACILLUS-SUBTILIS; DIFFRACTION DATA; DOMAIN	Histidine kinases allow bacteria, plants, and fungi to sense and respond to their environment. The 2.6 Angstrom resolution crystal structure of Thermotoga maritima CheA (290-671) histidine kinase reveals a dimer where the functions of dimerization, ATP binding, and regulation are segregated into domains. The kinase domain is unlike Ser/Thr/Tyr kinases but resembles two ATPases, Gyrase B and Hsp90. Structural analogies within this superfamily suggest that the P1 domain of CheA provides the nucleophilic histidine and activating glutamate for phosphotransfer. The regulatory domain, which binds the homologous receptor-coupling protein CheW, topologically resembles two SH3 domains and provides different protein recognition surfaces at each end. The dimerization domain forms a central four-helix bundle about which the kinase and regulatory domains pivot on conserved hinges to modulate transphosphorylation. Different subunit conformations suggest that relative domain motions link receptor response to kinase activity.	CALTECH, Dept Biol, Pasadena, CA 91125 USA; CALTECH, Dept Chem, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Simon, MI (corresponding author), CALTECH, Dept Biol, Pasadena, CA 91125 USA.	simonm@cco.caltech.edu		Bilwes Crane, Alexandrine/0000-0001-9922-0692	NIAID NIH HHS [AI19296] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019296] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Appleby JL, 1996, CELL, V86, P845, DOI 10.1016/S0092-8674(00)80158-0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bates AD, 1997, CURR BIOL, V7, pR778, DOI 10.1016/S0960-9822(06)00403-9; BOURRET RB, 1993, J BACTERIOL, V175, P2097, DOI 10.1128/JB.175.7.2097-2101.1993; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHOU KC, 1988, P NATL ACAD SCI USA, V85, P4295, DOI 10.1073/pnas.85.12.4295; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Crane BR, 1997, ACTA CRYSTALLOGR D, V53, P23, DOI 10.1107/S0907444996007263; EISENHABER F, 1995, CRIT REV BIOCHEM MOL, V30, P1, DOI 10.3109/10409239509085139; FREDRICK KL, 1994, J BACTERIOL, V176, P2727, DOI 10.1128/JB.176.9.2727-2735.1994; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Kato M, 1997, CELL, V88, P717, DOI 10.1016/S0092-8674(00)81914-5; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; KOFOID EC, 1988, P NATL ACAD SCI USA, V85, P4981, DOI 10.1073/pnas.85.14.4981; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McEvoy MM, 1998, P NATL ACAD SCI USA, V95, P7333, DOI 10.1073/pnas.95.13.7333; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morrison TB, 1997, J BACTERIOL, V179, P5543, DOI 10.1128/jb.179.17.5543-5550.1997; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Swanson RV, 1996, J BACTERIOL, V178, P484, DOI 10.1128/jb.178.2.484-489.1996; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; Varughese KI, 1998, MOL CELL, V2, P485, DOI 10.1016/S1097-2765(00)80148-3; Welch M, 1998, NAT STRUCT BIOL, V5, P25, DOI 10.1038/nsb0198-25; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; ZHOU HJ, 1995, BIOCHEMISTRY-US, V34, P13858, DOI 10.1021/bi00042a018; Zhou HJ, 1997, BIOCHEMISTRY-US, V36, P699, DOI 10.1021/bi961663p	51	372	381	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					131	141		10.1016/S0092-8674(00)80966-6	http://dx.doi.org/10.1016/S0092-8674(00)80966-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989504	Bronze			2022-12-01	WOS:000078023200015
J	Mahajan-Miklos, S; Tan, MW; Rahme, LG; Ausubel, FM				Mahajan-Miklos, S; Tan, MW; Rahme, LG; Ausubel, FM			Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa Caenorhabditis elegans pathogenesis model	CELL			English	Article							ESCHERICHIA-COLI; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; SENSITIVE MUTANT; GENE; PATHOGENICITY; SYRINGAE; IDENTIFICATION; LONGEVITY; DIAPAUSE	The human opportunistic pathogen Pseudomonas aeruginosa strain PA14 kills Caenorhabditis elegans. Using systematic mutagenesis of PA14 to identify mutants that fail to kill C. elegans and a C. elegans mutant that lacks P-glycoproteins, we identified phenazines, secreted P. aeruginosa pigments, as one of the mediators of killing. Analysis of C. elegans mutants with altered responses to oxidative stress suggests that phenazines exert their toxic effects on C. elegans through the generation of reactive oxygen species. Finally, we show that phenazines and other P. aeruginosa factors required for C. elegans killing are also required for pathogenesis in plants and mice, illustrating that this model tackles the dual challenges of identifying bacterial virulence factors as well as host responses to them.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Soc Fellows, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Shriners Burns Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ausubel, FM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.							ANDERSON DM, 1985, PHYTOPATHOLOGY, V75, P104, DOI 10.1094/Phyto-75-104; ANDREW PA, 1976, NEMATOLOGICA, V22, P451, DOI 10.1163/187529276X00454; Arrigo AP, 1998, BIOL CHEM, V379, P19; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BRENNER S, 1974, GENETICS, V77, P71; BROEKS A, 1995, EMBO J, V14, P1858, DOI 10.1002/j.1460-2075.1995.tb07178.x; Camhi S L, 1995, New Horiz, V3, P170; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; DORING D, 1993, PSEUDOMONAS AERUGINO, P245; ESSAR DW, 1990, J BACTERIOL, V172, P884, DOI 10.1128/jb.172.2.884-900.1990; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HARTMAN PS, 1982, GENETICS, V102, P159; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; ISHII N, 1993, MECH AGEING DEV, V68, P1, DOI 10.1016/0047-6374(93)90135-E; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; KENNEDY EP, 1996, ESCHERICHIA COLI SAL, P1064; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KING EO, 1954, J LAB CLIN MED, V44, P301; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; Lindquist S, 1992, CURR OPIN GENET DEV, V2, P748, DOI 10.1016/S0959-437X(05)80135-2; LOUBENS I, 1993, MOL MICROBIOL, V10, P329, DOI 10.1111/j.1365-2958.1993.tb01959.x; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Mavrodi DV, 1998, J BACTERIOL, V180, P2541, DOI 10.1128/JB.180.9.2541-2548.1998; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; Miller JH., 1972, EXPT MOL GENETICS; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; MUKHOPADHYAY P, 1988, J BACTERIOL, V170, P5479, DOI 10.1128/jb.170.12.5479-5488.1988; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; OHMAN DE, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P28; POOLE K, 1994, J ANTIMICROB CHEMOTH, V34, P453, DOI 10.1093/jac/34.4.453; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; Rahme LG, 1997, P NATL ACAD SCI USA, V94, P13245, DOI 10.1073/pnas.94.24.13245; Sage AE, 1997, MOL MICROBIOL, V23, P43, DOI 10.1046/j.1365-2958.1997.1681542.x; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SORENSEN RU, 1993, PSEUDOMONAS AERUGINO, P43; Strauss EJ, 1997, SCIENCE, V276, P707, DOI 10.1126/science.276.5313.707; STROM MS, 1986, J BACTERIOL, V165, P367, DOI 10.1128/jb.165.2.367-372.1986; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; TAN MW, 1999, IN PRESS P NATL ACAD; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TURNER JM, 1986, ADV MICROB PHYSIOL, V27, P211, DOI 10.1016/S0065-2911(08)60306-9; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; WILSON R, 1988, INFECT IMMUN, V56, P2515, DOI 10.1128/IAI.56.9.2515-2517.1988; Wood R E, 1976, Hosp Pract, V11, P91	50	579	623	4	76	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					47	56		10.1016/S0092-8674(00)80958-7	http://dx.doi.org/10.1016/S0092-8674(00)80958-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989496	Bronze			2022-12-01	WOS:000078023200007
J	de Lonlay-Debeney, P; Poggi-Travert, F; Fournet, JC; Sempoux, C; Vici, CD; Brunelle, F; Touati, G; Rahier, J; Junien, C; Nihoul-Fekete, C; Robert, JJ; Saudubray, JM				de Lonlay-Debeney, P; Poggi-Travert, F; Fournet, JC; Sempoux, C; Vici, CD; Brunelle, F; Touati, G; Rahier, J; Junien, C; Nihoul-Fekete, C; Robert, JJ; Saudubray, JM			Clinical features of 52 neonates with hyperinsulinism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOCAL ADENOMATOUS HYPERPLASIA; SULFONYLUREA RECEPTOR GENE; FAMILIAL HYPERINSULINISM; PARTIAL PANCREATECTOMY; DIABETES-MELLITUS; HYPOGLYCEMIA; INFANCY; MUTATION; TERM; DIAGNOSIS	Background Neonatal hyperinsulinemic hypoglycemia is often resistant to medical therapy and is often treated with near-total pancreatectomy. However, the pancreatic lesions may be focal and treatable by partial pancreatic resection. Methods We studied 52 neonates with hyperinsulinism who were treated surgically. The type and location of the pancreatic lesions were determined by preoperative pancreatic catheterization and intraoperative histologic studies. Partial pancreatectomy was performed in infants with focal lesions, and near-total pancreatectomy was performed in those with diffuse lesions. The postoperative outcome was determined by measurements of plasma glucose and glycosylated hemoglobin and by oral glucose-tolerance tests. Results Thirty neonates had diffuse beta-cell hyperfunction, and 22 had focal adenomatous islet-cell hyperplasia. Among the latter, the lesions were in the head of the pancreas in nine, the isthmus in three, the body in eight, and the tail in two. The clinical manifestations were similar in both groups. The infants with focal lesions had no symptoms of hypoglycemia and had normal preprandial and postprandial plasma glucose and glycosylated hemoglobin values and normal results on oral glucose-tolerance tests after partial pancreatectomy (performed in 19 of 22 neonates). By contrast, after near-total pancreatectomy, 13 of the patients with diffuse lesions had persistent hypoglycemia, type 1 diabetes mellitus developed in 8, and hyperglycemia developed in another 7; overall, only 2 patients with diffuse lesions had normal plasma glucose concentrations in the first year after surgery. Conclusions Among neonates with hyperinsulinism, about half may have focal islet-cell hyperplasia that can be treated with partial pancreatectomy. These neonates can be identified through pancreatic catheterization and intraoperative histologic studies. (N Engl J Med 1999;340:1169-75,) (C)1999, Massachusetts Medical Society.	Hop Necker Enfants Malad, Serv Metab, Federat Pediat, Dept Pediat, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Pathol, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Radiol, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Surg, F-75743 Paris 15, France; Hop Necker Enfants Malad, INSERM, U383, F-75743 Paris 15, France; Clin Univ St Luc, Dept Pathol, B-1200 Brussels, Belgium; Bambino Gesu Pediat Hosp, Div Metab, Rome, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; IRCCS Bambino Gesu	Saudubray, JM (corresponding author), Hop Necker Enfants Malad, Serv Metab, Federat Pediat, Dept Pediat, 149 Rue Sevres, F-75743 Paris 15, France.		; Dionisi-Vici, Carlo/K-2045-2018	Sempoux, Christine/0000-0003-1375-3979; Dionisi-Vici, Carlo/0000-0002-0007-3379				BORDI C, 1982, DIABETES CARE, V5, P122, DOI 10.2337/diacare.5.2.122; BRUINING G J, 1990, Current Opinion in Pediatrics, V2, P758, DOI 10.1097/00008480-199008000-00024; BRUNELLE F, 1989, PEDIATR RADIOL, V19, P100, DOI 10.1007/BF02387895; Craver RD, 1997, J PEDIATR SURG, V32, P1526, DOI 10.1016/S0022-3468(97)90584-4; deLonlay P, 1997, J CLIN INVEST, V100, P802, DOI 10.1172/JCI119594; DUBOIS J, 1995, PEDIATR RADIOL, V25, P512, DOI 10.1007/BF02015782; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1998, DIABETES CARE S1, V21, pS5; GLASER B, 1993, J PEDIATR-US, V123, P644, DOI 10.1016/S0022-3476(05)80970-9; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; GOOSSENS A, 1989, AM J SURG PATHOL, V13, P766, DOI 10.1097/00000478-198909000-00006; GOUDSWAARD WB, 1986, HUM PATHOL, V17, P46, DOI 10.1016/S0046-8177(86)80154-X; HOREV Z, 1991, J PEDIATR-US, V119, P717, DOI 10.1016/S0022-3476(05)80285-9; JAFFE R, 1980, LAB INVEST, V42, P356; Kukuvitis A, 1997, J CLIN ENDOCR METAB, V82, P1192, DOI 10.1210/jc.82.4.1192; LABRUNE P, 1990, J PEDIATR SURG, V25, P1246, DOI 10.1016/0022-3468(90)90519-F; LEIBOWITZ G, 1995, J CLIN ENDOCR METAB, V80, P386, DOI 10.1210/jc.80.2.386; LYONNET S, 1989, LANCET, V2, P671; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; POGGITRAVERT F, 1994, JOURN PAR PED PAR, P29; RAHIER J, 1984, DIABETOLOGIA, V26, P282; Rahier J, 1998, HISTOPATHOLOGY, V32, P15; SCARLETT JA, 1977, NEW ENGL J MED, V297, P1029, DOI 10.1056/NEJM197711102971903; Sempoux C, 1998, J CLIN ENDOCR METAB, V83, P1455, DOI 10.1210/jc.83.5.1455; Shilyansky J, 1997, J PEDIATR SURG, V32, P342, DOI 10.1016/S0022-3468(97)90207-4; SOLCIA E, 1997, TUMORS PANCREAS, P238; SPITZ L, 1992, ARCH DIS CHILD, V67, P201, DOI 10.1136/adc.67.2.201; Stanley CA, 1997, PEDIATR CLIN N AM, V44, P363, DOI 10.1016/S0031-3955(05)70481-8; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; THOMAS CG, 1977, ANN SURG, V185, P505, DOI 10.1097/00000658-197705000-00002; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; THORNTON PS, 1991, J PEDIATR-US, V119, P721, DOI 10.1016/S0022-3476(05)80286-0; THORNTON PS, 1993, J PEDIATR-US, V123, P637, DOI 10.1016/S0022-3476(05)80969-2; Touati G, 1998, EUR J PEDIATR, V157, P628, DOI 10.1007/s004310050900; Verkarre V, 1998, J CLIN INVEST, V102, P1286, DOI 10.1172/JCI4495	36	191	198	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1169	1175		10.1056/NEJM199904153401505	http://dx.doi.org/10.1056/NEJM199904153401505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202168	Bronze			2022-12-01	WOS:000079687700005
J	Li, LL; Keverne, EB; Aparicio, SA; Ishino, F; Barton, SC; Surani, MA				Li, LL; Keverne, EB; Aparicio, SA; Ishino, F; Barton, SC; Surani, MA			Regulation of maternal behavior and offspring growth by paternally expressed Peg3	SCIENCE			English	Article							IMPRINTED GENE; MICE; OXYTOCIN; PROTEIN; GENOMES; BRAIN; RATS	Imprinted genes display parent-of-origin-dependent monoallelic expression that apparently regulates complex mammalian traits, including growth and behavior. The Peg3 gene is expressed in embryos and the adult brain from the paternal allele only. A mutation in the Peg3 gene resulted in growth retardation, as well as a striking impairment of maternal behavior that frequently resulted in death of the offspring. This result may be partly due to defective neuronal connectivity, as well as reduced oxytocin neurons in the hypothalamus, because mutant mothers were deficient in milk ejection. This study provides further insights on the evolution of epigenetic regulation of imprinted gene dosage in modulating mammalian growth and behavior.	Univ Cambridge, Wellcome CRC Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Physiol Lab, Cambridge CB2 1QR, England; Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England; Tokyo Inst Technol, Ctr Gene Res, Midori Ku, Yokohama, Kanagawa 226, Japan	University of Cambridge; University of Cambridge; University of Cambridge; Tokyo Institute of Technology	Surani, MA (corresponding author), Univ Cambridge, Wellcome CRC Inst Canc & Dev Biol, Tennis Court Rd, Cambridge CB2 1QR, England.	as10021@mole.bio.cam.ac.uk		Aparicio, Samuel/0000-0002-0487-9599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLRINGER JF, 1980, J REPROD FERTIL, V59, P223, DOI 10.1530/jrf.0.0590223; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; CALAMANDREI G, 1994, BEHAV NEUROSCI, V108, P113, DOI 10.1037/0735-7044.108.1.113; CALDWELL JD, 1987, NEUROENDOCRINOLOGY, V46, P39, DOI 10.1159/000124794; CATTANACH BM, 1997, GENOMIC IMPRINTING, P118; FUNDELE RH, 1997, GENOMIC IMPRINTING, P98; HATTON GI, 1987, NEUROSCIENCE, V21, P923, DOI 10.1016/0306-4522(87)90047-9; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Keverne EB, 1996, DEV BRAIN RES, V92, P91, DOI 10.1016/0165-3806(95)00209-X; Kikyo N, 1997, DEV BIOL, V190, P66, DOI 10.1006/dbio.1997.8681; Kim J, 1997, GENOME RES, V7, P532, DOI 10.1101/gr.7.5.532; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464; MCCARTHY MM, 1990, HORM BEHAV, V24, P365, DOI 10.1016/0018-506X(90)90015-P; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; NOIROT E, 1969, ANIM BEHAV, V17, P542, DOI 10.1016/0003-3472(69)90161-4; NUMAN M, 1994, ACTA PAEDIATR, V83, P19, DOI 10.1111/j.1651-2227.1994.tb13261.x; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; SCOTT I, 1996, J NEUROENDOCRINOL, V8, P847; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; VANLEENGOED E, 1987, J ENDOCRINOL, V112, P275, DOI 10.1677/joe.0.1120275; YEO JAG, 1986, PHYSIOL BEHAV, V37, P23, DOI 10.1016/0031-9384(86)90378-1	26	408	415	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					330	333		10.1126/science.284.5412.330	http://dx.doi.org/10.1126/science.284.5412.330			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195900				2022-12-01	WOS:000079636400046
J	Yu, SP; Yeh, CH; Strasser, U; Tian, M; Choi, DW				Yu, SP; Yeh, CH; Strasser, U; Tian, M; Choi, DW			NMDA receptor-mediated K+ efflux and neuronal apoptosis	SCIENCE			English	Article							METHYL-D-ASPARTATE; OUTWARD POTASSIUM CURRENT; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; SYNAPTIC PLASTICITY; DIVALENT-CATIONS; CORTICAL-NEURONS; CELL-DEATH; RAT-BRAIN; GLUTAMATE	Neuronal death induced by activating N-methyl-D-aspartate (NMDA) receptors has been linked to Ca2+ and Na+ influx through associated channels. Whole-cell recording from cultured mouse cortical neurons revealed a NMDA-evoked outward current, INMDA-K, carried by K+ efflux at membrane potentials positive to -86 millivolts, Cortical neurons exposed to NMDA in medium containing reduced Na+ and Ca2+ (as found in ischemic brain tissue) Lost substantial intracellular K+ and underwent apoptosis. Both K+ loss and apoptosis were attenuated by increasing extracellular K+, even when voltage-gated Ca2+ channels were blocked. Thus NMDA receptor-mediated K+ efflux may contribute to neuronal apoptosis after brain ischemia.	Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Choi, DW (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA.	choid@neuro.wustl.edu			NINDS NIH HHS [NS 32636, NS 30337] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030337, P01NS032636] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ANWYL R, 1977, J PHYSIOL-LONDON, V273, P367, DOI 10.1113/jphysiol.1977.sp012099; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Bilney AJ, 1998, FEBS LETT, V424, P221, DOI 10.1016/S0014-5793(98)00172-0; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; Chen J, 1997, J NEUROCHEM, V69, P232; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; CSERNANSKY CA, 1994, J NEUROSCI RES, V38, P101, DOI 10.1002/jnr.490380113; Dallaporta B, 1998, J IMMUNOL, V160, P5605; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; FINIELS F, 1995, J NEUROCHEM, V65, P1027; Gwag BJ, 1997, NEUROSCIENCE, V77, P393, DOI 10.1016/S0306-4522(96)00473-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartnett KA, 1997, J NEUROCHEM, V68, P1836; HARVEY JA, 1968, BIOCHEM J, V108, P269, DOI 10.1042/bj1080269; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Inai Y, 1997, CELL STRUCT FUNCT, V22, P555, DOI 10.1247/csf.22.555; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lesort M, 1997, NEUROSCI LETT, V221, P213, DOI 10.1016/S0304-3940(96)13310-3; LI Y, 1995, STROKE, V26, P1252, DOI 10.1161/01.STR.26.7.1252; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Ogden F, 1998, J NEUROSCI RES, V53, P677, DOI 10.1002/(SICI)1097-4547(19980915)53:6<677::AID-JNR6>3.0.CO;2-2; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Qin ZH, 1996, BRAIN RES, V725, P166, DOI 10.1016/S0006-8993(96)00200-4; ROSE K, METHODS TOXICOLOGY I, V46, P93; Rudolph JG, 1997, NEUROSCI LETT, V221, P149, DOI 10.1016/S0304-3940(96)13313-9; SCHOUSBOE A, 1977, J NEUROCHEM, V29, P999, DOI 10.1111/j.1471-4159.1977.tb06503.x; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Takahashi M, 1996, BRAIN RES, V735, P1, DOI 10.1016/S0006-8993(96)00536-7; TEICHBERG VI, 1981, MOL CELL BIOCHEM, V39, P281, DOI 10.1007/BF00232580; Tenneti L, 1998, J NEUROCHEM, V71, P946; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Yu S. P., 1996, Society for Neuroscience Abstracts, V22, P1721; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 1998, NEUROBIOL DIS, V5, P81, DOI 10.1006/nbdi.1998.0186; [No title captured]	52	194	214	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					336	339		10.1126/science.284.5412.336	http://dx.doi.org/10.1126/science.284.5412.336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195902				2022-12-01	WOS:000079636400048
J	Davidson, MB; Schriger, DL; Peters, AL; Lorber, B				Davidson, MB; Schriger, DL; Peters, AL; Lorber, B			Relationship between fasting plasma glucose and glycosylated hemoglobin - Potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-ENZYMATIC GLYCOSYLATION; GLYCATION END-PRODUCTS; COLLAGEN-LINKED FLUORESCENCE; MAILLARD REACTION-PRODUCTS; NONENZYMATIC GLYCATION; LENS CRYSTALLINS; SKIN COLLAGEN; IMMUNOCHEMICAL DETECTION; MELLITUS; COMPLICATIONS	Context New criteria for the diagnosis of type 2 diabetes mellitus have recently been introduced that lowered the diagnostic fasting plasma glucose (FPC) concentration from 7.8 to 7.0 mmol/L (140 to 126 mg/dL). Objective To determine if individuals with diabetes diagnosed by the new FPC concentration criterion would have excessive glycosylation (elevated hemoglobin [HbA(1c)] levels). Definitions We determined the distribution of HbA(1c) levels in individuals using 4 classifications: (1) normal by the new criterion (FPG concentration <6.1 mmol/L [110 mg/dL]; (2) impaired fasting glucose by the new criterion (FPG concentration of 6.1-6.9 mmol/L [110-125 mg/dL]); (3) diabetes diagnosed solely by the new FPG concentration criterion of 7.0 through 7.7 mmol/L (126-139 mg/dL); and (4) diabetes diagnosed. by the previous FPG concentration criterion of 7.8 mmol/L (140 mg/dL) or higher. Design Cross-sectional analysis of 2 large data sets (NHANES III and Meta-Analysis Research Group [MRG] on the Diagnosis of Diabetes Using Glycated Hemoglobin) that contained individuals in whom FPG concentrations, 2-hour glucose concentrations using an oral glucose tolerance test, and an HbA(1c) level were simultaneously measured. We cross-tabulated FPG concentrations (<6.1 mmol/L [110 mg/dL], 6.1-6.9 mmol/L [110-125 mg/dL],7.0-7.7 mmol/L [126-139 mg/dl],and greater than or equal to 7.8 mmol/L [140 mg/dl]) and HbA(1c) levels separated into 3 intervals: normal, less than the upper limit of normal (ULN); slightly elevated, ULN to ULN plus 1%; and high, higher than ULN plus 1%. Results Among subjects with normal FPC concentrations, HbA(1c) levels in the NHANES I II land the MRC) data sets were normal in 97.3% (96.2%), slightly elevated in 2.7% (3.6%), and high in 0.1% (0.2%). Among individuals with impaired fasting glucose, HbA(1c) concentrations were normal in 86.7% (81.4%), slightly elevated in 13.1% (16.4%), and high in 0.2% (2.2%). Among diabetic patients diagnosed by the new FPC criterion only, HbA(1c) levels were normal in 60.9% (59.6%), slightly elevated in 35.8% (32.8%), and high in 3.4% (7.6%). In diabetic patients diagnosed by the former FPG criterion, HbA(1c) levels were normal in 18.6% (16.7%), slightly elevated in 32.5% (21.0%), and high in 48.9% (62.3%). Conclusions About 60% of the new cohort of diabetic patients in both data sets have normal HbA(1c) levels. We believe that diabetes should not be diagnosed in those with FPC concentrations less than 7.8 mmol/L (140 mg/dL) unless excessive glycosylation is evident. Individuals without excessive glycosylation but with moderate elevations of FPG concentrations (6.1-7.7 mmol/L [110-139 mg/dl]) should be diagnosed as having impaired fasting glucose and treated with an appropriate diet and exercise. This diagnostic labeling achieves the goal of early intervention without subjecting these persons to the potentially negative insurance, employment, social, and psychological consequences of a diagnosis of diabetes mellitus.	Charles R Drew Univ Med & Sci, Clin Trials Unit, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, Ctr Emergency Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA	Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Davidson, MB (corresponding author), Charles R Drew Univ Med & Sci, Clin Trials Unit, 1731 E 120th St,AFH Bldg,Mailpoint30, Los Angeles, CA 90059 USA.			Schriger, David/0000-0003-0242-1127; Peters, Anne/0000-0003-0520-0776				[Anonymous], 1995, DIABETES, V44, P968; BEISSWENGER PJ, 1995, DIABETES, V44, P824, DOI 10.2337/diabetes.44.7.824; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; Bucala R., 1995, DIABETES REV, V3, P258; *BUR CENS, 1995, CURR PO REP SER; CEFALU WT, 1991, DIABETES, V40, P902, DOI 10.2337/diabetes.40.7.902; Clements RS, 1998, J DIABETES COMPLICAT, V12, P28, DOI 10.1016/S1056-8727(97)00051-2; COHEN MP, 1995, J CLIN INVEST, V95, P2338, DOI 10.1172/JCI117926; DAVIDSON MB, 1995, DIABETES CARE, V18, P1065, DOI 10.2337/diacare.18.7.1065; DOMINICZAK MH, 1990, DIABETES CARE, V13, P468, DOI 10.2337/diacare.13.5.468; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Engelgau MM, 1997, DIABETES CARE, V20, P785, DOI 10.2337/diacare.20.5.785; GARLICK RL, 1984, J CLIN INVEST, V74, P1742, DOI 10.1172/JCI111592; GARLICK RL, 1988, DIABETES, V37, P1144, DOI 10.2337/diabetes.37.8.1144; Gavin JR, 1997, DIABETES CARE, V20, P1183; HARRIS M, 1979, DIABETES, V28, P1039; Harris MI, 1997, DIABETES CARE, V20, P1859, DOI 10.2337/diacare.20.12.1859; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HARRIS MI, 1995, DIABETES AM, P591; JARRETT RJ, 1976, LANCET, V2, P1009; KANESHIGE H, 1987, DIABETES, V36, P822, DOI 10.2337/diabetes.36.7.822; KNOWLER WC, 1994, DIABETES CARE, V17, P445, DOI 10.2337/diacare.17.5.445; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; LUTJENS A, 1985, DIABETOLOGIA, V28, P87; LYONS TJ, 1985, DIABETOLOGIA, V28, P2, DOI 10.1007/BF00276991; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MCLENNAN S, 1986, DIABETIC MED, V3, P141, DOI 10.1111/j.1464-5491.1986.tb00725.x; MITSUHASHI T, 1993, DIABETES, V42, P826, DOI 10.2337/diabetes.42.6.826; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; NAKAYAMA H, 1993, DIABETES, V42, P345, DOI 10.2337/diabetes.42.2.345; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Ono Y, 1998, DIABETES RES CLIN PR, V41, P131, DOI 10.1016/S0168-8227(98)00074-6; PAISEY RB, 1984, BRIT MED J, V288, P669, DOI 10.1136/bmj.288.6418.669; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; PETTITT DJ, 1980, LANCET, V2, P1050; Rohlfing C, 1998, DIABETES, V47, pA70; SAYEGH HA, 1979, LANCET, V2, P431, DOI 10.1016/S0140-6736(79)91489-2; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; SENSI M, 1995, DIABETES RES CLIN PR, V28, P9, DOI 10.1016/0168-8227(94)01061-4; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918; Tanaka Y, 1998, DIABETES CARE, V21, P116, DOI 10.2337/diacare.21.1.116; TARSIO JF, 1985, DIABETES, V34, P477, DOI 10.2337/diabetes.34.5.477; TATTERSALL RB, 1982, COMPLICATIONS DIABET, P271; UITTO J, 1982, CONNECT TISSUE RES, V10, P287, DOI 10.3109/03008208209008054; VISHWANATH V, 1986, DIABETES, V35, P916, DOI 10.2337/diabetes.35.8.916; VLASSARA H, 1983, DIABETES, V32, P670, DOI 10.2337/diabetes.32.7.670; VLASSARA H, 1981, P NATL ACAD SCI-BIOL, V78, P5190, DOI 10.1073/pnas.78.8.5190; Wolffenbuttel BHR, 1996, LANCET, V347, P513, DOI 10.1016/S0140-6736(96)91141-1; World Health Organization Expert Committee on Diabetes Mellitus, 1980, 646 WHO	54	139	143	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1203	1210		10.1001/jama.281.13.1203	http://dx.doi.org/10.1001/jama.281.13.1203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199430				2022-12-01	WOS:000079464400035
J	Barnett, AG; Underwood, MR; Vickers, MR				Barnett, AG; Underwood, MR; Vickers, MR			Effect of UK national guidelines on services to treat patients with acute low back pain: follow up questionnaire survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	Conference of the World Organisation of National Colleges, Academies and Academic Associations of General Practioners/Family Physicians	JUN, 1998	DUBLIN, IRELAND	World Org Natl Coll Acad & Acad Assoc Gen Practitioners Family Physicians					Queen Mary Univ London, St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, MRC,Epidemiol & Med Care Unit, London EC1M 6BQ, England	University of London; Queen Mary University London	Underwood, MR (corresponding author), Queen Mary Univ London, St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, MRC,Epidemiol & Med Care Unit, London EC1M 6BQ, England.	M.Underwood@mds.qmw.ac.uk	Underwood, Martin/D-6364-2015; Barnett, Adrian/I-9850-2012	Underwood, Martin/0000-0002-0309-1708; Barnett, Adrian/0000-0001-6339-0374				*CLIN STAND ADV GR, 1994, BACK PAIN REP CSAG B; DENNIS SM, 1997, THORAX S6, V52, pA18; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Moser CA, 1971, SURVEY METHODS SOCIA, P137; Underwood MR, 1997, BRIT J GEN PRACT, V47, P501	5	18	18	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	1999	318	7188					919	920		10.1136/bmj.318.7188.919	http://dx.doi.org/10.1136/bmj.318.7188.919			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	185GV	10102859	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000079660500029
J	Ghiglione, C; Carraway, KL; Amundadottir, LT; Boswell, RE; Perrimon, N; Duffy, JB				Ghiglione, C; Carraway, KL; Amundadottir, LT; Boswell, RE; Perrimon, N; Duffy, JB			The transmembrane molecule kekkon 1 acts in a feedback loop to negatively regulate the activity of the Drosophila EGF receptor during oogenesis	CELL			English	Article							DORSAL-VENTRAL AXIS; TYROSINE KINASE; SIGNALING PATHWAYS; SPEMANN ORGANIZER; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; GENE GURKEN; PDZ DOMAINS; PROTEIN; MELANOGASTER	We have identified the Drosophila transmembrane molecule kekkon 1 (kek1) as an inhibitor of the epidermal growth factor receptor (EGFR) and demonstrate that it acts in a negative feedback loop to modulate the activity of the EGFR tyrosine kinase. During oogenesis, kek1 is expressed in response to the Gurken/EGFR signaling pathway, and loss of kek1 activity is associated with an increase in EGFR signaling. Consistent with our loss-of-function studies, we demonstrate that ectopic overexpression of kek1 mimics a loss of EGFR activity. We show that the extracellular and transmembrane domains of Kek1 can inhibit and physically associate with the EGFR, suggesting potential models for this inhibitory mechanism.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Beth Israel Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Univ Colorado, Howard Hughes Med Inst, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Beth Israel Deaconess Medical Center; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.		Amundadottir, Laufey T/L-7656-2016	Amundadottir, Laufey T/0000-0003-1859-8971; Perrimon, Norbert/0000-0001-7542-472X	NATIONAL CANCER INSTITUTE [R01CA071702] Funding Source: NIH RePORTER; NCI NIH HHS [CA71702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHBURNER M, 1990, GENETICS, V126, P679; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRAND AH, 1993, DEVELOPMENT, V118, P401; CLIFFORD RJ, 1989, GENETICS, V123, P771; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; Greenwood S, 1997, DEVELOPMENT, V124, P4879; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Li W, 1997, Genet Eng (N Y), V19, P167; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; MELNICK MB, 1993, DEVELOPMENT, V118, P127; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NEUMANSILBERBERG FS, 1994, DEVELOPMENT, V120, P2457; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sapir A, 1998, DEVELOPMENT, V125, P191; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Schnorr JD, 1996, GENETICS, V144, P1545; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SMITH D, 1993, GENETICS, V135, P1063; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Speicher S, 1998, NEURON, V20, P221, DOI 10.1016/S0896-6273(00)80451-1; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STURTEVANT MA, 1994, DEVELOPMENT, V120, P2593; Suzuki Y, 1996, J BIOL CHEM, V271, P22522, DOI 10.1074/jbc.271.37.22522; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANDERGEER P, 1994, ANN REV CELL BIOL, V10, P208; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	59	176	191	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	1999	96	6					847	856		10.1016/S0092-8674(00)80594-2	http://dx.doi.org/10.1016/S0092-8674(00)80594-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102272	Bronze			2022-12-01	WOS:000079300100011
J	Smith, DE; Babcock, HP; Chu, S				Smith, DE; Babcock, HP; Chu, S			Single-polymer dynamics in steady shear flow	SCIENCE			English	Article							HYDRODYNAMIC INTERACTION; ELONGATIONAL FLOW; FLEXIBLE POLYMERS; DNA; DEFORMATION; MODEL; SCATTERING	The conformational dynamics of individual, flexible polymers in steady shear flow were directly observed by the use of video fluorescence microscopy. The probability distribution for the molecular extension was determined as a function of shear rate, (gamma)over dot, for two different polymer relaxation times, tau. In contrast to the behavior in pure elongational Flow, the average polymer extension in shear flow does not display a sharp coil-stretch transition. Large, aperiodic temporal fluctuations were observed, consistent with end-over-end tumbling of the molecule. The rate of these fluctuations (relative to the relaxation rate) increased as the Weissenberg number, (gamma)over dot tau, was increased.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA	Stanford University; Stanford University	Chu, S (corresponding author), Stanford Univ, Dept Phys, Varian Bldg, Stanford, CA 94305 USA.	schu@leland.stanford.edu	Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632; Babcock, Hazen/0000-0003-4835-3692				ATKINS EDT, 1992, BIOPOLYMERS, V32, P911, DOI 10.1002/bip.360320803; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; COTTRELL FR, 1969, J POLYM SCI A2, V7, P1415, DOI 10.1002/pol.1969.160070811; DEGENNES PG, 1974, J CHEM PHYS, V60, P5030, DOI 10.1063/1.1681018; Doyle PS, 1997, J FLUID MECH, V334, P251, DOI 10.1017/S0022112096004302; Doyle PS, 1998, J NON-NEWTON FLUID, V76, P79, DOI 10.1016/S0377-0257(97)00113-4; FULLER GG, 1980, RHEOL ACTA, V19, P580, DOI 10.1007/BF01517512; HINCH EJ, 1976, J FLUID MECH, V75, P765, DOI 10.1017/S0022112076000529; Jeffery GB, 1922, P R SOC LOND A-CONTA, V102, P161, DOI 10.1098/rspa.1922.0078; Kuhn W, 1943, HELV CHIM ACTA, V26, P1394, DOI 10.1002/hlca.19430260514; Larson R. G., 1988, CONSTITUTIVE EQUATIO; Lee EC, 1997, MACROMOLECULES, V30, P7313, DOI 10.1021/ma9706945; LINDNER P, 1988, COLLOID POLYM SCI, V266, P886, DOI 10.1007/BF01410843; LIU TW, 1989, J CHEM PHYS, V90, P5826, DOI 10.1063/1.456389; LUMLEY JL, 1969, ANNU REV FLUID MECH, V1, P367, DOI 10.1146/annurev.fl.01.010169.002055; MAGDA JJ, 1988, J CHEM PHYS, V89, P2504, DOI 10.1063/1.455044; PECORA R, 1991, SCIENCE, V251, P893, DOI 10.1126/science.2000490; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; PERKINS TT, IN PRESS FLEXIBLE CH; PETERLIN A, 1958, J CHEM PHYS, V28, P470, DOI 10.1063/1.1744160; PRESS WP, 1988, NUMERICAL RECIPES C, P442; ROUSE PE, 1953, J CHEM PHYS, V21, P1272, DOI 10.1063/1.1699180; SHAQFEH E, COMMUNICATION; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; Smith DE, 1998, SCIENCE, V281, P1335, DOI 10.1126/science.281.5381.1335; WANG MC, 1945, REV MOD PHYS, V17, P323, DOI 10.1103/RevModPhys.17.323; WARNER HR, 1972, IND ENG CHEM FUND, V11, P379, DOI 10.1021/i160043a017; WEDGEWOOD LE, 1988, J NON-NEWTON FLUID, V27, P245, DOI 10.1016/0377-0257(88)85016-X; WEDGEWOOD LE, 1991, J NON-NEWTON FLUID, V40, P119, DOI 10.1016/0377-0257(91)87029-W; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462	31	638	651	5	175	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	1999	283	5408					1724	1727		10.1126/science.283.5408.1724	http://dx.doi.org/10.1126/science.283.5408.1724			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175PF	10073935	Green Submitted			2022-12-01	WOS:000079102800048
J	Nykjaer, A; Dragun, D; Walther, D; Vorum, H; Jacobsen, C; Herz, J; Melsen, F; Christensen, EI; Willnow, TE				Nykjaer, A; Dragun, D; Walther, D; Vorum, H; Jacobsen, C; Herz, J; Melsen, F; Christensen, EI; Willnow, TE			An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D-3	CELL			English	Article							D-BINDING-PROTEIN; MEDIATED ENDOCYTOSIS; RECEPTOR; GP330; SERUM; 1,25-DIHYDROXYVITAMIN-D; COMPLEXES; HORMONE; MEGALIN; CELLS	Steroid hormones may enter cells by diffusion through the plasma membrane. However, we demonstrate here that some steroid hormones are taken up by receptor-mediated endocytosis of steroid-carrier complexes. We show that 25-(OH) vitamin D-3 in complex with its plasma carrier, the vitamin D-binding protein, is filtered through the glomerulus and reabsorbed in the proximal tubules by the endocytic receptor megalin. Endocytosis is required to preserve 25-(OH) vitamin D-3 and to deliver to the cells the precursor for generation of 1,25-(OH)(2) Vitamin D-3, a regulator of the calcium metabolism. Megalin(-/-) mice are unable to retrieve the steroid from the glomerular filtrate and develop vitamin D deficiency and bone disease.	Max Delbrueck Ctr Mol Med, D-13125 Berlin, Germany; Franz Volhard Clin, D-13125 Berlin, Germany; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Cell Biol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus, Denmark; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Aarhus University; Aarhus University; Aarhus University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Willnow, TE (corresponding author), Max Delbrueck Ctr Mol Med, D-13125 Berlin, Germany.			Dragun, Duska/0000-0002-0310-9269; Willnow, Thomas/0000-0001-9515-7921; Nykjaer, Anders/0000-0001-6422-6736	NHLBI NIH HHS [HL 20948, R37 HL063762] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762, P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIKLE DD, 1985, J CLIN ENDOCR METAB, V61, P969, DOI 10.1210/jcem-61-5-969; BIKLE DD, 1986, J CLIN ENDOCR METAB, V63, P954, DOI 10.1210/jcem-63-4-954; CHRISTENSEN EI, 1995, EUR J CELL BIOL, V66, P349; COOKE NE, 1997, VITAMIN D, P105; HADDAD JG, 1981, J CLIN INVEST, V67, P1550, DOI 10.1172/JCI110186; HADDAD JG, 1995, J STEROID BIOCHEM, V53, P1; Harrison HE, 1953, J CHRON DIS, V7, P346; KEENAN MJ, 1991, INT J BIOCHEM, V23, P1225, DOI 10.1016/0020-711X(91)90220-H; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; OMDAHL JL, 1980, J BIOL CHEM, V255, P7460; PORTO CS, 1991, ENDOCRINOLOGY, V129, P436, DOI 10.1210/endo-129-1-436; PORTO CS, 1995, J STEROID BIOCH MOL, V53, P1; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SIITERI PK, 1986, CLIN ENDOCRINOL META, V15, P247, DOI 10.1016/S0300-595X(86)80023-8; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; STEFANSSON S, 1995, J CELL SCI, V108, P2361; STJOHN A, 1992, NEPHRON, V61, P422; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; TERANISHI H, 1983, TOXICOL LETT, V15, P7; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YANG F, 1990, GENOMICS, V7, P509, DOI 10.1016/0888-7543(90)90193-X	25	754	785	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 19	1999	96	4					507	515		10.1016/S0092-8674(00)80655-8	http://dx.doi.org/10.1016/S0092-8674(00)80655-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052453	Bronze			2022-12-01	WOS:000078718600002
J	Malin, MC; Carr, MH				Malin, MC; Carr, MH			Groundwater formation of martian valleys	NATURE			English	Article							MARS; MORPHOLOGY; CHANNELS; ORIGIN	The martian surface shows large outflow channels, widely accepted as having been formed by gigantic floods that could have occurred under climatic conditions like those seen today(1-5). Also present are branching valley networks that commonly have tributaries(1-8). These valleys are much smaller than the outflow channels and their origins and ages have been controversial. For example, they might have formed through slow erosion by water running across the surface, either early or late in Mars' history(9-13), possibly protected from harsh conditions by ice cover(14-16). Alternatively, they might have formed through groundwater or ground-ice processes that undermine the surface and cause collapse, again either early or late in Mars' history(3,4). Long-duration surface runoff would imply climatic conditions quite different from the present environment. Here we present high-resolution images of martian valleys that support the view that ground water played an important role in their formation, although we are unable as yet to establish when this occurred.	Malin Space Sci Syst, San Diego, CA 92191 USA; US Geol Survey, Menlo Pk, CA 94025 USA	United States Department of the Interior; United States Geological Survey	Malin, MC (corresponding author), Malin Space Sci Syst, POB 910148, San Diego, CA 92191 USA.	malin@mss.com						[Anonymous], 1983, GEOL SOC AM BULL, V94, P1035; BAKER VR, 1974, ICARUS, V23, P27, DOI 10.1016/0019-1035(74)90101-8; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BAKER VR, 1986, J GEOPHYS RES-SOLID, V91, P3561, DOI 10.1029/JB091iB03p03561; BAKER VR, 1982, CHANNELS VALLEYS MAR; BRAKENRIDGE GR, 1985, GEOLOGY, V13, P859, DOI 10.1130/0091-7613(1985)13<859:AHSOMO>2.0.CO;2; CARR MH, 1983, ICARUS, V56, P476, DOI 10.1016/0019-1035(83)90168-9; CARR MH, 1979, J GEOPHYS RES, V84, P2995, DOI 10.1029/JB084iB06p02995; CARR MH, 1995, J GEOPHYS RES-PLANET, V100, P7479, DOI 10.1029/95JE00260; CARR MH, 1992, WATER MARS; CRADDOCK RA, 1993, J GEOPHYS RES-PLANET, V98, P3453, DOI 10.1029/92JE02508; GOLDSPIEL JM, 1993, ICARUS, V105, P479, DOI 10.1006/icar.1993.1143; Gulick VC, 1997, ICARUS, V130, P68, DOI 10.1006/icar.1997.5802; GULICK VC, 1989, NATURE, V341, P514, DOI 10.1038/341514a0; Gulick VC, 1998, J GEOPHYS RES-PLANET, V103, P19365, DOI 10.1029/98JE01321; KRINSLEY D, 1979, ICARUS, V39, P364, DOI 10.1016/0019-1035(79)90147-7; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; Masursky H., 1977, Journal of Geophysical Research, V82, P4016, DOI 10.1029/JS082i028p04016; NEWSOM HE, 1980, ICARUS, V44, P207, DOI 10.1016/0019-1035(80)90066-4; PIERI DC, 1980, SCIENCE, V210, P895, DOI 10.1126/science.210.4472.895; SHARP RP, 1975, GEOL SOC AM BULL, V86, P593, DOI 10.1130/0016-7606(1975)86<593:COM>2.0.CO;2; SODERBLOM LA, 1974, ICARUS, V22, P239, DOI 10.1016/0019-1035(74)90175-4; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; WALLACE D, 1979, ICARUS, V39, P385, DOI 10.1016/0019-1035(79)90148-9; [No title captured]	25	125	127	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1999	397	6720					589	591		10.1038/17551	http://dx.doi.org/10.1038/17551			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050852				2022-12-01	WOS:000078738500041
J	Herxheimer, A				Herxheimer, A			Secret out-of-court settlements in drug-injury cases	LANCET			English	Editorial Material											Herxheimer, A (corresponding author), 9 Pk Crescent, London N3 2NL, England.							Herxheimer A, 1996, Int J Risk Saf Med, V9, P201, DOI 10.3233/JRS-1996-9311; 1998, GEN MED COUNCIL  WIN, P7	2	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					517	518		10.1016/S0140-6736(99)00042-2	http://dx.doi.org/10.1016/S0140-6736(99)00042-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028977				2022-12-01	WOS:000078670200006
J	Montgomery, H; Clarkson, P; Barnard, M; Bell, J; Brynes, A; Dollery, C; Hajnal, J; Hemingway, H; Mercer, D; Jarman, P; Marshall, R; Prasad, K; Rayson, M; Saeed, N; Talmud, P; Thomas, L; Jubb, M; World, M; Humphries, S				Montgomery, H; Clarkson, P; Barnard, M; Bell, J; Brynes, A; Dollery, C; Hajnal, J; Hemingway, H; Mercer, D; Jarman, P; Marshall, R; Prasad, K; Rayson, M; Saeed, N; Talmud, P; Thomas, L; Jubb, M; World, M; Humphries, S			Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training	LANCET			English	Article							CHRONIC HEART-FAILURE; INSULIN-RESISTANCE; BODY-COMPOSITION; MUSCLE; RAT; BRADYKININ; METABOLISM; INDIVIDUALS; KALLIKREIN; TRANSPORT	Background The function of local renin-angiotensin systems in skeletal muscle and adipose tissue remains largely unknown. A polymorphism of the human angiotensin converting enzyme (ACE) gene has been identified in which the insertion (I) rather than deletion (D) allele is associated with lower ACE activity in body tissues and increased response to some aspects of physical training. We studied the association between the ACE gene insertion or deletion polymorphism and changes in body composition related to an intensive exercise programme, to investigate the metabolic effects of local human renin-angiotensin systems. Methods We used three independent methods (bioimpedance, multiple skinfold-thickness assessment of whole-body composition, magnetic resonance imaging of the mid-thigh) to study changes in body composition in young male army recruits over 10 weeks of intensive physical training. Findings Participants with the II genotype had a greater anabolic response than those with one or more D alleles for fat mass (0.55 vs -0.20 kg, p=0.04 by bioimpedance) and non-fat mass (1.31 vs -0.15 kg, p=0.01 by bioimpedance). Changes in body morphology with training measured by the other methods were also dependent on genotype. Interpretation II genotype, as a marker of low ACE activity in body tissues, may conserve a positive energy balance during rigorous training, which suggests enhanced metabolic efficiency. This finding may explain some of the survival and functional benefits of therapy with ACE inhibitors.	UCL, UCH, Rayne Inst, Ctr Cardiovasc Genet, London WC1E 6JJ, England; UCL Hosp, London, England; Imperial Coll, Sch Med, MRI Unit, London, England; Imperial Coll, Sch Med, Nutr & Dietet Dept, London, England; UCL, Dept Epidemiol & Publ Hlth, London, England; DERA, Ctr Human Sci, Farnborough, Hants, England; UCL, Dept Pulm Biochem, London, England; St George Hosp, Dept Cardiol, London, England; Optimal Performance Ltd, Farnham, Surrey, England; Royal Def Med Coll, HMS Dolphin, Hants, England	University of London; King's College London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Imperial College London; Imperial College London; University of London; University College London; University of London; University College London; St Georges University London	Montgomery, H (corresponding author), UCL, UCH, Rayne Inst, Ctr Cardiovasc Genet, Univ St, London WC1E 6JJ, England.	h.montgomery@ucl.ac.uk	Montgomery, Hugh/L-1229-2019; Thomas, Elizabeth Louise/AIF-0055-2022; Hemingway, Harry/C-1219-2009; Talmud, Philippa J/C-4402-2008; Montgomery, Hugh/C-2592-2008	Hemingway, Harry/0000-0003-2279-0624; Bell, Jimmy/0000-0003-3804-1281; Thomas, Elizabeth/0000-0003-4235-4694; Talmud, Philippa/0000-0002-5560-1933; Montgomery, Hugh/0000-0001-8797-5019; Jubb, Michael/0000-0001-5639-473X				Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Anker SD, 1997, CIRCULATION, V96, P526; BALL SG, 1993, LANCET, V342, P821; BLOOM SR, 1976, J PHYSIOL-LONDON, V258, P1; BOLLA MK, 1995, CLIN CHEM, V41, P1599; Brink M, 1996, J CLIN INVEST, V97, P2509, DOI 10.1172/JCI118698; BUNNEMANN B, 1992, J CARDIOVASC PHARM, V19, pS51, DOI 10.1097/00005344-199219006-00010; CAMPBELL DJ, 1993, HYPERTENSION, V21, P155, DOI 10.1161/01.HYP.21.2.155; CARRETERO O, 1965, EXPERIENTIA, V21, P141, DOI 10.1007/BF02141980; DANSER AHJ, 1995, CIRCULATION, V92, P1387, DOI 10.1161/01.CIR.92.6.1387; DIETZE G, 1980, AGENTS ACTIONS, V10, P335, DOI 10.1007/BF01971435; Dragovic T, 1996, DIABETES, V45, pS34, DOI 10.2337/diab.45.1.S34; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; DZAU VJ, 1988, CIRCULATION, V77, P1; Ghosh S, 1997, EUR J GASTROEN HEPAT, V9, P783, DOI 10.1097/00042737-199708000-00009; GOLDMAN J, 1987, MOL CELL ENDOCRINOL, V50, P183, DOI 10.1016/0303-7207(87)90016-5; Gutin B, 1996, AM J CLIN NUTR, V63, P287, DOI 10.1093/ajcn/63.3.287; Hennes MMI, 1996, HYPERTENSION, V28, P120, DOI 10.1161/01.HYP.28.1.120; HENRIKSEN EJ, 1995, METABOLISM, V44, P267, DOI 10.1016/0026-0495(95)90276-7; Hespel P, 1996, DIABETES, V45, pS99, DOI 10.2337/diab.45.1.S99; JAUCH KW, 1988, METABOLISM, V37, P185, DOI 10.1016/S0026-0495(98)90016-6; Jones BH, 1997, AM J PHYSIOL-REG I, V273, pR236, DOI 10.1152/ajpregu.1997.273.1.R236; Jonsson J R, 1994, Blood Press, V3, P72; KATSUYA T, 1995, ARTERIOSCL THROM VAS, V15, P779, DOI 10.1161/01.ATV.15.6.779; KEM DC, 1990, NEW ENGL J MED, V323, P1136, DOI 10.1056/NEJM199010183231609; Laycock SK, 1998, CIRC RES, V82, P1263, DOI 10.1161/01.RES.82.12.1263; LEVENS NR, 1986, J CARDIOVASC PHARM, V8, pS17, DOI 10.1097/00005344-198600101-00005; Linz W, 1996, DIABETES, V45, pS51, DOI 10.2337/diab.45.1.S51; MCKENZIE CA, 1995, AM J HUM GENET, V57, P1426; MESSERLI FH, 1977, CIRC RES, V40, P204, DOI 10.1161/01.RES.40.2.204; Montgomery HE, 1997, CIRCULATION, V96, P741; Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374; Rabito SF, 1996, DIABETES, V45, pS29, DOI 10.2337/diab.45.1.S29; Reisenleiter F, 1996, EUR J GASTROEN HEPAT, V8, P279, DOI 10.1097/00042737-199603000-00017; RENNIE MJ, 1976, BIOCHEM J, V156, P647, DOI 10.1042/bj1560647; Rossetti L, 1997, J CLIN INVEST, V100, P1831, DOI 10.1172/JCI119711; *SAS I, 1990, SAS US GUID; SCHIEFFER B, 1995, AM J PHYSIOL-HEART C, V269, pH1507, DOI 10.1152/ajpheart.1995.269.5.H1507; SENN S, 1991, STAT MED, V10, P1157; TOWNSEND RR, 1993, AM J PHYSIOL, V265, pE362, DOI 10.1152/ajpendo.1993.265.3.E362; WASSERMAN DH, 1986, BIOCH EXERCISE, V6, P167; WICKLMAYR M, 1980, AGENTS ACTIONS, V10, P339, DOI 10.1007/BF01971436; Wolin MS, 1997, BIOCHEM SOC T, V25, P934, DOI 10.1042/bst0250934; Zhang XP, 1997, CIRCULATION, V95, P176, DOI 10.1161/01.CIR.95.1.176	44	175	187	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1999	353	9152					541	545		10.1016/S0140-6736(98)07131-1	http://dx.doi.org/10.1016/S0140-6736(98)07131-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028982				2022-12-01	WOS:000078670200011
J	Litwin, MS				Litwin, MS			Urology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Litwin, MS (corresponding author), Univ Calif Los Angeles, Dept Urol, Box 951738, Los Angeles, CA 90095 USA.	mlitwin@ucla.edu		Litwin, Mark/0000-0002-2318-344X				Albertsen PC, 1998, JAMA-J AM MED ASSOC, V280, P975, DOI 10.1001/jama.280.11.975; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; Jacobsen SJ, 1998, UROLOGY, V52, P173, DOI 10.1016/S0090-4295(98)00171-X; Lander J, 1997, JAMA-J AM MED ASSOC, V278, P2157, DOI 10.1001/jama.278.24.2157; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; McConnell JD, 1998, NEW ENGL J MED, V338, P557, DOI 10.1056/NEJM199802263380901; Mettlin CJ, 1998, CANCER, V82, P249, DOI 10.1002/(SICI)1097-0142(19980115)82:2<249::AID-CNCR1>3.0.CO;2-M; Mettlin CJ, 1998, CANCER, V82, P1802, DOI 10.1002/1097-0142(19980501)82:9<1802::AID-CNCR34>3.0.CO;2-H; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; *SURV EP END RES, 1997, J NATL CANCER I, V89, P12; Wasson JH, 1998, NEW ENGL J MED, V338, P612, DOI 10.1056/NEJM199802263380909; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1999	281	6					495	496		10.1001/jama.281.6.495	http://dx.doi.org/10.1001/jama.281.6.495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FQ	10022088				2022-12-01	WOS:000078452900002
J	Rittenhouse, CD; Shouval, HZ; Paradiso, MA; Bear, MF				Rittenhouse, CD; Shouval, HZ; Paradiso, MA; Bear, MF			Monocular deprivation induces homosynaptic long-term depression in visual cortex	NATURE			English	Article							SYNAPTIC PLASTICITY; STRIATE CORTEX; TRANSMISSION; BLOCKADE; PERIOD	Brief monocular deprivation during early postnatal development can lead to a depression of synaptic transmission that renders visual cortical neurons unresponsive to subsequent visual stimulation through the deprived eye. The Bienenstock-Cooper-Munro (BCM) theory(1) proposes that homosynaptic mechanisms of long-term depression (LTD) account for the deprivation effects(2,3). Homosynaptic depression, by definition, occurs only at active synapses. Thus, in contrast to the commonly held view that the synaptic depression caused by monocular deprivation is simply a result of retinal inactivity, this theoretical framework indicates that the synaptic depression may actually be driven by the residual activity in the visually deprived retina(4). Here we examine the validity of this idea by comparing the consequences of brief monocular deprivation by lid suture with those of monocular inactivation by intra-ocular treatment with tetrodotoxin. Lid suture leaves the retina spontaneously active, whereas tetrodotoxin eliminates all activity. In agreement with the BCM theory, our results show that monocular lid suture causes a significantly greater depression of deprived-eye responses in kitten visual cortex than does treatment with tetrodotoxin. These findings have important implications for mechanisms of experience-dependent plasticity in the neocortex.	Brown Univ, Howard Hughes Med Inst, Providence, RI 02912 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Brown University; Howard Hughes Medical Institute; Brown University	Bear, MF (corresponding author), Brown Univ, Howard Hughes Med Inst, Providence, RI 02912 USA.	mbear@brown.edu		Bear, Mark/0000-0002-9903-2541				ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; Bear MF, 1998, DAHLEM WORK, P205; BEAR MF, 1990, J NEUROSCI, V10, P909; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; BEAR MF, 1996, CORTICAL PLASTICITY, P191; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Blais BS, 1999, P NATL ACAD SCI USA, V96, P1083, DOI 10.1073/pnas.96.3.1083; CHAPMAN B, 1986, NATURE, V324, P154, DOI 10.1038/324154a0; DUDEK SM, 1996, NEURON, V16, P1; GREUEL JM, 1987, DEV BRAIN RES, V34, P141, DOI 10.1016/0165-3806(87)90203-3; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; KAPLAN E, 1987, J PHYSIOL-LONDON, V391, P267, DOI 10.1113/jphysiol.1987.sp016737; Kirkwood A, 1997, P NATL ACAD SCI USA, V94, P3380, DOI 10.1073/pnas.94.7.3380; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; KIRKWOOD A, IN PRESS J NEUROSCI; Kojic L, 1997, DEV BRAIN RES, V101, P299, DOI 10.1016/S0165-3806(97)00083-7; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; RAMOA AS, 1988, EXP BRAIN RES, V73, P285; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; Rossi AF, 1996, SCIENCE, V273, P1104, DOI 10.1126/science.273.5278.1104; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; von der Malsburg C, 1973, Kybernetik, V14, P85; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1060, DOI 10.1152/jn.1965.28.6.1060	27	182	189	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					347	350		10.1038/16922	http://dx.doi.org/10.1038/16922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950426				2022-12-01	WOS:000078324600049
J	Usher, M; Cohen, JD; Servan-Schreiber, D; Rajkowski, J; Aston-Jones, G				Usher, M; Cohen, JD; Servan-Schreiber, D; Rajkowski, J; Aston-Jones, G			The role of locus coeruleus in the regulation of cognitive performance	SCIENCE			English	Article							NEURONS INVITRO; VISUAL-ATTENTION; RAT; INHIBITION; BEHAVIOR; POPULATION; MODULATION; VIGILANCE; CERULEUS; DYNAMICS	Noradrenergic locus coeruleus (LC) neurons were recorded in monkeys performing a visual discrimination task, and a computational model was developed addressing the role of the LC brain system in cognitive performance. Changes in spontaneous and stimulus-induced patterns of LC activity correlated closely with fluctuations in behavioral performance. The model explains these fluctuations in terms of changes in electrotonic coupling among LC neurons and predicts improved performance during epochs of high coupling and synchronized LC firing. Cross correlations of simultaneously recorded LC neurons confirmed this prediction, indicating that electronic coupling in LC may play an important role in attentional modulation and the regulation of goat-directed versus exploratory behaviors.	Univ Kent, Dept Psychol, Canterbury, Kent, England; Princeton Univ, Dept Psychol, Princeton, NJ 08540 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA	University of Kent; Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Aston-Jones, G (corresponding author), Univ Penn, VAMC 151, Dept Psychiat, Univ & Woodland Ave, Philadelphia, PA 19104 USA.	gaj@mailmed.upenn.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH045156, P01MH047566] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 55309, MH45156, MH47566] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELES M, 1982, ISRAEL J MED SCI, V18, P83; AGHAJANIAN GK, 1977, BRAIN RES, V136, P570, DOI 10.1016/0006-8993(77)90083-X; ASTONJONES G, 1994, J NEUROSCI, V14, P4467; BERNANDER O, 1994, NEURAL COMPUT, V6, P622, DOI 10.1162/neco.1994.6.4.622; CHRISTIE MJ, 1993, NEUROSCIENCE, V56, P129, DOI 10.1016/0306-4522(93)90568-Z; CHRISTIE MJ, 1989, J NEUROSCI, V9, P3584; Draguhn A, 1998, NATURE, V394, P189, DOI 10.1038/28184; EGAN TM, 1983, J PHYSIOL-LONDON, V345, P477, DOI 10.1113/jphysiol.1983.sp014990; Egeth HE, 1997, ANNU REV PSYCHOL, V48, P269, DOI 10.1146/annurev.psych.48.1.269; ENNIS M, 1986, BRAIN RES, V374, P299, DOI 10.1016/0006-8993(86)90424-5; FOOTE SL, 1980, P NATL ACAD SCI-BIOL, V77, P3033, DOI 10.1073/pnas.77.5.3033; FOOTE SL, 1983, PHYSIOL REV, V63, P844, DOI 10.1152/physrev.1983.63.3.844; GRANT SJ, 1988, BRAIN RES BULL, V21, P401, DOI 10.1016/0361-9230(88)90152-9; HARRIS GC, 1992, NEUROSCIENCE, V50, P253, DOI 10.1016/0306-4522(92)90420-7; HASSELMO ME, 1995, BEHAV BRAIN RES, V67, P1, DOI 10.1016/0166-4328(94)00113-T; Ishimatsu M, 1996, J NEUROSCI, V16, P5196; Ivanova S., 1997, Society for Neuroscience Abstracts, V23, P1587; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P227, DOI 10.1113/jphysiol.1984.sp015154; Kaelbling LP, 1996, J ARTIF INTELL RES, V4, P237, DOI 10.1613/jair.301; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P734, DOI 10.1085/jgp.59.6.734; Kuramoto Y., 1984, CHEM OSCILLATORS WAV; LLINAS R, 1974, J NEUROPHYSIOL, V37, P560, DOI 10.1152/jn.1974.37.3.560; MCCLELLAND JL, 1993, ATTENTION PERFORM, V14, P655; McMahon DG, 1996, BRAIN RES, V718, P89, DOI 10.1016/0006-8993(96)00043-1; MCMAHON DG, 1994, J NEUROPHYSIOL, V72, P2257, DOI 10.1152/jn.1994.72.5.2257; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; NELKEN I, 1990, BIOL CYBERN, V64, P51, DOI 10.1007/BF00203630; Niebur E, 1994, J Comput Neurosci, V1, P141, DOI 10.1007/BF00962722; OGREN SO, 1984, CATECHOLAMINES NEURO, P285; Osborne PB, 1996, J NEUROPHYSIOL, V76, P1559, DOI 10.1152/jn.1996.76.3.1559; RAJKOWSKI J, 1994, BRAIN RES BULL, V35, P607, DOI 10.1016/0361-9230(94)90175-9; RAYMOND JE, 1995, J EXP PSYCHOL HUMAN, V21, P653, DOI 10.1037/0096-1523.21.3.653; REEVES A, 1986, PSYCHOL REV, V93, P180, DOI 10.1037/0033-295X.93.2.180; Rumelhart D., 1986, PARALLEL DISTRIBUTED; SARA SJ, 1995, COGNITIVE BRAIN RES, V2, P181, DOI 10.1016/0926-6410(95)90007-1; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SELDEN NRW, 1990, BEHAV BRAIN RES, V39, P29, DOI 10.1016/0166-4328(90)90119-Y; SELDEN NRW, 1990, J NEUROSCI, V10, P531; SERVANSCHREIBER D, 1990, SCIENCE, V249, P892, DOI 10.1126/science.2392679; SHERMAN A, 1992, P NATL ACAD SCI USA, V89, P2471, DOI 10.1073/pnas.89.6.2471; SIEGLER RS, 1995, COGNITIVE PSYCHOL, V28, P225, DOI 10.1006/cogp.1995.1006; STROGATZ SH, 1991, J STAT PHYS, V63, P613, DOI 10.1007/BF01029202; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; Travagli R. A., 1994, Society for Neuroscience Abstracts, V20, P1734; TRAVAGLI RA, 1995, J NEUROPHYSIOL, V74, P519, DOI 10.1152/jn.1995.74.2.519; VANVREESWIJK C, 1994, J COMPUT NEUROSCI, V1, P303; WEICHSELGARTNER E, 1987, SCIENCE, V238, P778, DOI 10.1126/science.3672124	47	500	506	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1999	283	5401					549	554		10.1126/science.283.5401.549	http://dx.doi.org/10.1126/science.283.5401.549			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	159YM	9915705				2022-12-01	WOS:000078203300041
J	Chyb, S; Raghu, P; Hardie, RC				Chyb, S; Raghu, P; Hardie, RC			Polyunsaturated fatty acids activate the Drosophila light-sensitive channels TRP and TRPL	NATURE			English	Article							CAPACITATIVE CALCIUM-ENTRY; PROTEIN-KINASE-C; ARACHIDONIC-ACID; CATION CHANNELS; PHOTORECEPTORS; CA2+; PHOTOTRANSDUCTION; EXPRESSION; MUTANTS; GENE	Phototransduction in invertebrate microvillar photoreceptors is thought to be mediated by the activation of phospholipase C (PLC), but how this leads to gating of the light-sensitive channels is unknown(1,2). Most attention has focused on inositol-1,4,5-trisphosphate, a second messenger produced by PLC from phosphatidylinositol-4,5-bisphosphate; however, PLC also generates diacylglycerol, a potential precursor for several polyunsaturated fatty acids, such as arachidonic acid and linolenic acid. Here we show that both of these fatty acids reversibly activate native light-sensitive channels (transient receptor potential (TRP) and TRP-like (TRPL)) in Drosophila photoreceptors as well as recombinant TRPL channels expressed in Drosophila S2 cells. Recombinant channels are activated rapidly in both whole-cell recordings and inside-out patches, with a half-maximal effector concentration for linolenic acid of similar to 10 mu M Four different Lipoxygenase inhibitors, which might be expected to lead to build-up of endogenous fatty [GRAPHICS] acids, also activate native TRP and TRPL channels in intact photoreceptors, As arachidonic acid may not be found in Drosophila, we suggest that another polyunsaturated fatty acid, such as linolenic acid, may be a messenger of excitation in Drosophila photoreceptors.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	University of Cambridge	Hardie, RC (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.	rch14@hermes.cam.ac.uk	Padinjat, Raghu/Z-5578-2019; Chyb, Sylwester/B-5783-2009	Hardie, Roger/0000-0001-5531-3264	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; Hardie RC, 1997, CELL CALCIUM, V21, P431, DOI 10.1016/S0143-4160(97)90054-3; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; KARNOVSKY MJ, 1982, J CELL BIOL, V94, P1, DOI 10.1083/jcb.94.1.1; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; Pearn MT, 1996, J BIOL CHEM, V271, P4937; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Shim K, 1997, EXP EYE RES, V65, P717, DOI 10.1006/exer.1997.0383; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STARK WS, 1993, LIPIDS, V28, P345, DOI 10.1007/BF02536321; VANDERZEE L, 1995, BIOCHEM J, V305, P859, DOI 10.1042/bj3050859; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V98, P657, DOI 10.1093/oxfordjournals.jbchem.a135322; Zimmer S, 1997, N-S ARCH PHARMACOL, V355, P238	30	335	343	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					255	259		10.1038/16703	http://dx.doi.org/10.1038/16703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930700				2022-12-01	WOS:000078184800053
J	Hill, AF; Butterworth, RJ; Joiner, S; Jackson, G; Rossor, MN; Thomas, DJ; Frosh, A; Tolley, N; Bell, JE; Spencer, M; King, A; Al-Sarraj, S; Ironside, JW; Lantos, PL; Collinge, J				Hill, AF; Butterworth, RJ; Joiner, S; Jackson, G; Rossor, MN; Thomas, DJ; Frosh, A; Tolley, N; Bell, JE; Spencer, M; King, A; Al-Sarraj, S; Ironside, JW; Lantos, PL; Collinge, J			Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples	LANCET			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; STRAIN VARIATION; SCRAPIE; MICE; CJD; BSE; DIAGNOSIS; PROTEINS; ISOFORM; AGENT	Background Prion diseases are associated with the accumulation of an abnormal isoform of cellular prion protein (PrP(Sc)), which is the principal constituent of prions. Prions replicate in lymphoreticular tissues before neuroinvasion, suggesting that lymphoreticular biopsy samples may allow early diagnosis by detection of PrP(Sc) Variant Creutzfeldt-Jakob disease (variant CJD) is difficult to distinguish from common psychiatric disorders in its early stages and definitive diagnosis has relied on neuropathology. We studied lymphoreticular tissues from a necropsy series and assessed tonsillar biopsy samples as a diagnostic investigation for human prion disease. Methods Lymphoreticular tissues (68 tonsils, 64 spleens, and 40 lymph nodes) were obtained at necropsy from patients affected by prion disease and from neurological and normal controls. Tonsil biopsy sampling was done on 20 patients with suspected prion disease. Tissues were analysed by western blot to detect and type PrP(Sc), by PrP immunohistochemistry, or both. Findings All lymphoreticular tissues obtained at necropsy from patients with neuropathologically confirmed variant CJD, but not from patients with other prion diseases or controls, were positive for PrP(Sc). In addition, PrP(Sc) typing revealed a consistent pattern (designated type 4t) different from that seen in variant CJD brain (type 4) or in brain from other CJD subtypes (types 1-3). Tonsil biopsy tissue was positive in all eight patients with an adequate biopsy sample and whose subsequent course has confirmed, or is highly consistent with, a diagnosis of variant CJD and negative in all patients subsequently confirmed to have other diagnoses. Interpretation We found that if, in the appropriate clinical context, a tonsil biopsy sample was positive for PrP(Sc), variant CJD could be diagnosed, which obviates the need for a brain biopsy sample to be taken. Our results also show that variant CJD has a different pathogenesis to sporadic CJD.	St Marys Hosp, Imperial Coll Sch Med, Dept Neurogenet, London W2 1PG, England; St Marys Hosp, Specialist Prion Dis Clin, London W2 1PG, England; St Marys Hosp, Dept Neurol, London W2 1PG, England; St Marys Hosp, Dept Ear Nose & Throat Surg, London W2 1PG, England; Natl CJG Surveillance Unit, Edinburgh, Midlothian, Scotland; Inst Psychiat, Dept Neuropathol, London, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of London; King's College London	Collinge, J (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Neurogenet, Praed St, London W2 1PG, England.	j.collinge@ic.ac.uk	Hill, Andrew F./AAH-2854-2020; Rossor, Martin/C-1598-2008; Hill, Andrew F/B-4527-2009; Hill, Andrew/GZL-4124-2022	Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Hill, Andrew/0000-0001-5581-2354; Ironside, James/0000-0001-5869-2108; Jackson, Graham/0000-0002-3125-2011; Spencer, Michael/0000-0002-1646-5254; Rossor, Martin/0000-0001-8215-3120	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ADV COMM DANG PAT, 1998, TRANSM SPONG ENC AG; Bell JE, 1997, NEUROPATH APPL NEURO, V23, P26, DOI 10.1111/j.1365-2990.1997.tb01182.x; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; Brown P, 1995, Curr Opin Hematol, V2, P472; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUDKA H, 1995, BRAIN PATHOL, V5, P319, DOI 10.1111/j.1750-3639.1995.tb00609.x; CLARKE MC, 1994, RES VET SCI, V9, P215; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Collinge J, 1997, HUM MOL GENET, V6, P1699, DOI 10.1093/hmg/6.10.1699; Collinge J, 1998, NAT MED, V4, P1369, DOI 10.1038/3955; ESMONDE TFG, 1993, LANCET, V341, P205, DOI 10.1016/0140-6736(93)90068-R; FRASER H, 1992, E H S NEURO, P308; FRASER H, 1987, VET MICROBIOL, V13, P211, DOI 10.1016/0378-1135(87)90084-8; GOODBRAND IA, 1995, NEUROSCI LETT, V183, P127, DOI 10.1016/0304-3940(94)11131-2; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kawashima T, 1997, LANCET, V350, P68, DOI 10.1016/S0140-6736(05)66274-5; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; Lasmezas CI, 1996, J VIROL, V70, P1292; Murthy P, 1998, J LARYNGOL OTOL, V112, P41, DOI 10.1017/S0022215100139866; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Schreuder BEC, 1998, VET REC, V142, P564, DOI 10.1136/vr.142.21.564; STETLERSTEVENSO.M, 1998, MAJOR PROBLEMS PATHO, P22; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; WELLS GAH, 1994, VET REC, V135, P40, DOI 10.1136/vr.135.2.40; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2	35	539	551	0	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					183	189		10.1016/S0140-6736(98)12075-5	http://dx.doi.org/10.1016/S0140-6736(98)12075-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923873				2022-12-01	WOS:000078175600010
J	Prescott, SL; Macaubas, C; Smallacombe, T; Holt, BJ; Sly, PD; Holt, PG				Prescott, SL; Macaubas, C; Smallacombe, T; Holt, BJ; Sly, PD; Holt, PG			Development of allergen-specific T-cell memory in atopic and normal children	LANCET			English	Article							POSTNATAL MATURATION; INTERFERON-GAMMA; EARLY-CHILDHOOD; ASTHMA; RESPONSES; COMPETENCE; PREVALENCE; INDUCTION; DISEASES; INFANCY	Background In the past 20-30 years, there has been an increase in prevalence of allergic respiratory diseases, particularly amongst children. This study is a prospective analysis of the postnatal maturation of T-helper cell (Th) responses to aeroallergens in atopic and non-atopic infants. Methods We measured mononuclear-cell proliferative and cytokine responses to specific allergens and tetanus toroid in blood samples from atopic and non-atopic infants every 6 months from birth to 2 years of age. Cytokine analyses of responses to housedust-mite allergen used ELISA and reverse-transcriptase PCR. We also measured responses to Fel dl(cat allergen) and tetanus toroid. Findings Samples from 18 atopic and 13 non-atopic infants showed low-level Th2-skewed allergen-specific responses at birth, with little accompanying specific interferon-gamma production. Neonatal Th2 responses were lower in the atopic group than in the non-atopic group; the differences were significant for interleukin-4 (mRNA: beta-actin ratio 0.48 [SE 0.15] vs 0.15 [0.06], p=0.049), interleukin-6 (4750 [48] vs 1352 [51] pg/mL culture fluid, p=0.003), interleukin-10 (1162 [228] vs 485 [89], p=0.015), and interleukin-13 (7.1 [0.9] vs 0.9 [0.3], p=0.008). There was rapid suppression of Th2 responses during the first year of life in non-atopic children, but there was consolidation of responses in atopic children, associated with defective neonatal interferon-gamma production. Interpretation The continuation of fetal allergen-specific Th2 responses during infancy is a defining feature of the inductive phase of atopic disease, and is associated with decreased capacity for production of the Th1 cytokine interferon gamma by atopic neonates. These findings provide a plausible mechanism for persistence of the fetal Th2 responses during early childhood in atopic individuals and subsequent expression of disease.	TVW Telethon Inst Child Hlth Res, Div Cell Biol, W Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia	Holt, PG (corresponding author), TVW Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, W Perth, WA 6872, Australia.		Prescott, Susan/H-5665-2014; Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201				HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Piccinni MP, 1996, EUR J IMMUNOL, V26, P2293, DOI 10.1002/eji.1830261004; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75, DOI 10.1159/000237512; Prescott SL, 1998, J IMMUNOL, V160, P4730; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sudo N, 1997, J IMMUNOL, V159, P1739; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x	23	699	714	0	26	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					196	200		10.1016/S0140-6736(98)05104-6	http://dx.doi.org/10.1016/S0140-6736(98)05104-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923875				2022-12-01	WOS:000078175600012
J	Andersson, R; Lambe, M; Bergstrom, R				Andersson, R; Lambe, M; Bergstrom, R			Fertility patterns after appendicectomy: historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							SUSPECTED APPENDICITIS; TUBAL INFERTILITY; APPENDECTOMY; WOMEN; PERFORATION; LAPAROSCOPY; RISK; AGE	Objective To examine fertility patterns in women who had their appendix removed in childhood. Design Historical cohort study with computerised data and fertility data for this cohort and for an age matched cohort of women from the Swedish general population. The cohorts were followed to 1994, Setting General population. Participants 9840 women who were under 15 years when they underwent appendicectomy between 1964 and 1983; 47 590 control women, Main outcome measures Diagnoses at discharge. Distributions of age at birth of first child among women with perforated and non-perforated appendix and women who underwent appendicectomy but were found Co have a normal appendix compared with control women by using survival analysis methods. Parity distributions at the latest update of the registry were also examined, Results Women with a history of perforated appendix had a similar rate of first birth as the control women (adjusted hazard ratio 0.95; 95% confidence interval 0.88 to 1.04) and had a similar distribution of parity at the end of follow up. Women who had had a normal appendix removed had an increased rate of first births (1.48; 1.42 to 1.54) and on average had their first child at an earlier age and reached a higher parity than control women. Conclusion A history of perforated appendix in childhood does not seem to have long term negative consequences on female fertility. This may have important implications for the management of young women with suspected appendicitis as the liberal attitude to surgical explorations with a subsequently high rate of removal of a normal appendix is often justified by a perceived increased risk of infertility after perforation. Women whose appendix was found to be normal at appendicectomy in childhood seem to belong to a subgroup with a higher fertility than the general population.	Univ Hosp, Div Surg, Linkoping, Sweden; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden; Uppsala Univ, Dept Stat, Uppsala, Sweden	Karolinska Institutet; Uppsala University	Andersson, R (corresponding author), Ryhov Hosp, Dept Surg, S-55185 Jonkoping, Sweden.			Lambe, Mats/0000-0002-4624-3767				ANDERSSON R, 1994, BRIT MED J, V308, P107, DOI 10.1136/bmj.308.6921.107; ANDERSSON RE, 1992, EUR J SURG, V158, P37; BULL P, 1932, ACTA CHIR SCAND, V71, P155; CANTON G, 1984, GEN HOSP PSYCHIAT, V6, P191, DOI 10.1016/0163-8343(84)90039-2; Geerdsen J P, 1988, Nord Med, V103, P62; HOFFMANN J, 1989, BRIT J SURG, V76, P774, DOI 10.1002/bjs.1800760803; JADALLAH FA, 1994, EUR J SURG, V160, P41; JOYCE PR, 1981, AUST NZ J SURG, V51, P465, DOI 10.1111/j.1445-2197.1981.tb05987.x; KALLEN B, 1988, EPIDEMIOLOGY HUMAN R, P107; KUM CK, 1993, BRIT J SURG, V80, P1599, DOI 10.1002/bjs.1800801236; LALOS O, 1988, EUR J OBSTET GYN R B, V29, P129, DOI 10.1016/0028-2243(88)90139-6; MALT RA, 1986, NEW ENGL J MED, V315, P1546, DOI 10.1056/NEJM198612113152409; MUELLER BA, 1986, NEW ENGL J MED, V315, P1506, DOI 10.1056/NEJM198612113152402; PURI P, 1989, J PEDIATR SURG, V24, P547, DOI 10.1016/S0022-3468(89)80503-2; RAAF LE, 1969, ACTA CHIR SCAND, V135, P67; SPIRTOS NM, 1987, AM J OBSTET GYNECOL, V156, P90, DOI 10.1016/0002-9378(87)90212-2; THOMPSON WM, 1971, J PEDIATR SURG, V6, P458, DOI 10.1016/S0022-3468(71)80008-8; TRIMBOSKEMPER T, 1982, FERTIL STERIL, V37, P384; VASSILAS CA, 1988, BRIT J PSYCHIAT, V152, P706, DOI 10.1192/bjp.152.5.706; WIIG JN, 1979, ACTA CHIR SCAND, V145, P409	20	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					963	967		10.1136/bmj.318.7189.963	http://dx.doi.org/10.1136/bmj.318.7189.963			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195964	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000079751500016
J	Lin, Y; Sun, L; Nguyen, LV; Rachubinski, RA; Goodman, HM				Lin, Y; Sun, L; Nguyen, LV; Rachubinski, RA; Goodman, HM			The pex16p homolog SSE1 and storage organelle formation in Arabidopsis seeds	SCIENCE			English	Article							YEAST YARROWIA-LIPOLYTICA; PEROXISOME BIOGENESIS; THALIANA; PROTEIN; MUTANTS; PLANTS; BODIES	Mature Arabidopsis seeds are enriched in storage proteins and lipids, but lack starch. In the shrunken seed 1 (sse1) mutant, however, starch is favored over proteins and lipids as the major storage compound. SSE1 has 26 percent identity with Pex16p in Yarrowia lipolytica and complements pex16 mutants defective in the formation of peroxisomes and the transportation of plasma membrane- and cell wall-associated proteins, In Arabidopsis maturing seeds, SSE1 is required for protein and oil body biogenesis, both of which are endoplasmic reticulum-dependent. Starch accumulation in sse1 suggests that starch formation is a default storage deposition pathway.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Univ Alberta, Dept Anat & Cell Biol, Edmonton, AB T6G 2H7, Canada	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Alberta	Lin, Y (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEWLEY DJ, 1994, SEEDS PHYSL DEV GERM, pCH1; Chen ZJ, 1998, AM J BOT, V85, P492, DOI 10.2307/2446432; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; Huang AHC, 1996, PLANT PHYSIOL, V110, P1055, DOI 10.1104/pp.110.4.1055; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; MANSFIELD SG, 1992, CAN J BOT, V70, P151, DOI 10.1139/b92-021; MEINKE DW, 1994, PLANT CELL, V6, P1049, DOI 10.1105/tpc.6.8.1049; MINET M, 1992, PLANT J, V2, P417; Miquel M., 1995, SEED DEV GERMINATION, P169; OLSEN LJ, 1995, ANNU REV PLANT PHYS, V46, P123, DOI 10.1146/annurev.pp.46.060195.001011; Sarmiento C, 1997, PLANT J, V11, P783, DOI 10.1046/j.1365-313X.1997.11040783.x; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; Vitale A., 1995, SEED DEV GERMINATION, P73	17	86	108	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					328	330		10.1126/science.284.5412.328	http://dx.doi.org/10.1126/science.284.5412.328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195899				2022-12-01	WOS:000079636400045
J	Struhl, G; Greenwald, I				Struhl, G; Greenwald, I			Presenilin is required for activity and nuclear access of Notch in Drosophila	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE; IN-VIVO; RECEPTOR; LIN-12; GENE; EXPRESSION; CLEAVAGE; HOMOLOG	Presenilins are membrane proteins with multiple transmembrane domains that are thought to contribute to the development of Alzheimer's disease by affecting the processing of P-amyloid precursor protein(1). Presenilins also facilitate the activity of transmembrane receptors of the LIN-12/Notch family(2-5). After ligand-induced processing, the intracellular domain of LIN-12/Notch can enter the nucleus and participate in the transcriptional control of downstream target genes(6-9). Here we show that null mutations in the Drosophila Presenilin gene abolish Notch signal transduction and prevent its intracellular domain from entering the nucleus. Furthermore, we provide evidence that presenilin is required for the proteolytic release of the intracellular domain from the membrane following activation of Notch by ligand.	Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Struhl, G (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA.	struhl@cuccfa.ccc.columbia; greenwald@cuccfa.ccc.columbia.edu						BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Boulianne GL, 1997, NEUROREPORT, V8, P1025, DOI 10.1097/00001756-199703030-00041; CHOU TB, 1992, GENETICS, V131, P643; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; Hong CS, 1997, NEUROREPORT, V8, P665, DOI 10.1097/00001756-199702100-00017; Huppert SS, 1997, DEVELOPMENT, V124, P3283; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Levitan D, 1998, DEVELOPMENT, V125, P3599; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; LI XQ, 1994, PHYS PLASMAS, V1, P3008, DOI 10.1063/1.870541; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Marfany G, 1998, J NEUROGENET, V12, P41, DOI 10.3109/01677069809108554; MENNE TV, 1994, DEVELOPMENT, V120, P123; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5	28	689	722	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	1999	398	6727					522	525		10.1038/19091	http://dx.doi.org/10.1038/19091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206646				2022-12-01	WOS:000079662800050
J	Nightingale, SL				Nightingale, SL			New information for physicians regarding mammography results	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1164	1164		10.1001/jama.281.13.1164	http://dx.doi.org/10.1001/jama.281.13.1164			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199413				2022-12-01	WOS:000079464400008
J	Brose, K; Bland, KS; Wang, KH; Arnott, D; Henzel, W; Goodman, CS; Tessier-Lavigne, M; Kidd, T				Brose, K; Bland, KS; Wang, KH; Arnott, D; Henzel, W; Goodman, CS; Tessier-Lavigne, M; Kidd, T			Slit proteins bind robe receptors and have an evolutionarily conserved role in repulsive axon guidance	CELL			English	Article							GROWTH CONE GUIDANCE; FLOOR-PLATE; IMMUNOGLOBULIN SUPERFAMILY; EXTRACELLULAR PROTEIN; COMMISSURAL AXONS; SPINAL-CORD; ENCODES; MIDLINE; DROSOPHILA; HEDGEHOG	Extending axons in the developing nervous system are guided in part by repulsive cues. Genetic analysis in Drosophila, reported in a companion to this paper, identifies the Slit protein as a candidate ligand for the repulsive guidance receptor Roundabout (Robo). Here we describe the characterization of three mammalian Slit homologs and show that the Drosophila Slit protein and at least one of the mammalian Slit proteins, Slit2, are proteolytically processed and show specific, high-affinity binding to Robe proteins. Furthermore, recombinant Slit2 can repel embryonic spinal motor axons in cell culture. These results support the hypothesis that Slit proteins have an evolutionarily conserved role in axon guidance as repulsive ligands for Robe receptors.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Roche Holding; Genentech	Tessier-Lavigne, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA.	marctl@itsa.ucsf.edu	Wang, Kuan Hong/J-1150-2016; Kidd, Thomas/AAT-9993-2020	Wang, Kuan Hong/0000-0002-2249-5417; Henzel, William/0000-0003-2940-3797; Kidd, Thomas/0000-0001-7190-4208; Bland, Kimberly/0000-0003-4863-6772				Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BACHARVET KTN, 1999, IN PRESS NEURON; BLEBER AJ, 1994, METHOD CELL BIOL, P683; Bumcrot DA, 1996, CHEM BIOL, V3, P13, DOI 10.1016/S1074-5521(96)90077-0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GUTHRIE S, 1995, NEURON, V14, P1117, DOI 10.1016/0896-6273(95)90260-0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Itoh A, 1998, MOL BRAIN RES, V62, P175, DOI 10.1016/S0169-328X(98)00224-1; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lentz SI, 1997, J COMP NEUROL, V378, P547, DOI 10.1002/(SICI)1096-9861(19970224)378:4<547::AID-CNE9>3.0.CO;2-2; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; ROTHBERG JM, 1992, J MOL BIOL, V227, P367, DOI 10.1016/0022-2836(92)90891-M; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2	39	929	991	1	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	1999	96	6					795	806		10.1016/S0092-8674(00)80590-5	http://dx.doi.org/10.1016/S0092-8674(00)80590-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102268	Bronze			2022-12-01	WOS:000079300100007
J	Wang, KH; Brose, K; Arnott, D; Kidd, T; Goodman, CS; Henzel, W; Tessier-Lavigne, M				Wang, KH; Brose, K; Arnott, D; Kidd, T; Goodman, CS; Henzel, W; Tessier-Lavigne, M			Biochemical purification of a mammalian slit protein as a positive regulator of sensory axon elongation and branching	CELL			English	Article							NERVE GROWTH-FACTOR; SPINAL-CORD; NEURONS; BRAIN; NEUROTROPHIN-3; PROJECTIONS; INDUCTION; GUIDANCE; CULTURE; SYSTEM	Many neurons in both vertebrates and invertebrates innervate multiple targets by sprouting secondary axon collaterals (or branches) from a primary axon shaft. To begin to identify molecular regulators of axon branch initiation or extension, we studied the growth of single sensory axons in an in vitro collagen assay system and identified an activity in extracts of embryonic spinal cord and of postnatal and adult brain that promotes the elongation and formation of extensive branches by these axons. Biochemical purification of the activity from calf brain extracts led to the identification of an amino-terminal fragment of Slit2 as the main active component and to the discovery of a distinct activity that potentiates its effects. These results indicate that Slit proteins may function as positive regulators of axon collateral formation during the establishment or remodeling of neural circuits.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Genentech Inc, Dept Prot Chem, S San Francisco, CA 94080 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Roche Holding; Genentech	Tessier-Lavigne, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA.		Kidd, Thomas/AAT-9993-2020; Wang, Kuan Hong/J-1150-2016	Wang, Kuan Hong/0000-0002-2249-5417; Kidd, Thomas/0000-0001-7190-4208; Henzel, William/0000-0003-2940-3797				ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; Arnott D, 1998, ELECTROPHORESIS, V19, P968, DOI 10.1002/elps.1150190612; Arnott D, 1998, ANAL BIOCHEM, V258, P1, DOI 10.1006/abio.1998.2566; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; CAMPENOT RB, 1982, DEV BIOL, V93, P1, DOI 10.1016/0012-1606(82)90232-9; Castellani V, 1998, J NEUROSCI, V18, P4663; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; DIAMOND J, 1992, J NEUROSCI, V12, P1454; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gallo G, 1998, J NEUROSCI, V18, P5403, DOI 10.1523/JNEUROSCI.18-14-05403.1998; HARRIS WA, 1985, J NEUROSCI RES, V13, P101, DOI 10.1002/jnr.490130108; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HENZEL WJ, 1995, CURRENT PROTOCOLS PR, V1; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; HORYLEE F, 1993, P NATL ACAD SCI USA, V90, P2613, DOI 10.1073/pnas.90.7.2613; Itoh A, 1998, MOL BRAIN RES, V62, P175, DOI 10.1016/S0169-328X(98)00224-1; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; Lentz SI, 1999, J NEUROSCI, V19, P1038; LEVIMONTALCINI R, 1964, ANN NY ACAD SCI, V118, P149, DOI 10.1111/j.1749-6632.1964.tb33978.x; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; O'Leary D D, 1992, Curr Opin Neurobiol, V2, P70, DOI 10.1016/0959-4388(92)90165-H; OAKLEY RA, 1995, DEVELOPMENT, V121, P1341; OLEARY DDM, 1990, COLD SH Q B, V55, P453; Ozaki S, 1997, J COMP NEUROL, V380, P215; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; SATO M, 1994, NEURON, V13, P791, DOI 10.1016/0896-6273(94)90246-1; SCOTT SA, 1993, J COMP NEUROL, V337, P277, DOI 10.1002/cne.903370208; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; White FA, 1998, J NEUROSCI, V18, P1428; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Yang XM, 1998, J NEUROSCI, V18, P8369; YU WQ, 1994, J NEUROSCI, V14, P5872; ZHANG L, 1994, J NEUROSCI, V14, P5187	45	396	427	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	1999	96	6					771	784		10.1016/S0092-8674(00)80588-7	http://dx.doi.org/10.1016/S0092-8674(00)80588-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102266	Bronze			2022-12-01	WOS:000079300100005
J	Hojo, M; Morimoto, T; Maluccio, M; Asano, T; Morimoto, K; Lagman, M; Shimbo, T; Suthanthiran, M				Hojo, M; Morimoto, T; Maluccio, M; Asano, T; Morimoto, K; Lagman, M; Shimbo, T; Suthanthiran, M			Cyclosporine induces cancer progression by a cell-autonomous mechanism	NATURE			English	Article							GROWTH-FACTOR-BETA; MONOCLONAL-ANTIBODIES; CARCINOMA; TUMOR; EXPRESSION; THERAPY; MICE; TRANSPLANTATION; FACTOR-BETA-1; INTERLEUKIN-2	Malignancy is a common and dreaded complication following, organ transplantation(1-4). The high incidence of neoplasm and its aggressive progression, which are associated with immunosuppressive therapy, are thought to be due to the resulting impairment of the organ recipient's immune-surveillance system(5-9). Here we report a mechanism for the heightened malignancy that is independent of host immunity. We show that cyclosporine (cyclosporin A), an immunosuppressant that has had a major impact on improving patient outcome following organ transplantation(4,5), induces phenotypic changes, including invasiveness of non-transformed cells, by a cell-autonomous mechanism. Our studies show that cyclosporine treatment of adenocarcinoma cells results in striking morphological alterations, including membrane ruffling and numerous pseudopodial protrusions, increased cell motility, and anchorage-independent (invasive) growth. These changes are prevented by treatment with monoclonal antibodies directed at transforming growth factor-beta (TGF-beta). In vivo, cyclosporine enhances tumour growth in immunodeficient SCID-beige Mice; anti-TGF-beta monoclonal antibodies but not control antibodies prevent the cyclosporine-induced increase in the number of metastases. Our findings suggest that immunosuppressants like cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host's immune cells, and that cyclosporine-induced TGF-beta production is involved in this.	Cornell Univ, Weill Med Coll, Dept Transplantat Med & Extracorporeal Therapy, Div Nephrol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA; Teikyo Univ, Sch Med, Mizonokuchi Hosp, Dept Pediat,Takatsu Ku, Kawasaki, Kanagawa 213, Japan; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Natl Def Med Coll, Dept Urol, Tokorozawa, Saitama 359, Japan	Cornell University; Cornell University; Cornell University; Teikyo University; New York University; National Defense Medical College - Japan	Hojo, M (corresponding author), Cornell Univ, Weill Med Coll, Dept Transplantat Med & Extracorporeal Therapy, Div Nephrol, 525 E 68th St, New York, NY 10021 USA.		Suthanthiran, Manikkam/AAL-9104-2020					ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Asano T, 1997, J UROLOGY, V157, P2396, DOI 10.1016/S0022-5347(01)64787-6; ATREGA CI, 1993, J CLIN INVEST, V92, P2569; BERTRAM JS, 1980, CANCER LETT, V11, P63, DOI 10.1016/0304-3835(80)90130-5; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; COHENGOULD L, 1987, AM J PATHOL, V127, P327; COUCHMAN JR, 1985, EUR J CELL BIOL, V36, P182; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DASCH JR, 1989, J IMMUNOL, V142, P1536; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GUIRGUIS R, 1987, NATURE, V329, P261, DOI 10.1038/329261a0; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KHANNA A, 1994, TRANSPLANTATION, V57, P577; LI B, 1991, J EXP MED, V174, P1259, DOI 10.1084/jem.174.5.1259; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUHARA M, 1993, CARCINOGENESIS, V14, P1579, DOI 10.1093/carcin/14.8.1579; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; MOSIER DE, 1993, J EXP MED, V177, P191, DOI 10.1084/jem.177.1.191; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; SHIMIZU T, 1989, IMMUNOBIOLOGY, V178, P401, DOI 10.1016/S0171-2985(89)80062-2; SUTHANTHIRAN M, 1994, NEW ENGL J MED, V331, P365, DOI 10.1056/NEJM199408113310606; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; VANDERELST J, 1986, J NATL CANCER I, V77, P227; VandeVrie W, 1997, J CANCER RES CLIN, V123, P21, DOI 10.1007/BF01212610; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WOLF G, 1995, TRANSPLANTATION, V60, P237, DOI 10.1097/00007890-199508000-00005; YOKOYAMA I, 1991, CANCER, V68, P2095, DOI 10.1002/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y	30	871	917	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					530	534		10.1038/17401	http://dx.doi.org/10.1038/17401			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028970				2022-12-01	WOS:000078574900052
J	Kerschbaum, HH; Cahalan, MD				Kerschbaum, HH; Cahalan, MD			Single-channel recording of a store-operated Ca2+ channel in Jurkat T lymphocytes	SCIENCE			English	Article							CALCIUM CHANNELS; MAST-CELLS; DEPLETION; CONDUCTANCE; PERMEATION; CATIONS; MUSCLE	In T Lymphocytes, a store-operated calcium ion (Ca2+) entry mechanism termed the calcium release-activated Ca2+ channel (CRAC channel) underlies the sustained or oscillatory intracellular calcium concentration signal required for interleukin-2 gene expression and cell proliferation. The use of sodium ions as a current carrier enabled single-channel recordings of CRAC channels during activation, inactivation, and blockade of current in the presence of divalent cations. A Large conductance of 36 to 40 picosiemens indicates that 100 to 400 CRAC channels are present in T Lymphocytes.	Salzburg Univ, Inst Zool, Dept Anim Physiol, A-5020 Salzburg, Austria; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	Salzburg University; University of California System; University of California Irvine	Cahalan, MD (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS014609, R01NS014609] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41514] Funding Source: Medline; NINDS NIH HHS [NS-14609] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; BERS D, 1994, METHODS CELL BIOL, V40; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; KERSCHBAUM HH, UNPUB; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	14	128	135	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 5	1999	283	5403					836	839		10.1126/science.283.5403.836	http://dx.doi.org/10.1126/science.283.5403.836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933165				2022-12-01	WOS:000078496800042
J	Peled, A; Petit, I; Kollet, O; Magid, M; Ponomaryov, T; Byk, T; Nagler, A; Ben-Hur, H; Many, A; Shultz, L; Lider, O; Alon, R; Zipori, D; Lapidot, T				Peled, A; Petit, I; Kollet, O; Magid, M; Ponomaryov, T; Byk, T; Nagler, A; Ben-Hur, H; Many, A; Shultz, L; Lider, O; Alon, R; Zipori, D; Lapidot, T			Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4	SCIENCE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; BONE-MARROW; MULTILINEAGE HEMATOPOIESIS; IMMUNODEFICIENT MICE; SCID MICE; IN-VIVO; SDF-1; GENE; CHEMOATTRACTANT; MOUSE	Stem cell homing and repopulation are not well understood. The chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 were found to be critical for murine bone marrow engraftment by human severe combined immunodeficient (SCID) repopulating stem cells. Treatment of human cells with antibodies to CXCR4 prevented engraftment. In vitro CXCR4-dependent migration to SDF-1 of CD34(+)CD38(-/low) cells correlated with in vivo engraftment and stem cell function. Stem cell factor and interleukin-6 induced CXCR4 expression on CD34(+) cells, which potentiated migration to SDF-1 and engraftment in primary and secondary transplanted mice. Thus, up-regulation of CXCR4 expression may be useful for improving engraftment of repopulating stem cells in clinical transplantation.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel; Sourasky Med Ctr, IL-64239 Tel Aviv, Israel; Jackson Lab, Bar Harbor, ME 04609 USA	Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Jackson Laboratory	Lapidot, T (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	litsvee@weizmann.weizmann.ac.il	Petit, isabelle/AAF-5620-2020; Lapidot, Tsvee/A-1812-2010; ALON, RONEN/GRX-6987-2022; Kollet, Orit/A-6861-2008	Petit, isabelle/0000-0002-9782-0683; Alon, Ronen/0000-0001-9161-6369	PHS HHS [A130389] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Cashman JD, 1997, BLOOD, V89, P4307, DOI 10.1182/blood.V89.12.4307; Christianson SW, 1997, J IMMUNOL, V158, P3578; Civin CI, 1996, BLOOD, V88, P4102, DOI 10.1182/blood.V88.11.4102.bloodjournal88114102; Deichmann M, 1997, BLOOD, V89, P3522, DOI 10.1182/blood.V89.10.3522.3522_3522_3528; Kim CH, 1998, BLOOD, V91, P100, DOI 10.1182/blood.V91.1.100.100_100_110; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cellbio.11.1.35; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NOLTA JA, 1994, BLOOD, V83, P3041, DOI 10.1182/blood.V83.10.3041.3041; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Sawada S, 1998, J EXP MED, V187, P1439, DOI 10.1084/jem.187.9.1439; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Sutherland H J, 1995, J Hematother, V4, P3, DOI 10.1089/scd.1.1995.4.3; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	20	1385	1504	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1999	283	5403					845	848		10.1126/science.283.5403.845	http://dx.doi.org/10.1126/science.283.5403.845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	165AT	9933168				2022-12-01	WOS:000078496800045
J	Coker, WJ; Bhatt, BM; Blatchley, NF; Graham, JT				Coker, WJ; Bhatt, BM; Blatchley, NF; Graham, JT			Clinical findings for the first 1000 Gulf war veterans in the Ministry of Defence's medical assessment programme	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To review the clinical findings in the first 1000 veterans seen in the Ministry of Defence's Gulf war medical assessment programme to examine whether there was a particular illness related to service in the Gulf. Design Case series of 1000 veterans who presented to the programme between 11 October 1993 and 24 February 1997. Subjects Gulf war veterans. Main outcome measures Diagnosis of veterans' conditions according to ICD-10 (international classification of diseases, 10th revision). Cases referred for psychiatric assessment were reviewed for available diagnostic information from consultant psychiatrists. Results 588 (59%) veterans had more than one diagnosed condition, 387 (39%) had at least one condition for which no firm somatic or psychological diagnosis could be given, and in 90 (9%) veterans no other main diagnosis was made. Conditions characterised by fatigue were found in 239 (24%) of patients. At least 190 (19%) patients had a psychiatric condition, which in over half was due to post-traumatic stress disorder. Musculoskeletal disorders and respiratory conditions were also found to be relatively common (in 182 (18%) and 155 (16%) patients respectively). Conclusion Many Gulf war veterans had a wide variety of symptoms. This initial review shows no evidence or-a single illness, psychological or physical, to explain the pattern of symptoms seen in veterans in the assessment programme. As the veterans assessed by the programme were all self selected, the prevalence of illness in Gulf war veterans cannot be determined from this study. Furthermore, it is not known whether the veterans in this study were representative of sick veterans as a group.	Minist Def, Gulf Vet Illness Unit, London SW1A 2HB, England; RAF, British Def Staff, Washington, DC 20002 USA; Dutchess Kent Hosp, Catterick Garrison DL9 4DF, N Yorkshire, England		Blatchley, NF (corresponding author), Minist Def, Gulf Vet Illness Unit, Room 8276, London SW1A 2HB, England.	sma-mod.uk@btinternet.com						BEALE P, 1994, BRIT MED J, V308, P1574, DOI 10.1136/bmj.308.6943.1574c; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; *I MED, 1998, AD DEP VET AFF PERS; *IOW PERS GULF STU, 1997, JAMA-J AM MED ASSOC, V277, P238; Joseph SC, 1997, MIL MED, V162, P149; REVELL T, 1995, BRIT MED J, V310, P1073, DOI 10.1136/bmj.310.6986.1073a; WEATHERALL DJ, 1996, OXFORD TXB MED, P1035	9	79	81	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	1999	318	7179					290	296		10.1136/bmj.318.7179.290	http://dx.doi.org/10.1136/bmj.318.7179.290			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924053	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000078436700021
J	Widell, A; Christensson, B; Wiebe, T; Schalen, C; Hansson, HB; Allander, T; Persson, MAA				Widell, A; Christensson, B; Wiebe, T; Schalen, C; Hansson, HB; Allander, T; Persson, MAA			Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; NOSOCOMIAL TRANSMISSION; HEMODIALYSIS UNIT; RISK-FACTORS; B VIRUS; WORKERS; ASSAYS	Background: Despite screening of blood donors, hepatitis C virus (HCV) infection can occur in patients who receive multiple transfusions. Objective: To clarify mechanisms of nosocomial transmission of HCV. Design: Epidemiologic and molecular analyses of hepatitis C outbreaks. Setting: Pediatric oncology ward. Patients: Children with cancer. Measurements: Epidemiologic analysis, HCV RNA detection, genotyping, and hypervariable region 1 (HVR1) sequencing. Results: Ten cases of infection with acute HCV genotype 3a occurred between 1990 and 1993. Sequencing of HVR1 revealed three related strains. Despite an overhaul of hygiene procedures, a patient infected with genotype 1b generated nine subsequent infected patients in 1994. Several patients had high virus titers and strongly delayed anti-HCV antibody responses. All had permanent intravenous catheters. Multidose Vials used for flushing or treatment had probably been contaminated during periods of overlapping treatment Conclusions: Contamination of multidose vials was the most likely mode of HCV transmission; therefore, use of such Vials should be restricted. Rigorous adherence to hygiene routines remains essential to preventing transmission of bloodborne infections.	Malmo Univ Hosp, Dept Med Microbiol, S-20502 Malmo, Sweden; Univ Lund Hosp, Dept Infect Dis, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Pediat, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Hosp Infect Control, S-22185 Lund, Sweden; Malmo Univ Hosp, Reg Ctr Communicable Dis, S-20502 Malmo, Sweden; Univ Uppsala Hosp, Dept Clin Microbiol, S-75185 Uppsala, Sweden; Karolinska Hosp, Dept Med, S-17176 Stockholm, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska University Hospital	Widell, A (corresponding author), Malmo Univ Hosp, Dept Med Microbiol, S-20502 Malmo, Sweden.			Persson, Mats/0000-0002-5118-6584; Wiebe, Thomas/0000-0002-7567-9076				Abulrahi HA, 1997, LANCET, V349, P23, DOI 10.1016/S0140-6736(96)03508-8; ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; ALLANDER T, 1994, J MED VIROL, V43, P415, DOI 10.1002/jmv.1890430417; CHEN TZ, 1995, J MED VIROL, V46, P247, DOI 10.1002/jmv.1890460314; ElSayed NM, 1996, AM J TROP MED HYG, V55, P179, DOI 10.4269/ajtmh.1996.55.179; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; FARCI P, 1992, J INFECT DIS, V165, P1006, DOI 10.1093/infdis/165.6.1006; Flaum A., 1926, ACTA MED SCAND, V16, P544; Guadagnino V, 1997, HEPATOLOGY, V26, P1006, DOI 10.1053/jhep.1997.v26.pm0009328327; HAYASHI J, 1995, AM J GASTROENTEROL, V90, P794; POLISH LB, 1992, NEW ENGL J MED, V326, P721, DOI 10.1056/NEJM199203123261101; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHVARCZ R, 1995, LANCET, V346, P190, DOI 10.1016/S0140-6736(95)91252-5; Stuyver L, 1996, KIDNEY INT, V49, P889, DOI 10.1038/ki.1996.122; TEDDER RS, 1995, LANCET, V346, P137, DOI 10.1016/S0140-6736(95)91207-X; WIDELL A, 1994, J MED VIROL, V44, P272, DOI 10.1002/jmv.1890440311; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409; Widell A, 1997, TRANSFUSION, V37, P313, DOI 10.1046/j.1537-2995.1997.37397240215.x; Zeuzem S, 1996, J HEPATOL, V24, P3	19	89	92	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	1999	130	2					130	134		10.7326/0003-4819-130-2-199901190-00007	http://dx.doi.org/10.7326/0003-4819-130-2-199901190-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158KG	10068359				2022-12-01	WOS:000078114200006
J	Lopez-Girona, A; Furnari, B; Mondesert, O; Russell, P				Lopez-Girona, A; Furnari, B; Mondesert, O; Russell, P			Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein	NATURE			English	Article							CELL-CYCLE CONTROL; FISSION YEAST; EXPORT SIGNAL; SCHIZOSACCHAROMYCES-POMBE; CHECKPOINT PATHWAY; MITOTIC INDUCER; KINASE PATHWAY; CRM1; PHOSPHORYLATION; ACTIVATION	DNA damage activates a cell-cycle checkpoint that prevents mitosis while DNA repair is under way(1). The protein Chk1 enforces this checkpoint by phosphorylating the mitotic inducer Cdc25 (refs 2-6), Phosphorylation of Cdc25 by Chk1 creates a binding site in Cdc25 for 14-3-3 proteins(5-8), but it is not known how 14-3-3 proteins regulate Cdc25. Rad24 is a 14-3-3 protein that is important in the DNA-damage checkpoint in fission yeast(9). Here we show that Rad24 controls the intracellular distribution of Cdc25. Elimination of Rad24 causes nuclear accumulation of Cdc25. Activation of the DNA-damage checkpoint causes the net nuclear export of Cdc25 by a process that requires Chk1, Rad24 and nuclear-export machinery. Mutation of a putative nuclear-export signal in Rad24 impairs the nuclear exclusion of Rad24, the damage-induced nuclear export of Cdc25 and the damage checkpoint. Thus, Rad24 appears to function as an attachable nuclear-export signal that enhances the nuclear export of Cdc25 in response to DNA damage.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	prussell@scripps.edu						BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shiozaki K, 1997, METHOD ENZYMOL, V283, P506; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; SUZUKI H, 1970, J ANTIBIOT, V23, P473, DOI 10.7164/antibiotics.23.473; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	30	458	484	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 14	1999	397	6715					172	175		10.1038/16488	http://dx.doi.org/10.1038/16488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923681				2022-12-01	WOS:000078085000049
J	Brentlinger, PE; Hernan, MA; Hernandez-Diaz, S; Azaroff, LS; McCall, M				Brentlinger, PE; Hernan, MA; Hernandez-Diaz, S; Azaroff, LS; McCall, M			Childhood malnutrition and postwar reconstruction in rural El Salvador - A community-based survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY HEALTH-CARE; NUTRITIONAL-STATUS; DEVELOPING-COUNTRIES; CHILDREN; WATER; SURVEILLANCE; SANITATION; EXPERIENCE; MORTALITY	Context The 1992 peace settlement that ended the civil war in El Salvador included land redistribution and other provisions designed to improve the socioeconomic status of ex-combatants and vulnerable civilians. Objective To describe associations between postwar social and economic assistance programs, especially land reform, and current child health status as reflected by nutrition in a population of resettled rural refugees. Design A population-based cross-sectional survey of child nutritional status and principal elements of the reconstruction process. Setting A single rural municipality in northern El Salvador, Participants A representative sample of 761 children younger than 5 years, living in 27 villages. Main Outcome Measure Prevalence of stunting (low height for age) in children younger than 5 years. Results Prevalence of stunting was 32.4%. Stunting was significantly more prevalent among children whose families cultivated less land (odds ratio [OR] for stunting per additional hectare of redistributed land cultivated, 0.64; 95% confidence interval [CI], 0.44-0.93). Less than half of newly transferred land was being cultivated by its owners. Most of the children (84.7%) lived in families cultivating 2 hectares or less of redistributed land. Stunting was also more prevalent among children whose households lacked piped water (adjusted OR, 2.72; 95% CI, 1.87-3.96) vs those who had had piped water since before the cease-fire. Conclusions Malnutrition, particularly stunting, persisted at high levels and was strongly associated with delay in full cultivation of redistributed land and in provision of water.	Phys Human Rights, Boston, MA 02116 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Massachusetts, Work Environm Dept, Lowell, MA USA; Red Deer Reg Hosp, Red Deer, AB, Canada	Harvard University; Harvard T.H. Chan School of Public Health; University of Massachusetts System; University of Massachusetts Lowell	Brentlinger, PE (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.							ALLEN LH, 1995, J NUTR, V125, pS1119; Berckmans P, 1997, NEW ENGL J MED, V337, P1842, DOI 10.1056/NEJM199712183372512; BICEGO GT, 1993, SOC SCI MED, V36, P1207, DOI 10.1016/0277-9536(93)90241-U; Brentlinger PE, 1998, INT J GYNECOL OBSTET, V61, P59, DOI 10.1016/S0020-7292(98)00002-2; Brentlinger PE, 1996, BRIT MED J, V313, P1470, DOI 10.1136/bmj.313.7070.1470; BRISCOE J, 1984, AM J PUBLIC HEALTH, V74, P1009, DOI 10.2105/AJPH.74.9.1009; *CDCP, 1994, EPI INF VERS 6 COMP; Diskin M, 1996, LAT AM RES REV, V31, P111; Durham William H., 1979, SCARCITY SURVIVAL CE; EISENBERG C, 1983, NEW ENGL J MED, V308, P1028; EISENBERG C, 1990, EL SALVADOR HLTH CAR; ESREY SA, 1986, EPIDEMIOL REV, V8, P117, DOI 10.1093/oxfordjournals.epirev.a036290; GEIGER J, 1989, NEW ENGL J MED, V321, P1136, DOI 10.1056/NEJM198910193211629; GELLHORN A, 1983, CLEARINGHOUSE REP SC, V5, P1; GOLDEN MHN, 1994, EUR J CLIN NUTR, V48, pS58; *GOV EL SALV FAR M, 1992, EL AC PAZ EL SALV AC, V1; GrummerStrawn LM, 1996, B WORLD HEALTH ORGAN, V74, P369; Gutierrez G, 1996, B WORLD HEALTH ORGAN, V74, P189; Haas JD, 1996, NUTR REV, V54, pS41, DOI 10.1111/j.1753-4887.1996.tb03869.x; HERTZ E, 1994, SOC SCI MED, V39, P105, DOI 10.1016/0277-9536(94)90170-8; Martorell R, 1996, NUTR REV, V54, pS66; MARTORELL R, 1994, EUR J CLIN NUTR, V48, pS45; MARTORELL R, 1988, LINEAR GROWTH RETARD, V14; *NAT BIP COMM CENT, 1984, 040000004777 S N NAT; NEUMANN CG, 1994, EUR J CLIN NUTR, V48, pS90; OKUN DA, 1988, AM J PUBLIC HEALTH, V78, P1463, DOI 10.2105/AJPH.78.11.1463; PELLETIER DL, 1991, SOC SCI MED, V32, P887, DOI 10.1016/0277-9536(91)90244-7; POLLITT E, 1995, J NUTR, V125, pS1111; PROSTERMAN RL, 1976, COMP POLIT, V8, P339, DOI 10.2307/421404; Rawson I G, 1976, J Trop Pediatr Environ Child Health, V22, P12; RUEL MT, 1995, J NUTR, V125, P1222; Russbach R., 1994, MED GLOBAL SURVIVAL, V1, P188; SELIGSON MA, 1995, LAT AM RES REV, V30, P43; SIMON LR, 1981, EL SALVADOR REFORM 1; SPENCE J, 1997, CHAPULTEPECS 5 YEARS; STETLER HC, 1981, AM J TROP MED HYG, V30, P888, DOI 10.4269/ajtmh.1981.30.888; TAYLOR CE, 1992, INT J EPIDEMIOL, V21, P1043, DOI 10.1093/ije/21.6.1043; Torres-Rivas Edelberto, 1989, INTERPRETACION DESAR; TROWBRIDGE FL, 1979, AM J TROP MED HYG, V28, P135; *UN COM VERD EL SA, 1993, LOC ESP GUERR DOC AN; VALVERDE V, 1977, Ecology of Food and Nutrition, V6, P1, DOI 10.1080/03670244.1977.9990474; VICTORA CG, 1992, J NUTR, V122, P1105, DOI 10.1093/jn/122.5.1105; World Health Organization Expert Committee on Physical Status, 1995, WHO TECHN REP SER, V854; YUSUF ME, 1993, TROP GEOGR MED, V45, P93; 1995, LANCET, V345, P529; [No title captured]	46	14	15	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					184	190		10.1001/jama.281.2.184	http://dx.doi.org/10.1001/jama.281.2.184			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	155VJ	9917125				2022-12-01	WOS:000077966800042
J	Gokhale, RS; Tsuji, SY; Cane, DE; Khosla, C				Gokhale, RS; Tsuji, SY; Cane, DE; Khosla, C			Dissecting and exploiting intermodular communication in polyketide synthases	SCIENCE			English	Article							SACCHAROPOLYSPORA-ERYTHRAEA; ORGANIZATION; BIOSYNTHESIS; DOMAIN; GENE	Modular polyketide synthases catalyze the biosynthesis of medicinally important natural products through an assembly-line mechanism. Although these megasynthases display very precise overall selectivity, we show that their constituent modules are remarkably tolerant toward diverse incoming acyl chains. By appropriate engineering of linkers, which exist within and between polypeptides, it is possible to exploit this tolerance to facilitate the transfer of biosynthetic intermediates between unnaturally linked modules. This protein engineering strategy also provides insights into the evolution of modular polyketide synthases.	Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA	Stanford University; Stanford University; Stanford University; Brown University	Khosla, C (corresponding author), Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.			Khosla, Chaitan/0000-0001-6529-495X	NCI NIH HHS [CA66736] Funding Source: Medline; NIGMS NIH HHS [GM22172] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022172] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Belshaw PJ, 1999, SCIENCE, V284, P486, DOI 10.1126/science.284.5413.486; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; DONADIO S, 1992, GENE, V111, P51, DOI 10.1016/0378-1119(92)90602-L; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Gokhale RS, 1999, CHEM BIOL, V6, P117, DOI 10.1016/S1074-5521(99)80008-8; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Jacobsen JR, 1998, BIOCHEMISTRY-US, V37, P4928, DOI 10.1021/bi9729920; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; Kao CM, 1996, BIOCHEMISTRY-US, V35, P12363, DOI 10.1021/bi9616312; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; McDaniel R, 1997, CHEM BIOL, V4, P667, DOI 10.1016/S1074-5521(97)90222-2; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; Schupp T, 1998, FEMS MICROBIOL LETT, V159, P201, DOI 10.1111/j.1574-6968.1998.tb12861.x; Tsukamoto N, 1996, BIOCHEMISTRY-US, V35, P15244, DOI 10.1021/bi961972f	18	272	293	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					482	485		10.1126/science.284.5413.482	http://dx.doi.org/10.1126/science.284.5413.482			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205055				2022-12-01	WOS:000079792200046
J	Piguet, V; Gu, F; Foti, M; Demaurex, N; Gruenberg, J; Carpentier, JL; Trono, D				Piguet, V; Gu, F; Foti, M; Demaurex, N; Gruenberg, J; Carpentier, JL; Trono, D			Nef-induced CD4 degradation: A diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GOLGI NETWORK LOCALIZATION; DI-LEUCINE MOTIF; HIV-1 NEF; DOWN-REGULATION; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAIN; DILEUCINE MOTIF; PLASMA-MEMBRANE; COAT PROTEINS	The Nef protein of primate lentiviruses downregulates the cell surface expression of CD4 through a two-step process. First, Nef connects the cytoplasmic tail of CD4 with adaptor protein complexes (AP), thereby inducing the formation of CD4-specific clathrin-coated pits that rapidly endocytose the viral receptor. Second; Nef targets internalized CD4 molecules for degradation. Here we show that Nef accomplishes this second task by acting as a connector between CD4 and the beta subunit of COPI coatomers in endosomes. A sequence encompassing a critical acidic dipeptide, located nearby but distinct from the AP-binding determinant of HIV-1 Nef, is responsible for beta-COP recruitment and for routing to lysosomes. A novel class of endosomal sorting motif, based on acidic residues, is thus revealed, and beta-COP is identified as its downstream partner.	Univ Geneva, Fac Med, Dept Genet, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fac Med, Dept Microbiol, CH-1211 Geneva, Switzerland; Univ Geneva, Fac Med, Dept Morphol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fac Med, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fac Sci, Dept Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva	Trono, D (corresponding author), Univ Geneva, Fac Med, Dept Genet, CH-1211 Geneva 4, Switzerland.			Piguet, Vincent/0000-0001-6079-4517; Foti, Michelangelo/0000-0001-7199-4135; Demaurex, Nicolas/0000-0002-9933-6772	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034306] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI 34306-05] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hansen K, 1997, BIOCHEM BIOPH RES CO, V235, P455, DOI 10.1006/bbrc.1997.6821; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Mangasarian A, 1997, IMMUNITY, V6, P67, DOI 10.1016/S1074-7613(00)80243-5; Mangasarian A, 1999, J VIROL, V73, P1964, DOI 10.1128/JVI.73.3.1964-1973.1999; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; Oldridge J, 1998, TRENDS CELL BIOL, V8, P302, DOI 10.1016/S0962-8924(98)01318-X; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITNEY JA, 1995, CELL, V83, P703	69	246	250	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					63	73		10.1016/S0092-8674(00)80715-1	http://dx.doi.org/10.1016/S0092-8674(00)80715-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199403	Bronze			2022-12-01	WOS:000079843900009
J	Blake, GA; Qi, C; Hogerheijde, MR; Gurwell, MA; Muhleman, DO				Blake, GA; Qi, C; Hogerheijde, MR; Gurwell, MA; Muhleman, DO			Sublimation from icy jets as a probe of the interstellar volatile content of comets	NATURE			English	Article							HALE-BOPP C/1995-O1; WATER; ABUNDANCES; EVOLUTION; CHEMISTRY; HYAKUTAKE; RATIO	Comets are some of the most primitive bodies left over from the Solar System's early history. They may preserve both interstellar material and material from the proto-solar nebula, and so studies of their volatile components can provide dues about the evolution of gases and ices, as a collapsing molecular cloud transforms into a mature planetary system(1,2). Previous observations of emission from rotational transitions in molecules have averaged over large areas of the inner coma, and therefore include both molecules that sublimed from the nucleus and those that result from subsequent chemical processes in the coma. Here we present high-resolution observations of emission from the molecules HNC, DCN and HDO associated with comet Hale-Bopp, Our data reveal are-like structures-icy jets-offset from (but close to) the nucleus. The measured abundance ratios on 1-3" scales are substantially different from those on larger scales(3-5), and cannot be accounted for by models of chemical processes in the coma(2,6,7); they ape, however, similar to the values observed in the cores of dense interstellar clouds and young stellar objects. We therefore propose that sublimation from millimetre-sized icy grains ejected from the nucleus provides access to relatively unaltered volatiles. The D/H ratios inferred from our data suggest that, by mass, Hale-Bopp (and by inference the outer regions of the early solar nebula) consists of greater than or equal to 15-40% of largely unprocessed interstellar material.	CALTECH 150 21, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Colorado, JILA, Boulder, CO 80309 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	California Institute of Technology; University of Colorado System; University of Colorado Boulder; University of California System; University of California Berkeley; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Blake, GA (corresponding author), CALTECH 150 21, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.			Gurwell, Mark/0000-0003-0685-3621				Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; Bockelee-Morvan D, 1998, ICARUS, V133, P147, DOI 10.1006/icar.1998.5916; BOCKELEEMORVAN D, 1995, IN PRESS EARTH MOON; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; Dutrey A, 1997, ASTRON ASTROPHYS, V317, pL55; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; FESTOU MC, 1993, ASTRON ASTROPHYS REV, V5, P37, DOI 10.1007/BF00872923; Gautier D, 1997, ASTRON ASTROPHYS, V323, pL9; GREEN S, 1993, ASTROPHYS J SUPPL S, V85, P181, DOI 10.1086/191760; Harmon JK, 1997, SCIENCE, V278, P1921, DOI 10.1126/science.278.5345.1921; HOGERHEIJDE MR, 1998, THESIS LEIDEN U; Irvine WM, 1998, FARADAY DISCUSS, V109, P475, DOI 10.1039/a709289j; Irvine WM, 1998, NATURE, V393, P547, DOI 10.1038/31171; IRVINE WM, IN PRESS PROTOSTARS, V4; JACQ T, 1990, ASTRON ASTROPHYS, V228, P447; Jenniskens P, 1997, J CHEM PHYS, V107, P1232, DOI 10.1063/1.474468; Licandro J, 1998, ASTROPHYS J, V501, pL221, DOI 10.1086/311465; Meier R, 1998, SCIENCE, V279, P842, DOI 10.1126/science.279.5352.842; Meier R, 1998, SCIENCE, V279, P1707, DOI 10.1126/science.279.5357.1707; MUELLER BEA, IN PRESS EARTH MOON; Notesco G, 1997, ICARUS, V125, P471, DOI 10.1006/icar.1996.5648; Rodgers SD, 1998, ASTROPHYS J, V501, pL227, DOI 10.1086/311459; SCHILKE P, 1992, ASTRON ASTROPHYS, V256, P595; STERN A, UNPUB SCIENCE; VANDISHOECK EF, 1995, ASTROPHYS J, V447, P760, DOI 10.1086/175915; Willacy K, 1998, ASTRON ASTROPHYS, V338, P995; Wootten A., 1987, ASTROCHEMISTRY, V120, P311	28	55	56	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	1999	398	6724					213	216		10.1038/18372	http://dx.doi.org/10.1038/18372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UA	10094044				2022-12-01	WOS:000079228400044
J	Opferman, JT; Ober, BT; Ashton-Rickardt, PG				Opferman, JT; Ober, BT; Ashton-Rickardt, PG			Linear differentiation of cytotoxic effectors into memory T lymphocytes	SCIENCE			English	Article							CELL-MEDIATED CYTOTOXICITY; GERMINAL-CENTERS; TRANSGENIC MICE; B-CELLS; APOPTOSIS; PROLIFERATION; MOLECULES; DELETION; PROTEIN	A central question in immunology is the origin of Long-Lived T cell memory that confers protection against recurrent infection. The differentiation of nai:ve T cell receptor transgenic CD8(+) cells into effector cytotoxic T Lymphocytes (CTLs) and memory CD8(+) cells was studied. Memory CD8(+) cells that were generated after strong antigenic stimulation were the progeny of cytotoxic effecters and retained antigen-specific cytolytic activity 10 weeks after adoptive transfer to antigen-free recipient mice. Thus, potential vaccines based on CTL memory will require the differentiation of naiive cells into post-effector memory T cells.	Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Comm Immunol, Chicago, IL 60637 USA; Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Comm Dev Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Ashton-Rickardt, PG (corresponding author), Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Comm Immunol, Chicago, IL 60637 USA.		Opferman, Joseph T/M-5331-2018	Opferman, Joseph T/0000-0002-1147-5621	NIAID NIH HHS [5T32 AI07090] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007090] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Baltimore D, 1998, SCI AM, V279, P98, DOI 10.1038/scientificamerican0798-98; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; GEISBERG M, 1992, INT IMMUNOL, V4, P1273, DOI 10.1093/intimm/4.11.1273; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAWASAKI AEA, 1990, INT IMMUNOL, V7, P677; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LAIVANI A, 1997, J EXP MED, V186, P859; Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875; Liu Y, 1997, J EXP MED, V185, P251, DOI 10.1084/jem.185.2.251; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; McMichael A, 1998, CURR OPIN IMMUNOL, V10, P379, DOI 10.1016/S0952-7915(98)80107-6; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NEURATH MF, 1995, P NATL ACAD SCI USA, V92, P5336, DOI 10.1073/pnas.92.12.5336; OPFERMAN JT, UNPUB; RAZVI ES, 1995, ADV VIRUS RES, V45, P1, DOI 10.1016/S0065-3527(08)60057-3; Renner C, 1997, IMMUNOBIOLOGY, V197, P122, DOI 10.1016/S0171-2985(97)80062-9; RENNO T, 1995, J EXP MED, V181, P2283, DOI 10.1084/jem.181.6.2283; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	28	304	319	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	1999	283	5408					1745	1748		10.1126/science.283.5408.1745	http://dx.doi.org/10.1126/science.283.5408.1745			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175PF	10073942				2022-12-01	WOS:000079102800055
J	Holmes, MD; Hunter, DJ; Colditz, GA; Stampfer, MJ; Hankinson, SE				Holmes, MD; Hunter, DJ; Colditz, GA; Stampfer, MJ; Hankinson, SE			Association of dietary intake of fat and fatty acids with risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAT MAMMARY-TUMORS; NUDE-MICE; OLIVE OIL; DOCOSAHEXAENOIC ACID; LIPID-COMPOSITION; ADIPOSE-TISSUE; FISH-OIL; GROWTH; METASTASIS; DISEASE	Context High intakes of fat and specific fatty acids, including total, animal, saturated, polyunsaturated, and trans-unsaturated fats, have been postulated to increase breast cancer risk. Objective To determine whether intakes of fat and fatty acids are associated with breast cancer. Design and Setting Cohort study (Nurses' Health Study) conducted in the United States beginning in 1976. Participants A total of 88 795 women free of cancer in 1980 and followed up for 14 years. Main Outcome Measure Relative risk (RR) of invasive breast cancer for an incremental increase of fat intake, ascertained by food frequency questionnaire in 1980, 1984, 1986, and 1990. Results A total of 2956 women were diagnosed as having breast cancer. Compared with women obtaining 30.1% to 35% of energy from fat, women consuming 20% or less had a multivariate RR of breast cancer of 1.15 (95% confidence interval [CI], 0.73-1.80). In multivariate models, the RR (95% CI) for a 5%-of-energy increase was 0.97 (0.94-1.00) for total fat, 0.98 (0.96-1.01) for animal fat, 0.97 (0.93-1.02) for vegetable fat, 0.94 (0.88-1.01) for saturated fat, 0.91 (0.79-1.04) for polyunsaturated fat, and 0.94 (0.88-1.00) for monounsaturated fat. For a 1% increase in energy from trans-unsaturated fat, the values were 0.92 (0.86-0.98), and for a 0.1% increase in energy from omega-3 fat from fish, the values were 1.09 (1.03-1.16). In a model including fat, protein, and energy, the RR for a 5% increase in total fat, which can be interpreted as the risk of substituting this amount of fat for an equal amount of energy from carbohydrate, was 0.96 (95% CI, 0.93-0.99). In similar models, no significant association of risk was evident with any major types of fat. Conclusion We found no evidence that lower intake of total fat or specific major types of fat was associated with a decreased risk of breast cancer.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Cambridge Hosp, Dept Med, Cambridge, MA 02139 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Holmes, MD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYLSWORTH CF, 1984, J NATL CANCER I, V72, P637; Black AE, 1996, NUTR REV, V54, P170, DOI 10.1111/j.1753-4887.1996.tb03924.x; Carroll K K, 1975, Prog Biochem Pharmacol, V10, P308; CAVE WT, 1984, J NATL CANCER I, V73, P185; Caygill CPJ, 1996, BRIT J CANCER, V74, P159, DOI 10.1038/bjc.1996.332; COHEN LA, 1986, J NATL CANCER I, V77, P43; COLDITZ GA, 1995, AM J EPIDEMIOL, V142, P371, DOI 10.1093/oxfordjournals.aje.a117644; Connolly JM, 1996, NUTR CANCER, V25, P231, DOI 10.1080/01635589609514447; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; ENIG MG, 1983, J AM OIL CHEM SOC, V60, P1788, DOI 10.1007/BF02680357; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; GODLEY PA, 1995, BREAST CANCER RES TR, V35, P91, DOI 10.1007/BF00694749; GONZALEZ MJ, 1993, LIPIDS, V28, P827, DOI 10.1007/BF02536237; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407; HUBBARD NE, 1987, CANCER RES, V47, P671; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; Johnson RK, 1998, NEW ENGL J MED, V338, P918; JURKOWSKI JJ, 1985, J NATL CANCER I, V74, P1145; KARMALI RA, 1984, J NATL CANCER I, V73, P457, DOI 10.1093/jnci/73.2.457; KATZ EB, 1987, J NATL CANCER I, V79, P351; Kinoshita K, 1994, In Vivo, V8, P371; LAVECCHIA C, 1995, CANCER CAUSE CONTROL, V6, P545, DOI 10.1007/BF00054164; LONDON SJ, 1993, JNCI-J NATL CANCER I, V85, P785, DOI 10.1093/jnci/85.10.785; LUND E, 1993, CANCER CAUSE CONTROL, V4, P283; MARSHALL JR, 1992, EUR J CANCER, V28A, P1720, DOI 10.1016/0959-8049(92)90077-F; MARTINMORENO JM, 1994, INT J CANCER, V58, P774, DOI 10.1002/ijc.2910580604; National Research Council, 1989, DIET HLTH IMPL RED C; NOGUCHI M, 1995, ONCOLOGY-BASEL, V52, P265; PETREK JA, 1994, J NATL CANCER I, V86, P53, DOI 10.1093/jnci/86.1.53; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; Prentice RL, 1996, J NATL CANCER I, V88, P1738, DOI 10.1093/jnci/88.23.1738; Price GM, 1997, BRIT J NUTR, V77, P833, DOI 10.1079/BJN19970083; ROSE DP, 1995, JNCI-J NATL CANCER I, V87, P587, DOI 10.1093/jnci/87.8.587; ROSE DP, 1993, JNCI-J NATL CANCER I, V85, P1743, DOI 10.1093/jnci/85.21.1743; Simonsen N, 1998, AM J EPIDEMIOL, V147, P342; SLOVER HT, 1985, J AM OIL CHEM SOC, V62, P775, DOI 10.1007/BF03028753; TRICHOPOULOU A, 1995, JNCI-J NATL CANCER I, V87, P110, DOI 10.1093/jnci/87.2.110; *USDA, 1993, AGR HDB SER, V8; Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Witte JS, 1997, BREAST CANCER RES TR, V42, P243, DOI 10.1023/A:1005710211184; Wolk A, 1998, ARCH INTERN MED, V158, P41, DOI 10.1001/archinte.158.1.41; WYNDER EL, 1991, CANCER-AM CANCER SOC, V67, P746, DOI 10.1002/1097-0142(19910201)67:3<746::AID-CNCR2820670336>3.0.CO;2-1; ZHU ZR, 1995, NUTR CANCER, V24, P151, DOI 10.1080/01635589509514403	49	244	250	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1999	281	10					914	920		10.1001/jama.281.10.914	http://dx.doi.org/10.1001/jama.281.10.914			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172XH	10078488	Bronze			2022-12-01	WOS:000078950600036
J	Moller, H; Skakkebaek, NE				Moller, H; Skakkebaek, NE			Risk of testicular cancer in subfertile men: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEMEN QUALITY; EUROPEAN COUNTRIES; BIRTH COHORT; SPERMATOGENESIS; CRYPTORCHIDISM; DISORDERS; DENMARK; TESTIS	Objective To evaluate the association between subfertility in men and the subsequent risk of testicular cancer. Design Population based case-control study. Setting The Danish population Participants Cases were identified in the Danish Cancer Registry; controls were randomly selected from the Danish population with the computerised Danish Central Population Register. Men were interviewed by telephone; 514 men with cancer and 720 controls participated. Outcome measure Occurrence of testicular cancer. Results A reduced risk of testicular cancer was associated with paternity (relative risk 0.63; 95% confidence interval 0.47 to 085). In men who before the diagnosis of testicular cancer had a lower number of children than expected on the basis of their age, the relative risk was 1.98 (1.43 to 2.75). There was no corresponding protective effect associated with a higher number of children than expected. The associations were similar for seminoma and non-seminoma and were not influenced by adjustment for potential confounding factors. Conclusion These data are consistent with the hypothesis that male subfertility and testicular cancer share important aetiological factors.	Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen O, Denmark; Natl Univ Hosp, Dept Growth & Reprod, Copenhagen, Denmark	Danmarks Grundforskningsfond	Moller, H (corresponding author), Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, Sejrogade 11, DK-2100 Copenhagen O, Denmark.	cerefo@inet.uni2.dk		Moller, Henrik/0000-0001-8200-5929				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; Akre O, 1996, J NATL CANCER I, V88, P883, DOI 10.1093/jnci/88.13.883; Armstrong BK, 1992, MONOGRAPHS EPIDEMIOL, V21; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; BENDVOLD E, 1989, INT J FERTIL, V34, P401; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; BERTHELSEN JG, 1983, FERTIL STERIL, V39, P68; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; Breslow NE., 1980, IARC SCI PUBL, P5; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; COLEMAN MP, 1993, IARC SCI PUBL, V121, P521; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; FORMAN D, 1994, CANCER SURV, V20, P323; HANSEN PV, 1989, J NATL CANCER I, V81, P1246, DOI 10.1093/jnci/81.16.1246; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; HO GT, 1992, J UROLOGY, V148, P821, DOI 10.1016/S0022-5347(17)36732-0; Irvine S, 1996, BMJ-BRIT MED J, V312, P467, DOI 10.1136/bmj.312.7029.467; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; Moller H, 1996, CANCER CAUSE CONTROL, V7, P264, DOI 10.1007/BF00051302; MOLLER H, 1993, EUR UROL, V23, P8; Moller H, 1997, CANCER CAUSE CONTROL, V8, P904, DOI 10.1023/A:1018472530653; Moller H, 1996, INT J CANCER, V66, P287, DOI 10.1002/(SICI)1097-0215(19960503)66:3<287::AID-IJC2>3.0.CO;2-V; Pajarinen J, 1997, BRIT MED J, V314, P13, DOI 10.1136/bmj.314.7073.13; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Storm H H, 1991, IARC Sci Publ, P220	26	208	210	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	1999	318	7183					559	562		10.1136/bmj.318.7183.559	http://dx.doi.org/10.1136/bmj.318.7183.559			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037628	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000078966300020
J	O'Donnell, CA; McConnachie, A; Moffat, K; Drummond, N; Wilson, P; Ross, S				O'Donnell, CA; McConnachie, A; Moffat, K; Drummond, N; Wilson, P; Ross, S			Cross sectional study of social variation in use of an out of hours patient transport service	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Woodside Hlth Ctr, Dept Gen Practice, Glasgow G20 7LR, Lanark, Scotland; Univ Glasgow, Publ Hlth Res Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; University of Glasgow	O'Donnell, CA (corresponding author), Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland.			O'Donnell, Kate/0000-0002-5368-3779				Carlisle R, 1998, BRIT MED J, V316, P520, DOI 10.1136/bmj.316.7130.520; Carstairs V., 1991, DEPRIVATION HLTH SCO; Hallam L, 1997, BMJ-BRIT MED J, V314, P157, DOI 10.1136/bmj.314.7075.157; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; [No title captured]	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					566	567		10.1136/bmj.318.7183.566	http://dx.doi.org/10.1136/bmj.318.7183.566			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037631	Green Published			2022-12-01	WOS:000078966300026
J	Mortensen, PB; Pedersen, CB; Westergaard, T; Wohlfahrt, J; Ewald, H; Mors, O; Andersen, PK; Melbye, M				Mortensen, PB; Pedersen, CB; Westergaard, T; Wohlfahrt, J; Ewald, H; Mors, O; Andersen, PK; Melbye, M			Effects of family history and place and season of birth on the risk of schizophrenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISORDERS; WINTER	Background Although a family history of schizophrenia is the best-established risk factor for schizophrenia, environmental factors such as the place and season of birth may also be important. Methods Using data from the Civil Registration System in Denmark, we established a population-based cohort of 1.75 million persons whose mothers were Danish women born between 1935 and 1978. We linked this cohort to the Danish Psychiatric Central Register and identified 2669 cases of schizophrenia among cohort members and additional cases among their parents. Results The respective relative risks of schizophrenia for persons with a mother, father, or sibling who had schizophrenia were 9.31 (95 percent confidence interval, 7.24 to 11.96), 7.20 (95 percent confidence interval, 5.10 to 10.16), and 6.99 (95 percent confidence interval, 5.38 to 9.09), as compared with persons with no affected parents or siblings. The risk of schizophrenia was associated with the degree of urbanization of the place of birth (relative risk for the capital vs. rural areas, 2.40; 95 percent confidence interval, 2.13 to 2.70). The risk was also significantly associated with the season of birth; it was highest for births in February and March and lowest for births in August and September. The population attributable risk was 5.5 percent for a history of schizophrenia in a parent or sibling, 34.6 percent for urban place of birth, and 10.5 percent for the season of birth. Conclusions Although a history of schizophrenia in a parent or sibling is associated with the highest relative risk of having the disease, the place and season of birth account for many more cases on a population basis. (N Engl J Med 1999;340:603-8.) (C)1999, Massachusetts Medical Society.	Aarhus Univ Hosp, Hosp Psychiat, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark; Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark	Aarhus University; Aarhus University; Statens Serum Institut	Mortensen, PB (corresponding author), Aarhus Univ Hosp, Hosp Psychiat, Inst Basic Psychiat Res, Dept Psychiat Demog, Skovagervej 2, DK-8240 Risskov, Denmark.	ph.phl.pbm@aaa.dk	Mortensen, Preben B/D-2358-2015; Pedersen, Carsten Bøcker/B-8441-2013	Mortensen, Preben B/0000-0002-5230-9865; Pedersen, Carsten Bøcker/0000-0003-2077-8533; melbye, mads/0000-0001-8264-6785; Mors, Ole/0000-0002-5660-0393				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; BARR CE, 1990, ARCH GEN PSYCHIAT, V47, P869; BRESLOW NE, 1996, STAT APPL, V8, P23; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Clayton D., 1993, STAT MODELS EPIDEMIO; COTTER D, 1996, NEUROSCI INTELL UNIT, P17; EATON WW, 1988, HDB SCHIZOPHRENIA, V3, P169; Geddes JR, 1995, BRIT J PSYCHIAT, V167, P786, DOI 10.1192/bjp.167.6.786; GOLDSTEIN JM, 1990, BRIT J PSYCHIAT, V156, P819, DOI 10.1192/bjp.156.6.819; Gottesman I., 1991, SCHIZOPHRENIA GENESI; GOTTESMAN II, 1989, ARCH GEN PSYCHIAT, V46, P867; Hettema John M., 1996, British Journal of Psychiatry, V168, P205, DOI 10.1192/bjp.168.2.205; JABLENSKY A, 1995, BAILLIERES CLIN PSYC, V1, P283; KENDLER KS, 1995, BRIT J PSYCHIAT, V167, P184, DOI 10.1192/bjp.167.2.184; KENDLER KS, 1995, ARCH GEN PSYCHIAT, V52, P895; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P527; KENDLER KS, 1993, SCHIZOPHRENIA BULL, V19, P261, DOI 10.1093/schbul/19.2.261; KENDLER KS, 1990, PSYCHOL MED, V20, P311, DOI 10.1017/S0033291700017621; LEWIS G, 1992, LANCET, V340, P137, DOI 10.1016/0140-6736(92)93213-7; LEWIS MS, 1989, SCHIZOPHRENIA BULL, V15, P59, DOI 10.1093/schbul/15.1.59; Malig C, 1996, INT I VITAL REGISTRA, V66, P1; MCNEIL TF, 1995, EPIDEMIOL REV, V17, P107, DOI 10.1093/oxfordjournals.epirev.a036165; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; MUNKJORGENSEN P, 1995, THESIS ARHUS U ARHUS; OCALLAGHAN E, 1991, BRIT J PSYCHIAT, V158, P764, DOI 10.1192/bjp.158.6.764; *SAS I INC, 1996, SAS STAT SOFTW CHANG, P23; TAKEI N, 1995, J EPIDEMIOL COMMUN H, V49, P106, DOI 10.1136/jech.49.1.106; TORREY EF, 1990, SCHIZOPHRENIA BULL, V16, P591, DOI 10.1093/schbul/16.4.591; WESSELY S, 1991, BRIT J PSYCHIAT, V159, P795, DOI 10.1192/bjp.159.6.795; Westergaard T, 1997, J NATL CANCER I, V89, P939, DOI 10.1093/jnci/89.13.939; *WHO, 1967, MAN INT STAT CLASS D, V1; World Health Organization, 1974, GLOSS MENT DIS GUID	33	545	556	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					603	608		10.1056/NEJM199902253400803	http://dx.doi.org/10.1056/NEJM199902253400803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	169NP	10029644				2022-12-01	WOS:000078755700003
J	Ito, N; Rubin, GM				Ito, N; Rubin, GM			Gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle	CELL			English	Article							TSC2 GENE; PROTEIN; MELANOGASTER; EYE; DIFFERENTIATION; IDENTIFICATION; REPLICATION; PROGRESSION; TRANSITION; OMMATIDIUM	Tuberous sclerosis complex (TSC) is an autosomal dominant disorder leading to the widespread development of benign tumors that often contain giant cells. We show that the Drosophila gene gigas encodes a homolog of TSC2, a gene mutated in half of TSC patients. Clones of gigas mutant cells induced in imaginal discs differentiate normally to produce adult structures. However, the cells in these clones are enlarged and repeat S phase without entering M phase. Our results suggest that the TSC disorder may result from an underlying defect in cell cycle control. We have also identified a Drosophila homolog of TSC1.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Rubin, GM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	gerry@fruitfly.berkeley.edu		Rubin, Gerald/0000-0001-8762-8703	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033135, R37GM033135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Braet F, 1997, J MICROSC-OXFORD, V186, P84, DOI 10.1046/j.1365-2818.1997.1940755.x; CANAL I, 1994, EUR J NEUROSCI, V6, P1423, DOI 10.1111/j.1460-9568.1994.tb01004.x; CHOU TB, 1993, DEVELOPMENT, V119, P1359; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; FEN S, 1997, DEVELOPMENT, V124, P1497; FERRUS A, 1976, NATURE, V260, P425, DOI 10.1038/260425a0; GATEFF E, 1994, INT J DEV BIOL, V38, P565; Gomez MR, 1988, TUBEROUS SCLEROSIS; Hayashi S, 1996, DEVELOPMENT, V122, P1051; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; JOHNSON WG, 1991, ANN NY ACAD SCI, V615, P211; Karim FD, 1996, GENETICS, V143, P315; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kimmerly W, 1996, GENOME RES, V6, P414, DOI 10.1101/gr.6.5.414; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; Kylsten P, 1997, DEV BIOL, V192, P509, DOI 10.1006/dbio.1997.8770; Maheshwar MM, 1996, HUM MOL GENET, V5, P131, DOI 10.1093/hmg/5.1.131; MAKI C, 1989, GENE, V79, P289, DOI 10.1016/0378-1119(89)90211-4; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NELLIST M, 1993, CELL, V75, P1305; Neufeld TP, 1998, GENETICS, V148, P277; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PIRROTTA V, 1998, GENE DEV, V2, P1839; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SU TT, 1995, CELL, V81, P825, DOI 10.1016/0092-8674(95)90000-4; Su TT, 1998, CURR BIOL, V8, pR687, DOI 10.1016/S0960-9822(98)70436-1; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; Thomas BJ, 1997, GENE DEV, V11, P1289, DOI 10.1101/gad.11.10.1289; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Tsuchiya H, 1996, CANCER RES, V56, P429; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; WINBERG ML, 1992, DEVELOPMENT, V115, P903; Wolff Tanya, 1993, P1277; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; XU T, 1993, DEVELOPMENT, V117, P1223; [No title captured]	55	211	213	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					529	539		10.1016/S0092-8674(00)80657-1	http://dx.doi.org/10.1016/S0092-8674(00)80657-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052455	Bronze			2022-12-01	WOS:000078718600004
J	Kulkarni, RN; Bruning, JC; Winnay, JN; Postic, C; Magnuson, MA; Kahn, CR				Kulkarni, RN; Bruning, JC; Winnay, JN; Postic, C; Magnuson, MA; Kahn, CR			Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes	CELL			English	Article							MOLECULAR MECHANISMS; TARGETED DISRUPTION; FEEDBACK INHIBITION; GLUCOSE-TOLERANCE; ISLET CELLS; B-CELL; RESISTANCE; MELLITUS; GENE; MICE	Dysfunction of the pancreatic beta cell is an important defect in the pathogenesis of type 2 diabetes, although its exact relationship to the insulin resistance is unclear. To determine whether insulin signaling has a functional role in the beta cell we have used the Cre-loxP system to specifically inactivate the insulin receptor gene in the beta cells. The resultant mice exhibit a selective loss of insulin secretion in response to glucose and a progressive impairment of glucose tolerance. These data indicate an important functional role for the insulin receptor in glucose sensing by the pancreatic beta cell and suggest that defects in insulin signaling at the level of the beta cell may contribute to the observed alterations in insulin secretion in type 2 diabetes.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Vanderbilt University	Kahn, CR (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	kahnr@joslab.harvard.edu	Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021; Postic, Catherine/P-2271-2017; Kahn, Ronald/AAY-2435-2021	Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499; Postic, Catherine/0000-0002-1875-6960; Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031036, R37DK031036, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31036, P30 DK 36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; AMMON HPT, 1991, J ENDOCRINOL, V128, P27, DOI 10.1677/joe.0.1280027; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGOUD GM, 1987, DIABETES, V36, P959, DOI 10.2337/diabetes.36.8.959; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Efendic S, 1988, Adv Exp Med Biol, V246, P167; ELAHI D, 1982, NEW ENGL J MED, V306, P1196, DOI 10.1056/NEJM198205203062002; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FLIER JS, 1975, SCIENCE, V190, P63, DOI 10.1126/science.170678; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GILLIES MC, 1990, METABOLISM, V39, P1253, DOI 10.1016/0026-0495(90)90179-G; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HALES CN, 1994, DIABETOLOGIA, V37, pS162, DOI 10.1007/BF00400840; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; IVERSEN J, 1971, DIABETES, V20, P1; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Josefsen K, 1996, J ENDOCRINOL, V149, P145, DOI 10.1677/joe.0.1490145; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; LEAHY JL, 1990, ENDOCRINOLOGY, V126, P1593, DOI 10.1210/endo-126-3-1593; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MCRAE JR, 1981, METABOLISM, V30, P1065, DOI 10.1016/0026-0495(81)90049-4; METZGER D, 1995, P NATL ACAD SCI USA, V92, P6991, DOI 10.1073/pnas.92.15.6991; NESHER R, 1987, EUR J CLIN INVEST, V17, P266, DOI 10.1111/j.1365-2362.1987.tb01247.x; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; OMEARA NM, 1993, J CLIN INVEST, V92, P262, DOI 10.1172/JCI116560; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003; PFEIFER MA, 1982, DIABETES, V31, P154, DOI 10.2337/diabetes.31.2.154; Pictet R., 1972, HDB PHYSL, P25; Poitout V, 1996, ANNU REV MED, V47, P69; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; REAVEN GM, 1993, J CLIN ENDOCR METAB, V76, P44, DOI 10.1210/jc.76.1.44; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; TRENT DF, 1984, DIABETES, V33, P170, DOI 10.2337/diabetes.33.2.170; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; TURNER RC, 1988, BAILLIERE CLIN ENDOC, V2, P327, DOI 10.1016/S0950-351X(88)80035-1; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VAGUE P, 1982, METABOLISM, V31, P139, DOI 10.1016/0026-0495(82)90125-1; VANSCHRAVENDIJK CFH, 1987, ENDOCRINOLOGY, V121, P1784, DOI 10.1210/endo-121-5-1784; VANSCHRAVENDIJK CFH, 1985, ENDOCRINOLOGY, V117, P841; Velloso LA, 1995, FEBS LETT, V377, P353, DOI 10.1016/0014-5793(95)01370-9; VERSPOHL EJ, 1980, J CLIN INVEST, V65, P1230, DOI 10.1172/JCI109778; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; Weinhaus AJ, 1997, DIABETOLOGIA, V40, P374, DOI 10.1007/s001250050690; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wurst W., 1993, Gene targeting: a practical approach., P33	66	891	947	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					329	339		10.1016/S0092-8674(00)80546-2	http://dx.doi.org/10.1016/S0092-8674(00)80546-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025399	Bronze			2022-12-01	WOS:000078514600006
J	Vainio, S; Heikkila, M; Kispert, A; Chin, N; McMahon, AP				Vainio, S; Heikkila, M; Kispert, A; Chin, N; McMahon, AP			Female development in mammals is regulated by Wnt-4 signalling	NATURE			English	Article							MULLERIAN-INHIBITING SUBSTANCE; ADRENAL HYPOPLASIA CONGENITA; SIDE-CHAIN-CLEAVAGE; SEX DETERMINATION; Y-CHROMOSOME; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; MOLECULAR-GENETICS; TRANSGENIC MICE; FETAL MOUSE; EXPRESSION	In the mammalian embryo, both sexes are initially morphologically Indistinguishable: specific hormones are required for sex-specific development. Mullerian inhibiting substance and testosterone secreted by the differentiating embryonic testes result in the loss of female (Mullerian) or promotion of male (Wolffian) reproductive duct development, respectively. The signalling molecule Wnt-4 is crucial for female sexual development. At birth, sexual development in males with a mutation in Wnt-4 appears to be normal; however, Wnt-4-mutant females are masculinized-the Mullerian duct is absent white the Wolffian duct continues to develop. Wnt-4 is initially required in both sexes for formation of the Mullerian duct, then Wnt-4 in the developing ovary appears to suppress the development of Leydig cells; consequently, Wnt-4-mutant females ectopically activate testosterone biosynthesis. Wnt-4 may also be required for maintenance of the female germ line. Thus, the establishment of sexual dimorphism is under the control of both local and systemic signals.	Harvard Univ, Biolabs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Oulu, Fac Sci, Dept Biochem, Oulu 90570, Finland; Univ Oulu, Fac Med, Dept Biochem, Oulu 90570, Finland; Univ Oulu, Bioctr Oulu, Oulu 90570, Finland	Harvard University; Finland National Institute for Health & Welfare; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	McMahon, AP (corresponding author), Harvard Univ, Biolabs, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.	amcmahon@biosun.harvard.edu	McMahon, Andrew P/ABE-7520-2020	Vainio, Seppo/0000-0001-9319-3566				Andersson S, 1996, J CLIN ENDOCR METAB, V81, P130, DOI 10.1210/jc.81.1.130; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; BISHOP CE, 1985, NATURE, V315, P70, DOI 10.1038/315070a0; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BUEHR M, 1993, DEVELOPMENT, V117, P273; BURGOYNE PS, 1988, PHILOS T R SOC B, V322, P63, DOI 10.1098/rstb.1988.0114; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GRECO TL, 1994, ENDOCRINOLOGY, V135, P262, DOI 10.1210/en.135.1.262; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Hogan B., 2014, MANIPULATING MOUSE E; JOST A, 1953, RECENT PROG HORM RES, V8, P379; Kent J, 1996, DEVELOPMENT, V122, P2813; Kispert A, 1996, DEVELOPMENT, V122, P3627; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYET L, 1995, BIOL REPROD, V52, P444, DOI 10.1095/biolreprod52.2.444; MCLAREN A, 1991, BIOESSAYS, V13, P151, DOI 10.1002/bies.950130402; McLaren A, 1998, CURR BIOL, V8, pR175, DOI 10.1016/S0960-9822(98)70104-6; McLaren A, 1995, NATO ADV SCI INST SE, V279, P1; Miller C, 1998, DEVELOPMENT, V125, P3201; Morel Y, 1997, STEROIDS, V62, P176, DOI 10.1016/S0039-128X(96)00178-X; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Mustonen MVJ, 1997, BIOCHEM J, V325, P199, DOI 10.1042/bj3250199; Nordqvist K, 1997, INT J DEV BIOL, V41, P627; NORDQVIST K, 1994, NAT GENET, V7, P7, DOI 10.1038/ng0594-7; PALMER SJ, 1991, DEVELOPMENT, V112, P265; Parr BA, 1998, NATURE, V395, P707, DOI 10.1038/27221; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; VIGIER B, 1987, DEVELOPMENT, V100, P43; ZAMBONI L, 1983, J EXP ZOOL, V228, P173, DOI 10.1002/jez.1402280204; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	41	904	952	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 4	1999	397	6718					405	409		10.1038/17068	http://dx.doi.org/10.1038/17068			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989404				2022-12-01	WOS:000078461700038
J	Nightingale, SL				Nightingale, SL			Reporting adverse events and product problems electronically	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1999	281	5					408	408		10.1001/jama.281.5.408	http://dx.doi.org/10.1001/jama.281.5.408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YT	9952188				2022-12-01	WOS:000078318500010
J	Jakosky, BM				Jakosky, BM			Mars - Water, climate, and life	SCIENCE			English	Editorial Material									Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Jakosky, BM (corresponding author), Univ Colorado, Atmospher & Space Phys Lab, Campus Box 392, Boulder, CO 80309 USA.							Acuna MH, 1998, SCIENCE, V279, P1676, DOI 10.1126/science.279.5357.1676; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; *AM GEOPH UN, 1998, FALL M AM GEOPH UN 6; Brain DA, 1998, J GEOPHYS RES-PLANET, V103, P22689, DOI 10.1029/98JE02074; Carr M.H, 1996, WATER MARS; CHRISTENSEN PR, 1992, J GEOPHYS RES-PLANET, V97, P7719, DOI 10.1029/92JE00453; Jakosky BM, 1998, J GEOPHYS RES-PLANET, V103, P19359, DOI 10.1029/98JE01892; Jakosky Bruce, 1998, SEARCH LIFE OTHER PL; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053	10	11	11	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					648	649		10.1126/science.283.5402.648	http://dx.doi.org/10.1126/science.283.5402.648			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9988657				2022-12-01	WOS:000078324400028
J	Eyre-Walker, A; Keightley, PD				Eyre-Walker, A; Keightley, PD			High genomic deleterious mutation rates in hominids	NATURE			English	Article							GENES; POPULATIONS; DROSOPHILA; MOUSE; RISK	It has been suggested that humans may suffer a high genomic deleterious mutation rate(1,2). Here we test this hypothesis by applying a variant of a molecular approach(3) to estimate the deleterious mutation rate in hominids from the level of selective constraint in DNA sequences. Under conservative assumptions, we estimate that an average of 4.2 amino-acid-altering mutations per diploid per generation have occurred in the human lineage since humans separated from chimpanzees. Of these mutations, we estimate that at least 38% have been eliminated by natural selection, indicating that there have been more than 1.6 new deleterious mutations per diploid genome per generation. Thus, the deleterious mutation rate specific to protein-coding sequences alone is close to the upper limit tolerable by a species such as humans that has a low reproductive rate(4), indicating that the effects of deleterious mutations may have combined synergistically, Furthermore, the level of selective constraint in hominid protein-coding sequences is atypically low, A large number of slightly deleterious mutations may therefore have become fixed in hominid lineages.	Univ Sussex, Ctr Study Evolut, Brighton BN1 9QG, E Sussex, England; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Sussex; University of Sussex; University of Edinburgh	Eyre-Walker, A (corresponding author), Univ Sussex, Ctr Study Evolut, Brighton BN1 9QG, E Sussex, England.	A.C.Eyre-Walker@susx.ac.uk	Eyre-Walker, Adam/G-6216-2011	Eyre-Walker, Adam/0000-0001-5527-8729				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; Drake JW, 1998, GENETICS, V148, P1667; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; Hill K., 1996, ACHE LIFE HIST ECOLO; Howell N., 1979, DEMOGRAPHY DOBE KUNG; Ina Y, 1998, J MOL EVOL, V46, P521, DOI 10.1007/PL00006333; Keightley PD, 1996, GENETICS, V144, P1993; KIMURA M, 1966, GENETICS, V54, P1337; Kimura M., 1983, NEUTRAL THEORY MOL; KONDRASHOV AS, 1995, J THEOR BIOL, V175, P583, DOI 10.1006/jtbi.1995.0167; KONDRASHOV AS, 1993, HUM MUTAT, V2, P229, DOI 10.1002/humu.1380020312; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.1111/j.1558-5646.1994.tb02188.x, 10.2307/2410240]; Li W.H., 1997, MOL EVOLUTION; Melancon T., 1982, THESIS PENNSYLVANIA; MOHRENWEISER HW, 1981, P NATL ACAD SCI-BIOL, V78, P5729, DOI 10.1073/pnas.78.9.5729; MULLER HJ, 1950, AM J HUM GENET, V2, P111; NEEL JV, 1988, AM J HUM GENET, V42, P663; Nishida T., 1990, P63; OHTA T, 1995, J MOL EVOL, V40, P56, DOI 10.1007/BF00166595; Ophir R, 1997, GENE, V205, P191, DOI 10.1016/S0378-1119(97)00398-3; SIMMONS MJ, 1977, ANNU REV GENET, V11, P49, DOI 10.1146/annurev.ge.11.120177.000405; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0; WOLFE KH, 1993, J MOL EVOL, V37, P441, DOI 10.1007/BF00178874	30	286	289	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					344	347		10.1038/16915	http://dx.doi.org/10.1038/16915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950425				2022-12-01	WOS:000078324600048
J	Leyman, B; Geelen, D; Quintero, FJ; Blatt, MR				Leyman, B; Geelen, D; Quintero, FJ; Blatt, MR			A tobacco syntaxin with a role in hormonal control of guard cell ion channels	SCIENCE			English	Article							CALCIUM CHANNELS; ABSCISIC-ACID; EXOCYTOSIS; RECEPTOR; MEMBRANE; ENDOCYTOSIS; SECRETION; PROTEINS; HOMOLOG; CLONING	The plant hormone abscisic acid (ABA) regulates potassium and chloride ion channels at the plasma membrane of guard cells, Leading to stomatal closure that reduces transpirational water loss from the leaf. The tobacco Nt-SYR1 gene encodes a syntaxin that is associated with the plasma membrane. Syntaxins and related SNARE proteins aid intracellular vesicle trafficking, fusion, and secretion. Disrupting Nt-Syr1 function by cleavage with Clostridium botulinum type C toxin or competition with a soluble fragment of Nt-Syr1 prevents potassium and chloride ion channel response to ABA in guard cells and implicates Nt-Syr1 in an ABA-signaling cascade.	Univ London Wye Coll, Lab Plant Physiol & Biophys, Ashford TN25 5AH, Kent, England	Imperial College London	Blatt, MR (corresponding author), Univ London Wye Coll, Lab Plant Physiol & Biophys, Ashford TN25 5AH, Kent, England.		Quintero, Francisco J./AAG-2924-2019; Quintero, Francisco J/C-3086-2014	Quintero, Francisco J./0000-0001-8718-2975; Quintero, Francisco J/0000-0001-8718-2975; Blatt, Michael R/0000-0003-1361-4645				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BATTEY NH, 1993, NEW PHYTOL, V125, P307, DOI 10.1111/j.1469-8137.1993.tb03883.x; Blatt MR, 1997, PHYSIOL PLANTARUM, V100, P481, DOI 10.1034/j.1399-3054.1997.1000309.x; Conceicao ADS, 1997, PLANT CELL, V9, P571, DOI 10.2307/3870508; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; EIDNE KA, 1994, MEMBRANE PROTEIN EXP, P1; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; Grabov A, 1998, P NATL ACAD SCI USA, V95, P4778, DOI 10.1073/pnas.95.8.4778; Harlow E., 1988, ANTIBODIES LABORATOR, P1; Homann U, 1998, PLANTA, V206, P329, DOI 10.1007/s004250050408; Igarashi M, 1996, J CELL BIOL, V134, P205, DOI 10.1083/jcb.134.1.205; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KAISER CA, 1997, MOL CELLULAR BIOL YE, P91; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; LEYMAN B, UNPUB; Linial M, 1997, J PHYSIOL-LONDON, V504, P251, DOI 10.1111/j.1469-7793.1997.251be.x; LOUGUET P, 1990, BIOCHEM PHYSIOL PFL, V186, P273, DOI 10.1016/S0015-3796(11)80218-0; LOUVAINLANEUVE AD, 1995, J BIOL CHEM, V270, P23828; LUBBERT H, 1987, P NATL ACAD SCI USA, V84, P4332, DOI 10.1073/pnas.84.12.4332; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Sambrook J., 1989, MOL CLONING; SCHROEDER JI, 1995, PLANT MOL BIOL, V28, P353, DOI 10.1007/BF00020385; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Solsona C, 1998, BIOPHYS J, V74, P1061, DOI 10.1016/S0006-3495(98)74030-5; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; Thiel G, 1998, PLANT MOL BIOL, V38, P111, DOI 10.1023/A:1006038122009; Willmer C., 1996, STOMATA, P1; ZHANG RE, 1995, GENE, V159, P293, DOI 10.1016/0378-1119(95)00152-V	39	175	192	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1999	283	5401					537	540		10.1126/science.283.5401.537	http://dx.doi.org/10.1126/science.283.5401.537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159YM	9915701				2022-12-01	WOS:000078203300037
J	Schneider, MME; Borleffs, JCC; Stolk, RP; Jaspers, CAJJ; Hoepelman, AIM				Schneider, MME; Borleffs, JCC; Stolk, RP; Jaspers, CAJJ; Hoepelman, AIM			Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIMETHOPRIM-SULFAMETHOXAZOLE; INFECTION; AIDS	Background Prophylactic drugs for Pneumocystis carinii pneumonia (PCP) are strongly recommended for HIV-1-infected patients with CD4 cell counts of less than 200 cells/mu L. Because of the highly active antiretroviral therapy (HAART) currently available, we speculated that prophylaxis can be discontinued in patients with CD4 cell counts of more than 200 cells/mu L. Methods In this prospective observational study, PCP prophylaxis (primary or secondary) was discontinued in HIV-1-infected patients whose CD4 cell count had increased above 200 cells/mu L (documented twice with an interval of at least 1 month) as a result of HAART. Patients and their CD4 cell counts were monitored every 3 months. The primary endpoint of the study was the occurrence or reoccurrence of PCP. Findings 78 patients were enrolled: 62 patients were receiving prophylaxis for primary prevention of PCP and 16 patients for secondary prevention of PCP. At the time of discontinuation of prophylaxis, the mean CD4 cell count was 347 cells/mu L, and HIV-1-RNA was not detectable in 61 patients. The lowest mean CD4 cell count during prophylaxis was 79 cells/mu L. Patients stopped prophylaxis 9.8 (SD 6.4) months after they started HAART, The mean follow-up after discontinuation of prophylaxis was 12.7 (SD 7.6) months, and none of the patients developed PCP (97.5% one-sided CI 0-4.4%). Interpretation The preliminary results of this study indicate that PCP prophylaxis can be stopped safely in HIV-1-infected patients whose CD4 cell counts have increased above 200 cells/mu L after treatment with HAART.	Univ Utrecht Hosp, Dept Internal Med, Div Infect Dis & AIDS, NL-3508 GA Utrecht, Netherlands; Univ Utrecht Hosp, Eijkman Winkler Inst, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Julius Ctr Patient Oriented Res, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University	Schneider, MME (corresponding author), Univ Utrecht Hosp, Dept Internal Med, Div Infect Dis & AIDS, POB 85500, NL-3508 GA Utrecht, Netherlands.		Stolk, Ronald P/B-2341-2013	Stolk, Ronald P/0000-0002-0518-1205				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; MOORE RD, 1998, 5 C RETR OPP INF CHI, P184; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Roederer M, 1998, NAT MED, V4, P145, DOI 10.1038/nm0298-145; ROWE PM, 1998, LANCET, V350, P720; SCHNEIDER MME, 1995, J INFECT DIS, V171, P1632, DOI 10.1093/infdis/171.6.1632; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; Sepkowitz KA, 1998, LANCET, V351, P228, DOI 10.1016/S0140-6736(05)78279-9; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; *USPHS IDSA PREV O, 1997, MMWR-MORBID MORTAL W, V46, P1; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519	19	136	140	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					201	203		10.1016/S0140-6736(98)07204-3	http://dx.doi.org/10.1016/S0140-6736(98)07204-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923876				2022-12-01	WOS:000078175600013
J	Stebbins, CE; Kaelin, WG; Pavletich, NP				Stebbins, CE; Kaelin, WG; Pavletich, NP			Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function	SCIENCE			English	Article							HIPPEL-LINDAU GENE; ENDOTHELIAL GROWTH-FACTOR; RENAL-CARCINOMA; SOMATIC MUTATIONS; F-BOX; PROTEIN; PRODUCT; UBIQUITIN; BINDING; FAMILY	Mutation of the VHL tumor suppressor is associated with the inherited von Hippel-Lindau (VHL) cancer syndrome and the majority of kidney cancers. VHL binds the ELonginC-ELonginB complex and regulates Levels of hypoxia-inducible protei ns. The structure of the ternary complex at 2.7 angstrom resolution shows two interfaces, one between VHL and ELonginC and another between ELonginC and ELonginB. Tumorigenic mutations frequently occur in a 35-residue domain of VHL responsible for ELonginC binding. A mutational patch on a separate domain of VHL indicates a second macromolecular binding site. The structure extends the similarities to the SCF (Skp1-Cul1-F-box protein) complex that targets proteins for degradation, supporting the hypothesis that VHL may function in an analogous pathway.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Dept Biochem & Struct Biol, New York, NY 10021 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		Stebbins, Erec/N-2565-2018	Stebbins, Erec/0000-0001-6229-5308				ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KISHIDA T, 1995, CANCER RES, V55, P4544; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; Miller RT, 1996, FASEB J, V10, P171, DOI 10.1096/fasebj.10.1.8566539; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; SHUIN T, 1994, CANCER RES, V54, P2852; Siemeister G, 1996, CANCER RES, V56, P2299; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takagi Y, 1997, J BIOL CHEM, V272, P27444, DOI 10.1074/jbc.272.43.27444; Takagi Y, 1996, J BIOL CHEM, V271, P25562, DOI 10.1074/jbc.271.41.25562; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	41	656	675	5	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					455	461		10.1126/science.284.5413.455	http://dx.doi.org/10.1126/science.284.5413.455			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205047				2022-12-01	WOS:000079792200038
J	Takeda, K; Takeuchi, O; Tsujimura, T; Itami, S; Adachi, O; Kawai, T; Sanjo, H; Yoshikawa, K; Terada, N; Akira, S				Takeda, K; Takeuchi, O; Tsujimura, T; Itami, S; Adachi, O; Kawai, T; Sanjo, H; Yoshikawa, K; Terada, N; Akira, S			Limb and skin abnormalities in mice lacking IKK alpha	SCIENCE			English	Article							NF-KAPPA-B; TRANSCRIPTION; ACTIVATION; KINASE; DISRUPTION; INHIBITION; TWIST; GENE; BETA	The gene encoding inhibitor of kappa B (I kappa B) kinase alpha (IKK alpha; also called IKK1) was disrupted by gene targeting. IKK alpha-deficient mice died perinatally. In IKK alpha-deficient fetuses, Limb outgrowth was severely impaired despite unaffected skeletal development. The epidermal cells in IKK alpha-deficient fetuses were highly proliferative with dysregulated epidermal differentiation. In the basal layer, degradation of I kappa B and nuclear localization of nuclear factor kappa B (NF-kappa B) were not observed. Thus, IKK alpha is essential for NF-kappa B activation in the limb and skin during embryogenesis. In contrast, there was no impairment of NF-kappa B activation induced by either interleukin-1 or tumor necrosis factor-alpha in IKK alpha-deficient embryonic fibroblasts and thymocytes, indicating that IKK alpha is not essential for cytokine-induced activation of NF-kappa B.	Japan Sci & Technol Corp, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan; Japan Sci & Technol Corp, CREST, Nishinomiya, Hyogo 6638501, Japan; Hyogo Coll Med, Dept Pathol, Nishinomiya, Hyogo 6638501, Japan; Osaka Univ, Sch Med, Dept Dermatol, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Hyogo College of Medicine; Osaka University	Akira, S (corresponding author), Japan Sci & Technol Corp, Dept Biochem, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.		Takeda, Kiyoshi/C-9331-2009; Takeuchi, Osamu/AAG-9359-2019; Takeuchi, Osamu/D-6007-2011; Akira, Shizuo/C-3134-2009	Takeuchi, Osamu/0000-0002-1260-6232; Kawai, Taro/0000-0001-7510-4662				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOUZZI VE, 1997, NAT GENET, V15, P42; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; HOWARD TD, 1997, NAT GENET, V15, P41; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Ma SH, 1997, GENE EXPRESSION, V6, P361; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; PAN D, 1993, GENE DEV, V7, P694; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SCHWYTER DH, 1995, MOL CELL BIOL, V15, P3960; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TAKEDA K, UNPUB; Tomic-Canic M, 1998, J DERMATOL SCI, V17, P167, DOI 10.1016/S0923-1811(98)00016-4; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	23	519	544	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					313	316		10.1126/science.284.5412.313	http://dx.doi.org/10.1126/science.284.5412.313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195895				2022-12-01	WOS:000079636400041
J	Tanimoto, K; Liu, QH; Bungert, J; Engel, JD				Tanimoto, K; Liu, QH; Bungert, J; Engel, JD			Effects of altered gene order or orientation of the locus control region on human beta-globin gene expression in mice	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOME; DEVELOPMENTAL REGULATION; TRANSGENIC MICE; EPSILON-GLOBIN; GAMMA-GLOBIN; TRANSCRIPTION	The five human beta-type-globin genes, epsilon, G gamma, A gamma, delta and beta, are close together and are regulated by a locus control region (LCR) located at the 5' end of the locus(1,2). Here we investigate the functional consequences of this organization with respect to temporal regulation of the individual genes, by using recombination techniques to invert the order of either the genes or the LCR in vivo. Our analysis of transgenic mice bearing either normal or mutant transgenes leads to two new observations. First, the position of the epsilon-globin gene next to the LCR is mandatory for its expression during the yolk-sac stage of erythropoiesis. Second, LCR activity is orientation dependent, and so the LCR does not act as a simple enhancer to stimulate transcription of the globin genes. Thus, in the absence of any change in transgene integration position, transgene copy number, trans-acting factors or other resident genetic information, simple inversion of the human genes or the LCR fundamentally alters the transcription of beta-type globin genes.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Engel, JD (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.		Tanimoto, Keiji/B-2600-2014	Tanimoto, Keiji/0000-0003-1971-6546	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052356] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL024415] Funding Source: Medline; NIDDK NIH HHS [R01 DK052356, R01 DK052356-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DILLON N, 1997, MOL CELL, V1, P13; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; Hogan B., 1986, MANIPULATING MOUSE E; LI QL, 1994, BLOOD, V84, P1399; Liu QH, 1998, P NATL ACAD SCI USA, V95, P9944, DOI 10.1073/pnas.95.17.9944; Liu QH, 1997, P NATL ACAD SCI USA, V94, P169, DOI 10.1073/pnas.94.1.169; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SAUER B, 1990, New Biologist, V2, P441; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; YU JH, 1994, GENE, V139, P139, DOI 10.1016/0378-1119(94)90747-1; ZAFARANA G, 1995, MOL BIOL HEMOGLOBIN, P39	24	139	141	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 25	1999	398	6725					344	348		10.1038/18698	http://dx.doi.org/10.1038/18698			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DF	10192336				2022-12-01	WOS:000079369600054
J	Minami, M; Kinoshita, M; Kamoshida, Y; Tanimoto, H; Tabata, T				Minami, M; Kinoshita, M; Kamoshida, Y; Tanimoto, H; Tabata, T			Brinker is a target of Dpp in Drosophila that negatively regulates Dpp-dependent genes	NATURE			English	Article							WING DEVELOPMENT; EXPRESSION; GRADIENT; XENOPUS; MOTHERS; CELLS	Growth and patterning of the Drosophila wing is controlled in part by the long-range organizing activities of the Decapentaplegic protein (Dpp)(1-4). Dpp is synthesized by cells that line the anterior side of the anterior/posterior compartment border of the wing imaginal disc. From this source, Dpp is thought to generate a concentration gradient that patterns both anterior and posterior compartments. Among the gene targets that it regulates are optomotor blind (omb)(5), spalt (sal)(6), and daughters against dpp (dad)(7). We report here the molecular cloning of brinker (brk), and show that brk expression is repressed by npp. brk encodes, a protein that negatively regulates Dpp-dependent genes. Expression of brk in Xenopus embryos indicates that brk can also repress the targets of a vertebrate homologue of Dpp, bone morphogenetic protein 4 (BMP-4). The evolutionary conservation of Brk function underscores the importance of its negative role in proportioning Dpp activity.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Fuchu, Tokyo 1838526, Japan	University of Tokyo; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Tabata, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.		Tanimoto, Hiromu/J-6810-2016	Kinoshita, Noriyuki/0000-0002-1362-4045				BLITZ IL, 1995, DEVELOPMENT, V121, P993; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Duffy JB, 1998, DEVELOPMENT, V125, P2263; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Inoue H, 1998, MOL BIOL CELL, V9, P2145, DOI 10.1091/mbc.9.8.2145; JAZWINSKA A, 1998, A C DROS RES, V39, pA244; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Nieuwkoop P.D., 1994, SYSTEMATICAL CHRONOL, DOI 10.1201/9781003064565-29; RUSHLOW C, 1998, A C DROS RES, V39, pB245; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; WAGNERBERNHOLZ JT, 1991, GENE DEV, V5, P2467, DOI 10.1101/gad.5.12b.2467; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	27	190	193	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	1999	398	6724					242	246		10.1038/18451	http://dx.doi.org/10.1038/18451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UA	10094047				2022-12-01	WOS:000079228400054
J	Malnic, B; Hirono, J; Sato, T; Buck, LB				Malnic, B; Hirono, J; Sato, T; Buck, LB			Combinatorial receptor codes for odors	CELL			English	Article							OLFACTORY-BULB; CAENORHABDITIS-ELEGANS; LOCAL-DISTRIBUTION; MULTIGENE FAMILY; GENE-EXPRESSION; NEURONS; ORGANIZATION; EPITHELIUM; SYSTEM; CELLS	The discriminatory capacity of the mammalian olfactory system is such that thousands of volatile chemicals are perceived as having distinct odors. Here we used a combination of calcium imaging and single-cell RT-PCR to identify odorant receptors (ORs) for odorants with related structures but varied odors. We found that one OR recognizes multiple odorants and that one odorant is recognized by multiple ORs, but that different odorants are recognized by different combinations of ORs. Thus, the olfactory system uses a combinatorial receptor coding scheme to encode odor identities. Our studies also indicate that slight alterations in an odorant, or a change in its concentration, can change its "code," potentially explaining how such changes can alter perceived odor quality.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02115 USA; Electrotech Lab, Life Elect Res Ctr, Amagasaki, Hyogo 661, Japan	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; National Institute of Advanced Industrial Science & Technology (AIST)	Sato, T (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02115 USA.	tasato@etl.go.jp; lbuck@hms.harvard.edu	Sato, Takaaki/K-2898-2018; Malnic, Bettina/A-4905-2008	Sato, Takaaki/0000-0003-0746-9074; Malnic, Bettina/0000-0002-5877-4784				ADRIAN ED, 1950, BRIT MED BULL, V6, P330, DOI 10.1093/oxfordjournals.bmb.a073625; Amoore, 1970, MOL BASIS ODOR; Arctander S., 1969, PERFUME FLAVOR CHEM, VI and II; BEETS MGJ, 1970, PHARMACOL REV, V22, P1; BRUNJES PC, 1994, BRAIN RES REV, V19, P146; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; CAIN WS, 1988, STEVENS HDB EXPT PSY, V1, P409; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chou JH, 1996, COLD SPRING HARB SYM, V61, P157; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE KM, 1993, P NATL ACAD SCI USA, V90, P3329, DOI 10.1073/pnas.90.8.3329; HIRONO J, 1992, J NEUROSCI METH, V42, P185, DOI 10.1016/0165-0270(92)90098-X; HIRONO J, 1994, NEUROSCI LETT, V174, P201, DOI 10.1016/0304-3940(94)90021-3; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; LAING DG, 1989, PHYSIOL BEHAV, V46, P809, DOI 10.1016/0031-9384(89)90041-3; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; Laurent G, 1997, CURR OPIN NEUROBIOL, V7, P547, DOI 10.1016/S0959-4388(97)80035-9; LEVETEAU J, 1966, SCIENCE, V153, P175, DOI 10.1126/science.153.3732.175; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; POLAK EH, 1973, J THEOR BIOL, V40, P469, DOI 10.1016/0022-5193(73)90005-2; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RESTREPO D, 1993, J GEN PHYSIOL, V102, P907, DOI 10.1085/jgp.102.5.907; Sambrook J., 1989, MOL CLONING LAB MANU; SATO T, 1994, J NEUROPHYSIOL, V72, P2980, DOI 10.1152/jn.1994.72.6.2980; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Shepherd G. M., 1988, NEUROBIOLOGY; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; YOKOI M, 1995, P NATL ACAD SCI USA, V92, P3371, DOI 10.1073/pnas.92.8.3371; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	46	1550	1613	12	228	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 5	1999	96	5					713	723		10.1016/S0092-8674(00)80581-4	http://dx.doi.org/10.1016/S0092-8674(00)80581-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	174TB	10089886	Bronze			2022-12-01	WOS:000079050100014
J	Sequeira, W				Sequeira, W			Yoga in treatment of carpal-tunnel syndrome	LANCET			English	Editorial Material									Cook Cty Hosp, Rush Med Coll, Div Rheumatol, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County; Rush University	Sequeira, W (corresponding author), Cook Cty Hosp, Rush Med Coll, Div Rheumatol, Chicago, IL 60612 USA.							GARFINKEL MS, 1994, J RHEUMATOL, V21, P2341; Garfinkel MS, 1998, JAMA-J AM MED ASSOC, V280, P1601, DOI 10.1001/jama.280.18.1601; HASLOCK I, 1994, BRIT J RHEUMATOL, V33, P787; MEHTA S, 1990, YOGA INVENGAR WAY; MEYERS E, 1996, YOUGA YOU, P9; Vedanthan PK, 1998, ALLERGY ASTHMA PROC, V19, P3, DOI 10.2500/108854198778557971; vonSchroeder HP, 1996, HAND CLIN, V12, P643	7	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 27	1999	353	9154					689	690		10.1016/S0140-6736(98)00393-6	http://dx.doi.org/10.1016/S0140-6736(98)00393-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DR	10073507				2022-12-01	WOS:000078966400005
J	Buck, E; Li, JR; Chen, YB; Weng, GZ; Scarlata, S; Iyengar, R				Buck, E; Li, JR; Chen, YB; Weng, GZ; Scarlata, S; Iyengar, R			Resolution of a signal transfer region from a general binding domain in G beta for stimulation of phospholipase C-beta 2	SCIENCE			English	Article							OPIOID RECEPTOR ANTAGONISTS; MESSAGE-ADDRESS CONCEPT; SUBUNIT; DESIGN; GAMMA	Signaling by guanine nucleotide-binding proteins (G proteins) involves sequential protein-protein interactions. G protein-beta gamma subunit (G beta gamma) interactions with phospholipase C-beta 2 (PLC-beta 2) were studied to determine if all G beta contacts are required for signaling. A peptide encoding G beta amino acid residues 86 to 105 stimulated PLC-beta 2. Six residues (96 to 101) within this sequence could transfer signals and thus constitute a core signal transfer region. Another peptide, encoding G beta amino acid residues 115 to 135, did not substantially stimulate PLC-beta 2 by itself but inhibited G beta gamma stimulation, indicating that residues 115 to 135 constitute a general binding domain. Resolution of signal transfer regions from general binding domains indicates that all protein-protein contacts are not required for signal transfer and that it may be feasible to synthesize agonists and antagonists that regulate intracellular signal flaw.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11729 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Iyengar, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215, New York, NY 10029 USA.	iyengar@msvax.mssm.edu			NIDDK NIH HHS [DK-38761] Funding Source: Medline; NIGMS NIH HHS [GM-43125, GM-54508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; PORTOGHESE PS, 1989, TRENDS PHARMACOL SCI, V10, P230, DOI 10.1016/0165-6147(89)90267-8; PORTOGHESE PS, 1990, J MED CHEM, V33, P1714, DOI 10.1021/jm00168a028; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Runnels LW, 1998, BIOCHEMISTRY-US, V37, P15563, DOI 10.1021/bi9811258; SCHWYZER R, 1980, PROC R SOC SER B-BIO, V210, P5, DOI 10.1098/rspb.1980.0115; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Yan K, 1997, J BIOL CHEM, V272, P2056	14	33	34	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1332	1335		10.1126/science.283.5406.1332	http://dx.doi.org/10.1126/science.283.5406.1332			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037604				2022-12-01	WOS:000078839900043
J	Chae, CU; Pfeffer, MA; Glynn, RJ; Mitchell, GF; Taylor, JO; Hennekens, CH				Chae, CU; Pfeffer, MA; Glynn, RJ; Mitchell, GF; Taylor, JO; Hennekens, CH			Increased pulse pressure and risk of heart failure in the elderly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTOLIC BLOOD-PRESSURE; AGE-RELATED-CHANGES; MYOCARDIAL-INFARCTION; ARTERIAL DISTENSIBILITY; NORMOTENSIVE SUBJECTS; AORTIC COMPLIANCE; WAVE VELOCITY; HYPERTENSION; ATHEROSCLEROSIS; PROGRESSION	Context Arterial stiffness increases with age, Thus, pulse pressure, an index of arterial stiffening, may predict congestive heart failure (CHF) in the elderly. Objective To study prospectively the association between pulse pressure and risk of CHF, Design Prospective cohort study. Setting The community-based East Boston Senior Health Project, East Boston, Mass. Patients A total of 1621 men and women (mean [SD] age, 77.9 [5.0] years) free of CHF who had blood pressure measurements taken in 1988-1989 and were followed up for 3.8 years. Main Outcome Measure Incidence of CHF as ascertained by hospital discharge diagnosis (n = 208) and death certificates (n = 13), Results After controlling for age, sex, mean arterial pressure, history of coronary heart disease, diabetes mellitus, atrial fibrillation, valvular heart disease, and antihypertensive medication use, pulse pressure was an independent predictor of CHF. For each 10-mm Hg elevation in pulse pressure, there was a 14% increase in risk of CHF (95% confidence interval, 1.05-1.24; P = .003). Those in the highest tertile of pulse pressure (>67 mm Hg) had a 55% increased risk of CHF (P = .02) compared with those in the lowest (<54 mm Hg). Pulse pressure was more predictive than systolic blood pressure alone and was independent of diastolic blood pressure. Conclusion Pulse pressure, an easily measurable correlate of pulsatile hemodynamic load, is an independent predictor of risk of CHF in this elderly cohort.	Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; E Boston Neighborhood Hlth Ctr, E Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Chae, CU (corresponding author), Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.				NHLBI NIH HHS [HL-07575] Funding Source: Medline; NIA NIH HHS [N01AG02107] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVOLIO AP, 1986, ARTERIOSCLEROSIS, V6, P166, DOI 10.1161/01.ATV.6.2.166; Ayanian JZ, 1998, HEALTH AFFAIR, V17, P194, DOI 10.1377/hlthaff.17.6.194; Benetos A, 1997, HYPERTENSION, V30, P1410, DOI 10.1161/01.HYP.30.6.1410; BUCKBERG GD, 1972, CIRC RES, V30, P67, DOI 10.1161/01.RES.30.1.67; Cornoni-Huntley J., 1986, ESTABLISHED POPULATI; DARNE B, 1989, HYPERTENSION, V13, P392, DOI 10.1161/01.HYP.13.4.392; DZAU VJ, 1988, CIRCULATION, V77, P947, DOI 10.1161/01.CIR.77.5.947; FANG J, 1995, J HYPERTENS, V13, P413; FARRAR DJ, 1991, CIRCULATION, V83, P1754, DOI 10.1161/01.CIR.83.5.1754; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Franklin SS, 1997, CIRCULATION, V96, P308; FRANKLIN SS, 1994, AM HEART J, V128, P793, DOI 10.1016/0002-8703(94)90278-X; GARDIN JM, 1997, HYPERTENSION, V29, P195; GIRERD X, 1991, AM HEART J, V122, P1210, DOI 10.1016/0002-8703(91)90941-A; GLYNN RJ, 1993, AM J EPIDEMIOL, V138, P365, DOI 10.1093/oxfordjournals.aje.a116869; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; *HYP DET FOLL UP P, 1977, JAMA-J AM MED ASSOC, V237, P2385; KANNEL WB, 1994, BRIT HEART J, V72, P3; Kass DA, 1996, CIRCULATION, V93, P1533, DOI 10.1161/01.CIR.93.8.1533; KELLY R, 1989, CIRCULATION, V80, P1652, DOI 10.1161/01.CIR.80.6.1652; KELLY RP, 1992, CIRC RES, V71, P490, DOI 10.1161/01.RES.71.3.490; Kohno F, 1996, CIRCULATION, V93, P2080, DOI 10.1161/01.CIR.93.11.2080; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; LATSON TW, 1988, CIRC RES, V62, P884, DOI 10.1161/01.RES.62.5.884; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; LYON RT, 1987, J VASC SURG, V5, P59, DOI 10.1067/mva.1987.avs0050059; MADHAVAN S, 1994, HYPERTENSION, V23, P395, DOI 10.1161/01.HYP.23.3.395; MILNOR WR, 1975, CIRC RES, V36, P565, DOI 10.1161/01.RES.36.5.565; Mitchell GF, 1997, CIRCULATION, V96, P4254; Mitchell GF, 1996, CIRCULATION, V94, P2923, DOI 10.1161/01.CIR.94.11.2923; *NAT HEART LUNG BL, 1996, CONG HEART FAIL US N; OROURKE MF, 1982, ATERIAL FUNCTION HLT; SABA PS, 1993, J AM COLL CARDIOL, V22, P1873, DOI 10.1016/0735-1097(93)90772-S; SAEKI A, 1995, CIRC RES, V76, P132, DOI 10.1161/01.RES.76.1.132; SCHLATMANN TJM, 1977, AM J CARDIOL, V39, P13, DOI 10.1016/S0002-9149(77)80004-0; Smulyan H, 1997, J AM COLL CARDIOL, V29, P1407, DOI 10.1016/S0735-1097(97)00081-8; TING CT, 1986, J CLIN INVEST, V78, P1462, DOI 10.1172/JCI112737; URSCHEL CW, 1968, AM J PHYSIOL, V214, P298, DOI 10.1152/ajplegacy.1968.214.2.298; WATANABE H, 1993, J AM COLL CARDIOL, V21, P1497, DOI 10.1016/0735-1097(93)90330-4; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1	41	405	431	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					634	639		10.1001/jama.281.7.634	http://dx.doi.org/10.1001/jama.281.7.634			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YA	10029125	Bronze			2022-12-01	WOS:000078548400034
J	Buckley, CD; Pilling, D; Henriquez, NV; Parsonage, G; Threlfall, K; Scheel-Toellner, D; Simmons, DL; Albar, AN; Lord, JM; Salmon, M				Buckley, CD; Pilling, D; Henriquez, NV; Parsonage, G; Threlfall, K; Scheel-Toellner, D; Simmons, DL; Albar, AN; Lord, JM; Salmon, M			RGD peptides induce apoptosis by direct caspase-3 activation	NATURE			English	Article							CELL-DEATH; ADHESION; PROTEOLYSIS; INHIBITION; INTEGRINS; PROTEIN; CED-4	Synthetic peptides containing the arginine-glycine-aspartate (RGD) motif have been used extensively as inhibitors of integrin-ligand interactions in studies of cell adhesion, migration, growth and differentiation(1-3), because the RGD motif is an integrin-recognition motif found in many ligands. Here we report that RGD-containing peptides are able to directly induce apoptosis without any requirement for integrin-mediated cell clustering or signals. We show that RGD-containing peptides enter cells and directly induce autoprocessing and enzymatic activity of pro-caspase-3, a pro-apoptotic protein. Using the breast carcinoma cell line MCF-7, which has a functional deletion of the caspase-3 gene, we confirm that caspase-3 is required for RGD-mediated cell death, In addition to an RGD motif, pro-caspase-3 also contains a potential RGD-binding motif, aspartate-aspartate-methionine (DDM)(4), near the site of processing to produce the p12 and p17 subunits(5). On the basis of the ability of RGD-DDX interactions to trigger integrin activation(6), we suggest that RGD peptides induce apoptosis by triggering conformational changes that promote pro-caspase-3 autoprocessing and activation. These findings provide an alternative molecular explanation for the potent pro-apoptotic properties of RGD peptides in models of angiogenesis, inflammation and cancer metastasis(7-9).	Univ Birmingham, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Inst Canc Studies, MRC, Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow CM19 5AW, Essex, England; Royal Free Hosp, Dept Clin Immunol, London NW3 2PF, England; Univ Coll, Sch Med, London NW3 2PF, England	University of Birmingham; University of Birmingham; GlaxoSmithKline; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School	Salmon, M (corresponding author), Univ Birmingham, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England.	M.Salmon@bham.ac.uk	Buckley, Christopher/AAN-6378-2021; Henriquez, Nico/C-3758-2008	Buckley, Christopher/0000-0001-6924-6402; Pilling, Darrell/0000-0002-7413-2773; Lord, Janet/0000-0003-1030-6786	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; Jacobson MD, 1997, TRENDS CELL BIOL, V7, P467, DOI 10.1016/S0962-8924(97)01182-3; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LWEBUGAMUKASA JS, 1994, AM J RESP CELL MOL, V10, P347, DOI 10.1165/ajrcmb.10.4.8136151; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Salmon M, 1997, J CLIN INVEST, V99, P439, DOI 10.1172/JCI119178; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	382	421	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 11	1999	397	6719					534	539		10.1038/17409	http://dx.doi.org/10.1038/17409			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KN	10028971				2022-12-01	WOS:000078574900053
J	Hamamori, Y; Sartorelli, V; Ogryzko, V; Puri, PL; Wu, HY; Wang, JYJ; Nakatani, Y; Kedes, L				Hamamori, Y; Sartorelli, V; Ogryzko, V; Puri, PL; Wu, HY; Wang, JYJ; Nakatani, Y; Kedes, L			Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A	CELL			English	Article							LOOP-HELIX PROTEIN; TRANSCRIPTION FACTORS; MUSCLE DIFFERENTIATION; GENE-TRANSCRIPTION; DEVELOPING SOMITES; GROWTH-FACTOR; CELL-CYCLE; MYOD; COACTIVATOR; ACETYLATION	Histone acetyltransferases (HAT) play a critical role in transcriptional control by relieving repressive effects of chromatin, and yet how HATs themselves are regulated remains largely unknown. Here, it is shown that Twist directly binds two independent HAT domains of acetyltransferases, p300 and p300/CBP-associated factor (PCAF), and directly regulates their HAT activities. The N terminus of Twist is a primary domain interacting with both acetyltransferases, and the same domain is required for inhibition of p300-dependent transcription by Twist. Adenovirus E1A protein mimics the effects of Twist by inhibiting the HAT activities of p300 and PCAF. These findings establish a cogent argument for considering the HAT domains as a direct target for acetyltransferase regulation by both a cellular transcription factor and a viral oncoprotein.	Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Inst Med Genet, Los Angeles, CA 90033 USA; NICHHD, Lab Mol Growth Regulat, Bethesda, MD 20892 USA; Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA; Univ Rome La Sapienza, Policlin Umberto I, Inst Clin Med 1, Fdn Andrea Cesalpino,Lab Gene Express, I-00161 Rome, Italy	University of Southern California; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California San Diego; Sapienza University Rome; University Hospital Sapienza Rome	Hamamori, Y (corresponding author), Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Inst Med Genet, Los Angeles, CA 90033 USA.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389; Puri, Pier Lorenzo/0000-0003-4964-0095; Sartorelli, Vittorio/0000-0002-9284-3675	NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320, CA58320] Funding Source: Medline; Telethon [1072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon)		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BOULUKOS KE, 1993, ONCOGENE, V8, P237; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CARUSO M, 1993, ONCOGENE, V8, P267; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MARUYAMA K, 1987, ONCOGENE, V1, P361; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pullner A, 1996, J BIOL CHEM, V271, P31452, DOI 10.1074/jbc.271.49.31452; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; StanfieldOakley SA, 1996, J MOL BIOL, V256, P503, DOI 10.1006/jmbi.1996.0104; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WADE PA, 1997, CURR BIOL, V7, P82; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	55	317	326	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 5	1999	96	3					405	413		10.1016/S0092-8674(00)80553-X	http://dx.doi.org/10.1016/S0092-8674(00)80553-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025406	Bronze			2022-12-01	WOS:000078514600013
J	Ostermeier, C; Brunger, AT				Ostermeier, C; Brunger, AT			Structural basis of Rab effector specificity: Crystal structure of the small G protein Rab3A complexed with the effector domain of Rabphilin-3A	CELL			English	Article							SYNAPTIC-VESICLE FUSION; MACROMOLECULAR STRUCTURES; PHOSPHOLIPID-BINDING; ADENYLYL-CYCLASE; GTP HYDROLYSIS; MECHANISM; DIFFRACTION; RESOLUTION; TRANSPORT; ALPHA	The small G protein Rab3A plays an important role in the regulation of neurotransmitter release. The crystal structure of activated Rab3A/GTP/Mg2+ bound to the effector domain of rabphilin-3A was solved to 2.6 Angstrom resolution. Rabphilin-3A contacts Rab3A in two distinct areas. The first interface involves the Rab3A switch I and switch II regions, which are sensitive to the nucleotide-binding state of Rab3A. The second interface consists of a deep pocket in Rab3A that interacts with a SGAWFF structural element of rabphilin-3A. Sequence and structure analysis, and biochemical data suggest that this pocket, or Rab complementarity-determining region (RabCDR), establishes a specific interaction between each nab protein and its effecters. RabCDRs could be major determinants of effector specificity during vesicle trafficking and fusion.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University	Brunger, AT (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.	brunger@laplace.csb.yale.edu		Brunger, Axel/0000-0001-5121-2036				BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Conner S, 1998, DEV BIOL, V203, P334, DOI 10.1006/dbio.1998.9057; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DUMAS JJ, 1998, IN PRESS STRUCTURE; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATO M, 1994, BIOCHEM BIOPH RES CO, V205, P1776, DOI 10.1006/bbrc.1994.2875; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; MCKLEMAN CJ, 1996, MOL CELL BIOL, V16, P4985; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Neu M, 1997, PROTEINS, V27, P204, DOI 10.1002/(SICI)1097-0134(199702)27:2<204::AID-PROT6>3.0.CO;2-F; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pannu NS, 1998, ACTA CRYSTALLOGR D, V54, P1285, DOI 10.1107/S0907444998004119; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; *POV RAY TEAM, 1998, POV RAY PERS VIS RAY; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Sigler PB, 1996, ALFRED BENZON SYMP S, V39, P17; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YONG K, 1990, ACTA CRYSTALLOGR A, V46, P41	85	282	292	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					363	374		10.1016/S0092-8674(00)80549-8	http://dx.doi.org/10.1016/S0092-8674(00)80549-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025402	Bronze			2022-12-01	WOS:000078514600009
J	Udachin, KA; Ripmeester, JA				Udachin, KA; Ripmeester, JA			A complex clathrate hydrate structure showing bimodal guest hydration	NATURE			English	Article							STRUCTURE-H HYDRATE; GAS HYDRATE; FLUORIDE; MEXICO; GULF	Interactions between hydrophobic groups in water(1), as well as biomolecular hydration more generally(2-4), are intimately connected to the structure of liquid water around hydrophobic solutes. Such considerations have focused interest on clathrate hydrates: crystals in which a hydrogen-bonded network of water molecules encages hydrophobic guest molecules with which the water interacts only by non-directional van der Waals forces. Three structural families of clathrate hydrates have hitherto been recognized: cubic structure I (2MS . 6M(L). 46H(2)O) (ref, 5), cubic structure II (16M(S). 8M(L). 136H(2)O) (ref. 5) and hexagonal structure H (M-L. 3M(S). 2M(S). 34H(2)O) (refs 6, 7) hydrates (here M-L and M-S are the hydrophobic guest sites associated with large and small cavities, respectively). Here we report a new hydrate structure: 1.67 choline hydroxide;tetra-n-propylammonium fluoride . 30.33H(2)O. This structure has a number of unusual features; in particular the choline guest exhibits both hydrophobic and hydrophilic modes of hydration. Formally the structure consists of alternating stacks of structure H and structure II hydrates, and might conceivably be found in those settings (such as seafloor deposits over natural-gas fields) in which clathrate hydrates form naturally.	Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Ripmeester, JA (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.		Ripmeester, John A/G-1950-2011					[Anonymous], [No title captured]; BLOKZIJL W, 1993, ANGEW CHEM INT EDIT, V32, P1545, DOI 10.1002/anie.199315451; BOUQUIERE JP, 1994, ACTA CRYSTALLOGR B, V50, P566, DOI 10.1107/S0108768194002211; DAVIDSON DW, 1986, GEOCHIM COSMOCHIM AC, V50, P619, DOI 10.1016/0016-7037(86)90110-9; DYADIN YA, 1988, J INCLUSION PHENOM, V6, P565, DOI 10.1007/BF00656337; Gies H., 1991, INCLUSION COMPOUNDS, V5, P1; HEADGORDON T, 1995, P NATL ACAD SCI USA, V92, P8308, DOI 10.1073/pnas.92.18.8308; Jeffrey G. A., 1984, INCLUSION COMPOUNDS, V1, P135; KVENVOLDEN KA, 1994, ANN NY ACAD SCI, V715, P232, DOI 10.1111/j.1749-6632.1994.tb38838.x; LIPKOWSKI J, 1992, J INCLUS PHENOM MOL, V13, P295, DOI 10.1007/BF01042788; Lipscomb LA, 1996, BIOPOLYMERS, V38, P177, DOI 10.1002/(SICI)1097-0282(199602)38:2<177::AID-BIP4>3.0.CO;2-S; Martorana V, 1997, BIOPHYS J, V73, P31, DOI 10.1016/S0006-3495(97)78044-5; RIPMEESTER JA, 1987, NATURE, V325, P135, DOI 10.1038/325135a0; SASSEN R, 1994, ORG GEOCHEM, V22, P1029, DOI 10.1016/0146-6380(94)90036-1; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SLOAN ED, 1996, CLATHRATE HYDRATES N; Smelik EA, 1996, Z KRISTALLOGR, V211, P84; Udachin KA, 1997, SUPRAMOL CHEM, V8, P173, DOI 10.1080/10610279708034933	18	78	80	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					420	423		10.1038/17097	http://dx.doi.org/10.1038/17097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989406				2022-12-01	WOS:000078461700043
J	Wu, KJ; Polack, A; Dalla-Favera, R				Wu, KJ; Polack, A; Dalla-Favera, R			Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC	SCIENCE			English	Article							CELL-PROLIFERATION; HEAVY-CHAIN; RIBONUCLEOTIDE REDUCTASE; GROWTH-INHIBITION; MESSENGER-RNA; EXPRESSION; TRANSCRIPTION; ACTIVATION; PROTEIN-2; CYCLE	The protein encoded by the c-MYC proto-oncogene is a transcription factor that can both activate and repress the expression of target genes, but few of its transcriptional targets have been identified. Here, c-MYC is shown to repress the expression of the heavy subunit of the protein ferritin (H-ferritin), which sequesters intracellular iron, and to stimulate the expression of the iron regulatory protein-2 (IRP2), which increases the intracellular iron pool. Downregulation of the expression of H-ferritin gene was required for cell transformation by c-MYC. These results indicate that c-MYC coordinately regulates genes controlling intracellular iron concentrations and that this function is essential for the control of cell proliferation and transformation by c-MYC.	Columbia Univ, Dept Pathol, Div Oncol, New York, NY 10032 USA; GSF Munich, Natl Res Inst Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany	Columbia University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Dalla-Favera, R (corresponding author), Columbia Univ, Dept Pathol, Div Oncol, New York, NY 10032 USA.	rd10@columbia.edu	Wu, Kou-Juey/P-4654-2015		NATIONAL CANCER INSTITUTE [R01CA037165] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; BEVILACQUA MA, 1995, BIOCHEM J, V311, P769, DOI 10.1042/bj3110769; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BRODIE C, 1993, CANCER RES, V53, P3968; BROXMEYER HE, 1991, P NATL ACAD SCI USA, V88, P770, DOI 10.1073/pnas.88.3.770; CAZZOLA M, 1990, BLOOD, V75, P1903; Coccia EM, 1997, EUR J BIOCHEM, V250, P764, DOI 10.1111/j.1432-1033.1997.00764.x; Cooper CE, 1996, J BIOL CHEM, V271, P20291, DOI 10.1074/jbc.271.34.20291; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAMPSON IN, 1992, NUCLEIC ACIDS RES, V20, P2899, DOI 10.1093/nar/20.11.2899; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HENTZE MW, 1986, P NATL ACAD SCI USA, V83, P7226, DOI 10.1073/pnas.83.19.7226; HOYES KP, 1992, CANCER RES, V52, P4591; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kulp KS, 1996, TOXICOL APPL PHARM, V139, P356, DOI 10.1006/taap.1996.0176; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIAU G, 1991, J BIOL CHEM, V266, P18819; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MATTIA E, 1990, BIOCHEM J, V267, P553, DOI 10.1042/bj2670553; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Vet JAM, 1997, BBA-MOL BASIS DIS, V1360, P39, DOI 10.1016/S0925-4439(96)00063-4	37	272	279	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1999	283	5402					676	679		10.1126/science.283.5402.676	http://dx.doi.org/10.1126/science.283.5402.676			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924025				2022-12-01	WOS:000078324400039
J	Fielden, JM; Bradbury, NS				Fielden, JM; Bradbury, NS			Observational study of defibrillation in theatre	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Royal United Hosp NHS Trust, Bath BA1 3NG, Avon, England		Fielden, JM (corresponding author), Royal Berkshire Hosp, Reading RG1 5AN, Berks, England.	jonathan@jfielden.demon.cu.uk						ALDERSON K, 1996, TIMES           0302, P3; BELL JH, 1995, ANAESTHESIA, V50, P692, DOI 10.1111/j.1365-2044.1995.tb06095.x; CHAMBERLAIN D, 1992, RESUSCITATION, V24, P111, DOI 10.1016/0300-9572(92)90016-6; *RES COUNC UK, 1994, ADV LIF SUPP HDB; THAM KY, 1994, BRIT MED J, V309, P1408, DOI 10.1136/bmj.309.6966.1408a	5	11	11	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	1999	318	7178					232	233						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915731				2022-12-01	WOS:000078292300024
J	Groves, MR; Hanlon, N; Turowski, P; Hemmings, BA; Barford, D				Groves, MR; Hanlon, N; Turowski, P; Hemmings, BA; Barford, D			The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs	CELL			English	Article							SMALL-T-ANTIGEN; SV40 SMALL-T; REGULATORY SUBUNITS; TUMOR-ANTIGENS; CELL-GROWTH; B-SUBUNIT; A-SUBUNIT; IDENTIFICATION; NUCLEAR; FAMILY	The PR65/A subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit, generating functionally diverse heterotrimers. Mutations of the beta isoform of PR65 are associated with lung and colon tumors. The crystal structure of the PR65/A alpha subunit, at 2.3 Angstrom resolution, reveals the conformation of its 15 tandemly repeated HEAT sequences, degenerate motifs of similar to 39 amino acids present in a variety of proteins, including huntingtin and importin beta. Individual motifs are composed of a pair of antiparallel or helices that assemble in a mainly linear, repetitive fashion to form an elongated molecule characterized by a double layer of cw helices. Left-handed rotations at three interrepeat interfaces generate a novel left-hand superhelical conformation. The protein interaction interface is formed from the intrarepeat turns that are aligned to form a continuous ridge.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	University of Oxford; Friedrich Miescher Institute for Biomedical Research	Barford, D (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, S Parks Rd, Oxford OX1 3QU, England.	davidb@biop.ox.ac.uk		Groves, Matthew/0000-0001-9859-5177				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN SC, 1989, J BIOL CHEM, V264, P7267; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Enenkel C, 1996, P NATL ACAD SCI USA, V93, P12986, DOI 10.1073/pnas.93.23.12986; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Goodford P, 1996, J CHEMOMETR, V10, P107; Gusella JF, 1998, CURR OPIN NEUROBIOL, V8, P425, DOI 10.1016/S0959-4388(98)80071-8; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI B, 1990, J VIROL, V64, P5649, DOI 10.1128/JVI.64.11.5649-5651.1990; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLWARD TA, 1998, IN PRESS TRENDS BIOC; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Park HW, 1997, SCIENCE, V276, P21; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SAITO T, 1995, BIOCHEMISTRY-US, V34, P7376, DOI 10.1021/bi00022a010; Snaith HA, 1996, J CELL SCI, V109, P3001; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; Turowski P, 1997, EUR J BIOCHEM, V248, P200, DOI 10.1111/j.1432-1033.1997.t01-1-00200.x; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	64	343	352	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 8	1999	96	1					99	110		10.1016/S0092-8674(00)80963-0	http://dx.doi.org/10.1016/S0092-8674(00)80963-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989501	Bronze			2022-12-01	WOS:000078023200012
J	Hoecker, U; Tepperman, JM; Quail, PH				Hoecker, U; Tepperman, JM; Quail, PH			SPA1, a WD-repeat protein specific to phytochrome A signal transduction	SCIENCE			English	Article							LIGHT CONTROL; BAC LIBRARY; ARABIDOPSIS; KINASE; COP1; ENCODES; PHOSPHORYLATES; MUTANTS; PATHWAY; CLONING	The five members of the phytochrome photoreceptor family of Arabidopsis thaliana control morphogenesis differentially in response to light. Genetic analysis has identified a signaling pathway that is specifically activated by phytochrome A. A component in this pathway, SPA1 (for "suppressor of phyA-105"), functions in repression of photomorphogenesis and is required for normal photosensory specificity of phytochrome A. Molecular cloning of the SPA 7 gene indicates that SPA1 is a WD (tryptophan-aspartic acid)-repeat protein that also shares sequence similarity with protein kinases. SPA1 can localize to the nucleus, suggesting a possible function in phytochrome A-specific regulation of gene expression.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; ARS, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Quail, PH (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	quail@nature.berkeley.edu	Rosa, Bruce/F-6393-2010	Hoecker, Ute/0000-0002-5636-9777	NIGMS NIH HHS [GM-47475] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047475] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1996, PLANT J, V10, P1103, DOI 10.1046/j.1365-313X.1996.10061103.x; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; BEELER JF, 1994, MOL CELL BIOL, V14, P982, DOI 10.1128/MCB.14.2.982; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; Genoud T, 1998, PLANT CELL, V10, P889, DOI 10.1105/tpc.10.6.889; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; HOECKER U, UNPUB; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCNELLIS TW, 1994, PLANT CELL, V6, P1391, DOI 10.1105/tpc.6.10.1391; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; Reed Jason W., 1994, Seminars in Cell Biology, V5, P327, DOI 10.1006/scel.1994.1039; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	31	217	229	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					496	499		10.1126/science.284.5413.496	http://dx.doi.org/10.1126/science.284.5413.496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205059				2022-12-01	WOS:000079792200050
J	Stewart, JA; Dundas, R; Howard, RS; Rudd, AG; Wolfe, CDA				Stewart, JA; Dundas, R; Howard, RS; Rudd, AG; Wolfe, CDA			Ethnic differences in incidence of stroke: prospective study with stroke register	BRITISH MEDICAL JOURNAL			English	Article							BLACK-WHITE DIFFERENCES; CEREBROVASCULAR-DISEASE; CASE-FATALITY; NORTHERN MANHATTAN; INCIDENCE RATES; RISK-FACTORS; MORTALITY; COMMUNITY; HYPERTENSION; ENGLAND	Objective To identify ethnic differences in the. incidence of first ever stroke. Design A prospective community stroke register (1995-6) with multiple notification sources. Pathological classification of stroke in all cases was based on brain imaging or necropsy data. Rates were standardised to European and world populations and adjusted for age, sex, and social class in multivariate analysis. Setting A multi-ethnic population of 234 533 in south London, of whom 21% are black. Results 612 strokes were registered. The crude annual incidence rate tvas 1.3 strokes per 1000 population per year (95% confidence interval 1.20 to 1.41) and 1.25 per 1000 population per year (1.15 to 1.35) age adjusted to the standard European population. Incidence rates adjusted for age and sex were significantly higher in black compared with white people (P < 0.0001), with an incidence rate ratio of 2.21 (1.77 to 2.76), In multivariable analysis increasing age (P< 0.0001), male sex (P < 0.003), black ethnic group (P < 0.0001), and lower social class CP < 0.0001) in people aged 35-64 were independently associated with an increased incidence of stroke, Conclusions Incidence rates of stroke are higher in the black population; this is not explained by confounders such as social class, age, and sex. Ethnic differences in genetic, physiological, and behavioural risk factors for stroke require further elucidation to aid development of effective strategies for stroke prevention in multi-ethnic communities.	Guys Kings Coll, Dept Publ Hlth Sci, London SE1 3QD, England; St Thomass Sch Med, London SE1 3QD, England; St Thomas Hosp, Dept Neurol, London SE1 5EH, England; St Thomas Hosp, Stroke Unit, London SE1 5EH, England	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Wolfe, CDA (corresponding author), Guys Kings Coll, Dept Publ Hlth Sci, 5th Floor,Capital House, London SE1 3QD, England.			Dundas, Ruth/0000-0002-3836-4286; Wolfe, Charles/0000-0001-8264-0981	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BONITA R, 1984, AM J EPIDEMIOL, V120, P236, DOI 10.1093/oxfordjournals.aje.a113885; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; CASPER M, 1991, J EPIDEMIOL COMMUN H, V45, P302, DOI 10.1136/jech.45.4.302; CRUICKSHANK JK, 1980, BRIT MED J, V281, P1108, DOI 10.1136/bmj.281.6248.1108; *DIR PUBL HLTH, 1996, ANN REP 1995 1996; EISENBLATTER D, 1995, STROKE, V26, P919, DOI 10.1161/01.STR.26.6.919; GROSS CR, 1984, STROKE, V15, P249, DOI 10.1161/01.STR.15.2.249; HOWARD G, 1995, STROKE, V26, P1759, DOI 10.1161/01.STR.26.10.1759; KITTNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1267, DOI 10.1001/jama.264.10.1267; Korv J, 1997, CEREBROVASC DIS, V7, P154, DOI 10.1159/000108182; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; MALMGREN R, 1987, LANCET, V2, P1196; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; Parrish H M, 1966, Mo Med, V63, P816; SACCO RL, 1991, STROKE, V22, P1491, DOI 10.1161/01.STR.22.12.1491; Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; WOLFE CDA, 1993, J EPIDEMIOL COMMUN H, V47, P139, DOI 10.1136/jech.47.2.139	24	231	231	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					967	971		10.1136/bmj.318.7189.967	http://dx.doi.org/10.1136/bmj.318.7189.967			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195965	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000079751500017
J	Ashe, HL; Levine, M				Ashe, HL; Levine, M			Local inhibition and long-range enhancement of Dpp signal transduction by Sog	NATURE			English	Article							DORSAL-VENTRAL PATTERN; DROSOPHILA EMBRYO; MORPHOGEN GRADIENT; SHORT GASTRULATION; SPEMANN ORGANIZER; GENE; SPECIFICATION; LOCALIZATION; CHORDIN; ACTIVIN	Extracellular gradients of signalling molecules can specify different thresholds of gene activity in development. A gradient of Decapentaplegic (Dpp) activity subdivides the dorsal ectoderm of the Drosophila embryo into amnioserosa and dorsal epidennis(.1,2) The proteins Short gastrulation(3) (Sog) and Tolloid(4) (Tld) are required to shape this gradient. Sog has been proposed to form an inhibitory complex with either Dpp(5) or the related ligand Screw(6,7), and is subsequently processed by the protease Tld(5). Paradoxically, Sog appears to be required for amnioserosa formation(8), which is specified by peak Dpp signalling activity(1,2). Here we show that the misexpression of sag using the even-skipped stripe-2 enhancer(9) redistributes Dpp signalling in a mutant background in which npp is expressed throughout the embryo, Dpp activity is diminished near the Sog stripe and peak Dpp signalling is detected far from this stripe. However, a tethered form of Sog suppresses local Dpp activity without augmenting Dpp activity at a distance, indicating that diffusion of Sog may be required for enhanced Dpp activity and consequent amnioserosa formation, The long-distance stimulation of Dpp activity by Sog requires Tld, whereas Sog-mediated inhibition of Dpp does not The heterologous Dpp inhibitor Noggin(10) inhibits Dpp signalling but fails to augment Dpp activity. These results suggest an unusual strategy for generating a gradient threshold of growth-factor activity, whereby Sog and its protease specify peak Dpp signalling far from a localized source of Sog.	Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, 401 Barker Hall, Berkeley, CA 94720 USA.			Levine, Michael/0000-0001-7629-0081				ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; Konrad KD, 1998, P NATL ACAD SCI USA, V95, P6819, DOI 10.1073/pnas.95.12.6819; Kosman D, 1997, DEVELOPMENT, V124, P1343; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEWIS J, 1977, J THEOR BIOL, V65, P579, DOI 10.1016/0022-5193(77)90216-8; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neul JL, 1998, CELL, V95, P483, DOI 10.1016/S0092-8674(00)81616-5; Nguyen M, 1998, CELL, V95, P495, DOI 10.1016/S0092-8674(00)81617-7; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Rusch J, 1997, DEVELOPMENT, V124, P303; Rusch J, 1996, CURR OPIN GENET DEV, V6, P416, DOI 10.1016/S0959-437X(96)80062-1; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; TATEI K, 1995, MECH DEVELOP, V51, P157, DOI 10.1016/0925-4773(95)00349-5; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHARTON KA, 1993, DEVELOPMENT, V117, P807; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	28	149	155	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					427	431		10.1038/18892	http://dx.doi.org/10.1038/18892			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201373				2022-12-01	WOS:000079508200053
J	Gatzoulis, MA; Freeman, MA; Siu, SC; Webb, GD; Harris, L				Gatzoulis, MA; Freeman, MA; Siu, SC; Webb, GD; Harris, L			Atrial arrhythmia after surgical closure of atrial septal defects in adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COX-MAZE PROCEDURE; VENTRICULAR-FUNCTION; NATURAL-HISTORY; FOLLOW-UP; FIBRILLATION; SURGERY; CONCOMITANT; MANAGEMENT; REPAIR	Background Atrial flutter and atrial fibrillation are causes of morbidity in adults with an atrial septal defect. In this study, we attempted to identify risk factors for atrial flutter and fibrillation both before and after the surgical closure of an atrial septal defect. Methods We searched for preoperative and postoperative atrial flutter or fibrillation in 213 adult patients (82 men and 131 women) who underwent surgical closure of atrial septal defects because of symptoms, a substantial left-to-right shunt (ratio of pulmonary to systemic blood flow, >1.5:1), or both at Toronto Hospital between 1986 and 1997. Results Forty patients (19 percent) had sustained atrial flutter or fibrillation before surgery. As compared with the patients who did not have atrial flutter or fibrillation before surgery, those who did were older (mean [+/-SD] age, 59+/-11 vs. 37+/-3 years, P<0.001) and had higher mean pulmonary arterial pressures (25.0+/-9.7 vs. 19.7+/-8.2 mm Hg, P=0.001). There were no perioperative deaths. After a mean follow-up period of 3.8+/-2.5 years, 24 of the 40 patients (60 percent) continued to have atrial flutter or fibrillation. The mean age of these patients was greater than that of the 16 who converted to sinus rhythm (P=0.02). New-onset atrial flutter or atrial fibrillation was more likely to have developed at follow-up in patients who were older than 40 years at the time of surgery than in those who were 40 or younger (5 of 67 vs. 0 of 106, P=0.008). Late events (those occurring more than one month after surgery) included stroke in six patients (all but one with atrial flutter or fibrillation, one of whom died) and death from noncardiac causes in two patients. Multivariate analysis showed that older age (>40 years) at the time of surgery (P=0.001), the presence of preoperative atrial flutter or fibrillation (P<0.001), and the presence of postoperative atrial flutter or fibrillation or junctional rhythm (P=0.02) were predictive of late postoperative atrial flutter or fibrillation. Conclusions The risk of atrial flutter or atrial fibrillation in adults with atrial septal defects is related to the age at the time of surgical repair and the pulmonary arterial pressure. To reduce the morbidity associated with atrial flutter and fibrillation, the timely closure of atrial septal defects is warranted. (N Engl J Med 1999;340:839-46.) (C) 1999, Massachusetts Medical Society.	Univ Toronto, Toronto Hosp, Congenital Cardiac Ctr Adults, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; Toronto Congenital Cardiac Centre for Adults; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Gatzoulis, MA (corresponding author), Toronto Gen Hosp, Toronto Congenital Cardiac Ctr, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	gatzoul@ibm.net	Siu, Sam C/G-3346-2011	Siu, Sam C/0000-0002-1104-3669				[Anonymous], 1994, ARCH INTERN MED, V154, P2254; Blackshear JL, 1996, ANN THORAC SURG, V61, P755, DOI 10.1016/0003-4975(95)00887-X; BONCHEK LI, 1993, ANN THORAC SURG, V55, P607, DOI 10.1016/0003-4975(93)90262-G; BONOW RO, 1981, CIRCULATION, V63, P1315, DOI 10.1161/01.CIR.63.6.1315; BOOTH DC, 1988, J AM COLL CARDIOL, V12, P1231, DOI 10.1016/0735-1097(88)92605-8; CAMPBELL M, 1970, BRIT HEART J, V32, P820; COX DR, 1972, J R STAT SOC B, V34, P187; COX JL, 1995, J THORAC CARDIOV SUR, V110, P485, DOI 10.1016/S0022-5223(95)70245-8; Cox JL, 1996, NEW ENGL J MED, V334, P57; CRAIG RJ, 1968, CIRCULATION, V37, P805, DOI 10.1161/01.CIR.37.5.805; Gatzoulis MA, 1996, ANN THORAC SURG, V61, P657, DOI 10.1016/0003-4975(95)01043-2; Helber U, 1997, J AM COLL CARDIOL, V29, P1345, DOI 10.1016/S0735-1097(97)00058-2; HORVATH KA, 1992, J AM COLL CARDIOL, V20, P1156, DOI 10.1016/0735-1097(92)90372-T; Kamata J, 1997, ANN THORAC SURG, V64, P394, DOI 10.1016/S0003-4975(97)00139-2; KONSTANTINIDES S, 1995, NEW ENGL J MED, V333, P469, DOI 10.1056/NEJM199508243330801; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LIBERTHSON RR, 1981, AM J CARDIOL, V47, P56, DOI 10.1016/0002-9149(81)90289-7; Lin FY, 1996, J THORAC CARDIOV SUR, V111, P231, DOI 10.1016/S0022-5223(96)70420-8; MATTILA S, 1979, SCAND J THORAC CARD, V13, P21, DOI 10.3109/14017437909101781; MORILLO CA, 1995, CIRCULATION, V91, P1588, DOI 10.1161/01.CIR.91.5.1588; MURPHY JG, 1990, NEW ENGL J MED, V323, P1645, DOI 10.1056/NEJM199012133232401; NASRALLAH AT, 1976, CIRCULATION, V53, P329, DOI 10.1161/01.CIR.53.2.329; PERLOFF JK, 1995, NEW ENGL J MED, V333, P513, DOI 10.1056/NEJM199508243330809; POPIO KA, 1975, AM J CARDIOL, V36, P302, DOI 10.1016/0002-9149(75)90480-4; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Sandoval N, 1996, AM J CARDIOL, V77, P591, DOI 10.1016/S0002-9149(97)89312-5; Satoh T, 1996, J CARDIOVASC ELECTR, V7, P833, DOI 10.1111/j.1540-8167.1996.tb00596.x; SHAH D, 1994, BRIT HEART J, V71, P224; SUTTON MGS, 1981, CIRCULATION, V64, P402, DOI 10.1161/01.CIR.64.2.402; SUTTON MGSJ, 1979, CIRCULATION, V60, P1082, DOI 10.1161/01.CIR.60.5.1082; Vigano M, 1996, EUR J CARDIO-THORAC, V10, P490, DOI 10.1016/S1010-7940(96)80413-1; WARD C, 1994, BRIT HEART J, V71, P219	32	306	329	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1999	340	11					839	846		10.1056/NEJM199903183401103	http://dx.doi.org/10.1056/NEJM199903183401103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	176ZW	10080846				2022-12-01	WOS:000079183200003
J	Teran-Santos, J; Jimenez-Gomez, A; Cordero-Guevara, J				Teran-Santos, J; Jimenez-Gomez, A; Cordero-Guevara, J		Cooperative Grp Burgos-Santander	The association between sleep apnea and the risk of traffic accidents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUTOMOBILE ACCIDENTS; DAYTIME SLEEPINESS; POPULATION; DISORDERS; ADULTS; SCALE	Background and Methods Drowsiness and lack of concentration may contribute to traffic accidents. We conducted a case-control study of the relation between sleep apnea and the risk of traffic accidents. The case patients were 102 drivers who received emergency treatment at hospitals in Burgos or Santander, Spain, after highway traffic accidents between April and December 1995. The controls were 152 patients randomly selected from primary care centers in the same cities and matched with the case patients for age and sex. Respiratory polygraphy was used to screen the patients for sleep apnea at home, and conventional polysomnography was used to confirm the diagnosis. The apnea-hypopnea index (the total number of episodes of apnea and hypopnea divided by the number of hours of sleep) was calculated for each participant. Results The mean age of the participants was 44 years; 77 percent were men. As compared with those without sleep apnea, patients with an apnea-hypopnea index of 10 or higher had an odds ratio of 6.3 (95 percent confidence interval, 2.4 to 16.2) for having a traffic accident. This relation remained significant after adjustment for potential confounders, such as alcohol consumption, visual-refraction disorders, body-mass index, years of driving, age, history with respect to traffic accidents, use of medications causing drowsiness, and sleep schedule. Among subjects with an apnea-hypopnea index of 10 or more, the risk of an accident was higher among those who had consumed alcohol on the day of the accident than among those who had not. Conclusions There is a strong association between sleep apnea, as measured by the apnea-hypopnea index, and the risk of traffic accidents. (N Engl J Med 1999; 340:847-51.) (C) 1999, Massachusetts Medical Society.	Gen Yague Hosp, Burgos, Spain; HUM Valdecilla, Serv Resp, Santander 3900, Spain	Hospital General Yague; Hospital Universitario Marques de Valdecilla (HUMV)	Jimenez-Gomez, A (corresponding author), HUM Valdecilla, Serv Resp, Avda de Valdeilla S-N, Santander 3900, Spain.							ALDRICH MS, 1989, SLEEP, V12, P487, DOI 10.1093/sleep/12.6.487; ALTISENT R, 1992, MED CLIN-BARCELONA, V99, P584; ARMITAGE P., 1992, ESTADISTICA INVESTIG; Barbe F, 1995, Arch Bronconeumol, V31, P460; Duran J, 1996, ARCH BRONCONEUMOL, V32, P3; FINDLEY LJ, 1991, ARCH INTERN MED, V151, P1451, DOI 10.1001/archinte.151.7.1451; FINDLEY LJ, 1989, AM REV RESPIR DIS, V140, P529, DOI 10.1164/ajrccm/140.2.529; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; HARALDSSON PO, 1990, ACTA OTO-LARYNGOL, V110, P136, DOI 10.3109/00016489009122528; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; JENNUM P, 1992, CHEST, V102, P1371, DOI 10.1378/chest.102.5.1371; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; Norusis M.J., 1994, SPSS ADV STAT 61; PRADA C, 1995, MED CLIN-BARCELONA, V105, P601; RECHTSCHAFFEN A, 1968, 204 NIH PUBL; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; Wu H, 1996, NEUROLOGY, V46, P1254, DOI 10.1212/WNL.46.5.1254; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	21	829	856	0	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1999	340	11					847	851		10.1056/NEJM199903183401104	http://dx.doi.org/10.1056/NEJM199903183401104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	176ZW	10080847				2022-12-01	WOS:000079183200004
J	Gunn, TM; Miller, KA; He, L; Hyman, RV; Davis, RW; Azarani, A; Schlossman, SF; Duke-Cohan, JS; Barsh, GS				Gunn, TM; Miller, KA; He, L; Hyman, RV; Davis, RW; Azarani, A; Schlossman, SF; Duke-Cohan, JS; Barsh, GS			The mouse mahogany locus encodes a transmembrane form of human attractin	NATURE			English	Article							ALPHA-MSH; IN-VITRO; IV CD26; AGOUTI; PROTEIN; RECEPTORS; YELLOW; MICE; ANTAGONISM; MUTATIONS	Agouti protein and agouti-related protein are homologous paracrine signalling molecules that normally regulate hair colour and body weight, respectively, by antagonizing signalling through melanocortin receptors(1-7). Expression of Agouti is normally limited to the skin, but rare alleles from which Agouti is expressed ubiquitously, such as lethal yellow; have pleiotropic effects that include a yellow coat, obesity, increased linear growth, and immune defects(8-11). The mahogany (mg) mutation suppresses the effects of lethal yellow on pigmentation and body weight, and results of our previous genetic studies place mg downstream of transcription of Agouti but upstream of melanocortin receptors(12). Here we use positional cloning to identify a candidate gene for mahogany, Mgca. The predicted protein encoded by Mgca is a 1,428-amino-acid, single-transmembrane-domain protein that is expressed in many tissues, including pigment cells and the hypothalamus. The extracellular domain of the Mgca protein is the orthologue of human attractin, a circulating molecule produced by activated T cells that has been implicated in immune-cell interactions(13,14). These observations provide new insight into the regulation of energy metabolism and indicate a molecular basis for crosstalk between melanocortin-receptor signalling and immune function.	Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Stanford DNA Sequencing & Technol Ctr, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Barsh, GS (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.		Duke-Cohan, Jonathan/A-5812-2010	Duke-Cohan, Jonathan/0000-0002-9478-9609; Gunn, Teresa/0000-0003-2688-6420				BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BLANCHARD SG, 1995, BIOCHEMISTRY-US, V34, P10406, DOI 10.1021/bi00033a012; Catania A, 1996, PEPTIDES, V17, P675, DOI 10.1016/0196-9781(96)00037-X; Dinulescu DM, 1998, P NATL ACAD SCI USA, V95, P12707, DOI 10.1073/pnas.95.21.12707; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Duke-Cohan JS, 1998, P NATL ACAD SCI USA, V95, P11336, DOI 10.1073/pnas.95.19.11336; DUKECOHAN JS, 1995, J BIOL CHEM, V270, P14107, DOI 10.1074/jbc.270.23.14107; DukeCohan JS, 1996, J IMMUNOL, V156, P1714; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GASSER DL, 1973, J IMMUNOL, V110, P305; Hishida R, 1996, EMBO J, V15, P4111, DOI 10.1002/j.1460-2075.1996.tb00786.x; JACKSON IJ, 1994, PIGM CELL RES, V7, P73, DOI 10.1111/j.1600-0749.1994.tb00024.x; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; LANE PRISCILLA W., 1960, JOUR HEREDITY, V51, P228; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; Miller KA, 1997, GENETICS, V146, P1407; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ollmann MM, 1998, GENE DEV, V12, P316, DOI 10.1101/gad.12.3.316; OLLMANN MM, UNPUB J BIOL CHEM; Rajora N, 1997, J NEUROSCI, V17, P2181; RAMABO MJ, 1997, J MOL BIOL, V274, P650; ROBERTS DW, 1984, P NATL ACAD SCI-BIOL, V81, P2152, DOI 10.1073/pnas.81.7.2152; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; SIEGRIST W, 1994, CANCER RES, V54, P2604; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148; Zuberi AR, 1996, GENOMICS, V33, P75, DOI 10.1006/geno.1996.0161	29	165	180	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 11	1999	398	6723					152	156		10.1038/18217	http://dx.doi.org/10.1038/18217			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176DG	10086356				2022-12-01	WOS:000079135200045
J	Cancela, JM; Churchill, GC; Galione, A				Cancela, JM; Churchill, GC; Galione, A			Coordination of agonist-induced Ca2+-signalling patterns by NAADP in pancreatic acinar cells	NATURE			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC-ADP-RIBOSE; INDUCED CA2+ RELEASE; INOSITOL TRISPHOSPHATE; CALCIUM; OSCILLATIONS; CHANNELS; INACTIVATION; ACTIVATION; SYSTEM	Many hormones and neurotransmitters evoke Ca2+ release from intracellular stores, often triggering agonist-specific signatures of intracellular Ca2+ concentration(1-5), Inositol trisphosphate (InsP(3))(1) and cyclic adenosine 5 '-diphosphate-ribose (cADPR)(6,7) are established Ca2+-mobilizing messengers that activate Ca2+ release through intracellular InsP(3) and ryanodine receptors, respectively(8-10). However, in pancreatic acinar cells, neither mess enger can explain the complex pattern of Ca2+ signals triggered by the secretory hormone cholecystokinin (CCK). We show here that the Ca2+-mobilizing molecule nicotinic acid adenine dinucleotide phosphate (NAADP)(7,11-13), and endogenous metabolite of P-NADP, triggers a Ca2+ response that varies from short-lasting Ca2+ spikes to a complex mixture of short-lasting (1-2s) and long-lasting (0.2-1 min) Ca2+ spikes. Cells were significantly more sensitive to NAADP than to either cADPR or InsP(3), whereas higher conEeni trations of NAADP selectively inactivated CCK-evoked Ca2+ signals in pancreatic acinar cells, indicating that NAADP may function as an intracellular messenger in mammalian cells.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Galione, A (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		Galione, Antony/E-5884-2011	Galione, Antony/0000-0002-4132-7646; Cancela, Jose-Manuel/0000-0002-6234-1500	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Cancela JM, 1998, CURR BIOL, V8, P865, DOI 10.1016/S0960-9822(07)00347-8; Cancela JM, 1998, PFLUG ARCH EUR J PHY, V435, P746, DOI 10.1007/s004240050578; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; COBBOLD PH, 1991, CELL CALCIUM, V12, P87, DOI 10.1016/0143-4160(91)90011-3; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Wilson HL, 1998, BIOCHEM J, V331, P837, DOI 10.1042/bj3310837	29	307	311	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 4	1999	398	6722					74	76		10.1038/18032	http://dx.doi.org/10.1038/18032			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174KG	10078532				2022-12-01	WOS:000079033900054
J	Clayton, DD; Liu, WH; Dalgarno, A				Clayton, DD; Liu, WH; Dalgarno, A			Condensation of carbon in radioactive supernova gas	SCIENCE			English	Article							RADIATIVE ASSOCIATION; INTERSTELLAR CLOUDS; MURCHISON METEORITE; LARGE HYDROCARBONS; PRESOLAR GRAPHITE; CLUSTERS; MATTER; ORIGIN; GRAINS	Chemistry resulting in the formation of Large carbon-bearing molecules and dust in the interior of an expanding supernova was explored, and the equations governing their abundances were solved numerically, Carbon dust condenses from initially gaseous carbon and oxygen atoms because energetic electrons produced by radioactivity in the supernova cause dissociation of the carbon monoxide molecules, which would otherwise form and Limit the supply of carbon atoms, The resulting free carbon atoms enable carbon dust to grow faster by carbon association than the rate at which the dust can be destroyed by oxidation. The origin of presolar micrometer-sized carbon solids that are found in meteorites is thereby altered.	Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA; Oak Ridge Natl Lab, Div Phys, Oak Ridge, TN 37831 USA; Univ Tennessee, Dept Phys, Knoxville, TN 37996 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	Clemson University; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Clayton, DD (corresponding author), Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA.							Amari S, 1997, AIP CONF PROC, P287, DOI 10.1063/1.53330; Andreazza CM, 1997, MON NOT R ASTRON SOC, V287, P287, DOI 10.1093/mnras/287.2.287; BATES DR, 1983, ASTROPHYS J, V267, pL121, DOI 10.1086/184015; BERNATOWICZ T, 1997, ASTROPHYSICAL IMPLIC, P391; Bernatowicz TJ, 1996, ASTROPHYS J, V472, P760, DOI 10.1086/178105; Bernatowicz TJ, 1997, PHYS TODAY, V50, P26, DOI 10.1063/1.882049; Bettens RPA, 1997, ASTROPHYS J, V478, P585, DOI 10.1086/303834; BETTENS RPA, 1995, INT J MASS SPECTROM, V149, P321, DOI 10.1016/0168-1176(95)04266-N; Bettens RPA, 1996, ASTROPHYS J, V468, P686, DOI 10.1086/177726; BETTENS RPA, 1995, ASTROPHYS J, V443, P664, DOI 10.1086/175558; Choi BG, 1998, SCIENCE, V282, P1284, DOI 10.1126/science.282.5392.1284; Clayton D. D., 1981, P LUNAR PLANET SCI, V12B, P1781; CLAYTON DD, 1976, ASTROPHYS SPACE SCI, V42, P463, DOI 10.1007/BF01225970; CLAYTON DD, 1975, NATURE, V257, P36, DOI 10.1038/257036b0; Clayton DD, 1997, ASTROPHYS SPACE SCI, V251, P355, DOI 10.1023/A:1000799831553; CLAYTON DD, 1978, MOON PLANETS, V19, P109, DOI 10.1007/BF00896983; CLAYTON DD, 1991, ASTROPHYS J, V375, P221, DOI 10.1086/170184; Clayton DD, 1998, METEORIT PLANET SCI, V33, pA32; CLAYTON DD, 1998, LUNAR PLANET SCI, V29; FREED KF, 1982, ASTROPHYS J, V263, P718, DOI 10.1086/160543; HERBST E, 1991, MON NOT R ASTRON SOC, V253, P341, DOI 10.1093/mnras/253.2.341; HERBST E, 1994, MON NOT R ASTRON SOC, V268, P335, DOI 10.1093/mnras/268.2.335; Hoppe P, 1996, SCIENCE, V272, P1314, DOI 10.1126/science.272.5266.1314; LIU WH, 1995, ASTROPHYS J, V454, P472, DOI 10.1086/176498; LODDERS K, 1995, METEORITICS, V30, P661, DOI 10.1111/j.1945-5100.1995.tb01164.x; Lodders K, 1997, ASTROPHYS J, V484, pL71, DOI 10.1086/310757; LUCY LB, 1989, IAU C, V120, P164; MEZZACAPPA A, 1998, STELLAR EVOLUTION ST, P3; Nittler LR, 1996, ASTROPHYS J, V462, pL31, DOI 10.1088/1538-4357/462/1/L31; SHARP CM, 1995, GEOCHIM COSMOCHIM AC, V59, P1633, DOI 10.1016/0016-7037(95)00069-C; Terzieva R, 1998, ASTROPHYS J, V501, P207, DOI 10.1086/305811; Van Orden A, 1998, CHEM REV, V98, P2313, DOI 10.1021/cr970086n; WEAVER TA, 1993, PHYS REP, V227, P65, DOI 10.1016/0370-1573(93)90058-L; Woon DE, 1996, ASTROPHYS J, V465, P795, DOI 10.1086/177463	34	112	112	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1290	1292		10.1126/science.283.5406.1290	http://dx.doi.org/10.1126/science.283.5406.1290			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037591	Green Published			2022-12-01	WOS:000078839900030
J	Whitacre, CC; Reingold, SC; O'Looney, PA				Whitacre, CC; Reingold, SC; O'Looney, PA		Task Force Gender Multiple Sclerosis Autoimmuni	Biomedicine - A gender cap in autoimmunity	SCIENCE			English	Editorial Material							DISEASES		Ohio State Univ, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Natl Multiple Sclerosis Soc, Res Programs Dept, New York, NY 10017 USA	University System of Ohio; Ohio State University	Whitacre, CC (corresponding author), Ohio State Univ, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA.			Reingold, Stephen/0000-0003-4485-8634; Reiss, Carol/0000-0003-4353-8882				BEESON PB, 1994, AM J MED, V96, P457, DOI 10.1016/0002-9343(94)90173-2; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Sawcer S, 1997, TRENDS GENET, V13, P234, DOI 10.1016/S0168-9525(97)01140-2	3	654	665	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 26	1999	283	5406					1277	1278		10.1126/science.283.5406.1277	http://dx.doi.org/10.1126/science.283.5406.1277			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10084932				2022-12-01	WOS:000078839900028
J	Ulloa, L; Doody, J; Massague, J				Ulloa, L; Doody, J; Massague, J			Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway	NATURE			English	Article							FACTOR-BETA; SIGNALING PATHWAYS; SMAD PROTEINS; IFN-GAMMA; CELLS; EXPRESSION; RECEPTORS; IDENTIFICATION; TRANSDUCTION; ANTAGONIST	Transforming growth factor-beta (TGF-beta) and interferon-gamma (IFN-gamma) have opposite effects on diverse cellular functions(1-5), but the basis for this antagonism is not known(6). TGF-beta signals through a receptor serine kinase that phosphorylates and activates the transcription factors Smads 2 and 3 (refs 7, 8), whereas the IFN-gamma receptor and its associated protein tyrosine kinase Jak1 mediate phosphorylation and activation of the transcription factor Stat1 (refs 6, 9, 10). Here we present a basis for the integration of TGF-beta and IFN-gamma signals. IFN-gamma inhibits the TGF beta-induced phosphorylation of Smad3 and its attendant events, namely, the association of Smad3 with Smad4, the accumulation of Smad3 in the nucleus, and the activation of TGF beta-responsive genes. Acting through Jak1 and Stat1, IFN-gamma induces the expression of Smad7, an antagonistic SMAD(11,12), which prevents the interaction of Smad3 with the TGF-beta receptor. The results indicate a mechanism of transmodulation between the STAT and SMAD signal-transduction pathways.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.		Ulloa, Luis/AAE-8751-2019	Ulloa, Luis/0000-0002-7702-7549; Massague, Joan/0000-0001-9324-8408				BAUVOIS B, 1992, J IMMUNOL, V148, P3912; CACAMO J, 1994, MOL CELL BIOL, V14, P3810; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; KUMAR R, 1990, J BIOL CHEM, V265, P4578; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEE K, 1987, EXP CELL RES, V173, P156, DOI 10.1016/0014-4827(87)90341-7; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHMITT E, 1994, EUR J IMMUNOL, V24, P793, DOI 10.1002/eji.1830240403; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Spittler A, 1997, IMMUNOLOGY, V90, P286, DOI 10.1046/j.1365-2567.1997.00148.x; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tu GC, 1998, J BIOL CHEM, V273, P25125, DOI 10.1074/jbc.273.39.25125; Xiao BG, 1996, CLIN EXP IMMUNOL, V103, P475; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	677	729	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 25	1999	397	6721					710	713		10.1038/17826	http://dx.doi.org/10.1038/17826			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067896				2022-12-01	WOS:000078840100054
J	Vedhara, K; Cox, NKM; Wilcock, GK; Perks, P; Hunt, M; Anderson, S; Lightman, SL; Shanks, NM				Vedhara, K; Cox, NKM; Wilcock, GK; Perks, P; Hunt, M; Anderson, S; Lightman, SL; Shanks, NM			Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination	LANCET			English	Article							KILLER-CELL ACTIVITY; IMMUNE-RESPONSE; CORTISOL-LEVELS; OLDER ADULTS; VIRUS; MEN; CAREGIVERS; DISTRESS; BURDEN	Background There are many reports of psychological morbidity in spousal carers of patients with dementia. The consequences of this increased stress on the immune system are unclear. We investigated whether antibody responses to influenza vaccination differed between carers and a control group, and the relation of the antibody response to the hypothalamic-pituitary-adrenal (HPA) axis. Methods 50 spousal carers of dementia patients, median age 73 years (IQR 66-77), and 67 controls (68 years [66-71]) of similar socioeconomic status were enrolled. Anxiety and depression were measured by the Savage Aged Personality Screening Scale and stress by the Global Measure of Perceived Stress scale. Principal-component analysis was used to yield a summary score of emotional distress from these two scales. Salivary cortisol concentrations were measured over a single day at three times (0800-100, 1100-1300, and 2000-2200). Participants received a trivalent influenza vaccine and IgG antibody titres to each strain were measured on days 0, 7, 14, and 28. Findings Mean scores of emotional distress were significantly higher in carers at each time point than in controls (all p < 0.0003). Mean (SD) salivary cortisol concentrations, calculated as area under the curve (AUC), were higher in carers than controls at all three assessments (6 months 16.0 [8.0] vs 11.2 [4.4], p = 0.0001; respectively). Eight (16%) of 50 carers and 26 (39%) of 67 controls had a four-fold increase in at least one of the IgG titres (p = 0.007). There was an inverse relation between AUC cortisol and IgG antibody titre to the Nanchang strain that was significant on day 14 (r = -0.216, p = 0.039). Interpretation Elderly carers of spouses with dementia have increased activation of the hypothalamic-pituary-adrenal axis and a poor antibody response to influenza vaccine. Carers may be more vulnerable to infectious disease than the population of a similar age.	Univ Bristol, Dept Expt Psychol, Bristol BS8 1TN, Avon, England; Univ Bristol, Dept Med, Bristol BS8 1TN, Avon, England; Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England	University of Bristol; University of Bristol	Vedhara, K (corresponding author), Univ Bristol, Dept Expt Psychol, 8 Woodland Rd, Bristol BS8 1TN, Avon, England.		vedhara, kavita/G-3565-2010	Vedhara, Kavita/0000-0002-9940-7534				Braithwaite V, 1996, RES AGING, V18, P139, DOI 10.1177/0164027596182001; BRANTLEY PJ, 1988, J CONSULT CLIN PSYCH, V56, P549, DOI 10.1037/0022-006X.56.4.549; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Esterling BA, 1996, PSYCHOSOM MED, V58, P264, DOI 10.1097/00006842-199605000-00010; GLASER R, 1994, PSYCHONEUROENDOCRINO, V19, P765, DOI 10.1016/0306-4530(94)90023-X; GLASER R, 1993, BEHAV NEUROSCI, V107, P252; Ironson G, 1994, Int J Behav Med, V1, P90, DOI 10.1207/s15327558ijbm0101_6; Irwin M, 1997, ANN BEHAV MED, V19, P83, DOI 10.1007/BF02883324; IRWIN M, 1988, BIOL PSYCHIAT, V24, P173, DOI 10.1016/0006-3223(88)90272-7; KIECOLTGLASER JK, 1987, PSYCHOSOM MED, V49, P523, DOI 10.1097/00006842-198709000-00008; KIECOLTGLASER JK, 1984, PSYCHOSOM MED, V46, P15, DOI 10.1097/00006842-198401000-00004; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; KIRSCHBAUM C, 1995, PSYCHOSOM MED, V57, P468, DOI 10.1097/00006842-199509000-00009; LEVINE M, 1987, J AM GERIATR SOC, V35, P609, DOI 10.1111/j.1532-5415.1987.tb04335.x; Murray JM, 1997, AGING MENT HEALTH, V1, P256, DOI 10.1080/13607869757155; Rose R.M., 1980, PSYCHIAT CLIN N AM, V3, P251, DOI [DOI 10.1016/S0193-953X(18)30965-1, https://doi.org/10.1016/S0193-953X(18)30965-1]; SAVAGE D, 1993, SAVAGE AGED PERSONAL; SAVAGE D, 1990, SAVAGE PERSONALITY S; SAVAGE D, 1997, SCREENING PERSONALIT; SHIMADA M, 1995, HORM RES, V44, P213, DOI 10.1159/000184628; Vedhara K, 1997, J PSYCHOSOM RES, V42, P379, DOI 10.1016/S0022-3999(96)00351-0; WALLSTEN SM, 1993, INT J AGING HUM DEV, V37, P55, DOI 10.2190/FB4J-MNDK-YNTH-3XJP; Waltrowicz W, 1996, AUST J AGEING, V15, P115, DOI 10.1111/j.1741-6612.1996.tb00007.x	23	340	347	1	70	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 20	1999	353	9153					627	631		10.1016/S0140-6736(98)06098-X	http://dx.doi.org/10.1016/S0140-6736(98)06098-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	170QU	10030328				2022-12-01	WOS:000078818200012
J	Basham, B				Basham, B			Protein structure at your desk - PepTool	SCIENCE			English	Software Review							AMINO-ACID-SEQUENCE; SECONDARY-STRUCTURE		DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Basham, B (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.							Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; WISHART DS, 1994, J BIOMOL NMR, V4, P171	5	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 19	1999	283	5405					1132	1132		10.1126/science.283.5405.1132	http://dx.doi.org/10.1126/science.283.5405.1132			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GD	10075575				2022-12-01	WOS:000078738400038
J	Bhattacharya, SK; Ramchandani, S; Cervoni, N; Szyf, M				Bhattacharya, SK; Ramchandani, S; Cervoni, N; Szyf, M			A mammalian protein with specific demethylase activity for mCpG DNA	NATURE			English	Article							MOUSE EMBRYO; METHYLATION; METHYLTRANSFERASE; 5-METHYLCYTOSINE; GLYCOSYLASE; CELLS	DNA-methylation patterns are important for regulating genome functions, and are determined by the enzymatic processes of methylation and demethylation. The demethylating enzyme has now been identified: a mammalian complementary DNA encodes a methyl-CpG-binding domain, bears a demethylase activity that transforms methylated cytosine bases to cytosine, and demethylates a plasmid when the cDNA is translated or transiently transfected into human embryonal kidney cells in vitro. The discovery of this DNA demethylase should provide a basis for the molecular and developmental analysis of the role of DNA methylation and demethylation.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca	Bhattacharya, Sanjoy K/B-2001-2008					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; HENRICH B, 1998, MOL CELL BIOL, V18, P6538; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MONK M, 1987, DEVELOPMENT, V99, P371; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; Rost B, 1996, METHOD ENZYMOL, V266, P525; SIEGFRIED Z, 1997, CURR BIOL, V7, P305; Swisher JFA, 1998, NUCLEIC ACIDS RES, V26, P5573, DOI 10.1093/nar/26.24.5573; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; SZYF M, 1994, TRENDS PHARMACOL SCI, V7, P233; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4	28	529	563	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 18	1999	397	6720					579	583		10.1038/17533	http://dx.doi.org/10.1038/17533			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050851				2022-12-01	WOS:000078738500038
J	Coxon, JP; Gallen, IW				Coxon, JP; Gallen, IW			Laterality of lower limb amputation in diabetic patients: retrospective audit	BRITISH MEDICAL JOURNAL			English	Article							ULCERATION; RISK		Wycombe Gen Hosp, Children Diabet Ctr, High Wycombe HP11 2TT, Bucks, England		Gallen, IW (corresponding author), Wycombe Gen Hosp, Children Diabet Ctr, High Wycombe HP11 2TT, Bucks, England.							CTERCTEKO GC, 1981, BRIT J SURG, V68, P608, DOI 10.1002/bjs.1800680904; Lehto S, 1996, DIABETES CARE, V19, P607, DOI 10.2337/diacare.19.6.607; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; REIBER GE, 1996, DIABETIC MED, V13, P6; VEVES A, 1992, DIABETOLOGIA, V35, P660, DOI 10.1007/BF00400259	5	8	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					367	367		10.1136/bmj.318.7180.367	http://dx.doi.org/10.1136/bmj.318.7180.367			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933199	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000078572600028
J	Rahi, JS; Dezateux, C				Rahi, JS; Dezateux, C		British Congenital Cataract Interest Grp	National cross sectional study of detection of congenital and infantile cataract in the United Kingdom: role of childhood screening and surveillance	BRITISH MEDICAL JOURNAL			English	Article							AMBLYOPIA; SURGERY	Objectives To determine the mode of detection and timing of ophthalmic assessment of a nationally representative group of children with congenital and infantile cataract. Design Cross sectional study. Setting United Kingdom. Subjects All children burn in the United Kingdom and aged 15 years or under in whom congenital or infantile cataract was ne newly diagnosed between October 1995 and September 1996. Main outcome measures Proportion of cases detected through routine ocular examination and proportion assessed by an ophthalmologist by 3 months and 1 year of age. Results Data were complete for 235 (95%,) of 248 children identified. Of these, 83 (35%) were detected at the routine newborn examination and 30 (12%) at the 6-8 week examination; 82 children presented symptomatically. 137 (57%) children had been assessed by an ophthalmologist by the age of 3 months but 78 (33%) were not examined until after: 1 year of age. In 91 cases the child's carers suspected an eye defect before cataract was diagnosed. Conclusions A substantial proportion of children with congenital and infantile cataract are not diagnosed by 3 months of age, although routine ocular examination of all newborn and young infants is recommended nationally. Strategies to achieve earlier detection through screening and surveillance are required.				j.rahi@ich.ucl.ac.uk	Dezateux, Carol/A-3416-2009	Dezateux, Carol/0000-0001-9787-6276; Rahi, Jugnoo/0000-0002-5718-9209				AULD R, 1989, BR ORTHOPT J, V46, P30; *BRIT PAED SURV UN, 1997, 11 ANN REP 1996 1997; CAMPOS E, 1995, SURV OPHTHALMOL, V40, P23, DOI 10.1016/S0039-6257(95)80044-1; DAVIES PA, 1972, CLIN DEVEL MED, V44, P241; DEWINTER M, 1995, SCREENING CHILD HLTH; Foster A, 1997, PAEDIAT OPHTHALMOLOG, P3; HALL DM, 1996, HLTH ALL CHILDREN 3; HALL DMB, 1988, BRIT MED J, V296, P823, DOI 10.1136/bmj.296.6625.823; HALL SM, 1982, BRIT MED J, V285, P1096, DOI 10.1136/bmj.285.6348.1096; HING S, 1990, BRIT J OPHTHALMOL, V74, P73, DOI 10.1136/bjo.74.2.73; JOHNSON A, 1989, BMJ-BRIT MED J, V299, P545, DOI 10.1136/bmj.299.6698.545; Kirkwood B., 1988, BR K ESSENTIALS MED; Lambert SR, 1996, SURV OPHTHALMOL, V40, P427, DOI 10.1016/S0039-6257(96)82011-X; LLOYD IC, 1992, EYE, V6, P184, DOI 10.1038/eye.1992.37; LLOYD IC, 1995, BRIT J OPHTHALMOL, V79, P802, DOI 10.1136/bjo.79.9.802; Rahi J. S., 1998, IOVS, V39, pS899; Rahi JS, 1998, ARCH DIS CHILD, V78, P364, DOI 10.1136/adc.78.4.364; Rappo PD, 1996, PEDIATRICS, V98, P153; Robinson R, 1998, BMJ-BRIT MED J, V316, P1; *ROYAL COLL OPHTH, 1994, OPHTH SERV CHILDRE R; RUTTUM MS, 1987, PEDIATRICS, V79, P814; Shuttleworth GN, 1997, EYE, V11, P744, DOI 10.1038/eye.1997.189; STAYTE M, 1993, BRIT J OPHTHALMOL, V77, P228, DOI 10.1136/bjo.77.4.228; Taylor D, 1998, EYE, V12, P9, DOI 10.1038/eye.1998.5; TAYLOR DSI, 1982, T OPHTHAL SOC UK, V102, P441; VAEGAN TD, 1979, T OPHTHAL SOC UK, V99, P432; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; World Health Organization, 1992, INT STAT CLASS DIS H	28	68	71	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					362	365		10.1136/bmj.318.7180.362	http://dx.doi.org/10.1136/bmj.318.7180.362			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933197	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000078572600026
J	Sherlaw-Johnson, C; Gallivan, S; Jenkins, D				Sherlaw-Johnson, C; Gallivan, S; Jenkins, D			Withdrawing low risk women from cervical screening programmes: mathematical modelling study	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUS; CANCER; PREVALENCE; MANAGEMENT; SMEARS; HPV	Objective To evaluate the impact of policies for removing women before the recommended age of 64 from screening programmes for cervical cancer in the United Kingdom. Design A mathematical model of the clinical course of precancerous lesions which accounts for the influence of infection with the human papillomavirus, the effects of screening on the progression of disease, and the accuracy of the testing procedures. Two policies are compared: one in which women are withdrawn from the programme if their current smear is negative and they have a recent history of regular, negative results and one in which women are withdrawn if their current smear test is negative and a simultaneous test is negative for exposure to high risk types of human papillomavirus. Setting United Kingdom cervical screening programme. Main outcome measures The incidence of invasive cervical cancer and the use of resources. Results Early withdrawal of selected women from the programme is predicted to give rise to resource savings of up to 25% for smear tests and 18% for colposcopies when withdrawal occurs from age 50, the youngest age considered in the study. An increase in the incidence of invasive cervical cancer, by up to 2 cases/100 000 women each year is predicted. Testing for human papillomavirus infection to determine which women should be withdrawn from the programme makes little difference to outcome. Conclusions This model systematically analyses the consequences of screening options using available data and the clinical course of precancerous lesions. If further audit studies confirm the model's forecasts, a policy of early withdrawal might be considered. This would be likely to release substantial resources which could be channelled into other aspects of health care or may be more effectively used within the cervical screening programme to counteract the possible increase in cancer incidence that early withdrawal might bring.	Univ London Univ Coll, Dept Math, Clin Operat Res Unit, London WC1E 6BT, England; Univ Nottingham, Queens Med Ctr, Div Pathol, Nottingham NG7 2UH, England	University of London; University College London; University of Nottingham	Sherlaw-Johnson, C (corresponding author), Univ London Univ Coll, Dept Math, Clin Operat Res Unit, Gower St, London WC1E 6BT, England.	c.sherlaw-johnson@ucl.ac.uk						AUSTOKER J, 1994, BRIT MED J, V309, P241, DOI 10.1136/bmj.309.6949.241; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; Cruickshank ME, 1997, BRIT J OBSTET GYNAEC, V104, P586, DOI 10.1111/j.1471-0528.1997.tb11537.x; *DEP HLTH, 1996, STAT B DEP HLTH; DUNCAN I, 1992, GUIDELINES CLIN PRAC; Jenkins D, 1996, INT J CANCER, V65, P768; JENKINS D, 1998, PAPILLOMAVIRUS REP, V9, P89; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; MANDELBLATT J, 1991, AM J OBSTET GYNECOL, V164, P644, DOI 10.1016/S0002-9378(11)80040-2; MANSELL ME, 1994, BRIT J OBSTET GYNAEC, V101, P807, DOI 10.1111/j.1471-0528.1994.tb11952.x; MELKERT PWJ, 1993, INT J CANCER, V53, P919, DOI 10.1002/ijc.2910530609; *OFF NAT STAT, 1998, EST NEWL DIAGN CAS C; ORBELL S, 1995, J ROY SOC MED, V88, P389; PARKIN DM, 1982, PUBLIC HEALTH, V96, P3, DOI 10.1016/S0033-3506(82)80023-1; Rozendaal L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z; Sasieni PD, 1996, BRIT J CANCER, V73, P1001, DOI 10.1038/bjc.1996.196; SCHIFFMAN MH, 1994, EARLY DETECTION CANC, P265; SHERLAWJOHNSON C, 1994, J CLIN PATHOL, V47, P430, DOI 10.1136/jcp.47.5.430; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P1409, DOI 10.1136/bmj.306.6889.1409-c	21	35	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 6	1999	318	7180					356	360		10.1136/bmj.318.7180.356	http://dx.doi.org/10.1136/bmj.318.7180.356			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JN	9933195	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000078572600023
J	Tichelli, A; Socie, G; Henry-Amar, M; Marsh, J; Passweg, J; Schrezenmeier, H; McCann, S; Hows, J; Ljungman, P; Marin, P; Raghavachar, A; Locasciulli, A; Gratwohl, A; Bacigalupo, A				Tichelli, A; Socie, G; Henry-Amar, M; Marsh, J; Passweg, J; Schrezenmeier, H; McCann, S; Hows, J; Ljungman, P; Marin, P; Raghavachar, A; Locasciulli, A; Gratwohl, A; Bacigalupo, A		European Grp Blood MarrowTransplantation	Effectiveness of immunosuppressive therapy in older patients with aplastic anemia	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SAA WORKING PARTY; ANTILYMPHOCYTE GLOBULIN ALG; COLONY-STIMULATING-FACTOR; TERM FOLLOW-UP; ANTITHYMOCYTE GLOBULIN; RANDOMIZED TRIAL; METHYLPREDNISOLONE; CYCLOSPORINE; EVOLUTION	Background: Immunosuppressive therapy has been used for successful treatment of severe aplastic anemia, but little information is available on outcome in older patients. Objective: To evaluate outcome in patients older than 50 years of age who received immunosuppressive therapy for aplastic anemia. Design: Retrospective cohort study. Setting: 56 centers of the European Group for Blood and Marrow Transplantation (EBMT). Patients: 810 patients with aplastic anemia reported between 1974 and 1997. Patients were evaluated according to age group: 60 years of age or older (n = 127), 50 to 59 years of age (n = 115), and 20 to 49 years of age (n = 568; reference group). Intervention: Antilymphocyte globulin, cyclosporine, or both. Measurements: Survival, cause of death, response to treatment, relapse rate, and risk for late complications were analyzed in all patients and by age group. Results: The 5-year survival rate was 57% (95% CI, 46% to 66%) in patients 50 to 59 years of age and 50% (CI, 39% to 60%) in patients 60 years of age or older compared with 72% (CI, 68% to 76%) in patients younger than 50 years of age (P < 0.001). Response to therapy, relapse rate, and risk for clonal complications were similar in all three age groups (P > 0.2). Age was significantly associated with an increased risk for death (relative risk compared with patients 20 to 49 years of age, 1.80 [CI, 1.29 to 2.52] for patients 50 to 59 yea rs of age and 2.57 [CI, 1.87 to 3.53] for patients greater than or equal to 60 years of age), mainly because of bleeding or infection (P = 0.02). Response to immunosuppressive therapy in all patients at 12 months was 62% (CI, 58% to 66%); no difference was seen among the age groups in multivariate analysis (P > 0.2). Sixty-six of the 379 responding patients (17%) subsequently had relapse. The risk for clonal disorders at 10 years was 20% (CI, 15% to 27%). Conclusions: Response to immunosuppression in aplastic anemia is independent of age, but treatment is associated with increased mortality in older patients.	Kantonsspital, Dept Zent Lab, Hamatol Lab, CH-4031 Basel, Switzerland; Hop St Louis, Bone Marrow Transplant Unit, F-75475 Paris 10, France; Ctr Francois Baclesse, F-14076 Caen 5, France; Univ London St Georges Hosp, Div Haematol, London SW17 0RE, England; Univ Ulm, Innere Med Abt, D-89081 Ulm, Germany; Univ Ireland Trinity Coll, St James Hosp, Dublin 8, Ireland; Southmead Hlth Serv, Dept Transplantat Sci, Bristol BS10 5NB, Avon, England; Huddinge Hosp, Dept Med, S-14186 Huddinge, Sweden; Farreras Valenti, Postgrad Sch Haematol, E-08036 Barcelona, Spain; Osped San Gerardo, Pediat Clin, I-20052 Monza, Italy; Osped San Martino Genova, Div Ematol, Ctr Trapianti Midollo Osseo, I-16132 Genoa, Italy	Kantonsspital Aarau AG (KSA); University of Basel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Centre Francois Baclesse; St Georges University London; Ulm University; Trinity College Dublin; San Gerardo Hospital; University of Genoa; IRCCS AOU San Martino IST	Tichelli, A (corresponding author), Kantonsspital, Dept Zent Lab, Hamatol Lab, Petersgraben 4, CH-4031 Basel, Switzerland.		Ljungman, Per/M-4946-2019; Henry-Amar, Michel/S-9358-2019; passweg, jakob/AAG-3911-2020	Passweg, Jakob R/0000-0001-7092-3351; Henry-Amar, Michel/0000-0002-9357-6476				BACIGALUPO A, 1993, BRIT J HAEMATOL, V83, P145, DOI 10.1111/j.1365-2141.1993.tb04645.x; BACIGALUPO A, 1995, BLOOD, V85, P1348, DOI 10.1182/blood.V85.5.1348.bloodjournal8551348; BACIGALUPO A, 1988, BRIT J HAEMATOL, V70, P177, DOI 10.1111/j.1365-2141.1988.tb02460.x; CAMITTA B, 1983, BLOOD, V62, P883; CHAMPLIN RE, 1985, BLOOD, V66, P184, DOI 10.1182/blood.V66.1.184.184; Deeg HJ, 1998, BLOOD, V91, P3637; DEPLANQUE MM, 1988, BRIT J HAEMATOL, V70, P55; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; Doney K, 1997, ANN INTERN MED, V126, P107, DOI 10.7326/0003-4819-126-2-199701150-00003; DONEY K, 1992, BLOOD, V79, P2566; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; GLUCKMAN E, 1992, BLOOD, V79, P269; GLUCKMAN E, 1992, BLOOD, V79, P2540; KLINGEMANN HG, 1986, BLOOD, V67, P770; MARSH JCW, 1987, BLOOD, V70, P1046; MARSH JCW, 1991, BRIT J HAEMATOL, V77, P447; NAJEAN Y, 1990, BLOOD, V76, P2222; NISSEN C, 1993, BRIT J HAEMATOL, V83, P319, DOI 10.1111/j.1365-2141.1993.tb08288.x; Ohara A, 1997, BLOOD, V90, P1009, DOI 10.1182/blood.V90.3.1009.1009_1009_1013; Orazi A, 1997, AM J CLIN PATHOL, V107, P268, DOI 10.1093/ajcp/107.3.268; PAQUETTE RL, 1995, BLOOD, V85, P283, DOI 10.1182/blood.V85.1.283.bloodjournal851283; Passweg JR, 1997, BLOOD, V90, P858; Reiter E, 1997, BONE MARROW TRANSPL, V19, P1191, DOI 10.1038/sj.bmt.1700819; SCHREZENMEIER H, 1993, BRIT J HAEMATOL, V85, P371, DOI 10.1111/j.1365-2141.1993.tb03181.x; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SPECK B, 1986, EXP HEMATOL, V14, P126; Storb R, 1997, BLOOD, V89, P3890, DOI 10.1182/blood.V89.10.3890.3890_3890_3890; TICHELLI A, 1994, LEUKEMIA LYMPHOMA, V12, P167, DOI 10.3109/10428199409059587; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; Yamazaki E, 1997, BLOOD CELL MOL DIS, V23, P213, DOI 10.1006/bcmd.1997.0138; YOUNG N, 1988, BLOOD, V72, P1861; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367; YOUNG NS, 1992, BLOOD, V79, P1385, DOI 10.1182/blood.V79.6.1385.bloodjournal7961385	33	72	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	1999	130	3					193	+		10.7326/0003-4819-130-3-199902020-00004	http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162PD	10049197				2022-12-01	WOS:000078355000003
J	Belich, MP; Salmeron, A; Johnston, LH; Ley, SC				Belich, MP; Salmeron, A; Johnston, LH; Ley, SC			TPL-2 kinase regulates the proteolysis of the NF-kappa B-inhibitory protein NF-kappa B1 p105	NATURE			English	Article							DNA-BINDING SUBUNIT; TYROSINE KINASE; P50 SUBUNIT; ACTIVATION; PRECURSOR; PHOSPHORYLATION; GENERATION; PATHWAY; SIGNAL; ALPHA	The transcription factor NF-kappa B is composed of homodimeric and heterodimeric complexes of Rel/NF-kappa B-family polypeptides, which include Rel-A, c-Rel, Rel-B, NF-kappa B1/p50 and NF-kappa B2/p52 (ref. 1), The NF-kappa B1 gene encodes a larger precursor protein, p105, from which p50 is produced constitutively by proteasome-mediated removal of the p105 carboxy terminus(2.-5). The p105 precursor also acts as an NF kappa B-inhibitory protein, retaining associated p50, c-Rel and Rel-A proteins in the cytoplasm through its carboxy terminus(6,7). Following cell stimulation by agonists, p105 is proteolysed more rapidly and released Rel subunits translocate into the nucleus(8-10). Here we show that TPL-2 (ref. 11), which is homologous to MAP-kinase-kinase kinases in its catalytic domain(12), forms a complex with the carboxy terminus of p105, TPL-2 was originally identified, in a carboxy-terminal-deleted form, as an oncoprotein in rats(11) and is more than 90% identical to the human oncoprotein COT13. Expression of TPL-2 results in phosphorylation and increased degradation of p105 while maintaining p50 production. This releases associated Rel subunits or p50-Rel heterodimers to generate active nuclear NF-kappa B. Furthermore, kinase-inactive TPL-2 blocks the degradation of p105 induced by tumour-necrosis factor-alpha. TPL-2 is therefore a component of a new signalling pathway that controls proteolysis of NF-kappa B1 p105.	Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Ley, SC (corresponding author), Natl Inst Med Res, Div Cellular Immunol, Ridgeway,Mill Hill, London NW7 1AA, England.							ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; AOKI M, 1993, J BIOL CHEM, V268, P22723; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Huby RDJ, 1997, J CELL BIOL, V137, P1639, DOI 10.1083/jcb.137.7.1639; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	30	182	192	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					363	368		10.1038/16946	http://dx.doi.org/10.1038/16946			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950430				2022-12-01	WOS:000078324600053
J	Johansson, CB; Momma, S; Clarke, DL; Risling, M; Lendahl, U; Frisen, J				Johansson, CB; Momma, S; Clarke, DL; Risling, M; Lendahl, U; Frisen, J			Identification of a neural stem cell in the adult mammalian central nervous system	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; SUBVENTRICULAR ZONE; CNS PRECURSOR; GENE-TRANSFER; RAT-BRAIN; FOREBRAIN; NEURONS; IMMUNOREACTIVITY; EXPRESSION; GENERATION	New neurons are continuously added in specific regions of the adult mammalian central nervous system. These neurons are derived from multipotent stem cells whose identity has been enigmatic. In this work, we present evidence that ependymal cells are neural stem cells. Ependymal cells give rise to a rapidly proliferating cell type that generates neurons that migrate to the olfactory bulb. In response to spinal cord injury, ependymal cell proliferation increases dramatically to generate migratory cells that differentiate to astrocytes and participate in scar formation. These data demonstrate that ependymal cells are neural stem cells and identify a novel process in the response to central nervous system injury.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Med Nobel Inst, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Frisen, J (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.			Lendahl, Urban/0000-0001-9543-8141				ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Davidson BL, 1997, EXP NEUROL, V144, P125, DOI 10.1006/exnr.1996.6398; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DELBIGIO MR, 1995, GLIA, V14, P1, DOI 10.1002/glia.440140102; Doetsch F, 1997, J NEUROSCI, V17, P5046; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gage FH, 1998, NATURE, V392, P18; Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0; Gritti A, 1996, J NEUROSCI, V16, P1091; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KAWAMATA S, 1995, ACTA ANAT, V152, P205; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MCKAY R, 1997, SCIENCE, V276, P6671; MITSIADIS TA, 1995, J CELL BIOL, V130, P407, DOI 10.1083/jcb.130.2.407; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SANES JR, 1989, TRENDS NEUROSCI, V12, P21, DOI 10.1016/0166-2236(89)90152-5; SVENDSEN CN, 1995, EXP BRAIN RES, V102, P407; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Weiss S, 1996, J NEUROSCI, V16, P7599; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	36	1532	1688	5	125	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					25	34		10.1016/S0092-8674(00)80956-3	http://dx.doi.org/10.1016/S0092-8674(00)80956-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989494	Bronze			2022-12-01	WOS:000078023200005
J	Aylin, P; Bunting, J; De Stavola, B; Coleman, MP				Aylin, P; Bunting, J; De Stavola, B; Coleman, MP			Mortality from dementia in occupations at risk of exposure to bovine spongiform encephalopathy: analysis of death registrations	BRITISH MEDICAL JOURNAL			English	Article									St Marys Hosp, Imperial Coll Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Off Natl Stat, Hlth & Demog, London SW1V 2QQ, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	Imperial College London; University of London; London School of Hygiene & Tropical Medicine	Aylin, P (corresponding author), St Marys Hosp, Imperial Coll Med, Dept Epidemiol & Publ Hlth, Praed St, London W2 1PG, England.		Aylin, Paul/A-1073-2014; Coleman, Michel/AAA-9543-2020	Coleman, Michel/0000-0001-8940-3807; De Stavola, Bianca Lucia/0000-0001-7853-0528; Aylin, Paul/0000-0003-4589-1743				BRESLOW NE, 1987, IARC SCI PUBL, V82, P168; *NAT CJD SURV UN, 1997, 6 NCJDSU; ROBERTS GW, 1995, BRIT MED J, V311, P1419, DOI 10.1136/bmj.311.7017.1419a; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134	4	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1044	1045		10.1136/bmj.318.7190.1044	http://dx.doi.org/10.1136/bmj.318.7190.1044			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205102	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000080140000028
J	Laroia, G; Cuesta, R; Brewer, G; Schneider, RJ				Laroia, G; Cuesta, R; Brewer, G; Schneider, RJ			Control of mRNA decay by heat shock ubiquitin proteasome pathway	SCIENCE			English	Article							MESSENGER-RNA DEGRADATION; CYCLE MUTANT TS85; PROTEIN-DEGRADATION; BINDING PROTEIN; RICH ELEMENT; C-FOS; TRANSLATION; STABILITY; REGION	Cytokine and proto-oncogene messenger RNAs (mRNAs) are rapidly degraded through AU-rich elements in the 3' untranslated region. Rapid decay involves AU-rich binding protein AUF1, which complexes with heat shock proteins hsc70-hsp70, translation initiation factor elF4G, and poly(A) binding protein. AU-rich mRNA decay is associated with displacement of elF4G from AUF1, ubiquitination of AUF1, and 'degradation of AUF1 by proteasomes. Induction of hsp70 by heat shock, down-regulation of the ubiquitin-proteasome network, or inactivation of ubiquitinating enzyme E1 all result in hsp70 sequestration of AUF1 in the perinucleus-nucleus, and all three processes block decay of AU-rich mRNAs and AUF1 protein. These results link the rapid degradation of cytokine mRNAs to the ubiquitin-proteasome pathway.	NYU, Sch Med, Dept Microbiol & Biochem, New York, NY 10016 USA; Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	New York University; Wake Forest University	Schneider, RJ (corresponding author), NYU, Sch Med, Dept Microbiol & Biochem, New York, NY 10016 USA.	schner01@mcrcr6.med.nyu.edu			NCI NIH HHS [CA52443, CA42357] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052443, R01CA042357] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Bush KT, 1997, J BIOL CHEM, V272, P9086; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LAROIA G, UNPUB; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MOORE M, 1987, MOL CELL BIOL, V7, P4505, DOI 10.1128/MCB.7.12.4505; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	26	343	349	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					499	502		10.1126/science.284.5413.499	http://dx.doi.org/10.1126/science.284.5413.499			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205060				2022-12-01	WOS:000079792200051
J	Parrish, JK; Edelstein-Keshet, L				Parrish, JK; Edelstein-Keshet, L			Complexity, pattern, and evolutionary trade-offs in animal aggregation	SCIENCE			English	Editorial Material							SELFISH HERD; FISH; SCHOOLS; THERMOREGULATION; PREDATION; DOLPHINS; BEHAVIOR; BIRDS	One of the most striking patterns in biology is the formation of animal aggregations. Classically; aggregation has been viewed as an evolutionarily advantageous state, in which members derive the benefits of protection, mate choice, and centralized information, balanced by the costs of Limiting resources. Consisting of individual members, aggregations nevertheless function as an integrated whole, displaying a complex set of behaviors not possible at the Level of the individual organism. Complexity theory indicates that Large populations of units can self-organize into aggregations that generate pattern, store information, and engage in collective decision-making. This begs the question, are all emergent properties of animal aggregations functional or are some simply pattern? Solutions to this dilemma will necessitate a closer marriage of theoretical and modeling studies Linked to empirical work addressing the choices, and trajectories, of individuals constrained by membership in the group.	Univ Washington, Dept Zool, Seattle, WA 98195 USA; Univ British Columbia, Dept Math, Vancouver, BC V6T 1Z2, Canada	University of Washington; University of Washington Seattle; University of British Columbia	Parrish, JK (corresponding author), Univ Washington, Dept Zool, Seattle, WA 98195 USA.	jparrish@u.washington.edu	Fahimifar, Sepideh/M-5303-2019					ABRAHAMS MV, 1985, ENVIRON BIOL FISH, V13, P195, DOI 10.1007/BF00000931; Allee W., 1949, PRINCIPLES ANIMAL EC; Allee WC, 1931, ANIMAL AGGREGATION S; Belkovich V. M., 1991, DOLPHIN SOC DISCOVER; Ben-Jacob E, 1998, SCI AM, V279, P82, DOI 10.1038/scientificamerican1098-82; Bertram B.C.R., 1978, P64; Bonner JT, 1944, AM J BOT, V31, P175, DOI 10.2307/2437641; CLARK CW, 1986, THEOR POPUL BIOL, V30, P45, DOI 10.1016/0040-5809(86)90024-9; COULSON JC, 1968, NATURE, V217, P478, DOI 10.1038/217478a0; DENEUBOURG JL, 1989, ETHOL ECOL EVOL, V1, P295, DOI 10.1080/08927014.1989.9525500; Diamond JM., 1997, GUNS GERMS STEEL FAT; Edelstein-Keshet L, 1998, J MATH BIOL, V36, P515, DOI 10.1007/s002850050112; Edmunds M., 1974, DEFENSE IN ANIMALS; ELLIS PE, 1953, J EXP BIOL, V30, P214; ERMENTROUT GB, 1993, J THEOR BIOL, V160, P97, DOI 10.1006/jtbi.1993.1007; FISH D, 1973, NATURE, V241, P290; Flierl G, 1999, J THEOR BIOL, V196, P397, DOI 10.1006/jtbi.1998.0842; FORCADA J, 1994, MAR MAMMAL SCI, V10, P137, DOI 10.1111/j.1748-7692.1994.tb00256.x; FRETWELL S D, 1969, Acta Biotheoretica, V19, P16, DOI 10.1007/BF01601953; Giraldeau L.-A., 1988, P33; GRAHAM R, 1987, LAS SYN C COH SELF O; Grunbaum Daniel, 1997, P257; Haken H., 1983, SYNERGETICS INTRO NO, V3rd; HAMILTON WD, 1971, J THEOR BIOL, V31, P295, DOI 10.1016/0022-5193(71)90189-5; HEINRICH B, 1981, SCIENCE, V212, P565, DOI 10.1126/science.212.4494.563; Holldobler B., 1990, pi; HOOGLAND JL, 1979, ANIM BEHAV, V27, P394, DOI 10.1016/0003-3472(79)90174-X; Hunter J. R., 1967, Fishery Bulletin Fish and Wildlife Service US, V66, P13; KERMACK WO, 1922, R STAT SOC J, V115, P700; KRAUSE J, 1994, BIOL REV, V69, P187, DOI 10.1111/j.1469-185X.1994.tb01505.x; Lack D., 1954, P343; LANDEAU L, 1986, ANIM BEHAV, V34, P1372, DOI 10.1016/S0003-3472(86)80208-1; Langton C. G, 1995, ARTIFICIAL LIFE OVER; LAZARUS J, 1979, ANIM BEHAV, V27, P855, DOI 10.1016/0003-3472(79)90023-X; Levin Simon A., 1997, ANIMAL GROUPS 3 DIME, P245; LISSAMAN PB, 1970, SCIENCE, V168, P1003, DOI 10.1126/science.168.3934.1003; MCFARLAND WN, 1967, SCIENCE, V156, P260, DOI 10.1126/science.156.3772.260; Mech LD., 1970, WOLF ECOLOGY BEHAV E; MIMURA M, 1982, ADV BIOPHYS, V15, P19, DOI 10.1016/0065-227X(82)90004-1; MISUND OA, 1991, BEHAV SCH RELATED FI; MOGILNER A, IN PRESS J MATH BIOL; NORRIS KS, 1988, ETHOL SOCIOBIOL, V9, P149, DOI 10.1016/0162-3095(88)90019-2; Okubo A., 1986, Advances in Biophysics, V22, P1, DOI 10.1016/0065-227X(86)90003-1; Okubo A., 1980, DIFFUSION ECOLOGICAL; PARRISH JK, 1992, NETH J ZOOL, V42, P358, DOI 10.1163/156854291X00388; PARRISH JK, 1989, ANIM BEHAV, V38, P1048, DOI 10.1016/S0003-3472(89)80143-5; PARRISH JK, IN PRESS ENV BIOL FI; PARTRIDGE BL, 1983, ENVIRON BIOL FISH, V9, P253, DOI 10.1007/BF00692374; PEDLEY TJ, 1992, ANNU REV FLUID MECH, V24, P313, DOI 10.1146/annurev.fl.24.010192.001525; Pitcher T. J., 1983, PREDATORS PREY FISHE, P193; Pitcher TJ., 1993, Behaviour of teleost fishes, P363, DOI 10.1007/978-94-011-1578-0_12; RETTENMEYER CARL W., 1963, UNIV KANSAS SCI BULL, V44, P281; REYNOLDS CW, 1975, COMPUT GRAPHICS, V21, P75; Romey WL, 1996, ECOL MODEL, V92, P65, DOI 10.1016/0304-3800(95)00202-2; Schilt Carl R., 1997, P225; SCHNEIRLA TC, 1971, STUDY SOCIAL ORG; Smith E. A, 1981, HUNTER GATHERER FORA, P36; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Vabo R, 1997, FISH OCEANOGR, V6, P155, DOI 10.1046/j.1365-2419.1997.00037.x; Wakita J, 1998, J PHYS SOC JPN, V67, P3630, DOI 10.1143/JPSJ.67.3630; WATMOUGH J, 1995, J THEOR BIOL, V176, P391, DOI 10.1006/jtbi.1995.0207; Williams G. C., 1964, PUBLS MUS MICHIGAN S, V2, P349; Wittenberger J.F., 1985, Avian Biology, V8, P1; WURSIG B, 1980, FISH B-NOAA, V77, P871	64	809	842	5	265	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1999	284	5411					99	101		10.1126/science.284.5411.99	http://dx.doi.org/10.1126/science.284.5411.99			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102827	Green Published			2022-12-01	WOS:000079509000040
J	Nenner, F				Nenner, F			A mother's voice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1999	281	12					1065	1065		10.1001/jama.281.12.1065	http://dx.doi.org/10.1001/jama.281.12.1065			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	177EP	10188641				2022-12-01	WOS:000079197100001
J	Kidd, T; Bland, KS; Goodman, CS				Kidd, T; Bland, KS; Goodman, CS			Slit is the midline repellent for the robe receptor in Drosophila	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; GENETIC-ANALYSIS; CNS MIDLINE; MELANOGASTER; PROTEIN; FASCICULATION; ENCODES; LOCUS; EGF	Previous studies suggested that Roundabout (Robo) is a repulsive guidance receptor on growth cones that binds to an unknown midline ligand. Here we present genetic evidence that Slit is the midline Robe ligand; a companion paper presents biochemical evidence that Slit binds Robe. Slit is a large extracellular matrix protein expressed by midline glia. In slit mutants, growth cones enter the midline but never leave it; they abnormally continue to express high levels of Robe while at the midline. slit and robe display dosage-sensitive genetic interactions, indicating that they function in the same pathway. slit is also required for migration of muscle precursors away from the midline. Slit appears to function as a short-range repellent controlling axon crossing of the midline and as a long-range chemorepellent controlling mesoderm migration away from the midline.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Goodman, CS (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Kidd, Thomas/AAT-9993-2020	Kidd, Thomas/0000-0001-7190-4208; Bland, Kimberly/0000-0003-4863-6772	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18366] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; Hidalgo A, 1997, DEVELOPMENT, V124, P3253; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; KIDD T, 1998, CELL, V20, P25; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; LEWIS JO, 1994, MECH DEVELOP, V48, P81, DOI 10.1016/0925-4773(94)90018-3; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Noordermeer JN, 1998, NEURON, V21, P991, DOI 10.1016/S0896-6273(00)80618-2; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; Scholz H, 1997, MECH DEVELOP, V64, P137; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SONNENFELD MJ, 1994, MECH DEVELOP, V46, P3, DOI 10.1016/0925-4773(94)90033-7; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2	26	766	789	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	1999	96	6					785	794		10.1016/S0092-8674(00)80589-9	http://dx.doi.org/10.1016/S0092-8674(00)80589-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102267	Bronze			2022-12-01	WOS:000079300100006
J	LaPrade, RF; Swiontkowski, MF				LaPrade, RF; Swiontkowski, MF			New horizons in the treatment of osteoarthritis of the knee	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HYLAN		Univ Minnesota, Dept Orthopaed Surg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	LaPrade, RF (corresponding author), Univ Minnesota, Dept Orthopaed Surg, 420 Delaware Ave SE,Box 492, Minneapolis, MN 55455 USA.		LaPrade, Robert F./AFA-8673-2022	LaPrade, Robert F./0000-0002-9823-2306; Swiontkowski, Marc/0000-0001-7036-1782				Adams ME, 1995, OSTEOARTHR CARTILAGE, V3, P213, DOI 10.1016/S1063-4584(05)80013-5; BROWNE JE, 1998, T 8 ESSKA C NIC FRAN, P103; GABRIEL SE, 1995, J RHEUMATOL, V22, P23; Hangody L, 1998, ORTHOPEDICS, V21, P751, DOI 10.3928/0147-7447-19980701-04; Hangody L, 1997, Knee Surg Sports Traumatol Arthrosc, V5, P262, DOI 10.1007/s001670050061; Lussier A, 1996, J RHEUMATOL, V23, P1579; Minas T, 1998, J SPORT TRAUMATOL, V20, P90; PETERSON L, 1998, AM AC ORTH SURG 65 A; Simonian PT, 1998, AM J SPORT MED, V26, P491, DOI 10.1177/03635465980260040201	9	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1999	281	10					876	878		10.1001/jama.281.10.876	http://dx.doi.org/10.1001/jama.281.10.876			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172XH	10078464				2022-12-01	WOS:000078950600002
J	Casci, T; Vinos, J; Freeman, M				Casci, T; Vinos, J; Freeman, M			Sprouty, an intracellular inhibitor of Ras signaling	CELL			English	Article							DROSOPHILA EGF RECEPTOR; GUANINE-NUCLEOTIDE EXCHANGE; PROTEIN TYROSINE KINASE; VENTRAL ECTODERM; ADAPTER PROTEIN; GENETIC MOSAICS; PLASMA-MEMBRANE; SEVENLESS; ACTIVATION; PATHWAY	Sprouty was identified in a genetic screen as an inhibitor of Drosophila EGF receptor signaling. The Egfr triggers cell recruitment in the eye, and sprouty(-) eyes have excess photoreceptors, cone cells, and pigment cells. Sprouty's function is, however, more widespread. We show that it also interacts genetically with the receptor tyrosine kinases Torso and Sevenless, and it was first discovered through its effect on FGF receptor signaling. In contrast to an earlier proposal that Sprouty is extracellular, we show by biochemical analysis that Sprouty is an intracellular protein, associated with the inner surface of the plasma membrane. Sprouty binds to two intracellular components of the Ras pathway, Drk and Gap1. Our results indicate that Sprouty is a widespread inhibitor of Ras pathway signal transduction.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	mf1@mrc-lmb.cam.ac.uk		Casci, Tanita/0000-0002-1838-0027; Freeman, Matthew/0000-0003-0410-5451				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CASANOVA J, 1995, GENE DEV, V9, P2539, DOI 10.1101/gad.9.20.2539; CHERBAS L, 1994, DROSOPHILA MELANOGAS, P161; Chou TB, 1996, GENETICS, V144, P1673; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DIAZBENJUMEA FJ, 1990, P ROY SOC B-BIOL SCI, V242, P36, DOI 10.1098/rspb.1990.0100; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dominguez M, 1998, CURR BIOL, V8, P1039, DOI 10.1016/S0960-9822(98)70441-5; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; Golembo M, 1996, DEVELOPMENT, V122, P3363; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P2837; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HORTSCH M, 1994, METHOD CELL BIOL, V44, P289, DOI 10.1016/S0091-679X(08)60920-6; Howes R, 1998, J BIOL CHEM, V273, P4275, DOI 10.1074/jbc.273.7.4275; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; LAWRENCE PA, 1985, DROSOPHILA PRACTICAL, P229; Le N, 1998, MOL CELL BIOL, V18, P4844, DOI 10.1128/MCB.18.8.4844; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOW SH, 1991, J BIOL CHEM, V266, P13391; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; vandeGoor J, 1996, FEBS LETT, V380, P251, DOI 10.1016/0014-5793(96)00026-9; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Wasserman JD, 1997, TRENDS CELL BIOL, V7, P431, DOI 10.1016/S0962-8924(97)01143-4; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; WOLFF T, 1991, DEVELOPMENT, V113, P825; XU T, 1993, DEVELOPMENT, V117, P1223; [No title captured]	56	390	407	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	1999	96	5					655	665		10.1016/S0092-8674(00)80576-0	http://dx.doi.org/10.1016/S0092-8674(00)80576-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	174TB	10089881	Bronze			2022-12-01	WOS:000079050100009
J	Riou-Khamlichi, C; Huntley, R; Jacqmard, A; Murray, JAH				Riou-Khamlichi, C; Huntley, R; Jacqmard, A; Murray, JAH			Cytokinin activation of Arabidopsis cell division through a D-type cyclin	SCIENCE			English	Article							PLANT-CELLS; KINASE; THALIANA; TOBACCO; CULTURE; ALFALFA; FAMILY; PHASE; ACID	Cytokinins are plant hormones that regulate plant cell division. The D-type cyclin CycD3 was found to be elevated in a mutant of Arabidopsis-with a high level of cytokinin and to be rapidly induced by cytokinin application in both cell cultures and whole plants. Constitutive expression of CycD3 in transgenic plants allowed induction and maintenance of cell division in the absence of exogenous cytokinin. Results suggest that cytokinin activates Arabidopsis cell division through induction of CycD3 at the G(1)-S cell cycle phase transition.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; Univ Liege, Dept Biol Vegetale, Serv Physiol, B-4000 Liege, Belgium	University of Cambridge; University of Liege	Murray, JAH (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.		Huntley, Rachael/R-1036-2016; Murray, James AH/D-3399-2009; Huntley, Rachael/J-4951-2019	Huntley, Rachael/0000-0001-6718-3559; Murray, James AH/0000-0002-2282-3839; Huntley, Rachael/0000-0001-6718-3559; Riou, Catherine/0000-0001-6437-785X				ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; Bryant ja, 1985, CELL DIVISION CYCLE, P157; ChinAtkins AN, 1996, PLANTA, V198, P549, DOI 10.1007/BF00262641; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; COOKE R, 1981, PLANTA, V152, P1, DOI 10.1007/BF00384976; DAHL M, 1995, PLANT CELL, V7, P1847; Fuerst RAUA, 1996, PLANT PHYSIOL, V112, P1023, DOI 10.1104/pp.112.3.1023; Jacobs T, 1997, PLANT CELL, V9, P1021, DOI 10.1105/tpc.9.7.1021; JACQMARD A, 1994, CYTOKININS CHEM ACTI, P197; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; KAPROS T, 1992, PLANT PHYSIOL, V98, P621, DOI 10.1104/pp.98.2.621; KILBY NJ, 1995, PLANT J, V8, P637, DOI 10.1046/j.1365-313X.1995.08050637.x; KRAIGHER H, 1991, PHYTOCHEMISTRY, V30, P2249, DOI 10.1016/0031-9422(91)83623-S; LETHAM DS, 1978, PHYTOHORMONES RELATE, V2; Mader JC, 1996, J PLANT GROWTH REGUL, V15, P95, DOI 10.1007/BF00192938; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; MILLER CO, 1955, J AM CHEM SOC, V77, P1392, DOI 10.1021/ja01610a105; NAGATA T, 1994, INT J DEV BIOL, V38, P321; Redig P, 1996, FEBS LETT, V391, P175, DOI 10.1016/0014-5793(96)00728-4; RIOUKHAMLICHI C, UNPUB; Segers G, 1996, PLANT J, V10, P601, DOI 10.1046/j.1365-313X.1996.10040601.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SONI R, 1995, PLANT CELL, V7, P85, DOI 10.1105/tpc.7.1.85; Sorrell DA, 1999, PLANT PHYSIOL, V119, P343, DOI 10.1104/pp.119.1.343; Zhang K, 1996, PLANTA, V200, P2	25	585	647	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1541	1544		10.1126/science.283.5407.1541	http://dx.doi.org/10.1126/science.283.5407.1541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10066178				2022-12-01	WOS:000078959200050
J	Winckler, B; Forscher, P; Mellman, I				Winckler, B; Forscher, P; Mellman, I			A diffusion barrier maintains distribution of membrane proteins in polarized neurons	NATURE			English	Article							GROWTH CONE; HIPPOCAMPAL-NEURONS; LATERAL MOBILITY; CELLS; MOLECULES; RANVIER; FAMILY	The asymmetric distribution of proteins to distinct domains in the plasma membrane is crucial to the function of many polarized cells. In epithelia, distinct apical and basolateral surfaces are maintained by tight junctions that prevent diffusion of proteins and lipids between the two domains(1). Polarized neurons maintain axonal and somatodendritic plasma membrane domains without an obvious physical barrier. Indeed, the artificial lipid DiI encounters no diffusion barrier at the presumptive domain boundary, the axon hillock(2). By measuring the lateral mobility of membrane proteins using optical tweezers, we show here that some membrane proteins exhibit markedly reduced mobility in the initial segment of the axon. Disruption of F-actin and low levels of dimethyl sulphoxide (DMSO) abolish this diffusion barrier and lead to redistribution of membrane markers that had previously been polarized. Immobilization in the initial segment may reflect, at least in part, differential tethering to cytoskeletal components. Therefore, the ability to maintain a polarized distribution of membrane proteins depends on a specialized domain at the initial segment of the axon, which restricts lateral mobility and serves as a new type of diffusion barrier that acts in the absence of cell-cell contact.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, MCDB, New Haven, CT 06520 USA	Yale University; Yale University	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St,POB 208002, New Haven, CT 06520 USA.	ira.mellman@yale.edu	Mellman, Ira/ABG-5896-2020	Forscher, Paul/0000-0003-1988-5155				ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; Banker G., 1997, CULTURING NERVE CELL; BARTLES JR, 1995, TRENDS CELL BIOL, V5, P400, DOI 10.1016/S0962-8924(00)89089-3; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; Dargent B., 1998, Society for Neuroscience Abstracts, V24, P1078; DAVIS JQ, 1997, J CELL BIOL, V137, P703; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; KOBAYASHI T, 1992, NATURE, V359, P647, DOI 10.1038/359647a0; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KUSUMI A, 1993, BIOPHYS J, V65, P2021, DOI 10.1016/S0006-3495(93)81253-0; Kusumi A, 1998, METHOD CELL BIOL, V55, P173; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; MELLMAN I, 1996, COLD SPRING HARB SYM, V60, P745; PETERS A, 1968, J CELL BIOL, V39, P604, DOI 10.1083/jcb.39.3.604; SHEETZ MP, 1993, ANNU REV BIOPH BIOM, V22, P417, DOI 10.1146/annurev.bb.22.060193.002221; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Thompson C, 1996, J CELL SCI, V109, P2843; Vogt L, 1996, CURR BIOL, V6, P1153, DOI 10.1016/S0960-9822(02)70682-9; Winckler B, 1996, NATURE, V379, P213, DOI 10.1038/379213a0; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	26	320	325	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1999	397	6721					698	701		10.1038/17806	http://dx.doi.org/10.1038/17806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067893				2022-12-01	WOS:000078840100051
J	Irish, C; Herbert, J; Bennett, D; Gilham, G; Drobniewski, F; Williams, R; Smith, EG; Magee, JG; Watt, B; Chadwick, M; Watson, JM				Irish, C; Herbert, J; Bennett, D; Gilham, G; Drobniewski, F; Williams, R; Smith, EG; Magee, JG; Watt, B; Chadwick, M; Watson, JM			Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Brent & Harrow Hlth Author, Harrow HA1 3EX, Middx, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; Publ Hlth Lab Serv, Stat Unit, London NW9 5EQ, England; Univ London Kings Coll Hosp, Publ Hlth Lab Serv, Mycobacterium Reference Unit, London SE22 8QF, England; Univ Wales Hosp, Cardiff Publ Hlth Lab, Reg Ctr Mycobacteriol, Cardiff CF4 4XW, S Glam, Wales; Birmingham Heartlands Hosp, Birmingham Publ Hlth Lab, Reg Ctr Mycobacteriol, Birmingham B9 5ST, W Midlands, England; Newcastle Gen Hosp, Newcastle Publ Hlth Lab, Reg Ctr Mycobacteriol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; City Hosp Edinburgh, Scottish Mycobacteria Reference Lab, Edinburgh EH10 5SB, Midlothian, Scotland; Royal Brompton Hosp, Dept Microbiol, London SW3 6NP, England	Public Health England; Public Health England; King's College Hospital NHS Foundation Trust; King's College Hospital; Public Health England; University of London; King's College London; Cardiff University; Heart of England NHS Foundation Trust; University of Birmingham; Newcastle General Hospital; Royal Brompton Hospital	Irish, C (corresponding author), Brent & Harrow Hlth Author, Grace House, Harrow HA1 3EX, Middx, England.	charles@bhha.dcmon.co.uk						Drobniewski F A, 1997, Commun Dis Rep CDR Rev, V7, pR106; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; Hayward A C, 1995, Commun Dis Rep CDR Rev, V5, pR29; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; Warburton A R, 1993, Commun Dis Rep CDR Rev, V3, pR175	5	35	35	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 20	1999	318	7182					497	498		10.1136/bmj.318.7182.497	http://dx.doi.org/10.1136/bmj.318.7182.497			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170QT	10024255	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000078818100023
J	Hoon, MA; Adler, E; Lindemeier, J; Battey, JF; Ryba, NJP; Zuker, CS				Hoon, MA; Adler, E; Lindemeier, J; Battey, JF; Ryba, NJP; Zuker, CS			Putative mammalian taste receptors: A class of taste-specific GPCRs with distinct topographic selectivity	CELL			English	Article							PHEROMONE RECEPTORS; SWEET TASTE; CHORDA-TYMPANI; NECTURUS-MACULOSUS; MULTIGENE FAMILY; NERVE-FIBERS; RAT TONGUE; C-ELEGANS; TRANSDUCTION; CELLS	Taste represents a major form of sensory input in the animal kingdom. In mammals, taste perception begins with the recognition of tastant molecules by unknown membrane receptors localized on the apical surface of receptor cells of the tongue and palate epithelium. We report the cloning and characterization of two novel seven-transmembrane domain proteins expressed in topographically distinct subpopulations of taste receptor cells and taste buds. These proteins are specifically localized to the taste pore and are members of a new group of G protein-coupled receptors distantly related to putative mammalian pheromone receptors. We propose that these genes encode taste receptors.	Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA; Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD 20892 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Zuker, CS (corresponding author), Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA.	ryba@yoda.nidr.nih.gov; czuker4@flyeye.ucsd.edu		Ryba, Nicholas/0000-0002-2060-8393	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000561] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1; BEHE P, 1990, J GEN PHYSIOL, V96, P1061, DOI 10.1085/jgp.96.5.1061; Bernhardt SJ, 1996, J PHYSIOL-LONDON, V490, P325, DOI 10.1113/jphysiol.1996.sp021147; BRADLEY RM, 1985, ANAT REC, V212, P246, DOI 10.1002/ar.1092120305; BRAND JG, 1985, BRAIN RES, V334, P207, DOI 10.1016/0006-8993(85)90212-4; BrillatSavarin J. A., 1826, PHYSL GOUT MEDITATIO; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CAO Y, 1989, P NATL ACAD SCI USA, V95, P11987; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; Chaudhari N, 1996, J NEUROSCI, V16, P3817; Corey DP, 1996, CURR OPIN NEUROBIOL, V6, P437, DOI 10.1016/S0959-4388(96)80046-8; CUMMINGS TA, 1987, J COMP NEUROL, V261, P604, DOI 10.1002/cne.902610411; Cummings TA, 1996, J NEUROPHYSIOL, V75, P1256, DOI 10.1152/jn.1996.75.3.1256; Doolin RE, 1996, J GEN PHYSIOL, V107, P545, DOI 10.1085/jgp.107.4.545; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FRANK ME, 1991, J NEUROPHYSIOL, V65, P1452, DOI 10.1152/jn.1991.65.6.1452; FRANK ME, 1983, J NEUROPHYSIOL, V50, P941, DOI 10.1152/jn.1983.50.4.941; Furue H, 1997, BRAIN RES, V776, P133, DOI 10.1016/S0006-8993(97)00974-8; Furue H, 1998, J NEUROSCI METH, V84, P109, DOI 10.1016/S0165-0270(98)00104-6; GILBERTSON TA, 1992, J GEN PHYSIOL, V100, P803, DOI 10.1085/jgp.100.5.803; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hoffmann A, 1875, ARCH PATHOL ANAT PHY, V62, P516; Hoon MA, 1997, J DENT RES, V76, P831, DOI 10.1177/00220345970760040301; KAWAMURA Y, 1987, INTRO UMAMI BASIC TA; KINNAMON JC, 1988, J COMP NEUROL, V270, P1, DOI 10.1002/cne.902700102; KINNAMON JC, 1985, J COMP NEUROL, V235, P48, DOI 10.1002/cne.902350105; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1992, ANNU REV PHYSIOL, V54, P715, DOI 10.1146/annurev.physiol.54.1.715; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; KRIMM RF, 1987, PHYSIOL BEHAV, V41, P495, DOI 10.1016/0031-9384(87)90086-2; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; LUSH IE, 1984, GENET RES, V44, P151, DOI 10.1017/S0016672300026355; LUSH IE, 1989, GENET RES, V53, P95, DOI 10.1017/S0016672300027968; LUSH IE, 1981, GENET RES, V38, P93, DOI 10.1017/S0016672300020425; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MILLER IJ, 1990, PHYSIOL BEHAV, V47, P1213, DOI 10.1016/0031-9384(90)90374-D; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Naito T, 1998, P NATL ACAD SCI USA, V95, P5178, DOI 10.1073/pnas.95.9.5178; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEJAD MS, 1986, CHEM SENSES, V11, P283, DOI 10.1093/chemse/11.3.283; NOLTE C, 1992, J NEUROCYTOL, V21, P19, DOI 10.1007/BF01206895; Ogura T, 1997, J NEUROSCI, V17, P3580; ROYER SM, 1988, J COMP NEUROL, V270, P11, DOI 10.1002/cne.902700103; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SPIELMAN AI, 1992, SOC GEN PHY, V47, P307; Stewart RE, 1997, AM J PHYSIOL-CELL PH, V272, pC1, DOI 10.1152/ajpcell.1997.272.1.C1; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0	56	527	600	1	79	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 19	1999	96	4					541	551		10.1016/S0092-8674(00)80658-3	http://dx.doi.org/10.1016/S0092-8674(00)80658-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	168XN	10052456	Bronze			2022-12-01	WOS:000078718600005
J	Meda, HA; Diallo, B; Buchet, JP; Lison, D; Barennes, H; Ouangre, A; Sanou, M; Cousens, S; Tall, F; Van de Perre, P				Meda, HA; Diallo, B; Buchet, JP; Lison, D; Barennes, H; Ouangre, A; Sanou, M; Cousens, S; Tall, F; Van de Perre, P			Epidemic of fatal encephalopathy in preschool children in Burkina Faso and consumption of unripe ackee (Blighia sapida) fruit	LANCET			English	Article							JAMAICAN VOMITING SICKNESS	Background On March 21, 1998, the Regional Health Authority of Bobo-Dioulasso, Burkina Faso, asked the Centre Muraz to investigate an unexplained outbreak of epidemic fatal encephalopathy (EFE). We aimed to identify the cause of this epidemic. Methods We identified cases retrospectively through review of hearth-service records and interviews of family members, village chiefs, and local heaters. Active surveillance was started in administrative divisions within the study area in April, 1998, to identify further EFE-cases. We did a case-control study of households to investigate the risk from various environmental and health factors. Blood and urine samples were collected if possible and urine dicarboxylic acid concentrations measured by gas chromatography. Findings 29 cases of EFE were identified from January to May, 1998. Estimated age-specific attack rates (2-6 years) ranged from 31 to 847 per 100000 population (p < 0.001). The most common symptoms were hypotonia, vomiting, convulsions, and coma. Ali children died in 2-48 h. The only factor associated with EFE was the presence of ackee trees (Blighia sapida) within 100 m of households (odds ratio 5.1 [95% CI 1.8-14.7] p = 0.001). Poisoning with unripe ackee fruits was suggested by urine concentrations of dicarboxylic acids four to 200 times higher in cases (n = 2) than in controls (n = 3). Conclusion Consumption of unripe ackee fruit probably caused this epidemic and may lead to a substantial number of unexplained deaths in preschool children in west Africa every year. Educational campaigns have the potential to prevent these deaths.	Ctr Muraz, Bobo Dioulasso, Burkina Faso; Dist Sanitaire Secteur 22, Bobo Dioulasso, Burkina Faso; Univ Catholique Louvain, Unite Toxicol Ind & Med Travail, B-1200 Brussels, Belgium; Hop Natl Sanou Souro, Serv Pediat, Bobo Dioulasso, Burkina Faso; London Sch Hyg & Trop Med, London WC1, England	Centre Muraz; Universite Catholique Louvain; University of London; London School of Hygiene & Tropical Medicine	Meda, HA (corresponding author), Ctr Muraz, OCCGE 01 BP 153, Bobo Dioulasso, Burkina Faso.		Barennes, hubert/E-9728-2011; Lison, Dominique/A-8985-2010; Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427; Lison, Dominique/0000-0001-6557-2518				BARETZ BH, 1976, CLIN CHIM ACTA, V73, P199, DOI 10.1016/0009-8981(76)90325-9; BRUN T, 1988, LANCET, V1, P934; CHASE GW, 1990, J ASSOC OFF ANA CHEM, V73, P318; HADIDANE R, 1985, HUM TOXICOL, V4, P491, DOI 10.1177/096032718500400505; HAUTEKEETE ML, 1990, ACTA CLIN BELG, V45, P311, DOI 10.1080/17843286.1990.11718105; ISHIKAWA T, 1993, BRAIN DEV-JPN, V15, P192, DOI 10.1016/0387-7604(93)90064-F; LARSON J, 1994, AM J GASTROENTEROL, V89, P1577; MCTAGUE JA, 1994, ANN EMERG MED, V23, P1116, DOI 10.1016/S0196-0644(94)70112-1; MILLS J, 1987, BIOCHEM PHARMACOL, V36, P495, DOI 10.1016/0006-2952(87)90357-1; MOWAT AP, 1987, ANN NESTLE, V45, P24; SCOTT H. Harold, 1916, Annals of Tropical Medicine and Parasitology, V10, P1; SHIH VE, 1978, CLIN CHIM ACTA, V88, P539, DOI 10.1016/0009-8981(78)90289-9; Shimizu Nobuo, 1994, Acta Paediatrica Japonica, V36, P139; TANAKA K, 1976, CLIN CHIM ACTA, V69, P105, DOI 10.1016/0009-8981(76)90478-2; TANAKA K, 1976, NEW ENGL J MED, V295, P461, DOI 10.1056/NEJM197608262950901; TANAKA K, 1990, PROG CLIN BIOL RES, V321, P167; VONHOLT C, 1966, BIOCHIM BIOPHYS ACTA, V125, P11, DOI 10.1016/0005-2760(66)90139-1; WAINWRIGHT J, 1977, S AFR MED J, V52, P313; 1992, MORB MORT WKLY REP M, V41, P53	19	41	41	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					536	540		10.1016/S0140-6736(99)01088-0	http://dx.doi.org/10.1016/S0140-6736(99)01088-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028981				2022-12-01	WOS:000078670200010
J	Kubisch, C; Schroeder, BC; Friedrich, T; Lutjohann, B; El-Amraoui, A; Marlin, S; Petit, C; Jentsch, TJ				Kubisch, C; Schroeder, BC; Friedrich, T; Lutjohann, B; El-Amraoui, A; Marlin, S; Petit, C; Jentsch, TJ			KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness	CELL			English	Article							INHERITED CARDIAC-ARRHYTHMIAS; MYOSIN-VIIA GENE; LONG QT SYNDROME; KVLQT1 MUTATIONS; HEARING-LOSS; FAMILIES; JERVELL; K(V)LQT1; PROTEINS; LINKAGE	Potassium channels regulate electrical signaling and the ionic composition of biological fluids. Mutations in the three known genes of the KCNQ branch of the K+ channel gene family underlie inherited cardiac arrhythmias (in some cases associated with deafness) and neonatal epilepsy. We have now cloned KCNQ4, a novel member of this branch. It maps to the DFNA2 locus for a form of nonsyndromic dominant deafness. In the cochlea, it is expressed in sensory outer hair cells, A mutation in this gene in a DFNA2 pedigree changes a residue in the KCNQ4 pore region. It abolishes the potassium currents of wild-type KCNQ4 on which it exerts a strong dominant-negative effect. Whereas mutations in KCNQ1 cause deafness by affecting endolymph secretion, the mechanism leading to KCNQ4-related hearing loss is intrinsic to outer hair cells.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany; Inst Pasteur, Unite Genet Deficits Sensoriels, CNRS, URA 1968, F-75724 Paris 15, France	University of Hamburg; University Medical Center Hamburg-Eppendorf; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	jentsch@plexus.uke.uni-hamburg.de	Friedrich, Thomas/AAA-3418-2022; Kubisch, Christian/F-1893-2011	Kubisch, Christian/0000-0003-4220-0978; marlin, sandrine/0000-0002-4115-9806; Jentsch, Thomas/0000-0002-3509-2553; EL-AMRAOUI, Aziz/0000-0003-2692-4984; Petit, Christine/0000-0002-9069-002X				Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; COUCKE P, 1994, NEW ENGL J MED, V331, P425, DOI 10.1056/NEJM199408183310702; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Friedmann I, 1966, J Laryngol Otol, V80, P451, DOI 10.1017/S002221510006552X; GORLIN RJ, 1995, J PHYSL, V448, P73; Kakehata S, 1996, J NEUROSCI, V16, P4881; Kalatzis V, 1998, HUM MOL GENET, V7, P1589, DOI 10.1093/hmg/7.10.1589; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Mammano F, 1996, J PHYSIOL-LONDON, V496, P639, DOI 10.1113/jphysiol.1996.sp021715; Marrion NV, 1997, ANNU REV PHYSIOL, V59, P483, DOI 10.1146/annurev.physiol.59.1.483; MUSTAPHA M, 1999, IN PRESS HUM MOL GEN; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Nobili R, 1998, TRENDS NEUROSCI, V21, P159, DOI 10.1016/S0166-2236(97)01192-2; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Russell MW, 1996, HUM MOL GENET, V5, P1319, DOI 10.1093/hmg/5.9.1319; SAKAGAMI M, 1991, HEARING RES, V56, P168, DOI 10.1016/0378-5955(91)90166-7; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Spicer SS, 1996, HEARING RES, V100, P80, DOI 10.1016/0378-5955(96)00106-2; Spicer SS, 1998, HEARING RES, V118, P1, DOI 10.1016/S0378-5955(98)00006-9; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; VanCamp G, 1997, GENOMICS, V41, P70, DOI 10.1006/geno.1997.4624; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WILSON J, 1985, ARCH OTOLARYNGOL, V111, P2; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Yang WP, 1998, J BIOL CHEM, V273, P19419, DOI 10.1074/jbc.273.31.19419	41	633	683	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					437	446		10.1016/S0092-8674(00)80556-5	http://dx.doi.org/10.1016/S0092-8674(00)80556-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025409	hybrid			2022-12-01	WOS:000078514600016
J	Earnest, DJ; Liang, FQ; Ratcliff, M; Cassone, VM				Earnest, DJ; Liang, FQ; Ratcliff, M; Cassone, VM			Immortal time: Circadian clock properties of rat suprachiasmatic cell lines	SCIENCE			English	Article							NUCLEUS; DROSOPHILA	Cell lines derived from the rat suprachiasmatic nucleus (SCN) were screened for circadian clock properties distinctive of the SCN in situ. Immortalized SCN cells generated robust rhythms in uptake of the metabolic marker 2-deoxyglucose and in their content of neurotrophins. The phase relationship between these rhythms in vitro was identical to that exhibited by the SCN in vivo. Transplantation of SCN cell lines, but not mesencephalic or fibroblast Lines, restored the circadian activity rhythm in arrhythmic, SCN-lesioned rats. Thus, distinctive oscillator, pacemaker, and clock properties of the SCN are not only retained but also maintained in an appropriate circadian phase relationship by immortalized SCN progenitors.	Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Human Anat & Med Neurobiol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Earnest, DJ (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Human Anat & Med Neurobiol, College Stn, TX 77843 USA.	dearnest@tamu.edu	Cassone, Vincent/AAD-5191-2022	Earnest, David/0000-0003-4433-6481	NINDS NIH HHS [NS35822] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035822] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; EARNEST DJ, IN PRESS J NEUROBIOL; *HOUGHT MIFFL, 1979, AM HER DICT ENGL LAN; Liang FQ, 1998, EXP NEUROL, V151, P184, DOI 10.1006/exnr.1998.6804; Liang FQ, 1998, NEUROSCI LETT, V242, P89, DOI 10.1016/S0304-3940(98)00062-7; MOORE RY, 1983, FED PROC, V42, P2783; NEWMAN GC, 1990, J CEREBR BLOOD F MET, V10, P510, DOI 10.1038/jcbfm.1990.93; NEWMAN GC, 1986, BRAIN RES, V381, P345, DOI 10.1016/0006-8993(86)90086-7; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Schwartz WJ, 1991, SUPRACHIASMATIC NUCL, P144; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	17	104	106	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					693	695		10.1126/science.283.5402.693	http://dx.doi.org/10.1126/science.283.5402.693			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924030				2022-12-01	WOS:000078324400044
J	Qin, XF; Schwers, S; Yu, W; Papavasiliou, F; Suh, HY; Nussenzweig, A; Rajewsky, K; Nussenzweig, MC				Qin, XF; Schwers, S; Yu, W; Papavasiliou, F; Suh, HY; Nussenzweig, A; Rajewsky, K; Nussenzweig, MC			Secondary V(D)J recombination in B-1 cells	NATURE			English	Article							LY-1 B-CELLS; TRANSGENIC MOUSE; MICE; GENE; LYMPHOCYTES; ANTIGEN; EXPRESSION; TOLERANCE; RESPONSES; APOPTOSIS	B-1 B cells are a self-renewing population of B cells that differ from conventional B cells (B-2 cells) in that they are particularly predisposed to auto-antibody production(1-3). Although much is known about the signalling pathways that control B-1-cell growth and development (reviewed in ref. 4), less is known about why these cells are prone to produce autoreactive antibodies. Here we show that B-1 cells, like germinal-centre B cells(5-8), can express recombinase-activating genes 1 and 2 (RAG1 and RAG2) and undergo secondary V(D)J recombination of immunoglobulin genes. In addition, B cells from autoimmune-prone NZB mice show high levels of RAG messenger RNA and recombination. We propose that secondary immunoglobulin-gene rearrangements outside organized lymphoid organs may contribute to the development of autoreactive antibodies.	Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Univ Cologne, Inst Genet, D-50931 Cologne, Germany	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Cologne	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.	nussen@rockvax.rockefeller.edu	Nussenzweig, Michel/AAE-7292-2019	QIN, FRANK XIAOFENG/0000-0002-5395-0304; Rajewsky, Klaus/0000-0002-6633-6370				ARNOLD LW, 1994, J EXP MED, V179, P1585, DOI 10.1084/jem.179.5.1585; Cascalho M, 1997, J IMMUNOL, V159, P5795; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; HAYAKAWA K, 1983, J EXP MED, V157, P202, DOI 10.1084/jem.157.1.202; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; LALOR PA, 1989, EUR J IMMUNOL, V19, P501, DOI 10.1002/eji.1830190314; MURAKAMI M, 1994, J EXP MED, V180, P111, DOI 10.1084/jem.180.1.111; Murakami M, 1997, J EXP MED, V185, P791, DOI 10.1084/jem.185.4.791; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STALL AM, 1988, P NATL ACAD SCI USA, V85, P3546, DOI 10.1073/pnas.85.10.3546; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TAKI S, 1993, SCIENCE, V262, P1268, DOI 10.1126/science.8235657; Tarakhovsky A, 1997, J EXP MED, V185, P981, DOI 10.1084/jem.185.6.981; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TSUBATA T, 1994, CURR BIOL, V4, P8, DOI 10.1016/S0960-9822(00)00003-8	30	60	61	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					355	359		10.1038/16933	http://dx.doi.org/10.1038/16933			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9950428				2022-12-01	WOS:000078324600051
J	Alon, U; Surette, MG; Barkai, N; Leibler, S				Alon, U; Surette, MG; Barkai, N; Leibler, S			Robustness in bacterial chemotaxis	NATURE			English	Article							ESCHERICHIA-COLI; CHEB METHYLESTERASE; ADAPTATION; MODEL; METHYLATION; EXCITATION; COMPONENTS; MODULATION; MECHANISM; BEHAVIOR	Networks of interacting proteins orchestrate the responses of living cells to a variety of external stimuli(1), but how sensitive is the functioning of these protein networks to variations in their biochemical parameters? One possibility is chat to achieve appropriate function, the reaction rate constants and enzyme concentrations need to be adjusted in a precise manner, and any deviation from these 'fine-tuned' values ruins the network's performance. An alternative possibility is that key properties of biochemical networks are robust(2); that is, they are insensitive to the precise values of the biochemical parameters. Here we address this issue in experiments using chemotaxis of Escherichia coli, one of the best-characterized sensory systems(3,4). We focus on how response and adaptation to attractant signals vary with systematic changes in the intracellular concentration of the components of the chemotaxis network. We find that some properties, such as steady-state behaviour and adaptation time, show strong variations in response to varying protein concentrations. In contrast, the precision of adaptation is robust and does not vary with the protein concentrations. This is consistent with a recently proposed molecular mechanism for exact adaptation, where robustness is a direct consequence of the network's architecture(2).	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	Princeton University; Princeton University; University of Calgary	Leibler, S (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	leibler@princeton.edu						Alon U, 1998, EMBO J, V17, P4238, DOI 10.1093/emboj/17.15.4238; ASAKURA S, 1984, J MOL BIOL, V176, P349, DOI 10.1016/0022-2836(84)90494-7; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BERG HC, 1990, BIOPHYS J, V58, P919, DOI 10.1016/S0006-3495(90)82436-X; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Fell D., 1997, UNDERSTANDING CONTRO; Grishanin RN, 1997, J BACTERIOL, V179, P24, DOI 10.1128/jb.179.1.24-30.1997; HAURI DC, 1995, BIOPHYS J, V68, P708, DOI 10.1016/S0006-3495(95)80232-8; KIRSCH ML, 1993, J BIOL CHEM, V268, P25350; Levin MD, 1998, BIOPHYS J, V74, P175, DOI 10.1016/S0006-3495(98)77777-X; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; RUSSELL CB, 1989, J BACTERIOL, V171, P3609, DOI 10.1128/jb.171.7.3609-3618.1989; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; SEGEL LA, 1986, J THEOR BIOL, V120, P151, DOI 10.1016/S0022-5193(86)80171-0; SIMMS SA, 1985, J BIOL CHEM, V260, P161; Spiro PA, 1997, P NATL ACAD SCI USA, V94, P7263, DOI 10.1073/pnas.94.14.7263; STEWART RC, 1988, COLD SPRING HARB SYM, V53, P27, DOI 10.1101/SQB.1988.053.01.007; STOCK J, 1985, CELL, V42, P683, DOI 10.1016/0092-8674(85)90125-4; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; WEIS RM, 1988, P NATL ACAD SCI USA, V85, P83, DOI 10.1073/pnas.85.1.83; WEIS RM, 1990, J BACTERIOL, V172, P1099, DOI 10.1128/jb.172.2.1099-1105.1990; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987	30	839	862	2	96	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					168	171		10.1038/16483	http://dx.doi.org/10.1038/16483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923680				2022-12-01	WOS:000078085000048
J	Pickering, TG				Pickering, TG			Advances in the treatment of hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ISOLATED SYSTOLIC HYPERTENSION; ANTIHYPERTENSIVE TREATMENT; DOUBLE-BLIND; DISEASE; RISK		New York Presbyterian Hosp, Hypertens Ctr, New York, NY 10021 USA	NewYork-Presbyterian Hospital	Pickering, TG (corresponding author), New York Presbyterian Hosp, Hypertens Ctr, 520 E 70th St, New York, NY 10021 USA.							Appel Lawrence J., 1995, Annals of Epidemiology, V5, P119, DOI 10.1016/1047-2797(94)00056-Y; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; Black HR, 1997, ARCH INTERN MED, V157, P2413; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; CURB JD, 1996, JAMA-J AM MED ASSOC, V227, P1356; de Lorgeril M, 1998, ARCH INTERN MED, V158, P1181, DOI 10.1001/archinte.158.11.1181; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hansson L, 1998, J HYPERTENS, V16, pS22; Hole DJ, 1998, J HYPERTENS, V16, P119, DOI 10.1097/00004872-199816010-00017; *JOINT NAT COMM PR, 1997, ARCH INTERN MED, V157, P2446; Lever AF, 1998, LANCET, V352, P179, DOI 10.1016/S0140-6736(98)03228-0; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; Pahor M, 1998, ARCH INTERN MED, V158, P1340, DOI 10.1001/archinte.158.12.1340; Philipp T, 1997, BMJ-BRIT MED J, V315, P154, DOI 10.1136/bmj.315.7101.154; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597	23	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					114	116		10.1001/jama.281.2.114	http://dx.doi.org/10.1001/jama.281.2.114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917098				2022-12-01	WOS:000077966800002
J	Ban, C; Junop, M; Yang, W				Ban, C; Junop, M; Yang, W			Transformation of MutL by ATP binding and hydrolysis: A switch in DNA mismatch repair	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; HSP90 MOLECULAR CHAPERONE; N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; REPLICATION FIDELITY; NUCLEOTIDE-BINDING; IN-VIVO	The MutL DNA mismatch repair protein has recently been shown to be an ATPase and to belong to an emerging ATPase superfamily that includes DNA topoisomerase II and Hsp90. We report here the crystal structures of a 40 kDa ATPase fragment of E. coli MutL (LN40) complexed with a substrate analog, ADPnP, and with product ADP. More than 60 residues that are disordered in the apoprotein structure become ordered and contribute to both ADPnP binding and dimerization of LN40. Hydrolysis of ATP, signified by subsequent release of the gamma-phosphate, releases two key loops and leads to dissociation of the LN40 dimer. Dimerization of the LN40 region is required for and is the rate-limiting step in ATP hydrolysis by Mutt. The ATPase activity of MutL is stimulated by DNA and likely acts as a switch to coordinate DNA mismatch repair.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Yang, W (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	wei.yang@nih.gov	Yang, Wei/D-4926-2011; Yang, Wei/ABB-4785-2020; Junop, Murray S/E-4160-2015; Ban, Changill/F-5426-2013	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195; Junop, Murray S/0000-0001-6676-5717; 				ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; FENG G, 1995, BIOTECHNIQUES, V19, P956; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; PATA JD, 1995, RNA, V1, P466; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SHCHERBAKOVA P, 1999, IN PRESS MOL CELL BI; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WILLIAMSON MS, 1985, GENETICS, V110, P609; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	42	329	336	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					85	97		10.1016/S0092-8674(00)80717-5	http://dx.doi.org/10.1016/S0092-8674(00)80717-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199405	Bronze			2022-12-01	WOS:000079843900011
J	Weng, GZ; Bhalla, US; Iyengar, R				Weng, GZ; Bhalla, US; Iyengar, R			Complexity in biological signaling systems	SCIENCE			English	Editorial Material							SIMPLE 2-STATE MODEL; CYCLASE; ULTRASENSITIVITY; TRANSDUCTION; TRANSIENT; RECEPTOR; PROTEINS; TERMS	Biological signaling pathways interact with one another to form complex networks. Complexity arises from the Large number of components, many with isoforms that have partially overlapping functions; from the connections among components; and from the spatial relationship between components. The origins of the complex behavior of signaling networks and analytical approaches to deal with the emergent complexity are discussed here.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Univ Agr Sci Bangalore, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Agricultural Sciences Bangalore	Iyengar, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215, New York, NY 10029 USA.		Han, Liqi/K-6127-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054508, GM-54508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Amundson J, 1993, Curr Opin Neurobiol, V3, P375, DOI 10.1016/0959-4388(93)90131-H; ANGLISTER L, 1994, NEURON, V12, P783, DOI 10.1016/0896-6273(94)90331-X; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BHALLA US, 1998, BOOK GENESIS EXPLORI; BIRNBAUMER L, 1980, J BIOL CHEM, V255, P3542; BIRNBAUMER L, 1980, J BIOL CHEM, V255, P3552; BLACK JW, 1986, BRIT J PHARMACOL, V89, P547, DOI 10.1111/j.1476-5381.1986.tb11155.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAUN S, 1979, BIOCHEMISTRY-US, V18, P2134, DOI 10.1021/bi00577a045; BRAY D, 1995, NATURE, V378, P419, DOI 10.1038/378419e0; Destexhe A, 1994, J Comput Neurosci, V1, P195, DOI 10.1007/BF00961734; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; IYENGAR R, 1980, J BIOL CHEM, V255, P3558; LAPORTE DC, 1984, J BIOL CHEM, V259, P4068; Leadlay PF, 1997, CURR OPIN CHEM BIOL, V1, P162, DOI 10.1016/S1367-5931(97)80005-1; Marder E, 1996, NATURE, V384, P113, DOI 10.1038/384113a0; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Segel I. H, 1975, ENZYME KINETICS BEHA; Stiles JR, 1996, P NATL ACAD SCI USA, V93, P5747, DOI 10.1073/pnas.93.12.5747; TANG YH, 1995, PHILOS T ROY SOC B, V349, P179, DOI 10.1098/rstb.1995.0102; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671	29	442	480	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	1999	284	5411					92	96		10.1126/science.284.5411.92	http://dx.doi.org/10.1126/science.284.5411.92			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102825	Green Accepted			2022-12-01	WOS:000079509000038
J	Robinson, NJ; Procter, CM; Connolly, EL; Guerinot, ML				Robinson, NJ; Procter, CM; Connolly, EL; Guerinot, ML			A ferric-chelate reductase for iron uptake from soils	NATURE			English	Article							RESPIRATORY BURST OXIDASE; ARABIDOPSIS-THALIANA; GENE FAMILY; SACCHAROMYCES-CEREVISIAE; EVOLUTION; PROTEIN; CLONES; CELLS	Iron deficiency afflicts more than three billion people worldwide(1), and plants are the principal source of iron in most diets. Low availability of iron often limits plant growth because iron forms insoluble ferric oxides, leaving only a small, organically complexed fraction in soil solutions(2). The enzyme ferric-chelate reductase is required for most plants to acquire soluble iron. Here we report the isolation of the FRO2 gene, which is expressed in iron-deficient roots of Arabidopsis. FRO2 belongs to a superfamily of flavocytochromes that transport electrons across membranes. It possesses intramembranous binding sites for haem and cytoplasmic binding sites for nucleotide cofactors that donate and transfer electrons. We show that FRO2 is allelic to the frd1 mutations that impair the activity of ferric-chelate reductase(3). There is a nonsense mutation within the first exon of FRO2 in frd1-1 and a missense mutation within FRO2 in frd1-3. Introduction of functional FRO2 complements the frd1-1 phenotype in transgenic plants. The isolation of FRO2 has implications for the generation of crops with improved nutritional quality and increased growth in iron-deficient soils.	Newcastle Univ, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Newcastle University - UK; Dartmouth College	Robinson, NJ (corresponding author), Newcastle Univ, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.robinson@ncl.ac.uk; mary.lou.guerinot@dartmouth.edu	Connolly, Erin L/B-7648-2013; Robinson, Nigel J/J-6363-2012	Robinson, Nigel J/0000-0001-5586-1092				BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIENFAIT HF, 1985, J BIOENERG BIOMEMBR, V17, P73, DOI 10.1007/BF00744199; BRUGGEMANN W, 1993, PLANTA, V190, P151, DOI 10.1007/BF00196606; CHANEY RL, 1972, PLANT PHYSIOL, V50, P208, DOI 10.1104/pp.50.2.208; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Eide D, 1997, CH MICROBIOL SER, P342; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; Grusak MA, 1996, PLANT PHYSIOL, V110, P329, DOI 10.1104/pp.110.1.329; GUERINOT ML, 1994, PLANT PHYSIOL, V104, P815, DOI 10.1104/pp.104.3.815; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; McDowell JM, 1996, GENETICS, V142, P587; MILPETZ F, 1995, TRENDS BIOCHEM SCI, V20, P204, DOI 10.1016/S0968-0004(00)89009-X; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PETERMAN TK, 1991, MOL GEN GENET, V230, P145, DOI 10.1007/BF00290662; Robinson NJ, 1997, PLANT SOIL, V196, P245, DOI 10.1023/A:1004258225806; ROGERS SG, 1988, METHOD ENZYMOL, V253, P253; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Torres MA, 1998, PLANT J, V14, P365, DOI 10.1046/j.1365-313X.1998.00136.x; VOYTAS DF, 1990, GENETICS, V126, P713; Yi Y, 1996, PLANT J, V10, P835, DOI 10.1046/j.1365-313X.1996.10050835.x	28	869	943	9	172	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1999	397	6721					694	697		10.1038/17800	http://dx.doi.org/10.1038/17800			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067892				2022-12-01	WOS:000078840100050
J	Chuang, PT; McMahon, AP				Chuang, PT; McMahon, AP			Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein	NATURE			English	Article							SONIC-HEDGEHOG; SIGNALING PATHWAY; GENE; RECEPTOR; CARTILAGE; POLARITY; MICE	The Hedgehog signalling pathway is essential for the development of diverse tissues during embryogenesis(1). Signalling is activated by binding: of Hedgehog protein to the multipass membrane protein Patched (Ptc)(2,3). We have now identified a novel component in the vertebrate signalling pathway, which we name Hip (for Hedgehog-interacting protein) because of its ability to bind Hedgehog proteins. Hip encodes a membrane glycoprotein that binds to all three mammalian Hedgehog proteins with an affinity comparable to that of Ptc-1. Hip-expressing cells are located next to cells that express each Hedgehog gene. Hip expression is induced by ectopic Hedgehog signalling and is lost in Hedgehog mutants. Thus, Hip, like Ptc-1, is a general transcriptional target of Hedgehog signalling. Overexpression of Hip in cartilage, where Indian hedgehog (Ihh) controls growth(4), leads to a shortened skeleton that resembles that seen when Ihh function is lost (B. St-Jacques, M. Hammerschmidt & A.P.M., in preparation). Our findings support a model in which Hip attenuates Hedgehog signalling as a result of binding to Hedgehog proteins: a negative regulatory feedback loop established in this way could thus modulate the responses to any Hedgehog signal.	Harvard Univ, Biolabs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Chuang, PT (corresponding author), Harvard Univ, Biolabs, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020					Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hogan B., 2014, MANIPULATING MOUSE E; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; JESSELL TM, 1992, HARVEY LECT, V86, P87; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Schneider D, 1996, GENE, V177, P243, DOI 10.1016/0378-1119(96)00310-1; Schwabe JWR, 1998, TRENDS GENET, V14, P229, DOI 10.1016/S0168-9525(98)01477-2; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Yang Y, 1997, DEVELOPMENT, V124, P4393	29	598	621	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1999	397	6720					617	621		10.1038/17611	http://dx.doi.org/10.1038/17611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169GE	10050855				2022-12-01	WOS:000078738500050
J	Krishna, S; Taylor, AM; Supanaranond, W; Pukrittayakamee, S; ter Kuile, F; Tawfiq, KM; Holloway, PAH; White, NJ				Krishna, S; Taylor, AM; Supanaranond, W; Pukrittayakamee, S; ter Kuile, F; Tawfiq, KM; Holloway, PAH; White, NJ			Thiamine deficiency and malaria in adults from southeast Asia	LANCET			English	Article							ERYTHROCYTE TRANSKETOLASE ACTIVITY; PLASMODIUM-FALCIPARUM; PARACETAMOL; FEVER	Background Thiamine deficiency (beriberi) is common in some parts of southeast Asia. Acute thiamine deficiency can mimic many complications of malaria, such as encephalopathy and lactic acidosis. We examined the incidence of thiamine deficiency in adults admitted to hospital with malaria in Thailand. Methods For this prospective study, we recruited consecutive patients with malaria or other febrile illness who presented to Paholpolpayuhasena Hospital, Kanchanaburi, Thailand, between May and July, 1.992. We used the activation coefficient (a) for transketolase activity in erythrocytes to measure thiamine deficiency (defined as alpha>1.31) in patients with severe and uncomplicated malaria and in controls (patients' relatives and healthy volunteers). To exclude the possibility of interference in the assays, transketolase activity was also measured in erythrocytes used to culture parasites. Findings 12 (52%) of 23 patients with severe malaria and ten (19%) of 54 patients with uncomplicated malaria had ct values above the normal range (p<0.0001 and p=0.0014, respectively, compared with controls), which indicated severe thiamine deficiency. Thiamine deficiency was more severe in patients with cerebral malaria than in those with uncomplicated malaria and the controls (p=0.008). Interpretation In adults admitted to hospital in Thailand, thiamine deficiency commonly complicates acute falciparum malaria, particularly in severe infections, and could contribute to dysfunction of the central nervous system.	Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Clin Biochem, Oxford OX3 9DU, England	Mahidol University; University of Oxford; University of Oxford	Krishna, S (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England.		White, Nicholas J/I-4629-2012; Kuile, Feiko ter/ABD-6681-2020; White, Nick/AAC-6527-2019	Kuile, Feiko ter/0000-0003-3663-5617; White, Nick/0000-0002-1897-1978; Krishna, Sanjeev/0000-0003-0066-0634	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1990, Trans R Soc Trop Med Hyg, V84 Suppl 2, P1; BAINES M, 1988, ANN CLIN BIOCHEM, V25, P698, DOI 10.1177/000456328802500617; BAYOUMI RA, 1976, CLIN CHEM, V22, P327; BRIN M, 1960, J NUTR, V71, P273, DOI 10.1093/jn/71.3.273; HERVE C, 1995, CLIN CHIM ACTA, V234, P91, DOI 10.1016/0009-8981(94)05980-7; KRISHNA S, 1993, BRIT J CLIN PHARMACO, V36, P585, DOI 10.1111/j.1365-2125.1993.tb00419.x; KRISHNA S, 1995, T ROY SOC TROP MED H, V89, P197, DOI 10.1016/0035-9203(95)90494-8; KRISHNA S, 1995, T ROY SOC TROP MED H, V89, P507, DOI 10.1016/0035-9203(95)90087-X; Krishna S, 1996, BRIT J CLIN PHARMACO, V41, P29, DOI 10.1111/j.1365-2125.1996.tb00155.x; MCCONACHIE I, 1988, INTENS CARE MED, V14, P628; MOUNT JN, 1987, ANN CLIN BIOCHEM, V24, P41, DOI 10.1177/000456328702400106; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; SAUBERLICH HE, 1967, AM J CLIN NUTR, V20, P528, DOI 10.1093/ajcn/20.6.528; Schaal KP., 1996, OXFORD TXB MED, V1, P680; SMEETS EHJ, 1971, CLIN CHIM ACTA, V33, P379, DOI 10.1016/0009-8981(71)90496-7; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; VICTOR M, 1989, WERNICKEKORSAKOFF SY; VIMOKESANT SL, 1975, AM J CLIN NUTR, V28, P1458, DOI 10.1093/ajcn/28.12.1458; WHITE NJ, 1992, ADV PARASIT, V31, P83, DOI 10.1016/S0065-308X(08)60021-4	19	49	51	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1999	353	9152					546	549		10.1016/S0140-6736(98)06316-8	http://dx.doi.org/10.1016/S0140-6736(98)06316-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028983				2022-12-01	WOS:000078670200012
J	Eto, K; Tsubamoto, Y; Terauchi, Y; Sugiyama, T; Kishimoto, T; Takahashi, N; Yamauchi, N; Kubota, N; Murayama, S; Aizawa, S; Akanuma, Y; Aizawa, S; Kasai, H; Yazaki, Y; Kadowaki, T				Eto, K; Tsubamoto, Y; Terauchi, Y; Sugiyama, T; Kishimoto, T; Takahashi, N; Yamauchi, N; Kubota, N; Murayama, S; Aizawa, S; Akanuma, Y; Aizawa, S; Kasai, H; Yazaki, Y; Kadowaki, T			Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion	SCIENCE			English	Article							PANCREATIC BETA-CELLS; CYTOSOLIC CA2+; ISLETS; RELEASE; DEHYDROGENASE; NUCLEOTIDES; GLYCOLYSIS; CHANNELS	Glucose metabolism in glycolysis and in mitochondria is pivotal to glucose-induced insulin secretion from pancreatic beta cells. One or more factors derived from glycolysis other than pyruvate appear to be required for the generation of mitochondrial signals that Lead to insulin secretion. The electrons of the glycolysis-derived reduced form of nicotinamide adenine dinucleotide (NADH) are transferred to mitochondria through the NADH shuttle system. By abolishing the NADH shuttle function, glucose-induced increases in NADH autofluorescence, mitochondrial membrane potential, and adenosine triphosphate content were reduced and glucose-induced insulin secretion was abrogated. The NADH shuttle evidently couples glycolysis with activation of mitochondrial energy metabolism to trigger insulin secretion.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Pathol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 113, Japan; Shinshu Univ, Sch Med, Dept Geriatr Endocrinol & Metab, Matsumoto, Nagano 390, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Chiyoda Ku, Tokyo 100, Japan; Kumamoto Univ, Sch Med, Dept Morphogenesis, Inst Mol Embryol & Genet, Kumamoto 862, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Shinshu University; Asahi Life Foundation; Kumamoto University	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Kubota, Naoto/N-7892-2015; Terauchi, Yasuo/AAO-4347-2020	Kasai, Haruo/0000-0003-2327-9027				ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; DUKES ID, 1994, J BIOL CHEM, V269, P10979; ERECINSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1101, P273, DOI 10.1016/0167-4838(92)90555-R; ETO K, UNPUB; GARDNER RS, 1974, ANAL BIOCHEM, V59, P272, DOI 10.1016/0003-2697(74)90033-5; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAMAKAWA N, 1995, CELL CALCIUM, V17, P21, DOI 10.1016/0143-4160(95)90099-3; HEDESKOV CJ, 1987, BIOCHEM J, V241, P161, DOI 10.1042/bj2410161; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Litsky ML, 1997, BIOCHEMISTRY-US, V36, P7071, DOI 10.1021/bi970180y; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MALAISSE WJ, 1982, ENDOCRINOLOGY, V111, P392, DOI 10.1210/endo-111-2-392; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Zawalich WS, 1997, J BIOL CHEM, V272, P3527, DOI 10.1074/jbc.272.6.3527	27	372	377	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 12	1999	283	5404					981	985		10.1126/science.283.5404.981	http://dx.doi.org/10.1126/science.283.5404.981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974390				2022-12-01	WOS:000078574800047
J	Rajagopal, I				Rajagopal, I			Software - All-in-one sequence analysis	SCIENCE			English	Software Review									Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Rajagopal, I (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.								0	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					652	653		10.1126/science.283.5402.652	http://dx.doi.org/10.1126/science.283.5402.652			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9988660				2022-12-01	WOS:000078324400031
J	Huang, JD; Brady, ST; Richards, BW; Stenoien, D; Resau, JH; Copeland, NG; Jenkins, NA				Huang, JD; Brady, ST; Richards, BW; Stenoien, D; Resau, JH; Copeland, NG; Jenkins, NA			Direct interaction of microtubule- and actin-based transport motors	NATURE			English	Article							ATAXIC MUTANT RAT; DILUTE COAT COLOR; BRAIN MYOSIN-V; UNCONVENTIONAL MYOSIN; AXONAL-TRANSPORT; PURKINJE-CELLS; KINESIN HEAVY; GENE; CLONING; PROTEIN	The microtubule network is thought to be used for long-range transport of cellular components in animal cells whereas the actin network is proposed to be used for short-range transport(1), although the mechanism(s) by which this transport is coordinated is poorly understood. For example, in sea urchins long-range Ca2+-regulated transport of exocytotic vesicles requires a microtubule-based motor, whereas an actin-based motor is used for short-range transport(2), In neurons, microtubule-based kinesin motor proteins are used for long-range vesicular transport(3) but microtubules do not extend into the neuronal termini, where actin filaments form the cytoskeletal framework(4), and kinesins are rapidly degraded upon their arrival in neuronal termini(5), indicating that vesicles may have to be transferred from microtubules to actin tracks to reach their final destination. Here we show that an actin-based vesicle-transport motor, MyoVA (ref. 6), can interact directly with a microtubule-based transport motor, KhcU. As would be expected if these complexes were functional, they also contain kinesin light chains and the localization of MyoVA and KhcU overlaps in the cell, These results indicate that cellular transport is, in part, coordinated through the direct interaction of different motor molecules.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Ft Detrick, MD 21702 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jenkins, NA (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Ft Detrick, MD 21702 USA.		/C-4277-2009	/0000-0001-7531-2816				Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BRADY ST, 1995, TRENDS CELL BIOL, V5, P159, DOI 10.1016/S0962-8924(00)88980-1; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; DEKKEROHNO K, 1993, LAB ANIM SCI, V43, P370; DekkerOhno K, 1996, BRAIN RES, V714, P226, DOI 10.1016/0006-8993(95)01560-4; Evans LL, 1997, J CELL SCI, V110, P439; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; LEBEUX YJ, 1975, CELL TISSUE RES, V160, P37; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; PRASAD R, 1993, CANCER RES, V53, P5624; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; TSAN JT, 1997, YEAST 2 HYBRID SYSTE, P217; Wu XF, 1997, J CELL SCI, V110, P847	30	288	295	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 21	1999	397	6716					267	270		10.1038/16722	http://dx.doi.org/10.1038/16722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	159QH	9930703				2022-12-01	WOS:000078184800056
J	Neelon, FA; Harvey, EN				Neelon, FA; Harvey, EN			The Babinski sign	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Duke Univ, Med Ctr, Durham, NC 27710 USA; Family Serv Greater Lowell, Lowell, MA 01852 USA	Duke University	Neelon, FA (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.								0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					196	196		10.1056/NEJM199901213400305	http://dx.doi.org/10.1056/NEJM199901213400305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895399				2022-12-01	WOS:000078202900005
J	Montefiori, DC; Moore, JP				Montefiori, DC; Moore, JP			HIV vaccines - Magic of the occult?	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZATION; GP41; ANTIBODIES; PROTEINS		Duke Univ, Med Ctr, Dept Surg, Ctr AIDS Res, Durham, NC 27710 USA; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA	Duke University; Rockefeller University	Montefiori, DC (corresponding author), Duke Univ, Med Ctr, Dept Surg, Ctr AIDS Res, Durham, NC 27710 USA.							ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; CRANAGE MP, 1993, AIDS RES HUM RETROV, V9, P13, DOI 10.1089/aid.1993.9.13; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Graham BS, 1998, J INFECT DIS, V177, P310, DOI 10.1086/514209; HANSON CV, 1994, AIDS RES HUM RETROV, V10, P645, DOI 10.1089/aid.1994.10.645; Heilman CA, 1998, NAT MED, V4, P532, DOI 10.1038/nm0598supp-532; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; MONTEFIORI DC, 1991, NATURE, V354, P439, DOI 10.1038/354439c0; MONTEFIORI DC, 1994, VIROLOGY, V205, P82, DOI 10.1006/viro.1994.1622; Moore JP, 1998, NATURE, V393, P630, DOI 10.1038/31359; MORRIS B, 1995, WILSON LIBR BULL, V69, P101; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; VANCOTT TC, 1995, AIDS RES HUM RETROV, V11, P1379, DOI 10.1089/aid.1995.11.1379; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514	24	24	26	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					336	337		10.1126/science.283.5400.336	http://dx.doi.org/10.1126/science.283.5400.336			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9925493				2022-12-01	WOS:000078067000029
J	Cates, W				Cates, W			Chlamydial infections and the risk of ectopic pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EPIDEMIOLOGY		Family Hlth Int, Res Triangle Pk, NC 27709 USA		Cates, W (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.							[Anonymous], [No title captured]; Burstein GR, 1998, JAMA-J AM MED ASSOC, V280, P521, DOI 10.1001/jama.280.6.521; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P6; CHOW WH, 1987, EPIDEMIOL REV, V9, P70, DOI 10.1093/oxfordjournals.epirev.a036309; Egger M, 1998, BRIT MED J, V316, P1776, DOI 10.1136/bmj.316.7147.1776; Orr DP, 1997, J ADOLESCENT HEALTH, V20, P3, DOI 10.1016/S1054-139X(96)00220-0; Ostergaard L, 1998, BRIT MED J, V317, P26, DOI 10.1136/bmj.317.7150.26; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103	9	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					117	118		10.1001/jama.281.2.117	http://dx.doi.org/10.1001/jama.281.2.117			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917099				2022-12-01	WOS:000077966800003
J	Tiedge, H; Bloom, FE; Richter, D				Tiedge, H; Bloom, FE; Richter, D			Perspectives: Neuroscience - RNA, whither goest thou?	SCIENCE			English	Editorial Material							VASOPRESSIN MESSENGER-RNA; ELECTRON-MICROSCOPIC EVIDENCE; AXONAL COMPARTMENTALIZATION; OLFACTORY-BULB; BC1 RNA; DENDRITES; PROTEIN; LOCALIZATION; NEURONS; TRANSPORT		SUNY Hlth Sci Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, Hamburg, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Scripps Research Institute; University of Hamburg	Tiedge, H (corresponding author), SUNY Hlth Sci Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA.	tiedge@hscbklyn.edu; fbloom@scripps.edu; richter@uke.uni-hamburg.de						Crino P, 1998, P NATL ACAD SCI USA, V95, P2313, DOI 10.1073/pnas.95.5.2313; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Knowles RB, 1997, P NATL ACAD SCI USA, V94, P14804, DOI 10.1073/pnas.94.26.14804; Landry M, 1998, NEUROSCIENCE, V84, P897, DOI 10.1016/S0306-4522(97)00567-8; LINK W, 1995, P NATL ACAD SCI USA, V92, P5734, DOI 10.1073/pnas.92.12.5734; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MELIA KR, 1994, EXP NEUROL, V130, P394, DOI 10.1006/exnr.1994.1219; MOHR E, 1995, P NATL ACAD SCI USA, V92, P4377, DOI 10.1073/pnas.92.10.4377; MOHR E, 1993, VASOPRESSIN, P119; MOHR E, 1997, NEUROENDOCRINOLOGY R, P55; Muslimov IA, 1998, J CELL BIOL, V141, P1601, DOI 10.1083/jcb.141.7.1601; Muslimov IA, 1997, J NEUROSCI, V17, P4722; Prakash N, 1997, EUR J NEUROSCI, V9, P523, DOI 10.1111/j.1460-9568.1997.tb01629.x; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; TIEDGE H, 1993, J NEUROSCI, V13, P4214; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; TREMBLEAU A, 1994, J NEUROSCI, V14, P39; TREMBLEAU A, 1995, EUR J NEUROSCI, V7, P2249, DOI 10.1111/j.1460-9568.1995.tb00646.x; Trembleau A, 1996, NEUROSCIENCE, V70, P113, DOI 10.1016/0306-4522(95)00328-G; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Wallace CS, 1998, J NEUROSCI, V18, P26; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3	28	81	81	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1999	283	5399					186	187		10.1126/science.283.5399.186	http://dx.doi.org/10.1126/science.283.5399.186			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9925478				2022-12-01	WOS:000077976700028
J	Stapleton, A				Stapleton, A			Prevention of recurrent urinary-tract infections in women	LANCET			English	Editorial Material							UROPATHOGENIC ESCHERICHIA-COLI; CYTOKINE RESPONSES; EPITHELIAL-CELLS; RISK-FACTORS		Univ Washington, Dept Med, Div Infect Dis, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Stapleton, A (corresponding author), Univ Washington, Dept Med, Div Infect Dis, Seattle, WA 98195 USA.		Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659				Brumfitt W, 1998, J ANTIMICROB CHEMOTH, V42, P363, DOI 10.1093/jac/42.3.363; FOXMAN B, 1990, AM J PUBLIC HEALTH, V80, P331, DOI 10.2105/AJPH.80.3.331; FOXMAN B, 1995, J INFECT DIS, V171, P1514, DOI 10.1093/infdis/171.6.1514; Gupta K, 1998, J INFECT DIS, V178, P446, DOI 10.1086/515635; HEDGES SR, 1995, TRENDS MICROBIOL, V3, P266, DOI 10.1016/S0966-842X(00)88941-6; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; HOOTON TM, 1991, JAMA-J AM MED ASSOC, V265, P64, DOI 10.1001/jama.265.1.64; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; LEFFLER H, 1981, INFECT IMMUN, V34, P920, DOI 10.1128/IAI.34.3.920-929.1981; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; SCHAEFFER AJ, 1981, NEW ENGL J MED, V304, P1062, DOI 10.1056/NEJM198104303041802; SMITH S, 1996, CLIN INFECT DIS, V25, P63; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; Stapleton A, 1997, INFECT DIS CLIN N AM, V11, P719, DOI 10.1016/S0891-5520(05)70382-2; Stapleton AE, 1998, INFECT IMMUN, V66, P3856, DOI 10.1128/IAI.66.8.3856-3861.1998; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Zopf D, 1996, LANCET, V347, P1017, DOI 10.1016/S0140-6736(96)90150-6	19	21	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1999	353	9146					7	8		10.1016/S0140-6736(05)74875-3	http://dx.doi.org/10.1016/S0140-6736(05)74875-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155FC	10023942				2022-12-01	WOS:000077934800007
J	Belshaw, PJ; Walsh, CT; Stachelhaus, T				Belshaw, PJ; Walsh, CT; Stachelhaus, T			Aminoacyl-CoAs as probes of condensation domain selectivity in nonribosomal peptide synthesis	SCIENCE			English	Article							SYNTHETASE GENES; GRAMICIDIN-S; BIOSYNTHESIS; IDENTIFICATION	In nonribosomal biosynthesis of peptide antibiotics by multimodular synthetases, amino acid monomers are activated by the adenylation domains of the synthetase and loaded onto the adjacent carrier protein domains as thioesters, then the formation of peptide bonds and translocation of the growing chain are effected by the synthetase's condensation domains. Whether the condensation domains have any editing function has been unknown. Synthesis of aminoacyl-coenzyme A (CoA) molecules and direct enzymatic transfer of aminoacyl-phosphopantetheine to the carrier domains allow the adenylation domain editing function to be bypassed. This method was used to demonstrate that the first condensation domain of tyrocidine synthetase shows low selectivity at the donor residue (D-phenylalanine) and higher selectivity at the acceptor residue (L-proline) in the formation of the chain-initiating D-Phe-L-Pro dipeptidyl-enzyme intermediate.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walsh, CT (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.				NIGMS NIH HHS [GM20011] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DECRECYLAGARD V, 1995, CR ACAD SCI III-VIE, V318, P927; deCrecyLagard V, 1997, J BACTERIOL, V179, P705, DOI 10.1128/jb.179.3.705-713.1997; Dittmann E, 1997, MOL MICROBIOL, V26, P779, DOI 10.1046/j.1365-2958.1997.6131982.x; Gehring AM, 1998, CHEM BIOL, V5, P573, DOI 10.1016/S1074-5521(98)90115-6; HORI K, 1989, J BIOCHEM-TOKYO, V106, P639, DOI 10.1093/oxfordjournals.jbchem.a122909; Jakubowski H, 1998, BIOCHEMISTRY-US, V37, P5147, DOI 10.1021/bi972528v; KELLER U, 1987, J BIOL CHEM, V262, P5852; KLEINKAUF H, 1981, ADV BIOTECHNOL, V3, P83; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; Zhu WM, 1998, MOL MICROBIOL, V29, P629, DOI 10.1046/j.1365-2958.1998.00961.x	19	254	271	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					486	489		10.1126/science.284.5413.486	http://dx.doi.org/10.1126/science.284.5413.486			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205056				2022-12-01	WOS:000079792200047
J	Ge, M; Chen, Z; Onishi, HR; Kohler, J; Silver, LL; Kerns, R; Fukuzawa, S; Thompson, C; Kahne, D				Ge, M; Chen, Z; Onishi, HR; Kohler, J; Silver, LL; Kerns, R; Fukuzawa, S; Thompson, C; Kahne, D			Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala	SCIENCE			English	Article							GLYCOPEPTIDE ANTIBIOTICS; ESCHERICHIA-COLI; D-ALANINE; DIMERIZATION	Vancomycin is an important drug for the treatment of Cram-positive bacterial infections. Resistance to vancomycin has begun to appear, posing a serious public health threat. Vancomycin analogs containing modified carbohydrates are very active against resistant microorganisms. Results presented here show that these carbohydrate derivatives operate by a different mechanism than vancomycin; moreover, peptide binding is not required for activity. It is proposed that carbohydrate-modified vancomycin compounds are effective against resistant bacteria because they interact directly with bacterial proteins involved in the transglycosylation step of cell wall biosynthesis. These results suggest new strategies for designing glycopeptide antibiotics that overcome bacterial resistance.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Merck Res Labs, Infect Dis, Rahway, NJ 07065 USA	Princeton University; Merck & Company	Kahne, D (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	dkahne@princeton.edu	Silver, Lynn L/A-7789-2009	Silver, Lynn L/0000-0002-8416-0487				Allen NE, 1997, ANTIMICROB AGENTS CH, V41, P66, DOI 10.1128/AAC.41.1.66; Allen NE, 1997, J ANTIBIOT, V50, P677, DOI 10.7164/antibiotics.50.677; ANDERSON JS, 1965, P NATL ACAD SCI USA, V53, P881, DOI 10.1073/pnas.53.4.881; BARNA JCJ, 1984, ANNU REV MICROBIOL, V38, P339, DOI 10.1146/annurev.mi.38.100184.002011; BOOTH PM, 1987, J CHEM SOC CHEM COMM, P1694, DOI 10.1039/c39870001694; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; CRISTOFARO MF, 1995, J ANTIBIOT, V48, P805, DOI 10.7164/antibiotics.48.805; DiBerardino M, 1996, FEBS LETT, V392, P184, DOI 10.1016/0014-5793(96)00809-5; Evans DA, 1998, ANGEW CHEM INT EDIT, V37, P2700, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2700::AID-ANIE2700>3.0.CO;2-P; Gale E. F., 1981, MOL BASIS ANTIBIOTIC; Ge M, 1998, J AM CHEM SOC, V120, P11014, DOI 10.1021/ja982414m; GE M, UNPUB; Malabarba A, 1997, MED RES REV, V17, P69, DOI 10.1002/(SICI)1098-1128(199701)17:1<69::AID-MED3>3.0.CO;2-R; MIRELMAN D, 1976, BIOCHEMISTRY-US, V15, P1781, DOI 10.1021/bi00654a001; NAGARAJAN R, 1988, J CHEM SOC CHEM COMM, P1306, DOI 10.1039/c39880001306; NAGARAJAN R, 1989, J ANTIBIOT, V42, P63, DOI 10.7164/antibiotics.42.63; NAGARJAN R, 1993, J ANTIBIOT, V46, P1181, DOI 10.7164/antibiotics.46.1181; Nicolaou K. C., 1999, ANGEW CHEM, V111, P253; Nicolaou KC, 1998, ANGEW CHEM INT EDIT, V37, P2708, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2708::AID-ANIE2708>3.0.CO;2-E; ONISHI HR, 1974, ANN NY ACAD SCI, V235, P406, DOI 10.1111/j.1749-6632.1974.tb43280.x; PERKINS HR, 1969, BIOCHEM J, V111, P195, DOI 10.1042/bj1110195; Rao JH, 1998, SCIENCE, V280, P708, DOI 10.1126/science.280.5364.708; Rao JH, 1997, J AM CHEM SOC, V119, P10286, DOI 10.1021/ja971225l; Sharman GJ, 1997, J AM CHEM SOC, V119, P12041, DOI 10.1021/ja964477f; Solenberg PJ, 1997, CHEM BIOL, V4, P195, DOI 10.1016/S1074-5521(97)90288-X; SOMNER EA, 1990, ANTIMICROB AGENTS CH, V34, P413, DOI 10.1128/AAC.34.3.413; Sundram UN, 1996, J AM CHEM SOC, V118, P13107, DOI 10.1021/ja9621298; Thompson C, 1999, J AM CHEM SOC, V121, P1237, DOI 10.1021/ja983504u; UMBREIT JN, 1972, J BACTERIOL, V112, P1306, DOI 10.1128/JB.112.3.1306-1309.1972; VANHEIJENOORT Y, 1978, FEBS LETT, V89, P141, DOI 10.1016/0014-5793(78)80540-7; VANHEIJENOORT Y, 1980, FEBS LETT, V110, P241, DOI 10.1016/0014-5793(80)80082-2; Williams DH, 1998, SCIENCE, V280, P711, DOI 10.1126/science.280.5364.711	32	312	336	4	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					507	511		10.1126/science.284.5413.507	http://dx.doi.org/10.1126/science.284.5413.507			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205063				2022-12-01	WOS:000079792200054
J	Hu, YL; Baud, V; Delhase, M; Zhang, PL; Deerinck, T; Ellisman, M; Johnson, R; Karin, M				Hu, YL; Baud, V; Delhase, M; Zhang, PL; Deerinck, T; Ellisman, M; Johnson, R; Karin, M			Abnormal morphogenesis but intact IKK activation in mice lacking the IKK alpha subunit of I kappa B kinase	SCIENCE			English	Article							MULTIFUNCTIONAL REGULATORS; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; DROSOPHILA EMBRYO; INDUCED APOPTOSIS; CELL-DEATH; COMPLEX; BETA; DEFECTS; PHOSPHORYLATION	The oligomeric I kappa B kinase (IKK) is composed of three polypeptides: IKK alpha and IKK beta, the catalytic subunits, and IKK gamma, a regulatory subunit. IKK alpha and IKK beta are similar in structure and thought to have similar function-phosphorylation of the I kappa B inhibitors in response to proinflammatory stimuli. Such phosphorylation Leads to degradation of I kappa B and activation of nuclear factor kappa B transcription factors. The physiological function of these protein kinases was explored by analysis of IKK alpha-deficient mice. IKK alpha was not required for activation of IKK and degradation of I kappa B by proinflammatory stimuli. Instead, loss of IKK alpha interfered with multiple morphogenetic events, including Limb and skeletal patterning and proliferation and differentiation of epidermal keratinocytes.	Univ Calif San Diego, Ctr Canc, Lab Gene Regulat & Signal Transduct, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Ctr Canc, Lab Gene Regulat & Signal Transduct, Dept Pharmacol, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Baud, Veronique/F-7699-2013; Delhase, Mireille/ABE-5256-2021; Baud, Veronique/AAL-3950-2020; Johnson, Randall/AAM-1189-2021	Baud, Veronique/0000-0002-4090-718X; Delhase, Mireille/0000-0003-2312-1051; Baud, Veronique/0000-0002-4090-718X; Johnson, Randall/0000-0002-4084-6639	NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [R01 AI43477] Funding Source: Medline; NIEHS NIH HHS [R37 ES04151] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAUD V, UNPUB; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BENIRSCHKE K., 1995, PATHOLOGY HUMAN PLAC; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Joyner AL, 1993, GENE TARGETING PRACT; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Karsenty G, 1998, DEV GENET, V22, P301, DOI 10.1002/(SICI)1520-6408(1998)22:4&lt;301::AID-DVG1&gt;3.0.CO;2-A; Katagiri T, 1998, DEV GENET, V22, P340, DOI 10.1002/(SICI)1520-6408(1998)22:4<340::AID-DVG4>3.0.CO;2-6; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOCHHAR DM, 1977, HDB TERATOLOGY, V2, P453; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.0.CO;2-8; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	40	695	738	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					316	320		10.1126/science.284.5412.316	http://dx.doi.org/10.1126/science.284.5412.316			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195896				2022-12-01	WOS:000079636400042
J	Viswanathan, A; You, HJ; Doetsch, PW				Viswanathan, A; You, HJ; Doetsch, PW			Phenotypic change caused by transcriptional bypass of uracil in nondividing cells	SCIENCE			English	Article							BASE EXCISION-REPAIR; ESCHERICHIA-COLI; DNA-DAMAGE; TRANSCRIBED STRAND; COCKAYNE-SYNDROME; RNA-POLYMERASE; COUPLED REPAIR; MUTT PROTEIN; MUTATION; SITES	Cytosine deamination to uracil occurs frequently in cellular DNA. In vitro, RNA polymerase efficiently inserts adenine opposite to uracil, resulting in Ci to A base substitutions. In vivo, uracil could potentially alter transcriptional fidelity, resulting in production of mutant proteins. This study demonstrates that in nondividing Escherichia coli cells, a DNA template base replaced with uracil in a stop codon in the firefly Luciferase gene results in conversion of inactive to active Luciferase, The Level of transcriptional base substitution is dependent on the capacity to repair uracil, These results provide evidence for a DNA damage-dependent, transcription-driven pathway for generating mutant proteins in nondividing cells.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Doetsch, PW (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.			You, Ho Jin/0000-0002-0530-4017	NCI NIH HHS [CA73041, CA78622] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073041, R01CA078622] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Althaus IW, 1996, BIOCHEM PHARMACOL, V51, P1373, DOI 10.1016/0006-2952(96)00061-5; BRIDGES BA, 1995, NATURE, V375, P741, DOI 10.1038/375741a0; Bridges BA, 1996, CANCER SURV, V28, P155; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CHEN YH, 1993, J BIOL CHEM, V268, P5849; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DEMARINI DM, 1992, MUTAT RES, V267, P1, DOI 10.1016/0027-5107(92)90106-C; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH P, 1998, DNA DAMAGE REPAIR OX, P97; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; Friedberg EC, 1995, DNA REPAIR MUTAGENES; GALLANT J, 1979, MECH AGEING DEV, V10, P27, DOI 10.1016/0047-6374(79)90068-X; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; Harris RS, 1997, GENE DEV, V11, P2426, DOI 10.1101/gad.11.18.2426; KATO M, 1993, BIOL PHARM BULL, V16, P552; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LIU J, 1995, MOL CELL BIOL, V15, P6729; Liu J, 1998, NUCLEIC ACIDS RES, V26, P1707, DOI 10.1093/nar/26.7.1707; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; ORGEL LE, 1963, P NATL ACAD SCI USA, V49, P517, DOI 10.1073/pnas.49.4.517; SALANEWBY GB, 1994, BBA-PROTEIN STRUCT M, V1206, P155, DOI 10.1016/0167-4838(94)90084-1; Sandigursky M, 1998, NUCLEIC ACIDS RES, V26, P1282, DOI 10.1093/nar/26.5.1282; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Vassylyev DG, 1996, STRUCTURE, V4, P1381, DOI 10.1016/S0969-2126(96)00145-1; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Yamaguchi M, 1997, MOL CELL BIOCHEM, V173, P169, DOI 10.1023/A:1006833111236; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	38	83	86	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	1999	284	5411					159	162		10.1126/science.284.5411.159	http://dx.doi.org/10.1126/science.284.5411.159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102819				2022-12-01	WOS:000079509000058
J	Berger, A				Berger, A			Science commentary: what is involved in intracyoplasmic sperm injection?	BRITISH MEDICAL JOURNAL			English	Article																		Bonduelle M, 1996, HUM REPROD, V11, P131, DOI 10.1093/humrep/11.suppl_4.131; Storeng RT, 1998, ACTA OBSTET GYN SCAN, V77, P191, DOI 10.1034/j.1600-0412.1998.770212.x; Tuerlings JHAM, 1998, FERTIL STERIL, V69, P899, DOI 10.1016/S0015-0282(98)00050-8	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1999	318	7185					705	705						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182JK	10074015				2022-12-01	WOS:000079495700025
J	Carrion, AM; Link, WA; Ledo, F; Mellstrom, B; Naranjo, JR				Carrion, AM; Link, WA; Ledo, F; Mellstrom, B; Naranjo, JR			DREAM is a Ca2+-regulated transcriptional repressor	NATURE			English	Article							GENE-EXPRESSION; CALCIUM; PATHWAYS; FOS; ACTIVATION; NEURONS; KINASES	Fluxes in amounts of intracellular calcium ions are important determinants of gene expression(1-3). So far, Ca2+-regulated kinases and phosphatases have been implicated in changing the phosphorylation status of key transcription factors and thereby modulating their function(4,5). In addition, direct effecters of Ca2+ induced gene expression have been suggested to exist in the nucleus(2), although no such effecters have been identified yet. Expression of the human prodynorphin gene, which is involved in memory acquisition and pain(6,7), is regulated through its downstream regulatory element (DRE) sequence, which acts as a location-dependent gene silencer(8). Here we isolate a new transcriptional repressor, DRE-antagonist modulator (DREAM), which specifically binds to the DRE. DREAM contains four Ca2+-binding domains of the EF-hand type. Upon stimulation by Ca2+, DREAM's ability to bind to the DRE and its repressor function are prevented. Mutation of the EF-hands abolishes the response of DREAM to Ca2+. In addition to the prodynorphin promoter, DREAM represses transcription from the early response gene c-fos. Thus, DREAM represents the first known Ca2+-binding protein to function as a DNA-binding transcriptional regulator.	CSIC, Inst Neurobiol S Ramon & Cajal, Madrid 28002, Spain	Consejo Superior de Investigaciones Cientificas (CSIC)	Naranjo, JR (corresponding author), CSIC, Inst Neurobiol S Ramon & Cajal, Av Dr Arce 37, Madrid 28002, Spain.	jrnaranjo@samba.cnb.uam.es	Carrion, Angel Manuel/K-5875-2014; NARANJO, Jose R/K-1950-2014; Link, Wolfgang/F-4435-2012	Carrion, Angel Manuel/0000-0001-8158-9512; NARANJO, Jose R/0000-0002-0270-3469; Link, Wolfgang/0000-0002-3340-5165				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Carrion AM, 1998, MOL CELL BIOL, V18, P6921, DOI 10.1128/MCB.18.12.6921; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; Johnson CM, 1997, J NEUROSCI, V17, P6189; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0	18	479	499	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 4	1999	398	6722					80	84		10.1038/18044	http://dx.doi.org/10.1038/18044			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174KG	10078534				2022-12-01	WOS:000079033900056
J	Sigal, LJ; Crotty, S; Andino, R; Rock, KL				Sigal, LJ; Crotty, S; Andino, R; Rock, KL			Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen	NATURE			English	Article							MHC CLASS-I; MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN POLIOVIRUS RECEPTOR; MINOR H-ANTIGENS; VACCINIA VIRUS; TRANSGENIC MICE; CROSS-REACT; MOLECULES; PATHWAY; VIVO	Cytotoxic T lymphocytes (CTLs) are thought to detect viral infections by monitoring the surface of all cells for the presence of viral peptides bound to major histocompatibility complex (MHC) class I molecules. In most cells, peptides presented by MHC class I molecules are derived exclusively from proteins synthesized by the antigen-bearing cells'. Macrophages and dendritic cells also have an alternative MHC class I pathway that can present peptides derived from extracellular antigens; however, the physiological role of this process is unclear(2). Here we show that virally infected non-haematopoietic cells are unable to stimulate primary CTL-mediated immunity directly. Instead, bone-marrow-derived cells are required as antigen-presenting cells (APCs) to initiate anti-viral CTL responses. In these APCs, the alternative (exogenous) MHC class I pathway is the obligatory mechanism for the initiation of CTL responses to viruses that infect only non-haematopoietic cells.	Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Francisco	Rock, KL (corresponding author), Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA.		Crotty, Shane/AAE-8446-2019; Sigal, Luis/AAL-1849-2021; Crotty, Shane/AAC-6703-2019	Crotty, Shane/0000-0002-6484-6262; Sigal, Luis/0000-0001-6642-5472				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BACHMANN MF, 1995, EUR J IMMUNOL, V25, P1739, DOI 10.1002/eji.1830250637; BEVAN MJ, 1976, J IMMUNOL, V117, P2233; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BULLER RML, 1985, NATURE, V317, P813, DOI 10.1038/317813a0; Huang AYC, 1996, IMMUNITY, V4, P349, DOI 10.1016/S1074-7613(00)80248-4; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; LEE MS, 1992, J VIROL, V66, P2617, DOI 10.1128/JVI.66.5.2617-2630.1992; MNDL S, 1998, P NATL ACAD SCI USA, V95, P8216; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; REN R, 1992, J VIROL, V66, P296, DOI 10.1128/JVI.66.1.296-304.1992; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; RESTIFO NP, 1995, J IMMUNOL, V154, P4414; Rock KL, 1996, J IMMUNOL, V156, P3721; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; Shen ZH, 1997, J IMMUNOL, V158, P2723; Sigal LJ, 1998, J IMMUNOL, V161, P2740; SOUSA CRE, 1995, J EXP MED, V182, P841, DOI 10.1084/jem.182.3.841; TAYLOR G, 1991, J GEN VIROL, V72, P125, DOI 10.1099/0022-1317-72-1-125; VANKAER L, 1992, CELL, V71, pS120; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369; ZINKERNAGEL RM, 1980, CLIN IMMUNOL IMMUNOP, V15, P565, DOI 10.1016/0090-1229(80)90067-7	29	474	486	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 4	1999	398	6722					77	80		10.1038/18038	http://dx.doi.org/10.1038/18038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174KG	10078533				2022-12-01	WOS:000079033900055
J	Taylor, KL; Cheng, NQ; Williams, RW; Steven, AC; Wickner, RB				Taylor, KL; Cheng, NQ; Williams, RW; Steven, AC; Wickner, RB			Prion domain initiation of amyloid formation in vitro from native Ure2p	SCIENCE			English	Article							YEAST SUP35 PROTEIN; SACCHAROMYCES-CEREVISIAE; IN-VITRO; PROPAGATION; DETERMINANT; TRANSLATION; TERMINATION; PSI(+); GENES; ERF1	The [URE3] non-Mendelian genetic element of Saccharomyces cerevisiae is an infectious protein (prion) form of Ure2p, a regulator of nitrogen catabolism. Here, synthetic Ure2p(1-65) were shown to polymerize to form filaments 40 to 45 angstroms in diameter with more than 60 percent beta sheet. Ure2p(1-65) specifically induced full-length native Ure2p to copolymerize under conditions where native Ure2p alone did not polymerize. Like Ure2p in extracts of [URE3] strains, these 180- to 220-angstrom-diameter filaments were protease resistant, The Ure2p(1-65)-Ure2p cofilaments could seed polymerization of native Ure2p to form thicker, Less regular filaments. All filaments stained with Congo Red to produce the green birefringence typical of amyloid. This self-propagating amyloid formation can explain the properties of [URE3].	NIDDKD, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; NIAMSD, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Uniformed Services University of the Health Sciences - USA	Wickner, RB (corresponding author), NIDDKD, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA.	wickner@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK024943] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Cooper T. G., 1982, MOL BIOL YEAST SACCH, V2, P39; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; EDSKES HK, IN PRESS P NATL ACAD; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; GLENNER GG, 1981, PROG HISTOCHEM CYTOC, V13, P1; GLENNER GG, 1971, SCIENCE, V174, P712, DOI 10.1126/science.174.4010.712; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; HIRS CHW, 1986, ENZYME STRUCTURE, V130, P311; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kisilevsky R, 1997, CRIT REV BIOCHEM MOL, V32, P361, DOI 10.3109/10409239709082674; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PRUSINER SB, 1996, FIELDS VIROLOGY, V2, P2901; SCHOUN J, 1969, CR ACAD SCI D NAT, V269, P1412; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; TAYLOR KJ, UNPUB; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; WILLIAMS RW, 1983, J MOL BIOL, V166, P581, DOI 10.1016/S0022-2836(83)80285-X; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	34	257	258	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1999	283	5406					1339	1343		10.1126/science.283.5406.1339	http://dx.doi.org/10.1126/science.283.5406.1339			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AM	10037606				2022-12-01	WOS:000078839900045
J	Eriksson, JG; Forsen, T; Tuomilehto, J; Winter, PD; Osmond, C; Barker, DJP				Eriksson, JG; Forsen, T; Tuomilehto, J; Winter, PD; Osmond, C; Barker, DJP			Catch-up growth in childhood and death from coronary heart disease: longitudinal study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX; FOLLOW-UP; CARDIOVASCULAR-DISEASE; BIRTH-WEIGHT; FETAL; MEN; MORTALITY; AGE; OVERWEIGHT; INSULIN	Objective To examine whether catch-up growth during childhood modifies the increased risk of death from coronary heart disease that is associated with reduced intrauterine growth. Design Follow up study of men whose body size at birth, was recorded and who had an average of 10 measurements taken of their height and weight through childhood. Setting Helsinki, Finland. Subjects 3041 men who were born in Helsinki University Central Hospital during 1924-33 and who went to school in Helsinki. Main outcome measures Hazard ratios fur death from coronary heart disease. Results Death from coronary heart disease was associated with low birth weight and, more strongly, with a low ponderal index at birth. Men who died from coronary heart disease had an above average body mass index at all ages from 7 to 15 years. In a simultaneous regression the hazard ratio for death from the disease increased by 14% (95%, confidence interval 8% to 19%; P < 0.0001) for each unit (kg/m(3)) decrease in ponderal index at birth and by 22% (10% to 36%; P = 0.0001) for each unit (kg/m(2)) increase in body mass index at 11 years of age. Body mass index in childhood was strongly related to maternal body mass index, which in turn was related to coronary heart disease. The extent of crowding in the home during childhood, although related to, body mass index in childhood, was not related to later coronary heart disease. Conclusion The highest death rates from coronary heart disease occurred in boys who were thin at birth but whose weight caught up so that they had an average or above average body mass from the age of 7 years. Death from coronary heart disease may be a consequence of poor prenatal nutrition followed by improved postnatal nutrition.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton S016 6YD, Hants, England; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, SF-00300 Helsinki, Finland	University of Southampton; Finland National Institute for Health & Welfare	Barker, DJP (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton S016 6YD, Hants, England.	david.barker@mrc.soton.ac.uk	Fahimifar, Sepideh/M-5303-2019	Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; CASEY VA, 1992, AM J CLIN NUTR, V56, P14, DOI 10.1093/ajcn/56.1.14; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; FRISCH RE, 1990, BAILLIERE CLIN OB GY, V4, P419, DOI 10.1016/S0950-3552(05)80302-5; GUILLAUME M, 1995, INT J OBESITY, V19, pS5; GUNNELL D, 1996, J EPIDEMIOL COMMUNIT, V50, P580; Gunnell DJ, 1998, AM J CLIN NUTR, V67, P1111, DOI 10.1093/ajcn/67.6.1111; GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Law CM, 1996, J HYPERTENS, V14, P935; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MARMOT MG, 1984, LANCET, V1, P1003; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; NIETO FJ, 1992, AM J EPIDEMIOL, V136, P201, DOI 10.1093/oxfordjournals.aje.a116486; PITTS GC, 1986, GROWTH, V50, P419; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROBINSON SM, 1991, BRIT J OBSTET GYNAEC, V98, P1223, DOI 10.1111/j.1471-0528.1991.tb15393.x; ROLLANDCACHERA MF, 1998, HUMAN GROWTH DEV, P51; ROYSTON P, 1991, STAT MED, V10, P675, DOI 10.1002/sim.4780100502; TANNER JM, 1989, FOETUS MAN; Vanhala M, 1998, BRIT MED J, V317, P319, DOI 10.1136/bmj.317.7154.319; WAALER HT, 1984, ACTA MED SCAND, P1; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; YLIAHO T, 1991, TETAALAINEN HELSINGI	31	835	851	0	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	1999	318	7181					427	431		10.1136/bmj.318.7181.427	http://dx.doi.org/10.1136/bmj.318.7181.427			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BF	9974455	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000078670100024
J	Geier, E; Pfeifer, G; Wilm, M; Lucchiari-Hartz, M; Baumeister, W; Eichmann, K; Niedermann, G				Geier, E; Pfeifer, G; Wilm, M; Lucchiari-Hartz, M; Baumeister, W; Eichmann, K; Niedermann, G			A giant protease with potential to substitute for some functions of the proteasome	SCIENCE			English	Article							TRIPEPTIDYL-PEPTIDASE-II; RAT-LIVER; INHIBITION; LACTACYSTIN; PROTEINS; CELLS	An alanyl-alanyl-phenylalanyl-7-amino-4-methylcoumarin-hydrolyzing protease particle copurifying with 265 proteasomes was isolated and identified as tripeptidyl peptidase II(TPPII), a cytosolic subtilisin-like peptidase of unknown function. The particle is larger than the 265 proteasome and has a rod-shaped, dynamic supramolecular structure. TPPII exhibits enhanced activity in proteasome inhibitor-adapted cells and degrades polypeptides by exo- as well as predominantly trypsin-like endoproteolytic cleavage. TPPII may thus participate in extralysosomal polypeptide degradation and may in part account for nonproteasomal epitope generation as postulated for certain major histocompatibility complex class I alleles, In addition, TPPII may be able to substitute for some metabolic functions of the proteasome.	Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany	Max Planck Society; Max Planck Society; European Molecular Biology Laboratory (EMBL)	Niedermann, G (corresponding author), Max Planck Inst Immunobiol, Stubeweg 51, D-79108 Freiburg, Germany.	niedermann@immunbio.mpg.de		Wilm, Matthias/0000-0002-5461-6834				BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1986, J BIOL CHEM, V261, P2409; Benham AM, 1998, J IMMUNOL, V161, P83; Bermpohl F, 1998, FEBS LETT, V428, P152, DOI 10.1016/S0014-5793(98)00515-8; Bush KT, 1997, J BIOL CHEM, V272, P9086; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GEIER E, UNPUB; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KIRSCHKE H, 1977, ACTA BIOL MED GER, V36, P185; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; NISHIMURA T, 1983, EUR J BIOCHEM, V137, P23, DOI 10.1111/j.1432-1033.1983.tb07790.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TOMKINSON B, 1994, BIOCHEM J, V304, P517, DOI 10.1042/bj3040517; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; Wang X, 1998, J IMMUNOL, V160, P788; WILM M, UNPUB; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	28	300	322	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1999	283	5404					978	981		10.1126/science.283.5404.978	http://dx.doi.org/10.1126/science.283.5404.978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166KM	9974389				2022-12-01	WOS:000078574800046
J	Huse, M; Chen, YG; Massague, J; Kuriyan, J				Huse, M; Chen, YG; Massague, J; Kuriyan, J			Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12	CELL			English	Article							GROWTH-FACTOR-BETA; DEPENDENT PROTEIN-KINASE; TYROSINE KINASE; CATALYTIC SUBUNIT; INSULIN-RECEPTOR; BINDING-PROTEIN; FAMILY; SUBSTRATE; MECHANISM; ACTIVATION	Activation of the type I TGF beta receptor (T beta R-I) requires phosphorylation of a regulatory segment known as the GS region, located upstream of the serine/threonine kinase domain in the cytoplasmic portion of the receptor, The crystal structure of a fragment of unphosphorylated T beta R-I, containing both the GS region and the catalytic domain, has been determined in complex with the FK506-binding protein FKBP12. T beta R-I adopts an inactive conformation that is maintained by the unphosphorylated GS region, FKBP12 binds to the GS region of the receptor, capping the T beta R-II phosphorylation sites and further stabilizing the inactive conformation of T beta R-I. Certain structural features at the catalytic center of T beta R-I are characteristic of tyrosine kinases rather than Ser/Thr kinases.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Kuriyan, J (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.	kuriyan@rocky2.rockefeller.edu		Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG RN, 1979, BIOCHEMISTRY-US, V18, P1230, DOI 10.1021/bi00574a018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; KLEYWEGT GJ, 1993, ESF CCP4 NEWSLETTER, V28, P56; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LU G, 1999, IN PRESS FIND NCS PR; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; ROBERTS JR, 1990, PHYS SCRIPTA, V41, P9, DOI 10.1088/0031-8949/41/1/003; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Stockwell BR, 1998, CHEM BIOL, V5, P385, DOI 10.1016/S1074-5521(98)90072-2; Stockwell BR, 1998, CURR BIOL, V8, P761, DOI 10.1016/S0960-9822(98)70299-4; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILSON KP, 1995, ACTA CRYSTALLOGR D, V51, P511, DOI 10.1107/S0907444994014514; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	59	349	379	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 5	1999	96	3					425	436		10.1016/S0092-8674(00)80555-3	http://dx.doi.org/10.1016/S0092-8674(00)80555-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	165HE	10025408	Bronze			2022-12-01	WOS:000078514600015
J	Rosen, H; Hajdu, R; Silver, L; Kropp, H; Dorso, K; Kohler, J; Sundelof, JG; Huber, J; Hammond, GG; Jackson, JJ; Gill, CJ; Thompson, R; Pelak, BA; Epstein-Toney, JH; Lankas, G; Wilkening, RR; Wildonger, KJ; Blizzard, TA; DiNinno, FP; Ratcliffe, RW; Heck, JV; Kozarich, JW; Hammond, ML				Rosen, H; Hajdu, R; Silver, L; Kropp, H; Dorso, K; Kohler, J; Sundelof, JG; Huber, J; Hammond, GG; Jackson, JJ; Gill, CJ; Thompson, R; Pelak, BA; Epstein-Toney, JH; Lankas, G; Wilkening, RR; Wildonger, KJ; Blizzard, TA; DiNinno, FP; Ratcliffe, RW; Heck, JV; Kozarich, JW; Hammond, ML			Reduced immunotoxicity and preservation of antibacterial activity in a releasable side-chain carbapenem antibiotic	SCIENCE			English	Article							PENICILLIN-BINDING PROTEINS; STAPHYLOCOCCUS-AUREUS; RESISTANCE; VANCOMYCIN; L-749,345; PRIMATES	A carbapenem antibiotic, L-786,392, was designed so that the side chain that provides high-affinity binding to the penicillin-binding proteins responsible for bacterial resistance was also the structural basis for ameliorating immunopathology. Expulsion of the side chain upon opening of the beta-lactam ring retained antibacterial activity while safely expelling the immunodominant epitope. L-786,392 was well tolerated in animal safety studies and had significant in vitro and in vivo activities against methicillin- and vancomycin-resistant Staphylococci and vancomycin-resistant Enterococci.	Merck Res Labs, Rahway, NJ 07065 USA	Merck & Company	Rosen, H (corresponding author), Merck Res Labs, Rahway, NJ 07065 USA.		Silver, Lynn L/A-7789-2009	Silver, Lynn L/0000-0002-8416-0487				BRANDER C, 1995, J IMMUNOL, V155, P2670; COYETTE J, 1977, EUR J BIOCHEM, V75, P225, DOI 10.1111/j.1432-1033.1977.tb11521.x; DELENCASTRE H, 1994, J ANTIMICROB CHEMOTH, V33, P7, DOI 10.1093/jac/33.1.7; GEORGOPAPADAKOU NH, 1982, ANTIMICROB AGENTS CH, V22, P172, DOI 10.1128/AAC.22.1.172; Gill CJ, 1998, ANTIMICROB AGENTS CH, V42, P1996, DOI 10.1128/AAC.42.8.1996; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; GRALNICK H, 1971, JAMA-J AM MED ASSOC, V199, P725; HAJDU R, UNPUB; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Hiramatsu K, 1997, AM J INFECT CONTROL, V25, P405; HUBER J, 1994, 34TH INT C ANT AG CH, P126; Jacoby G, 1997, ANTIMICROB AGENTS CH, V41, P1830, DOI 10.1128/AAC.41.8.1830; KLAUS MV, 1973, J GERONTOL, V28, P312, DOI 10.1093/geronj/28.3.312; KNUDSEN LF, 1947, J AM STAT ASSOC, V42, P282, DOI 10.2307/2280657; Lankas GR, 1996, TOXICOLOGY, V108, P207, DOI 10.1016/0300-483X(96)03305-7; LEVINE BB, 1976, MANUAL CLIN IMMUNOLO, P637; Michel M, 1997, LANCET, V349, P1901, DOI 10.1016/S0140-6736(96)11192-2; Petz LD, 1986, MANUAL CLIN LAB IMMU, P613; SPRATT BG, 1977, EUR J BIOCHEM, V72, P341, DOI 10.1111/j.1432-1033.1977.tb11258.x; Sundelof JG, 1997, ANTIMICROB AGENTS CH, V41, P1743, DOI 10.1128/AAC.41.8.1743	21	31	34	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 29	1999	283	5402					703	706		10.1126/science.283.5402.703	http://dx.doi.org/10.1126/science.283.5402.703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BC	9924033				2022-12-01	WOS:000078324400047
J	Brown, AD; Garber, AM				Brown, AD; Garber, AM			Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEGATIVE CERVICAL SMEARS; QUALITY-CONTROL; SCREENING POLICIES; BREAST-CANCER; PAP SMEARS; SYSTEM; EFFICACY; CYTOLOGY; MODEL; PROVIDE	Context ThinPrep, AutoPap, and Papnet are 3 new technologies that increase the sensitivity and cost of cervical cancer screening. Objective To estimate the cost-effectiveness of these technological enhancements to Papanicolaou (Pap) tests, Design We estimated the increase in sensitivity from using these technologies by combining results of 8 studies meeting defined criteria. We used published literature and additional sources for cost estimates. To estimate overall cost-effectiveness, we applied a 9-state time-varying transition state model to these data and information about specific populations. Setting A hypothetical program serving a cohort of 20- to 65-year-old women who begin screening at the same age and are representative of the US population. Results The new technologies increased life expectancy by 5 hours to 1.6 days, varying with the technology and the frequency of screening. All 3 technologies also increased the cost per woman screened by $30 to $257 (1996 US dollars). AutoPap dominated ThinPrep in the base case. At each screening interval, AutoPap increased survival at the lowest cost, The cost per year of life saved rose from $7777 with quadrennial screening to $166 000 with annual screening. Papnet produced more life-years at a higher cost per year of life saved. However, when used with triennial screening, each of them produced more life-years at lower cost than conventional Pap testing every 2 years. The cost-effectiveness ratio of each technology improved with increases in the prevalence of disease, decreases in the sensitivity of conventional Pap testing, and increases in the improvement in sensitivity produced by the technology. Conclusions Technologies to increase the sensitivity of Pap testing are more cost-effective when incorporated into infrequent screening. Increases in sensitivity and de creases in cost may eventually make each technology more cost-effective.	Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA 94305 USA; Univ Oxford, Dept Publ Hlth & Primary Care, Oxford OX3 7LF, England	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Oxford	Garber, AM (corresponding author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, 30 Alta Rd, Stanford, CA 94305 USA.	garber@stanford.edu	Garber, Alan M/F-1476-2010					[Anonymous], 1986, BMJ-BRIT MED J, V293, P659; Bedrossian C, 1998, AM J CLIN PATHOL, V109, P10; Benneyan JC, 1996, ANN OPER RES, V67, P235, DOI 10.1007/BF02187031; Bolick DR, 1998, ACTA CYTOL, V42, P209, DOI 10.1159/000331548; BOON ME, 1993, DIAGN CYTOPATHOL, V9, P411, DOI 10.1002/dc.2840090408; BOON ME, 1994, MODERN PATHOL, V7, P957; BUCKNER S, 1997, ACTA CYTOL, V41, P1544; CHAMBERLAIN J, 1986, SCREENING CANC UTERI, P161; COLGAN TJ, 1995, ACTA CYTOL, V39, P1191; *COMM GYN PRACT AM, 1998, ACOG COMMITTEE OPINI, V1, P1; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; Doornewaard H, 1997, ACTA CYTOL, V41, P74, DOI 10.1159/000332308; EDDY D, 1978, RATIONALE CANC SCR 3; EDDY D, 1980, SCREENING CANC THEOR, P308; EDDY DM, 1987, CANCER, V60, P1117, DOI 10.1002/1097-0142(19870901)60:5<1117::AID-CNCR2820600533>3.0.CO;2-H; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; Food and Drug Administration (FDA), 1994, PESTICIDE ANAL MANUA, V3, P1; HUTCHINSON M, 1995, ACTA CYTOL, V39, P968; Hutchinson ML, 1996, ACTA CYTOL, V40, P4; Jenny J, 1997, ACTA CYTOL, V41, P82, DOI 10.1159/000332310; JOHANNESSON M, 1993, J HEALTH ECON, V12, P459, DOI 10.1016/0167-6296(93)90005-Y; KAMINSKY FC, 1995, ACTA CYTOL, V39, P232; KAMINSKY FC, 1995, ACTA CYTOL, V39, P239; Keeney R.L., 1993, DECISIONS MULTIPLE O, DOI [DOI 10.1017/CBO9781139174084, 10.1017/CBO9781139174084, DOI 10.1109/TSMC.1979.4310245]; KeyhaniRofagha S, 1996, DIAGN CYTOPATHOL, V14, P316, DOI 10.1002/(SICI)1097-0339(199605)14:4<316::AID-DC7>3.0.CO;2-D; Koss LG, 1997, HUM PATHOL, V28, P1196, DOI 10.1016/S0046-8177(97)90258-6; KOSS LG, 1993, CANCER-AM CANCER SOC, V71, P1406, DOI 10.1002/cncr.2820710405; KOSS LG, 1994, AM J CLIN PATHOL, V101, P220, DOI 10.1093/ajcp/101.2.220; Lee KR, 1996, ACTA CYTOL, V40, P895; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LUCE BR, 1996, COST EFFECTIVENESS H, P176; Mandelblatt J, 1997, AM J PUBLIC HEALTH, V87, P1182, DOI 10.2105/AJPH.87.7.1182; McGoogan E, 1996, ACTA CYTOL, V40, P107; McMeekin, 1997, Medscape Womens Health, V2, P1; Miller WC, 1998, J CLIN EPIDEMIOL, V51, P219, DOI 10.1016/S0895-4356(97)00264-3; *NEOP INC, 1996, AUT 300 QC AUT PAP S, P10; NIH, 1996, CERV CANC NAT I HLTH, P1; O'Leary TJ, 1998, JAMA-J AM MED ASSOC, V279, P235, DOI 10.1001/jama.279.3.235; PARKIN DM, 1986, J EPIDEMIOL COMMUN H, V40, P143, DOI 10.1136/jech.40.2.143; Raab SS, 1997, AM J CLIN PATHOL, V108, P525; Radensky PW, 1998, ACTA CYTOL, V42, P246, DOI 10.1159/000331553; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Roberts JM, 1997, MED J AUSTRALIA, V167, P466, DOI 10.5694/j.1326-5377.1997.tb126672.x; Rosenthal DL, 1996, ACTA CYTOL, V40, P120; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SHEETS EE, 1995, J GYNECOL TECH, V1, P27; SHERMAN ME, 1995, ACTA CYTOL, V39, P983; SLAGEL DD, 1995, DIAGN CYTOPATHOL, V13, P26, DOI 10.1002/dc.2840130107; STOLER M, 1996, ACTA CYTOL, V40, P1045; Tezuka F, 1996, ACTA CYTOL, V40, P513; Torrance GW, 1996, COST EFFECTIVENESS H, P276; vanBallegooijen M, 1997, BRIT J CANCER, V76, P651, DOI 10.1038/bjc.1997.440; Wilbur DC, 1996, ACTA CYTOL, V40, P127; 1997, EC REPORT PRESIDENT	55	98	100	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					347	353		10.1001/jama.281.4.347	http://dx.doi.org/10.1001/jama.281.4.347			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929088				2022-12-01	WOS:000078111300034
J	Nogales, E; Whittaker, M; Milligan, RA; Downing, KH				Nogales, E; Whittaker, M; Milligan, RA; Downing, KH			High-resolution model of the microtubule	CELL			English	Article							MOTOR-PROTEIN COMPLEX; 3-DIMENSIONAL STRUCTURE; ALPHA-TUBULIN; BETA-TUBULIN; INDIVIDUAL MICROTUBULES; CRYOELECTRON MICROSCOPY; LIMITED PROTEOLYSIS; BINDING-SITE; AMINO-ACIDS; LATTICE	A high-resolution model of the microtubule has been obtained by docking the crystal structure of tubulin into a 20 Angstrom map of the microtubule. The excellent fit indicates the similarity of the tubulin conformation in both polymers and defines the orientation of the tubulin structure within the microtubule. Long C-terminal helices form the crest on the outside of the protofilament, while long loops define the microtubule lumen. The exchangeable nucleotide in beta-tubulin is exposed at the plus end of the microtubule, while the proposed catalytic residue in alpha-tubulin is exposed at the minus end. Extensive longitudinal interfaces between monomers have polar and hydrophobic components. At the lateral contacts, a nucleotide-sensitive helix interacts with a loop that contributes to the binding site of taxol in beta-tubulin.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Scripps Research Institute	Nogales, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA.	enogales@ibl.gov			NIGMS NIH HHS [GM52468, GM51487, GM46033] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM051487, R01GM052468] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; AMOS LA, 1974, J CELL SCI, V14, P523; ANDREU JM, 1993, CELL MOTIL CYTOSKEL, V26, P1, DOI 10.1002/cm.970260102; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BROWN HR, 1983, ARCH BIOCHEM BIOPHYS, V220, P46, DOI 10.1016/0003-9861(83)90385-5; BURNS RG, 1993, MICROTUBULES, P3; CHAU MF, 1998, IN PRESS BIOCHEMISTR; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; CHRETIEN D, 1992, J CELL BIOL, V117, P1031, DOI 10.1083/jcb.117.5.1031; DAI K, 1994, J BACTERIOL, V175, P130; dePereda JM, 1996, BIOCHEMISTRY-US, V35, P14184, DOI 10.1021/bi961356j; Derry WB, 1998, CANCER RES, V58, P1177; Evangelio JA, 1998, CELL MOTIL CYTOSKEL, V39, P73, DOI 10.1002/(SICI)1097-0169(1998)39:1<73::AID-CM7>3.0.CO;2-H; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HIROSE K, 1995, J MOL BIOL, V251, P329, DOI 10.1006/jmbi.1995.0437; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; LUDUENA R F, 1992, Current Opinion in Cell Biology, V4, P53, DOI 10.1016/0955-0674(92)90058-K; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MARTIN SR, 1993, BIOPHYS J, V65, P578, DOI 10.1016/S0006-3495(93)81091-9; MARUTA H, 1986, J CELL BIOL, V103, P571, DOI 10.1083/jcb.103.2.571; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Nogales E, 1997, J STRUCT BIOL, V118, P119, DOI 10.1006/jsbi.1997.3841; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; REIJO RA, 1994, MOL BIOL CELL, V5, P29, DOI 10.1091/mbc.5.1.29; SACKETT DL, 1986, J BIOL CHEM, V261, P9070; SACKETT DL, 1995, PROTEIN-STRUCT FUNCT, P255; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Sosa H, 1996, J MOL BIOL, V260, P743, DOI 10.1006/jmbi.1996.0434; WALKER RA, 1989, J CELL BIOL, V108, P931, DOI 10.1083/jcb.108.3.931; Wilson PJ, 1997, CELL MOTIL CYTOSKEL, V37, P20, DOI 10.1002/(SICI)1097-0169(1997)37:1<20::AID-CM3>3.3.CO;2-7	42	928	955	1	71	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					79	88		10.1016/S0092-8674(00)80961-7	http://dx.doi.org/10.1016/S0092-8674(00)80961-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989499	Bronze			2022-12-01	WOS:000078023200010
J	Yuzhakov, A; Kelman, Z; O'Donnell, M				Yuzhakov, A; Kelman, Z; O'Donnell, M			Trading places on DNA-a three-point switch underlies primer handoff from primase to the replicative DNA polymerase	CELL			English	Article							ONE HOLOENZYME PARTICLE; LAGGING-STRAND REPLICATION; ESCHERICHIA-COLI; SLIDING CLAMPS; BINDING PROTEIN; III HOLOENZYME; MACHINE; LOADER; HELICASE; ANTIGEN	This study reports a primase-to-polymerase switch in E. coli that closely links primase action with extension by DNA polymerase III holoenzyme. We find that primase tightly grips its RNA primer, protecting it from the action of other proteins. However, primase must be displaced before the beta sliding clamp can be assembled on the primed site. A single subunit of the holoenzyme, chi, is dedicated to this primase displacement task. The displacement mechanism depends on a third protein, SSB. Primase requires contact to SSB for its grip on the primed site. The chi subunit also binds SSB, upon which the primase-to-SSB contact is destabilized leading to dissociation of primase and assembly of beta onto the RNA primer. The conservation of this three-point switch, in which two proteins exchange places on DNA via mutually exclusive interaction with a third protein, is discussed.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; Cornell Univ, Coll Med, Grad Program Mol Biol, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Cornell University	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	odonnel@rockvax.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHASE JW, 1984, J BIOL CHEM, V259, P805; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KELMAN Z, 1995, METHODS ENZYMOLOGY D; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.bi.63.070194.002523; MEYER RR, 1982, J BACTERIOL, V150, P433, DOI 10.1128/JB.150.1.433-435.1982; MOK M, 1987, J BIOL CHEM, V262, P16644; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; RICHE D, 1989, Science and Sports, V4, P41, DOI 10.1016/S0765-1597(89)80006-1; SILVER LL, 1982, J BIOL CHEM, V257, P1696; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; Sun WL, 1998, J MOL BIOL, V276, P689, DOI 10.1006/jmbi.1997.1471; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; Turner J, 1995, METHOD ENZYMOL, V262, P442; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	32	186	187	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 8	1999	96	1					153	163		10.1016/S0092-8674(00)80968-X	http://dx.doi.org/10.1016/S0092-8674(00)80968-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	156VR	9989506	Bronze			2022-12-01	WOS:000078023200017
J	Shen, K; Meyer, T				Shen, K; Meyer, T			Dynamic control of CaMKII translocation and localization in hippocampal neurons by NMDA receptor stimulation	SCIENCE			English	Article							PROTEIN-KINASE-II; LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY; GLUTAMATE RECEPTORS; SYNAPTIC JUNCTIONS; MUTANT MICE; CALMODULIN; AUTOPHOSPHORYLATION; PHOSPHORYLATION; ACTIVATION	Calcium-calmodulin-dependent protein kinase II (CaMKII) is thought to increase synaptic strength by phosphorylating postsynaptic density (PSD) ion channels and signaling proteins. It is shown that N-methyl-D-aspartate (NMDA) receptor stimulation reversibly translocates green fluorescent protein-tagged CaMKII from an F-actin-bound to a PSD-bound state. The translocation time was controlled by the ratio of expressed beta-CaMKII to alpha-CaMKII isoforms. Although F-actin dissociation into the cytosol required autophosphorylation of or calcium-calmodulin binding to beta-CaMKII, PSD translocation required binding of calcium-calmodulin to either the alpha- or beta-CaMKII subunits. Autophosphorylation of CaMKII indirectly prolongs its PSD localization by increasing the calmodulin-binding affinity.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Meyer, T (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	tobias@cellbio.duke.edu		Meyer, Tobias/0000-0003-4339-3804	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048113, R55GM048113] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-48113] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; Gordon JA, 1996, NEURON, V17, P491, DOI 10.1016/S0896-6273(00)80181-6; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HU BR, 1995, J NEUROCHEM, V64, P277; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Raman B, 1996, J BIOL CHEM, V271, P17067, DOI 10.1074/jbc.271.29.17067; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; SUZUKI T, 1994, J NEUROCHEM, V63, P1529, DOI 10.1046/j.1471-4159.1994.63041529.x; Teruel MN, 1997, BIOPHYS J, V73, P1785, DOI 10.1016/S0006-3495(97)78209-2; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252; Yoshimura Y, 1997, J BIOL CHEM, V272, P26354, DOI 10.1074/jbc.272.42.26354	31	507	526	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1999	284	5411					162	166		10.1126/science.284.5411.162	http://dx.doi.org/10.1126/science.284.5411.162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10102820				2022-12-01	WOS:000079509000059
J	Fink, HW; Schonenberger, C				Fink, HW; Schonenberger, C			Electrical conduction through DNA molecules	NATURE			English	Article							HOLOGRAPHY	The question of whether DNA is able to transport electrons has attracted much interest, particularly as this ability may play a role as a repair mechanism after radiation damage to the DNA helix(1). Experiments addressing DNA conductivity have involved a large number of DNA strands doped with intercalated donor and acceptor molecules, and the conductivity has been assessed from electron transfer rates as a function of the distance between the donor and acceptor sites(2,3). But the experimental results remain contradictory, as do theoretical predictions(4). Here we report direct measurements of electrical current as a function of the potential applied across a few DNA molecules associated into single ropes at least 600 nm long, which indicate efficient conduction through the ropes. We find that the resistivity values derived fi om these measurements are comparable to those of conducting polymers, and indicate that DNA transports electrical current as efficiently as a good semiconductor. This property, and the fact that DNA molecules of specific composition ranging in length from just a few nucleotides to chains several tens of micrometres long can be routinely prepared, makes DNA ideally suited for the construction of mesoscopic electronic devices.	Univ Basel, Inst Phys, CH-4056 Basel, Switzerland	University of Basel	Fink, HW (corresponding author), Univ Basel, Inst Phys, Klingelbergstr 82, CH-4056 Basel, Switzerland.	finkhw@ubaclu.unibas.ch	Schönenberger, Christian/N-3187-2017	Schönenberger, Christian/0000-0002-5652-460X				Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Austin RH, 1997, PHYS TODAY, V50, P32, DOI 10.1063/1.881674; Beratan DN, 1997, CHEM BIOL, V4, P3, DOI 10.1016/S1074-5521(97)90230-1; Dandliker PJ, 1997, SCIENCE, V275, P1465, DOI 10.1126/science.275.5305.1465; FINK HW, 1990, PHYS REV LETT, V65, P1204, DOI 10.1103/PhysRevLett.65.1204; Fink HW, 1997, J OPT SOC AM A, V14, P2168, DOI 10.1364/JOSAA.14.002168; Lewis FD, 1997, SCIENCE, V277, P673, DOI 10.1126/science.277.5326.673; Schmid H, 1997, APPL PHYS LETT, V70, P2679, DOI 10.1063/1.118978	8	1042	1097	5	220	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					407	410		10.1038/18855	http://dx.doi.org/10.1038/18855			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201370				2022-12-01	WOS:000079508200047
J	Tetsu, O; McCormick, F				Tetsu, O; McCormick, F			beta-catenin regulates expression of cyclin D1 in colon carcinoma cells	NATURE			English	Article							CANCER; OVEREXPRESSION; GENE; ACTIVATION; PROMOTER; COMPLEX; XENOPUS; LESSONS; LEF-1; APC	Mutations in the adenomatous polyposis coli (APC) tumour-suppressor gene occur in most human colon cancers(1) Loss of functional APC protein results in the accumulation of beta-catenin(2). Mutant forms of beta-catenin have been discovered in colon cancers that retain wild-type APC genes(3,4), and also in melanomas(5), medulloblastomas(6), prostate cancer(7) and gastric(8) and hepatocellular(9,10) carcinomas. The accumulation of beta-catenin activates genes that are responsive to transcription factors of the TCF/LEF family, with which beta-catenin interacts(11-15). Here we show that beta-catenin activates transcription from the cyclin D1 promoter, and that sequences within the promoter that are related to consensus TCF/LEF-binding sites are necessary for activation. The oncoprotein p21(ras) further activates transcription of the cyclin D1 gene, through sites within the promoter that bind the transcriptional regulators Ets or CREB. Cells expressing mutant beta-catenin produce high levels of cyclin D1 messenger RNA and protein constitutively. Furthermore, expression of a dominant-negative form of TCF in colon-cancer cells strongly inhibits expression of cyclin DI without affecting expression of cyclin D2, cyclinE, or cyclin-dependent kinases 2, 4 or 6. This dominant-negative TCF causes cells to arrest in the G1 phase of the cell cycle; this phenotype can be rescued by expression of cyclin D1 under the cytomegalovirus promoter. Abnormal levels of beta-catenin may therefore contribute to neoplastic transformation by causing accumulation of cyclin D1.	Univ Calif San Francisco, Sch Med, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	McCormick, F (corresponding author), Univ Calif San Francisco, Sch Med, Canc Res Inst, San Francisco, CA 94143 USA.	mccormick@cc.ucsf.edu		Tetsu, Osamu/0000-0003-1820-7539				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; GEISE K, 1995, GENE DEV, V9, P995; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUBER O, 1996, MECH DEVELOP, V59, P310; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lahti JM, 1997, J BIOL CHEM, V272, P10859; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Miyoshi Y, 1998, CANCER RES, V58, P2524; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Zhang T, 1997, CANCER RES, V57, P169; Zurawel RH, 1998, CANCER RES, V58, P896	28	3143	3251	3	196	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					422	426		10.1038/18884	http://dx.doi.org/10.1038/18884			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201372				2022-12-01	WOS:000079508200052
J	Frost, G; Leeds, AA; Dore, CJ; Madeiros, S; Brading, S; Dornhorst, A				Frost, G; Leeds, AA; Dore, CJ; Madeiros, S; Brading, S; Dornhorst, A			Glycaemic index as a determinant of serum HDL-cholesterol concentration	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; METABOLIC CONTROL; DIETARY FIBER; GLYCEMIC LOAD; INSULIN; RISK; CARBOHYDRATE; FAT; FOODS	Background Diet influences the prevalence of coronary heart disease (CHD). Insulin sensitivity and concentrations of HDL cholesterol, two metabolic predictors of CHD, are also influenced by diet. Dietary carbohydrates with a high glycaemic index cause a high postprandial glucose and insulin response, and are associated with decreased insulin sensitivity and an increased risk of CHD. This study examined whether the glycaemic index or dietary carbohydrates is a determinant of serum HDL-cholesterol concentrations. Method Dietary, anthropometric, and biochemical data from the 1986-87 Survey of British Adults (n=2200) were reanalysed by a multiple regression model, which examined the relation between serum total cholesterol, HDL-cholesterol, and calculated LDL-cholesterol concentrations and various dietary characteristics, including the type of carbohydrate, the glycaemic index, and fat intake. Findings Among the 1420 participants with complete data, there was a significant negative relation between serum HDL-cholesterol concentration and the glycaemic index of the diet for both men (regression coefficient -0.00724 [95% CI -0.0101 to -0.00434], p=0.02) and women (-0.01326 [-0.0162 to -0.0102], p<0.0001). No other significant relation was found with total cholesterol or LDL-cholesterol concentration or with any other dietary carbohydrate or fat constituent. Interpretation In a cross-sectional study of middle-aged adults, the glycaemic index of the diet was the only dietary variable significantly related to serum HDL-cholesterol concentration. Thus, the glycaemic index of the diet is a stronger predictor than dietary fat intake of serum HDL-cholesterol concentration.	Hammersmith Hosp NHS Trust, Dept Nutr & Dietet, London W12 0HS, England; Univ London Kings Coll, Dept Nutr, London WC2R 2LS, England; Univ London Imperial Coll Sci Technol & Med, Dept Metab Stat & Evaluat, London, England; Univ London Imperial Coll Sci Technol & Med, Dept Metab Med, Div Invest Sci, London, England	Imperial College London; University of London; King's College London; Imperial College London; Imperial College London	Frost, G (corresponding author), Hammersmith Hosp NHS Trust, Dept Nutr & Dietet, London W12 0HS, England.	gfrost@rpms.ac.uk	Dore, Caroline J/J-4716-2012	Dore, Caroline J/0000-0001-9796-4970				BORNET FRJ, 1987, AM J CLIN NUTR, V45, P588, DOI 10.1093/ajcn/45.3.588; CHEN YDI, 1993, J CLIN ENDOCR METAB, V76, P347, DOI 10.1210/jc.76.2.347; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; FAO/WHO, 1998, CARB HUM NUTR REP JO; FONTVIEILLE AM, 1992, DIABETIC MED, V9, P444, DOI 10.1111/j.1464-5491.1992.tb01815.x; FOSTERPOWELL K, 1995, AM J CLIN NUTR, V62, P871; Frost G, 1996, METABOLISM, V45, P669, DOI 10.1016/S0026-0495(96)90129-8; Frost G, 1998, METABOLISM, V47, P1245, DOI 10.1016/S0026-0495(98)90331-6; FROST G, 1994, DIABETIC MED, V11, P397, DOI 10.1111/j.1464-5491.1994.tb00292.x; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GREGORY J, 1998, DIETARY NUTR SURVEY; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; JENKINS DJA, 1982, AM J CLIN NUTR, V35, P1339, DOI 10.1093/ajcn/35.6.1339; JENKINS DJA, 1987, AM J CLIN NUTR, V46, P66, DOI 10.1093/ajcn/46.1.66; Jeppesen J, 1998, J INTERN MED, V243, P293; Liu S, 1998, FASEB J, V12, pA260; MARSHALL JA, 1991, AM J EPIDEMIOL, V134, P590, DOI 10.1093/oxfordjournals.aje.a116132; Marshall JA, 1997, DIABETOLOGIA, V40, P430, DOI 10.1007/s001250050697; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545; Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5; SLABBER M, 1994, AM J CLIN NUTR, V60, P48, DOI 10.1093/ajcn/60.1.48; TENKANEN L, 1994, ARCH INTERN MED, V154, P2714, DOI 10.1001/archinte.1994.00420230107012; VANDOKKUM W, 1990, EUR J CLIN NUTR, V44, P665; Wolever T M, 1990, World Rev Nutr Diet, V62, P120; WOLEVER TMS, 1995, DIABETES CARE, V18, P962, DOI 10.2337/diacare.18.7.962; WOLEVER TMS, 1992, DIABETIC MED, V9, P451, DOI 10.1111/j.1464-5491.1992.tb01816.x	28	289	303	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1045	1048		10.1016/S0140-6736(98)07164-5	http://dx.doi.org/10.1016/S0140-6736(98)07164-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199351				2022-12-01	WOS:000079614000010
J	Seeling, JM; Miller, JR; Gil, R; Moon, RT; White, R; Virshup, DM				Seeling, JM; Miller, JR; Gil, R; Moon, RT; White, R; Virshup, DM			Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A	SCIENCE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; INSULIN; PATHWAY; PHOSPHORYLATION; IDENTIFICATION; SPECIFICITY; INHIBITION; AXIS	Dysregulation of Wnt-beta-catenin signaling disrupts axis formation in vertebrate embryos and underlies multiple human malignancies. The adenomatous polyposis coli (APC) protein, axin, and glycogen synthase kinase 3 beta form a Wnt-regulated signaling complex that mediates the phosphorylation-dependent degradation of beta-catenin. A protein phosphatase 2A (PP2A) regulatory subunit, B56, interacted with APC in the yeast two-hybrid system. Expression of B56 reduced the abundance of beta-catenin and inhibited transcription of beta-catenin target genes in mammalian cells and Xenopus embryo explants. The B56-dependent decrease in beta-catenin was blocked by oncogenic mutations in beta-catenin or APC, and by proteasome inhibitors. B56 may direct PP2A to dephosphorylate specific components of the APC-dependent signaling complex and thereby inhibit Wnt signaling.	Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84132 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84132 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Virshup, DM (corresponding author), Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84132 USA.	david.virshup@hci.utah.edu	Moon, Randall T/B-1743-2014; Gil, Rosario/R-6932-2018; Virshup, David M/C-1449-2009; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Gil, Rosario/0000-0002-9397-1003; Virshup, David M/0000-0001-6976-850X; Moon, Randall/0000-0002-9352-1408	NCI NIH HHS [3P30CA42014, R01 CA71074, T32CA09602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071074, P30CA042014, T32CA009602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MCCRIGHT B, UNPUB; MCLELLAN T, 1985, CYTOGENET CELL GENET, V39, P224, DOI 10.1159/000132139; Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; SEELING JM, UNPUB; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUGANUMA M, 1992, CARCINOGENESIS, V13, P1841, DOI 10.1093/carcin/13.10.1841; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Voeller HJ, 1998, CANCER RES, V58, P2520; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	30	352	355	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2089	2091		10.1126/science.283.5410.2089	http://dx.doi.org/10.1126/science.283.5410.2089			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10092233				2022-12-01	WOS:000079369800048
J	Li, HS; Chen, JH; Wu, W; Fagaly, T; Zhou, LJ; Yuan, WL; Dupuis, S; Jiang, ZH; Nash, W; Gick, C; Ornitz, DM; Wu, JY; Rao, Y				Li, HS; Chen, JH; Wu, W; Fagaly, T; Zhou, LJ; Yuan, WL; Dupuis, S; Jiang, ZH; Nash, W; Gick, C; Ornitz, DM; Wu, JY; Rao, Y			Vertebrate slit, a secreted ligand for the transmembrane protein roundabout, is a repellent for olfactory bulb axons	CELL			English	Article							GROWTH CONE GUIDANCE; ODORANT RECEPTOR EXPRESSION; CENTRAL-NERVOUS-SYSTEM; DORSAL-ROOT GANGLIA; MITRAL TUFTED CELLS; EMBRYO SPINAL-CORD; C-ELEGANS; COMMISSURAL AXONS; MOTOR AXONS; FLOOR-PLATE	The olfactory bulb plays a central role in olfactory information processing through its connections with both peripheral and cortical structures. Axons projecting from the olfactory bulb to the telencephalon are guided by a repulsive activity in the septum. The molecular nature of the repellent is not known. We report here the isolation of vertebrate homologs of the Drosophila slit gene and show that Slit protein binds to the transmembrane protein Roundabout (Robo). Slit is expressed in the septum whereas Robe is expressed in the olfactory bulb. Functionally, Slit acts as a chemorepellent for olfactory bulb axons. These results establish a ligand-receptor relationship between two molecules important for neural development, suggest a role for Slit in olfactory bulb axon guidance, and reveal the existence of a new family of axon guidance molecules.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurobiol & Anat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Shanghai Res Ctr Life Sci, Mol Neurobiol Lab, Shanghai 200031, Peoples R China; Chinese Acad Sci, Chinese Inst Neurosci, Shanghai 200031, Peoples R China	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Wu, JY (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.	jwu@pharmdec.wustl.edu; raoyi@thalamus.wustl.edu	Chen, Jinhui/A-7138-2009	Chen, Jinhui/0000-0002-6864-7121; Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114197-01A2] Funding Source: Medline; NEI NIH HHS [R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; BRUNJES PC, 1986, BRAIN RES REV, V11, P1, DOI 10.1016/0165-0173(86)90008-1; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Getchell TV., 1991, SMELL TASTE HLTH DIS, P19; Greer C. A., 1991, SMELL TASTE HLTH DIS, P65; GUTHRIE S, 1995, NEURON, V14, P1117, DOI 10.1016/0896-6273(95)90260-0; GUTHRIE S, 1994, NEUROPROTOCOLS, V4, P116; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HINDS JW, 1972, J COMP NEUROL, V146, P233, DOI 10.1002/cne.901460207; HINDS JW, 1973, J COMP NEUROL, V151, P281, DOI 10.1002/cne.901510305; Hirata T, 1997, J NEUROBIOL, V32, P415, DOI 10.1002/(SICI)1097-4695(199704)32:4<415::AID-NEU5>3.0.CO;2-9; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; Itoh A, 1998, MOL BRAIN RES, V62, P175, DOI 10.1016/S0169-328X(98)00224-1; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Keynes R, 1997, NEURON, V18, P889, DOI 10.1016/S0896-6273(00)80329-3; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; KOLODZIEJ PA, 1995, NEURON, V15, P273, DOI 10.1016/0896-6273(95)90033-0; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; Li HS, 1997, DEVELOPMENT, V124, P603; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OPPENHEIM RW, 1988, J COMP NEUROL, V275, P159, DOI 10.1002/cne.902750202; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; Price J.L., 1987, P179; Puschel AW, 1996, EUR J NEUROSCI, V8, P1317, DOI 10.1111/j.1460-9568.1996.tb01593.x; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Reed RR, 1996, COLD SPRING HARB SYM, V61, P165; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROTHBERG JM, 1992, J MOL BIOL, V227, P367, DOI 10.1016/0022-2836(92)90891-M; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; Sato Y, 1998, J NEUROSCI, V18, P7800; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SCHWOB JE, 1984, J COMP NEUROL, V223, P177, DOI 10.1002/cne.902230204; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shepherd G. M., 1990, SYNAPTIC ORG BRAIN, P133; Shipley Michael T., 1995, P899; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; Sugisaki N, 1996, J NEUROBIOL, V29, P127, DOI 10.1002/(SICI)1097-4695(199602)29:2<127::AID-NEU1>3.0.CO;2-C; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; WRIGHT DE, 1995, J COMP NEUROL, V351, P329, DOI 10.1002/cne.903510302; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; YAGINUMA H, 1991, J COMP NEUROL, V304, P78, DOI 10.1002/cne.903040107; Yoshihara Y, 1997, J NEUROSCI, V17, P5830; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2	84	381	414	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	1999	96	6					807	818		10.1016/S0092-8674(00)80591-7	http://dx.doi.org/10.1016/S0092-8674(00)80591-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102269	Bronze			2022-12-01	WOS:000079300100008
J	Methot, N; Basler, K				Methot, N; Basler, K			Hedgehog controls limb development by regulating the activities of distinct transcriptional activator and repressor forms of Cubitus interruptus	CELL			English	Article							KINESIN-RELATED PROTEIN; DROSOPHILA-MELANOGASTER; GENE-EXPRESSION; TARGET GENES; PATTERN; SIGNAL; GLI; COMPARTMENTS; RECEPTOR; DOMINANT	Hedgehog (Hh) proteins play diverse organizing roles in development by regulating gene expression in responding cells, The Gli homolog Cubitus interruptus (Ci) is involved in controlling the transcription of Hh target genes, A repressor form of Ci arises in the absence of Hh signaling by proteolytic cleavage of intact Ci. We show that this cleavage is essential for limb patterning and is regulated by Hh in vivo. We provide evidence for the existence of a distinct activator form of Ci, which does not arise by mere prevention of Ci proteolysis, but rather depends on a separate regulatory step subject to Hh control, These different activities of Ci regulate overlapping but distinct subsets of Hh target genes, Thus, limb development is organized by the integration of different transcriptional outputs of Hh signaling.	Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Basler, Konrad/0000-0003-3534-1529				Ahmed A, 1997, GENE, V197, P367, DOI 10.1016/S0378-1119(97)00285-0; Alcedo J, 1997, BIOL CHEM, V378, P583; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hepker J, 1997, DEVELOPMENT, V124, P549; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Locke J, 1996, GENOME RES, V6, P155, DOI 10.1101/gr.6.2.155; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; Pignoni F, 1997, DEVELOPMENT, V124, P271; PREAT T, 1993, GENETICS, V135, P1047; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; Schweizer L, 1998, MECH DEVELOP, V78, P141, DOI 10.1016/S0925-4773(98)00163-4; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SLUSARSKI DC, 1995, GENETICS, V139, P229; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Von Ohlen T, 1997, MECH DEVELOP, V68, P149, DOI 10.1016/S0925-4773(97)00150-0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	37	313	320	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	1999	96	6					819	831		10.1016/S0092-8674(00)80592-9	http://dx.doi.org/10.1016/S0092-8674(00)80592-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	178ZY	10102270	Bronze, Green Accepted			2022-12-01	WOS:000079300100009
J	Steffen, R; Collard, F; Tornieporth, N; Campbell-Forrester, S; Ashley, D; Thompson, S; Mathewson, JJ; Maes, E; Stephenson, B; DuPont, HL; von Sonnenburg, F				Steffen, R; Collard, F; Tornieporth, N; Campbell-Forrester, S; Ashley, D; Thompson, S; Mathewson, JJ; Maes, E; Stephenson, B; DuPont, HL; von Sonnenburg, F			Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLAMMATORY BOWEL-DISEASE; ESCHERICHIA-COLI; CLINICAL-TRIALS; PREVENTION; QUALITY; LIFE	Context Traveler's diarrhea (TD) can incapacitate travelers. Characteristics of TD could be helpful in identifying individuals who might benefit from a vaccine against TD, Objective To determine epidemiology, etiology, and impact of TD in Jamaica. Design Two-armed, cross-sectional survey conducted between March 1996 and May 1997, Setting Sangster International Airport and 10 hotels in Montego Bay area, Jamaica. Subjects To investigate epidemiology and impact, 30369 short-term visitors completed a questionnaire just before boarding their homebound aircrafts, To investigate etiology, 322 patients (hotel guests) with TD provided stool samples. Main Outcome Measures Attack and incidence rates of reported diarrhea and of classically defined TD (greater than or equal to 3 unformed stool samples in 24 hours and greater than or equal to 1 accompanying symptom), incapacity, risk factors, and etiology. Results The attack rate for diarrhea was 23.6% overall, with 11.7% having classically defined TD, For a mean duration of stay of 4 to 7 days, the incidence rate was 20.9% (all TD) and 10.0% (classic TD), Among airport respondents, the incapacity lasted a mean of 11.6 hours. Less than 3% of all travelers avoided potentially highrisk food and beverages. The most frequently detected pathogens were enterotoxigenic Escherichia coli, Rotavirus, and Salmonella species. Conclusions A realistic plan for reducing TD is needed. Preventive measures such as the improvement of hygienic conditions at the destination, and/or the development of vaccines against the most frequent pathogens associated with TD may contribute toward achieving this goal.	Univ Zurich, Inst Social & Prevent Med, Div Epidemiol & Prevent Communicable Dis, CH-8006 Zurich, Switzerland; SmithKline Beecham Biol, Rixensart, Belgium; Univ Munich, Div Int Med & Publ Hlth, Munich, Germany; Minist Hlth Jamaica, Western Area Hlth Adm, Kingston, Jamaica; Cornwall Reg Hosp, Dept Microbiol, Montego Bay, Jamaica; Univ Texas, Ctr Infect Dis, Houston, TX USA; Lewin Grp, Mechelen, Belgium; McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; St Lukes Episcopal Hosp, Houston, TX 77030 USA	University of Zurich; GlaxoSmithKline; University of Munich; University of Texas System; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Saint Lukes Episcopal Hospital	Steffen, R (corresponding author), Univ Zurich, Inst Social & Prevent Med, Div Epidemiol & Prevent Communicable Dis, Sumatrastr 30, CH-8006 Zurich, Switzerland.	travclin@ifspm.unizh.ch	DuPont, Herbert/AAH-6776-2021					Beecham HJ, 1997, AM J TROP MED HYG, V57, P699, DOI 10.4269/ajtmh.1997.57.699; BERLIN OGW, 1994, CLIN INFECT DIS, V18, P606, DOI 10.1093/clinids/18.4.606; BLACK RE, 1990, REV INFECT DIS, V12, P573; *CAN COORD OFF HLT, 1994, GUID EC EV PHARM; CARTWRIGHT R, 1992, PHLS MICROBIOLOGY DI, V9, P121; Cartwright R. Y., 1997, World Health Statistics Quarterly, V50, P102; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; DUPONT HL, 1980, MICROBIOLOGY PATHOPH, P219; FARTHING MJG, 1992, GASTROENTEROLOGY INT, V5, P162; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441; HOLMGREN J, 1990, SCAND J INFECT DIS S, V70, P149; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MATHEWSON JJ, 1987, J CLIN MICROBIOL, V25, P1917, DOI 10.1128/JCM.25.10.1917-1919.1987; Mattila, 1995, J Travel Med, V2, P77, DOI 10.1111/j.1708-8305.1995.tb00631.x; MITCHELL A, 1988, J CLIN GASTROENTEROL, V10, P306, DOI 10.1097/00004836-198806000-00014; MURRAY BE, 1987, J INFECT DIS, V155, P809, DOI 10.1093/infdis/155.4.809; PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X; PEREDES P, IN PRESS J TRAVEL ME; PICKERING LK, 1977, J INFECT DIS, V135, P1003, DOI 10.1093/infdis/135.6.1003; RYAN NJ, 1993, J CLIN MICROBIOL, V31, P3264, DOI 10.1128/JCM.31.12.3264-3269.1993; STEFFEN R, 1994, JAMA-J AM MED ASSOC, V272, P885, DOI 10.1001/jama.272.11.885; STEFFEN R, 1983, JAMA-J AM MED ASSOC, V249, P1176; STUCKI A, 1997, THESIS U ZURICH ZURI; SVENNERHOLM AM, 1995, ADV EXP MED BIOL, V371, P1623; VIBOUD GI, 1993, J CLIN MICROBIOL, V31, P558, DOI 10.1128/JCM.31.3.558-564.1993; WHO, 1996, WHOPSA962, P5	28	114	118	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					811	817		10.1001/jama.281.9.811	http://dx.doi.org/10.1001/jama.281.9.811			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071002	Bronze			2022-12-01	WOS:000078804300031
J	Piccolo, S; Agius, E; Leyns, L; Bhattacharyya, S; Grunz, H; Bouwmeester, T; De Robertis, EM				Piccolo, S; Agius, E; Leyns, L; Bhattacharyya, S; Grunz, H; Bouwmeester, T; De Robertis, EM			The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals	NATURE			English	Article							ANTERIOR PRIMITIVE ENDODERM; SPEMANN ORGANIZER; INDUCTION; MOUSE; GASTRULATION; REQUIREMENT; MESODERM	Embryological and genetic evidence indicates that the vertebrate head is induced by a different set of signals from those that organize trunk-tail development(1-6). The gene cerberus encodes a secreted protein that is expressed in anterior endoderm and has the unique property of inducing ectopic heads in the absence of trunk structures(1). Here we show that the cerberus protein functions as a multivalent growth-factor antagonist in the extracellular space: it binds to Nodal, BMP and Wnt proteins via independent sites. The expression of cerberus during gastrulation is activated by earlier nodal-related signals in endoderm and by Spemann-organizer factors that repress signalling by BMP and Wnt. In order for the head territory to form, we propose that signals involved in trunk development, such as those involving BMP, Wnt and Nodal proteins, must be inhibited in rostral regions.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; European Molecular Biology Laboratory (EMBL)	De Robertis, EM (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.		agius, Eric/AHC-9705-2022	Leyns, Luc/0000-0001-7124-3155; PICCOLO, STEFANO/0000-0002-2037-0004; Agius, Eric/0000-0003-2123-9283	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD021502, R37 HD021502-13] Funding Source: Medline; Telethon [E.0815] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon)		Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Bouwmeester T, 1997, BIOESSAYS, V19, P855, DOI 10.1002/bies.950191005; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Chang CB, 1997, DEVELOPMENT, V124, P827; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Henry GL, 1998, SCIENCE, V281, P91, DOI 10.1126/science.281.5373.91; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; JONES CM, 1995, DEVELOPMENT, V121, P3651; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rhinn M, 1998, DEVELOPMENT, V125, P845; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Varlet I, 1997, DEVELOPMENT, V124, P1033; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5	24	654	700	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 25	1999	397	6721					707	710		10.1038/17820	http://dx.doi.org/10.1038/17820			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171AP	10067895	Green Accepted			2022-12-01	WOS:000078840100053
J	Graziano, MSA; Reiss, LAJ; Gross, CG				Graziano, MSA; Reiss, LAJ; Gross, CG			A neuronal representation of the location of nearby sounds	NATURE			English	Article							VISUAL RESPONSES; PREMOTOR CORTEX; PERCEPTION; SPACE; MONKEY	Humans can accurately perceive the location of a sound source-not only the direction, but also the distance(1-9). Sounds near the head, within ducking or reaching distance, have a special saliency. However, little is known about this perception of auditory distance. The direction to a sound source can be determined by interaural differences, and the mechanisms of direction perception have been studied intensively(1); but except for studies on echolocation in the bat(10), little is known about how neurons encode information on auditory distance. Here we describe neurons in the brain of macaque monkeys (Macaca fascicularis) that represent the auditory space surrounding the head, within roughly 30 cm, These neurons, which are located in the ventral premotor cortex, have spatial receptive fields that extend a limited distance outward from the head.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	Princeton University	Graziano, MSA (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.	graziano@princeton.edu		Reiss, Lina/0000-0001-7746-9796				ASHMEAD DH, 1990, PERCEPT PSYCHOPHYS, V47, P326, DOI 10.3758/BF03210871; BLAUERT J, 1997, SPAETIAL HEARING PSY; BOUSSAOUD D, 1993, EXP BRAIN RES, V93, P423; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; CLIFTON RK, 1994, J EXP PSYCHOL HUMAN, V20, P876, DOI 10.1037/0096-1523.20.4.876; Cohen J., 1983, APPL MULTIPLE REGRES, V2nd ed.; COLEMAN PD, 1968, J ACOUST SOC AM, V44, P631, DOI 10.1121/1.1911132; COLEMAN PD, 1963, PSYCHOL BULL, V60, P302, DOI 10.1037/h0045716; COLEMAN PD, 1962, J ACOUST SOC AM, V34, P345, DOI 10.1121/1.1928121; Edwards AS, 1955, J GEN PSYCHOL, V52, P327, DOI 10.1080/00221309.1955.9920247; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; Gamble E. A., 1909, PSYCHOL REV, V16, P416, DOI DOI 10.1037/H0073666; GARDNER MB, 1969, J ACOUST SOC AM, V45, P47, DOI 10.1121/1.1911372; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; Graziano MSA, 1998, CURR OPIN NEUROBIOL, V8, P195, DOI 10.1016/S0959-4388(98)80140-2; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; Graziano MSA, 1997, SCIENCE, V277, P239, DOI 10.1126/science.277.5323.239; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; GRAZIANO MSA, 1996, NEUR ABS, V22, P398; MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302; MERSHON DH, 1979, PERCEPTION, V8, P311, DOI 10.1068/p080311; MERSHON DH, 1975, PERCEPT PSYCHOPHYS, V18, P409, DOI 10.3758/BF03204113; Rizzolatti G, 1997, SCIENCE, V277, P190, DOI 10.1126/science.277.5323.190; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X; SUGA N, 1979, SCIENCE, V206, P351, DOI 10.1126/science.482944; von Bekesy G., 1960, EXPT HEARING	26	228	231	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					428	430		10.1038/17115	http://dx.doi.org/10.1038/17115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	164KA	9989407				2022-12-01	WOS:000078461700046
J	Li, P; Wilding, TJ; Kim, SJ; Calejesan, AA; Huettner, JE; Zhuo, M				Li, P; Wilding, TJ; Kim, SJ; Calejesan, AA; Huettner, JE; Zhuo, M			Kainate-receptor-mediated sensory synaptic transmission in mammalian spinal cord	NATURE			English	Article							SUBSTANTIA-GELATINOSA NEURONS; DORSAL HORN; GLUTAMATE RECEPTORS; IN-VITRO; RAT; DESENSITIZATION; AMPA; 2,3-BENZODIAZEPINES; ANTAGONISM; ACTIVATION	Glutamate, the major excitatory neurotransmitter in the central nervous system, activates three different receptors that directly gate ion channels, namely receptors for AMPA (alpha-amino-3-hydroxy-5-methyl isoxozole propionic acid), NMDA (N-methyl-D-aspartate), and kainate, a structural analogue of glutamate. The contribution of AMPA and NMDA receptors to synaptic transmission and plasticity is well established(1). Recent work on the physiological function of kainate receptors has focused on the hippocampus(2), where repetitive activation of the mossy-fibre pathway generates a slow, kainate-receptor-mediated excitatory postsynaptic current (EPSC)(3-5). Here we show that high-intensity single-shock stimulation (of duration 200 microseconds) of primary afferent sensory fibres produces a fast, kainate-receptor-mediated EPSC in the superficial dorsal horn of the spinal cord. Activation of low-threshold afferent fibres generates typical AMPA-receptor-mediated EPSCs only, indicating that kainate receptors may be restricted to synapses formed by high-threshold nociceptive (pain-sensing) and thermoreceptive primary afferent fibres. Consistent with this possibility, kainate-receptor-mediated EPSCs are blocked by the analgesic mu-opiate-receptor agonist Damgo and spinal blockade of both kainate and AMPA receptors produces antinociception, Thus, spinal kainate receptors contribute to transmission of somatosensory inputs from the periphery to the brain.	Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Zhuo, M (corresponding author), Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA.		Huettner, James E/C-5219-2012; Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030888] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS030888] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABA H, 1994, J PHYSIOL-LONDON, V478, P87, DOI 10.1113/jphysiol.1994.sp020232; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Coggeshall RE, 1996, DEV BRAIN RES, V92, P81, DOI 10.1016/0165-3806(95)00207-3; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; FITZGERALD M, 1994, J COMP NEUROL, V348, P225, DOI 10.1002/cne.903480205; HUANG LYM, 1985, J NEUROSCI METH, V14, P91, DOI 10.1016/0165-0270(85)90119-0; Jones KA, 1997, NEUROPHARMACOLOGY, V36, P853, DOI 10.1016/S0028-3908(97)00066-X; KUMAZAWA T, 1978, J COMP NEUROL, V177, P417, DOI 10.1002/cne.901770305; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; Li P, 1998, NATURE, V393, P695, DOI 10.1038/31496; LIGHT AR, 1979, J COMP NEUROL, V186, P151, DOI 10.1002/cne.901860204; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; Pelletier JC, 1996, J MED CHEM, V39, P343, DOI 10.1021/jm950740w; PETRALIA RS, 1994, J COMP NEUROL, V349, P85, DOI 10.1002/cne.903490107; TODD AJ, 1994, J NEUROSCI, V14, P774; TOLLE TR, 1993, J NEUROSCI, V13, P5009, DOI 10.1523/JNEUROSCI.13-12-05009.1993; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; Wilding TJ, 1997, J NEUROSCI, V17, P2713; WILDING TJ, 1995, MOL PHARMACOL, V47, P582; WISDEN W, 1993, J NEUROSCI, V13, P3582; YAKSH TL, 1994, TXB PAIN, P165; YOSHIMURA M, 1990, J PHYSIOL-LONDON, V430, P315, DOI 10.1113/jphysiol.1990.sp018293; Zhuo M, 1998, EUR J PHARMACOL, V349, P211, DOI 10.1016/S0014-2999(98)00197-6	28	214	228	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					161	164		10.1038/16469	http://dx.doi.org/10.1038/16469			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923678				2022-12-01	WOS:000078085000046
J	Sorensen, HT; Rothman, KJ; Gillman, MW; Steffensen, FH; Fischer, P; Sabroe, S				Sorensen, HT; Rothman, KJ; Gillman, MW; Steffensen, FH; Fischer, P; Sabroe, S			Historical cohort study of in utero exposure to uterotonic drugs and cognitive function in young adult life	BRITISH MEDICAL JOURNAL			English	Article									Aarhus Univ Hosp, Dept Internal Med 5, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Epidemiol & Social Med, Danish Epidemiol Sci Ctr, DK-8000 Aarhus, Denmark; Boston Univ, Sch Med, Dept Epidemiol & Prevent Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Cty N Jutland, Conscript Adm, DK-9000 Aalborg, Denmark	Aarhus University; Aarhus University; Boston University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Sorensen, HT (corresponding author), Aarhus Univ Hosp, Dept Internal Med 5, DK-8000 Aarhus C, Denmark.		Steffensen, Flemming Hald/AAH-8742-2020; Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Rothman, Kenneth/0000-0003-2398-1705; Steffensen, Flemming Hald/0000-0003-0252-6631				DAWOOD MY, 1989, AM J PERINAT, V6, P167, DOI 10.1055/s-2007-999569; FRIEDMAN EA, 1979, AM J OBSTET GYNECOL, V133, P718, DOI 10.1016/0002-9378(79)90025-5; JOHNSON JD, 1984, AM J DIS CHILD, V138, P1047, DOI 10.1001/archpedi.1984.02140490047011; Mortensen EL, 1989, SCAND J PSYCHOL, V30, P3115; SEIDMAN DS, 1991, PEDIATRICS, V88, P828	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 13	1999	318	7181					433	434		10.1136/bmj.318.7181.433	http://dx.doi.org/10.1136/bmj.318.7181.433			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	168BF	18751140	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000078670100026
J	Keane, FM; Munn, SE; du Vivier, AWP; Taylor, NF; Higgins, EM				Keane, FM; Munn, SE; du Vivier, AWP; Taylor, NF; Higgins, EM			Analysis of Chinese herbal creams prescribed for dermatological conditions	BRITISH MEDICAL JOURNAL			English	Article							ECZEMA	Objective To determine whether Chinese herbal creams used for the treatment of dermatological conditions contain steroids. Design 11 herbal creams obtained from patients attending general and paediatric dermatology outpatient clinics were analysed with high resolution gas chromatography and mass spectrometry Setting Departments of dermatology and clinical biochemistry Main outcome measure Presence of steroid. Results Eight creams contained dexamethasone at a mean concentration of 456 mu g/g (range 64 to 1500 mu g/g). All were applied to areas of sensitive skin such as face and flexures. Conclusion Greater regulation needs to be imposed on Chinese herbalists to prevent illegal and inappropriate prescribing of potent steroids.	Univ London Kings Coll Hosp, Dept Dermatol, London SE5 9RS, England; Univ London Kings Coll Hosp, Dept Clin Biochem, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Keane, FM (corresponding author), Univ London Kings Coll Hosp, Dept Dermatol, London SE5 9RS, England.							ALLEN BR, 1990, LANCET, V336, P177, DOI 10.1016/0140-6736(90)91696-8; HUGHES JR, 1994, BRIT J DERMATOL, V130, P261, DOI 10.1111/j.1365-2133.1994.tb02916.x; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; ODRISCOLL J, 1992, BRIT J DERMATOL, V127, P543, DOI 10.1111/j.1365-2133.1992.tb14859.x; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E	7	77	79	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					563	564		10.1136/bmj.318.7183.563	http://dx.doi.org/10.1136/bmj.318.7183.563			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	18751138	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000078966300024
